ticker,rpa_date_utc,rpa_time_utc,rp_entity_id,entity_name,relevance,event_sentiment_score,group,sub_type,event_text,news_type,source_name,headline
BMY,2024-01-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
BMY,2024-01-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The clinical trial results with repotrectinib,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
BMY,2024-01-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
BMY,2024-01-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The clinical trial results with repotrectinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
BMY,2024-01-02,11:59:20,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib,NEWS-FLASH,Dow Jones Newswires,European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
BMY,2024-01-02,12:48:20,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol Myers Squibb's application seeking approval of repotrectinib,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Augtyro Advances in Europe -- Market Talk
BMY,2024-01-02,12:48:20,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol Myers Squibb's application seeking approval of repotrectinib,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Augtyro Advances in Europe -- Market Talk
BMY,2024-01-03,14:17:47,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Neutral From Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Neutral From Buy by B of A Securities
BMY,2024-01-03,14:17:47,94637C,Bristol-Myers Squibb Co.,100,-0.8,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $60.00/Share From $68.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $60.00/Share From $68.00 by B of A Securities
BMY,2024-01-03,15:01:00,94637C,Bristol-Myers Squibb Co.,91,-0.58,analyst-ratings,negative,Bank of America downgrades Bristol-Myers Squibb to neutral from buy,FULL-ARTICLE,Dow Jones Newswires,Exclusivity Loss Concerns Sideline a Bristol-Myers Bull -- Market Talk
BMY,2024-01-03,15:01:00,94637C,Bristol-Myers Squibb Co.,91,-0.58,analyst-ratings,negative,Bank of America downgrades Bristol-Myers Squibb to neutral from buy,FULL-ARTICLE,Dow Jones Newswires,Exclusivity Loss Concerns Sideline a Bristol-Myers Bull -- Market Talk
BMY,2024-01-03,15:28:34,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol Myers Squibb downgraded to neutral from buy at BofA Securities,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb downgraded to neutral from buy at BofA Securities
BMY,2024-01-08,06:51:13,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Bristol Myers Squibb and Evotec extended and expanded this partnership,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
BMY,2024-01-08,06:51:13,94637C,Bristol-Myers Squibb Co.,98,0.0,products-services,,Bristol Myers Squibb announced that a Phase II study for,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
BMY,2024-01-17,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO GU 2024 -4-
BMY,2024-01-17,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO GU 2024 -4-
BMY,2024-01-17,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO GU 2024 -4-
BMY,2024-01-17,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -4-
BMY,2024-01-17,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -4-
BMY,2024-01-17,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -4-
BMY,2024-01-23,13:30:00,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio"
BMY,2024-01-23,13:30:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio"
BMY,2024-01-23,13:30:30,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Abecma,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Abecma is also approved in Japan,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Abecma,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Abecma is also approved in Japan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:53,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,20:44:39,94637C,Bristol-Myers Squibb Co.,100,-0.48,government,,"Merck, J&J, Bristol Myers CEOs to Testify in Congress",FULL-ARTICLE,Dow Jones Newswires,"Merck, J&J, Bristol Myers CEOs to Testify in Congress on Drug Prices"
BMY,2024-01-26,20:59:38,94637C,Bristol-Myers Squibb Co.,100,-0.48,government,,"Merck, J&J, Bristol Myers CEOs to Testify in Congress",FULL-ARTICLE,Dow Jones Newswires,"Merck, J&J, Bristol Myers CEOs to Testify in Congress on Drug Prices"
BMY,2024-01-30,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted both applications Priority Review,PRESS-RELEASE,Business Wire,Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
BMY,2024-01-30,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: A sBLA for Breyanzi,PRESS-RELEASE,Business Wire,Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
BMY,2024-01-30,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
BMY,2024-01-30,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted both applications Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
BMY,2024-01-30,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: A sBLA for Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
BMY,2024-01-30,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
BMY,2024-01-30,12:38:42,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Two Added Breyanzi Indications
BMY,2024-01-30,12:53:42,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Two Added Breyanzi Indications
BMY,2024-01-30,14:31:02,94637C,Bristol-Myers Squibb Co.,100,0.5,stock-picks,buy,"Thinking about buying stock in Agape ATP, Tempest Therapeutics, Nu Holdings, Bristol-Myers Squibb, or Petros Pharmaceuticals?",PRESS-RELEASE,PR Newswire,"Thinking about buying stock in Agape ATP, Tempest Therapeutics, Nu Holdings, Bristol-Myers Squibb, or Petros Pharmaceuticals?"
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Net $1.76B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Net $1.76B >BMY
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q EPS 87c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q EPS 87c >BMY
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Adj EPS $1.70,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Adj EPS $1.70 >BMY
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 4Q Rev $11.48B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Rev $11.48B >BMY
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers Squibb posted fourth quarter revenues of $11.5 billion, an increase of 1%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS of $0.87,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Reports Full-Year Revenues of $45.0 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol-Myers Squibb Co.: Completes Purchase of Mirati Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Provides 2024 Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Non-GAAP EPS Range $7.10 to $7.40,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.9 billion compared to $1.7 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: International revenues were $975 million compared to $970 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Augtyro received U.S. regulatory approval in non-small cell lung cancer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted both applications Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.57,products-services,granted,Bristol-Myers Squibb Co.: Abecma Japan's MHLW granted manufacturing and marketing approval of the sNDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: FULL YEAR FINANCIAL RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,revenues,,Bristol-Myers Squibb Co.: FULL YEAR PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 1% to $31.6 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Revlimid worldwide revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Revenues for in-line products were $34.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $8.6 billion compared to $7.8 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues increased 10% to $5.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers Squibb Co.: The company agreed to acquire Karuna Therapeutics, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: Karuna's New Drug Application for KarXT,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers Squibb Co.: the company agreed to acquire RayzeBio, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol-Myers Squibb Co.: The company reached an exclusive license and collaboration agreement with SystImmune,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,"Bristol-Myers Squibb Co.: On January 23, 2024, the company announced it had successfully completed its acquisition of Mirati Therapeutics, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,dividends,,"Bristol-Myers Squibb Co.: In December, the company announced that the Board declared a quarterly dividend of $0.60",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,dividends,up,Bristol-Myers Squibb Co.: the company has increased its dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,approved,"Bristol-Myers Squibb Co.: in December, the company announced that the Board authorized the repurchase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total 2024 revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2024 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, February 2, 2024, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.87 $ 0.96 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED DECEMBER 31, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,Bristol-Myers Squibb Co.: New Product Portfolio Reblozyl,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products(b) Revlimid,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products(b) Revlimid,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -9-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,92,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $31,555 $13,451",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -9-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,477 $11,406",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -10-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-MYERS SQUIBB COMPANY 2024 FULL YEAR FINANCIAL GUIDANCE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -11-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers Squibb posted fourth quarter revenues of $11.5 billion, an increase of 1%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS of $0.87,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Reports Full-Year Revenues of $45.0 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol-Myers Squibb Co.: Completes Purchase of Mirati Therapeutics,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Provides 2024 Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Non-GAAP EPS Range $7.10 to $7.40,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.9 billion compared to $1.7 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: International revenues were $975 million compared to $970 million,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Augtyro received U.S. regulatory approval in non-small cell lung cancer,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted both applications Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.57,products-services,granted,Bristol-Myers Squibb Co.: Abecma Japan's MHLW granted manufacturing and marketing approval of the sNDA,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: FULL YEAR FINANCIAL RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,revenues,,Bristol-Myers Squibb Co.: FULL YEAR PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 1% to $31.6 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Revlimid worldwide revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Revenues for in-line products were $34.3 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $8.6 billion compared to $7.8 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues increased 10% to $5.3 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers Squibb Co.: The company agreed to acquire Karuna Therapeutics, Inc.",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: Karuna's New Drug Application for KarXT,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers Squibb Co.: the company agreed to acquire RayzeBio, Inc.",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol-Myers Squibb Co.: The company reached an exclusive license and collaboration agreement with SystImmune,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,"Bristol-Myers Squibb Co.: On January 23, 2024, the company announced it had successfully completed its acquisition of Mirati Therapeutics, Inc.",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,dividends,,"Bristol-Myers Squibb Co.: In December, the company announced that the Board declared a quarterly dividend of $0.60",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,dividends,up,Bristol-Myers Squibb Co.: the company has increased its dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,approved,"Bristol-Myers Squibb Co.: in December, the company announced that the Board authorized the repurchase",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total 2024 revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2024 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -6-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, February 2, 2024, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -6-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -7-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.87 $ 0.96 $,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED DECEMBER 31, 2023",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,Bristol-Myers Squibb Co.: New Product Portfolio Reblozyl,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products(b) Revlimid,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2023",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products(b) Revlimid,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -9-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,92,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $31,555 $13,451",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -9-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,477 $11,406",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -10-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-MYERS SQUIBB COMPANY 2024 FULL YEAR FINANCIAL GUIDANCE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -11-
BMY,2024-02-02,12:01:24,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb results top expectations,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb results top expectations as newer drugs help fuel growth
BMY,2024-02-02,12:01:24,94637C,Bristol-Myers Squibb Co.,100,-0.5,revenues,down,Revlimid sales fell 36%,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb results top expectations as newer drugs help fuel growth
BMY,2024-02-02,12:01:24,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb results top expectations,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb results top expectations as newer drugs help fuel growth
BMY,2024-02-02,12:01:24,94637C,Bristol-Myers Squibb Co.,100,-0.5,revenues,down,Revlimid sales fell 36%,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb results top expectations as newer drugs help fuel growth
BMY,2024-02-02,12:04:58,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Sees Total 2024 Rev to Increase,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees Total 2024 Rev to Increase by Low Single-Digits >BMY
BMY,2024-02-02,12:31:17,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol Myers Squibb 4Q Revenue Boosted,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb 4Q Revenue Boosted by Eliquis, Opdivo"
BMY,2024-02-02,12:31:17,94637C,Bristol-Myers Squibb Co.,100,-0.67,earnings,down,Bristol Myers Squibb's profit fell in the fourth quarter,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb 4Q Revenue Boosted by Eliquis, Opdivo"
BMY,2024-02-02,12:38:44,94637C,Bristol-Myers Squibb Co.,93,0.7,earnings,above-expectations,Bristol Myers Squibb beat earnings and revenue expectations in the fourth quarter,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' New Drugs Drive Upbeat Outlook. The Stock Is On the Mend. -- Barrons.com
BMY,2024-02-02,12:38:44,94637C,Bristol-Myers Squibb Co.,93,0.68,revenues,up,Revenue from Bristol Myers' new product portfolio jumped 66% to $1.1 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' New Drugs Drive Upbeat Outlook. The Stock Is On the Mend. -- Barrons.com
BMY,2024-02-02,12:46:17,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol Myers Squibb 4Q Revenue Boosted,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb 4Q Revenue Boosted by Eliquis, Opdivo"
BMY,2024-02-02,12:46:17,94637C,Bristol-Myers Squibb Co.,100,-0.67,earnings,down,Bristol Myers Squibb's profit fell in the fourth quarter,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb 4Q Revenue Boosted by Eliquis, Opdivo"
BMY,2024-02-02,13:04:37,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb reported adjusted earnings of $1.70 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Shares Rise On Fourth-Quarter Earnings Beat -- IBD
BMY,2024-02-02,13:04:37,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Factset expected Bristol Myers to earn $1.55 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Shares Rise On Fourth-Quarter Earnings Beat -- IBD
BMY,2024-02-02,15:36:51,94637C,Bristol-Myers Squibb Co.,98,0.61,earnings,positive,Bristol-Myers Squibb earned $1.70 per share,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Stock Yo-Yoes, Trying To Avoid A Fourth Day In The Red, On So-So Earnings -- IBD"
BMY,2024-02-02,15:36:51,94637C,Bristol-Myers Squibb Co.,98,0.0,earnings,,Bristol-Myers also issued guidance for 2024,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Stock Yo-Yoes, Trying To Avoid A Fourth Day In The Red, On So-So Earnings -- IBD"
BMY,2024-02-02,19:11:00,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb's fourth-quarter earnings topped Wall Street,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb Earnings Top Expectations
BMY,2024-02-02,19:26:00,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb's fourth-quarter earnings topped Wall Street,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb Earnings Top Expectations
BMY,2024-02-06,00:11:56,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Meyers Acquires 1,789 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Meyers Acquires 1,789 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-02-06,11:37:02,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Neutral From Buy,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Neutral From Buy by Redburn Atlantic
BMY,2024-02-06,11:37:02,94637C,Bristol-Myers Squibb Co.,100,-0.84,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $54.00/Share From $77.00 by Redburn Atlantic,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $54.00/Share From $77.00 by Redburn Atlantic
BMY,2024-02-06,16:25:22,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
BMY,2024-02-06,16:25:23,94637C,Bristol-Myers Squibb Co.,100,-0.8,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $51.00/Share From $58.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $51.00/Share From $58.00 by Wells Fargo
BMY,2024-02-07,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Applications based on results from CheckMate -77T, the company's second positive Phase 3 randomized trial",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
BMY,2024-02-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Acceptance of U.S. -3-
BMY,2024-02-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Acceptance of U.S. -3-
BMY,2024-02-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Acceptance of U.S. -4-
BMY,2024-02-07,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Applications based on results from CheckMate -77T, the company's second positive Phase 3 randomized trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
BMY,2024-02-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2024-02-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2024-02-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2024-02-12,18:47:27,94637C,Bristol-Myers Squibb Co.,100,0.29,credit-ratings,confirmation,Moody's Confirms Bristol-Myers Squibb At A2,NEWS-FLASH,Dow Jones Newswires,Moody's Confirms Bristol-Myers Squibb At A2; Outlook Is Negative
BMY,2024-02-13,13:00:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Enters Collaboration With Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence
BMY,2024-02-14,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro(TM) (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY,2024-02-14,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,2023 the U.S. Food and Drug Administration approved Augtyro,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro(TM) (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY,2024-02-14,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.63,products-services,,Augtyro was also granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro(TM) (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY,2024-02-14,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro(TM) (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY,2024-02-14,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,2023 the U.S. Food and Drug Administration approved Augtyro,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro(TM) (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY,2024-02-14,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.63,products-services,,Augtyro was also granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro(TM) (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY,2024-02-14,12:25:25,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Bristol Myers's $4.1 billion acquisition of Turning Point Therapeutics in 2022,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Speedy FDA Review of Expanded Augtyro Use
BMY,2024-02-14,12:40:25,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Bristol Myers's $4.1 billion acquisition of Turning Point Therapeutics in 2022,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Speedy FDA Review of Expanded Augtyro Use
BMY,2024-02-14,14:45:11,94637C,Bristol-Myers Squibb Co.,100,0.26,credit-ratings,set,S&PGR Rates Bristol-Myers Squibb's Senior Unsecured Notes 'A,NEWS-FLASH,Dow Jones Newswires,S&PGR Rates Bristol-Myers Squibb's Senior Unsecured Notes 'A'
BMY,2024-02-14,14:45:11,94637C,Bristol-Myers Squibb Co.,100,-0.38,credit-ratings,downgrade,S&PGR Rates Bristol-Myers Squibb's Senior Unsecured Notes 'A,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Rates Bristol-Myers Squibb's Senior Unsecured Notes 'A'
BMY,2024-02-14,14:45:11,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,Bristol-Myers Squibb Co.: rising demand for the company's other leading products,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Rates Bristol-Myers Squibb's Senior Unsecured Notes 'A'
BMY,2024-02-14,15:24:02,94637C,Bristol-Myers Squibb Co.,100,0.26,credit-ratings,set,Moody's Assigns A2 Rating To Bristol-Myers Squibb's Sr. Notes,NEWS-FLASH,Dow Jones Newswires,Moody's Assigns A2 Rating To Bristol-Myers Squibb's Sr. Notes; Outlook Is Negative
BMY,2024-02-14,18:45:05,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Bristol-Myers issued in October backing another purchase--Mirati Therapeutics,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Is on a Borrowing Binge -- WSJ
BMY,2024-02-15,00:57:00,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
BMY,2024-02-15,00:57:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb's acquisition of Karuna is,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
BMY,2024-02-15,00:57:01,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
BMY,2024-02-15,00:57:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb's acquisition of Karuna is,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
BMY,2024-02-15,01:10:16,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb: Will Issue $500M of Floating Rate Notes,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: Will Issue $500M of Floating Rate Notes Due 2026 >BMY
BMY,2024-02-15,21:58:38,94637C,Bristol-Myers Squibb Co.,98,0.53,labor-issues,,Appointed Senior Vice President and Controller of Bristol-Myers Squibb Company,RNS-SEC8K,Dow Jones Newswires,"Bristol-Myers Squibb Files 8K - Director, Officer or Compensation Filing >BMY"
BMY,2024-02-20,12:56:57,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Bristol Myers acquired in a deal that closed in January,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Priority FDA Review of Expanded Krazati Use
BMY,2024-02-20,13:11:57,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Bristol Myers acquired in a deal that closed in January,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Priority FDA Review of Expanded Krazati Use
BMY,2024-02-22,08:10:40,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2023 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2023 (BMY)"
BMY,2024-02-22,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE:BMY),PRESS-RELEASE,Dow Jones Newswires,Press Release: Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE:BMY),PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE:BMY),PRESS-RELEASE,GlobeNewswire,Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE:BMY),PRESS-RELEASE,Dow Jones Newswires,Press Release: Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:04:43,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Immunocore Announces Clinical Trial Collaboration and Supply Agreement With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Immunocore Announces Clinical Trial Collaboration and Supply Agreement With Bristol Myers Squibb to Evaluate IMC-F106C With Nivolumab in Its Registrational Phase 3 First-Line Advanced Cutaneous Melanoma Trial
BMY,2024-02-22,21:16:50,94637C,Bristol-Myers Squibb Co.,99,0.54,equity-actions,completed,"Bristol-Myers Squibb Co.: the ""Company"") completed the public offering",RNS-SEC8K,Dow Jones Newswires,Bristol-Myers Squibb Files 8K - Other Events >BMY
BMY,2024-02-22,21:16:50,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: the Company's proposed acquisitions of Karuna Therapeutics, Inc.",RNS-SEC8K,Dow Jones Newswires,Bristol-Myers Squibb Files 8K - Other Events >BMY
BMY,2024-02-23,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
BMY,2024-02-23,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
BMY,2024-02-23,11:59:27,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl for Treatment of Adults With Transfusion-Dependent Anemia Due to Low- to Intermediate-Risk Myelodysplastic Syndromes
BMY,2024-02-26,13:35:00,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition Of RayzeBio,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Completes Acquisition Of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform >BMY"
BMY,2024-02-26,13:35:00,94637C,Bristol-Myers Squibb Co.,100,0.82,acquisitions-mergers,completed,"Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB)",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform"
BMY,2024-02-26,13:35:01,94637C,Bristol-Myers Squibb Co.,100,0.82,acquisitions-mergers,completed,"Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB)",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform"
BMY,2024-03-01,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2024-03-01,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on May 1, 2024, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2024-03-01,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2024-03-01,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on May 1, 2024, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2024-03-06,12:30:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Partnership between Agenus and Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
BMY,2024-03-06,12:30:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Partnership between Agenus and Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
BMY,2024-03-06,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-03-06,22:09:48,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-03-07,19:23:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab), in combination with cisplatin and gemcitabine",PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma"
BMY,2024-03-07,19:23:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab), in combination with cisplatin and gemcitabine",PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma"
BMY,2024-03-07,19:23:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab), in combination with cisplatin and gemcitabine",PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma"
BMY,2024-03-07,19:23:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab), in combination with cisplatin and gemcitabine",PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma"
BMY,2024-03-07,19:23:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab), in combination with cisplatin and gemcitabine",PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma"
BMY,2024-03-07,19:23:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab), in combination with cisplatin and gemcitabine",PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma"
BMY,2024-03-07,19:24:20,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Opdivo in Combination With Cisplatin and Gemcitabine,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Approves Opdivo in Combination With Cisplatin and Gemcitabine for Certain Carcinoma Patients
BMY,2024-03-07,19:24:20,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Opdivo in Combination With Cisplatin and Gemcitabine,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Approves Opdivo in Combination With Cisplatin and Gemcitabine for Certain Carcinoma Patients
BMY,2024-03-07,19:24:20,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Opdivo in Combination With Cisplatin and Gemcitabine,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Approves Opdivo in Combination With Cisplatin and Gemcitabine for Certain Carcinoma Patients
BMY,2024-03-07,19:57:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb said the U.S. Food and Drug Administration approved Opdivo, in combination with cisplatin and gemcitabine",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Combination Gets FDA Approval for Common Type of Bladder Cancer
BMY,2024-03-07,19:57:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb said the U.S. Food and Drug Administration approved Opdivo, in combination with cisplatin and gemcitabine",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Combination Gets FDA Approval for Common Type of Bladder Cancer
BMY,2024-03-07,19:57:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb said the U.S. Food and Drug Administration approved Opdivo, in combination with cisplatin and gemcitabine",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Combination Gets FDA Approval for Common Type of Bladder Cancer
BMY,2024-03-07,20:12:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb said the U.S. Food and Drug Administration approved Opdivo, in combination with cisplatin and gemcitabine",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Combination Gets FDA Approval for Common Type of Bladder Cancer
BMY,2024-03-07,20:12:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb said the U.S. Food and Drug Administration approved Opdivo, in combination with cisplatin and gemcitabine",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Combination Gets FDA Approval for Common Type of Bladder Cancer
BMY,2024-03-07,20:12:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb said the U.S. Food and Drug Administration approved Opdivo, in combination with cisplatin and gemcitabine",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Combination Gets FDA Approval for Common Type of Bladder Cancer
BMY,2024-03-11,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024"
BMY,2024-03-11,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024"
BMY,2024-03-11,20:56:05,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024"
BMY,2024-03-11,20:56:05,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024"
BMY,2024-03-12,21:43:44,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Chmn Caforio Acquires 122,307 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Chmn Caforio Acquires 122,307 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-12,21:46:33,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 45,804 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 45,804 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,00:02:16,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Ceo Boerner Acquires 35,231 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CEO Boerner Acquires 35,231 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,00:03:50,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Gallman Acquires 2,065 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Gallman Acquires 2,065 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,00:06:58,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Officer Hoch Acquires 3,043 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Officer Hoch Acquires 3,043 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,00:32:36,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Holzer Acquires 4,131 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Holzer Acquires 4,131 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,00:41:25,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 24,739 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Acquires 24,739 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,01:14:11,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Poole Acquires 4,083 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Poole Acquires 4,083 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,01:25:30,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Plenge Acquires 7,178 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Plenge Acquires 7,178 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,01:55:22,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Leung Acquires 30,124 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Leung Acquires 30,124 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,01:55:47,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Lenkowsky Acquires 10,693 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Lenkowsky Acquires 10,693 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-15,01:35:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R),PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R) as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2024-03-15,01:35:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi(R) (lisocabtagene maraleucel; Bristol-Myers Squibb Co.:,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R) as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2024-03-15,01:35:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's -2-
BMY,2024-03-15,01:35:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R),NEWS-FLASH,Dow Jones Newswires,U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R) As The First And Only CAR T Cell Therapy For Adults With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Lymphoma (SLL) >BMY
BMY,2024-03-15,09:40:31,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R) as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2024-03-15,09:40:31,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi(R) (lisocabtagene maraleucel; Bristol-Myers Squibb Co.:,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R) as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2024-03-15,09:40:31,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers -2-
BMY,2024-03-15,11:58:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb cell therapy gets FDA green light,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb cell therapy gets FDA green light to treat common type of leukemia
BMY,2024-03-15,11:58:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Co.'s cell therapy Breyanzi won U.S. Food and Drug Administration approval,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb cell therapy gets FDA green light to treat common type of leukemia
BMY,2024-03-15,11:58:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: the company's earnings call last month,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb cell therapy gets FDA green light to treat common type of leukemia
BMY,2024-03-15,11:58:00,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Breyanzi sales growth,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb cell therapy gets FDA green light to treat common type of leukemia
BMY,2024-03-15,22:27:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Committee Votes In Favor Of Bristol Myers Squibb's And 2seventy Bio's Abecma,NEWS-FLASH,Dow Jones Newswires,FDA Advisory Committee Votes In Favor Of Bristol Myers Squibb's And 2seventy Bio's Abecma For Triple-Class Exposed Multiple Myeloma In Earlier Lines Of Therapy >BMY
BMY,2024-03-15,22:27:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma,PRESS-RELEASE,Business Wire,FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
BMY,2024-03-15,22:27:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
BMY,2024-03-15,22:49:42,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approval",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approval"
BMY,2024-03-15,23:04:42,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approval",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approval"
BMY,2024-03-18,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
BMY,2024-03-18,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY),PRESS-RELEASE,GlobeNewswire,Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
BMY,2024-03-18,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
BMY,2024-03-18,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY),PRESS-RELEASE,Dow Jones Newswires,Press Release: Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
BMY,2024-03-18,12:03:28,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Perspective Therapeutics, Bristol Myers Squibb Collaborating to",NEWS-FLASH,Dow Jones Newswires,"Perspective Therapeutics, Bristol Myers Squibb Collaborating to Evaluate Combo of Perspective's [(212) Pb]VMT01 and BMY's Nivolumab in Melanoma Patients >CATX"
BMY,2024-03-18,12:44:00,94637C,Bristol-Myers Squibb Co.,100,0.5,acquisitions-mergers,completed,"Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio"
BMY,2024-03-18,12:44:00,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of -2,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Completes Acquisition of -2-
BMY,2024-03-18,12:44:01,94637C,Bristol-Myers Squibb Co.,100,0.5,acquisitions-mergers,completed,"Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio"
BMY,2024-03-18,12:44:40,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics
BMY,2024-03-18,13:32:35,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of PureTech,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC $14B Acquisition of PRTC's Karuna by BMS Completed
BMY,2024-03-18,13:32:35,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Karuna and BMS teams on,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC $14B Acquisition of PRTC's Karuna by BMS Completed
BMY,2024-03-18,13:32:35,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC $14B Acquisition of PRTC's Karuna by BMS Completed
BMY,2024-03-18,13:32:36,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of PureTech,FULL-ARTICLE,Dow Jones Newswires,PureTech Health PLC $14B Acquisition of PRTC's Karuna by BMS Completed
BMY,2024-03-18,13:32:36,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Karuna and BMS teams on,FULL-ARTICLE,Dow Jones Newswires,PureTech Health PLC $14B Acquisition of PRTC's Karuna by BMS Completed
BMY,2024-03-18,13:32:36,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics,FULL-ARTICLE,Dow Jones Newswires,PureTech Health PLC $14B Acquisition of PRTC's Karuna by BMS Completed
BMY,2024-03-18,13:52:00,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of PureTech,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BMY,2024-03-18,13:52:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Karuna and BMS teams on,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BMY,2024-03-18,13:52:00,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BMY,2024-03-18,13:52:00,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of -2,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Completes Acquisition of -2-
BMY,2024-03-18,13:52:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Completes Acquisition of -2-
BMY,2024-03-18,13:52:00,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition Of PureTech,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Completes Acquisition Of PureTech's Founded Entity Karuna Therapeutics For $14 Billion PRTC.LN
BMY,2024-03-18,13:52:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of PureTech,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BMY,2024-03-18,13:52:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Karuna and BMS teams on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BMY,2024-03-18,13:52:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BMY,2024-03-18,13:52:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Completes -2-
BMY,2024-03-19,10:59:00,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,"Psoriasis, teams up with Bristol Myers Squibb for",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in ""SO, Have You Found It?"" Campaign"
BMY,2024-03-19,11:02:44,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Psoriasis, teams up with Bristol Myers Squibb for",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in ""SO, Have You Found It?"" Campaign"
BMY,2024-03-20,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces CheckMate -9DW -3-
BMY,2024-03-20,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces CheckMate -9DW -3-
BMY,2024-03-20,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces CheckMate -9DW -4-
BMY,2024-03-20,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2024-03-20,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2024-03-20,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2024-03-20,11:30:20,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol Myers said the Phase 3 study evaluating Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Opdivo/Yervoy Combo Hits Main Goal in Liver Cancer
BMY,2024-03-20,11:30:20,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol Myers said the Phase 3 study evaluating Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Opdivo/Yervoy Combo Hits Main Goal in Liver Cancer
BMY,2024-03-20,11:45:20,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol Myers said the Phase 3 study evaluating Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Opdivo/Yervoy Combo Hits Main Goal in Liver Cancer
BMY,2024-03-20,11:45:20,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol Myers said the Phase 3 study evaluating Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Opdivo/Yervoy Combo Hits Main Goal in Liver Cancer
BMY,2024-03-20,20:45:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Abecma,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-03-20,20:45:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Abecma (idecabtagene -2-
BMY,2024-03-20,20:45:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Abecma,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-03-20,20:45:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Abecma -2-
BMY,2024-03-20,21:22:54,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets EU OK for Cancer Treatment,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets EU OK for Cancer Treatment
BMY,2024-03-20,21:37:54,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets EU OK for Cancer Treatment,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets EU OK for Cancer Treatment
BMY,2024-03-25,12:00:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance-,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
BMY,2024-03-25,12:00:00,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at the -3-
BMY,2024-03-25,12:00:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at the -4-
BMY,2024-03-25,12:14:35,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance-,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
BMY,2024-03-25,12:14:35,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2024-03-25,12:14:35,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2024-03-28,20:02:05,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Phase 3 Clinical Trial Evaluating Zeposia,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Phase 3 Clinical Trial Evaluating Zeposia Did Not Meet Its Primary Endpoint >BMY
BMY,2024-03-28,20:05:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: FDA approval of KRAZATI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol-Myers Squibb Co.: The U.S. FDA granted accelerated approval for KRAZATI as a targeted treatment,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:01,94637C,Bristol-Myers Squibb Co.,100,0.44,products-services,conditional,"Bristol-Myers Squibb Co.: In 2023, Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for KRAZATI",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:01,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,The U.S. FDA accepted for priority review the supplemental new drug application (sNDA) for KRAZATI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:01,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,"Bristol-Myers Squibb Co.: In 2022, the FDA granted breakthrough therapy designation for KRAZATI",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:01,94637C,Bristol-Myers Squibb Co.,100,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,0.62,products-services,positive,Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: FDA approval of KRAZATI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol-Myers Squibb Co.: The U.S. FDA granted accelerated approval for KRAZATI as a targeted treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,0.44,products-services,conditional,"Bristol-Myers Squibb Co.: In 2023, Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for KRAZATI",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,The U.S. FDA accepted for priority review the supplemental new drug application (sNDA) for KRAZATI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,"Bristol-Myers Squibb Co.: In 2022, the FDA granted breakthrough therapy designation for KRAZATI",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:07:00,94637C,Bristol-Myers Squibb Co.,100,0.62,products-services,positive,Phase 3 Study Evaluating KRAZATI Met the Primary Endpoint,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Announces That Phase 3 Study Evaluating KRAZATI Met the Primary Endpoint >BMY
BMY,2024-03-28,20:27:47,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Zeposia is approved by regulators,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Drug Misses Endpoint in Crohn's Disease Trial
BMY,2024-03-28,20:42:48,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Zeposia is approved by regulators,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Drug Misses Endpoint in Crohn's Disease Trial
BMY,2024-04-01,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.62,products-services,positive,Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival,PRESS-RELEASE,Business Wire,Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,The U.S. FDA accepted for priority review the supplemental new drug application (sNDA) for KRAZATI,PRESS-RELEASE,Business Wire,Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Krazati was granted accelerated approval,PRESS-RELEASE,Business Wire,Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.44,products-services,conditional,"In 2023, Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for KRAZATI",PRESS-RELEASE,Business Wire,Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Fda granted breakthrough therapy designation for KRAZATI,PRESS-RELEASE,Business Wire,Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:10,94637C,Bristol-Myers Squibb Co.,100,0.62,products-services,positive,Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival,PRESS-RELEASE,Dow Jones Newswires,Press Release: Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:10,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,The U.S. FDA accepted for priority review the supplemental new drug application (sNDA) for KRAZATI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:10,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Krazati was granted accelerated approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:10,94637C,Bristol-Myers Squibb Co.,100,0.44,products-services,conditional,"In 2023, Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for KRAZATI",PRESS-RELEASE,Dow Jones Newswires,Press Release: Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:10,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Fda granted breakthrough therapy designation for KRAZATI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:32:07,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Says Phase 3 Study Evaluating KRAZATI,NEWS-FLASH,Dow Jones Newswires,Zai Lab Partner Bristol Myers Squibb Says Phase 3 Study Evaluating KRAZATI as Monotherapy for Certain Non-Small Cell Lung Cancer Patients Met Primary Endpoint >ZLAB
BMY,2024-04-02,22:47:26,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Shanahan Acquires 2,110 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Shanahan Acquires 2,110 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-04-03,00:08:00,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,Bristol-Myers Squibb Co.: Reblozyl is also approved in the United States,PRESS-RELEASE,Business Wire,European Commission Expands Approval of Bristol Myers Squibb's Reblozyl(R) (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
BMY,2024-04-03,00:08:01,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,Bristol-Myers Squibb Co.: Reblozyl is also approved in the United States,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Commission Expands Approval of Bristol Myers Squibb's Reblozyl(R) (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
BMY,2024-04-03,20:18:36,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Standard BioTools Signs Multi-Year Deal With Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Standard BioTools Signs Multi-Year Deal With Bristol Myers Squibb
BMY,2024-04-05,13:05:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb And 2seventy Bio's Abecma,NEWS-FLASH,Dow Jones Newswires,U.S. FDA Approves Bristol Myers Squibb And 2seventy Bio's Abecma For Triple-Class Exposed Relapsed Or Refractory Multiple Myeloma After Two Prior Lines Of Therapy >BMY
BMY,2024-04-05,13:05:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
BMY,2024-04-05,13:05:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: The companies' broad clinical development program for Abecma,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb and -2-
BMY,2024-04-05,13:05:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb and -2-
BMY,2024-04-05,13:06:53,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
BMY,2024-04-05,13:06:53,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: The companies' broad clinical development program for Abecma,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers -2-
BMY,2024-04-05,13:06:53,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers -2-
BMY,2024-04-06,17:15:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: The consistency of efficacy results across all EMERGENT clinical trial programs,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
BMY,2024-04-06,17:15:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: The consistency of efficacy results across all EMERGENT clinical trial programs,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
BMY,2024-04-18,15:14:46,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
BMY,2024-04-18,15:14:46,94637C,Bristol-Myers Squibb Co.,100,0.38,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $52.00/Share From $51.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $52.00/Share From $51.00 by Wells Fargo
BMY,2024-04-22,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Collaborations between Bristol Myers Squibb and Cellares,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster"
BMY,2024-04-22,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Collaborations between Bristol Myers Squibb and Cellares,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster"
BMY,2024-04-22,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Collaborations between Bristol Myers Squibb and Cellares,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster"
BMY,2024-04-22,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Collaborations between Bristol Myers Squibb and Cellares,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster"
BMY,2024-04-25,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 1Q Rev $11.9B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Rev $11.9B >BMY
BMY,2024-04-25,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb 1Q Loss $11.91B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Loss $11.91B >BMY
BMY,2024-04-25,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb 1Q Loss/Shr $5.89,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Loss/Shr $5.89 >BMY
BMY,2024-04-25,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb 1Q Adj Loss/Shr $4.40,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Adj Loss/Shr $4.40 >BMY
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: FIRST QUARTER RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: First Quarter Revenues were $11.9 Billion, increasing 5%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Non-GAAP Loss Per Share was $(4.40),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Achieved U.S. Approval of Abecma,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Updating 2024 Non-GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the first quarter of 2024,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,equity-actions,,"Bristol-Myers Squibb Co.: On a GAAP basis, income tax expense was $392 million",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: the company reported net loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.65,revenues,up,Bristol-Myers Squibb Co.: Growth Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,"Administration (FDA) approved Opdivo, in combination with cisplatin and gemcitabine",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,"Administration (FDA) approved Opdivo, in combination with cisplatin and gemcitabine",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,"Administration (FDA) approved Opdivo, in combination with cisplatin and gemcitabine",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol-Myers Squibb Co.: Abecma The FDA approved Abecma,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb and Cellares announced a worldwide capacity reservation and supply agreement,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.22,acquisitions-mergers,,Bristol-Myers Squibb Co.: Prioritizing investing in key growth brands;,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: the company's first quarter 2024 earnings conference call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.64,earnings,up,Bristol-Myers Squibb Co.: Non-GAAP EPS was updated,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: 2024 Non-GAAP EPS Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: February Diluted EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Revised Diluted EPS $0.40 - $0.70,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: 2024 line-item guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.68,revenues,down,Bristol-Myers Squibb Co.: Total Revenues Low,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Operating Expenses(1) Low,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $7.10 - $7.40,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2024 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, April 25, 2024, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2024",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -7-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,94,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -7-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: FIRST QUARTER RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: First Quarter Revenues were $11.9 Billion, increasing 5%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Non-GAAP Loss Per Share was $(4.40),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Achieved U.S. Approval of Abecma,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Updating 2024 Non-GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the first quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,equity-actions,,"Bristol-Myers Squibb Co.: On a GAAP basis, income tax expense was $392 million",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: the company reported net loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,98,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,865 $11,337",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -8-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.65,revenues,up,Bristol-Myers Squibb Co.: Growth Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,"Administration (FDA) approved Opdivo, in combination with cisplatin and gemcitabine",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,"Administration (FDA) approved Opdivo, in combination with cisplatin and gemcitabine",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,"Administration (FDA) approved Opdivo, in combination with cisplatin and gemcitabine",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol-Myers Squibb Co.: Abecma The FDA approved Abecma,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb and Cellares announced a worldwide capacity reservation and supply agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.22,acquisitions-mergers,,Bristol-Myers Squibb Co.: Prioritizing investing in key growth brands;,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: the company's first quarter 2024 earnings conference call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.64,earnings,up,Bristol-Myers Squibb Co.: Non-GAAP EPS was updated,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: 2024 Non-GAAP EPS Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: February Diluted EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Revised Diluted EPS $0.40 - $0.70,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: 2024 line-item guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.68,revenues,down,Bristol-Myers Squibb Co.: Total Revenues Low,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Operating Expenses(1) Low,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $7.10 - $7.40,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2024 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, April 25, 2024, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -7-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,94,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -7-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,98,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,865 $11,337",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -8-
BMY,2024-04-25,11:00:45,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb 1Q Growth Portfolio Revenue $4.8B, Up 8%",NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb 1Q Growth Portfolio Revenue $4.8B, Up 8% >BMY"
BMY,2024-04-25,11:02:37,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol-Myers Squibb 1Q U.S. Revenue Rose 7% to $8.5B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q U.S. Revenue Rose 7% to $8.5B >BMY
BMY,2024-04-25,11:03:06,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb reports narrower-than-expected first-quarter loss,FULL-ARTICLE,MarketWatch,"MW Bristol Myers Squibb reports narrower-than-expected first-quarter loss, sales top estimates"
BMY,2024-04-25,11:03:06,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb Co. on Thursday reported better-than-expected,FULL-ARTICLE,MarketWatch,"MW Bristol Myers Squibb reports narrower-than-expected first-quarter loss, sales top estimates"
BMY,2024-04-25,11:03:06,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb Reports Narrower-Than-Expected First-Quarter Loss,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Reports Narrower-Than-Expected First-Quarter Loss, Sales Top Estimates -- MarketWatch"
BMY,2024-04-25,11:03:06,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb Co. on Thursday reported better-than-expected,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Reports Narrower-Than-Expected First-Quarter Loss, Sales Top Estimates -- MarketWatch"
BMY,2024-04-25,11:05:29,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb Cuts 2024 View To EPS 40c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cuts 2024 View To EPS 40c-EPS 70c >BMY
BMY,2024-04-25,11:06:09,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Still Sees 2024 Total Revenue Up,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Still Sees 2024 Total Revenue Up Low-Single Digits >BMY
BMY,2024-04-25,11:37:24,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Cuts '24 EPS View,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss"
BMY,2024-04-25,11:37:24,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb cut its 2024 earnings projection,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss"
BMY,2024-04-25,11:37:24,94637C,Bristol-Myers Squibb Co.,100,0.58,equity-actions,down,Bristol-Myers aims to cut costs,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss"
BMY,2024-04-25,11:52:23,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Cuts '24 EPS View,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss"
BMY,2024-04-25,11:52:23,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb cut its 2024 earnings projection,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss"
BMY,2024-04-25,11:52:23,94637C,Bristol-Myers Squibb Co.,100,0.58,equity-actions,down,Bristol-Myers aims to cut costs,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss"
BMY,2024-04-25,12:12:05,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers Squibb Co.: the company reported better-than-expected first-quarter results,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb shares fall amid sluggish sales of some newer drugs
BMY,2024-04-25,12:36:32,94637C,Bristol-Myers Squibb Co.,100,-0.51,labor-issues,,"Bristol Myers Shedding 2,200 Jobs in",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Shedding 2,200 Jobs in Cost Savings Push"
BMY,2024-04-25,12:36:59,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Cuts Full-Year Earnings Forecast,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com"
BMY,2024-04-25,12:36:59,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers Squibb posted a narrower quarterly loss,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com"
BMY,2024-04-25,12:36:59,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers reported adjusted earnings of $2.05 a share,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com"
BMY,2024-04-25,12:36:59,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers acquired radiopharmaceutical therapeutics company RayzeBio,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com"
BMY,2024-04-25,12:51:31,94637C,Bristol-Myers Squibb Co.,100,-0.51,labor-issues,,"Bristol Myers Shedding 2,200 Jobs in",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Shedding 2,200 Jobs in Cost Savings Push"
BMY,2024-04-25,13:49:39,94637C,Bristol-Myers Squibb Co.,100,-0.51,labor-issues,,"Bristol Myers Squibb to Cut 2,200 Jobs as",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb to Cut 2,200 Jobs as Part of $1.5 Billion Cost-Cutting Effort -- WSJ"
BMY,2024-04-25,14:23:53,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb Cuts '24 EPS Outlook,FULL-ARTICLE,Dow Jones Newswires,"Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts"
BMY,2024-04-25,14:23:53,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers now expects full-year adjusted EPS in the range of 40 cents to 70 cents,FULL-ARTICLE,Dow Jones Newswires,"Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts"
BMY,2024-04-25,14:38:53,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb Cuts '24 EPS Outlook,FULL-ARTICLE,Dow Jones Newswires,"Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts"
BMY,2024-04-25,14:38:53,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers now expects full-year adjusted EPS in the range of 40 cents to 70 cents,FULL-ARTICLE,Dow Jones Newswires,"Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts"
BMY,2024-04-25,15:15:05,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers reported strong sales of $11.87 billion,FULL-ARTICLE,Dow Jones Newswires,Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma -- WSJ
BMY,2024-04-25,15:15:05,94637C,Bristol-Myers Squibb Co.,99,-0.51,labor-issues,,"Bristol Myers will shed 2,200 employees this year",FULL-ARTICLE,Dow Jones Newswires,Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma -- WSJ
BMY,2024-04-25,15:15:05,94637C,Bristol-Myers Squibb Co.,99,0.65,acquisitions-mergers,,"Spree, acquiring Karuna Therapeutics for $14 billion",FULL-ARTICLE,Dow Jones Newswires,Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma -- WSJ
BMY,2024-04-26,06:01:28,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers reported strong sales of $11.87 billion,FULL-ARTICLE,Dow Jones Newswires,Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma ---- By David Wainer
BMY,2024-04-26,06:01:28,94637C,Bristol-Myers Squibb Co.,99,-0.51,labor-issues,,"Bristol-Myers will shed 2,200 employees this year",FULL-ARTICLE,Dow Jones Newswires,Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma ---- By David Wainer
BMY,2024-04-26,06:01:28,94637C,Bristol-Myers Squibb Co.,99,0.65,acquisitions-mergers,,"Spree, acquiring Karuna Therapeutics for $14 billion",FULL-ARTICLE,Dow Jones Newswires,Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma ---- By David Wainer
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and,PRESS-RELEASE,Business Wire,CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: Recommendation based on results from CheckMate -901, the first Phase 3 trial",PRESS-RELEASE,Business Wire,CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved the use of Opdivo,PRESS-RELEASE,Business Wire,CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: Recommendation based on results from CheckMate -901, the first Phase 3 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved the use of Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,13:42:44,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2024-04-26,13:42:44,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $43.00/Share From $51.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $43.00/Share From $51.00 by Barclays
BMY,2024-04-26,18:21:14,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital
BMY,2024-04-26,18:21:14,94637C,Bristol-Myers Squibb Co.,100,-0.8,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $48.00/Share From $55.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $48.00/Share From $55.00 by BMO Capital
BMY,2024-04-29,10:00:05,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for,PRESS-RELEASE,PR Newswire,Repertoire(R) Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
BMY,2024-04-29,10:00:05,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: Our collaboration with Repertoire aims to,PRESS-RELEASE,PR Newswire,Repertoire(R) Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
BMY,2024-04-29,10:00:05,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Repertoire(R) Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
BMY,2024-04-29,10:00:05,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: Our collaboration with Repertoire aims to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Repertoire(R) Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
BMY,2024-04-30,09:00:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Research collaboration with Bristol Myers Squibb (NYSE: BMY) to,PRESS-RELEASE,Business Wire,Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb
BMY,2024-05-01,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration,PRESS-RELEASE,GlobeNewswire,Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
BMY,2024-05-01,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb will have rights to opt-in to such genome editing tools,PRESS-RELEASE,GlobeNewswire,Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
BMY,2024-05-01,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
BMY,2024-05-01,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb will have rights to opt-in to such genome editing tools,PRESS-RELEASE,Dow Jones Newswires,Press Release: Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
BMY,2024-05-01,12:01:51,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Editas Medicine Announces Two-Yr Extension to Collaboration With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Editas Medicine Announces Two-Yr Extension to Collaboration With Bristol Myers Squibb >EDIT
BMY,2024-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
BMY,2024-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2024-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2024-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -4-
BMY,2024-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Application based on results from CheckMate -67T, the first Phase 3 trial",PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
BMY,2024-05-06,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
BMY,2024-05-06,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Application based on results from CheckMate -67T, the first Phase 3 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
BMY,2024-05-06,11:00:04,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers: European Medicines Agency Validates Application for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: European Medicines Agency Validates Application for Opdivo Plus Yervoy for the First-Line Treatment of Adults With Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-05-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-05-07,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-05-10,20:30:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 3 -3-
BMY,2024-05-10,20:30:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 3 -3-
BMY,2024-05-10,20:30:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 3 -4-
BMY,2024-05-10,20:30:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -3-
BMY,2024-05-10,20:30:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -3-
BMY,2024-05-10,20:30:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -4-
BMY,2024-05-10,20:42:19,94637C,Bristol-Myers Squibb Co.,100,-0.65,products-services,negative,Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
BMY,2024-05-10,20:57:19,94637C,Bristol-Myers Squibb Co.,100,-0.65,products-services,negative,Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
BMY,2024-05-10,22:24:13,94637C,Bristol-Myers Squibb Co.,100,0.0,stock-picks,,"Stocks to Watch: FAT Brands, Xponential Fitness, Bristol Myers Squibb",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch: FAT Brands, Xponential Fitness, Bristol Myers Squibb"
BMY,2024-05-13,20:09:12,94637C,Bristol-Myers Squibb Co.,96,0.65,revenues,up,Camzyos sales are growing,FULL-ARTICLE,Dow Jones Newswires,Cytokinetics Slumps Despite 'Pristine' Results For Bristol Myers-Rivaling Heart Drug -- IBD
BMY,2024-05-14,13:47:39,94637C,Bristol-Myers Squibb Co.,96,0.65,revenues,up,Camzyos sales are growing,FULL-ARTICLE,Dow Jones Newswires,Cytokinetics Reverses Higher On 'Pristine' Results For Bristol Myers-Rivaling Heart Drug -- IBD
BMY,2024-05-14,20:02:08,94637C,Bristol-Myers Squibb Co.,96,0.65,revenues,up,Camzyos sales are growing,FULL-ARTICLE,Dow Jones Newswires,Cytokinetics Reverses Higher On 'Pristine' Results For Bristol Myers-Rivaling Heart Drug -- IBD
BMY,2024-05-16,00:57:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Cell Therapy Breyanzi Approved By The U.S. Food And Drug Administration,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved By The U.S. Food And Drug Administration For Relapsed Or Refractory Follicular Lymphoma >BMY
BMY,2024-05-16,00:57:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
BMY,2024-05-16,00:57:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi(R) (lisocabtagene maraleucel; Bristol-Myers Squibb Co.:,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
BMY,2024-05-16,00:57:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's CAR T Cell Therapy -2-
BMY,2024-05-16,00:57:01,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's CAR T Cell Therapy -2-
BMY,2024-05-16,01:05:57,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb: FDA Granted Accelerated Approval for CAR T Cell Therapy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: FDA Granted Accelerated Approval for CAR T Cell Therapy Breyanzi >BMY
BMY,2024-05-16,09:39:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
BMY,2024-05-16,09:39:36,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi(R) (lisocabtagene maraleucel; Bristol-Myers Squibb Co.:,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
BMY,2024-05-16,09:39:36,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's CAR T Cell -2-
BMY,2024-05-16,09:39:36,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's CAR T Cell -2-
BMY,2024-05-16,10:33:58,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets FDA OK of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma
BMY,2024-05-16,10:48:58,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets FDA OK of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: The application is based on results from CheckMate -67T, the first Phase 3 trial",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: The application is based on results from CheckMate -67T, the first Phase 3 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Updated Action -3-
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Updated Action -3-
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Updated Action -3-
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2024-05-22,07:09:24,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2024 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2024 (BMY)"
BMY,2024-05-22,07:30:06,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Additional funding,PRESS-RELEASE,PR Newswire,NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
BMY,2024-05-22,07:30:30,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Additional funding,PRESS-RELEASE,PR Newswire,NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
BMY,2024-05-22,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: The Company enters strategic collaboration with the Access to Oncology Medicines (ATOM) Coalition to,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
BMY,2024-05-22,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: The Company enters strategic collaboration with the Access to Oncology Medicines (ATOM) Coalition to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
BMY,2024-05-22,16:09:09,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: The Company enters strategic collaboration with the Access to Oncology Medicines (ATOM) Coalition to,PRESS-RELEASE,DJ Global Press Release Wire,Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Efficacy and safety data from the Phase 2/3,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms"
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: First results from the Phase 1 study,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms"
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: A phase II/III study of,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -2-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: KRYSTAL-12: Phase 3 Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -3-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -8-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -8-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -8-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -12-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -12-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -13-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -14-
BMY,2024-05-23,21:05:02,94637C,Bristol-Myers Squibb Co.,91,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -16-
BMY,2024-05-23,21:05:02,94637C,Bristol-Myers Squibb Co.,91,0.63,products-services,,Augtyro was also granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -16-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Efficacy and safety data from the Phase 2/3,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms"
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: First results from the Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms"
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: A phase II/III study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -2-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: KRYSTAL-12: Phase 3 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: Phase II study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -8-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -8-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -8-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -12-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -12-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -13-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -14-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,91,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -16-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,91,0.63,products-services,,Augtyro was also granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -16-
BMY,2024-05-28,20:05:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol-Myers Squibb Co.: our agreement with Bristol Myers Squibb in,PRESS-RELEASE,Business Wire,"Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration"
BMY,2024-05-28,20:05:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol-Myers Squibb Co.: our agreement with Bristol Myers Squibb in,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration"
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: Approval based on results from CheckMate -901, the first Phase 3 trial",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: Approval based on results from CheckMate -901, the first Phase 3 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2024-05-29,11:04:37,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination With Cisplatin,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients With Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-29,11:04:37,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination With Cisplatin,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients With Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-30,15:51:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food And Drug Administration Approves Bristol Myers Squibb's Breyanzi,NEWS-FLASH,Dow Jones Newswires,U.S. Food And Drug Administration Approves Bristol Myers Squibb's Breyanzi As A New CAR T Cell Therapy For Relapsed Or Refractory Mantle Cell Lymphoma >BMY
BMY,2024-05-30,15:51:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
BMY,2024-05-30,15:53:39,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Additionally, data from the Phase 3 KRYSTAL-12 study of KRAZATI(R) (adagrasib)",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO(R) Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: Finally, five-year follow-up results",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO(R) Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.63,products-services,,Augtyro was also granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.71,products-services,,Krazati was granted accelerated approval,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.44,products-services,conditional,"In 2024, the European Commission (EC) granted conditional marketing authorization for KRAZATI",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.7,products-services,,"Bristol-Myers Squibb Co.: In 2022, the FDA granted breakthrough therapy designation for KRAZATI",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -4-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -4-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -5-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,97,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -8-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Additionally, data from the Phase 3 KRYSTAL-12 study of KRAZATI(R) (adagrasib)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO(R) Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: Finally, five-year follow-up results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO(R) Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.63,products-services,,Augtyro was also granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.71,products-services,,Krazati was granted accelerated approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.44,products-services,conditional,"In 2024, the European Commission (EC) granted conditional marketing authorization for KRAZATI",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.7,products-services,,"Bristol-Myers Squibb Co.: In 2022, the FDA granted breakthrough therapy designation for KRAZATI",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -5-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,97,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -8-
BMY,2024-06-03,14:13:00,94637C,Bristol-Myers Squibb Co.,95,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO(R) Annual Meeting
BMY,2024-06-03,14:13:00,94637C,Bristol-Myers Squibb Co.,95,0.62,products-services,positive,Breyanzi demonstrated consistent clinical benefit,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO(R) Annual Meeting
BMY,2024-06-03,14:13:00,94637C,Bristol-Myers Squibb Co.,95,0.57,products-services,granted,Fda also granted Breyanzi approval,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO(R) Annual Meeting
BMY,2024-06-03,14:13:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi Demonstrates -2-
BMY,2024-06-03,14:13:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi Demonstrates -3-
BMY,2024-06-03,14:13:01,94637C,Bristol-Myers Squibb Co.,96,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO(R) Annual Meeting
BMY,2024-06-03,14:13:01,94637C,Bristol-Myers Squibb Co.,96,0.62,products-services,positive,Breyanzi demonstrated consistent clinical benefit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO(R) Annual Meeting
BMY,2024-06-03,14:13:01,94637C,Bristol-Myers Squibb Co.,96,0.57,products-services,granted,Fda also granted Breyanzi approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO(R) Annual Meeting
BMY,2024-06-03,14:13:01,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Breyanzi -2-
BMY,2024-06-03,14:13:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Breyanzi -3-
BMY,2024-06-04,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,marketing,,Bristol-Myers Squibb Co.: the company will participate in the Goldman Sachs 45(th) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the Goldman Sachs 45(th) Annual Global Healthcare Conference
BMY,2024-06-04,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BMY,2024-06-04,12:00:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo (nivolumab) -4-
BMY,2024-06-04,12:00:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo (nivolumab) -4-
BMY,2024-06-04,12:00:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo (nivolumab) -4-
BMY,2024-06-05,11:00:09,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,I-Mab Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
BMY,2024-06-05,11:00:09,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY),PRESS-RELEASE,PR Newswire,I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
BMY,2024-06-05,11:00:10,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,I-Mab Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
BMY,2024-06-05,11:00:10,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY),PRESS-RELEASE,Dow Jones Newswires,Press Release: I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
BMY,2024-06-05,11:02:57,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,I-Mab Announces Collaboration With Bristol Myers Squibb to,NEWS-FLASH,Dow Jones Newswires,I-Mab Announces Collaboration With Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
BMY,2024-06-12,05:30:25,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Eqs-News: Evotec SE / Key word(s): Miscellaneous Evotec announces progress in neuroscience collaboration with,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb
BMY,2024-06-12,05:30:25,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb announced that a Phase II study for,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb
BMY,2024-06-12,06:00:21,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Evotec SE: our neuroscience partnership with Bristol Myers Squibb and our shared commitment to innovation and patient care,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2024-06-12,06:00:21,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb announced that a Phase II study for,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2024-06-13,20:46:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"U.S. Food and Drug Administration Approves Augtyro(TM) (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor",PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Approves Augtyro(TM) (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors"
BMY,2024-06-13,20:46:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of,PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Approves Augtyro(TM) (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors"
BMY,2024-06-13,20:46:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"U.S. Food and Drug Administration Approves Augtyro(TM) (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor",PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Augtyro(TM) (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors"
BMY,2024-06-13,20:46:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of,PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Augtyro(TM) (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors"
BMY,2024-06-13,20:46:45,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb: FDA Approves Augtyro,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Approves Augtyro for NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY,2024-06-13,20:47:36,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Fda Granted Accelerated Approval of Augtyro,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Granted Accelerated Approval of Augtyro for Adult and Pediatric Patients 12 Years of Age and Older With Solid Tumors >BMY
BMY,2024-06-13,21:08:48,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval
BMY,2024-06-13,21:23:48,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval
BMY,2024-06-18,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2024-06-18,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on August 1, 2024, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2024-06-18,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2024-06-18,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on August 1, 2024, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2024-06-18,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.47,labor-issues,,Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
BMY,2024-06-18,20:16:01,94637C,Bristol-Myers Squibb Co.,100,0.47,labor-issues,,Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
BMY,2024-06-20,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024"
BMY,2024-06-20,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024"
BMY,2024-06-20,11:07:26,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024"
BMY,2024-06-20,11:07:26,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024"
BMY,2024-06-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
BMY,2024-06-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: Validation is based on results from CheckMate -67T, the first Phase 3 trial",PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
BMY,2024-06-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2024-06-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2024-06-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2024-06-21,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
BMY,2024-06-21,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: Validation is based on results from CheckMate -67T, the first Phase 3 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
BMY,2024-06-21,23:30:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Second FDA approval for KRAZATI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:00,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,"Bristol-Myers Squibb Co.: In 2022, the FDA granted breakthrough therapy designation for KRAZATI",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: The company partnered with QIAGEN to,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval Of KRAZATI(R) (adagrasib),NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval Of KRAZATI(R) (adagrasib) In Combination With Cetuximab For Adult Patients With Previously Treated KRAS G12C-Mutated Locally Advanced Or Metastatic Colorectal Cancer (CRC) >BMY
BMY,2024-06-21,23:30:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Second FDA approval for KRAZATI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:01,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,"Bristol-Myers Squibb Co.: In 2022, the FDA granted breakthrough therapy designation for KRAZATI",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: The company partnered with QIAGEN to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-07-09,10:59:04,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,complete,Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart,PRESS-RELEASE,PR Newswire,Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
BMY,2024-07-09,10:59:04,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,complete,Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart,PRESS-RELEASE,Dow Jones Newswires,Press Release: Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
BMY,2024-07-10,23:41:09,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2024-07-10,23:41:09,94637C,Bristol-Myers Squibb Co.,100,-0.56,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $41.00/Share From $43.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $41.00/Share From $43.00 by Barclays
BMY,2024-07-18,13:15:44,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bms executed a 15-year virtual power purchase agreement,PRESS-RELEASE,DJ Global Press Release Wire,Bristol Myers Squibb Reaches Major Milestone in Environmental Sustainability
BMY,2024-07-19,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Medicines -3-
BMY,2024-07-19,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Medicines -3-
BMY,2024-07-19,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Medicines -4-
BMY,2024-07-19,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2024-07-19,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2024-07-19,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2024-07-23,11:37:31,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Hold by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Hold by Deutsche Bank
BMY,2024-07-23,11:37:31,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $45.00/Share From $53.00 by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $45.00/Share From $53.00 by Deutsche Bank
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q Adj EPS $2.07,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Adj EPS $2.07 >BMY
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: SECOND QUARTER RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Second Quarter Revenues were $12.2 Billion, increasing 9%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS was $0.83,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Achieved U.S. Approval of Breyanzi,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the second quarter of 2024,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 1% to $3.4 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.71,products-services,,The FDA granted accelerated approval for Krazati in combination with cetuximab,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.71,products-services,,The FDA granted accelerated approval for Krazati in combination with cetuximab,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Fda granted accelerated approval (repotrectinib) of Augtyro,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) approved Opdivo in combination with cisplatin and gemcitabine,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) approved Opdivo in combination with cisplatin and gemcitabine,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) approved Opdivo in combination with cisplatin and gemcitabine,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: Krazati Results from the Phase 3 KRYSTAL-12 study evaluating Krazati,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 2Q Rev $12.2B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Rev $12.2B >BMY
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,97,0.71,products-services,,Bristol-Myers Squibb Co.: Breyanzi The FDA granted accelerated approval for Breyanzi,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,97,-0.68,revenues,down,Bristol-Myers Squibb Co.: Total Revenues Low,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,97,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $0.40 - $0.70,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: The 2024 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.58,indexes,,"In June 2024, Bristol Myers Squibb was added to the 2023 Dow Jones Sustainability Index",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q Net $1.68B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Net $1.68B >BMY
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED JUNE 30, 2024",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -6-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE SIX MONTHS ENDED JUNE 30, 2024",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -6-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q EPS 83c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q EPS 83c >BMY
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $12,201 $11,226",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -7-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: SECOND QUARTER RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Second Quarter Revenues were $12.2 Billion, increasing 9%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS was $0.83,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Achieved U.S. Approval of Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the second quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 1% to $3.4 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.71,products-services,,The FDA granted accelerated approval for Krazati in combination with cetuximab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.71,products-services,,The FDA granted accelerated approval for Krazati in combination with cetuximab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Fda granted accelerated approval (repotrectinib) of Augtyro,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) approved Opdivo in combination with cisplatin and gemcitabine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) approved Opdivo in combination with cisplatin and gemcitabine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) approved Opdivo in combination with cisplatin and gemcitabine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: Krazati Results from the Phase 3 KRYSTAL-12 study evaluating Krazati,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,97,0.71,products-services,,Bristol-Myers Squibb Co.: Breyanzi The FDA granted accelerated approval for Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,97,-0.68,revenues,down,Bristol-Myers Squibb Co.: Total Revenues Low,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,97,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $0.40 - $0.70,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: The 2024 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.58,indexes,,"In June 2024, Bristol Myers Squibb was added to the 2023 Dow Jones Sustainability Index",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED JUNE 30, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE SIX MONTHS ENDED JUNE 30, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $12,201 $11,226",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2024-07-26,11:01:15,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb results beat expectations,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb results beat expectations as newer drugs deliver growth
BMY,2024-07-26,11:04:08,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Now Sees 2024 Total Rev Up,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Now Sees 2024 Total Rev Up Upper End of Low Single-Digit Range >BMY
BMY,2024-07-26,11:04:55,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb Raises 2024 View To EPS 60c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raises 2024 View To EPS 60c-EPS 90c Vs Prior Guidance 40c-70c >BMY
BMY,2024-07-26,11:14:09,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb Earnings Easily Beat,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps -- IBD
BMY,2024-07-26,11:14:09,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: the company reported adjusted earnings of $2.07 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps -- IBD
BMY,2024-07-26,11:28:22,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers reported second-quarter adjusted earnings of $2.07 a share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Jumps. A Sales Jump for Eliquis Boosts Earnings. -- Barrons.com
BMY,2024-07-26,11:39:53,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers 2Q Adjusted EPS Tops Views,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:39:53,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers Squibb's second-quarter earnings exceeded Wall Street expectations,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:39:53,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers boosted its 2024 earnings projection,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:39:53,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: The company now expects revenue,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:39:53,94637C,Bristol-Myers Squibb Co.,100,-0.51,labor-issues,,"Bristol-Myers Squibb Co.: In April, the company said it would lay off 2,200 employees",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:54:53,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers 2Q Adjusted EPS Tops Views,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:54:53,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers Squibb's second-quarter earnings exceeded Wall Street expectations,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:54:53,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers boosted its 2024 earnings projection,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:54:53,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: The company now expects revenue,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:54:53,94637C,Bristol-Myers Squibb Co.,100,-0.51,labor-issues,,"Bristol-Myers Squibb Co.: In April, the company said it would lay off 2,200 employees",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,13:53:09,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb 2Q Adj EPS Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb 2Q Adj EPS Beat Expectations
BMY,2024-07-26,13:53:09,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb's second-quarter earnings exceeded Wall Street expectations,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb 2Q Adj EPS Beat Expectations
BMY,2024-07-26,14:08:10,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb 2Q Adjusted EPS Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb 2Q Adjusted EPS Beat Expectations
BMY,2024-07-26,14:08:10,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb's second-quarter earnings exceeded Wall Street expectations,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb 2Q Adjusted EPS Beat Expectations
BMY,2024-07-26,14:51:08,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Opdivo SALES GROW,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD"
BMY,2024-07-26,14:51:08,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Eliquis sales climbed 7%,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD"
BMY,2024-07-26,14:51:08,94637C,Bristol-Myers Squibb Co.,99,0.7,earnings,up,Bristol Myers also raised its outlook for the year,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD"
BMY,2024-07-26,20:16:40,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Opdivo SALES GROW,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD"
BMY,2024-07-26,20:16:40,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Eliquis sales climbed 7%,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD"
BMY,2024-07-26,20:16:40,94637C,Bristol-Myers Squibb Co.,99,0.7,earnings,up,Bristol Myers also raised its outlook for the year,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD"
BMY,2024-07-26,21:24:00,94637C,Bristol-Myers Squibb Co.,92,0.7,earnings,above-expectations,Stronger-than-anticipated earnings from Bristol-Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Health Care Up After Bristol-Myers Earnings -- Health Care Roundup
BMY,2024-07-26,21:39:01,94637C,Bristol-Myers Squibb Co.,92,0.7,earnings,above-expectations,Stronger-than-anticipated earnings from Bristol-Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Health Care Up After Bristol-Myers Earnings -- Health Care Roundup
BMY,2024-07-29,12:22:35,94637C,Bristol-Myers Squibb Co.,100,-0.98,analyst-ratings,negative,Bristol-Myers Squibb Cut to Underweight From Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Underweight From Equal-Weight by Barclays
BMY,2024-08-05,22:02:02,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Gallman Acquires 677 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Gallman Acquires 677 Of Bristol-Myers Squibb Co >BMY
BMY,2024-08-08,05:30:35,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Evotec SE: our neuroscience partnership with Bristol Myers Squibb.,PRESS-RELEASE,DGAP News,EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
BMY,2024-08-08,05:30:35,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Evotec SE: our neuroscience partnership with Bristol Myers Squibb.,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
BMY,2024-08-08,05:31:58,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Evotec SE: our neuroscience partnership with Bristol Myers Squibb.,PRESS-RELEASE,DGAP News,EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
BMY,2024-08-08,05:31:58,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Evotec SE: our neuroscience partnership with Bristol Myers Squibb.,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
BMY,2024-08-08,05:51:19,94637C,Bristol-Myers Squibb Co.,97,0.49,partnerships,,Evotec SE: our neuroscience partnership with Bristol Myers Squibb.,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
BMY,2024-08-08,09:25:55,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Evotec Gets $25 Million From Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Evotec Gets $25 Million From Bristol Myers Squibb Partnership
BMY,2024-08-08,09:40:55,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Evotec Gets $25 Million From Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Evotec Gets $25 Million From Bristol Myers Squibb Partnership
BMY,2024-08-12,15:05:27,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Hold by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Hold by TD Cowen
BMY,2024-08-12,15:05:27,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $53.00/Share From $45.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $53.00/Share From $45.00 by TD Cowen
BMY,2024-08-13,05:30:36,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Evotec SE: the Company has further extended and expanded its partnership with Bristol Myers Squibb,PRESS-RELEASE,DGAP News,EQS-News: Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb
BMY,2024-08-13,05:30:36,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Evotec SE: the Company has further extended and expanded its partnership with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb
BMY,2024-08-13,05:31:43,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Evotec SE: the Company has further extended and expanded its partnership with Bristol Myers Squibb,PRESS-RELEASE,DGAP News,EQS-News: Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb
BMY,2024-08-13,05:31:43,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Evotec SE: the Company has further extended and expanded its partnership with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb
BMY,2024-08-13,06:02:41,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Evotec SE: the Company has further extended and expanded its partnership with Bristol Myers Squibb,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
BMY,2024-08-19,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Breyanzi also received approval,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental New Drug Application for Breyanzi,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:00,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -2-
BMY,2024-08-19,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Breyanzi also received approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental New Drug Application for Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:06,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR,NEWS-FLASH,Dow Jones Newswires,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives U.S. Food and Drug -3-
BMY,2024-08-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives U.S. Food and Drug -3-
BMY,2024-08-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives U.S. Food and Drug -4-
BMY,2024-08-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives U.S. -3-
BMY,2024-08-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives U.S. -3-
BMY,2024-08-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives U.S. -4-
BMY,2024-08-22,07:07:35,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2024 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2024 (BMY)"
BMY,2024-08-22,14:26:29,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Barclays
BMY,2024-08-22,14:26:29,94637C,Bristol-Myers Squibb Co.,100,0.4,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $42.00/Share From $41.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $42.00/Share From $41.00 by Barclays
BMY,2024-08-26,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance on ELIQUIS(R) (apixaban),PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
BMY,2024-08-26,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Johnson & Johnson Collaboration on milvexian,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
BMY,2024-08-26,10:59:00,94637C,Bristol-Myers Squibb Co.,92,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Across -3-
BMY,2024-08-26,10:59:00,94637C,Bristol-Myers Squibb Co.,92,-0.54,products-services,,Bristol-Myers Squibb Co.: TEMPORARY INTERRUPTION,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Across -3-
BMY,2024-08-26,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Across -4-
BMY,2024-08-26,11:03:47,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance on ELIQUIS(R) (apixaban),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
BMY,2024-08-26,11:03:47,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Johnson & Johnson Collaboration on milvexian,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
BMY,2024-08-26,11:03:47,94637C,Bristol-Myers Squibb Co.,92,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2024-08-26,11:03:47,94637C,Bristol-Myers Squibb Co.,92,-0.54,products-services,,Bristol-Myers Squibb Co.: TEMPORARY INTERRUPTION,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2024-08-26,11:03:47,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2024-08-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-08-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-08-28,18:54:33,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Hold by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Hold by Jefferies
BMY,2024-08-28,18:54:33,94637C,Bristol-Myers Squibb Co.,100,0.5,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $51.00/Share From $49.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $51.00/Share From $49.00 by Jefferies
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Efficacy and safety data from the randomized Phase 3,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO -5-
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO -5-
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO -5-
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Efficacy and safety data from the randomized Phase 3,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -5-
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -5-
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -5-
BMY,2024-09-10,21:45:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2024-09-10,21:45:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on November 1, 2024, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2024-09-10,21:45:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2024-09-10,21:45:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on November 1, 2024, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2024-09-12,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024"
BMY,2024-09-12,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024"
BMY,2024-09-12,11:11:14,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024"
BMY,2024-09-12,11:11:14,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024"
BMY,2024-09-15,12:55:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Landmark 10-Year -4-
BMY,2024-09-15,12:55:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Landmark 10-Year -4-
BMY,2024-09-15,12:55:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Landmark 10-Year -4-
BMY,2024-09-16,09:37:23,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2024-09-16,09:37:23,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2024-09-16,09:37:23,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2024-09-23,14:05:42,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital
BMY,2024-09-26,22:56:35,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Bristol-Myers Squibb Schizophrenia Drug,NEWS-FLASH,Dow Jones Newswires,FDA Approves Bristol-Myers Squibb Schizophrenia Drug Cobenfy -- WSJ
BMY,2024-09-26,23:35:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout -- IBD
BMY,2024-09-26,23:35:36,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Karuna Therapeutics, acquired by Bristol Myers in $14 billion",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout -- IBD
BMY,2024-09-27,01:05:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food And Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline,NEWS-FLASH,Dow Jones Newswires,"U.S. Food And Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline And Trospium Chloride), A First-In-Class Muscarinic Agonist For The Treatment Of Schizophrenia In Adults >BMY"
BMY,2024-09-27,06:00:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Puretech-Invented KarXT Receives U.S. Food And Drug Administration Approval,NEWS-FLASH,Dow Jones Newswires,PureTech-Invented KarXT Receives U.S. Food And Drug Administration Approval For The Treatment Of Schizophrenia In Adults >PRTC
BMY,2024-09-27,06:00:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Puretech-Invented KarXT Receives U.S. Food and Drug Administration Approval,PRESS-RELEASE,Business Wire,PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
BMY,2024-09-27,06:00:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Karuna Therapeutics, which was acquired by Bristol Myers Squibb (NYSE: BMY)",PRESS-RELEASE,Business Wire,PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
BMY,2024-09-27,06:00:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Karuna and BMS teams for,PRESS-RELEASE,Business Wire,PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
BMY,2024-09-27,06:00:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Puretech-Invented KarXT Receives U.S. Food and Drug Administration Approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
BMY,2024-09-27,06:00:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Karuna Therapeutics, which was acquired by Bristol Myers Squibb (NYSE: BMY)",PRESS-RELEASE,Dow Jones Newswires,Press Release: PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
BMY,2024-09-27,06:00:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Karuna and BMS teams for,PRESS-RELEASE,Dow Jones Newswires,Press Release: PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
BMY,2024-09-27,09:15:43,94637C,Bristol-Myers Squibb Co.,100,0.0,stock-picks,,"Stocks to Watch Friday: Bristol Myers Squibb, EchoStar, Costco -- WSJ",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Friday: Bristol Myers Squibb, EchoStar, Costco -- WSJ"
BMY,2024-09-27,09:37:39,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline,PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults"
BMY,2024-09-27,13:33:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets FDA Approval for Schizophrenia Drug,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Gets FDA Approval for Schizophrenia Drug
BMY,2024-09-27,13:34:38,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Breaks Out -- IBD
BMY,2024-09-27,13:34:38,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Karuna Therapeutics, acquired by Bristol Myers in $14 billion",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Breaks Out -- IBD
BMY,2024-09-27,13:48:51,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets FDA Approval for Schizophrenia Drug,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Gets FDA Approval for Schizophrenia Drug
BMY,2024-09-27,14:02:59,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital
BMY,2024-09-27,14:02:59,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $53.00/Share From $48.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $53.00/Share From $48.00 by BMO Capital
BMY,2024-09-27,15:06:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data from Two -2-
BMY,2024-09-27,15:06:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data from Two -4-
BMY,2024-09-27,15:10:19,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -2-
BMY,2024-09-27,15:10:19,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -4-
BMY,2024-09-27,23:38:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food And Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline,NEWS-FLASH,Dow Jones Newswires,"U.S. Food And Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline And Trospium Chloride), A First-In-Class Muscarinic Agonist For The Treatment Of Schizophrenia In Adults >BMY"
BMY,2024-09-27,23:38:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline,PRESS-RELEASE,Business Wire,"CORRECTING AND REPLACING/U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults"
BMY,2024-09-30,11:00:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,"Prime Medicine, Inc. (Nasdaq: PRME) today announced a strategic research collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY)",PRESS-RELEASE,GlobeNewswire,Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
BMY,2024-09-30,11:00:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,"Prime Medicine, Inc. (Nasdaq: PRME) today announced a strategic research collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
BMY,2024-09-30,11:01:05,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Prime Medicine Announces Research Collaboration, License Agreement With Bristol Myers Squibb",NEWS-FLASH,Dow Jones Newswires,"Prime Medicine Announces Research Collaboration, License Agreement With Bristol Myers Squibb"
BMY,2024-09-30,15:52:19,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb joined hands with the Emirates Thalassemia Society and Dubai Science Park to,PRESS-RELEASE,PR Newswire,Bristol Myers Squibb Marks 10 Years of Global Patient Week with Community Initiatives in the Region
BMY,2024-09-30,15:55:49,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb joined hands with the Emirates Thalassemia Society and Dubai Science Park to,PRESS-RELEASE,PR Newswire,Bristol Myers Squibb Marks 10 Years of Global Patient Week with Community Initiatives in the Region
BMY,2024-10-03,21:37:31,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb: FDA Approved Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Approved Opdivo for Adult Patients With Resectable Non-Small Cell Lung Cancer >BMY
BMY,2024-10-03,22:35:15,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Gallman Acquires 2,910 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Gallman Acquires 2,910 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-10-07,17:47:42,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Hold by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Hold by TD Cowen
BMY,2024-10-07,17:47:42,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $59.00/Share From $53.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $59.00/Share From $53.00 by TD Cowen
BMY,2024-10-07,18:52:02,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Barclays
BMY,2024-10-07,18:52:02,94637C,Bristol-Myers Squibb Co.,100,0.4,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $43.00/Share From $42.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $43.00/Share From $42.00 by Barclays
BMY,2024-10-08,06:05:58,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol-Myers Squibb acquired Karuna for $14 billion,FULL-ARTICLE,Dow Jones Newswires,Heard on the Street: Alzheimer's Drug Comes Full Circle --- Bristol-Myers' newly approved schizophrenia treatment sparks fresh interest in its first intended use ---- By David Wainer
BMY,2024-10-09,22:13:37,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by UBS
BMY,2024-10-09,22:13:37,94637C,Bristol-Myers Squibb Co.,100,0.7,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $54.00/Share From $50.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $54.00/Share From $50.00 by UBS
BMY,2024-10-17,16:43:25,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Initiated at Market Perform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Market Perform by Bernstein
BMY,2024-10-17,16:43:25,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $56.00/Share by Bernstein,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $56.00/Share by Bernstein
BMY,2024-10-23,05:29:44,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb expand proteomics partnership,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec and Bristol Myers Squibb expand proteomics partnership
BMY,2024-10-23,05:29:44,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb expand proteomics partnership,PRESS-RELEASE,DGAP News,EQS-News: Evotec and Bristol Myers Squibb expand proteomics partnership
BMY,2024-10-23,05:30:43,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb expand proteomics partnership,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec and Bristol Myers Squibb expand proteomics partnership
BMY,2024-10-23,05:30:43,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb expand proteomics partnership,PRESS-RELEASE,DGAP News,EQS-News: Evotec and Bristol Myers Squibb expand proteomics partnership
BMY,2024-10-23,06:01:22,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb Expand Proteomics Partnership,PRESS-RELEASE,DJ Global Press Release Wire,Evotec and Bristol Myers Squibb Expand Proteomics Partnership
BMY,2024-10-25,12:42:02,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Neutral From Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Neutral From Buy by Citigroup
BMY,2024-10-25,12:42:02,94637C,Bristol-Myers Squibb Co.,100,-0.84,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $55.00/Share From $75.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $55.00/Share From $75.00 by Citigroup
BMY,2024-10-28,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: our long-term clinical trials,"" said",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
BMY,2024-10-28,10:59:28,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: our long-term clinical trials,"" said",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
BMY,2024-10-28,22:25:26,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb 2024 Guidance,FULL-ARTICLE,Dow Jones Newswires,Correction to Bristol-Myers Squibb 2024 Guidance Headline on July 26
BMY,2024-10-28,22:25:26,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb Raises 2024 View To EPS 60c,FULL-ARTICLE,Dow Jones Newswires,Correction to Bristol-Myers Squibb 2024 Guidance Headline on July 26
BMY,2024-10-28,22:40:26,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb 2024 Guidance,FULL-ARTICLE,Dow Jones Newswires,Correction to Bristol-Myers Squibb 2024 Guidance Headline on July 26
BMY,2024-10-28,22:40:26,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb Raises 2024 View To EPS 60c,FULL-ARTICLE,Dow Jones Newswires,Correction to Bristol-Myers Squibb 2024 Guidance Headline on July 26
BMY,2024-10-31,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q EPS 60c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q EPS 60c >BMY
BMY,2024-10-31,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q Adj EPS $1.80,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Adj EPS $1.80 >BMY
BMY,2024-10-31,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q Net $1.2B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Net $1.2B >BMY
BMY,2024-10-31,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 3Q Rev $11.9B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Rev $11.9B >BMY
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: THIRD QUARTER RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Third Quarter Revenues were $11.9 Billion, increasing 8%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS was $0.60,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Co.: Raising 2024 Revenue Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,892 $10,966",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -7-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the third quarter of 2024.,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,"Higher demand for Eliquis, partially offset by generic",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,The FDA approved Opdivo for the treatment,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,91,0.62,products-services,positive,Opdivo has previously shown clinical benefit,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,-0.68,revenues,down,Bristol-Myers Squibb Co.: Upper end of low Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,-0.13,equity-actions,up,Bristol-Myers Squibb Co.: Low single-digit Operating Expenses(1) increase 4% to 5%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $0.60 - $0.90,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2024 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -5-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -5-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,92,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -6-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: THIRD QUARTER RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Third Quarter Revenues were $11.9 Billion, increasing 8%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS was $0.60,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Co.: Raising 2024 Revenue Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the third quarter of 2024.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,"Higher demand for Eliquis, partially offset by generic",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,The FDA approved Opdivo for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,91,0.62,products-services,positive,Opdivo has previously shown clinical benefit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -5-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -5-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,92,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -6-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,892 $10,966",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -7-
BMY,2024-10-31,11:02:46,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Raising 2024 Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raising 2024 Rev Guidance to About +5% (+6% Adjusting for Foreign Exchange) >BMY
BMY,2024-10-31,11:03:05,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb Raises FY24 View To Adj EPS 75c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raises FY24 View To Adj EPS 75c-Adj EPS 95c >BMY
BMY,2024-10-31,11:10:37,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers earnings top estimates,FULL-ARTICLE,MarketWatch,MW Bristol Myers earnings top estimates and company raises guidance
BMY,2024-10-31,11:10:37,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Earnings Top Estimates,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Earnings Top Estimates And Company Raises Guidance -- MarketWatch
BMY,2024-10-31,11:13:07,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Earnings Top Q3 Estimates,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance -- IBD
BMY,2024-10-31,11:13:07,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb reported adjusted earnings of $1.80 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance -- IBD
BMY,2024-10-31,11:25:42,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Lifts 2024 Outlook After 3Q Sales,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Lifts 2024 Outlook After 3Q Sales Climb
BMY,2024-10-31,11:25:42,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb bumped full-year guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Lifts 2024 Outlook After 3Q Sales Climb
BMY,2024-10-31,11:25:42,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,"For the third quarter, Bristol-Myers posted a profit of $1.2 billion",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Lifts 2024 Outlook After 3Q Sales Climb
BMY,2024-10-31,11:40:33,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers also raised its full-year 2024 revenue guidance,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Stock Rises After Earnings Beat, Guidance Hike -- Barrons.com"
BMY,2024-10-31,11:40:42,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Lifts 2024 Outlook After 3Q Sales,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Lifts 2024 Outlook After 3Q Sales Climb
BMY,2024-10-31,11:40:42,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb bumped full-year guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Lifts 2024 Outlook After 3Q Sales Climb
BMY,2024-10-31,11:40:42,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,"For the third quarter, Bristol-Myers posted a profit of $1.2 billion",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Lifts 2024 Outlook After 3Q Sales Climb
BMY,2024-10-31,12:15:52,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers also raised its full-year 2024 revenue guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Rises. The Drugmaker Hiked Guidance After Sales Beat. -- Barrons.com
BMY,2024-10-31,14:45:18,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers also raised its full-year 2024 revenue guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Rises. The Drugmaker Hiked Guidance After Sales Beat. -- Barrons.com
BMY,2024-10-31,20:13:39,94637C,Bristol-Myers Squibb Co.,99,0.82,revenues,up,Breyanzi revenue climbed 143%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Screams To A Year-High After Walloping Profit Expectations -- IBD
BMY,2024-10-31,20:13:39,94637C,Bristol-Myers Squibb Co.,99,0.0,analyst-ratings,neutral,He retained his market perform rating on Bristol Myers,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Screams To A Year-High After Walloping Profit Expectations -- IBD
BMY,2024-10-31,20:13:39,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Opdivo sales rose 7%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Screams To A Year-High After Walloping Profit Expectations -- IBD
BMY,2024-10-31,20:16:01,94637C,Bristol-Myers Squibb Co.,97,0.0,products-services,,Bristol-Myers Squibb Co.: The trial enrolled participants,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY(TM) (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
BMY,2024-10-31,20:27:10,94637C,Bristol-Myers Squibb Co.,97,0.0,products-services,,Bristol-Myers Squibb Co.: The trial enrolled participants,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY(TM) (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
BMY,2024-11-01,15:46:29,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital
BMY,2024-11-01,15:46:29,94637C,Bristol-Myers Squibb Co.,100,0.68,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $57.00/Share From $53.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $57.00/Share From $53.00 by BMO Capital
BMY,2024-11-04,16:24:32,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,Vp Holzer Registers 700 Of Bristol-Myers Squibb Co >BMY,RNS-SEC144,Dow Jones Newswires,VP Holzer Registers 700 Of Bristol-Myers Squibb Co >BMY
BMY,2024-11-05,22:00:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-11-05,22:00:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-11-05,22:43:53,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Buys 1,830 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Buys 1,830 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-11-05,22:44:44,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Chmn Boerner Acquires 1,476 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Chmn Boerner Acquires 1,476 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-11-05,22:53:56,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,Vp Holzer Sells 700 Of Bristol-Myers Squibb Co,FULL-ARTICLE,Dow Jones Newswires,VP Holzer Sells 700 Of Bristol-Myers Squibb Co >BMY
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance on ELIQUIS(R) (apixaban),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Johnson & Johnson Collaboration on milvexian,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Pfizer Alliance ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Johnson & Johnson Collaboration ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,92,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued -3-
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.54,products-services,,Bristol-Myers Squibb Co.: TEMPORARY INTERRUPTION,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued -4-
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued -4-
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued -4-
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance on ELIQUIS(R) (apixaban),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Johnson & Johnson Collaboration on milvexian,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Pfizer Alliance ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Johnson & Johnson Collaboration ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,92,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the -3-
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.54,products-services,,Bristol-Myers Squibb Co.: TEMPORARY INTERRUPTION,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the -4-
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the -4-
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the -4-
BMY,2024-11-11,13:00:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab,PRESS-RELEASE,GlobeNewswire,CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
BMY,2024-11-11,13:00:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab,PRESS-RELEASE,GlobeNewswire,CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
BMY,2024-11-11,13:00:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab,PRESS-RELEASE,Dow Jones Newswires,Press Release: CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
BMY,2024-11-11,13:00:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab,PRESS-RELEASE,Dow Jones Newswires,Press Release: CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
BMY,2024-11-11,15:13:40,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol Myers, AbbVie acquired emraclidine's maker, Cerevel Therapeutics for $8.7 billion",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails -- IBD
BMY,2024-11-11,15:47:29,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,Bristol Myers acquired the drug after buying developer Karuna Therapeutics in 2023,FULL-ARTICLE,Dow Jones Newswires,AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. -- Barrons.com
BMY,2024-11-11,16:00:25,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"In September, the U.S. Food and Drug Administration approved Bristol Myers Squibb's (BMY) schizophrenia drug",FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
BMY,2024-11-12,13:05:11,94637C,Bristol-Myers Squibb Co.,100,0.94,analyst-ratings,positive,Bristol-Myers Squibb Raised to Outperform From Market Perform by Leerink,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raised to Outperform From Market Perform by Leerink Partners
BMY,2024-11-12,13:05:11,94637C,Bristol-Myers Squibb Co.,100,0.8,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $73.00/Share From $55.00 by Leerink,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $73.00/Share From $55.00 by Leerink Partners
BMY,2024-11-12,13:37:19,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2024-11-12,13:37:19,94637C,Bristol-Myers Squibb Co.,100,0.72,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $39.00/Share From $36.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $39.00/Share From $36.00 by Morgan Stanley
BMY,2024-11-12,16:38:49,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital
BMY,2024-11-12,16:38:49,94637C,Bristol-Myers Squibb Co.,100,0.66,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $61.00/Share From $57.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $61.00/Share From $57.00 by BMO Capital
BMY,2024-11-12,19:07:19,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by Citigroup
BMY,2024-11-12,19:07:19,94637C,Bristol-Myers Squibb Co.,100,0.74,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $60.00/Share From $55.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $60.00/Share From $55.00 by Citigroup
BMY,2024-11-15,10:29:15,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Initiated at Peer Perform by Wolfe Research,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Peer Perform by Wolfe Research
BMY,2024-11-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval for repotrectinib,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,2023 the U.S. Food and Drug Administration approved Augtyro(R) (repotrectinib),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.63,products-services,,Repotrectinib was granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval for repotrectinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,2023 the U.S. Food and Drug Administration approved Augtyro(R) (repotrectinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.63,products-services,,Repotrectinib was granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:05,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,12:01:57,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Gets Positive CHMP Opinion for Augtyro,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets Positive CHMP Opinion for Augtyro in Two Indications >BMY
BMY,2024-11-15,12:34:13,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,The U.S. Food and Drug Administration last year approved Augtyro,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug
BMY,2024-11-15,12:34:13,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,Bristol Myers reported Augtyro sales of $23 million for the first nine months of 2024,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug
BMY,2024-11-15,12:49:13,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,The U.S. Food and Drug Administration last year approved Augtyro,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug
BMY,2024-11-15,12:49:13,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,Bristol Myers reported Augtyro sales of $23 million for the first nine months of 2024,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug
BMY,2024-11-15,13:23:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-11-15,13:23:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-11-15,13:23:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2024-11-15,13:23:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2024-11-15,13:23:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2024-11-15,13:23:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-11-15,13:23:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-11-15,13:23:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2024-11-15,13:23:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2024-11-15,13:23:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2024-11-15,13:23:57,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol-Myers Squibb Gets Positive CHMP Opinion for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Gets Positive CHMP Opinion for Opdivo Plus Yervoy for First-Line Treatment of Adult Patients With Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer >BMY
BMY,2024-11-19,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: First OS and progression-free survival results from a Phase 1 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
BMY,2024-11-19,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Presentations at ASH 2024 -5-
BMY,2024-11-19,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Presentations at ASH 2024 -5-
BMY,2024-11-19,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Presentations at ASH 2024 -6-
BMY,2024-11-19,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Presentations at ASH 2024 -6-
BMY,2024-11-19,11:59:38,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: First OS and progression-free survival results from a Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
BMY,2024-11-19,11:59:38,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's -5-
BMY,2024-11-19,11:59:38,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's -5-
BMY,2024-11-19,11:59:38,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's -6-
BMY,2024-11-19,11:59:38,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's -6-
BMY,2024-11-20,02:43:43,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,,Bristol-MYERS SQUIBB CANADA WINS THE 2024 PRIX GALIEN INNOVATIVE PRODUCT AWARD,PRESS-RELEASE,Canadian News Wire,BRISTOL-MYERS SQUIBB CANADA WINS THE 2024 PRIX GALIEN INNOVATIVE PRODUCT AWARD
BMY,2024-11-22,08:06:25,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2024 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2024 (BMY)"
BMY,2024-12-03,13:00:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: We are excited to partner with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M
BMY,2024-12-09,22:45:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Updated Phase 1 data for CD19 NEX-T(R) CAR T cell,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
BMY,2024-12-09,22:45:01,94637C,Bristol-Myers Squibb Co.,98,0.0,products-services,,Bristol-Myers Squibb Co.: Updated Data of Phase 1 Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Highlights Progress of Cell -2-
BMY,2024-12-09,22:45:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Highlights Progress of Cell -3-
BMY,2024-12-09,22:45:01,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Highlights Progress of Cell -3-
BMY,2024-12-09,22:45:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Highlights Progress of Cell -4-
BMY,2024-12-09,22:51:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Updated Phase 1 data for CD19 NEX-T(R) CAR T cell,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
BMY,2024-12-09,22:51:00,94637C,Bristol-Myers Squibb Co.,98,0.0,products-services,,Bristol-Myers Squibb Co.: Updated Data of Phase 1 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Highlights -2-
BMY,2024-12-09,22:51:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Highlights -3-
BMY,2024-12-09,22:51:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Highlights -3-
BMY,2024-12-09,22:51:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Highlights -4-
BMY,2024-12-10,12:50:27,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $63.00/Share by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $63.00/Share by B of A Securities
BMY,2024-12-11,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Announces Dividend Increase,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Dividend Increase >BMY
BMY,2024-12-11,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Announces Dividend Increase,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2024-12-11,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2024-12-11,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on February 3, 2025, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2024-12-11,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Announces Dividend Increase,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2024-12-11,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2024-12-11,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on February 3, 2025, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2024-12-11,21:17:49,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Raises Quarterly Dividend to 62c Vs. 60c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raises Quarterly Dividend to 62c Vs. 60c >BMY
BMY,2024-12-16,13:19:01,94637C,Bristol-Myers Squibb Co.,100,0.94,analyst-ratings,positive,Bristol-Myers Squibb Raised to Buy From Hold by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raised to Buy From Hold by Jefferies
BMY,2024-12-16,13:19:01,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $70.00/Share From $63.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $70.00/Share From $63.00 by Jefferies
BMY,2024-12-18,14:00:02,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,"Insitro Inc.: our partnership with Bristol Myers Squibb scientists and leaders, who understood and invested in our vision",PRESS-RELEASE,Business Wire,insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS
BMY,2024-12-19,04:41:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare,PRESS-RELEASE,PR Newswire,Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare
BMY,2024-12-19,04:41:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare,PRESS-RELEASE,Dow Jones Newswires,Press Release: Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare
BMY,2024-12-19,06:30:10,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bioarctic announces global license agreement with Bristol Myers Squibb,PRESS-RELEASE,Cision News,BioArctic: BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
BMY,2024-12-19,06:30:10,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bioarctic announces global license agreement with Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,BioArctic: BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
BMY,2024-12-19,06:48:29,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bioarctic announces global license agreement with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
BMY,2024-12-19,06:48:30,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bioarctic announces global license agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
BMY,2024-12-19,06:51:48,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bioarctic Enters Global License Agreement With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,BioArctic Enters Global License Agreement With Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta Antibody Program
BMY,2024-12-19,06:52:36,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bioarctic announces global license agreement with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
BMY,2024-12-19,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025"
BMY,2024-12-19,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025"
BMY,2024-12-19,12:05:44,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025"
BMY,2024-12-19,12:05:44,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025"
BMY,2024-12-23,11:45:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-12-23,11:45:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-12-23,11:45:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2024-12-23,11:45:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2024-12-23,11:45:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2024-12-23,11:45:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-12-23,11:45:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-12-23,11:45:16,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo Plus Yervoy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo Plus Yervoy for the First-Line Treatment of Adult Patients With Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-12-23,11:45:16,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo Plus Yervoy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo Plus Yervoy for the First-Line Treatment of Adult Patients With Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-12-23,12:41:51,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,The Food and Drug Administration in September 2022 approved Sotyktu,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis
BMY,2024-12-23,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.88,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
BMY,2024-12-23,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: These topline results represent the first Phase 3 clinical trials,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
BMY,2024-12-23,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline -2-
BMY,2024-12-23,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.88,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
BMY,2024-12-23,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: These topline results represent the first Phase 3 clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
BMY,2024-12-23,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2024-12-23,11:59:30,94637C,Bristol-Myers Squibb Co.,100,0.88,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results From Two Pivotal Phase 3 Trials Evaluating Sotyktu,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Positive Topline Results From Two Pivotal Phase 3 Trials Evaluating Sotyktu in Adults With Psoriatic Arthritis >BMY
BMY,2024-12-23,12:00:16,94637C,Bristol-Myers Squibb Co.,100,0.62,products-services,positive,Bristol-Myers: Phase 3 Studies of Sotyktu in Psoriatic Arthritis Met Primary Endpoint,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers: Phase 3 Studies of Sotyktu in Psoriatic Arthritis Met Primary Endpoint >BMY
BMY,2024-12-23,12:26:51,94637C,Bristol-Myers Squibb Co.,100,0.62,products-services,positive,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis
BMY,2024-12-23,12:26:51,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,The Food and Drug Administration in September 2022 approved Sotyktu,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis
BMY,2024-12-23,12:26:51,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers reported Sotyktu sales of $163 million for the first nine months of 2024,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis
BMY,2024-12-23,12:41:51,94637C,Bristol-Myers Squibb Co.,100,0.62,products-services,positive,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis
BMY,2024-12-23,12:41:51,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers reported Sotyktu sales of $163 million for the first nine months of 2024,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis
BMY,2024-12-27,22:37:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo,PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Approves Opdivo Qvantig(TM) (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo(R) (nivolumab) Indications1,2"
BMY,2024-12-27,22:37:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo -2-
BMY,2024-12-27,22:37:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo -4-
BMY,2024-12-27,22:37:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo -5-
BMY,2024-12-27,22:37:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo -6-
BMY,2024-12-27,22:37:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo -7-
BMY,2024-12-27,22:37:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo -8-
BMY,2024-12-27,22:57:55,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives FDA Approval for Cancer Treatment,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Receives FDA Approval for Cancer Treatment
BMY,2024-12-27,23:03:59,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo,PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Opdivo Qvantig(TM) (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo(R) (nivolumab) Indications1,2"
BMY,2024-12-27,23:12:55,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives FDA Approval for Cancer Treatment,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Receives FDA Approval for Cancer Treatment
BMY,2024-12-30,11:30:03,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approval Of Bristol Myers Squibb's Opdivo,NEWS-FLASH,Dow Jones Newswires,Halozyme Announces FDA Approval Of Bristol Myers Squibb's Opdivo Qvantig(TM) With ENHANZE(R) For Subcutaneous Use In Most Previously Approved Adult Solid Tumor Opdivo(R) (nivolumab) Indications >HALO
BMY,2024-12-30,11:30:03,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approval of Bristol Myers Squibb's Opdivo,PRESS-RELEASE,PR Newswire,Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig(TM) with ENHANZE(R) for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo(R) (nivolumab) Indications
BMY,2024-12-30,11:30:03,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approval of Bristol Myers Squibb's Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig(TM) with ENHANZE(R) for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo(R) (nivolumab) Indications
BMY,2024-01-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
BMY,2024-01-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The clinical trial results with repotrectinib,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
BMY,2024-01-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
BMY,2024-01-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The clinical trial results with repotrectinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
BMY,2024-01-02,11:59:20,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib,NEWS-FLASH,Dow Jones Newswires,European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
BMY,2024-01-02,12:48:20,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol Myers Squibb's application seeking approval of repotrectinib,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Augtyro Advances in Europe -- Market Talk
BMY,2024-01-02,12:48:20,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol Myers Squibb's application seeking approval of repotrectinib,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Augtyro Advances in Europe -- Market Talk
BMY,2024-01-03,14:17:47,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Neutral From Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Neutral From Buy by B of A Securities
BMY,2024-01-03,14:17:47,94637C,Bristol-Myers Squibb Co.,100,-0.8,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $60.00/Share From $68.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $60.00/Share From $68.00 by B of A Securities
BMY,2024-01-03,15:01:00,94637C,Bristol-Myers Squibb Co.,91,-0.58,analyst-ratings,negative,Bank of America downgrades Bristol-Myers Squibb to neutral from buy,FULL-ARTICLE,Dow Jones Newswires,Exclusivity Loss Concerns Sideline a Bristol-Myers Bull -- Market Talk
BMY,2024-01-03,15:01:00,94637C,Bristol-Myers Squibb Co.,91,-0.58,analyst-ratings,negative,Bank of America downgrades Bristol-Myers Squibb to neutral from buy,FULL-ARTICLE,Dow Jones Newswires,Exclusivity Loss Concerns Sideline a Bristol-Myers Bull -- Market Talk
BMY,2024-01-03,15:28:34,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol Myers Squibb downgraded to neutral from buy at BofA Securities,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb downgraded to neutral from buy at BofA Securities
BMY,2024-01-08,06:51:13,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Bristol Myers Squibb and Evotec extended and expanded this partnership,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
BMY,2024-01-08,06:51:13,94637C,Bristol-Myers Squibb Co.,98,0.0,products-services,,Bristol Myers Squibb announced that a Phase II study for,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
BMY,2024-01-17,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO GU 2024 -4-
BMY,2024-01-17,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO GU 2024 -4-
BMY,2024-01-17,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO GU 2024 -4-
BMY,2024-01-17,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -4-
BMY,2024-01-17,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -4-
BMY,2024-01-17,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -4-
BMY,2024-01-23,13:30:00,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio"
BMY,2024-01-23,13:30:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio"
BMY,2024-01-23,13:30:30,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Abecma,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Abecma is also approved in Japan,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Abecma,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Abecma is also approved in Japan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,12:13:53,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-01-26,20:44:39,94637C,Bristol-Myers Squibb Co.,100,-0.48,government,,"Merck, J&J, Bristol Myers CEOs to Testify in Congress",FULL-ARTICLE,Dow Jones Newswires,"Merck, J&J, Bristol Myers CEOs to Testify in Congress on Drug Prices"
BMY,2024-01-26,20:59:38,94637C,Bristol-Myers Squibb Co.,100,-0.48,government,,"Merck, J&J, Bristol Myers CEOs to Testify in Congress",FULL-ARTICLE,Dow Jones Newswires,"Merck, J&J, Bristol Myers CEOs to Testify in Congress on Drug Prices"
BMY,2024-01-30,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted both applications Priority Review,PRESS-RELEASE,Business Wire,Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
BMY,2024-01-30,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: A sBLA for Breyanzi,PRESS-RELEASE,Business Wire,Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
BMY,2024-01-30,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
BMY,2024-01-30,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted both applications Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
BMY,2024-01-30,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: A sBLA for Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
BMY,2024-01-30,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
BMY,2024-01-30,12:38:42,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Two Added Breyanzi Indications
BMY,2024-01-30,12:53:42,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Two Added Breyanzi Indications
BMY,2024-01-30,14:31:02,94637C,Bristol-Myers Squibb Co.,100,0.5,stock-picks,buy,"Thinking about buying stock in Agape ATP, Tempest Therapeutics, Nu Holdings, Bristol-Myers Squibb, or Petros Pharmaceuticals?",PRESS-RELEASE,PR Newswire,"Thinking about buying stock in Agape ATP, Tempest Therapeutics, Nu Holdings, Bristol-Myers Squibb, or Petros Pharmaceuticals?"
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Net $1.76B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Net $1.76B >BMY
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q EPS 87c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q EPS 87c >BMY
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Adj EPS $1.70,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Adj EPS $1.70 >BMY
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 4Q Rev $11.48B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Rev $11.48B >BMY
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers Squibb posted fourth quarter revenues of $11.5 billion, an increase of 1%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS of $0.87,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Reports Full-Year Revenues of $45.0 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol-Myers Squibb Co.: Completes Purchase of Mirati Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Provides 2024 Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Non-GAAP EPS Range $7.10 to $7.40,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.9 billion compared to $1.7 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: International revenues were $975 million compared to $970 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Augtyro received U.S. regulatory approval in non-small cell lung cancer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted both applications Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.57,products-services,granted,Bristol-Myers Squibb Co.: Abecma Japan's MHLW granted manufacturing and marketing approval of the sNDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: FULL YEAR FINANCIAL RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,revenues,,Bristol-Myers Squibb Co.: FULL YEAR PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 1% to $31.6 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Revlimid worldwide revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Revenues for in-line products were $34.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $8.6 billion compared to $7.8 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues increased 10% to $5.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers Squibb Co.: The company agreed to acquire Karuna Therapeutics, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: Karuna's New Drug Application for KarXT,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers Squibb Co.: the company agreed to acquire RayzeBio, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol-Myers Squibb Co.: The company reached an exclusive license and collaboration agreement with SystImmune,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,"Bristol-Myers Squibb Co.: On January 23, 2024, the company announced it had successfully completed its acquisition of Mirati Therapeutics, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,dividends,,"Bristol-Myers Squibb Co.: In December, the company announced that the Board declared a quarterly dividend of $0.60",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,dividends,up,Bristol-Myers Squibb Co.: the company has increased its dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,approved,"Bristol-Myers Squibb Co.: in December, the company announced that the Board authorized the repurchase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total 2024 revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2024 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, February 2, 2024, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.87 $ 0.96 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED DECEMBER 31, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,Bristol-Myers Squibb Co.: New Product Portfolio Reblozyl,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products(b) Revlimid,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products(b) Revlimid,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -9-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,92,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $31,555 $13,451",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -9-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,477 $11,406",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -10-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-MYERS SQUIBB COMPANY 2024 FULL YEAR FINANCIAL GUIDANCE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -11-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers Squibb posted fourth quarter revenues of $11.5 billion, an increase of 1%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS of $0.87,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Reports Full-Year Revenues of $45.0 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol-Myers Squibb Co.: Completes Purchase of Mirati Therapeutics,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Provides 2024 Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Non-GAAP EPS Range $7.10 to $7.40,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.9 billion compared to $1.7 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: International revenues were $975 million compared to $970 million,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Augtyro received U.S. regulatory approval in non-small cell lung cancer,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted both applications Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.57,products-services,granted,Bristol-Myers Squibb Co.: Abecma Japan's MHLW granted manufacturing and marketing approval of the sNDA,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: FULL YEAR FINANCIAL RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,revenues,,Bristol-Myers Squibb Co.: FULL YEAR PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 1% to $31.6 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Revlimid worldwide revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Revenues for in-line products were $34.3 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $8.6 billion compared to $7.8 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues increased 10% to $5.3 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers Squibb Co.: The company agreed to acquire Karuna Therapeutics, Inc.",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: Karuna's New Drug Application for KarXT,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers Squibb Co.: the company agreed to acquire RayzeBio, Inc.",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol-Myers Squibb Co.: The company reached an exclusive license and collaboration agreement with SystImmune,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,"Bristol-Myers Squibb Co.: On January 23, 2024, the company announced it had successfully completed its acquisition of Mirati Therapeutics, Inc.",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,dividends,,"Bristol-Myers Squibb Co.: In December, the company announced that the Board declared a quarterly dividend of $0.60",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,dividends,up,Bristol-Myers Squibb Co.: the company has increased its dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,approved,"Bristol-Myers Squibb Co.: in December, the company announced that the Board authorized the repurchase",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total 2024 revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2024 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -6-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, February 2, 2024, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -6-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -7-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.87 $ 0.96 $,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED DECEMBER 31, 2023",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,Bristol-Myers Squibb Co.: New Product Portfolio Reblozyl,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products(b) Revlimid,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2023",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -8-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products(b) Revlimid,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -9-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,92,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $31,555 $13,451",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -9-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,477 $11,406",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -10-
BMY,2024-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-MYERS SQUIBB COMPANY 2024 FULL YEAR FINANCIAL GUIDANCE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -11-
BMY,2024-02-02,12:01:24,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb results top expectations,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb results top expectations as newer drugs help fuel growth
BMY,2024-02-02,12:01:24,94637C,Bristol-Myers Squibb Co.,100,-0.5,revenues,down,Revlimid sales fell 36%,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb results top expectations as newer drugs help fuel growth
BMY,2024-02-02,12:01:24,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb results top expectations,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb results top expectations as newer drugs help fuel growth
BMY,2024-02-02,12:01:24,94637C,Bristol-Myers Squibb Co.,100,-0.5,revenues,down,Revlimid sales fell 36%,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb results top expectations as newer drugs help fuel growth
BMY,2024-02-02,12:04:58,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Sees Total 2024 Rev to Increase,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees Total 2024 Rev to Increase by Low Single-Digits >BMY
BMY,2024-02-02,12:31:17,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol Myers Squibb 4Q Revenue Boosted,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb 4Q Revenue Boosted by Eliquis, Opdivo"
BMY,2024-02-02,12:31:17,94637C,Bristol-Myers Squibb Co.,100,-0.67,earnings,down,Bristol Myers Squibb's profit fell in the fourth quarter,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb 4Q Revenue Boosted by Eliquis, Opdivo"
BMY,2024-02-02,12:38:44,94637C,Bristol-Myers Squibb Co.,93,0.7,earnings,above-expectations,Bristol Myers Squibb beat earnings and revenue expectations in the fourth quarter,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' New Drugs Drive Upbeat Outlook. The Stock Is On the Mend. -- Barrons.com
BMY,2024-02-02,12:38:44,94637C,Bristol-Myers Squibb Co.,93,0.68,revenues,up,Revenue from Bristol Myers' new product portfolio jumped 66% to $1.1 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' New Drugs Drive Upbeat Outlook. The Stock Is On the Mend. -- Barrons.com
BMY,2024-02-02,12:46:17,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol Myers Squibb 4Q Revenue Boosted,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb 4Q Revenue Boosted by Eliquis, Opdivo"
BMY,2024-02-02,12:46:17,94637C,Bristol-Myers Squibb Co.,100,-0.67,earnings,down,Bristol Myers Squibb's profit fell in the fourth quarter,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb 4Q Revenue Boosted by Eliquis, Opdivo"
BMY,2024-02-02,13:04:37,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb reported adjusted earnings of $1.70 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Shares Rise On Fourth-Quarter Earnings Beat -- IBD
BMY,2024-02-02,13:04:37,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Factset expected Bristol Myers to earn $1.55 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Shares Rise On Fourth-Quarter Earnings Beat -- IBD
BMY,2024-02-02,15:36:51,94637C,Bristol-Myers Squibb Co.,98,0.61,earnings,positive,Bristol-Myers Squibb earned $1.70 per share,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Stock Yo-Yoes, Trying To Avoid A Fourth Day In The Red, On So-So Earnings -- IBD"
BMY,2024-02-02,15:36:51,94637C,Bristol-Myers Squibb Co.,98,0.0,earnings,,Bristol-Myers also issued guidance for 2024,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Stock Yo-Yoes, Trying To Avoid A Fourth Day In The Red, On So-So Earnings -- IBD"
BMY,2024-02-02,19:11:00,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb's fourth-quarter earnings topped Wall Street,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb Earnings Top Expectations
BMY,2024-02-02,19:26:00,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb's fourth-quarter earnings topped Wall Street,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb Earnings Top Expectations
BMY,2024-02-06,00:11:56,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Meyers Acquires 1,789 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Meyers Acquires 1,789 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-02-06,11:37:02,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Neutral From Buy,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Neutral From Buy by Redburn Atlantic
BMY,2024-02-06,11:37:02,94637C,Bristol-Myers Squibb Co.,100,-0.84,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $54.00/Share From $77.00 by Redburn Atlantic,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $54.00/Share From $77.00 by Redburn Atlantic
BMY,2024-02-06,16:25:22,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
BMY,2024-02-06,16:25:23,94637C,Bristol-Myers Squibb Co.,100,-0.8,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $51.00/Share From $58.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $51.00/Share From $58.00 by Wells Fargo
BMY,2024-02-07,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Applications based on results from CheckMate -77T, the company's second positive Phase 3 randomized trial",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
BMY,2024-02-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Acceptance of U.S. -3-
BMY,2024-02-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Acceptance of U.S. -3-
BMY,2024-02-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Acceptance of U.S. -4-
BMY,2024-02-07,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Applications based on results from CheckMate -77T, the company's second positive Phase 3 randomized trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
BMY,2024-02-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2024-02-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2024-02-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2024-02-12,18:47:27,94637C,Bristol-Myers Squibb Co.,100,0.29,credit-ratings,confirmation,Moody's Confirms Bristol-Myers Squibb At A2,NEWS-FLASH,Dow Jones Newswires,Moody's Confirms Bristol-Myers Squibb At A2; Outlook Is Negative
BMY,2024-02-13,13:00:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Enters Collaboration With Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence
BMY,2024-02-14,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro(TM) (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY,2024-02-14,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,2023 the U.S. Food and Drug Administration approved Augtyro,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro(TM) (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY,2024-02-14,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.63,products-services,,Augtyro was also granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro(TM) (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY,2024-02-14,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro(TM) (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY,2024-02-14,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,2023 the U.S. Food and Drug Administration approved Augtyro,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro(TM) (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY,2024-02-14,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.63,products-services,,Augtyro was also granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro(TM) (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY,2024-02-14,12:25:25,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Bristol Myers's $4.1 billion acquisition of Turning Point Therapeutics in 2022,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Speedy FDA Review of Expanded Augtyro Use
BMY,2024-02-14,12:40:25,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Bristol Myers's $4.1 billion acquisition of Turning Point Therapeutics in 2022,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Speedy FDA Review of Expanded Augtyro Use
BMY,2024-02-14,14:45:11,94637C,Bristol-Myers Squibb Co.,100,0.26,credit-ratings,set,S&PGR Rates Bristol-Myers Squibb's Senior Unsecured Notes 'A,NEWS-FLASH,Dow Jones Newswires,S&PGR Rates Bristol-Myers Squibb's Senior Unsecured Notes 'A'
BMY,2024-02-14,14:45:11,94637C,Bristol-Myers Squibb Co.,100,-0.38,credit-ratings,downgrade,S&PGR Rates Bristol-Myers Squibb's Senior Unsecured Notes 'A,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Rates Bristol-Myers Squibb's Senior Unsecured Notes 'A'
BMY,2024-02-14,14:45:11,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,Bristol-Myers Squibb Co.: rising demand for the company's other leading products,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Rates Bristol-Myers Squibb's Senior Unsecured Notes 'A'
BMY,2024-02-14,15:24:02,94637C,Bristol-Myers Squibb Co.,100,0.26,credit-ratings,set,Moody's Assigns A2 Rating To Bristol-Myers Squibb's Sr. Notes,NEWS-FLASH,Dow Jones Newswires,Moody's Assigns A2 Rating To Bristol-Myers Squibb's Sr. Notes; Outlook Is Negative
BMY,2024-02-14,18:45:05,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Bristol-Myers issued in October backing another purchase--Mirati Therapeutics,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Is on a Borrowing Binge -- WSJ
BMY,2024-02-15,00:57:00,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
BMY,2024-02-15,00:57:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb's acquisition of Karuna is,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
BMY,2024-02-15,00:57:01,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
BMY,2024-02-15,00:57:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb's acquisition of Karuna is,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
BMY,2024-02-15,01:10:16,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb: Will Issue $500M of Floating Rate Notes,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: Will Issue $500M of Floating Rate Notes Due 2026 >BMY
BMY,2024-02-15,21:58:38,94637C,Bristol-Myers Squibb Co.,98,0.53,labor-issues,,Appointed Senior Vice President and Controller of Bristol-Myers Squibb Company,RNS-SEC8K,Dow Jones Newswires,"Bristol-Myers Squibb Files 8K - Director, Officer or Compensation Filing >BMY"
BMY,2024-02-20,12:56:57,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Bristol Myers acquired in a deal that closed in January,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Priority FDA Review of Expanded Krazati Use
BMY,2024-02-20,13:11:57,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Bristol Myers acquired in a deal that closed in January,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Priority FDA Review of Expanded Krazati Use
BMY,2024-02-22,08:10:40,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2023 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2023 (BMY)"
BMY,2024-02-22,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE:BMY),PRESS-RELEASE,Dow Jones Newswires,Press Release: Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE:BMY),PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE:BMY),PRESS-RELEASE,GlobeNewswire,Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE:BMY),PRESS-RELEASE,Dow Jones Newswires,Press Release: Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
BMY,2024-02-22,12:04:43,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Immunocore Announces Clinical Trial Collaboration and Supply Agreement With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Immunocore Announces Clinical Trial Collaboration and Supply Agreement With Bristol Myers Squibb to Evaluate IMC-F106C With Nivolumab in Its Registrational Phase 3 First-Line Advanced Cutaneous Melanoma Trial
BMY,2024-02-22,21:16:50,94637C,Bristol-Myers Squibb Co.,99,0.54,equity-actions,completed,"Bristol-Myers Squibb Co.: the ""Company"") completed the public offering",RNS-SEC8K,Dow Jones Newswires,Bristol-Myers Squibb Files 8K - Other Events >BMY
BMY,2024-02-22,21:16:50,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: the Company's proposed acquisitions of Karuna Therapeutics, Inc.",RNS-SEC8K,Dow Jones Newswires,Bristol-Myers Squibb Files 8K - Other Events >BMY
BMY,2024-02-23,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
BMY,2024-02-23,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
BMY,2024-02-23,11:59:27,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl for Treatment of Adults With Transfusion-Dependent Anemia Due to Low- to Intermediate-Risk Myelodysplastic Syndromes
BMY,2024-02-26,13:35:00,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition Of RayzeBio,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Completes Acquisition Of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform >BMY"
BMY,2024-02-26,13:35:00,94637C,Bristol-Myers Squibb Co.,100,0.82,acquisitions-mergers,completed,"Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB)",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform"
BMY,2024-02-26,13:35:01,94637C,Bristol-Myers Squibb Co.,100,0.82,acquisitions-mergers,completed,"Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB)",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform"
BMY,2024-03-01,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2024-03-01,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on May 1, 2024, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2024-03-01,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2024-03-01,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on May 1, 2024, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2024-03-06,12:30:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Partnership between Agenus and Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
BMY,2024-03-06,12:30:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Partnership between Agenus and Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
BMY,2024-03-06,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-03-06,22:09:48,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-03-07,19:23:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab), in combination with cisplatin and gemcitabine",PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma"
BMY,2024-03-07,19:23:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab), in combination with cisplatin and gemcitabine",PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma"
BMY,2024-03-07,19:23:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab), in combination with cisplatin and gemcitabine",PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma"
BMY,2024-03-07,19:23:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab), in combination with cisplatin and gemcitabine",PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma"
BMY,2024-03-07,19:23:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab), in combination with cisplatin and gemcitabine",PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma"
BMY,2024-03-07,19:23:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab), in combination with cisplatin and gemcitabine",PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma"
BMY,2024-03-07,19:24:20,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Opdivo in Combination With Cisplatin and Gemcitabine,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Approves Opdivo in Combination With Cisplatin and Gemcitabine for Certain Carcinoma Patients
BMY,2024-03-07,19:24:20,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Opdivo in Combination With Cisplatin and Gemcitabine,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Approves Opdivo in Combination With Cisplatin and Gemcitabine for Certain Carcinoma Patients
BMY,2024-03-07,19:24:20,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Opdivo in Combination With Cisplatin and Gemcitabine,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Approves Opdivo in Combination With Cisplatin and Gemcitabine for Certain Carcinoma Patients
BMY,2024-03-07,19:57:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb said the U.S. Food and Drug Administration approved Opdivo, in combination with cisplatin and gemcitabine",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Combination Gets FDA Approval for Common Type of Bladder Cancer
BMY,2024-03-07,19:57:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb said the U.S. Food and Drug Administration approved Opdivo, in combination with cisplatin and gemcitabine",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Combination Gets FDA Approval for Common Type of Bladder Cancer
BMY,2024-03-07,19:57:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb said the U.S. Food and Drug Administration approved Opdivo, in combination with cisplatin and gemcitabine",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Combination Gets FDA Approval for Common Type of Bladder Cancer
BMY,2024-03-07,20:12:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb said the U.S. Food and Drug Administration approved Opdivo, in combination with cisplatin and gemcitabine",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Combination Gets FDA Approval for Common Type of Bladder Cancer
BMY,2024-03-07,20:12:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb said the U.S. Food and Drug Administration approved Opdivo, in combination with cisplatin and gemcitabine",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Combination Gets FDA Approval for Common Type of Bladder Cancer
BMY,2024-03-07,20:12:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers Squibb said the U.S. Food and Drug Administration approved Opdivo, in combination with cisplatin and gemcitabine",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Combination Gets FDA Approval for Common Type of Bladder Cancer
BMY,2024-03-11,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024"
BMY,2024-03-11,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024"
BMY,2024-03-11,20:56:05,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024"
BMY,2024-03-11,20:56:05,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024"
BMY,2024-03-12,21:43:44,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Chmn Caforio Acquires 122,307 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Chmn Caforio Acquires 122,307 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-12,21:46:33,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 45,804 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 45,804 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,00:02:16,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Ceo Boerner Acquires 35,231 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CEO Boerner Acquires 35,231 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,00:03:50,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Gallman Acquires 2,065 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Gallman Acquires 2,065 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,00:06:58,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Officer Hoch Acquires 3,043 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Officer Hoch Acquires 3,043 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,00:32:36,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Holzer Acquires 4,131 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Holzer Acquires 4,131 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,00:41:25,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 24,739 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Acquires 24,739 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,01:14:11,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Poole Acquires 4,083 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Poole Acquires 4,083 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,01:25:30,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Plenge Acquires 7,178 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Plenge Acquires 7,178 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,01:55:22,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Leung Acquires 30,124 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Leung Acquires 30,124 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-13,01:55:47,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Lenkowsky Acquires 10,693 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Lenkowsky Acquires 10,693 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-03-15,01:35:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R),PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R) as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2024-03-15,01:35:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi(R) (lisocabtagene maraleucel; Bristol-Myers Squibb Co.:,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R) as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2024-03-15,01:35:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's -2-
BMY,2024-03-15,01:35:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R),NEWS-FLASH,Dow Jones Newswires,U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R) As The First And Only CAR T Cell Therapy For Adults With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Lymphoma (SLL) >BMY
BMY,2024-03-15,09:40:31,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R) as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2024-03-15,09:40:31,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi(R) (lisocabtagene maraleucel; Bristol-Myers Squibb Co.:,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers Squibb's Breyanzi(R) as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2024-03-15,09:40:31,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers -2-
BMY,2024-03-15,11:58:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb cell therapy gets FDA green light,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb cell therapy gets FDA green light to treat common type of leukemia
BMY,2024-03-15,11:58:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Co.'s cell therapy Breyanzi won U.S. Food and Drug Administration approval,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb cell therapy gets FDA green light to treat common type of leukemia
BMY,2024-03-15,11:58:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: the company's earnings call last month,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb cell therapy gets FDA green light to treat common type of leukemia
BMY,2024-03-15,11:58:00,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Breyanzi sales growth,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb cell therapy gets FDA green light to treat common type of leukemia
BMY,2024-03-15,22:27:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Committee Votes In Favor Of Bristol Myers Squibb's And 2seventy Bio's Abecma,NEWS-FLASH,Dow Jones Newswires,FDA Advisory Committee Votes In Favor Of Bristol Myers Squibb's And 2seventy Bio's Abecma For Triple-Class Exposed Multiple Myeloma In Earlier Lines Of Therapy >BMY
BMY,2024-03-15,22:27:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma,PRESS-RELEASE,Business Wire,FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
BMY,2024-03-15,22:27:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
BMY,2024-03-15,22:49:42,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approval",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approval"
BMY,2024-03-15,23:04:42,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approval",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approval"
BMY,2024-03-18,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
BMY,2024-03-18,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY),PRESS-RELEASE,GlobeNewswire,Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
BMY,2024-03-18,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
BMY,2024-03-18,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY),PRESS-RELEASE,Dow Jones Newswires,Press Release: Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
BMY,2024-03-18,12:03:28,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Perspective Therapeutics, Bristol Myers Squibb Collaborating to",NEWS-FLASH,Dow Jones Newswires,"Perspective Therapeutics, Bristol Myers Squibb Collaborating to Evaluate Combo of Perspective's [(212) Pb]VMT01 and BMY's Nivolumab in Melanoma Patients >CATX"
BMY,2024-03-18,12:44:00,94637C,Bristol-Myers Squibb Co.,100,0.5,acquisitions-mergers,completed,"Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio"
BMY,2024-03-18,12:44:00,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of -2,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Completes Acquisition of -2-
BMY,2024-03-18,12:44:01,94637C,Bristol-Myers Squibb Co.,100,0.5,acquisitions-mergers,completed,"Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio"
BMY,2024-03-18,12:44:40,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics
BMY,2024-03-18,13:32:35,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of PureTech,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC $14B Acquisition of PRTC's Karuna by BMS Completed
BMY,2024-03-18,13:32:35,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Karuna and BMS teams on,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC $14B Acquisition of PRTC's Karuna by BMS Completed
BMY,2024-03-18,13:32:35,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC $14B Acquisition of PRTC's Karuna by BMS Completed
BMY,2024-03-18,13:32:36,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of PureTech,FULL-ARTICLE,Dow Jones Newswires,PureTech Health PLC $14B Acquisition of PRTC's Karuna by BMS Completed
BMY,2024-03-18,13:32:36,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Karuna and BMS teams on,FULL-ARTICLE,Dow Jones Newswires,PureTech Health PLC $14B Acquisition of PRTC's Karuna by BMS Completed
BMY,2024-03-18,13:32:36,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics,FULL-ARTICLE,Dow Jones Newswires,PureTech Health PLC $14B Acquisition of PRTC's Karuna by BMS Completed
BMY,2024-03-18,13:52:00,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of PureTech,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BMY,2024-03-18,13:52:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Karuna and BMS teams on,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BMY,2024-03-18,13:52:00,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BMY,2024-03-18,13:52:00,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of -2,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Completes Acquisition of -2-
BMY,2024-03-18,13:52:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Completes Acquisition of -2-
BMY,2024-03-18,13:52:00,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition Of PureTech,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Completes Acquisition Of PureTech's Founded Entity Karuna Therapeutics For $14 Billion PRTC.LN
BMY,2024-03-18,13:52:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of PureTech,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BMY,2024-03-18,13:52:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Karuna and BMS teams on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BMY,2024-03-18,13:52:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BMY,2024-03-18,13:52:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Completes -2-
BMY,2024-03-19,10:59:00,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,"Psoriasis, teams up with Bristol Myers Squibb for",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in ""SO, Have You Found It?"" Campaign"
BMY,2024-03-19,11:02:44,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Psoriasis, teams up with Bristol Myers Squibb for",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in ""SO, Have You Found It?"" Campaign"
BMY,2024-03-20,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces CheckMate -9DW -3-
BMY,2024-03-20,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces CheckMate -9DW -3-
BMY,2024-03-20,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces CheckMate -9DW -4-
BMY,2024-03-20,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2024-03-20,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2024-03-20,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2024-03-20,11:30:20,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol Myers said the Phase 3 study evaluating Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Opdivo/Yervoy Combo Hits Main Goal in Liver Cancer
BMY,2024-03-20,11:30:20,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol Myers said the Phase 3 study evaluating Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Opdivo/Yervoy Combo Hits Main Goal in Liver Cancer
BMY,2024-03-20,11:45:20,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol Myers said the Phase 3 study evaluating Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Opdivo/Yervoy Combo Hits Main Goal in Liver Cancer
BMY,2024-03-20,11:45:20,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol Myers said the Phase 3 study evaluating Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Opdivo/Yervoy Combo Hits Main Goal in Liver Cancer
BMY,2024-03-20,20:45:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Abecma,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-03-20,20:45:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Abecma (idecabtagene -2-
BMY,2024-03-20,20:45:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Abecma,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
BMY,2024-03-20,20:45:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Abecma -2-
BMY,2024-03-20,21:22:54,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets EU OK for Cancer Treatment,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets EU OK for Cancer Treatment
BMY,2024-03-20,21:37:54,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets EU OK for Cancer Treatment,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets EU OK for Cancer Treatment
BMY,2024-03-25,12:00:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance-,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
BMY,2024-03-25,12:00:00,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at the -3-
BMY,2024-03-25,12:00:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at the -4-
BMY,2024-03-25,12:14:35,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance-,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
BMY,2024-03-25,12:14:35,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2024-03-25,12:14:35,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2024-03-28,20:02:05,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Phase 3 Clinical Trial Evaluating Zeposia,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Phase 3 Clinical Trial Evaluating Zeposia Did Not Meet Its Primary Endpoint >BMY
BMY,2024-03-28,20:05:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: FDA approval of KRAZATI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol-Myers Squibb Co.: The U.S. FDA granted accelerated approval for KRAZATI as a targeted treatment,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:01,94637C,Bristol-Myers Squibb Co.,100,0.44,products-services,conditional,"Bristol-Myers Squibb Co.: In 2023, Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for KRAZATI",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:01,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,The U.S. FDA accepted for priority review the supplemental new drug application (sNDA) for KRAZATI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:01,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,"Bristol-Myers Squibb Co.: In 2022, the FDA granted breakthrough therapy designation for KRAZATI",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:01,94637C,Bristol-Myers Squibb Co.,100,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,0.62,products-services,positive,Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: FDA approval of KRAZATI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol-Myers Squibb Co.: The U.S. FDA granted accelerated approval for KRAZATI as a targeted treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,0.44,products-services,conditional,"Bristol-Myers Squibb Co.: In 2023, Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for KRAZATI",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,The U.S. FDA accepted for priority review the supplemental new drug application (sNDA) for KRAZATI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,"Bristol-Myers Squibb Co.: In 2022, the FDA granted breakthrough therapy designation for KRAZATI",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:05:02,94637C,Bristol-Myers Squibb Co.,100,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
BMY,2024-03-28,20:07:00,94637C,Bristol-Myers Squibb Co.,100,0.62,products-services,positive,Phase 3 Study Evaluating KRAZATI Met the Primary Endpoint,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Announces That Phase 3 Study Evaluating KRAZATI Met the Primary Endpoint >BMY
BMY,2024-03-28,20:27:47,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Zeposia is approved by regulators,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Drug Misses Endpoint in Crohn's Disease Trial
BMY,2024-03-28,20:42:48,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Zeposia is approved by regulators,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Drug Misses Endpoint in Crohn's Disease Trial
BMY,2024-04-01,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.62,products-services,positive,Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival,PRESS-RELEASE,Business Wire,Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,The U.S. FDA accepted for priority review the supplemental new drug application (sNDA) for KRAZATI,PRESS-RELEASE,Business Wire,Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Krazati was granted accelerated approval,PRESS-RELEASE,Business Wire,Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.44,products-services,conditional,"In 2023, Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for KRAZATI",PRESS-RELEASE,Business Wire,Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Fda granted breakthrough therapy designation for KRAZATI,PRESS-RELEASE,Business Wire,Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS(G12C) -Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:10,94637C,Bristol-Myers Squibb Co.,100,0.62,products-services,positive,Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival,PRESS-RELEASE,Dow Jones Newswires,Press Release: Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:10,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,The U.S. FDA accepted for priority review the supplemental new drug application (sNDA) for KRAZATI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:10,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Krazati was granted accelerated approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:10,94637C,Bristol-Myers Squibb Co.,100,0.44,products-services,conditional,"In 2023, Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for KRAZATI",PRESS-RELEASE,Dow Jones Newswires,Press Release: Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:30:10,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Fda granted breakthrough therapy designation for KRAZATI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
BMY,2024-04-01,11:32:07,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Says Phase 3 Study Evaluating KRAZATI,NEWS-FLASH,Dow Jones Newswires,Zai Lab Partner Bristol Myers Squibb Says Phase 3 Study Evaluating KRAZATI as Monotherapy for Certain Non-Small Cell Lung Cancer Patients Met Primary Endpoint >ZLAB
BMY,2024-04-02,22:47:26,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Shanahan Acquires 2,110 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Shanahan Acquires 2,110 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-04-03,00:08:00,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,Bristol-Myers Squibb Co.: Reblozyl is also approved in the United States,PRESS-RELEASE,Business Wire,European Commission Expands Approval of Bristol Myers Squibb's Reblozyl(R) (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
BMY,2024-04-03,00:08:01,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,Bristol-Myers Squibb Co.: Reblozyl is also approved in the United States,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Commission Expands Approval of Bristol Myers Squibb's Reblozyl(R) (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
BMY,2024-04-03,20:18:36,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Standard BioTools Signs Multi-Year Deal With Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Standard BioTools Signs Multi-Year Deal With Bristol Myers Squibb
BMY,2024-04-05,13:05:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb And 2seventy Bio's Abecma,NEWS-FLASH,Dow Jones Newswires,U.S. FDA Approves Bristol Myers Squibb And 2seventy Bio's Abecma For Triple-Class Exposed Relapsed Or Refractory Multiple Myeloma After Two Prior Lines Of Therapy >BMY
BMY,2024-04-05,13:05:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
BMY,2024-04-05,13:05:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: The companies' broad clinical development program for Abecma,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb and -2-
BMY,2024-04-05,13:05:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb and -2-
BMY,2024-04-05,13:06:53,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
BMY,2024-04-05,13:06:53,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: The companies' broad clinical development program for Abecma,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers -2-
BMY,2024-04-05,13:06:53,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers -2-
BMY,2024-04-06,17:15:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: The consistency of efficacy results across all EMERGENT clinical trial programs,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
BMY,2024-04-06,17:15:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: The consistency of efficacy results across all EMERGENT clinical trial programs,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
BMY,2024-04-18,15:14:46,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
BMY,2024-04-18,15:14:46,94637C,Bristol-Myers Squibb Co.,100,0.38,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $52.00/Share From $51.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $52.00/Share From $51.00 by Wells Fargo
BMY,2024-04-22,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Collaborations between Bristol Myers Squibb and Cellares,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster"
BMY,2024-04-22,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Collaborations between Bristol Myers Squibb and Cellares,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster"
BMY,2024-04-22,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Collaborations between Bristol Myers Squibb and Cellares,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster"
BMY,2024-04-22,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Collaborations between Bristol Myers Squibb and Cellares,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster"
BMY,2024-04-25,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 1Q Rev $11.9B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Rev $11.9B >BMY
BMY,2024-04-25,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb 1Q Loss $11.91B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Loss $11.91B >BMY
BMY,2024-04-25,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb 1Q Loss/Shr $5.89,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Loss/Shr $5.89 >BMY
BMY,2024-04-25,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb 1Q Adj Loss/Shr $4.40,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Adj Loss/Shr $4.40 >BMY
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: FIRST QUARTER RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: First Quarter Revenues were $11.9 Billion, increasing 5%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Non-GAAP Loss Per Share was $(4.40),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Achieved U.S. Approval of Abecma,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Updating 2024 Non-GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the first quarter of 2024,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,equity-actions,,"Bristol-Myers Squibb Co.: On a GAAP basis, income tax expense was $392 million",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: the company reported net loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.65,revenues,up,Bristol-Myers Squibb Co.: Growth Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,"Administration (FDA) approved Opdivo, in combination with cisplatin and gemcitabine",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,"Administration (FDA) approved Opdivo, in combination with cisplatin and gemcitabine",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,"Administration (FDA) approved Opdivo, in combination with cisplatin and gemcitabine",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol-Myers Squibb Co.: Abecma The FDA approved Abecma,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb and Cellares announced a worldwide capacity reservation and supply agreement,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.22,acquisitions-mergers,,Bristol-Myers Squibb Co.: Prioritizing investing in key growth brands;,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: the company's first quarter 2024 earnings conference call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.64,earnings,up,Bristol-Myers Squibb Co.: Non-GAAP EPS was updated,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: 2024 Non-GAAP EPS Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: February Diluted EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Revised Diluted EPS $0.40 - $0.70,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: 2024 line-item guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.68,revenues,down,Bristol-Myers Squibb Co.: Total Revenues Low,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Operating Expenses(1) Low,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $7.10 - $7.40,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2024 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, April 25, 2024, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2024",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -7-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,94,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -7-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: FIRST QUARTER RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: First Quarter Revenues were $11.9 Billion, increasing 5%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Non-GAAP Loss Per Share was $(4.40),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Achieved U.S. Approval of Abecma,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Updating 2024 Non-GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the first quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,equity-actions,,"Bristol-Myers Squibb Co.: On a GAAP basis, income tax expense was $392 million",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: the company reported net loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,98,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,865 $11,337",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -8-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.65,revenues,up,Bristol-Myers Squibb Co.: Growth Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,"Administration (FDA) approved Opdivo, in combination with cisplatin and gemcitabine",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,"Administration (FDA) approved Opdivo, in combination with cisplatin and gemcitabine",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,"Administration (FDA) approved Opdivo, in combination with cisplatin and gemcitabine",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol-Myers Squibb Co.: Abecma The FDA approved Abecma,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb and Cellares announced a worldwide capacity reservation and supply agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.22,acquisitions-mergers,,Bristol-Myers Squibb Co.: Prioritizing investing in key growth brands;,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: the company's first quarter 2024 earnings conference call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.64,earnings,up,Bristol-Myers Squibb Co.: Non-GAAP EPS was updated,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: 2024 Non-GAAP EPS Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: February Diluted EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Revised Diluted EPS $0.40 - $0.70,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: 2024 line-item guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.68,revenues,down,Bristol-Myers Squibb Co.: Total Revenues Low,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Operating Expenses(1) Low,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $7.10 - $7.40,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2024 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, April 25, 2024, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -7-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,94,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -7-
BMY,2024-04-25,10:59:01,94637C,Bristol-Myers Squibb Co.,98,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,865 $11,337",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -8-
BMY,2024-04-25,11:00:45,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb 1Q Growth Portfolio Revenue $4.8B, Up 8%",NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb 1Q Growth Portfolio Revenue $4.8B, Up 8% >BMY"
BMY,2024-04-25,11:02:37,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol-Myers Squibb 1Q U.S. Revenue Rose 7% to $8.5B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q U.S. Revenue Rose 7% to $8.5B >BMY
BMY,2024-04-25,11:03:06,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb reports narrower-than-expected first-quarter loss,FULL-ARTICLE,MarketWatch,"MW Bristol Myers Squibb reports narrower-than-expected first-quarter loss, sales top estimates"
BMY,2024-04-25,11:03:06,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb Co. on Thursday reported better-than-expected,FULL-ARTICLE,MarketWatch,"MW Bristol Myers Squibb reports narrower-than-expected first-quarter loss, sales top estimates"
BMY,2024-04-25,11:03:06,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb Reports Narrower-Than-Expected First-Quarter Loss,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Reports Narrower-Than-Expected First-Quarter Loss, Sales Top Estimates -- MarketWatch"
BMY,2024-04-25,11:03:06,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb Co. on Thursday reported better-than-expected,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Reports Narrower-Than-Expected First-Quarter Loss, Sales Top Estimates -- MarketWatch"
BMY,2024-04-25,11:05:29,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb Cuts 2024 View To EPS 40c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cuts 2024 View To EPS 40c-EPS 70c >BMY
BMY,2024-04-25,11:06:09,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Still Sees 2024 Total Revenue Up,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Still Sees 2024 Total Revenue Up Low-Single Digits >BMY
BMY,2024-04-25,11:37:24,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Cuts '24 EPS View,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss"
BMY,2024-04-25,11:37:24,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb cut its 2024 earnings projection,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss"
BMY,2024-04-25,11:37:24,94637C,Bristol-Myers Squibb Co.,100,0.58,equity-actions,down,Bristol-Myers aims to cut costs,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss"
BMY,2024-04-25,11:52:23,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Cuts '24 EPS View,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss"
BMY,2024-04-25,11:52:23,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb cut its 2024 earnings projection,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss"
BMY,2024-04-25,11:52:23,94637C,Bristol-Myers Squibb Co.,100,0.58,equity-actions,down,Bristol-Myers aims to cut costs,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss"
BMY,2024-04-25,12:12:05,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers Squibb Co.: the company reported better-than-expected first-quarter results,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb shares fall amid sluggish sales of some newer drugs
BMY,2024-04-25,12:36:32,94637C,Bristol-Myers Squibb Co.,100,-0.51,labor-issues,,"Bristol Myers Shedding 2,200 Jobs in",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Shedding 2,200 Jobs in Cost Savings Push"
BMY,2024-04-25,12:36:59,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Cuts Full-Year Earnings Forecast,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com"
BMY,2024-04-25,12:36:59,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers Squibb posted a narrower quarterly loss,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com"
BMY,2024-04-25,12:36:59,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers reported adjusted earnings of $2.05 a share,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com"
BMY,2024-04-25,12:36:59,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers acquired radiopharmaceutical therapeutics company RayzeBio,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com"
BMY,2024-04-25,12:51:31,94637C,Bristol-Myers Squibb Co.,100,-0.51,labor-issues,,"Bristol Myers Shedding 2,200 Jobs in",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Shedding 2,200 Jobs in Cost Savings Push"
BMY,2024-04-25,13:49:39,94637C,Bristol-Myers Squibb Co.,100,-0.51,labor-issues,,"Bristol Myers Squibb to Cut 2,200 Jobs as",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb to Cut 2,200 Jobs as Part of $1.5 Billion Cost-Cutting Effort -- WSJ"
BMY,2024-04-25,14:23:53,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb Cuts '24 EPS Outlook,FULL-ARTICLE,Dow Jones Newswires,"Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts"
BMY,2024-04-25,14:23:53,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers now expects full-year adjusted EPS in the range of 40 cents to 70 cents,FULL-ARTICLE,Dow Jones Newswires,"Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts"
BMY,2024-04-25,14:38:53,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb Cuts '24 EPS Outlook,FULL-ARTICLE,Dow Jones Newswires,"Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts"
BMY,2024-04-25,14:38:53,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers now expects full-year adjusted EPS in the range of 40 cents to 70 cents,FULL-ARTICLE,Dow Jones Newswires,"Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts"
BMY,2024-04-25,15:15:05,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers reported strong sales of $11.87 billion,FULL-ARTICLE,Dow Jones Newswires,Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma -- WSJ
BMY,2024-04-25,15:15:05,94637C,Bristol-Myers Squibb Co.,99,-0.51,labor-issues,,"Bristol Myers will shed 2,200 employees this year",FULL-ARTICLE,Dow Jones Newswires,Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma -- WSJ
BMY,2024-04-25,15:15:05,94637C,Bristol-Myers Squibb Co.,99,0.65,acquisitions-mergers,,"Spree, acquiring Karuna Therapeutics for $14 billion",FULL-ARTICLE,Dow Jones Newswires,Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma -- WSJ
BMY,2024-04-26,06:01:28,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers reported strong sales of $11.87 billion,FULL-ARTICLE,Dow Jones Newswires,Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma ---- By David Wainer
BMY,2024-04-26,06:01:28,94637C,Bristol-Myers Squibb Co.,99,-0.51,labor-issues,,"Bristol-Myers will shed 2,200 employees this year",FULL-ARTICLE,Dow Jones Newswires,Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma ---- By David Wainer
BMY,2024-04-26,06:01:28,94637C,Bristol-Myers Squibb Co.,99,0.65,acquisitions-mergers,,"Spree, acquiring Karuna Therapeutics for $14 billion",FULL-ARTICLE,Dow Jones Newswires,Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma ---- By David Wainer
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and,PRESS-RELEASE,Business Wire,CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: Recommendation based on results from CheckMate -901, the first Phase 3 trial",PRESS-RELEASE,Business Wire,CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved the use of Opdivo,PRESS-RELEASE,Business Wire,CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: Recommendation based on results from CheckMate -901, the first Phase 3 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved the use of Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-04-26,13:42:44,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2024-04-26,13:42:44,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $43.00/Share From $51.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $43.00/Share From $51.00 by Barclays
BMY,2024-04-26,18:21:14,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital
BMY,2024-04-26,18:21:14,94637C,Bristol-Myers Squibb Co.,100,-0.8,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $48.00/Share From $55.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $48.00/Share From $55.00 by BMO Capital
BMY,2024-04-29,10:00:05,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for,PRESS-RELEASE,PR Newswire,Repertoire(R) Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
BMY,2024-04-29,10:00:05,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: Our collaboration with Repertoire aims to,PRESS-RELEASE,PR Newswire,Repertoire(R) Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
BMY,2024-04-29,10:00:05,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Repertoire(R) Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
BMY,2024-04-29,10:00:05,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: Our collaboration with Repertoire aims to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Repertoire(R) Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
BMY,2024-04-30,09:00:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Research collaboration with Bristol Myers Squibb (NYSE: BMY) to,PRESS-RELEASE,Business Wire,Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb
BMY,2024-05-01,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration,PRESS-RELEASE,GlobeNewswire,Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
BMY,2024-05-01,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb will have rights to opt-in to such genome editing tools,PRESS-RELEASE,GlobeNewswire,Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
BMY,2024-05-01,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
BMY,2024-05-01,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb will have rights to opt-in to such genome editing tools,PRESS-RELEASE,Dow Jones Newswires,Press Release: Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
BMY,2024-05-01,12:01:51,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Editas Medicine Announces Two-Yr Extension to Collaboration With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Editas Medicine Announces Two-Yr Extension to Collaboration With Bristol Myers Squibb >EDIT
BMY,2024-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
BMY,2024-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2024-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2024-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -4-
BMY,2024-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Application based on results from CheckMate -67T, the first Phase 3 trial",PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
BMY,2024-05-06,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
BMY,2024-05-06,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Application based on results from CheckMate -67T, the first Phase 3 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
BMY,2024-05-06,11:00:04,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers: European Medicines Agency Validates Application for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: European Medicines Agency Validates Application for Opdivo Plus Yervoy for the First-Line Treatment of Adults With Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-05-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-05-07,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-05-10,20:30:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 3 -3-
BMY,2024-05-10,20:30:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 3 -3-
BMY,2024-05-10,20:30:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 3 -4-
BMY,2024-05-10,20:30:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -3-
BMY,2024-05-10,20:30:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -3-
BMY,2024-05-10,20:30:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -4-
BMY,2024-05-10,20:42:19,94637C,Bristol-Myers Squibb Co.,100,-0.65,products-services,negative,Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
BMY,2024-05-10,20:57:19,94637C,Bristol-Myers Squibb Co.,100,-0.65,products-services,negative,Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
BMY,2024-05-10,22:24:13,94637C,Bristol-Myers Squibb Co.,100,0.0,stock-picks,,"Stocks to Watch: FAT Brands, Xponential Fitness, Bristol Myers Squibb",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch: FAT Brands, Xponential Fitness, Bristol Myers Squibb"
BMY,2024-05-13,20:09:12,94637C,Bristol-Myers Squibb Co.,96,0.65,revenues,up,Camzyos sales are growing,FULL-ARTICLE,Dow Jones Newswires,Cytokinetics Slumps Despite 'Pristine' Results For Bristol Myers-Rivaling Heart Drug -- IBD
BMY,2024-05-14,13:47:39,94637C,Bristol-Myers Squibb Co.,96,0.65,revenues,up,Camzyos sales are growing,FULL-ARTICLE,Dow Jones Newswires,Cytokinetics Reverses Higher On 'Pristine' Results For Bristol Myers-Rivaling Heart Drug -- IBD
BMY,2024-05-14,20:02:08,94637C,Bristol-Myers Squibb Co.,96,0.65,revenues,up,Camzyos sales are growing,FULL-ARTICLE,Dow Jones Newswires,Cytokinetics Reverses Higher On 'Pristine' Results For Bristol Myers-Rivaling Heart Drug -- IBD
BMY,2024-05-16,00:57:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Cell Therapy Breyanzi Approved By The U.S. Food And Drug Administration,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved By The U.S. Food And Drug Administration For Relapsed Or Refractory Follicular Lymphoma >BMY
BMY,2024-05-16,00:57:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
BMY,2024-05-16,00:57:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi(R) (lisocabtagene maraleucel; Bristol-Myers Squibb Co.:,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
BMY,2024-05-16,00:57:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's CAR T Cell Therapy -2-
BMY,2024-05-16,00:57:01,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's CAR T Cell Therapy -2-
BMY,2024-05-16,01:05:57,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb: FDA Granted Accelerated Approval for CAR T Cell Therapy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: FDA Granted Accelerated Approval for CAR T Cell Therapy Breyanzi >BMY
BMY,2024-05-16,09:39:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
BMY,2024-05-16,09:39:36,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi(R) (lisocabtagene maraleucel; Bristol-Myers Squibb Co.:,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
BMY,2024-05-16,09:39:36,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's CAR T Cell -2-
BMY,2024-05-16,09:39:36,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's CAR T Cell -2-
BMY,2024-05-16,10:33:58,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets FDA OK of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma
BMY,2024-05-16,10:48:58,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets FDA OK of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: The application is based on results from CheckMate -67T, the first Phase 3 trial",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: The application is based on results from CheckMate -67T, the first Phase 3 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Updated Action -3-
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Updated Action -3-
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Updated Action -3-
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2024-05-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2024-05-22,07:09:24,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2024 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2024 (BMY)"
BMY,2024-05-22,07:30:06,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Additional funding,PRESS-RELEASE,PR Newswire,NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
BMY,2024-05-22,07:30:30,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Additional funding,PRESS-RELEASE,PR Newswire,NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
BMY,2024-05-22,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: The Company enters strategic collaboration with the Access to Oncology Medicines (ATOM) Coalition to,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
BMY,2024-05-22,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: The Company enters strategic collaboration with the Access to Oncology Medicines (ATOM) Coalition to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
BMY,2024-05-22,16:09:09,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: The Company enters strategic collaboration with the Access to Oncology Medicines (ATOM) Coalition to,PRESS-RELEASE,DJ Global Press Release Wire,Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Efficacy and safety data from the Phase 2/3,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms"
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: First results from the Phase 1 study,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms"
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: A phase II/III study of,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -2-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: KRYSTAL-12: Phase 3 Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -3-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -8-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -8-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -8-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -12-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -12-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -13-
BMY,2024-05-23,21:05:01,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -14-
BMY,2024-05-23,21:05:02,94637C,Bristol-Myers Squibb Co.,91,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -16-
BMY,2024-05-23,21:05:02,94637C,Bristol-Myers Squibb Co.,91,0.63,products-services,,Augtyro was also granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO & -16-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Efficacy and safety data from the Phase 2/3,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms"
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: First results from the Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms"
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: A phase II/III study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -2-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: KRYSTAL-12: Phase 3 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: Phase II study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -8-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -8-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -8-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -12-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -12-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -13-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -14-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,91,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -16-
BMY,2024-05-23,22:27:33,94637C,Bristol-Myers Squibb Co.,91,0.63,products-services,,Augtyro was also granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -16-
BMY,2024-05-28,20:05:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol-Myers Squibb Co.: our agreement with Bristol Myers Squibb in,PRESS-RELEASE,Business Wire,"Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration"
BMY,2024-05-28,20:05:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol-Myers Squibb Co.: our agreement with Bristol Myers Squibb in,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration"
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: Approval based on results from CheckMate -901, the first Phase 3 trial",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: Approval based on results from CheckMate -901, the first Phase 3 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2024-05-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2024-05-29,11:04:37,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination With Cisplatin,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients With Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-29,11:04:37,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination With Cisplatin,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients With Unresectable or Metastatic Urothelial Carcinoma
BMY,2024-05-30,15:51:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food And Drug Administration Approves Bristol Myers Squibb's Breyanzi,NEWS-FLASH,Dow Jones Newswires,U.S. Food And Drug Administration Approves Bristol Myers Squibb's Breyanzi As A New CAR T Cell Therapy For Relapsed Or Refractory Mantle Cell Lymphoma >BMY
BMY,2024-05-30,15:51:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
BMY,2024-05-30,15:53:39,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Additionally, data from the Phase 3 KRYSTAL-12 study of KRAZATI(R) (adagrasib)",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO(R) Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: Finally, five-year follow-up results",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO(R) Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.63,products-services,,Augtyro was also granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.71,products-services,,Krazati was granted accelerated approval,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.44,products-services,conditional,"In 2024, the European Commission (EC) granted conditional marketing authorization for KRAZATI",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.7,products-services,,"Bristol-Myers Squibb Co.: In 2022, the FDA granted breakthrough therapy designation for KRAZATI",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -4-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -4-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -5-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,97,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Multiple New -8-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Additionally, data from the Phase 3 KRYSTAL-12 study of KRAZATI(R) (adagrasib)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO(R) Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: Finally, five-year follow-up results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO(R) Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.63,products-services,,Augtyro was also granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.71,products-services,,Krazati was granted accelerated approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.44,products-services,conditional,"In 2024, the European Commission (EC) granted conditional marketing authorization for KRAZATI",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.7,products-services,,"Bristol-Myers Squibb Co.: In 2022, the FDA granted breakthrough therapy designation for KRAZATI",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -5-
BMY,2024-06-03,12:00:03,94637C,Bristol-Myers Squibb Co.,97,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -8-
BMY,2024-06-03,14:13:00,94637C,Bristol-Myers Squibb Co.,95,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO(R) Annual Meeting
BMY,2024-06-03,14:13:00,94637C,Bristol-Myers Squibb Co.,95,0.62,products-services,positive,Breyanzi demonstrated consistent clinical benefit,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO(R) Annual Meeting
BMY,2024-06-03,14:13:00,94637C,Bristol-Myers Squibb Co.,95,0.57,products-services,granted,Fda also granted Breyanzi approval,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO(R) Annual Meeting
BMY,2024-06-03,14:13:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi Demonstrates -2-
BMY,2024-06-03,14:13:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi Demonstrates -3-
BMY,2024-06-03,14:13:01,94637C,Bristol-Myers Squibb Co.,96,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO(R) Annual Meeting
BMY,2024-06-03,14:13:01,94637C,Bristol-Myers Squibb Co.,96,0.62,products-services,positive,Breyanzi demonstrated consistent clinical benefit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO(R) Annual Meeting
BMY,2024-06-03,14:13:01,94637C,Bristol-Myers Squibb Co.,96,0.57,products-services,granted,Fda also granted Breyanzi approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO(R) Annual Meeting
BMY,2024-06-03,14:13:01,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Breyanzi -2-
BMY,2024-06-03,14:13:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Breyanzi -3-
BMY,2024-06-04,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,marketing,,Bristol-Myers Squibb Co.: the company will participate in the Goldman Sachs 45(th) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the Goldman Sachs 45(th) Annual Global Healthcare Conference
BMY,2024-06-04,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BMY,2024-06-04,12:00:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo (nivolumab) -4-
BMY,2024-06-04,12:00:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo (nivolumab) -4-
BMY,2024-06-04,12:00:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo (nivolumab) -4-
BMY,2024-06-05,11:00:09,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,I-Mab Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
BMY,2024-06-05,11:00:09,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY),PRESS-RELEASE,PR Newswire,I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
BMY,2024-06-05,11:00:10,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,I-Mab Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
BMY,2024-06-05,11:00:10,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY),PRESS-RELEASE,Dow Jones Newswires,Press Release: I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
BMY,2024-06-05,11:02:57,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,I-Mab Announces Collaboration With Bristol Myers Squibb to,NEWS-FLASH,Dow Jones Newswires,I-Mab Announces Collaboration With Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
BMY,2024-06-12,05:30:25,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Eqs-News: Evotec SE / Key word(s): Miscellaneous Evotec announces progress in neuroscience collaboration with,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb
BMY,2024-06-12,05:30:25,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb announced that a Phase II study for,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb
BMY,2024-06-12,06:00:21,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Evotec SE: our neuroscience partnership with Bristol Myers Squibb and our shared commitment to innovation and patient care,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2024-06-12,06:00:21,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb announced that a Phase II study for,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2024-06-13,20:46:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"U.S. Food and Drug Administration Approves Augtyro(TM) (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor",PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Approves Augtyro(TM) (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors"
BMY,2024-06-13,20:46:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of,PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Approves Augtyro(TM) (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors"
BMY,2024-06-13,20:46:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"U.S. Food and Drug Administration Approves Augtyro(TM) (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor",PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Augtyro(TM) (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors"
BMY,2024-06-13,20:46:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of,PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Augtyro(TM) (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors"
BMY,2024-06-13,20:46:45,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb: FDA Approves Augtyro,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Approves Augtyro for NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY,2024-06-13,20:47:36,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Fda Granted Accelerated Approval of Augtyro,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Granted Accelerated Approval of Augtyro for Adult and Pediatric Patients 12 Years of Age and Older With Solid Tumors >BMY
BMY,2024-06-13,21:08:48,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval
BMY,2024-06-13,21:23:48,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval
BMY,2024-06-18,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2024-06-18,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on August 1, 2024, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2024-06-18,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2024-06-18,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on August 1, 2024, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2024-06-18,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.47,labor-issues,,Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
BMY,2024-06-18,20:16:01,94637C,Bristol-Myers Squibb Co.,100,0.47,labor-issues,,Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
BMY,2024-06-20,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024"
BMY,2024-06-20,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024"
BMY,2024-06-20,11:07:26,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024"
BMY,2024-06-20,11:07:26,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024"
BMY,2024-06-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
BMY,2024-06-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: Validation is based on results from CheckMate -67T, the first Phase 3 trial",PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
BMY,2024-06-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2024-06-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2024-06-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2024-06-21,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
BMY,2024-06-21,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: Validation is based on results from CheckMate -67T, the first Phase 3 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
BMY,2024-06-21,23:30:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Second FDA approval for KRAZATI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:00,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,"Bristol-Myers Squibb Co.: In 2022, the FDA granted breakthrough therapy designation for KRAZATI",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: The company partnered with QIAGEN to,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval Of KRAZATI(R) (adagrasib),NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval Of KRAZATI(R) (adagrasib) In Combination With Cetuximab For Adult Patients With Previously Treated KRAS G12C-Mutated Locally Advanced Or Metastatic Colorectal Cancer (CRC) >BMY
BMY,2024-06-21,23:30:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Second FDA approval for KRAZATI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:01,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,"Bristol-Myers Squibb Co.: In 2022, the FDA granted breakthrough therapy designation for KRAZATI",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-06-21,23:30:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: The company partnered with QIAGEN to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(R) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BMY,2024-07-09,10:59:04,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,complete,Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart,PRESS-RELEASE,PR Newswire,Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
BMY,2024-07-09,10:59:04,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,complete,Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart,PRESS-RELEASE,Dow Jones Newswires,Press Release: Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
BMY,2024-07-10,23:41:09,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2024-07-10,23:41:09,94637C,Bristol-Myers Squibb Co.,100,-0.56,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $41.00/Share From $43.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $41.00/Share From $43.00 by Barclays
BMY,2024-07-18,13:15:44,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bms executed a 15-year virtual power purchase agreement,PRESS-RELEASE,DJ Global Press Release Wire,Bristol Myers Squibb Reaches Major Milestone in Environmental Sustainability
BMY,2024-07-19,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Medicines -3-
BMY,2024-07-19,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Medicines -3-
BMY,2024-07-19,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Medicines -4-
BMY,2024-07-19,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2024-07-19,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2024-07-19,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2024-07-23,11:37:31,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Hold by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Hold by Deutsche Bank
BMY,2024-07-23,11:37:31,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $45.00/Share From $53.00 by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $45.00/Share From $53.00 by Deutsche Bank
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q Adj EPS $2.07,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Adj EPS $2.07 >BMY
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: SECOND QUARTER RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Second Quarter Revenues were $12.2 Billion, increasing 9%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS was $0.83,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Achieved U.S. Approval of Breyanzi,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the second quarter of 2024,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 1% to $3.4 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.71,products-services,,The FDA granted accelerated approval for Krazati in combination with cetuximab,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.71,products-services,,The FDA granted accelerated approval for Krazati in combination with cetuximab,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Fda granted accelerated approval (repotrectinib) of Augtyro,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) approved Opdivo in combination with cisplatin and gemcitabine,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) approved Opdivo in combination with cisplatin and gemcitabine,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) approved Opdivo in combination with cisplatin and gemcitabine,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: Krazati Results from the Phase 3 KRYSTAL-12 study evaluating Krazati,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 2Q Rev $12.2B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Rev $12.2B >BMY
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,97,0.71,products-services,,Bristol-Myers Squibb Co.: Breyanzi The FDA granted accelerated approval for Breyanzi,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,97,-0.68,revenues,down,Bristol-Myers Squibb Co.: Total Revenues Low,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,97,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $0.40 - $0.70,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: The 2024 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.58,indexes,,"In June 2024, Bristol Myers Squibb was added to the 2023 Dow Jones Sustainability Index",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q Net $1.68B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Net $1.68B >BMY
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED JUNE 30, 2024",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -6-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE SIX MONTHS ENDED JUNE 30, 2024",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -6-
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q EPS 83c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q EPS 83c >BMY
BMY,2024-07-26,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $12,201 $11,226",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -7-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: SECOND QUARTER RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Second Quarter Revenues were $12.2 Billion, increasing 9%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS was $0.83,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Achieved U.S. Approval of Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the second quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 1% to $3.4 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.71,products-services,,The FDA granted accelerated approval for Krazati in combination with cetuximab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.71,products-services,,The FDA granted accelerated approval for Krazati in combination with cetuximab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Fda granted accelerated approval (repotrectinib) of Augtyro,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) approved Opdivo in combination with cisplatin and gemcitabine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) approved Opdivo in combination with cisplatin and gemcitabine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) approved Opdivo in combination with cisplatin and gemcitabine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: Krazati Results from the Phase 3 KRYSTAL-12 study evaluating Krazati,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,97,0.71,products-services,,Bristol-Myers Squibb Co.: Breyanzi The FDA granted accelerated approval for Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,97,-0.68,revenues,down,Bristol-Myers Squibb Co.: Total Revenues Low,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,97,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $0.40 - $0.70,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: The 2024 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.58,indexes,,"In June 2024, Bristol Myers Squibb was added to the 2023 Dow Jones Sustainability Index",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED JUNE 30, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE SIX MONTHS ENDED JUNE 30, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2024-07-26,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $12,201 $11,226",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2024-07-26,11:01:15,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb results beat expectations,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb results beat expectations as newer drugs deliver growth
BMY,2024-07-26,11:04:08,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Now Sees 2024 Total Rev Up,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Now Sees 2024 Total Rev Up Upper End of Low Single-Digit Range >BMY
BMY,2024-07-26,11:04:55,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb Raises 2024 View To EPS 60c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raises 2024 View To EPS 60c-EPS 90c Vs Prior Guidance 40c-70c >BMY
BMY,2024-07-26,11:14:09,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb Earnings Easily Beat,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps -- IBD
BMY,2024-07-26,11:14:09,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: the company reported adjusted earnings of $2.07 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps -- IBD
BMY,2024-07-26,11:28:22,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers reported second-quarter adjusted earnings of $2.07 a share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Jumps. A Sales Jump for Eliquis Boosts Earnings. -- Barrons.com
BMY,2024-07-26,11:39:53,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers 2Q Adjusted EPS Tops Views,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:39:53,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers Squibb's second-quarter earnings exceeded Wall Street expectations,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:39:53,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers boosted its 2024 earnings projection,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:39:53,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: The company now expects revenue,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:39:53,94637C,Bristol-Myers Squibb Co.,100,-0.51,labor-issues,,"Bristol-Myers Squibb Co.: In April, the company said it would lay off 2,200 employees",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:54:53,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers 2Q Adjusted EPS Tops Views,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:54:53,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers Squibb's second-quarter earnings exceeded Wall Street expectations,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:54:53,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers boosted its 2024 earnings projection,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:54:53,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: The company now expects revenue,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,11:54:53,94637C,Bristol-Myers Squibb Co.,100,-0.51,labor-issues,,"Bristol-Myers Squibb Co.: In April, the company said it would lay off 2,200 employees",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales
BMY,2024-07-26,13:53:09,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb 2Q Adj EPS Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb 2Q Adj EPS Beat Expectations
BMY,2024-07-26,13:53:09,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb's second-quarter earnings exceeded Wall Street expectations,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb 2Q Adj EPS Beat Expectations
BMY,2024-07-26,14:08:10,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb 2Q Adjusted EPS Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb 2Q Adjusted EPS Beat Expectations
BMY,2024-07-26,14:08:10,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb's second-quarter earnings exceeded Wall Street expectations,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb 2Q Adjusted EPS Beat Expectations
BMY,2024-07-26,14:51:08,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Opdivo SALES GROW,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD"
BMY,2024-07-26,14:51:08,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Eliquis sales climbed 7%,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD"
BMY,2024-07-26,14:51:08,94637C,Bristol-Myers Squibb Co.,99,0.7,earnings,up,Bristol Myers also raised its outlook for the year,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD"
BMY,2024-07-26,20:16:40,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Opdivo SALES GROW,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD"
BMY,2024-07-26,20:16:40,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Eliquis sales climbed 7%,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD"
BMY,2024-07-26,20:16:40,94637C,Bristol-Myers Squibb Co.,99,0.7,earnings,up,Bristol Myers also raised its outlook for the year,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD"
BMY,2024-07-26,21:24:00,94637C,Bristol-Myers Squibb Co.,92,0.7,earnings,above-expectations,Stronger-than-anticipated earnings from Bristol-Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Health Care Up After Bristol-Myers Earnings -- Health Care Roundup
BMY,2024-07-26,21:39:01,94637C,Bristol-Myers Squibb Co.,92,0.7,earnings,above-expectations,Stronger-than-anticipated earnings from Bristol-Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Health Care Up After Bristol-Myers Earnings -- Health Care Roundup
BMY,2024-07-29,12:22:35,94637C,Bristol-Myers Squibb Co.,100,-0.98,analyst-ratings,negative,Bristol-Myers Squibb Cut to Underweight From Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Underweight From Equal-Weight by Barclays
BMY,2024-08-05,22:02:02,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Gallman Acquires 677 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Gallman Acquires 677 Of Bristol-Myers Squibb Co >BMY
BMY,2024-08-08,05:30:35,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Evotec SE: our neuroscience partnership with Bristol Myers Squibb.,PRESS-RELEASE,DGAP News,EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
BMY,2024-08-08,05:30:35,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Evotec SE: our neuroscience partnership with Bristol Myers Squibb.,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
BMY,2024-08-08,05:31:58,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Evotec SE: our neuroscience partnership with Bristol Myers Squibb.,PRESS-RELEASE,DGAP News,EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
BMY,2024-08-08,05:31:58,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Evotec SE: our neuroscience partnership with Bristol Myers Squibb.,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
BMY,2024-08-08,05:51:19,94637C,Bristol-Myers Squibb Co.,97,0.49,partnerships,,Evotec SE: our neuroscience partnership with Bristol Myers Squibb.,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
BMY,2024-08-08,09:25:55,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Evotec Gets $25 Million From Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Evotec Gets $25 Million From Bristol Myers Squibb Partnership
BMY,2024-08-08,09:40:55,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Evotec Gets $25 Million From Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Evotec Gets $25 Million From Bristol Myers Squibb Partnership
BMY,2024-08-12,15:05:27,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Hold by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Hold by TD Cowen
BMY,2024-08-12,15:05:27,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $53.00/Share From $45.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $53.00/Share From $45.00 by TD Cowen
BMY,2024-08-13,05:30:36,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Evotec SE: the Company has further extended and expanded its partnership with Bristol Myers Squibb,PRESS-RELEASE,DGAP News,EQS-News: Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb
BMY,2024-08-13,05:30:36,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Evotec SE: the Company has further extended and expanded its partnership with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb
BMY,2024-08-13,05:31:43,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Evotec SE: the Company has further extended and expanded its partnership with Bristol Myers Squibb,PRESS-RELEASE,DGAP News,EQS-News: Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb
BMY,2024-08-13,05:31:43,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Evotec SE: the Company has further extended and expanded its partnership with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb
BMY,2024-08-13,06:02:41,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Evotec SE: the Company has further extended and expanded its partnership with Bristol Myers Squibb,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
BMY,2024-08-19,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Breyanzi also received approval,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental New Drug Application for Breyanzi,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:00,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -2-
BMY,2024-08-19,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Breyanzi also received approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental New Drug Application for Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-19,10:59:06,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR,NEWS-FLASH,Dow Jones Newswires,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2024-08-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives U.S. Food and Drug -3-
BMY,2024-08-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives U.S. Food and Drug -3-
BMY,2024-08-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives U.S. Food and Drug -4-
BMY,2024-08-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives U.S. -3-
BMY,2024-08-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives U.S. -3-
BMY,2024-08-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives U.S. -4-
BMY,2024-08-22,07:07:35,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2024 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2024 (BMY)"
BMY,2024-08-22,14:26:29,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Barclays
BMY,2024-08-22,14:26:29,94637C,Bristol-Myers Squibb Co.,100,0.4,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $42.00/Share From $41.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $42.00/Share From $41.00 by Barclays
BMY,2024-08-26,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance on ELIQUIS(R) (apixaban),PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
BMY,2024-08-26,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Johnson & Johnson Collaboration on milvexian,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
BMY,2024-08-26,10:59:00,94637C,Bristol-Myers Squibb Co.,92,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Across -3-
BMY,2024-08-26,10:59:00,94637C,Bristol-Myers Squibb Co.,92,-0.54,products-services,,Bristol-Myers Squibb Co.: TEMPORARY INTERRUPTION,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Across -3-
BMY,2024-08-26,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Across -4-
BMY,2024-08-26,11:03:47,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance on ELIQUIS(R) (apixaban),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
BMY,2024-08-26,11:03:47,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Johnson & Johnson Collaboration on milvexian,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
BMY,2024-08-26,11:03:47,94637C,Bristol-Myers Squibb Co.,92,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2024-08-26,11:03:47,94637C,Bristol-Myers Squibb Co.,92,-0.54,products-services,,Bristol-Myers Squibb Co.: TEMPORARY INTERRUPTION,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2024-08-26,11:03:47,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2024-08-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-08-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-08-28,18:54:33,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Hold by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Hold by Jefferies
BMY,2024-08-28,18:54:33,94637C,Bristol-Myers Squibb Co.,100,0.5,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $51.00/Share From $49.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $51.00/Share From $49.00 by Jefferies
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Efficacy and safety data from the randomized Phase 3,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO -5-
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO -5-
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO -5-
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Efficacy and safety data from the randomized Phase 3,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -5-
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -5-
BMY,2024-09-09,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -5-
BMY,2024-09-10,21:45:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2024-09-10,21:45:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on November 1, 2024, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2024-09-10,21:45:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2024-09-10,21:45:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on November 1, 2024, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2024-09-12,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024"
BMY,2024-09-12,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024"
BMY,2024-09-12,11:11:14,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024"
BMY,2024-09-12,11:11:14,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024"
BMY,2024-09-15,12:55:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Landmark 10-Year -4-
BMY,2024-09-15,12:55:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Landmark 10-Year -4-
BMY,2024-09-15,12:55:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Landmark 10-Year -4-
BMY,2024-09-16,09:37:23,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2024-09-16,09:37:23,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2024-09-16,09:37:23,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2024-09-23,14:05:42,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital
BMY,2024-09-26,22:56:35,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Bristol-Myers Squibb Schizophrenia Drug,NEWS-FLASH,Dow Jones Newswires,FDA Approves Bristol-Myers Squibb Schizophrenia Drug Cobenfy -- WSJ
BMY,2024-09-26,23:35:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout -- IBD
BMY,2024-09-26,23:35:36,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Karuna Therapeutics, acquired by Bristol Myers in $14 billion",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout -- IBD
BMY,2024-09-27,01:05:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food And Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline,NEWS-FLASH,Dow Jones Newswires,"U.S. Food And Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline And Trospium Chloride), A First-In-Class Muscarinic Agonist For The Treatment Of Schizophrenia In Adults >BMY"
BMY,2024-09-27,06:00:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Puretech-Invented KarXT Receives U.S. Food And Drug Administration Approval,NEWS-FLASH,Dow Jones Newswires,PureTech-Invented KarXT Receives U.S. Food And Drug Administration Approval For The Treatment Of Schizophrenia In Adults >PRTC
BMY,2024-09-27,06:00:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Puretech-Invented KarXT Receives U.S. Food and Drug Administration Approval,PRESS-RELEASE,Business Wire,PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
BMY,2024-09-27,06:00:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Karuna Therapeutics, which was acquired by Bristol Myers Squibb (NYSE: BMY)",PRESS-RELEASE,Business Wire,PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
BMY,2024-09-27,06:00:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Karuna and BMS teams for,PRESS-RELEASE,Business Wire,PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
BMY,2024-09-27,06:00:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Puretech-Invented KarXT Receives U.S. Food and Drug Administration Approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
BMY,2024-09-27,06:00:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Karuna Therapeutics, which was acquired by Bristol Myers Squibb (NYSE: BMY)",PRESS-RELEASE,Dow Jones Newswires,Press Release: PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
BMY,2024-09-27,06:00:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Karuna and BMS teams for,PRESS-RELEASE,Dow Jones Newswires,Press Release: PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
BMY,2024-09-27,09:15:43,94637C,Bristol-Myers Squibb Co.,100,0.0,stock-picks,,"Stocks to Watch Friday: Bristol Myers Squibb, EchoStar, Costco -- WSJ",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Friday: Bristol Myers Squibb, EchoStar, Costco -- WSJ"
BMY,2024-09-27,09:37:39,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline,PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults"
BMY,2024-09-27,13:33:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets FDA Approval for Schizophrenia Drug,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Gets FDA Approval for Schizophrenia Drug
BMY,2024-09-27,13:34:38,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Breaks Out -- IBD
BMY,2024-09-27,13:34:38,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Karuna Therapeutics, acquired by Bristol Myers in $14 billion",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Breaks Out -- IBD
BMY,2024-09-27,13:48:51,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets FDA Approval for Schizophrenia Drug,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Gets FDA Approval for Schizophrenia Drug
BMY,2024-09-27,14:02:59,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital
BMY,2024-09-27,14:02:59,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $53.00/Share From $48.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $53.00/Share From $48.00 by BMO Capital
BMY,2024-09-27,15:06:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data from Two -2-
BMY,2024-09-27,15:06:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data from Two -4-
BMY,2024-09-27,15:10:19,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -2-
BMY,2024-09-27,15:10:19,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -4-
BMY,2024-09-27,23:38:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food And Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline,NEWS-FLASH,Dow Jones Newswires,"U.S. Food And Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline And Trospium Chloride), A First-In-Class Muscarinic Agonist For The Treatment Of Schizophrenia In Adults >BMY"
BMY,2024-09-27,23:38:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline,PRESS-RELEASE,Business Wire,"CORRECTING AND REPLACING/U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults"
BMY,2024-09-30,11:00:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,"Prime Medicine, Inc. (Nasdaq: PRME) today announced a strategic research collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY)",PRESS-RELEASE,GlobeNewswire,Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
BMY,2024-09-30,11:00:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,"Prime Medicine, Inc. (Nasdaq: PRME) today announced a strategic research collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
BMY,2024-09-30,11:01:05,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Prime Medicine Announces Research Collaboration, License Agreement With Bristol Myers Squibb",NEWS-FLASH,Dow Jones Newswires,"Prime Medicine Announces Research Collaboration, License Agreement With Bristol Myers Squibb"
BMY,2024-09-30,15:52:19,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb joined hands with the Emirates Thalassemia Society and Dubai Science Park to,PRESS-RELEASE,PR Newswire,Bristol Myers Squibb Marks 10 Years of Global Patient Week with Community Initiatives in the Region
BMY,2024-09-30,15:55:49,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb joined hands with the Emirates Thalassemia Society and Dubai Science Park to,PRESS-RELEASE,PR Newswire,Bristol Myers Squibb Marks 10 Years of Global Patient Week with Community Initiatives in the Region
BMY,2024-10-03,21:37:31,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb: FDA Approved Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Approved Opdivo for Adult Patients With Resectable Non-Small Cell Lung Cancer >BMY
BMY,2024-10-03,22:35:15,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Gallman Acquires 2,910 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Gallman Acquires 2,910 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-10-07,17:47:42,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Hold by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Hold by TD Cowen
BMY,2024-10-07,17:47:42,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $59.00/Share From $53.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $59.00/Share From $53.00 by TD Cowen
BMY,2024-10-07,18:52:02,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Barclays
BMY,2024-10-07,18:52:02,94637C,Bristol-Myers Squibb Co.,100,0.4,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $43.00/Share From $42.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $43.00/Share From $42.00 by Barclays
BMY,2024-10-08,06:05:58,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol-Myers Squibb acquired Karuna for $14 billion,FULL-ARTICLE,Dow Jones Newswires,Heard on the Street: Alzheimer's Drug Comes Full Circle --- Bristol-Myers' newly approved schizophrenia treatment sparks fresh interest in its first intended use ---- By David Wainer
BMY,2024-10-09,22:13:37,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by UBS
BMY,2024-10-09,22:13:37,94637C,Bristol-Myers Squibb Co.,100,0.7,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $54.00/Share From $50.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $54.00/Share From $50.00 by UBS
BMY,2024-10-17,16:43:25,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Initiated at Market Perform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Market Perform by Bernstein
BMY,2024-10-17,16:43:25,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $56.00/Share by Bernstein,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $56.00/Share by Bernstein
BMY,2024-10-23,05:29:44,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb expand proteomics partnership,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec and Bristol Myers Squibb expand proteomics partnership
BMY,2024-10-23,05:29:44,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb expand proteomics partnership,PRESS-RELEASE,DGAP News,EQS-News: Evotec and Bristol Myers Squibb expand proteomics partnership
BMY,2024-10-23,05:30:43,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb expand proteomics partnership,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec and Bristol Myers Squibb expand proteomics partnership
BMY,2024-10-23,05:30:43,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb expand proteomics partnership,PRESS-RELEASE,DGAP News,EQS-News: Evotec and Bristol Myers Squibb expand proteomics partnership
BMY,2024-10-23,06:01:22,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb Expand Proteomics Partnership,PRESS-RELEASE,DJ Global Press Release Wire,Evotec and Bristol Myers Squibb Expand Proteomics Partnership
BMY,2024-10-25,12:42:02,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Neutral From Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Neutral From Buy by Citigroup
BMY,2024-10-25,12:42:02,94637C,Bristol-Myers Squibb Co.,100,-0.84,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $55.00/Share From $75.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $55.00/Share From $75.00 by Citigroup
BMY,2024-10-28,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: our long-term clinical trials,"" said",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
BMY,2024-10-28,10:59:28,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: our long-term clinical trials,"" said",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
BMY,2024-10-28,22:25:26,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb 2024 Guidance,FULL-ARTICLE,Dow Jones Newswires,Correction to Bristol-Myers Squibb 2024 Guidance Headline on July 26
BMY,2024-10-28,22:25:26,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb Raises 2024 View To EPS 60c,FULL-ARTICLE,Dow Jones Newswires,Correction to Bristol-Myers Squibb 2024 Guidance Headline on July 26
BMY,2024-10-28,22:40:26,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb 2024 Guidance,FULL-ARTICLE,Dow Jones Newswires,Correction to Bristol-Myers Squibb 2024 Guidance Headline on July 26
BMY,2024-10-28,22:40:26,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb Raises 2024 View To EPS 60c,FULL-ARTICLE,Dow Jones Newswires,Correction to Bristol-Myers Squibb 2024 Guidance Headline on July 26
BMY,2024-10-31,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q EPS 60c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q EPS 60c >BMY
BMY,2024-10-31,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q Adj EPS $1.80,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Adj EPS $1.80 >BMY
BMY,2024-10-31,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q Net $1.2B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Net $1.2B >BMY
BMY,2024-10-31,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 3Q Rev $11.9B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Rev $11.9B >BMY
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: THIRD QUARTER RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Third Quarter Revenues were $11.9 Billion, increasing 8%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS was $0.60,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Co.: Raising 2024 Revenue Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,892 $10,966",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -7-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the third quarter of 2024.,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,"Higher demand for Eliquis, partially offset by generic",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,The FDA approved Opdivo for the treatment,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,91,0.62,products-services,positive,Opdivo has previously shown clinical benefit,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,-0.68,revenues,down,Bristol-Myers Squibb Co.: Upper end of low Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,-0.13,equity-actions,up,Bristol-Myers Squibb Co.: Low single-digit Operating Expenses(1) increase 4% to 5%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $0.60 - $0.90,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2024 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -5-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -5-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,92,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -6-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: THIRD QUARTER RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Third Quarter Revenues were $11.9 Billion, increasing 8%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS was $0.60,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Co.: Raising 2024 Revenue Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the third quarter of 2024.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,"Higher demand for Eliquis, partially offset by generic",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,The FDA approved Opdivo for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,91,0.62,products-services,positive,Opdivo has previously shown clinical benefit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -5-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -5-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,92,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -6-
BMY,2024-10-31,10:59:02,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,892 $10,966",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -7-
BMY,2024-10-31,11:02:46,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Raising 2024 Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raising 2024 Rev Guidance to About +5% (+6% Adjusting for Foreign Exchange) >BMY
BMY,2024-10-31,11:03:05,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb Raises FY24 View To Adj EPS 75c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raises FY24 View To Adj EPS 75c-Adj EPS 95c >BMY
BMY,2024-10-31,11:10:37,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers earnings top estimates,FULL-ARTICLE,MarketWatch,MW Bristol Myers earnings top estimates and company raises guidance
BMY,2024-10-31,11:10:37,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Earnings Top Estimates,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Earnings Top Estimates And Company Raises Guidance -- MarketWatch
BMY,2024-10-31,11:13:07,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Earnings Top Q3 Estimates,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance -- IBD
BMY,2024-10-31,11:13:07,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb reported adjusted earnings of $1.80 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance -- IBD
BMY,2024-10-31,11:25:42,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Lifts 2024 Outlook After 3Q Sales,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Lifts 2024 Outlook After 3Q Sales Climb
BMY,2024-10-31,11:25:42,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb bumped full-year guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Lifts 2024 Outlook After 3Q Sales Climb
BMY,2024-10-31,11:25:42,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,"For the third quarter, Bristol-Myers posted a profit of $1.2 billion",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Lifts 2024 Outlook After 3Q Sales Climb
BMY,2024-10-31,11:40:33,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers also raised its full-year 2024 revenue guidance,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Stock Rises After Earnings Beat, Guidance Hike -- Barrons.com"
BMY,2024-10-31,11:40:42,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Lifts 2024 Outlook After 3Q Sales,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Lifts 2024 Outlook After 3Q Sales Climb
BMY,2024-10-31,11:40:42,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb bumped full-year guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Lifts 2024 Outlook After 3Q Sales Climb
BMY,2024-10-31,11:40:42,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,"For the third quarter, Bristol-Myers posted a profit of $1.2 billion",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Lifts 2024 Outlook After 3Q Sales Climb
BMY,2024-10-31,12:15:52,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers also raised its full-year 2024 revenue guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Rises. The Drugmaker Hiked Guidance After Sales Beat. -- Barrons.com
BMY,2024-10-31,14:45:18,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers also raised its full-year 2024 revenue guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Rises. The Drugmaker Hiked Guidance After Sales Beat. -- Barrons.com
BMY,2024-10-31,20:13:39,94637C,Bristol-Myers Squibb Co.,99,0.82,revenues,up,Breyanzi revenue climbed 143%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Screams To A Year-High After Walloping Profit Expectations -- IBD
BMY,2024-10-31,20:13:39,94637C,Bristol-Myers Squibb Co.,99,0.0,analyst-ratings,neutral,He retained his market perform rating on Bristol Myers,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Screams To A Year-High After Walloping Profit Expectations -- IBD
BMY,2024-10-31,20:13:39,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Opdivo sales rose 7%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Screams To A Year-High After Walloping Profit Expectations -- IBD
BMY,2024-10-31,20:16:01,94637C,Bristol-Myers Squibb Co.,97,0.0,products-services,,Bristol-Myers Squibb Co.: The trial enrolled participants,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY(TM) (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
BMY,2024-10-31,20:27:10,94637C,Bristol-Myers Squibb Co.,97,0.0,products-services,,Bristol-Myers Squibb Co.: The trial enrolled participants,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY(TM) (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
BMY,2024-11-01,15:46:29,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital
BMY,2024-11-01,15:46:29,94637C,Bristol-Myers Squibb Co.,100,0.68,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $57.00/Share From $53.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $57.00/Share From $53.00 by BMO Capital
BMY,2024-11-04,16:24:32,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,Vp Holzer Registers 700 Of Bristol-Myers Squibb Co >BMY,RNS-SEC144,Dow Jones Newswires,VP Holzer Registers 700 Of Bristol-Myers Squibb Co >BMY
BMY,2024-11-05,22:00:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-11-05,22:00:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2024-11-05,22:43:53,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Buys 1,830 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Buys 1,830 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-11-05,22:44:44,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Chmn Boerner Acquires 1,476 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Chmn Boerner Acquires 1,476 Of Bristol-Myers Squibb Co >BMY"
BMY,2024-11-05,22:53:56,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,Vp Holzer Sells 700 Of Bristol-Myers Squibb Co,FULL-ARTICLE,Dow Jones Newswires,VP Holzer Sells 700 Of Bristol-Myers Squibb Co >BMY
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance on ELIQUIS(R) (apixaban),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Johnson & Johnson Collaboration on milvexian,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Pfizer Alliance ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Johnson & Johnson Collaboration ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,92,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued -3-
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.54,products-services,,Bristol-Myers Squibb Co.: TEMPORARY INTERRUPTION,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued -4-
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued -4-
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Showcases the Continued -4-
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance on ELIQUIS(R) (apixaban),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Johnson & Johnson Collaboration on milvexian,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Pfizer Alliance ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Johnson & Johnson Collaboration ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,92,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the -3-
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.54,products-services,,Bristol-Myers Squibb Co.: TEMPORARY INTERRUPTION,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the -4-
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the -4-
BMY,2024-11-11,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Showcases the -4-
BMY,2024-11-11,13:00:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab,PRESS-RELEASE,GlobeNewswire,CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
BMY,2024-11-11,13:00:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab,PRESS-RELEASE,GlobeNewswire,CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
BMY,2024-11-11,13:00:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab,PRESS-RELEASE,Dow Jones Newswires,Press Release: CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
BMY,2024-11-11,13:00:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab,PRESS-RELEASE,Dow Jones Newswires,Press Release: CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
BMY,2024-11-11,15:13:40,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol Myers, AbbVie acquired emraclidine's maker, Cerevel Therapeutics for $8.7 billion",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails -- IBD
BMY,2024-11-11,15:47:29,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,Bristol Myers acquired the drug after buying developer Karuna Therapeutics in 2023,FULL-ARTICLE,Dow Jones Newswires,AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. -- Barrons.com
BMY,2024-11-11,16:00:25,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"In September, the U.S. Food and Drug Administration approved Bristol Myers Squibb's (BMY) schizophrenia drug",FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
BMY,2024-11-12,13:05:11,94637C,Bristol-Myers Squibb Co.,100,0.94,analyst-ratings,positive,Bristol-Myers Squibb Raised to Outperform From Market Perform by Leerink,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raised to Outperform From Market Perform by Leerink Partners
BMY,2024-11-12,13:05:11,94637C,Bristol-Myers Squibb Co.,100,0.8,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $73.00/Share From $55.00 by Leerink,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $73.00/Share From $55.00 by Leerink Partners
BMY,2024-11-12,13:37:19,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2024-11-12,13:37:19,94637C,Bristol-Myers Squibb Co.,100,0.72,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $39.00/Share From $36.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $39.00/Share From $36.00 by Morgan Stanley
BMY,2024-11-12,16:38:49,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital
BMY,2024-11-12,16:38:49,94637C,Bristol-Myers Squibb Co.,100,0.66,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $61.00/Share From $57.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $61.00/Share From $57.00 by BMO Capital
BMY,2024-11-12,19:07:19,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by Citigroup
BMY,2024-11-12,19:07:19,94637C,Bristol-Myers Squibb Co.,100,0.74,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $60.00/Share From $55.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $60.00/Share From $55.00 by Citigroup
BMY,2024-11-15,10:29:15,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Initiated at Peer Perform by Wolfe Research,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Peer Perform by Wolfe Research
BMY,2024-11-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval for repotrectinib,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,2023 the U.S. Food and Drug Administration approved Augtyro(R) (repotrectinib),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.63,products-services,,Repotrectinib was granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval for repotrectinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,2023 the U.S. Food and Drug Administration approved Augtyro(R) (repotrectinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.63,products-services,,Repotrectinib was granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,11:59:05,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY,2024-11-15,12:01:57,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Gets Positive CHMP Opinion for Augtyro,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets Positive CHMP Opinion for Augtyro in Two Indications >BMY
BMY,2024-11-15,12:34:13,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,The U.S. Food and Drug Administration last year approved Augtyro,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug
BMY,2024-11-15,12:34:13,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,Bristol Myers reported Augtyro sales of $23 million for the first nine months of 2024,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug
BMY,2024-11-15,12:49:13,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,The U.S. Food and Drug Administration last year approved Augtyro,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug
BMY,2024-11-15,12:49:13,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,Bristol Myers reported Augtyro sales of $23 million for the first nine months of 2024,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug
BMY,2024-11-15,13:23:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-11-15,13:23:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-11-15,13:23:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2024-11-15,13:23:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2024-11-15,13:23:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2024-11-15,13:23:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-11-15,13:23:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-11-15,13:23:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2024-11-15,13:23:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2024-11-15,13:23:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2024-11-15,13:23:57,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol-Myers Squibb Gets Positive CHMP Opinion for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Gets Positive CHMP Opinion for Opdivo Plus Yervoy for First-Line Treatment of Adult Patients With Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer >BMY
BMY,2024-11-19,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: First OS and progression-free survival results from a Phase 1 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
BMY,2024-11-19,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Presentations at ASH 2024 -5-
BMY,2024-11-19,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Presentations at ASH 2024 -5-
BMY,2024-11-19,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Presentations at ASH 2024 -6-
BMY,2024-11-19,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Presentations at ASH 2024 -6-
BMY,2024-11-19,11:59:38,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: First OS and progression-free survival results from a Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
BMY,2024-11-19,11:59:38,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's -5-
BMY,2024-11-19,11:59:38,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's -5-
BMY,2024-11-19,11:59:38,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's -6-
BMY,2024-11-19,11:59:38,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's -6-
BMY,2024-11-20,02:43:43,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,,Bristol-MYERS SQUIBB CANADA WINS THE 2024 PRIX GALIEN INNOVATIVE PRODUCT AWARD,PRESS-RELEASE,Canadian News Wire,BRISTOL-MYERS SQUIBB CANADA WINS THE 2024 PRIX GALIEN INNOVATIVE PRODUCT AWARD
BMY,2024-11-22,08:06:25,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2024 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2024 (BMY)"
BMY,2024-12-03,13:00:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: We are excited to partner with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M
BMY,2024-12-09,22:45:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Updated Phase 1 data for CD19 NEX-T(R) CAR T cell,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
BMY,2024-12-09,22:45:01,94637C,Bristol-Myers Squibb Co.,98,0.0,products-services,,Bristol-Myers Squibb Co.: Updated Data of Phase 1 Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Highlights Progress of Cell -2-
BMY,2024-12-09,22:45:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Highlights Progress of Cell -3-
BMY,2024-12-09,22:45:01,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Highlights Progress of Cell -3-
BMY,2024-12-09,22:45:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Highlights Progress of Cell -4-
BMY,2024-12-09,22:51:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Updated Phase 1 data for CD19 NEX-T(R) CAR T cell,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
BMY,2024-12-09,22:51:00,94637C,Bristol-Myers Squibb Co.,98,0.0,products-services,,Bristol-Myers Squibb Co.: Updated Data of Phase 1 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Highlights -2-
BMY,2024-12-09,22:51:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Highlights -3-
BMY,2024-12-09,22:51:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Highlights -3-
BMY,2024-12-09,22:51:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Highlights -4-
BMY,2024-12-10,12:50:27,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $63.00/Share by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $63.00/Share by B of A Securities
BMY,2024-12-11,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Announces Dividend Increase,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Dividend Increase >BMY
BMY,2024-12-11,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Announces Dividend Increase,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2024-12-11,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2024-12-11,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on February 3, 2025, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2024-12-11,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Announces Dividend Increase,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2024-12-11,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2024-12-11,21:17:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on February 3, 2025, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2024-12-11,21:17:49,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Raises Quarterly Dividend to 62c Vs. 60c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raises Quarterly Dividend to 62c Vs. 60c >BMY
BMY,2024-12-16,13:19:01,94637C,Bristol-Myers Squibb Co.,100,0.94,analyst-ratings,positive,Bristol-Myers Squibb Raised to Buy From Hold by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raised to Buy From Hold by Jefferies
BMY,2024-12-16,13:19:01,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $70.00/Share From $63.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $70.00/Share From $63.00 by Jefferies
BMY,2024-12-18,14:00:02,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,"Insitro Inc.: our partnership with Bristol Myers Squibb scientists and leaders, who understood and invested in our vision",PRESS-RELEASE,Business Wire,insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS
BMY,2024-12-19,04:41:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare,PRESS-RELEASE,PR Newswire,Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare
BMY,2024-12-19,04:41:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare,PRESS-RELEASE,Dow Jones Newswires,Press Release: Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare
BMY,2024-12-19,06:30:10,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bioarctic announces global license agreement with Bristol Myers Squibb,PRESS-RELEASE,Cision News,BioArctic: BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
BMY,2024-12-19,06:30:10,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bioarctic announces global license agreement with Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,BioArctic: BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
BMY,2024-12-19,06:48:29,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bioarctic announces global license agreement with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
BMY,2024-12-19,06:48:30,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bioarctic announces global license agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
BMY,2024-12-19,06:51:48,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bioarctic Enters Global License Agreement With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,BioArctic Enters Global License Agreement With Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta Antibody Program
BMY,2024-12-19,06:52:36,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bioarctic announces global license agreement with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
BMY,2024-12-19,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025"
BMY,2024-12-19,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025"
BMY,2024-12-19,12:05:44,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025"
BMY,2024-12-19,12:05:44,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025"
BMY,2024-12-23,11:45:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-12-23,11:45:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-12-23,11:45:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2024-12-23,11:45:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2024-12-23,11:45:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2024-12-23,11:45:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-12-23,11:45:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-12-23,11:45:16,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo Plus Yervoy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo Plus Yervoy for the First-Line Treatment of Adult Patients With Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-12-23,11:45:16,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo Plus Yervoy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo Plus Yervoy for the First-Line Treatment of Adult Patients With Microsatellite Instability--High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY,2024-12-23,12:41:51,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,The Food and Drug Administration in September 2022 approved Sotyktu,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis
BMY,2024-12-23,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.88,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
BMY,2024-12-23,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: These topline results represent the first Phase 3 clinical trials,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
BMY,2024-12-23,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline -2-
BMY,2024-12-23,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.88,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
BMY,2024-12-23,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: These topline results represent the first Phase 3 clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
BMY,2024-12-23,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2024-12-23,11:59:30,94637C,Bristol-Myers Squibb Co.,100,0.88,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results From Two Pivotal Phase 3 Trials Evaluating Sotyktu,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Positive Topline Results From Two Pivotal Phase 3 Trials Evaluating Sotyktu in Adults With Psoriatic Arthritis >BMY
BMY,2024-12-23,12:00:16,94637C,Bristol-Myers Squibb Co.,100,0.62,products-services,positive,Bristol-Myers: Phase 3 Studies of Sotyktu in Psoriatic Arthritis Met Primary Endpoint,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers: Phase 3 Studies of Sotyktu in Psoriatic Arthritis Met Primary Endpoint >BMY
BMY,2024-12-23,12:26:51,94637C,Bristol-Myers Squibb Co.,100,0.62,products-services,positive,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis
BMY,2024-12-23,12:26:51,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,The Food and Drug Administration in September 2022 approved Sotyktu,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis
BMY,2024-12-23,12:26:51,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers reported Sotyktu sales of $163 million for the first nine months of 2024,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis
BMY,2024-12-23,12:41:51,94637C,Bristol-Myers Squibb Co.,100,0.62,products-services,positive,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis
BMY,2024-12-23,12:41:51,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers reported Sotyktu sales of $163 million for the first nine months of 2024,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Phase 3 Sotyktu Studies Hit Goals in Psoriatic Arthritis
BMY,2024-12-27,22:37:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo,PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Approves Opdivo Qvantig(TM) (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo(R) (nivolumab) Indications1,2"
BMY,2024-12-27,22:37:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo -2-
BMY,2024-12-27,22:37:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo -4-
BMY,2024-12-27,22:37:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo -5-
BMY,2024-12-27,22:37:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo -6-
BMY,2024-12-27,22:37:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo -7-
BMY,2024-12-27,22:37:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo -8-
BMY,2024-12-27,22:57:55,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives FDA Approval for Cancer Treatment,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Receives FDA Approval for Cancer Treatment
BMY,2024-12-27,23:03:59,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo,PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Opdivo Qvantig(TM) (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo(R) (nivolumab) Indications1,2"
BMY,2024-12-27,23:12:55,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives FDA Approval for Cancer Treatment,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Receives FDA Approval for Cancer Treatment
BMY,2024-12-30,11:30:03,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approval Of Bristol Myers Squibb's Opdivo,NEWS-FLASH,Dow Jones Newswires,Halozyme Announces FDA Approval Of Bristol Myers Squibb's Opdivo Qvantig(TM) With ENHANZE(R) For Subcutaneous Use In Most Previously Approved Adult Solid Tumor Opdivo(R) (nivolumab) Indications >HALO
BMY,2024-12-30,11:30:03,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approval of Bristol Myers Squibb's Opdivo,PRESS-RELEASE,PR Newswire,Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig(TM) with ENHANZE(R) for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo(R) (nivolumab) Indications
BMY,2024-12-30,11:30:03,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approval of Bristol Myers Squibb's Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig(TM) with ENHANZE(R) for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo(R) (nivolumab) Indications
BMY,2024-01-15,07:00:08,97C893,Bloomsbury Publishing PLC,100,0.53,labor-issues,,Bloomsbury Appoints Head of,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Bloomsbury Appoints Head of Investor Relations
BMY,2024-02-01,15:11:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: our interim results in October,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Bloomsbury launches latest Sarah J. Maas novel
BMY,2024-02-14,07:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Full year outlook,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2024-02-20,09:42:53,97C893,Bloomsbury Publishing PLC,94,0.0,revenues,,Bloomsbury Publishing PLC: Initially forecasted to generate revenue of GBP291.4 million,PRESS-RELEASE,DJ Global Press Release Wire,Bloomsbury Publishing IR head credits Sarah J. Maas novel in part for stronger financial performance
BMY,2024-02-20,09:42:53,97C893,Bloomsbury Publishing PLC,94,0.64,earnings,up,Bloomsbury Publishing PLC: This surge in profitability,PRESS-RELEASE,DJ Global Press Release Wire,Bloomsbury Publishing IR head credits Sarah J. Maas novel in part for stronger financial performance
BMY,2024-05-20,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: the Company's Preliminary Results for the year ended 29 February 2024,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Investor Presentation
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Audited Preliminary Results for the year ended 29 February 2024,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.6,revenues,up,Bloomsbury Publishing PLC: Consumer revenue growth of 49% to GBP249.2m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: GBP37m turnover in 2027/28,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: our full year dividend to 14.69 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 46.62p 30.56p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 39.11p 24.54p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.68,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 63% to GBP41.5m (2022/23: GBP25.4m),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: GBP37m turnover.,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation was GBP4.9m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.82,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 110% to GBP37.4m (2022/23: GBP17.8m),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Revenues in the division were GBP93.4m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.86,revenues,up,Bloomsbury Publishing PLC: BDR revenue has grown from GBP6.3m in 2018/19 to GBP26.6m in 2023/24,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: Special Interest revenue increased by 6% to GBP22.9m (2022/23: GBP21.7m),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,-0.57,labor-issues,,Bloomsbury Publishing PLC: and step down as Director of the Company,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: GBP37m turnover.,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: o Goal: Expand international revenues.,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: US revenues increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year - - - - - -,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year 32,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year - - - - - -,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -5-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,92,-0.13,equity-actions,up,Bloomsbury Publishing PLC: Print costs are increased by 2% from 2024/2025,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 108,175",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,92,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 40,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 17,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.0,revenues,,Bloomsbury Publishing PLC: During the year sales,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.0,assets,,Bloomsbury Publishing PLC: Total assets,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.0,equity-actions,,Bloomsbury Publishing PLC: Factors affecting tax charge for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,98,0.0,equity-actions,,Bloomsbury Publishing PLC: Tax charge for the year before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,98,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 39.11 p 24.54p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,98,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,98,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 46.62 p 30.56p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,98,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2024-05-23,06:00:22,97C893,Bloomsbury Publishing PLC,99,-0.57,labor-issues,,Bloomsbury Publishing PLC: and step down as Director of the company,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Chairman Succession Announcement
BMY,2024-05-23,07:03:25,97C893,Bloomsbury Publishing PLC,100,-0.43,labor-issues,,Bloomsbury Publishing's Chairman Richard Lambert to Retire,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing's Chairman Richard Lambert to Retire
BMY,2024-05-23,07:05:47,97C893,Bloomsbury Publishing PLC,100,0.64,earnings,up,Bloomsbury Publishing Posts Record Profit,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Posts Record Profit and Revenue
BMY,2024-05-24,15:51:32,97C893,Bloomsbury Publishing PLC,99,0.57,acquisitions-mergers,completed,Bloomsbury Publishing PLC: Having completed 33 acquisitions,PRESS-RELEASE,DJ Global Press Release Wire,Bloomsbury Publishing Plc CEO Nigel Newton Reflects on Exceptional Year and Upgraded Forecasts
BMY,2024-05-29,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.62,acquisitions-mergers,,Bloomsbury Publishing PLC: Acquisition of Rowman & Littlefield,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Acquisition
BMY,2024-05-29,06:39:22,97C893,Bloomsbury Publishing PLC,100,0.55,acquisitions-mergers,,Bloomsbury Publishing Acquires Rowman & Littlefield's Academic Publishing Business for $83 Mln,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Acquires Rowman & Littlefield's Academic Publishing Business for $83 Mln
BMY,2024-06-07,07:18:05,97C893,Bloomsbury Publishing PLC,100,0.95,analyst-ratings,positive,Bloomsbury Publishing Started at Buy by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Bloomsbury Publishing Started at Buy by Deutsche Bank
BMY,2024-06-07,07:18:05,97C893,Bloomsbury Publishing PLC,100,0.0,price-targets,set,Bloomsbury Publishing Target Started at 753.00p by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Bloomsbury Publishing Target Started at 753.00p by Deutsche Bank
BMY,2024-06-14,12:48:12,97C893,Bloomsbury Publishing PLC,99,0.47,labor-issues,,Bloomsbury Publishing PLC: Board Appointment,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Board Appointment
BMY,2024-06-14,16:01:31,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: year and revenues,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -4-
BMY,2024-06-14,16:01:31,97C893,Bloomsbury Publishing PLC,98,-0.49,equity-actions,up,Bloomsbury Publishing PLC: Cost inflation Print Supply Costs Increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -5-
BMY,2024-07-16,06:00:10,97C893,Bloomsbury Publishing PLC,99,0.62,acquisitions-mergers,,Bloomsbury announced the transformational acquisition of Rowman and Littlefield,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2024-07-16,06:58:37,97C893,Bloomsbury Publishing PLC,92,0.0,revenues,,Bloomsbury Digital Resources revenue to GBP41 million for fiscal 2028,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Posts In-Line Performance
BMY,2024-07-16,14:41:52,97C893,Bloomsbury Publishing PLC,99,0.0,investor-relations,,Bloomsbury Publishing PLC: Results of the 2024 Annual General Meeting,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Results of the 2024 Annual General Meeting
BMY,2024-09-02,10:31:47,97C893,Bloomsbury Publishing PLC,99,0.52,insider-trading,,"Bloomsbury Publishing PLC: the Company's Non-executive Chairman, purchased 162 ordinary shares of GBP0.0125",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Director/PDMR Shareholding
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.7,earnings,up,Bloomsbury Publishing PLC: Upgrading full year expectations after,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.56,products-services,,Bloomsbury Publishing PLC: We have been awarded the Great Place to Work,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.58,revenues,up,Bloomsbury Publishing PLC: Non-Consumer revenue growth of 3% to GBP48.5m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: GBP41m revenue in 2027/28,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: First Half Results 2024/25,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 24.68p 17.47p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 20.10p 13.66p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: Interim dividend per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: BDR revenue grew 2%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation was GBP2.7m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.66,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 58% to GBP22.1m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.38,dividends,up,Bloomsbury Publishing PLC: The interim dividend will increase by 5%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: GBP41m of revenue in 2027/28,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Special Interest revenue was GBP10.0m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.38,dividends,up,Bloomsbury Publishing PLC: The interim dividend will increase by 5%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 103.6,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,91,-0.13,equity-actions,up,Bloomsbury Publishing PLC: Print costs are increased by 2% from 2025/2026,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,91,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 70.8,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,91,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 133.9,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,90,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 37,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,94,0.0,dividends,,Bloomsbury Publishing PLC: The proposed interim dividend of 3.89 pence per ordinary share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,94,0.61,earnings,positive,Bloomsbury Publishing PLC: Basic earnings per share 20.38p 13.81p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,94,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,94,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,96,0.0,equity-actions,,Bloomsbury Publishing PLC: Transaction costs of GBP0.7 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,96,0.0,revenues,,"Bloomsbury Publishing PLC: From 28 May 2024, revenue of GBP7.2 million",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2024-10-24,07:15:07,97C893,Bloomsbury Publishing PLC,100,0.65,revenues,up,Bloomsbury Publishing Reports Record Revenue,FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Reports Record Revenue, Profit"
BMY,2024-10-24,07:15:07,97C893,Bloomsbury Publishing PLC,100,0.38,dividends,up,Bloomsbury Publishing PLC: The company said its interim dividend will increase 5%,FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Reports Record Revenue, Profit"
BMY,2024-11-07,06:23:53,97C893,Bloomsbury Publishing PLC,100,0.95,analyst-ratings,positive,Bloomsbury Publishing Started at Buy by Berenberg,NEWS-FLASH,Dow Jones Newswires,Bloomsbury Publishing Started at Buy by Berenberg
BMY,2024-11-07,06:23:53,97C893,Bloomsbury Publishing PLC,100,0.0,price-targets,set,Bloomsbury Publishing Target Started at 825p by Berenberg,NEWS-FLASH,Dow Jones Newswires,Bloomsbury Publishing Target Started at 825p by Berenberg
BMY,2024-12-09,09:18:06,97C893,Bloomsbury Publishing PLC,99,0.52,insider-trading,,"Bloomsbury Publishing PLC: the Company's Non-executive Chairman, purchased 62 ordinary shares of GBP0.0125",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Director/PDMR Shareholding
BMY,2024-01-15,07:00:08,97C893,Bloomsbury Publishing PLC,100,0.53,labor-issues,,Bloomsbury Appoints Head of,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Bloomsbury Appoints Head of Investor Relations
BMY,2024-02-01,15:11:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: our interim results in October,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Bloomsbury launches latest Sarah J. Maas novel
BMY,2024-02-14,07:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Full year outlook,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2024-02-20,09:42:53,97C893,Bloomsbury Publishing PLC,94,0.0,revenues,,Bloomsbury Publishing PLC: Initially forecasted to generate revenue of GBP291.4 million,PRESS-RELEASE,DJ Global Press Release Wire,Bloomsbury Publishing IR head credits Sarah J. Maas novel in part for stronger financial performance
BMY,2024-02-20,09:42:53,97C893,Bloomsbury Publishing PLC,94,0.64,earnings,up,Bloomsbury Publishing PLC: This surge in profitability,PRESS-RELEASE,DJ Global Press Release Wire,Bloomsbury Publishing IR head credits Sarah J. Maas novel in part for stronger financial performance
BMY,2024-05-20,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: the Company's Preliminary Results for the year ended 29 February 2024,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Investor Presentation
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Audited Preliminary Results for the year ended 29 February 2024,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.6,revenues,up,Bloomsbury Publishing PLC: Consumer revenue growth of 49% to GBP249.2m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: GBP37m turnover in 2027/28,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: our full year dividend to 14.69 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 46.62p 30.56p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 39.11p 24.54p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.68,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 63% to GBP41.5m (2022/23: GBP25.4m),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: GBP37m turnover.,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation was GBP4.9m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.82,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 110% to GBP37.4m (2022/23: GBP17.8m),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Revenues in the division were GBP93.4m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.86,revenues,up,Bloomsbury Publishing PLC: BDR revenue has grown from GBP6.3m in 2018/19 to GBP26.6m in 2023/24,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: Special Interest revenue increased by 6% to GBP22.9m (2022/23: GBP21.7m),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,-0.57,labor-issues,,Bloomsbury Publishing PLC: and step down as Director of the Company,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: GBP37m turnover.,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: o Goal: Expand international revenues.,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: US revenues increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year - - - - - -,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year 32,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year - - - - - -,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -5-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,92,-0.13,equity-actions,up,Bloomsbury Publishing PLC: Print costs are increased by 2% from 2024/2025,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 108,175",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,92,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 40,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 17,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.0,revenues,,Bloomsbury Publishing PLC: During the year sales,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.0,assets,,Bloomsbury Publishing PLC: Total assets,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.0,equity-actions,,Bloomsbury Publishing PLC: Factors affecting tax charge for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,98,0.0,equity-actions,,Bloomsbury Publishing PLC: Tax charge for the year before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,98,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 39.11 p 24.54p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,98,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,98,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 46.62 p 30.56p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2024-05-23,06:00:16,97C893,Bloomsbury Publishing PLC,98,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2024-05-23,06:00:22,97C893,Bloomsbury Publishing PLC,99,-0.57,labor-issues,,Bloomsbury Publishing PLC: and step down as Director of the company,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Chairman Succession Announcement
BMY,2024-05-23,07:03:25,97C893,Bloomsbury Publishing PLC,100,-0.43,labor-issues,,Bloomsbury Publishing's Chairman Richard Lambert to Retire,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing's Chairman Richard Lambert to Retire
BMY,2024-05-23,07:05:47,97C893,Bloomsbury Publishing PLC,100,0.64,earnings,up,Bloomsbury Publishing Posts Record Profit,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Posts Record Profit and Revenue
BMY,2024-05-24,15:51:32,97C893,Bloomsbury Publishing PLC,99,0.57,acquisitions-mergers,completed,Bloomsbury Publishing PLC: Having completed 33 acquisitions,PRESS-RELEASE,DJ Global Press Release Wire,Bloomsbury Publishing Plc CEO Nigel Newton Reflects on Exceptional Year and Upgraded Forecasts
BMY,2024-05-29,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.62,acquisitions-mergers,,Bloomsbury Publishing PLC: Acquisition of Rowman & Littlefield,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Acquisition
BMY,2024-05-29,06:39:22,97C893,Bloomsbury Publishing PLC,100,0.55,acquisitions-mergers,,Bloomsbury Publishing Acquires Rowman & Littlefield's Academic Publishing Business for $83 Mln,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Acquires Rowman & Littlefield's Academic Publishing Business for $83 Mln
BMY,2024-06-07,07:18:05,97C893,Bloomsbury Publishing PLC,100,0.95,analyst-ratings,positive,Bloomsbury Publishing Started at Buy by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Bloomsbury Publishing Started at Buy by Deutsche Bank
BMY,2024-06-07,07:18:05,97C893,Bloomsbury Publishing PLC,100,0.0,price-targets,set,Bloomsbury Publishing Target Started at 753.00p by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Bloomsbury Publishing Target Started at 753.00p by Deutsche Bank
BMY,2024-06-14,12:48:12,97C893,Bloomsbury Publishing PLC,99,0.47,labor-issues,,Bloomsbury Publishing PLC: Board Appointment,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Board Appointment
BMY,2024-06-14,16:01:31,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: year and revenues,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -4-
BMY,2024-06-14,16:01:31,97C893,Bloomsbury Publishing PLC,98,-0.49,equity-actions,up,Bloomsbury Publishing PLC: Cost inflation Print Supply Costs Increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -5-
BMY,2024-07-16,06:00:10,97C893,Bloomsbury Publishing PLC,99,0.62,acquisitions-mergers,,Bloomsbury announced the transformational acquisition of Rowman and Littlefield,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2024-07-16,06:58:37,97C893,Bloomsbury Publishing PLC,92,0.0,revenues,,Bloomsbury Digital Resources revenue to GBP41 million for fiscal 2028,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Posts In-Line Performance
BMY,2024-07-16,14:41:52,97C893,Bloomsbury Publishing PLC,99,0.0,investor-relations,,Bloomsbury Publishing PLC: Results of the 2024 Annual General Meeting,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Results of the 2024 Annual General Meeting
BMY,2024-09-02,10:31:47,97C893,Bloomsbury Publishing PLC,99,0.52,insider-trading,,"Bloomsbury Publishing PLC: the Company's Non-executive Chairman, purchased 162 ordinary shares of GBP0.0125",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Director/PDMR Shareholding
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.7,earnings,up,Bloomsbury Publishing PLC: Upgrading full year expectations after,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.56,products-services,,Bloomsbury Publishing PLC: We have been awarded the Great Place to Work,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.58,revenues,up,Bloomsbury Publishing PLC: Non-Consumer revenue growth of 3% to GBP48.5m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: GBP41m revenue in 2027/28,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: First Half Results 2024/25,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 24.68p 17.47p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 20.10p 13.66p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: Interim dividend per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: BDR revenue grew 2%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation was GBP2.7m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.66,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 58% to GBP22.1m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.38,dividends,up,Bloomsbury Publishing PLC: The interim dividend will increase by 5%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: GBP41m of revenue in 2027/28,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Special Interest revenue was GBP10.0m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.38,dividends,up,Bloomsbury Publishing PLC: The interim dividend will increase by 5%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 103.6,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,91,-0.13,equity-actions,up,Bloomsbury Publishing PLC: Print costs are increased by 2% from 2025/2026,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,91,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 70.8,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,91,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 133.9,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,90,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 37,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,94,0.0,dividends,,Bloomsbury Publishing PLC: The proposed interim dividend of 3.89 pence per ordinary share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,94,0.61,earnings,positive,Bloomsbury Publishing PLC: Basic earnings per share 20.38p 13.81p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,94,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,94,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,96,0.0,equity-actions,,Bloomsbury Publishing PLC: Transaction costs of GBP0.7 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2024-10-24,06:00:17,97C893,Bloomsbury Publishing PLC,96,0.0,revenues,,"Bloomsbury Publishing PLC: From 28 May 2024, revenue of GBP7.2 million",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2024-10-24,07:15:07,97C893,Bloomsbury Publishing PLC,100,0.65,revenues,up,Bloomsbury Publishing Reports Record Revenue,FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Reports Record Revenue, Profit"
BMY,2024-10-24,07:15:07,97C893,Bloomsbury Publishing PLC,100,0.38,dividends,up,Bloomsbury Publishing PLC: The company said its interim dividend will increase 5%,FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Reports Record Revenue, Profit"
BMY,2024-11-07,06:23:53,97C893,Bloomsbury Publishing PLC,100,0.95,analyst-ratings,positive,Bloomsbury Publishing Started at Buy by Berenberg,NEWS-FLASH,Dow Jones Newswires,Bloomsbury Publishing Started at Buy by Berenberg
BMY,2024-11-07,06:23:53,97C893,Bloomsbury Publishing PLC,100,0.0,price-targets,set,Bloomsbury Publishing Target Started at 825p by Berenberg,NEWS-FLASH,Dow Jones Newswires,Bloomsbury Publishing Target Started at 825p by Berenberg
BMY,2024-12-09,09:18:06,97C893,Bloomsbury Publishing PLC,99,0.52,insider-trading,,"Bloomsbury Publishing PLC: the Company's Non-executive Chairman, purchased 62 ordinary shares of GBP0.0125",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Director/PDMR Shareholding
BMY,2021-01-04,08:58:27,94637C,Bristol-Myers Squibb Co.,100,-0.65,equity-actions,halt,Bmy) Halted due to news,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Co. Rt (BMY) Halted due to news dissemination
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 39(th) Annual Virtual Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present at J.P. Morgan's 39(th) Annual Virtual Healthcare Conference
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,granted,Bristol-Myers Squibb Co.: The EMA's decision to validate our application,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Business Wire,"European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma"
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -4-
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2021-01-04,11:59:07,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
BMY,2021-01-04,11:59:07,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,granted,Bristol-Myers Squibb Co.: The EMA's decision to validate our application,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
BMY,2021-01-04,11:59:07,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Dow Jones Newswires,"Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma"
BMY,2021-01-04,11:59:11,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,NEWS-FLASH,Dow Jones Newswires,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
BMY,2021-01-04,12:02:31,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 39th Annual Virtual Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present at J.P. Morgan's 39th Annual Virtual Healthcare Conference
BMY,2021-01-04,14:19:10,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers: EMA Validates Two Applications,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: EMA Validates Two Applications for Expanded Opdivo Approval
BMY,2021-01-04,14:34:10,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers: EMA Validates Two Applications,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: EMA Validates Two Applications for Expanded Opdivo Approval
BMY,2021-01-04,21:34:02,94637C,Bristol-Myers Squibb Co.,99,0.44,credit,reduction,Bristol-Myers Squibb Co.: This reflects our assumption that BMY will continue to prioritize debt reduction,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGRBulletin: Bristol-Myers Squibb Co.'s CVR Expires
BMY,2021-01-06,01:14:30,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Ahmed Acquires 7,286 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Ahmed Acquires 7,286 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-01-06,01:15:03,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 8,693 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Elkins Acquires 8,693 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-01-06,01:15:13,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 12,609 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Acquires 12,609 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-01-07,11:00:16,94637C,Bristol-Myers Squibb Co.,100,0.0,equity-actions,,Biomedicines Launches with $62 Million Series A Financing,PRESS-RELEASE,Business Wire,Endeavor BioMedicines Launches with $62 Million Series A Financing and Mission to Reverse the Course of Devastating Pulmonary Disease
BMY,2021-01-07,11:00:16,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: Pending results from the monotherapy study, Endeavor anticipates initiating a second Phase 2 study",PRESS-RELEASE,Business Wire,Endeavor BioMedicines Launches with $62 Million Series A Financing and Mission to Reverse the Course of Devastating Pulmonary Disease
BMY,2021-01-07,12:00:18,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb to Advance Next-Generation T cell Therapies for Solid Tumors
BMY,2021-01-11,11:59:23,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization >BMY
BMY,2021-01-11,11:59:23,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization
BMY,2021-01-11,11:59:24,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization
BMY,2021-01-11,12:01:01,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol-Myers announces $2 bln incremental share buyback,NEWS-FLASH,MarketWatch,MW Bristol-Myers announces $2 bln incremental share buyback authorization
BMY,2021-01-11,12:04:14,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers adds $2 billion to share buyback program,FULL-ARTICLE,MarketWatch,MW Bristol Myers adds $2 billion to share buyback program
BMY,2021-01-11,12:04:14,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers Adds $2 Billion To Share Buyback Program,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Adds $2 Billion To Share Buyback Program -- MarketWatch
BMY,2021-01-11,12:19:18,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers Boosts Buyback Program by $2 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Boosts Buyback Program by $2 Billion >BMY
BMY,2021-01-11,12:34:18,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers Boosts Buyback Program by $2 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Boosts Buyback Program by $2 Billion
BMY,2021-01-11,13:30:25,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Bristol-Myers Squibb Co.: Our collaboration with GRAIL,PRESS-RELEASE,Business Wire,"GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease"
BMY,2021-01-11,13:30:25,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,Bristol-Myers Squibb Co.: Our collaboration with GRAIL,PRESS-RELEASE,Dow Jones Newswires,"Press Release: GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease"
BMY,2021-01-11,16:54:47,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Giovanni Caforio Presents at 39th Annual JPMorgan Virtual Healthcare Conference,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio Presents at 39th Annual JPMorgan Virtual Healthcare Conference - (Transcript) >BMY
BMY,2021-01-11,19:05:24,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,"Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling"
BMY,2021-01-11,19:07:28,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling"
BMY,2021-01-12,21:56:09,94637C,Bristol-Myers Squibb Co.,95,0.44,products-services,,Ticker: BMY) also boosted its share-buying program by,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Looks to Its Drug Pipeline to Turbocharge Growth -- Barrons.com
BMY,2021-01-13,18:30:05,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,"Bristol-Myers Squibb Co.: Today, Allyx Therapeutics announced the completion of a license agreement with Bristol Myers Squibb to develop Allyx's novel therapy",PRESS-RELEASE,PR Newswire,Allyx Therapeutics Announces License For The Treatment of Cognitive Deficits in Neurodegenerative Disorders From Bristol Myers Squibb And Yale
BMY,2021-01-13,18:30:05,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: We look forward to advancing ALX-001 in clinical trials as soon as the beginning of 2021,PRESS-RELEASE,PR Newswire,Allyx Therapeutics Announces License For The Treatment of Cognitive Deficits in Neurodegenerative Disorders From Bristol Myers Squibb And Yale
BMY,2021-01-20,12:21:08,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Wednesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Two Opdivo Indications >BMY
BMY,2021-01-20,12:36:08,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Wednesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Two Opdivo Indications
BMY,2021-01-21,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Fourth Quarter 2020 Earnings Call to,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Earnings Call Time Change; Fourth Quarter 2020 Earnings Call to Occur on February 4, 2021 at 10 a.m. (Eastern Time)"
BMY,2021-01-22,18:18:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Press Release: U.S. Food and Drug Administration Approves OPDIVO(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves OPDIVO(R) (nivolumab) in Combination with CABOMETYX(R) (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
BMY,2021-01-22,18:18:01,94637C,Bristol-Myers Squibb Co.,100,-0.48,legal,,Opdivo and CABOMETYX in the CheckMate -9ER trial make,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves OPDIVO(R) (nivolumab) in Combination with CABOMETYX(R) (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
BMY,2021-01-23,08:57:47,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2020 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2020 (BMY)"
BMY,2021-02-01,11:59:00,94637C,Bristol-Myers Squibb Co.,97,0.57,products-services,granted,Zeposia was approved by the U.S. Food and Drug Administration (FDA) for the treatment,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Application for Zeposia(R) (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug Administration
BMY,2021-02-01,11:59:00,94637C,Bristol-Myers Squibb Co.,97,0.57,products-services,granted,European Medicines Agency validated Bristol Myers Squibb's Marketing Authorization Application,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Application for Zeposia(R) (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug Administration
BMY,2021-02-01,11:59:01,94637C,Bristol-Myers Squibb Co.,98,0.57,products-services,granted,Zeposia was approved by the U.S. Food and Drug Administration (FDA) for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Application for Zeposia(R) (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug Administration
BMY,2021-02-01,11:59:01,94637C,Bristol-Myers Squibb Co.,98,0.57,products-services,granted,European Medicines Agency validated Bristol Myers Squibb's Marketing Authorization Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Application for Zeposia(R) (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug Administration
BMY,2021-02-01,12:45:07,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Zeposia,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Zeposia in Ulcerative Colitis >BMY
BMY,2021-02-01,13:00:07,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Zeposia,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Zeposia in Ulcerative Colitis
BMY,2021-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Sta to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland",PRESS-RELEASE,Business Wire,"WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland"
BMY,2021-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.88,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla(R) (apremilast)
BMY,2021-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla(R) (apremilast)
BMY,2021-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.88,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla(R) (apremilast)
BMY,2021-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla(R) (apremilast)
BMY,2021-02-02,11:59:13,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Sta to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland",NEWS-FLASH,Dow Jones Newswires,"WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland"
BMY,2021-02-02,11:59:22,94637C,Bristol-Myers Squibb Co.,100,0.88,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results From Second Pivotal Phase 3 Psoriasis Study,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Positive Topline Results From Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla
BMY,2021-02-02,12:00:01,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Bristol Myers Squibb to Sell Couvet, Switzerland, Plant to",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb to Sell Couvet, Switzerland, Plant to WuXi STA >BMY"
BMY,2021-02-02,12:11:09,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Sta to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland",PRESS-RELEASE,Dow Jones Newswires,"Press Release: WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland"
BMY,2021-02-03,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Preclinical data,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
BMY,2021-02-03,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: Our collaboration with BMS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
BMY,2021-02-03,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Preclinical data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
BMY,2021-02-03,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: Our collaboration with BMS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
BMY,2021-02-03,21:11:29,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co. said Wednesday it will take over development and manufacturing of a potential Covid-19,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb to Take Over Promising Potential Treatment Against Coronavirus Variants
BMY,2021-02-04,11:30:02,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $950,000,000",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
BMY,2021-02-04,11:30:02,94637C,Bristol-Myers Squibb Co.,93,0.48,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is available on Global Bondholder Services,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Tender Offers for -3-
BMY,2021-02-04,11:30:02,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $950,000,000",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
BMY,2021-02-04,11:30:02,94637C,Bristol-Myers Squibb Co.,93,0.48,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is available on Global Bondholder Services,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers 4Q Adj EPS $1.46,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers 4Q Adj EPS $1.46 >BMY
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers 4Q Loss/Shr $4.45,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers 4Q Loss/Shr $4.45 >BMY
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers 4Q Loss $10B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers 4Q Loss $10B >BMY
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Sees FY Adj EPS $7.35,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Sees FY Adj EPS $7.35-Adj EPS $7.55 >BMY
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers 4Q Rev $11.1B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers 4Q Rev $11.1B >BMY
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.52,revenues,up,"Bristol Myers Squibb posted fourth quarter revenues of $11.1 billion, an increase of 39%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Full-Year Revenues of $42.5 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Full-Year Loss Per Share of $3.99,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol-Myers Squibb Co.: Completes Acquisition of MyoKardia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol-Myers Squibb Co.: Announces Debt Tender Offer,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb Co.: Raises 2021 Non-GAAP EPS Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.62,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increased 79%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: The results in the current quarter,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: FULL-YEAR PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The U.S. FDA granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Ec) has approved Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: TRANSCEND CLL 004: longer-term follow-up from the Phase I study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,Successfully completed its acquisition of MyoKardia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,credit,,Bristol-Myers Squibb Co.: the company announced a debt tender offer,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,,Bristol-Myers Squibb Co.: the company plans to repurchase $3.0-$4.0 billion of its shares,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers Squibb Co.: By 2030, the company will purchase 100% of the electricity it uses from renewable sources, and",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: There will be a conference call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.58,security,,Bristol-Myers Squibb Co.: cyber-attacks on the company's information systems,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED DECEMBER 31, 2020",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Celgene product revenues from November 20, 2019",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2020",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Celgene product revenues from November 20, 2019",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -6-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -6-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -7-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.52,revenues,up,"Bristol Myers Squibb posted fourth quarter revenues of $11.1 billion, an increase of 39%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Full-Year Revenues of $42.5 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Full-Year Loss Per Share of $3.99,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol-Myers Squibb Co.: Completes Acquisition of MyoKardia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol-Myers Squibb Co.: Announces Debt Tender Offer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb Co.: Raises 2021 Non-GAAP EPS Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.62,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increased 79%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: The results in the current quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: FULL-YEAR PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The U.S. FDA granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Ec) has approved Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: TRANSCEND CLL 004: longer-term follow-up from the Phase I study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,Successfully completed its acquisition of MyoKardia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,credit,,Bristol-Myers Squibb Co.: the company announced a debt tender offer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,,Bristol-Myers Squibb Co.: the company plans to repurchase $3.0-$4.0 billion of its shares,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers Squibb Co.: By 2030, the company will purchase 100% of the electricity it uses from renewable sources, and",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: There will be a conference call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.58,security,,Bristol-Myers Squibb Co.: cyber-attacks on the company's information systems,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED DECEMBER 31, 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Celgene product revenues from November 20, 2019",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Celgene product revenues from November 20, 2019",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2021-02-04,11:59:38,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb Sees 2021 Worldwide Revenue Up,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees 2021 Worldwide Revenue Up in High-Single Digits >BMY
BMY,2021-02-04,12:01:34,94637C,Bristol-Myers Squibb Co.,100,0.4,earnings,up,Bristol-Myers Q4 loss per share 45 cents vs loss 55 cents a year ago,NEWS-FLASH,MarketWatch,MW Bristol-Myers Q4 loss per share 45 cents vs loss 55 cents a year ago
BMY,2021-02-04,12:01:46,94637C,Bristol-Myers Squibb Co.,100,0.46,earnings,above-expectations,Bristol-Myers Q4 adj. EPS $1.46; FactSet consensus $1.42,NEWS-FLASH,MarketWatch,MW Bristol-Myers Q4 adj. EPS $1.46; FactSet consensus $1.42
BMY,2021-02-04,12:02:12,94637C,Bristol-Myers Squibb Co.,100,0.48,revenues,above-expectations,Bristol-Myers Q4 revenue $11.068 bln vs. $7.945 bln; FactSet consensus $10.728 bln,NEWS-FLASH,MarketWatch,MW Bristol-Myers Q4 revenue $11.068 bln vs. $7.945 bln; FactSet consensus $10.728 bln
BMY,2021-02-04,12:02:41,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Sees 2021 EPS $3.12,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees 2021 EPS $3.12-EPS $3.32 >BMY
BMY,2021-02-04,12:03:19,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers now sees 2021 EPS of $3.12 to $3.32,NEWS-FLASH,MarketWatch,MW Bristol-Myers now sees 2021 EPS of $3.12 to $3.32
BMY,2021-02-04,12:04:06,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers now sees 2021 adj. EPS $7.35 to $7.55,NEWS-FLASH,MarketWatch,MW Bristol-Myers now sees 2021 adj. EPS $7.35 to $7.55 up from prior range of $7.15 to $7.45
BMY,2021-02-04,12:06:51,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers now sees 2021 revenue up,NEWS-FLASH,MarketWatch,MW Bristol-Myers now sees 2021 revenue up in high-single digits
BMY,2021-02-04,12:21:45,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol Myers posts $10 billion loss as,FULL-ARTICLE,MarketWatch,MW Bristol Myers posts $10 billion loss as it books charges relating to MyoKardia and Celgene
BMY,2021-02-04,12:21:45,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol Myers Posts $10 Billion Loss As,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Posts $10 Billion Loss As It Books Charges Relating To MyoKardia And Celgene -- MarketWatch
BMY,2021-02-04,12:29:15,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,12:29:15,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: net loss attributable to the company was $10.03 billion,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,12:29:15,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Opdivo sales climbed 2%,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,12:44:15,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,"Bristol Myers Squibb Posts 4Q Adjusted Profit, Growth",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adjusted Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,12:44:15,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: net loss attributable to the company was $10.03 billion,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adjusted Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,12:44:15,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Opdivo sales climbed 2%,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adjusted Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,14:50:03,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,14:50:03,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: net loss attributable to the company was $10.03 billion,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,14:50:03,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Opdivo sales climbed 2%,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,15:11:58,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: The company reported non-GAAP earnings of $1.46 per share for the quarter,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Just Beat Estimates. The Stock Isn't Going Anywhere. -- Barrons.com
BMY,2021-02-04,22:15:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co CEO Giovanni Caforio on Q4 2020 Results -- Earnings Call,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Co CEO Giovanni Caforio on Q4 2020 Results -- Earnings Call Transcript >BMY
BMY,2021-02-05,20:02:38,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves New Treatment From Bristol-Myers,NEWS-FLASH,Dow Jones Newswires,FDA Approves New Treatment From Bristol-Myers Unit for Adults With Relapsed or Refractory Large-B-Cell Lymphoma
BMY,2021-02-08,16:04:49,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Bristol Myers Squibb's CAR,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Bristol Myers Squibb's CAR-T Therapy -- MarketWatch
BMY,2021-02-08,16:04:49,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda approves Bristol Myers Squibb's CAR,FULL-ARTICLE,MarketWatch,MW FDA approves Bristol Myers Squibb's CAR-T therapy
BMY,2021-02-08,17:12:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Inrebic(R) (fedratinib),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Inrebic(R) (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
BMY,2021-02-08,17:12:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The Inrebic development program,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Inrebic(R) (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
BMY,2021-02-08,17:12:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Inrebic(R) (fedratinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Inrebic(R) (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
BMY,2021-02-08,17:12:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The Inrebic development program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Inrebic(R) (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
BMY,2021-02-08,17:12:11,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Inrebic,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Inrebic for Adult Patients With Newly Diagnosed and Previously Treated Myelofibrosis
BMY,2021-02-08,17:56:25,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Says EC Approves Inrebic,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says EC Approves Inrebic to Treat Myelofibrosis Patients
BMY,2021-02-08,18:11:25,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Says EC Approves Inrebic,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says EC Approves Inrebic to Treat Myelofibrosis Patients
BMY,2021-02-09,00:30:13,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 2,406 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Acquires 2,406 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-02-09,00:30:24,94637C,Bristol-Myers Squibb Co.,100,0.0,insider-trading,,Chmn Caforio Gifts 480 Of Bristol-Myers Squibb Co >BMY,TABULAR-MATERIAL,Dow Jones Newswires,Chmn Caforio Gifts 480 Of Bristol-Myers Squibb Co >BMY
BMY,2021-02-09,00:30:44,94637C,Bristol-Myers Squibb Co.,100,0.0,insider-trading,,"Vp Leung Gifts 87,704 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Leung Gifts 87,704 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-02-09,14:00:21,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Lyfebulb and Bristol Myers Squibb teams for,PRESS-RELEASE,PR Newswire,Lyfebulb and Bristol Myers Squibb Announce the Finalists for the 2021 MS Innovation Challenge
BMY,2021-02-11,12:30:04,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer
BMY,2021-02-11,12:30:04,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer
BMY,2021-02-11,12:31:08,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for Discovery and Development of Next Generation Engineered Toxin Bodies for Treatment of Cancer
BMY,2021-02-11,13:57:33,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Molecular Templates in Cancer Collaboration With Bristol Myers,FULL-ARTICLE,Dow Jones Newswires,Molecular Templates in Cancer Collaboration With Bristol Myers >MTEM
BMY,2021-02-11,14:12:34,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Molecular Templates in Cancer Collaboration With Bristol Myers,FULL-ARTICLE,Dow Jones Newswires,Molecular Templates in Cancer Collaboration With Bristol Myers
BMY,2021-02-19,02:29:01,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $950,000,000",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Early Participation Results and Early Settlement of Tender Offers for Up to an Aggregate Purchase Price of Up to $4.0 Billion
BMY,2021-02-19,09:46:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb Enters Agreement to Acquire Forbius,PRESS-RELEASE,Business Wire,"TGFb inhibitors Pipeline Insight Report 2021: In 2020, Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio - ResearchAndMarkets.com"
BMY,2021-02-19,10:42:00,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Collaboration between Five Prime Therapeutics and BMS,PRESS-RELEASE,Business Wire,Global TIM-3 Inhibitor Pipeline Insight Report 2021: Emerging Drugs Include Cobolimab (GlaxoSmithKline) & BMS-986258 (Bristol-Myers Squibb) - ResearchAndMarkets.com
BMY,2021-02-19,22:04:00,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $950,000,000",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
BMY,2021-02-19,22:04:01,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $950,000,000",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
BMY,2021-02-22,12:00:10,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo(R)
BMY,2021-02-22,12:00:10,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo(R)
BMY,2021-02-22,12:03:54,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Compugen Expands Clinical Collaboration Agreement With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Compugen Expands Clinical Collaboration Agreement With Bristol Myers Squibb With Phase 1b Combination Study of COM701 With Opdivo
BMY,2021-02-22,23:15:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: the acquisition of Celgene;,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and Celgene Issue Notices of -2-
BMY,2021-02-23,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Raymond James Virtual 42(nd) Annual Institutional Investors Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Raymond James Virtual 42(nd) Annual Institutional Investors Conference
BMY,2021-02-23,12:04:34,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Raymond James Virtual 42nd Annual Institutional Investors Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Raymond James Virtual 42nd Annual Institutional Investors Conference
BMY,2021-02-23,14:00:03,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Proud to partner with Bristol Myers Squibb on,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb and the American Music Therapy Association Team Up with Ben Platt and Sister-in-Law Courtney Platt to Launch MS in Harmony, a First-of-its-Kind Music Therapy Offering for People Living with Multiple Sclerosis (MS)"
BMY,2021-02-23,14:33:34,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Proud to partner with Bristol Myers Squibb on,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb and the American Music Therapy Association Team Up with Ben Platt and Sister-in-Law Courtney Platt to Launch MS in Harmony, a First-of-its-Kind Music Therapy Offering for People Living with Multiple Sclerosis (MS)"
BMY,2021-02-24,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.26,corporate-responsibility,,Bristol Myers Squibb Donates $11 Million to,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Donates $11 Million to Advance Health Equity
BMY,2021-02-24,12:07:23,94637C,Bristol-Myers Squibb Co.,100,0.26,corporate-responsibility,,Bristol Myers Squibb Donates $11 Million to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Donates $11 Million to Advance Health Equity
BMY,2021-02-24,12:10:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in the Cowen Virtual 41(st) Annual Health Care Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Take Part in the Cowen Virtual 41(st) Annual Health Care Conference
BMY,2021-02-24,12:10:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in the Cowen Virtual 41st Annual Health Care Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in the Cowen Virtual 41st Annual Health Care Conference
BMY,2021-02-26,11:25:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) in Combination with Cabometyx(R) (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
BMY,2021-02-26,11:25:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2021-02-26,11:25:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2021-02-26,11:25:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-02-26,11:25:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) in Combination with Cabometyx(R) (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
BMY,2021-02-26,11:25:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2021-02-26,11:25:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-02-26,11:25:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-02-26,11:25:40,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo in Combination With Cabometyx as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
BMY,2021-03-01,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2021-03-01,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on May 3, 2021 to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2021-03-02,21:38:26,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co (BMY) Presents at 42nd Annual Raymond James Institutional Investor Conference,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Co (BMY) Presents at 42nd Annual Raymond James Institutional Investor Conference (Transcript) >BMY
BMY,2021-03-03,19:52:50,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co. Management Presents at Cowen Virtual 41st Annual Health Care Conference Call,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Co. Management Presents at Cowen Virtual 41st Annual Health Care Conference Call Transcript >BMY
BMY,2021-03-03,22:56:25,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 14,405 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Acquires 14,405 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-03,22:57:45,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 16,006 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 16,006 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-09,21:57:51,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Company (BMY) Presents at Barclays Global Healthcare Conference,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Company (BMY) Presents at Barclays Global Healthcare Conference (Transcript) >BMY
BMY,2021-03-11,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021"
BMY,2021-03-11,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: During a conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021"
BMY,2021-03-11,12:06:19,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021"
BMY,2021-03-11,12:06:19,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: During a conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021"
BMY,2021-03-11,22:58:06,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: This partnership with Lyfebulb represents one of many with the MS,PRESS-RELEASE,PR Newswire,Lyfebulb and Bristol Myers Squibb Announce the Winner of the 2021 Innovation Challenge in Multiple Sclerosis
BMY,2021-03-12,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Aveo Oncology Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA(R) (tivozanib) in Combination with OPDIVO(R) (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma
BMY,2021-03-12,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Aveo Oncology Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA(R) (tivozanib) in Combination with OPDIVO(R) (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma
BMY,2021-03-12,12:07:40,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Aveo Oncology: Collaboration With Bristol Myers Squibb to,NEWS-FLASH,Dow Jones Newswires,AVEO Oncology: Collaboration With Bristol Myers Squibb to Evaluate Fotivda in Combination With Opdivo in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma
BMY,2021-03-12,23:53:47,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp von Autenried Acquires 10,285 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP von Autenried Acquires 10,285 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:54:08,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 3,918 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Acquires 3,918 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:55:33,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Santiago Acquires 4,821 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Santiago Acquires 4,821 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:56:04,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Powell Acquires 15,506 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Powell Acquires 15,506 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:56:43,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Leung Acquires 19,173 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Leung Acquires 19,173 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:57:17,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Schmukler Acquires 16,986 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Schmukler Acquires 16,986 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:57:51,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 2,211 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Acquires 2,211 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:58:44,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 3,696 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 3,696 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:59:22,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Eid Acquires 3,942 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Eid Acquires 3,942 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-13,00:01:19,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Dubow Acquires 3,494 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Dubow Acquires 3,494 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-13,00:01:28,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Boerner Acquires 12,364 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Boerner Acquires 12,364 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-13,00:01:41,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Chmn Caforio Acquires 88,476 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Chmn Caforio Acquires 88,476 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-19,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food And Drug Administration (FDA) Accepts Bristol Myers Squibb's Application,NEWS-FLASH,Dow Jones Newswires,U.S. Food And Drug Administration (FDA) Accepts Bristol Myers Squibb's Application For Mavacamten In Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) >BMY
BMY,2021-03-19,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb's Application,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb's Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
BMY,2021-03-19,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: The NDA submission,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb's Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
BMY,2021-03-19,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb's Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb's Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
BMY,2021-03-19,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: The NDA submission,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb's Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
BMY,2021-03-19,10:59:47,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Accepts Application for Mavacamten,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: FDA Accepts Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy >BMY
BMY,2021-03-19,11:21:48,94637C,Bristol-Myers Squibb Co.,96,0.0,products-services,,Bristol-Myers Squibb Co.: The company said its FDA filing is based on the results of a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: FDA to Review Mavacamten in Hypertrophic Cardiomyopathy >BMY
BMY,2021-03-19,11:21:48,94637C,Bristol-Myers Squibb Co.,96,0.62,acquisitions-mergers,,"Myokardia Inc., which Bristol Myers bought last year",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: FDA to Review Mavacamten in Hypertrophic Cardiomyopathy >BMY
BMY,2021-03-19,11:36:48,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: The company said its FDA filing is based on the results of a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: FDA to Review Mavacamten in Hypertrophic Cardiomyopathy
BMY,2021-03-19,11:36:48,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,"Myokardia Inc., which Bristol Myers bought last year",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: FDA to Review Mavacamten in Hypertrophic Cardiomyopathy
BMY,2021-03-24,20:42:16,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co",FULL-ARTICLE,Dow Jones Newswires,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-25,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,"Bristol-Myers Squibb Co.: RELATIVITY-047 (CA224-047) is a randomized, double-blind Phase 2/3 study",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival"
BMY,2021-03-25,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces RELATIVITY-047, a -4-"
BMY,2021-03-25,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces RELATIVITY-047, a -4-"
BMY,2021-03-25,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces RELATIVITY-047, a -5-"
BMY,2021-03-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,"Bristol-Myers Squibb Co.: RELATIVITY-047 (CA224-047) is a randomized, double-blind Phase 2/3 study",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival"
BMY,2021-03-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2021-03-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2021-03-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -5-
BMY,2021-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: The application is based on results from CheckMate -274, the first positive Phase 3 trial",PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2021-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2021-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2021-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2021-03-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-03-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: The application is based on results from CheckMate -274, the first positive Phase 3 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-03-29,10:59:12,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,NEWS-FLASH,Dow Jones Newswires,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo as Adjuvant Treatment for Patients With Muscle-Invasive Urothelial Carcinoma
BMY,2021-03-30,12:05:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma
BMY,2021-03-30,12:05:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: Press Release: Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma
BMY,2021-04-02,17:15:46,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Mily Acquires 3,394 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Mily Acquires 3,394 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-04-07,07:00:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Psioxus Therapeutics Updates Agreement with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration
BMY,2021-04-07,07:00:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to,PRESS-RELEASE,Business Wire,PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration
BMY,2021-04-08,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo (nivolumab) -3-
BMY,2021-04-08,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo (nivolumab) -4-
BMY,2021-04-08,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo (nivolumab) -5-
BMY,2021-04-08,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo (nivolumab) -5-
BMY,2021-04-08,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2021-04-08,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2021-04-08,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -5-
BMY,2021-04-08,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -5-
BMY,2021-04-08,11:28:25,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Yervoy Show Positive Phase 3 Results,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb's Opdivo, Yervoy Show Positive Phase 3 Results for Additional Application"
BMY,2021-04-08,11:43:25,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Yervoy Show Positive Phase 3 Results,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb's Opdivo, Yervoy Show Positive Phase 3 Results for Additional Application"
BMY,2021-04-08,23:35:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,CORRECTING and REPLACING Bristol Myers Squibb -4-
BMY,2021-04-08,23:35:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,CORRECTING and REPLACING Bristol Myers Squibb -4-
BMY,2021-04-08,23:35:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,CORRECTING and REPLACING Bristol Myers Squibb -5-
BMY,2021-04-08,23:35:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,CORRECTING and REPLACING Bristol Myers Squibb -5-
BMY,2021-04-13,11:21:06,94637C,Bristol-Myers Squibb Co.,100,0.94,analyst-ratings,positive,Bristol Myers Squibb upgraded to buy from hold,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb upgraded to buy from hold at Truist
BMY,2021-04-13,12:11:12,94637C,Bristol-Myers Squibb Co.,100,0.94,analyst-ratings,positive,Bristol Myers Squibb Raised to Buy From Hold by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Raised to Buy From Hold by Truist Securities
BMY,2021-04-13,12:11:12,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol Myers Squibb Price Target Raised to $74.00/Share From $66.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Raised to $74.00/Share From $66.00 by Truist Securities
BMY,2021-04-14,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cabometyx(R) (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
BMY,2021-04-14,20:16:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2021-04-14,20:16:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2021-04-14,20:16:00,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2021-04-14,20:16:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -6-
BMY,2021-04-14,20:16:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cabometyx(R) (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
BMY,2021-04-14,20:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-04-14,20:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-04-14,20:16:01,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-04-14,20:16:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -6-
BMY,2021-04-14,20:16:53,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab),NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination With Cabometyx(R) (cabozantinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
BMY,2021-04-14,20:28:54,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets EU Approval for Renal Cell Carcinoma Treatment,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets EU Approval for Renal Cell Carcinoma Treatment
BMY,2021-04-14,20:28:54,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Co. said Wednesday the European Commission has approved its drug nivolumab,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets EU Approval for Renal Cell Carcinoma Treatment
BMY,2021-04-14,20:43:54,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets EU Approval for Renal Cell Carcinoma Treatment,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets EU Approval for Renal Cell Carcinoma Treatment
BMY,2021-04-14,20:43:54,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Co. said Wednesday the European Commission has approved its drug nivolumab,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets EU Approval for Renal Cell Carcinoma Treatment
BMY,2021-04-16,17:10:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma...."
BMY,2021-04-16,17:11:57,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma...."
BMY,2021-04-16,17:14:33,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets FDA OK For Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA OK For Opdivo in First-Line Gastric Cancer Treatment >BMY
BMY,2021-04-16,17:29:32,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets FDA OK For Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA OK For Opdivo in First-Line Gastric Cancer Treatment
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-04-23,10:51:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg(R) (azacitidine tablets,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg(R) (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
BMY,2021-04-23,10:51:00,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: The study enrolled 472 patients,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg(R) (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
BMY,2021-04-23,10:51:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg(R) (azacitidine tablets,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg(R) (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
BMY,2021-04-23,10:51:01,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: The study enrolled 472 patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg(R) (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
BMY,2021-04-23,10:52:40,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg (Azacitidine Tablets,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg (Azacitidine Tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults With Acute Myeloid Leukemia in First Remission
BMY,2021-04-23,14:00:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla(R) (apremilast)
BMY,2021-04-23,14:00:01,94637C,Bristol-Myers Squibb Co.,99,0.31,corporate-responsibility,,Bristol Myers Squibb will host a virtual Investor Event on Friday,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Positive Data from -2-
BMY,2021-04-23,14:00:01,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Positive Data from -2-
BMY,2021-04-23,14:00:41,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Presents Positive Data From Two Pivotal Phase 3 Psoriasis Studies,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Presents Positive Data From Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla
BMY,2021-04-23,14:00:59,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Presents Positive Data From Two Pivotal Phase 3 Psoriasis Studies,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Presents Positive Data From Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla
BMY,2021-04-23,14:01:44,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla(R) (apremilast)
BMY,2021-04-23,14:01:44,94637C,Bristol-Myers Squibb Co.,99,0.31,corporate-responsibility,,Bristol Myers Squibb will host a virtual Investor Event on Friday,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2021-04-23,14:01:44,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2021-04-24,07:21:18,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2021 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2021 (BMY)"
BMY,2021-04-26,05:50:29,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Bristol MYERS SQUIBB EXTENDS COLLABORATION WITH EVOTEC IN,PRESS-RELEASE,DJ Global Press Release Wire,Bristol Myers Squibb Exercises Option to Extend Targeted Protein Degradation Partnership with Evotec
BMY,2021-04-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in the 7(th) Annual Truist Life Sciences Summit,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Take Part in the 7(th) Annual Truist Life Sciences Summit
BMY,2021-04-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in the 7th Annual Truist Life Sciences Summit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in the 7th Annual Truist Life Sciences Summit
BMY,2021-04-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will participate in a fireside chat at the 7(th) Annual Virtual Truist Life Sciences Summit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in the 7th Annual Truist Life Sciences Summit
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 1Q Adj EPS $1.74,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q Adj EPS $1.74 >BMY
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Sees FY EPS $3.18,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY EPS $3.18-EPS $3.38 >BMY
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 1Q EPS 89c,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q EPS 89c >BMY
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Sees FY Adj EPS $7.35,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY Adj EPS $7.35-Adj EPS $7.55 >BMY
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 1Q Net $2B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q Net $2B >BMY
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 1Q Rev $11.1B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q Rev $11.1B >BMY
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports First Quarter Financial Results for 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports First Quarter Revenues of $11.1 Billion, an Increase of 3% YoY",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts First Quarter Earnings Per Share of $0.89,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Presents Positive Results from POETYK-1 and POETYK-PSO-2 Phase 3 Trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Announces FDA Acceptance of New Drug Application,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.24,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 6% to $2.2 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced the FDA approved Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -274 is the first positive Phase 3 trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Fda has approved Breyanzi(R) (lisocabtagene maraleucel,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.31,credit,,Bristol-Myers Squibb Co.: the company purchased approximately $4.0 billion in aggregate purchase price of certain debt,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,-0.58,security,,Bristol-Myers Squibb Co.: cyber-attacks on the company's information systems,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports First Quarter Financial Results for 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports First Quarter Revenues of $11.1 Billion, an Increase of 3% YoY",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts First Quarter Earnings Per Share of $0.89,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Presents Positive Results from POETYK-1 and POETYK-PSO-2 Phase 3 Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Announces FDA Acceptance of New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.24,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 6% to $2.2 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced the FDA approved Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -274 is the first positive Phase 3 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Fda has approved Breyanzi(R) (lisocabtagene maraleucel,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.31,credit,,Bristol-Myers Squibb Co.: the company purchased approximately $4.0 billion in aggregate purchase price of certain debt,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.58,security,,Bristol-Myers Squibb Co.: cyber-attacks on the company's information systems,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2021-04-29,11:00:27,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb Sees 2021 Worldwide Revenues Up,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees 2021 Worldwide Revenues Up High-Single Digits
BMY,2021-04-29,11:00:46,94637C,Bristol-Myers Squibb Co.,100,0.88,earnings,up,Bristol Myers Squibb Q1 EPS 89 cents vs. per-share loss 34 cents a year ago,NEWS-FLASH,MarketWatch,Bristol Myers Squibb Q1 EPS 89 cents vs. per-share loss 34 cents a year ago
BMY,2021-04-29,11:01:12,94637C,Bristol-Myers Squibb Co.,100,0.4,earnings,up,Bristol Myers Q1 adj. EPS $1.74 vs. $1.72 a year ago,NEWS-FLASH,MarketWatch,Bristol Myers Q1 adj. EPS $1.74 vs. $1.72 a year ago; FactSet consensus $1.81
BMY,2021-04-29,11:01:31,94637C,Bristol-Myers Squibb Co.,100,-0.27,revenues,below-expectations,Bristol Myers Q1 revenue $11.07 bln vs. $10.78 bln a year ago; FactSet consensus $11.13 bln,NEWS-FLASH,MarketWatch,Bristol Myers Q1 revenue $11.07 bln vs. $10.78 bln a year ago; FactSet consensus $11.13 bln
BMY,2021-04-29,11:02:55,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,unchanged,Bristol Myers affirms 2021 adj. EPS outlook $7.35-$7.55,NEWS-FLASH,MarketWatch,Bristol Myers affirms 2021 adj. EPS outlook $7.35-$7.55
BMY,2021-04-29,11:11:22,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Revlimid sales rose 1%,FULL-ARTICLE,MarketWatch,"Bristol Myers Squibb stock falls, as profit and revenue rise but miss expectations"
BMY,2021-04-29,11:11:22,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Eliquis sales grew 9%,FULL-ARTICLE,MarketWatch,"Bristol Myers Squibb stock falls, as profit and revenue rise but miss expectations"
BMY,2021-04-29,11:11:22,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Revlimid sales rose 1%,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Stock Falls, As Profit And Revenue Rise But Miss Expectations -- MarketWatch"
BMY,2021-04-29,11:11:22,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Eliquis sales grew 9%,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Stock Falls, As Profit And Revenue Rise But Miss Expectations -- MarketWatch"
BMY,2021-04-29,11:20:27,94637C,Bristol-Myers Squibb Co.,94,0.65,revenues,up,Bristol-Myers Squibb Co. Thursday posted first-quarter revenue growth,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb 1Q Revenue, Profit Land Below Expectations"
BMY,2021-04-29,11:35:28,94637C,Bristol-Myers Squibb Co.,94,0.65,revenues,up,Bristol-Myers Squibb Co. Thursday posted first-quarter revenue growth,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb 1Q Revenue, Profit Land Below Expectations"
BMY,2021-04-29,13:04:56,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb reported earnings early Thursday,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Stock Fell After Earnings. Here's Why. -- Barrons.com
BMY,2021-04-29,13:04:56,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers (ticker: BMY) reported non-GAAP earnings of $1.74 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Stock Fell After Earnings. Here's Why. -- Barrons.com
BMY,2021-04-29,13:20:03,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb reported earnings early Thursday,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Stock Fell After Earnings. Here's Why.
BMY,2021-04-29,13:20:03,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers (ticker: BMY) reported non-GAAP earnings of $1.74 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Stock Fell After Earnings. Here's Why.
BMY,2021-04-29,20:49:03,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb's CEO Giovanni Caforio on Q1 2021 Results -- Earnings Call,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb's CEO Giovanni Caforio on Q1 2021 Results -- Earnings Call Transcript >BMY
BMY,2021-04-29,20:49:03,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-myers-squibbs-bmy-ceo-giovanni-caforio-on-q1-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb's CEO Giovanni Caforio on Q1 2021 Results -- Earnings Call Transcript >BMY
BMY,2021-04-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-04-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -274 is one of four positive Phase 3 trials,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-04-30,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-04-30,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -274 is one of four positive Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-04-30,11:13:31,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Opdivo in Muscle-Invasive Urothelial Carcinoma
BMY,2021-04-30,11:28:30,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Opdivo in Muscle-Invasive Urothelial Carcinoma
BMY,2021-04-30,13:55:43,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol Myers Squibb bought the biotech Celgene for $80 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Deal Sweetener for Celgene Looked Good at the Time. Why Shareholders Missed Out on an Extra $6 Billion. -- Barrons.com
BMY,2021-04-30,13:55:43,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,"Celgene drugs, ozanimod, received FDA approval",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Deal Sweetener for Celgene Looked Good at the Time. Why Shareholders Missed Out on an Extra $6 Billion. -- Barrons.com
BMY,2021-05-03,13:11:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Findings from the interim analysis,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology's 70(th) Annual Scientific Session
BMY,2021-05-03,13:11:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Findings from the interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology's 70th Annual Scientific Session
BMY,2021-05-04,20:00:52,94637C,Bristol-Myers Squibb Co.,100,-0.57,credit-ratings,withdrawn,Fitch Plans to Withdraw Bristol-Myers Squibb 's Ratings,NEWS-FLASH,Dow Jones Newswires,Fitch Plans to Withdraw Bristol-Myers Squibb 's Ratings
BMY,2021-05-04,20:00:52,94637C,Bristol-Myers Squibb Co.,100,-0.57,credit-ratings,withdrawn,Fitch Plans to Withdraw Bristol-Myers Squibb 's Ratings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Fitch Plans to Withdraw Bristol-Myers Squibb 's Ratings
BMY,2021-05-05,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference
BMY,2021-05-05,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference
BMY,2021-05-06,12:03:22,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,Canadian News Wire,DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative
BMY,2021-05-06,12:03:22,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: PR) DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,(PR) DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative
BMY,2021-05-06,12:03:22,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: Press Release: DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative
BMY,2021-05-06,12:03:22,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: Press Release: DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative
BMY,2021-05-06,12:04:44,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Research Collaboration With Bristol Myers Squibb for,NEWS-FLASH,Dow Jones Newswires,DarwinHealth Announces a Research Collaboration With Bristol Myers Squibb for a Novel Cancer Target DiscoveryInitiative
BMY,2021-05-06,13:15:07,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,Apixaban was launched in China in 2013,PRESS-RELEASE,PR Newswire,"China Apixaban Market Report 2021-2025 Featuring BMS/Pfizer EEIG (ELIQUIS), Chia Tai Tianqing (Anbeining), Jiangsu Hansoh (Zexin), Sichuan Kelun (Pukesha), & Jiangsu Sinobiopharma (Yipaiping)"
BMY,2021-05-07,20:58:12,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Vessey Sells 30,546 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Sells 30,546 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-05-07,20:59:11,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Dubow Sells 3,119 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Dubow Sells 3,119 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-05-11,20:40:13,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 9,251 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Acquires 9,251 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-05-11,20:40:43,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Schmukler Sells 15,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Schmukler Sells 15,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-05-11,20:40:53,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Eid Sells 1,118 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Eid Sells 1,118 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-05-12,15:43:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: In collaboration with the community, we're working to",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders
BMY,2021-05-12,15:43:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Research at -6-
BMY,2021-05-12,15:43:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Research at -6-
BMY,2021-05-12,15:43:00,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Research at -8-
BMY,2021-05-12,15:43:00,94637C,Bristol-Myers Squibb Co.,90,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Research at -10-
BMY,2021-05-12,15:43:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Research at -11-
BMY,2021-05-12,15:45:17,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: In collaboration with the community, we're working to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders
BMY,2021-05-12,15:45:17,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: A Phase 3 Study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -3-
BMY,2021-05-12,15:45:17,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -6-
BMY,2021-05-12,15:45:17,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -6-
BMY,2021-05-12,15:45:17,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -8-
BMY,2021-05-12,15:45:17,94637C,Bristol-Myers Squibb Co.,90,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -10-
BMY,2021-05-12,15:45:17,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -11-
BMY,2021-05-18,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb Announce Exclusive Global License for Agenus,PRESS-RELEASE,GlobeNewswire,Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Pleased to partner with Bristol Myers Squibb to,PRESS-RELEASE,GlobeNewswire,Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb Announce Exclusive Global License for Agenus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Pleased to partner with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb Announce Exclusive Global License for Agenus,PRESS-RELEASE,Business Wire,Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Pleased to partner with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb Announce Exclusive Global License for Agenus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Pleased to partner with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:18,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb Announce Exclusive Global License for Agenus,NEWS-FLASH,Dow Jones Newswires,"Agenus, Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program"
BMY,2021-05-18,11:30:56,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb Announce Exclusive Global License for Agenus,NEWS-FLASH,Dow Jones Newswires,Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:48:54,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol-Myers Licenses Agenus AGEN1777 Program >BMY,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Licenses Agenus AGEN1777 Program >BMY AGEN
BMY,2021-05-18,12:03:54,94637C,Bristol-Myers Squibb Co.,95,0.39,products-services,,Bristol Myers Squibb Co. and Agenus Inc. Tuesday said they signed a licensing agreement,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Licenses Agenus AGEN1777 Program
BMY,2021-05-19,08:00:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb",PRESS-RELEASE,Business Wire,"Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb"
BMY,2021-05-19,10:53:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Exscientia collaboration with Bristol Myers Squibb,PRESS-RELEASE,LSE Regulatory News Service (RNS),Frontier IP Group plc Exscientia collaboration with Bristol Myers Squibb
BMY,2021-05-19,21:00:02,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces LAG-3-Blocking -4-
BMY,2021-05-19,21:00:02,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces LAG-3-Blocking -4-
BMY,2021-05-19,21:00:02,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces LAG-3-Blocking -5-
BMY,2021-05-19,21:00:02,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces LAG-3-Blocking -6-
BMY,2021-05-19,21:01:30,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2021-05-19,21:01:30,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2021-05-19,21:01:30,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -5-
BMY,2021-05-19,21:01:30,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -6-
BMY,2021-05-20,10:59:31,94637C,Bristol-Myers Squibb Co.,100,0.47,labor-issues,,Bristol Myers Squibb Names Manuel Hidalgo Medina to Board,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Names Manuel Hidalgo Medina to Board
BMY,2021-05-20,17:26:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) as Adjuvant Treatment,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy
BMY,2021-05-20,17:26:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) has approved Opdivo(R) (nivolumab,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy
BMY,2021-05-20,17:27:18,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Opdivo as Adjuvant Treatment,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: FDA Approves Opdivo as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients Who Have Received Neoadjuvant Chemoradiotherapy
BMY,2021-05-20,17:40:49,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Gets FDA OK For Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Gets FDA OK For Opdivo as Adjuvant in Upper Gastrointestinal Cancers
BMY,2021-05-20,17:55:49,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Gets FDA OK For Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Gets FDA OK For Opdivo as Adjuvant in Upper Gastrointestinal Cancers
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Yervoy received approval from the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Yervoy was also approved in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,97,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,97,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Yervoy received approval from the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Yervoy was also approved in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,97,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,97,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-05-21,20:47:51,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,Yervoy was approved by the U.S. Food and Drug Administration in 2018,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: CHMP Recommends Approval of Opdivo Plus Yervoy for Colorectal Cancer
BMY,2021-05-21,21:02:52,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,Yervoy was approved by the U.S. Food and Drug Administration in 2018,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: CHMP Recommends Approval of Opdivo Plus Yervoy for Colorectal Cancer
BMY,2021-05-23,15:35:00,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Zeposia was approved by the U.S. Food and Drug Administration (FDA) for the treatment,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data at -2-
BMY,2021-05-23,15:35:00,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,European Medicines Agency validated Bristol Myers Squibb's Marketing Authorization Application,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data at -2-
BMY,2021-05-23,15:35:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Zeposia was approved by the U.S. Food and Drug Administration (FDA) for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -2-
BMY,2021-05-23,15:35:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,European Medicines Agency validated Bristol Myers Squibb's Marketing Authorization Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -2-
BMY,2021-05-25,12:01:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Xencor and Bristol Myers Squibb Enter License Agreement,PRESS-RELEASE,Business Wire,Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend(TM) XmAb(R) Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
BMY,2021-05-25,12:01:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Xencor and Bristol Myers Squibb Enter License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend(TM) XmAb(R) Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
BMY,2021-05-25,12:01:06,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Xencor and Bristol Myers Squibb Enter License Agreement,NEWS-FLASH,Dow Jones Newswires,Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend(TM) XmAb(R) Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
BMY,2021-05-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in Bernstein's 37(th) Annual Strategic Decisions Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Take Part in Bernstein's 37(th) Annual Strategic Decisions Conference
BMY,2021-05-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in Bernstein's 37th Annual Strategic Decisions Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in Bernstein's 37th Annual Strategic Decisions Conference
BMY,2021-05-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will participate in a fireside chat at Bernstein's 37(th) Annual Strategic Decisions Virtual Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in Bernstein's 37th Annual Strategic Decisions Conference
BMY,2021-05-27,20:13:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food And Drug Administration Approves Bristol Myers Squibb's Zeposia(R) (ozanimod),NEWS-FLASH,Dow Jones Newswires,"U.S. Food And Drug Administration Approves Bristol Myers Squibb's Zeposia(R) (ozanimod), An Oral Treatment For Adults With Moderately To Severely Active Ulcerative Colitis1 >BMY"
BMY,2021-05-27,20:13:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia(R) (ozanimod),PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia(R) (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis(1)"
BMY,2021-05-27,20:13:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia(R) (ozanimod),PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia(R) (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1"
BMY,2021-06-01,11:30:02,94637C,Bristol-Myers Squibb Co.,100,0.47,labor-issues,,"Bristol Myers Squibb, Joins Coya Therapeutics(TM) Board of Directors",PRESS-RELEASE,GlobeNewswire,"Ann Lee, Ph.D., SVP at Bristol Myers Squibb, Joins Coya Therapeutics(TM) Board of Directors"
BMY,2021-06-01,11:30:02,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Juno Therapeutics, which was acquired by BMS",PRESS-RELEASE,GlobeNewswire,"Ann Lee, Ph.D., SVP at Bristol Myers Squibb, Joins Coya Therapeutics(TM) Board of Directors"
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: the first positive Phase 3 trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -6-
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -6-
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Deucravacitinib: An analysis of musculoskeletal disease improvements from the Phase 2 trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,93,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at EULAR 2021 Highlight -2-
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Immunosuppression: In clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at EULAR 2021 Highlight -3-
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Deucravacitinib: An analysis of musculoskeletal disease improvements from the Phase 2 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at EULAR -2-
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Immunosuppression: In clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at EULAR -3-
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: the first positive Phase 3 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -6-
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -6-
BMY,2021-06-02,10:59:30,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo Plus Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:00:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab),PRESS-RELEASE,Canadian News Wire,Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:00:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab),PRESS-RELEASE,Canadian News Wire,Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:00:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:00:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:01:07,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves Opdivo Plus Yervoy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: Health Canada Approves Opdivo Plus Yervoy as First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:01:07,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves Opdivo Plus Yervoy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: Health Canada Approves Opdivo Plus Yervoy as First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:02:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO Plus YERVOY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: Health Canada Approves OPDIVO Plus YERVOY as First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:02:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO Plus YERVOY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: Health Canada Approves OPDIVO Plus YERVOY as First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-03,20:15:11,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol-Myers Squibb acquired these two companies,PRESS-RELEASE,PR Newswire,"China Nivolumab Markets Report, 2016-2020 & 2021-2025 Featuring Bristol-Myers Squibb, Medarex, & Ono Pharmaceuticals"
BMY,2021-06-03,20:15:11,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Nivolumab was launched in China in 2018,PRESS-RELEASE,PR Newswire,"China Nivolumab Markets Report, 2016-2020 & 2021-2025 Featuring Bristol-Myers Squibb, Medarex, & Ono Pharmaceuticals"
BMY,2021-06-03,21:01:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: Opdivo has now demonstrated superior first,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BMY,2021-06-03,21:01:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data from CheckMate -4-
BMY,2021-06-03,21:01:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data from CheckMate -4-
BMY,2021-06-03,21:01:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data from CheckMate -6-
BMY,2021-06-03,21:01:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data from CheckMate -6-
BMY,2021-06-03,21:01:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: Opdivo has now demonstrated superior first,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BMY,2021-06-03,21:01:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data -4-
BMY,2021-06-03,21:01:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data -4-
BMY,2021-06-03,21:01:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data -6-
BMY,2021-06-03,21:01:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data -6-
BMY,2021-06-04,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in Goldman Sachs 42(nd) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Take Part in Goldman Sachs 42(nd) Annual Global Healthcare Conference
BMY,2021-06-04,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference
BMY,2021-06-04,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will participate in a fireside chat at the Goldman Sachs 42(nd) Annual Global Healthcare Virtual Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference
BMY,2021-06-04,20:37:26,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Eid Acquires 1,416 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Eid Acquires 1,416 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-06-07,18:50:36,94637C,Bristol-Myers Squibb Co.,100,0.09,credit-ratings,affirmation,Fitch Affirms Bristol-Myers Squibb's IDR at 'A-,NEWS-FLASH,Dow Jones Newswires,Fitch Affirms Bristol-Myers Squibb's IDR at 'A-'; Withdraws Ratings; Outlook Revised to Stable
BMY,2021-06-07,18:50:40,94637C,Bristol-Myers Squibb Co.,100,0.09,credit-ratings,affirmation,Fitch Affirms Bristol-Myers Squibb's IDR at 'A-,PRESS-RELEASE,Dow Jones Newswires,Press Release: Fitch Affirms Bristol-Myers Squibb's IDR at 'A-'; Withdraws Ratings; Outlook Revised to Stable
BMY,2021-06-07,18:50:50,94637C,Bristol-Myers Squibb Co.,100,0.0,credit-ratings,affirmation,Fitch Affirms Bristol-Myers,PRESS-RELEASE,Dow Jones Newswires,Press Release: Fitch Affirms Bristol-Myers -2-
BMY,2021-06-10,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma
BMY,2021-06-10,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: All enrolled patients,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma
BMY,2021-06-10,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma
BMY,2021-06-10,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: All enrolled patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma
BMY,2021-06-10,10:59:37,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results From Phase 3 TRANSFORM Trial,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Positive Topline Results From Phase 3 TRANSFORM Trial Evaluating Breyanzi
BMY,2021-06-10,11:05:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021"
BMY,2021-06-10,11:05:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: During a conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021"
BMY,2021-06-10,11:07:19,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021"
BMY,2021-06-10,11:07:19,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: During a conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021"
BMY,2021-06-10,11:28:13,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol Myers Squibb said a Phase 3 study of,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says Phase 3 Lymphoma Study Meets Objectives
BMY,2021-06-10,11:43:14,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol Myers Squibb said a Phase 3 study of,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says Phase 3 Lymphoma Study Meets Objectives
BMY,2021-06-10,19:36:56,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 42nd Annual Global Healthcare Conference,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript) >BMY
BMY,2021-06-14,12:00:01,94637C,Bristol-Myers Squibb Co.,94,0.34,products-services,,Nektar Therapeutics (Nasdaq: NKTR) will supply bempegaldesleukin to Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
BMY,2021-06-14,12:00:01,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Successful collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
BMY,2021-06-14,12:00:01,94637C,Bristol-Myers Squibb Co.,95,0.34,products-services,,Nektar Therapeutics (Nasdaq: NKTR) will supply bempegaldesleukin to Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
BMY,2021-06-14,12:00:01,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,Successful collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
BMY,2021-06-14,12:46:52,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Exelixis in Clinical Trial Collaboration with Bristol Myers,FULL-ARTICLE,Dow Jones Newswires,Exelixis in Clinical Trial Collaboration with Bristol Myers
BMY,2021-06-14,12:46:52,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Nektar Therapeutics will supply bempegaldesleukin to Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Exelixis in Clinical Trial Collaboration with Bristol Myers
BMY,2021-06-14,13:01:52,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Exelixis in Clinical Trial Collaboration with Bristol Myers,FULL-ARTICLE,Dow Jones Newswires,Exelixis in Clinical Trial Collaboration with Bristol Myers
BMY,2021-06-14,13:01:52,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Nektar Therapeutics will supply bempegaldesleukin to Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Exelixis in Clinical Trial Collaboration with Bristol Myers
BMY,2021-06-14,15:00:08,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol-Myers Squibb Co.: Clinical trial activity in the pancreatic cancer,PRESS-RELEASE,PR Newswire,"World Pancreatic Cancer Market Report 2021-2031: Bristol Myers Squibb Leads Industry Sponsors with the Highest Overall Number of Clinical Trials, Followed by Roche"
BMY,2021-06-17,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2021-06-17,20:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on August 2, 2021 to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2021-06-17,22:30:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration,PRESS-RELEASE,Business Wire,Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate
BMY,2021-06-17,22:34:44,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration,NEWS-FLASH,Dow Jones Newswires,Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate
BMY,2021-06-17,22:38:27,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate
BMY,2021-06-18,00:13:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,It Inks Agreement With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Eisai Shares Rise 9.6% After It Inks Agreement With Bristol Myers Squibb for Cancer Drug Development
BMY,2021-06-18,13:34:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Onureg(R) (azacitidine tablets,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Onureg(R) (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
BMY,2021-06-18,13:34:01,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: The study enrolled 472 patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Onureg(R) (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
BMY,2021-06-18,14:00:07,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,Bristol Myers Squibb received approval from the US FDA for its product,PRESS-RELEASE,PR Newswire,"Global Regenerative Medicine Market Outlook 2021-2026: Major Players are Amgen, Bristol Myers Squibb, Dendreon, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Osiris, Organogenesis, and Vericel"
BMY,2021-06-24,12:30:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Continued collaboration with Bristol Myers Squibb on,PRESS-RELEASE,DJ Global Press Release Wire,Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
BMY,2021-06-24,12:30:01,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,Continued collaboration with Bristol Myers Squibb on,FULL-ARTICLE,Dow Jones Newswires,Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
BMY,2021-06-24,12:30:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Continued collaboration with Bristol Myers Squibb on,PRESS-RELEASE,GlobeNewswire,Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
BMY,2021-06-24,12:30:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Continued collaboration with Bristol Myers Squibb on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
BMY,2021-06-24,12:30:02,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Continued collaboration with Bristol Myers Squibb on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
BMY,2021-06-24,12:33:37,94637C,Bristol-Myers Squibb Co.,100,0.46,equity-actions,,Prothena to Get $80 M From Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Prothena to Get $80 M From Bristol Myers Squibb for Exclusive US License to PRX005 >PRTA
BMY,2021-06-25,10:50:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma
BMY,2021-06-25,10:50:01,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: The study enrolled 140 patients,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma
BMY,2021-06-25,10:50:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma
BMY,2021-06-25,10:50:01,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: The study enrolled 140 patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma
BMY,2021-06-25,10:51:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene Vicleucel) for Relapsed and Refractory Multiple Myeloma
BMY,2021-06-25,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-06-25,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2021-06-25,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-06-25,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-06-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-06-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-06-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-06-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-06-29,11:06:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Yervoy received approval from the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Yervoy was also approved in Japan by the Ministry of Health, Labour and Welfare (MHLW)",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2021-06-29,11:06:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2021-06-29,11:06:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2021-06-29,11:06:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Yervoy received approval from the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Yervoy was also approved in Japan by the Ministry of Health, Labour and Welfare (MHLW)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-06-29,11:06:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-06-29,11:06:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-06-29,11:09:43,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo Plus Yervoy for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-07-06,13:20:10,94637C,Bristol-Myers Squibb Co.,91,0.39,products-services,,Agenus Inc.: the company said a licensing deal with Bristol Myers Squibb Co. (BMY),FULL-ARTICLE,MarketWatch,MW Agenus says its Bristol Myers Squibb licensing deal has up to $1.3 billion in milestone payments
BMY,2021-07-06,13:20:10,94637C,Bristol-Myers Squibb Co.,91,0.39,products-services,,Agenus Inc.: the company said a licensing deal with Bristol Myers Squibb Co. (BMY),FULL-ARTICLE,Dow Jones Newswires,Agenus Says Its Bristol Myers Squibb Licensing Deal Has Up To $1.3 Billion In Milestone Payments -- MarketWatch
BMY,2021-07-06,20:39:37,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Santiago Acquires 522 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Santiago Acquires 522 Of Bristol-Myers Squibb Co >BMY
BMY,2021-07-06,20:40:01,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 4,570 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Acquires 4,570 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-07-16,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -4-
BMY,2021-07-16,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -5-
BMY,2021-07-16,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -5-
BMY,2021-07-16,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -4-
BMY,2021-07-16,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -5-
BMY,2021-07-16,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -5-
BMY,2021-07-16,11:10:37,94637C,Bristol-Myers Squibb Co.,100,-0.65,products-services,negative,Bristol Myers says late-stage trial of head and neck cancer treatment failed,FULL-ARTICLE,MarketWatch,MW Bristol Myers says late-stage trial of head and neck cancer treatment failed to meet main goals
BMY,2021-07-16,11:10:37,94637C,Bristol-Myers Squibb Co.,100,-0.65,products-services,negative,Bristol Myers Says Late-stage Trial Of Head And Neck Cancer Treatment Failed,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says Late-stage Trial Of Head And Neck Cancer Treatment Failed To Meet Main Goals -- MarketWatch
BMY,2021-07-24,07:29:16,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2021 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2021 (BMY)"
BMY,2021-07-27,11:30:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Pleased to collaborate with Bristol Myers Squibb and advance BridgeBio,PRESS-RELEASE,PR Newswire,"BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO(R) (nivolumab) in Advanced Solid Tumors with KRAS Mutations"
BMY,2021-07-27,11:30:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Pleased to collaborate with Bristol Myers Squibb and advance BridgeBio,PRESS-RELEASE,Dow Jones Newswires,"Press Release: BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO(R) (nivolumab) in Advanced Solid Tumors with KRAS Mutations"
BMY,2021-07-27,11:32:28,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bridgebio Announces Clinical Collaboration With Bristol Myers Squibb to,NEWS-FLASH,Dow Jones Newswires,BridgeBio Announces Clinical Collaboration With Bristol Myers Squibb to Study BBP-398
BMY,2021-07-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Sees FY EPS $2.77,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY EPS $2.77-EPS $2.97 >BMY
BMY,2021-07-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 2Q EPS 47c,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q EPS 47c >BMY
BMY,2021-07-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Sees FY Adj EPS $7.35,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY Adj EPS $7.35-Adj EPS $7.55 >BMY
BMY,2021-07-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 2Q Adj EPS $1.93,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Adj EPS $1.93 >BMY
BMY,2021-07-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 2Q Net $1.1B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Net $1.1B >BMY
BMY,2021-07-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 2Q Rev $11.7B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Rev $11.7B >BMY
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports Second Quarter Revenues of $11.7 Billion, an Increase of 16% YoY",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Second Quarter Earnings Per Share of $0.47,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.4,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increased 30%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: FIRST HALF PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Commission (EC) has approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Commission (EC) has approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,products-services,positive,"Bristol-Myers Squibb Co.: the company announced positive topline results from TRANSFORM, a global, randomized, multicenter Phase 3 study",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the FDA approved Zeposia(R) (ozanimod),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: the company and Eisai Co., Ltd. announced that the companies have entered into an exclusive global strategic collaboration",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol-Myers Squibb Co.: the company and Agenus Inc. (NASDAQ: AGEN) announced that they have entered into a definitive agreement,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: the company's Annual Report on Form 10-K for the year ended December 31, 2020",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED JUNE 30, 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE SIX MONTHS ENDED JUNE 30, 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -6-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports Second Quarter Revenues of $11.7 Billion, an Increase of 16% YoY",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Second Quarter Earnings Per Share of $0.47,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.4,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increased 30%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: FIRST HALF PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Commission (EC) has approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Commission (EC) has approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,products-services,positive,"Bristol-Myers Squibb Co.: the company announced positive topline results from TRANSFORM, a global, randomized, multicenter Phase 3 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the FDA approved Zeposia(R) (ozanimod),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: the company and Eisai Co., Ltd. announced that the companies have entered into an exclusive global strategic collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol-Myers Squibb Co.: the company and Agenus Inc. (NASDAQ: AGEN) announced that they have entered into a definitive agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: the company's Annual Report on Form 10-K for the year ended December 31, 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED JUNE 30, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE SIX MONTHS ENDED JUNE 30, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,98,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2021-07-28,11:00:28,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb Sees FY21 Worldwide Revenues Up,NEWS-FLASH,Dow Jones Newswires,Correct: Bristol Myers Squibb Sees FY21 Worldwide Revenues Up in High-Single Digits
BMY,2021-07-28,11:00:58,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Q2 EPS 47 cents,NEWS-FLASH,MarketWatch,MW Bristol Myers Q2 EPS 47 cents vs. loss per share 4 cents a year ago
BMY,2021-07-28,11:01:12,94637C,Bristol-Myers Squibb Co.,100,0.46,earnings,above-expectations,Bristol Myers Q2 adj. EPS $1.93; FactSet consensus $1.89,NEWS-FLASH,MarketWatch,MW Bristol Myers Q2 adj. EPS $1.93; FactSet consensus $1.89
BMY,2021-07-28,11:01:47,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 2Q Opdivo Revenue $1.91 Billion,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Opdivo Revenue $1.91 Billion >BMY
BMY,2021-07-28,11:01:53,94637C,Bristol-Myers Squibb Co.,100,0.48,revenues,above-expectations,Bristol Myers Q2 revenue $11.703 bln vs. $10.129 bln a year ago; FactSet consensus $11.269 bln,NEWS-FLASH,MarketWatch,MW Bristol Myers Q2 revenue $11.703 bln vs. $10.129 bln a year ago; FactSet consensus $11.269 bln
BMY,2021-07-28,11:03:40,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers now sees full-year EPS of $2.77 to $2.97,NEWS-FLASH,MarketWatch,MW Bristol Myers now sees full-year EPS of $2.77 to $2.97 vs. prior $3.18 to $3.38
BMY,2021-07-28,11:04:05,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers still sees full-year adj. EPS of $7.35 to $7.55,NEWS-FLASH,MarketWatch,MW Bristol Myers still sees full-year adj. EPS of $7.35 to $7.55
BMY,2021-07-28,11:04:22,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers now sees full-year revenue up,NEWS-FLASH,MarketWatch,MW Bristol Myers now sees full-year revenue up in high-single-digits
BMY,2021-07-28,11:12:35,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers swings to profit,FULL-ARTICLE,MarketWatch,MW Bristol Myers swings to profit to beat second-quarter estimates as Opdivo returns to growth
BMY,2021-07-28,11:12:35,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers updated its full-year EPS guidance,FULL-ARTICLE,MarketWatch,MW Bristol Myers swings to profit to beat second-quarter estimates as Opdivo returns to growth
BMY,2021-07-28,11:12:35,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers Swings To Profit,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Swings To Profit To Beat Second-quarter Estimates As Opdivo Returns To Growth -- MarketWatch
BMY,2021-07-28,11:12:35,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers updated its full-year EPS guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Swings To Profit To Beat Second-quarter Estimates As Opdivo Returns To Growth -- MarketWatch
BMY,2021-07-28,14:08:55,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Ticker: BMY) markets in collaboration with Pfizer (PFE),FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Stock Rises After Modest Earnings Beat -- Barrons.com
BMY,2021-07-28,15:10:04,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Ticker: BMY) markets in collaboration with Pfizer,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Stock Rises After Modest Earnings Beat
BMY,2021-07-28,17:21:21,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol Myers Squibb CEO Giovanni Caforio on Q2 2021 Results -- Earnings Call,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb CEO Giovanni Caforio on Q2 2021 Results -- Earnings Call Transcript >BMY
BMY,2021-07-29,12:39:48,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol Myers Squibb Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Is Maintained at Equal-Weight by Morgan Stanley
BMY,2021-07-29,12:39:48,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol Myers Squibb Price Target Raised to $71.00/Share From $62.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Raised to $71.00/Share From $62.00 by Morgan Stanley
BMY,2021-07-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-07-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Approval is based on Phase 3 results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-07-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opdivo also received approval from the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-07-30,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2021-07-30,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2021-07-30,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2021-07-30,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-07-30,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Approval is based on Phase 3 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-07-30,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opdivo also received approval from the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-07-30,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-07-30,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-07-30,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-07-30,10:59:20,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab),NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients With Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-07-30,12:00:16,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Says EC Approves Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says EC Approves Opdivo as Adjuvant Treatment in Esophageal or Gastroesophageal Junction Cancer
BMY,2021-07-30,12:00:16,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opdivo received approval from the U.S. Food and Drug Administration,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says EC Approves Opdivo as Adjuvant Treatment in Esophageal or Gastroesophageal Junction Cancer
BMY,2021-07-30,12:15:16,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Says EC Approves Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says EC Approves Opdivo as Adjuvant Treatment in Esophageal or Gastroesophageal Junction Cancer
BMY,2021-07-30,12:15:16,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opdivo received approval from the U.S. Food and Drug Administration,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says EC Approves Opdivo as Adjuvant Treatment in Esophageal or Gastroesophageal Junction Cancer
BMY,2021-08-03,11:00:01,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland"
BMY,2021-08-03,11:00:01,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland"
BMY,2021-08-03,11:00:06,94637C,Bristol-Myers Squibb Co.,100,0.55,acquisitions-mergers,,"Bristol-Myers Squibb Co.: today announced that it has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland",PRESS-RELEASE,PR Newswire,"WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland"
BMY,2021-08-03,11:00:06,94637C,Bristol-Myers Squibb Co.,100,0.41,assets,open,"Bristol-Myers Squibb Co.: Opened in 2018, this facility",PRESS-RELEASE,PR Newswire,"WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland"
BMY,2021-08-03,11:00:13,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland"
BMY,2021-08-03,11:01:37,94637C,Bristol-Myers Squibb Co.,100,0.55,acquisitions-mergers,,"Bristol-Myers Squibb Co.: today announced that it has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland",PRESS-RELEASE,PR Newswire,"WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland"
BMY,2021-08-03,11:01:37,94637C,Bristol-Myers Squibb Co.,100,0.41,assets,open,"Bristol-Myers Squibb Co.: Opened in 2018, this facility",PRESS-RELEASE,PR Newswire,"WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland"
BMY,2021-08-03,20:50:05,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp von Autenried Sells 25,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP von Autenried Sells 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-03,20:53:53,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Vessey Sells 158,393 Of Bristol-Myers Squibb Co",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Sells 158,393 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-03,20:56:27,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Leung Sells 29,390 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Leung Sells 29,390 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-03,20:57:44,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Dubow Sells 2,466 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Dubow Sells 2,466 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-03,21:22:14,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 22,667 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Elkins Acquires 22,667 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-04,20:49:40,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Powell Sells 23,280 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Powell Sells 23,280 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-04,20:50:00,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 20,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Caforio Sells 20,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-09,20:34:17,94637C,Bristol-Myers Squibb Co.,100,-0.51,labor-issues,,Bonney Resigns From Board of Bristol-Myers Squibb,RNS-SEC8K,Dow Jones Newswires,Michael Bonney Resigns From Board of Bristol-Myers Squibb in Connection With Appointment as Executive Chairman of Alnylam Pharmaceuticals
BMY,2021-08-10,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol Myers Squibb (NYSE: BMY) announced its collaboration with Florida Agricultural and Mechanical University, Howard University, Morgan",PRESS-RELEASE,Business Wire,Bristol Myers Squibb and Five Leading Historically Black Colleges and Universities Launch Tomorrow's Innovators to Create Custom Biopharma Educational Programming and Increase Recruitment of Black Talent in the Biopharma Industry
BMY,2021-08-10,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol Myers Squibb (NYSE: BMY) announced its collaboration with Florida Agricultural and Mechanical University, Howard University, Morgan",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and Five Leading Historically Black Colleges and Universities Launch Tomorrow's Innovators to Create Custom Biopharma Educational Programming and Increase Recruitment of Black Talent in the Biopharma Industry
BMY,2021-08-16,21:53:42,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Cfo Elkins Sells 99,691 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Elkins Sells 99,691 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Bristol Myers Squibb's Applications,PRESS-RELEASE,Business Wire,"EMA Validates Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma"
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Bristol Myers Squibb's Applications,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -2-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Bristol Myers Squibb's Applications,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -3-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Bristol Myers Squibb's Applications,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -4-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -4-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Bristol Myers Squibb's Applications,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -5-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -5-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -5-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Bristol Myers Squibb's Applications,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -6-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Bristol Myers Squibb's Applications,PRESS-RELEASE,Dow Jones Newswires,"Press Release: EMA Validates Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma"
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: EMA Validates Bristol Myers -4-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: EMA Validates Bristol Myers -5-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: EMA Validates Bristol Myers -5-
BMY,2021-08-17,11:00:19,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Applications for Opdivo,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: EMA Validates Applications for Opdivo + Yervoy, Opdivo + Chemotherapy as First-Line Treatments for Certain Carcinomas"
BMY,2021-08-17,11:34:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb: EMA Validates Two Opdivo Applications,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: EMA Validates Two Opdivo Applications
BMY,2021-08-17,11:34:36,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers said the applications based on positive results from a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: EMA Validates Two Opdivo Applications
BMY,2021-08-17,11:49:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb: EMA Validates Two Opdivo Applications,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: EMA Validates Two Opdivo Applications
BMY,2021-08-17,11:49:36,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers said the applications based on positive results from a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: EMA Validates Two Opdivo Applications
BMY,2021-08-18,11:00:03,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: our strategic collaboration with Exscientia.,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Exercises Option to Develop Exscientia's AI-designed, Immune-modulating Drug Candidate"
BMY,2021-08-19,13:34:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma"
BMY,2021-08-19,13:34:00,94637C,Bristol-Myers Squibb Co.,100,0.44,products-services,,Bristol-Myers Squibb Co.: Abecma expands upon,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma"
BMY,2021-08-19,13:34:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma"
BMY,2021-08-19,13:34:01,94637C,Bristol-Myers Squibb Co.,100,0.44,products-services,,Bristol-Myers Squibb Co.: Abecma expands upon,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma"
BMY,2021-08-20,15:45:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma
BMY,2021-08-23,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)
BMY,2021-08-23,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The sBLA submitted to the FDA is based on results from the,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)
BMY,2021-08-23,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)
BMY,2021-08-23,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: The sBLA submitted to the FDA is based on results from the,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)
BMY,2021-08-23,11:19:27,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Orencia,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Orencia in Acute Graft-Vs-Host Disease >BMY
BMY,2021-08-23,11:19:27,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Orencia in Acute Graft-Vs-Host Disease >BMY
BMY,2021-08-23,11:19:27,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Orencia is currently approved in the U.S.,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Orencia in Acute Graft-Vs-Host Disease >BMY
BMY,2021-08-23,11:34:27,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Orencia,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Orencia in Acute Graft-Vs-Host Disease
BMY,2021-08-23,11:34:27,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Orencia in Acute Graft-Vs-Host Disease
BMY,2021-08-23,11:34:27,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Orencia is currently approved in the U.S.,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Orencia in Acute Graft-Vs-Host Disease
BMY,2021-09-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in Morgan Stanley 19(th) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Take Part in Morgan Stanley 19(th) Annual Global Healthcare Conference
BMY,2021-09-08,10:59:00,94637C,Bristol-Myers Squibb Co.,98,0.0,products-services,,Bristol-Myers Squibb Co.: Phase 3 data,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage Cancers
BMY,2021-09-08,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO 2021 -4-
BMY,2021-09-08,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO 2021 -6-
BMY,2021-09-08,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO 2021 -6-
BMY,2021-09-08,10:59:09,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Phase 3 data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage Cancers
BMY,2021-09-08,10:59:09,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at -4-
BMY,2021-09-08,10:59:09,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at -6-
BMY,2021-09-08,10:59:09,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at -6-
BMY,2021-09-08,11:01:12,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers: Updated Phase 3 Data,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers: Updated Phase 3 Data From CheckMate -577 Reinforce Benefit of Opdivo in Earlier Stages of Esophageal, Gastroesophageal Cancers"
BMY,2021-09-08,11:10:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021"
BMY,2021-09-08,11:10:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: During a conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021"
BMY,2021-09-08,11:10:09,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021"
BMY,2021-09-08,11:10:09,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: During a conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021"
BMY,2021-09-08,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,GlobeNewswire,Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo(R) for Treatment of HER2-Expressing Solid Tumors
BMY,2021-09-08,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo(R) for Treatment of HER2-Expressing Solid Tumors
BMY,2021-09-08,11:30:11,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bolt Biotherapeutics Announces Clinical Collaboration With Bristol Myers Squibb to,NEWS-FLASH,Dow Jones Newswires,Bolt Biotherapeutics Announces Clinical Collaboration With Bristol Myers Squibb to Study BDC-1001 in Combination With Opdivo(R) for Treatment of HER2-Expressing Solid Tumors
BMY,2021-09-09,13:00:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Trial Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy CG0070 in Combination with OPDIVO(R) (nivolumab) in Metastatic Urothelial Cancer
BMY,2021-09-09,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2021-09-09,20:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on November 1, 2021 to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2021-09-17,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma whose Tumors Express PD-L1 with CPS >= 5"
BMY,2021-09-17,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2021-09-17,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-09-17,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma whose Tumors Express PD-L1 with CPS >= 5"
BMY,2021-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-09-17,10:59:51,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo + Chemotherapy for Patients With HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma Whose Tumors Express PD-L1 With CPS >= 5"
BMY,2021-09-17,11:15:03,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Gets Positive CHMP Opinion for Opdivo,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets Positive CHMP Opinion for Opdivo in Gastric, Esophageal Cancers >BMY"
BMY,2021-09-17,11:15:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers said the recommendation is based on results from a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets Positive CHMP Opinion for Opdivo in Gastric, Esophageal Cancers >BMY"
BMY,2021-09-17,11:30:03,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Gets Positive CHMP Opinion for Opdivo,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets Positive CHMP Opinion for Opdivo in Gastric, Esophageal Cancers"
BMY,2021-09-17,11:30:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers said the recommendation is based on results from a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets Positive CHMP Opinion for Opdivo in Gastric, Esophageal Cancers"
BMY,2021-09-20,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
BMY,2021-09-20,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: The BLA submission,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
BMY,2021-09-20,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
BMY,2021-09-20,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: The BLA submission,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
BMY,2021-09-20,11:37:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Relatlimab,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Relatlimab/Opdivo Combo in Melanoma >BMY
BMY,2021-09-20,11:37:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Relatlimab/Opdivo Combo in Melanoma >BMY
BMY,2021-09-20,11:52:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Relatlimab,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Relatlimab/Opdivo Combo in Melanoma
BMY,2021-09-20,11:52:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Relatlimab/Opdivo Combo in Melanoma
BMY,2021-09-22,21:20:47,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-09-27,11:06:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications,PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma"
BMY,2021-09-27,11:06:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -648 is one of four positive Phase 3 trials,PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma"
BMY,2021-09-27,11:06:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications,PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma"
BMY,2021-09-27,11:06:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -648 is one of four positive Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma"
BMY,2021-09-27,11:13:30,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Accepts Applications for Opdivo (nivolumab),NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: FDA Accepts Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma >BMY"
BMY,2021-09-30,13:45:00,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at the EADV 30(th) -2-
BMY,2021-09-30,13:52:42,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at the -2-
BMY,2021-10-01,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
BMY,2021-10-01,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
BMY,2021-10-01,10:59:46,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Application for Mavacamten,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: European Medicines Agency Validates Application for Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy >BMY
BMY,2021-10-01,11:00:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma
BMY,2021-10-01,11:00:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2021-10-01,11:00:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2021-10-01,11:00:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2021-10-01,11:00:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma
BMY,2021-10-01,11:00:13,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,NEWS-FLASH,Dow Jones Newswires,European Medicines Agency Validates Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients With Unresectable or Metastatic Melanoma
BMY,2021-10-01,11:05:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Hold Investor Event on November 16,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Hold Investor Event on November 16
BMY,2021-10-01,11:05:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Hold Investor Event on November 16,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Hold Investor Event on November 16
BMY,2021-10-01,11:37:51,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Relatlimab/Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: EMA Validates Relatlimab/Opdivo Combo Application in Melanoma >BMY
BMY,2021-10-01,11:37:51,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Relatlimab/Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: EMA Validates Relatlimab/Opdivo Combo Application in Melanoma >BMY
BMY,2021-10-01,11:52:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Relatlimab/Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: EMA Validates Relatlimab/Opdivo Combo Application in Melanoma
BMY,2021-10-01,11:52:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Relatlimab/Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: EMA Validates Relatlimab/Opdivo Combo Application in Melanoma
BMY,2021-10-06,22:44:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol Myers' $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Business Wire,Entwistle & Cappucci LLP Files a Securities Class Action Complaint Against Bristol-Myers Squibb Company
BMY,2021-10-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Provides Update on Phase 2 Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
BMY,2021-10-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
BMY,2021-10-07,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Provides Update on Phase 2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
BMY,2021-10-07,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
BMY,2021-10-07,10:59:36,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Provides Update on Phase 2 Study,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
BMY,2021-10-08,00:20:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Business Wire,"BRISTOL MYERS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-10-08,00:20:00,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,Business Wire,"BRISTOL MYERS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-10-08,05:30:33,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec expands neuroscience collaboration with Bristol Myers Squibb to,PRESS-RELEASE,DGAP News,PRESS RELEASE: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type
BMY,2021-10-08,05:30:33,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec expands neuroscience collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type
BMY,2021-10-08,05:31:25,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec expands neuroscience collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type
BMY,2021-10-08,05:31:25,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec expands neuroscience collaboration with Bristol Myers Squibb to,PRESS-RELEASE,DGAP News,PRESS RELEASE: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type
BMY,2021-10-08,05:50:31,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include Novel Cell Type
BMY,2021-10-08,12:56:04,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2021-10-08,12:56:04,94637C,Bristol-Myers Squibb Co.,100,-0.52,price-targets,downgrade,Bristol Myers Squibb Price Target Cut to $68.00/Share From $71.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Cut to $68.00/Share From $71.00 by Barclays
BMY,2021-10-09,02:50:01,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS APPH, BMY, EAR, HYZN, INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-11,13:07:22,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol Myers Squibb Is Maintained at Buy by Berenberg,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Is Maintained at Buy by Berenberg
BMY,2021-10-11,13:07:22,94637C,Bristol-Myers Squibb Co.,100,-0.62,price-targets,downgrade,Bristol Myers Squibb Price Target Cut to $71.00/Share From $75.00 by Berenberg,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Cut to $71.00/Share From $75.00 by Berenberg
BMY,2021-10-11,19:15:44,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, EAR Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-12,02:47:25,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANVS, BMY, HNST, PYPL INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-12,12:27:38,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol Myers Squibb Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Is Maintained at Equal-Weight by Morgan Stanley
BMY,2021-10-12,12:27:38,94637C,Bristol-Myers Squibb Co.,100,-0.68,price-targets,downgrade,Bristol Myers Squibb Price Target Cut to $66.00/Share From $71.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Cut to $66.00/Share From $71.00 by Morgan Stanley
BMY,2021-10-12,12:30:03,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody
BMY,2021-10-12,12:30:04,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody
BMY,2021-10-12,12:30:41,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Agenus to Receive $20M Milestone Payment From Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Agenus to Receive $20M Milestone Payment From Bristol Myers Squibb With Dosing of First Patient With Its TIGIT Bispecific Antibody
BMY,2021-10-12,17:02:39,94637C,Bristol-Myers Squibb Co.,100,-0.57,acquisitions-mergers,rumor-denied,Bristol Myers Didn't Bid for Acceleron,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Didn't Bid for Acceleron as Merck Circled -- Market Talk
BMY,2021-10-12,17:02:39,94637C,Bristol-Myers Squibb Co.,100,-0.59,acquisitions-mergers,rejected,Acceleron rejected the initial bid,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Didn't Bid for Acceleron as Merck Circled -- Market Talk
BMY,2021-10-12,20:30:40,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"BMY, EAR, SLQT SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced interim results from the Phase 3 open-label extension trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2021-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: U.S. FDA-APPROVED INDICATIONS FOR ZEPOSIA,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2021-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2021-10-13,11:08:29,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced interim results from the Phase 3 open-label extension trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2021-10-13,11:08:29,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: U.S. FDA-APPROVED INDICATIONS FOR ZEPOSIA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2021-10-13,11:08:29,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2021-10-13,23:46:11,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Bristol-Myers Squibb Co.: INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company,PRESS-RELEASE,DJ Global Press Release Wire,INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-13,23:46:11,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-14,02:36:12,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, HNST, PYPL INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-15,02:32:17,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"APPH, BMY, WDH SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-15,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Zeposia was approved by the FDA for the treatment of adults with relapsing forms of multiple sclerosis,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:13,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia as a Treatment for Adult Patients With Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Zeposia (ozanimod),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Zeposia was approved by the FDA for the treatment of adults with relapsing forms of multiple sclerosis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Zeposia (ozanimod),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration approved Zeposia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-16,02:50:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"APPH, BMY, EAR, HYZN SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-18,17:53:20,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS APPH, BMY, WDH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-19,02:50:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, HNST, HYZN, SAM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-19,04:19:58,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Dr. Reddy's Laboratories: Obtained FDA Approval for Lenalidomide,NEWS-FLASH,Dow Jones Newswires,Dr. Reddy's Laboratories: Obtained FDA Approval for Lenalidomide Capsules >RDY
BMY,2021-10-19,22:21:20,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of APPH, BMY, WDH Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-20,15:30:07,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,European Medicines Agency (EMA) approval of Bristol Myers Squibb's Zeposia,PRESS-RELEASE,PR Newswire,"Bristol Myers Squibb's Zeposia Launch Trajectories Diverge in Germany and the UK Following Negative NICE Decision; Janssen's Ponvory Could Likewise Stumble, According to Spherix Global Insights"
BMY,2021-10-20,20:17:23,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Bristol-Myers Squibb Co.: INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company,PRESS-RELEASE,DJ Global Press Release Wire,INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-20,20:17:23,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-21,03:02:32,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of APPH, BMY, EAR, HYZN Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma ..."
BMY,2021-10-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2021-10-21,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2021-10-21,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma ..."
BMY,2021-10-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-10-21,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-10-21,11:00:19,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb: European Commission Approves Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: European Commission Approves Opdivo Plus Chemotherapy for Certain Cancers
BMY,2021-10-22,02:41:12,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"APPH, BMY, EAR SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-22,19:55:00,94637C,Bristol-Myers Squibb Co.,99,-0.52,legal,,"Litigation has been filed against Bristol-Myers Squibb Company (""Bristol-Myers",PRESS-RELEASE,Business Wire,"BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action -- Contact Lieff Cabraser"
BMY,2021-10-22,19:55:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Business Wire,"BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action -- Contact Lieff Cabraser"
BMY,2021-10-23,14:15:24,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Class Action Lawsuit Filed Against Bristol-Myers Squibb Company,PRESS-RELEASE,DJ Global Press Release Wire,CELG Investor Alert: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-23,14:15:24,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,CELG Investor Alert: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-24,08:01:38,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2021 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2021 (BMY)"
BMY,2021-10-25,10:45:00,94637C,Bristol-Myers Squibb Co.,95,0.39,products-services,,Tcr(2) Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,TCR(2) Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo(R) and Yervoy(R) in Mesothelin-Expressing Solid Tumors
BMY,2021-10-25,10:45:00,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY),PRESS-RELEASE,GlobeNewswire,TCR(2) Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo(R) and Yervoy(R) in Mesothelin-Expressing Solid Tumors
BMY,2021-10-25,10:45:01,94637C,Bristol-Myers Squibb Co.,95,0.39,products-services,,Tcr(2) Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: TCR(2) Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo(R) and Yervoy(R) in Mesothelin-Expressing Solid Tumors
BMY,2021-10-25,10:45:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY),PRESS-RELEASE,Dow Jones Newswires,Press Release: TCR(2) Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo(R) and Yervoy(R) in Mesothelin-Expressing Solid Tumors
BMY,2021-10-25,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Third Quarter 2021 Earnings Call to,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)"
BMY,2021-10-25,11:03:15,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Press Release: Bristol Myers Squibb Announces Earnings,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)"
BMY,2021-10-25,11:03:15,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Third Quarter 2021 Earnings Call to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)"
BMY,2021-10-25,12:55:13,94637C,Bristol-Myers Squibb Co.,93,0.55,acquisitions-mergers,interest,Bristol Myers Squibb Co. has expressed interest in acquiring the smaller biopharmaceutical company,FULL-ARTICLE,Dow Jones Newswires,Aurinia Pharmaceuticals Shares Rally on Report of Bristol Myers Interest >AUPH
BMY,2021-10-25,13:10:13,94637C,Bristol-Myers Squibb Co.,93,0.55,acquisitions-mergers,interest,Bristol Myers Squibb Co. has expressed interest in acquiring the smaller biopharmaceutical company,FULL-ARTICLE,Dow Jones Newswires,Aurinia Pharmaceuticals Shares Rally on Report of Bristol Myers Interest
BMY,2021-10-25,18:15:36,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of APPH, BMY, EAR Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-26,02:28:32,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS APPH, BMY, EAR, HYZN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-26,13:00:02,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: our existing relationship with Bristol Myers Squibb in,PRESS-RELEASE,Business Wire,Ubiquigent Extends and Expands Drug Discovery Collaboration With Bristol Myers Squibb
BMY,2021-10-26,17:46:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Business Wire,"BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action -- Contact Lieff Cabraser"
BMY,2021-10-26,18:55:11,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Expected to Post Higher 3Q Sales,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb Expected to Post Higher 3Q Sales -- Earnings Preview
BMY,2021-10-26,18:55:11,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co. is set to report its third-quarter earnings on Wednesday morning,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb Expected to Post Higher 3Q Sales -- Earnings Preview
BMY,2021-10-26,19:50:08,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS APPH, BMY, EAR INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 3Q Adj EPS $2.00,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q Adj EPS $2.00 >BMY
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Sees FY EPS $2.68,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY EPS $2.68-EPS $2.83 >BMY
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Sees FY Adj EPS $7.40,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY Adj EPS $7.40-Adj EPS $7.55 >BMY
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 3Q EPS 69c,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q EPS 69c >BMY
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 3Q Net $1.5B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q Net $1.5B >BMY
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 3Q Rev $11.6B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q Rev $11.6B >BMY
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports Third Quarter Revenues of $11.6 Billion, an Increase of 10% YoY",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Third Quarter Earnings Per Share of $0.69,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: Achieves FDA Priority Review for Third,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Demand for Revlimid, Eliquis and",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Demand for Eliquis, Revlimid and",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.4,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increased 30%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: NINE-MONTH PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for mavacamten,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the European Commission (EC) has approved Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Applications (sBLA) for both Opdivo(R),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the EMA has validated its Type II Variation MAA for both Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Ema has recommended approval of Zeposia(R) (ozanimod),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the FDA has accepted its supplemental sBLA for Orencia(R) (abatacept),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: the company announced a collaboration with five Historically Black Colleges and Universities (HBCU) to,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,-0.49,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -5-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,96,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.70 $ 0.83 $,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -5-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports Third Quarter Revenues of $11.6 Billion, an Increase of 10% YoY",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Third Quarter Earnings Per Share of $0.69,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: Achieves FDA Priority Review for Third,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Demand for Revlimid, Eliquis and",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Demand for Eliquis, Revlimid and",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.4,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increased 30%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: NINE-MONTH PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for mavacamten,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the European Commission (EC) has approved Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Applications (sBLA) for both Opdivo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the EMA has validated its Type II Variation MAA for both Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Ema has recommended approval of Zeposia(R) (ozanimod),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the FDA has accepted its supplemental sBLA for Orencia(R) (abatacept),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: the company announced a collaboration with five Historically Black Colleges and Universities (HBCU) to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.49,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -5-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.70 $ 0.83 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -5-
BMY,2021-10-27,11:00:36,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb Sees FY Worldwide Rev Increasing,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY Worldwide Rev Increasing in High-Single Digits >BMY
BMY,2021-10-27,11:00:55,94637C,Bristol-Myers Squibb Co.,100,-0.59,equity-actions,up,Bristol Myers Squibb Sees FY Research and Development Expenses Increasing,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY Research and Development Expenses Increasing in Low-Single Digits >BMY
BMY,2021-10-27,11:11:10,94637C,Bristol-Myers Squibb Co.,100,-0.32,earnings,down,Bristol Myers Squibb Q3 EPS 69 cents vs. 82 cents a year ago,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb Q3 EPS 69 cents vs. 82 cents a year ago
BMY,2021-10-27,11:11:26,94637C,Bristol-Myers Squibb Co.,100,0.46,earnings,above-expectations,Bristol Myers Squibb Q3 adj. EPS $2.00; FactSet consensus $1.92,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb Q3 adj. EPS $2.00; FactSet consensus $1.92
BMY,2021-10-27,11:11:52,94637C,Bristol-Myers Squibb Co.,100,0.48,revenues,above-expectations,Bristol Myers Squibb Q3 revenue $11.624 bln vs. $10.540 bln a year ago; FactSet consensus $11.612 bln,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb Q3 revenue $11.624 bln vs. $10.540 bln a year ago; FactSet consensus $11.612 bln
BMY,2021-10-27,11:13:13,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb lowers full-year guidance,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb lowers full-year guidance
BMY,2021-10-27,11:13:36,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb now sees full-year EPS of $2.68 to $2.83,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb now sees full-year EPS of $2.68 to $2.83 vs. prior $2.77 to $2.97
BMY,2021-10-27,11:14:03,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb now sees full-year adj. EPS of $7.40 to $7.55,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb now sees full-year adj. EPS of $7.40 to $7.55 vs. prior $7.35 to $7.55
BMY,2021-10-27,11:14:14,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb now sees full-year revenue up,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb now sees full-year revenue up in high-single digits
BMY,2021-10-27,11:18:10,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol-Myers Squibb Posts 3Q Sales Growth,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb Posts 3Q Sales Growth as R&D Spending Rises
BMY,2021-10-27,11:21:32,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb Narrows Full-Year Earnings Guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Narrows Full-Year Earnings Guidance
BMY,2021-10-27,11:33:11,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol-Myers Squibb Posts 3Q Sales Growth,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb Posts 3Q Sales Growth as R&D Spending Rises
BMY,2021-10-27,11:36:32,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb Narrows Full-Year Earnings Guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Narrows Full-Year Earnings Guidance
BMY,2021-10-27,11:49:55,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,"Bristol Myers Squibb says sales of Revlimid, Eliquis increased in the third quarter",FULL-ARTICLE,MarketWatch,"MW Bristol Myers Squibb says sales of Revlimid, Eliquis increased in the third quarter"
BMY,2021-10-27,11:49:55,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,"Bristol Myers Squibb Says Sales Of Revlimid, Eliquis Increased In The Third Quarter",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Says Sales Of Revlimid, Eliquis Increased In The Third Quarter -- MarketWatch"
BMY,2021-10-27,17:28:46,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol Myers Squibb CEO Giovanni Caforio on Q3 2021 Results -- Earnings Call,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb CEO Giovanni Caforio on Q3 2021 Results -- Earnings Call Transcript >BMY
BMY,2021-10-27,23:13:00,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company,PRESS-RELEASE,Business Wire,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-10-27,23:13:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol-Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Business Wire,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-10-28,03:05:03,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS APPH, BMY, EAR, HEPS INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-28,13:28:00,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company,PRESS-RELEASE,Business Wire,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-10-28,13:28:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol-Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Business Wire,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-10-28,13:53:47,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2021-10-28,13:53:47,94637C,Bristol-Myers Squibb Co.,100,-0.44,price-targets,downgrade,Bristol Myers Squibb Price Target Cut to $66.00/Share From $68.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Cut to $66.00/Share From $68.00 by Barclays
BMY,2021-10-28,21:15:24,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Bristol-Myers Squibb Co.: Investor Alert: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company,PRESS-RELEASE,DJ Global Press Release Wire,Investor Alert: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-28,21:15:24,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,Investor Alert: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-29,03:05:16,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"BMY, EAR, HYZN SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits Filed on Behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-30,02:50:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, EAR, HYZN, WDH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-01,12:52:21,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol Myers Squibb Cut to Hold From Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Cut to Hold From Buy by Argus Research
BMY,2021-11-01,16:43:03,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-11-01,16:43:03,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol-Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-11-01,16:43:03,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company,PRESS-RELEASE,Dow Jones Newswires,"Press Release: SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-11-01,16:43:03,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol-Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Dow Jones Newswires,"Press Release: SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-11-01,18:01:15,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, EAR, HYZN Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-02,02:44:41,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, HEPS, HMLP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-02,19:00:35,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, EAR, HYZN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-03,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Immunosuppression: In clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ACR Convergence 2021 -3-
BMY,2021-11-03,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,"Bristol-Myers Squibb Co.: However, abatacept was present",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ACR Convergence 2021 -3-
BMY,2021-11-03,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Immunosuppression: In clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ACR -3-
BMY,2021-11-03,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,"Bristol-Myers Squibb Co.: However, abatacept was present",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ACR -3-
BMY,2021-11-03,23:50:03,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-03,23:50:03,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-04,06:14:22,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, EAR, HYZN, WDH Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-04,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Inspirna Announces Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,Inspirna Announces Clinical Collaboration with Bristol Myers Squibb to Study RGX-104 in Combination with Yervoy(R) (ipilimumab) for Treatment of Metastatic Endometrial Cancer
BMY,2021-11-04,14:16:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First clinical results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight More than 80 Abstracts at ASH 2021 Demonstrating Strength of Innovative Therapeutic Platforms Improving Outcomes for a Broad Range of Hematologic Diseases
BMY,2021-11-04,14:16:00,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Efficacy Clinical Trials,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight More than 80 -2-
BMY,2021-11-04,14:16:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: Six-Year Results from the Phase 3,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight More than 80 -2-
BMY,2021-11-04,14:16:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,"Bristol-Myers Squibb Co.: First Results from a Phase 1, Open-Label Study",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight More than 80 -2-
BMY,2021-11-04,14:16:00,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,"Bristol-Myers Squibb Co.: Cellular Sunday, Life Results",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight More than 80 -3-
BMY,2021-11-04,14:16:00,94637C,Bristol-Myers Squibb Co.,97,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight More than 80 -3-
BMY,2021-11-04,14:16:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight More than 80 -4-
BMY,2021-11-04,14:16:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First clinical results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight More than 80 Abstracts at ASH 2021 Demonstrating Strength of Innovative Therapeutic Platforms Improving Outcomes for a Broad Range of Hematologic Diseases
BMY,2021-11-04,14:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: Six-Year Results from the Phase 3,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -2-
BMY,2021-11-04,14:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,"Bristol-Myers Squibb Co.: First Results from a Phase 1, Open-Label Study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -2-
BMY,2021-11-04,14:16:01,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,"Bristol-Myers Squibb Co.: Cellular Sunday, Life Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -3-
BMY,2021-11-04,14:16:01,94637C,Bristol-Myers Squibb Co.,97,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -3-
BMY,2021-11-04,14:16:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -4-
BMY,2021-11-05,01:25:03,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Bristol-Myers Squibb Company - BMY
BMY,2021-11-05,01:25:03,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Dow Jones Newswires,Press Release: FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Bristol-Myers Squibb Company - BMY
BMY,2021-11-05,15:02:59,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"BMY, HNST, WDH SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-06,02:50:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"BMY, HEPS, HMLP INVESTOR ALERT BY CLAIMSFILER: Pending Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-08,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Pfizer Alliance) ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
BMY,2021-11-08,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: The milvexian Phase 2 clinical trial program,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
BMY,2021-11-08,11:59:18,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Pfizer Alliance) ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
BMY,2021-11-08,11:59:18,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: The milvexian Phase 2 clinical trial program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
BMY,2021-11-08,18:41:49,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, HNST, WDH Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-09,04:28:34,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, EAR, HMLP, SAM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-09,14:16:28,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Bristol-Myers Squibb Co.: INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company,PRESS-RELEASE,DJ Global Press Release Wire,INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-11-09,14:16:28,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-11-09,17:45:43,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, HNST, WDH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-10,07:00:32,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,"Evotec SE: Chief Scientific Officer of Evotec, said: ""Our collaboration with BMS",PRESS-RELEASE,DJ Global Press Release Wire,Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2021-11-10,17:16:05,94637C,Bristol-Myers Squibb Co.,100,0.0,credit-ratings,action,Moody's Announces Completion Of A Periodic Review Of Ratings Of Bristol-Myers Squibb Company,NEWS-FLASH,Dow Jones Newswires,Moody's Announces Completion Of A Periodic Review Of Ratings Of Bristol-Myers Squibb Company
BMY,2021-11-10,20:41:03,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-10,20:41:03,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-11,03:50:01,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, EAR, HYZN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-11,12:00:07,94637C,Bristol-Myers Squibb Co.,98,0.22,acquisitions-mergers,,Bristol Myers Squibb's strategic investment in Compugen,PRESS-RELEASE,PR Newswire,Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment
BMY,2021-11-11,12:00:07,94637C,Bristol-Myers Squibb Co.,99,0.22,acquisitions-mergers,,Bristol Myers Squibb's strategic investment in Compugen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment
BMY,2021-11-12,00:47:30,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, HYZN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-12,00:47:30,94637C,Bristol-Myers Squibb Co.,94,0.59,equity-actions,,Bristol-Myers Squibb Co.: MISLEADING PROSPECTUS,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, HYZN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-12,12:00:11,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R),PRESS-RELEASE,PR Newswire,Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R) and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
BMY,2021-11-12,12:00:11,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R),PRESS-RELEASE,PR Newswire,Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R) and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
BMY,2021-11-12,12:00:11,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: our collaboration with Compugen to,PRESS-RELEASE,PR Newswire,Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R) and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
BMY,2021-11-12,12:04:21,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Compugen Presents Preliminary Results From Phase 1/2 Dose Escalation Study of COM701 With Opdivo,NEWS-FLASH,Dow Jones Newswires,"Compugen Presents Preliminary Results From Phase 1/2 Dose Escalation Study of COM701 With Opdivo, BMS-986207"
BMY,2021-11-12,12:04:21,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Compugen Presents Preliminary Results From Phase 1/2 Dose Escalation Study of COM701 With Opdivo,NEWS-FLASH,Dow Jones Newswires,"Compugen Presents Preliminary Results From Phase 1/2 Dose Escalation Study of COM701 With Opdivo, BMS-986207"
BMY,2021-11-12,12:15:20,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R) and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
BMY,2021-11-12,12:15:20,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R) and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
BMY,2021-11-12,12:15:20,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: our collaboration with Compugen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R) and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
BMY,2021-11-13,03:50:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"BMY, EAR, HMLP SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-15,19:00:51,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, HMLP, NVAX INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-16,03:50:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, EAR, HEPS, HMLP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-16,19:25:51,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, HMLP, NVAX Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-18,00:38:02,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-18,00:38:02,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-18,04:50:09,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, EAR, HMLP, NVAX Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-19,03:50:03,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Bristol-Myers Squibb Company - BMY
BMY,2021-11-19,03:50:03,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Dow Jones Newswires,Press Release: FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Bristol-Myers Squibb Company - BMY
BMY,2021-11-19,10:46:56,94637C,Bristol-Myers Squibb Co.,100,0.95,analyst-ratings,positive,Bristol Myers Squibb Initiated at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Initiated at Outperform by BMO Capital
BMY,2021-11-19,10:46:56,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol Myers Squibb Price Target Announced at $72.00/Share by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Announced at $72.00/Share by BMO Capital
BMY,2021-11-19,12:19:58,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Myokardia Inc., which Bristol-Myers bought last year",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers: FDA Extends Review of Heart-Drug Mavacamten by Three Months
BMY,2021-11-19,12:34:58,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Myokardia Inc., which Bristol-Myers bought last year",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers: FDA Extends Review of Heart-Drug Mavacamten by Three Months
BMY,2021-11-19,13:49:35,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol Myers Squibb started at outperform with $72 stock price target at BMO Capital,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb started at outperform with $72 stock price target at BMO Capital
BMY,2021-11-20,03:00:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"BMY, EAR, HEPS, HMLP INVESTOR ALERT BY CLAIMSFILER: Pending Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-22,18:30:41,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"BMY, HMLP, NVAX SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-23,03:56:31,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, CTXS, OWLT INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-23,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
BMY,2021-11-23,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: More information about the open-label extension trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
BMY,2021-11-23,11:59:00,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration (FDA) approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -2-
BMY,2021-11-23,11:59:00,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -2-
BMY,2021-11-23,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
BMY,2021-11-23,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: More information about the open-label extension trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
BMY,2021-11-23,11:59:01,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration (FDA) approved Zeposia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -2-
BMY,2021-11-23,11:59:01,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -2-
BMY,2021-11-23,11:59:30,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval of Zeposia,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval of Zeposia for Use in Adults With Moderately to Severely Active Ulcerative Colitis
BMY,2021-11-23,12:14:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets Europe OK for Zeposia,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Europe OK for Zeposia in Ulcerative Colitis >BMY
BMY,2021-11-23,12:29:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets Europe OK for Zeposia,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Europe OK for Zeposia in Ulcerative Colitis
BMY,2021-11-24,05:06:04,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMY, HEPS, PTON and Z"
BMY,2021-11-24,21:16:04,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-24,21:16:04,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-24,22:26:23,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp von Autenried Sells 51,134 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP von Autenried Sells 51,134 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-11-25,04:34:40,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, CTXS, STNE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-27,03:50:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, CTXS, OWLT, PTON Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-29,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
BMY,2021-11-29,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
BMY,2021-11-29,12:29:59,94637C,Bristol-Myers Squibb Co.,96,0.58,acquisitions-mergers,,Amgen bought Otezla from Celgene Corp. for $13.4 billion,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb: Deucravacitinib Applications Advance in U.S., Europe"
BMY,2021-11-29,12:29:59,94637C,Bristol-Myers Squibb Co.,96,0.6,acquisitions-mergers,approval,Regulatory approval Celgene's $74 billion acquisition,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb: Deucravacitinib Applications Advance in U.S., Europe"
BMY,2021-11-29,12:44:58,94637C,Bristol-Myers Squibb Co.,96,0.58,acquisitions-mergers,,Amgen bought Otezla from Celgene Corp. for $13.4 billion,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb: Deucravacitinib Applications Advance in U.S., Europe"
BMY,2021-11-29,12:44:58,94637C,Bristol-Myers Squibb Co.,96,0.6,acquisitions-mergers,approval,Regulatory approval Celgene's $74 billion acquisition,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb: Deucravacitinib Applications Advance in U.S., Europe"
BMY,2021-11-30,04:44:09,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, OWLT, PTON, ZG INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-12-01,04:34:02,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMY, CTXS, HEPS and STNE"
BMY,2021-12-02,00:53:02,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,CLAIMSFILER ALERTS BRISTOL MYERS Investors to Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
BMY,2021-12-02,00:53:02,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,PR Newswire,CLAIMSFILER ALERTS BRISTOL MYERS Investors to Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
BMY,2021-12-02,00:53:02,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Dow Jones Newswires,Press Release: CLAIMSFILER ALERTS BRISTOL MYERS Investors to Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
BMY,2021-12-02,00:53:02,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,Dow Jones Newswires,Press Release: CLAIMSFILER ALERTS BRISTOL MYERS Investors to Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
BMY,2021-12-02,04:16:41,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, LSPD, PTON, ZG Investors, Lead Plaintiff Deadlines Set"
BMY,2021-12-03,12:16:15,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
BMY,2021-12-03,12:16:15,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted for priority review its supplemental Biologics License Application for Reblozyl luspatercept-aamt,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
BMY,2021-12-03,12:16:15,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers also said the European Medicines Agency has validated the Type II variation for Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
BMY,2021-12-03,12:31:15,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
BMY,2021-12-03,12:31:15,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted for priority review its supplemental Biologics License Application for Reblozyl luspatercept-aamt,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
BMY,2021-12-03,12:31:15,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers also said the European Medicines Agency has validated the Type II variation for Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
BMY,2021-12-04,03:50:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Business Wire,"BRISTOL MYERS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Bristol-Myers Squibb Company - BMY"
BMY,2021-12-04,03:50:00,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,Business Wire,"BRISTOL MYERS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Bristol-Myers Squibb Company - BMY"
BMY,2021-12-06,23:28:20,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Boerner Acquires 1,288 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Boerner Acquires 1,288 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-12-06,23:28:30,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 4,294 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Elkins Acquires 4,294 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-12-06,23:28:50,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 4,294 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Acquires 4,294 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-12-09,13:31:33,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol Myers Squibb Initiated at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Initiated at Equal-Weight by Wells Fargo
BMY,2021-12-09,13:31:33,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol Myers Squibb Price Target Announced at $58.00/Share by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Announced at $58.00/Share by Wells Fargo
BMY,2021-12-11,13:30:00,94637C,Bristol-Myers Squibb Co.,95,0.4,products-services,start,Bristol-Myers Squibb Co.: All enrolled patients,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results"
BMY,2021-12-11,13:30:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi (lisocabtagene -2-
BMY,2021-12-13,00:30:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Antengene Announces Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo(R) (nivolumab) in Advanced Solid Tumors
BMY,2021-12-13,00:30:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Antengene Announces Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo(R) (nivolumab) in Advanced Solid Tumors
BMY,2021-12-13,00:34:22,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Antengene, Bristol Myers Squibb to Collaborate on",NEWS-FLASH,Dow Jones Newswires,"Antengene, Bristol Myers Squibb to Collaborate on Clinical Evaluation of ATG-017 in Combination With Opdivo(R) (nivolumab) in Advanced Solid Tumors >6996.HK"
BMY,2021-12-13,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol Myers Squibb Announces Dividend Increase And Additional $15 Billion Share Repurchase Authorization,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Dividend Increase And Additional $15 Billion Share Repurchase Authorization >BMY
BMY,2021-12-13,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol-Myers Squibb Co.: Increase in 2022 Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Co.: The Board of Directors has declared a quarterly dividend of fifty-four cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Co.: This amount represents a 10.2% increase in the quarterly dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Co.: At this quarterly dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol-Myers Squibb Co.: Multi-Year Share Repurchase,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:03,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:03,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol-Myers Squibb Co.: Increase in 2022 Dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Co.: The Board of Directors has declared a quarterly dividend of fifty-four cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:03,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Co.: This amount represents a 10.2% increase in the quarterly dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Co.: At this quarterly dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:03,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol-Myers Squibb Co.: Multi-Year Share Repurchase,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:42,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Declares Dividend of 54,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Declares Dividend of 54c >BMY
BMY,2021-12-13,12:01:03,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol Myers Squibb raises quarterly dividend by 10.2% to 54 cents,NEWS-FLASH,MarketWatch,"MW Bristol Myers Squibb raises quarterly dividend by 10.2% to 54 cents a share, adds $15 bln to share buybacks"
BMY,2021-12-13,12:01:06,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Declares Qtrly Div of 50c/Shr,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Declares Qtrly Div of 50c/Shr on $2 Convertible Preferred Stk >BMY
BMY,2021-12-13,12:06:38,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Raises Quarterly Dividend,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Raises Quarterly Dividend And Adds $15 Billion To Share Buyback Program -- MarketWatch
BMY,2021-12-13,12:06:38,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Co.: the company announced a 10.2% increase in its quarterly dividend,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Raises Quarterly Dividend And Adds $15 Billion To Share Buyback Program -- MarketWatch
BMY,2021-12-13,12:06:38,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb raises quarterly dividend,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb raises quarterly dividend and adds $15 billion to share buyback program
BMY,2021-12-13,12:06:38,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Co.: the company announced a 10.2% increase in its quarterly dividend,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb raises quarterly dividend and adds $15 billion to share buyback program
BMY,2021-12-13,12:11:28,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol-Myers Squibb adds $15 billion to stock buyback program,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb adds $15 billion to stock buyback program
BMY,2021-12-13,12:15:28,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,"Bristol-Myers Squibb Raises Dividend,",FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb Raises Dividend, Buyback Authorization"
BMY,2021-12-13,12:30:28,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,"Bristol-Myers Squibb Raises Dividend,",FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb Raises Dividend, Buyback Authorization"
BMY,2021-12-13,12:43:08,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Raises Its Dividend,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Raises Its Dividend and Adds $15 Billion to Its Buyback Plan. The Stock Jumps. -- Barrons.com
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Immatics N.V.: our existing collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb's global clinical development,PRESS-RELEASE,Business Wire,Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Immatics N.V.: our existing collaboration with Bristol Myers Squibb to,PRESS-RELEASE,GlobeNewswire,Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb's global clinical development,PRESS-RELEASE,GlobeNewswire,Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Immatics N.V.: our existing collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb's global clinical development,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Immatics N.V.: our existing collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb's global clinical development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Immatics N.V.: our existing collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb's global clinical development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,12:09:12,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Immatics N.V.: our existing collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,12:09:12,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb's global clinical development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,12:24:40,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Bristol Myers, Immatics to Collaborate on",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers, Immatics to Collaborate on IMA401 >BMY IMTX"
BMY,2021-12-14,12:39:40,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Bristol Myers, Immatics to Collaborate on",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers, Immatics to Collaborate on IMA401"
BMY,2021-12-15,17:14:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda OKs Bristol Myers' Orencia,FULL-ARTICLE,Dow Jones Newswires,FDA OKs Bristol Myers' Orencia in Acute Graft-Vs-Host Disease >BMY
BMY,2021-12-15,17:14:22,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers reported revenue of $2.44 billion for the first nine months of the year,FULL-ARTICLE,Dow Jones Newswires,FDA OKs Bristol Myers' Orencia in Acute Graft-Vs-Host Disease >BMY
BMY,2021-12-15,17:29:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda OKs Bristol Myers' Orencia,FULL-ARTICLE,Dow Jones Newswires,FDA OKs Bristol Myers' Orencia in Acute Graft-Vs-Host Disease
BMY,2021-12-15,17:29:22,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers reported revenue of $2.44 billion for the first nine months of the year,FULL-ARTICLE,Dow Jones Newswires,FDA OKs Bristol Myers' Orencia in Acute Graft-Vs-Host Disease
BMY,2021-12-15,20:13:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Orencia(R) (abatacept) in,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Orencia(R) (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)...
BMY,2021-12-15,20:13:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Orencia(R) (abatacept) in,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Orencia(R) (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)...
BMY,2021-12-15,20:14:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Orencia in,NEWS-FLASH,Dow Jones Newswires,U.S. FDA Approves Orencia in Combination With Calcineurin Inhibitor and Methotrexate for Prevention of Acute Graft Versus Host Disease
BMY,2021-12-17,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022"
BMY,2021-12-17,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: During a conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022"
BMY,2021-12-17,12:47:24,94637C,Bristol-Myers Squibb Co.,100,0.95,analyst-ratings,positive,Bristol Myers Squibb Initiated at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Initiated at Buy by Goldman Sachs
BMY,2021-12-17,12:47:24,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol Myers Squibb Price Target Announced at $72.00/Share by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Announced at $72.00/Share by Goldman Sachs
BMY,2021-12-17,22:10:00,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Vessey Sells 19,298 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Sells 19,298 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-12-20,13:58:46,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda OKs Bristol Myers' Orencia,FULL-ARTICLE,Dow Jones Newswires,Correction to FDA OKs Bristol Myers' Orencia Story
BMY,2021-12-20,14:13:46,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda OKs Bristol Myers' Orencia,FULL-ARTICLE,Dow Jones Newswires,Correction to FDA OKs Bristol Myers' Orencia Story
BMY,2021-12-23,17:54:16,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,"C. Announces Investigations of Bristol-Myers Squibb Company (NYSE: BMY), Eargo, Inc.",PRESS-RELEASE,GlobeNewswire,"Lifshitz Law Firm, P.C. Announces Investigations of Bristol-Myers Squibb Company (NYSE: BMY), Eargo, Inc. (NASDAQGS: EAR), Hyzon Motors Inc. (NASDAQ: HYZN), Nano-X Imaging Ltd. (NASDAQ: NNOX), and View, Inc. (NASDAQGM: VIEW)"
BMY,2021-01-04,08:58:27,94637C,Bristol-Myers Squibb Co.,100,-0.65,equity-actions,halt,Bmy) Halted due to news,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Co. Rt (BMY) Halted due to news dissemination
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 39(th) Annual Virtual Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present at J.P. Morgan's 39(th) Annual Virtual Healthcare Conference
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,granted,Bristol-Myers Squibb Co.: The EMA's decision to validate our application,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Business Wire,"European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma"
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -4-
BMY,2021-01-04,11:59:06,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2021-01-04,11:59:07,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
BMY,2021-01-04,11:59:07,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,granted,Bristol-Myers Squibb Co.: The EMA's decision to validate our application,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
BMY,2021-01-04,11:59:07,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Dow Jones Newswires,"Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma"
BMY,2021-01-04,11:59:11,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,NEWS-FLASH,Dow Jones Newswires,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
BMY,2021-01-04,12:02:31,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 39th Annual Virtual Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present at J.P. Morgan's 39th Annual Virtual Healthcare Conference
BMY,2021-01-04,14:19:10,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers: EMA Validates Two Applications,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: EMA Validates Two Applications for Expanded Opdivo Approval
BMY,2021-01-04,14:34:10,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers: EMA Validates Two Applications,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: EMA Validates Two Applications for Expanded Opdivo Approval
BMY,2021-01-04,21:34:02,94637C,Bristol-Myers Squibb Co.,99,0.44,credit,reduction,Bristol-Myers Squibb Co.: This reflects our assumption that BMY will continue to prioritize debt reduction,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGRBulletin: Bristol-Myers Squibb Co.'s CVR Expires
BMY,2021-01-06,01:14:30,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Ahmed Acquires 7,286 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Ahmed Acquires 7,286 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-01-06,01:15:03,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 8,693 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Elkins Acquires 8,693 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-01-06,01:15:13,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 12,609 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Acquires 12,609 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-01-07,11:00:16,94637C,Bristol-Myers Squibb Co.,100,0.0,equity-actions,,Biomedicines Launches with $62 Million Series A Financing,PRESS-RELEASE,Business Wire,Endeavor BioMedicines Launches with $62 Million Series A Financing and Mission to Reverse the Course of Devastating Pulmonary Disease
BMY,2021-01-07,11:00:16,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: Pending results from the monotherapy study, Endeavor anticipates initiating a second Phase 2 study",PRESS-RELEASE,Business Wire,Endeavor BioMedicines Launches with $62 Million Series A Financing and Mission to Reverse the Course of Devastating Pulmonary Disease
BMY,2021-01-07,12:00:18,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb to Advance Next-Generation T cell Therapies for Solid Tumors
BMY,2021-01-11,11:59:23,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization >BMY
BMY,2021-01-11,11:59:23,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization
BMY,2021-01-11,11:59:24,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization
BMY,2021-01-11,12:01:01,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol-Myers announces $2 bln incremental share buyback,NEWS-FLASH,MarketWatch,MW Bristol-Myers announces $2 bln incremental share buyback authorization
BMY,2021-01-11,12:04:14,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers adds $2 billion to share buyback program,FULL-ARTICLE,MarketWatch,MW Bristol Myers adds $2 billion to share buyback program
BMY,2021-01-11,12:04:14,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers Adds $2 Billion To Share Buyback Program,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Adds $2 Billion To Share Buyback Program -- MarketWatch
BMY,2021-01-11,12:19:18,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers Boosts Buyback Program by $2 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Boosts Buyback Program by $2 Billion >BMY
BMY,2021-01-11,12:34:18,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers Boosts Buyback Program by $2 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Boosts Buyback Program by $2 Billion
BMY,2021-01-11,13:30:25,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Bristol-Myers Squibb Co.: Our collaboration with GRAIL,PRESS-RELEASE,Business Wire,"GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease"
BMY,2021-01-11,13:30:25,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,Bristol-Myers Squibb Co.: Our collaboration with GRAIL,PRESS-RELEASE,Dow Jones Newswires,"Press Release: GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease"
BMY,2021-01-11,16:54:47,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Giovanni Caforio Presents at 39th Annual JPMorgan Virtual Healthcare Conference,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio Presents at 39th Annual JPMorgan Virtual Healthcare Conference - (Transcript) >BMY
BMY,2021-01-11,19:05:24,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,"Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling"
BMY,2021-01-11,19:07:28,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling"
BMY,2021-01-12,21:56:09,94637C,Bristol-Myers Squibb Co.,95,0.44,products-services,,Ticker: BMY) also boosted its share-buying program by,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Looks to Its Drug Pipeline to Turbocharge Growth -- Barrons.com
BMY,2021-01-13,18:30:05,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,"Bristol-Myers Squibb Co.: Today, Allyx Therapeutics announced the completion of a license agreement with Bristol Myers Squibb to develop Allyx's novel therapy",PRESS-RELEASE,PR Newswire,Allyx Therapeutics Announces License For The Treatment of Cognitive Deficits in Neurodegenerative Disorders From Bristol Myers Squibb And Yale
BMY,2021-01-13,18:30:05,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: We look forward to advancing ALX-001 in clinical trials as soon as the beginning of 2021,PRESS-RELEASE,PR Newswire,Allyx Therapeutics Announces License For The Treatment of Cognitive Deficits in Neurodegenerative Disorders From Bristol Myers Squibb And Yale
BMY,2021-01-20,12:21:08,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Wednesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Two Opdivo Indications >BMY
BMY,2021-01-20,12:36:08,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Wednesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Two Opdivo Indications
BMY,2021-01-21,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Fourth Quarter 2020 Earnings Call to,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Earnings Call Time Change; Fourth Quarter 2020 Earnings Call to Occur on February 4, 2021 at 10 a.m. (Eastern Time)"
BMY,2021-01-22,18:18:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Press Release: U.S. Food and Drug Administration Approves OPDIVO(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves OPDIVO(R) (nivolumab) in Combination with CABOMETYX(R) (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
BMY,2021-01-22,18:18:01,94637C,Bristol-Myers Squibb Co.,100,-0.48,legal,,Opdivo and CABOMETYX in the CheckMate -9ER trial make,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves OPDIVO(R) (nivolumab) in Combination with CABOMETYX(R) (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
BMY,2021-01-23,08:57:47,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2020 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2020 (BMY)"
BMY,2021-02-01,11:59:00,94637C,Bristol-Myers Squibb Co.,97,0.57,products-services,granted,Zeposia was approved by the U.S. Food and Drug Administration (FDA) for the treatment,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Application for Zeposia(R) (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug Administration
BMY,2021-02-01,11:59:00,94637C,Bristol-Myers Squibb Co.,97,0.57,products-services,granted,European Medicines Agency validated Bristol Myers Squibb's Marketing Authorization Application,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Application for Zeposia(R) (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug Administration
BMY,2021-02-01,11:59:01,94637C,Bristol-Myers Squibb Co.,98,0.57,products-services,granted,Zeposia was approved by the U.S. Food and Drug Administration (FDA) for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Application for Zeposia(R) (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug Administration
BMY,2021-02-01,11:59:01,94637C,Bristol-Myers Squibb Co.,98,0.57,products-services,granted,European Medicines Agency validated Bristol Myers Squibb's Marketing Authorization Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Application for Zeposia(R) (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug Administration
BMY,2021-02-01,12:45:07,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Zeposia,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Zeposia in Ulcerative Colitis >BMY
BMY,2021-02-01,13:00:07,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Zeposia,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Zeposia in Ulcerative Colitis
BMY,2021-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Sta to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland",PRESS-RELEASE,Business Wire,"WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland"
BMY,2021-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.88,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla(R) (apremilast)
BMY,2021-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla(R) (apremilast)
BMY,2021-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.88,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla(R) (apremilast)
BMY,2021-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla(R) (apremilast)
BMY,2021-02-02,11:59:13,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Sta to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland",NEWS-FLASH,Dow Jones Newswires,"WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland"
BMY,2021-02-02,11:59:22,94637C,Bristol-Myers Squibb Co.,100,0.88,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results From Second Pivotal Phase 3 Psoriasis Study,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Positive Topline Results From Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla
BMY,2021-02-02,12:00:01,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Bristol Myers Squibb to Sell Couvet, Switzerland, Plant to",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb to Sell Couvet, Switzerland, Plant to WuXi STA >BMY"
BMY,2021-02-02,12:11:09,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Sta to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland",PRESS-RELEASE,Dow Jones Newswires,"Press Release: WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland"
BMY,2021-02-03,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Preclinical data,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
BMY,2021-02-03,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: Our collaboration with BMS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
BMY,2021-02-03,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Preclinical data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
BMY,2021-02-03,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: Our collaboration with BMS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
BMY,2021-02-03,21:11:29,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co. said Wednesday it will take over development and manufacturing of a potential Covid-19,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb to Take Over Promising Potential Treatment Against Coronavirus Variants
BMY,2021-02-04,11:30:02,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $950,000,000",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
BMY,2021-02-04,11:30:02,94637C,Bristol-Myers Squibb Co.,93,0.48,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is available on Global Bondholder Services,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Tender Offers for -3-
BMY,2021-02-04,11:30:02,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $950,000,000",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
BMY,2021-02-04,11:30:02,94637C,Bristol-Myers Squibb Co.,93,0.48,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is available on Global Bondholder Services,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers 4Q Adj EPS $1.46,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers 4Q Adj EPS $1.46 >BMY
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers 4Q Loss/Shr $4.45,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers 4Q Loss/Shr $4.45 >BMY
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers 4Q Loss $10B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers 4Q Loss $10B >BMY
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Sees FY Adj EPS $7.35,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Sees FY Adj EPS $7.35-Adj EPS $7.55 >BMY
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers 4Q Rev $11.1B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers 4Q Rev $11.1B >BMY
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.52,revenues,up,"Bristol Myers Squibb posted fourth quarter revenues of $11.1 billion, an increase of 39%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Full-Year Revenues of $42.5 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Full-Year Loss Per Share of $3.99,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol-Myers Squibb Co.: Completes Acquisition of MyoKardia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol-Myers Squibb Co.: Announces Debt Tender Offer,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb Co.: Raises 2021 Non-GAAP EPS Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.62,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increased 79%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: The results in the current quarter,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: FULL-YEAR PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The U.S. FDA granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Ec) has approved Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: TRANSCEND CLL 004: longer-term follow-up from the Phase I study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,Successfully completed its acquisition of MyoKardia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,credit,,Bristol-Myers Squibb Co.: the company announced a debt tender offer,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,,Bristol-Myers Squibb Co.: the company plans to repurchase $3.0-$4.0 billion of its shares,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers Squibb Co.: By 2030, the company will purchase 100% of the electricity it uses from renewable sources, and",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: There will be a conference call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.58,security,,Bristol-Myers Squibb Co.: cyber-attacks on the company's information systems,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED DECEMBER 31, 2020",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Celgene product revenues from November 20, 2019",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2020",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Celgene product revenues from November 20, 2019",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -6-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -6-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -7-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.52,revenues,up,"Bristol Myers Squibb posted fourth quarter revenues of $11.1 billion, an increase of 39%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Full-Year Revenues of $42.5 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Full-Year Loss Per Share of $3.99,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol-Myers Squibb Co.: Completes Acquisition of MyoKardia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol-Myers Squibb Co.: Announces Debt Tender Offer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol-Myers Squibb Co.: Raises 2021 Non-GAAP EPS Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.62,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increased 79%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: The results in the current quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: FULL-YEAR PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The U.S. FDA granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Ec) has approved Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: TRANSCEND CLL 004: longer-term follow-up from the Phase I study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,acquisitions-mergers,completed,Successfully completed its acquisition of MyoKardia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,credit,,Bristol-Myers Squibb Co.: the company announced a debt tender offer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,,Bristol-Myers Squibb Co.: the company plans to repurchase $3.0-$4.0 billion of its shares,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers Squibb Co.: By 2030, the company will purchase 100% of the electricity it uses from renewable sources, and",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: There will be a conference call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.58,security,,Bristol-Myers Squibb Co.: cyber-attacks on the company's information systems,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED DECEMBER 31, 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Celgene product revenues from November 20, 2019",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Celgene product revenues from November 20, 2019",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2021-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2021-02-04,11:59:38,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb Sees 2021 Worldwide Revenue Up,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees 2021 Worldwide Revenue Up in High-Single Digits >BMY
BMY,2021-02-04,12:01:34,94637C,Bristol-Myers Squibb Co.,100,0.4,earnings,up,Bristol-Myers Q4 loss per share 45 cents vs loss 55 cents a year ago,NEWS-FLASH,MarketWatch,MW Bristol-Myers Q4 loss per share 45 cents vs loss 55 cents a year ago
BMY,2021-02-04,12:01:46,94637C,Bristol-Myers Squibb Co.,100,0.46,earnings,above-expectations,Bristol-Myers Q4 adj. EPS $1.46; FactSet consensus $1.42,NEWS-FLASH,MarketWatch,MW Bristol-Myers Q4 adj. EPS $1.46; FactSet consensus $1.42
BMY,2021-02-04,12:02:12,94637C,Bristol-Myers Squibb Co.,100,0.48,revenues,above-expectations,Bristol-Myers Q4 revenue $11.068 bln vs. $7.945 bln; FactSet consensus $10.728 bln,NEWS-FLASH,MarketWatch,MW Bristol-Myers Q4 revenue $11.068 bln vs. $7.945 bln; FactSet consensus $10.728 bln
BMY,2021-02-04,12:02:41,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Sees 2021 EPS $3.12,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees 2021 EPS $3.12-EPS $3.32 >BMY
BMY,2021-02-04,12:03:19,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers now sees 2021 EPS of $3.12 to $3.32,NEWS-FLASH,MarketWatch,MW Bristol-Myers now sees 2021 EPS of $3.12 to $3.32
BMY,2021-02-04,12:04:06,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers now sees 2021 adj. EPS $7.35 to $7.55,NEWS-FLASH,MarketWatch,MW Bristol-Myers now sees 2021 adj. EPS $7.35 to $7.55 up from prior range of $7.15 to $7.45
BMY,2021-02-04,12:06:51,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers now sees 2021 revenue up,NEWS-FLASH,MarketWatch,MW Bristol-Myers now sees 2021 revenue up in high-single digits
BMY,2021-02-04,12:21:45,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol Myers posts $10 billion loss as,FULL-ARTICLE,MarketWatch,MW Bristol Myers posts $10 billion loss as it books charges relating to MyoKardia and Celgene
BMY,2021-02-04,12:21:45,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol Myers Posts $10 Billion Loss As,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Posts $10 Billion Loss As It Books Charges Relating To MyoKardia And Celgene -- MarketWatch
BMY,2021-02-04,12:29:15,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,12:29:15,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: net loss attributable to the company was $10.03 billion,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,12:29:15,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Opdivo sales climbed 2%,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,12:44:15,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,"Bristol Myers Squibb Posts 4Q Adjusted Profit, Growth",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adjusted Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,12:44:15,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: net loss attributable to the company was $10.03 billion,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adjusted Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,12:44:15,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Opdivo sales climbed 2%,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adjusted Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,14:50:03,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,14:50:03,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: net loss attributable to the company was $10.03 billion,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,14:50:03,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Opdivo sales climbed 2%,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts 4Q Adj Profit, Growth for Eliquis, Opdivo"
BMY,2021-02-04,15:11:58,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: The company reported non-GAAP earnings of $1.46 per share for the quarter,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Just Beat Estimates. The Stock Isn't Going Anywhere. -- Barrons.com
BMY,2021-02-04,22:15:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co CEO Giovanni Caforio on Q4 2020 Results -- Earnings Call,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Co CEO Giovanni Caforio on Q4 2020 Results -- Earnings Call Transcript >BMY
BMY,2021-02-05,20:02:38,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves New Treatment From Bristol-Myers,NEWS-FLASH,Dow Jones Newswires,FDA Approves New Treatment From Bristol-Myers Unit for Adults With Relapsed or Refractory Large-B-Cell Lymphoma
BMY,2021-02-08,16:04:49,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Bristol Myers Squibb's CAR,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Bristol Myers Squibb's CAR-T Therapy -- MarketWatch
BMY,2021-02-08,16:04:49,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda approves Bristol Myers Squibb's CAR,FULL-ARTICLE,MarketWatch,MW FDA approves Bristol Myers Squibb's CAR-T therapy
BMY,2021-02-08,17:12:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Inrebic(R) (fedratinib),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Inrebic(R) (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
BMY,2021-02-08,17:12:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The Inrebic development program,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Inrebic(R) (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
BMY,2021-02-08,17:12:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Inrebic(R) (fedratinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Inrebic(R) (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
BMY,2021-02-08,17:12:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The Inrebic development program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Inrebic(R) (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
BMY,2021-02-08,17:12:11,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Inrebic,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Inrebic for Adult Patients With Newly Diagnosed and Previously Treated Myelofibrosis
BMY,2021-02-08,17:56:25,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Says EC Approves Inrebic,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says EC Approves Inrebic to Treat Myelofibrosis Patients
BMY,2021-02-08,18:11:25,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Says EC Approves Inrebic,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says EC Approves Inrebic to Treat Myelofibrosis Patients
BMY,2021-02-09,00:30:13,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 2,406 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Acquires 2,406 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-02-09,00:30:24,94637C,Bristol-Myers Squibb Co.,100,0.0,insider-trading,,Chmn Caforio Gifts 480 Of Bristol-Myers Squibb Co >BMY,TABULAR-MATERIAL,Dow Jones Newswires,Chmn Caforio Gifts 480 Of Bristol-Myers Squibb Co >BMY
BMY,2021-02-09,00:30:44,94637C,Bristol-Myers Squibb Co.,100,0.0,insider-trading,,"Vp Leung Gifts 87,704 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Leung Gifts 87,704 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-02-09,14:00:21,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Lyfebulb and Bristol Myers Squibb teams for,PRESS-RELEASE,PR Newswire,Lyfebulb and Bristol Myers Squibb Announce the Finalists for the 2021 MS Innovation Challenge
BMY,2021-02-11,12:30:04,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer
BMY,2021-02-11,12:30:04,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer
BMY,2021-02-11,12:31:08,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for Discovery and Development of Next Generation Engineered Toxin Bodies for Treatment of Cancer
BMY,2021-02-11,13:57:33,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Molecular Templates in Cancer Collaboration With Bristol Myers,FULL-ARTICLE,Dow Jones Newswires,Molecular Templates in Cancer Collaboration With Bristol Myers >MTEM
BMY,2021-02-11,14:12:34,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Molecular Templates in Cancer Collaboration With Bristol Myers,FULL-ARTICLE,Dow Jones Newswires,Molecular Templates in Cancer Collaboration With Bristol Myers
BMY,2021-02-19,02:29:01,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $950,000,000",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Early Participation Results and Early Settlement of Tender Offers for Up to an Aggregate Purchase Price of Up to $4.0 Billion
BMY,2021-02-19,09:46:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb Enters Agreement to Acquire Forbius,PRESS-RELEASE,Business Wire,"TGFb inhibitors Pipeline Insight Report 2021: In 2020, Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio - ResearchAndMarkets.com"
BMY,2021-02-19,10:42:00,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Collaboration between Five Prime Therapeutics and BMS,PRESS-RELEASE,Business Wire,Global TIM-3 Inhibitor Pipeline Insight Report 2021: Emerging Drugs Include Cobolimab (GlaxoSmithKline) & BMS-986258 (Bristol-Myers Squibb) - ResearchAndMarkets.com
BMY,2021-02-19,22:04:00,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $950,000,000",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
BMY,2021-02-19,22:04:01,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $950,000,000",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
BMY,2021-02-22,12:00:10,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo(R)
BMY,2021-02-22,12:00:10,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo(R)
BMY,2021-02-22,12:03:54,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Compugen Expands Clinical Collaboration Agreement With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Compugen Expands Clinical Collaboration Agreement With Bristol Myers Squibb With Phase 1b Combination Study of COM701 With Opdivo
BMY,2021-02-22,23:15:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: the acquisition of Celgene;,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and Celgene Issue Notices of -2-
BMY,2021-02-23,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Raymond James Virtual 42(nd) Annual Institutional Investors Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Raymond James Virtual 42(nd) Annual Institutional Investors Conference
BMY,2021-02-23,12:04:34,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Raymond James Virtual 42nd Annual Institutional Investors Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Raymond James Virtual 42nd Annual Institutional Investors Conference
BMY,2021-02-23,14:00:03,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Proud to partner with Bristol Myers Squibb on,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb and the American Music Therapy Association Team Up with Ben Platt and Sister-in-Law Courtney Platt to Launch MS in Harmony, a First-of-its-Kind Music Therapy Offering for People Living with Multiple Sclerosis (MS)"
BMY,2021-02-23,14:33:34,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Proud to partner with Bristol Myers Squibb on,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb and the American Music Therapy Association Team Up with Ben Platt and Sister-in-Law Courtney Platt to Launch MS in Harmony, a First-of-its-Kind Music Therapy Offering for People Living with Multiple Sclerosis (MS)"
BMY,2021-02-24,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.26,corporate-responsibility,,Bristol Myers Squibb Donates $11 Million to,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Donates $11 Million to Advance Health Equity
BMY,2021-02-24,12:07:23,94637C,Bristol-Myers Squibb Co.,100,0.26,corporate-responsibility,,Bristol Myers Squibb Donates $11 Million to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Donates $11 Million to Advance Health Equity
BMY,2021-02-24,12:10:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in the Cowen Virtual 41(st) Annual Health Care Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Take Part in the Cowen Virtual 41(st) Annual Health Care Conference
BMY,2021-02-24,12:10:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in the Cowen Virtual 41st Annual Health Care Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in the Cowen Virtual 41st Annual Health Care Conference
BMY,2021-02-26,11:25:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) in Combination with Cabometyx(R) (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
BMY,2021-02-26,11:25:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2021-02-26,11:25:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2021-02-26,11:25:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-02-26,11:25:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) in Combination with Cabometyx(R) (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
BMY,2021-02-26,11:25:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2021-02-26,11:25:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-02-26,11:25:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-02-26,11:25:40,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo in Combination With Cabometyx as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
BMY,2021-03-01,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2021-03-01,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on May 3, 2021 to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2021-03-02,21:38:26,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co (BMY) Presents at 42nd Annual Raymond James Institutional Investor Conference,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Co (BMY) Presents at 42nd Annual Raymond James Institutional Investor Conference (Transcript) >BMY
BMY,2021-03-03,19:52:50,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co. Management Presents at Cowen Virtual 41st Annual Health Care Conference Call,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Co. Management Presents at Cowen Virtual 41st Annual Health Care Conference Call Transcript >BMY
BMY,2021-03-03,22:56:25,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 14,405 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Acquires 14,405 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-03,22:57:45,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 16,006 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 16,006 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-09,21:57:51,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Company (BMY) Presents at Barclays Global Healthcare Conference,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Company (BMY) Presents at Barclays Global Healthcare Conference (Transcript) >BMY
BMY,2021-03-11,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021"
BMY,2021-03-11,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: During a conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021"
BMY,2021-03-11,12:06:19,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021"
BMY,2021-03-11,12:06:19,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: During a conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021"
BMY,2021-03-11,22:58:06,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: This partnership with Lyfebulb represents one of many with the MS,PRESS-RELEASE,PR Newswire,Lyfebulb and Bristol Myers Squibb Announce the Winner of the 2021 Innovation Challenge in Multiple Sclerosis
BMY,2021-03-12,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Aveo Oncology Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA(R) (tivozanib) in Combination with OPDIVO(R) (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma
BMY,2021-03-12,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Aveo Oncology Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA(R) (tivozanib) in Combination with OPDIVO(R) (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma
BMY,2021-03-12,12:07:40,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Aveo Oncology: Collaboration With Bristol Myers Squibb to,NEWS-FLASH,Dow Jones Newswires,AVEO Oncology: Collaboration With Bristol Myers Squibb to Evaluate Fotivda in Combination With Opdivo in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma
BMY,2021-03-12,23:53:47,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp von Autenried Acquires 10,285 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP von Autenried Acquires 10,285 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:54:08,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 3,918 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Acquires 3,918 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:55:33,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Santiago Acquires 4,821 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Santiago Acquires 4,821 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:56:04,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Powell Acquires 15,506 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Powell Acquires 15,506 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:56:43,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Leung Acquires 19,173 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Leung Acquires 19,173 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:57:17,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Schmukler Acquires 16,986 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Schmukler Acquires 16,986 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:57:51,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 2,211 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Acquires 2,211 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:58:44,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 3,696 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 3,696 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-12,23:59:22,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Eid Acquires 3,942 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Eid Acquires 3,942 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-13,00:01:19,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Dubow Acquires 3,494 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Dubow Acquires 3,494 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-13,00:01:28,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Boerner Acquires 12,364 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Boerner Acquires 12,364 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-13,00:01:41,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Chmn Caforio Acquires 88,476 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Chmn Caforio Acquires 88,476 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-19,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food And Drug Administration (FDA) Accepts Bristol Myers Squibb's Application,NEWS-FLASH,Dow Jones Newswires,U.S. Food And Drug Administration (FDA) Accepts Bristol Myers Squibb's Application For Mavacamten In Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) >BMY
BMY,2021-03-19,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb's Application,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb's Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
BMY,2021-03-19,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: The NDA submission,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb's Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
BMY,2021-03-19,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb's Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb's Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
BMY,2021-03-19,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: The NDA submission,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb's Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
BMY,2021-03-19,10:59:47,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Accepts Application for Mavacamten,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: FDA Accepts Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy >BMY
BMY,2021-03-19,11:21:48,94637C,Bristol-Myers Squibb Co.,96,0.0,products-services,,Bristol-Myers Squibb Co.: The company said its FDA filing is based on the results of a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: FDA to Review Mavacamten in Hypertrophic Cardiomyopathy >BMY
BMY,2021-03-19,11:21:48,94637C,Bristol-Myers Squibb Co.,96,0.62,acquisitions-mergers,,"Myokardia Inc., which Bristol Myers bought last year",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: FDA to Review Mavacamten in Hypertrophic Cardiomyopathy >BMY
BMY,2021-03-19,11:36:48,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: The company said its FDA filing is based on the results of a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: FDA to Review Mavacamten in Hypertrophic Cardiomyopathy
BMY,2021-03-19,11:36:48,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,"Myokardia Inc., which Bristol Myers bought last year",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: FDA to Review Mavacamten in Hypertrophic Cardiomyopathy
BMY,2021-03-24,20:42:16,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co",FULL-ARTICLE,Dow Jones Newswires,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-03-25,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,"Bristol-Myers Squibb Co.: RELATIVITY-047 (CA224-047) is a randomized, double-blind Phase 2/3 study",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival"
BMY,2021-03-25,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces RELATIVITY-047, a -4-"
BMY,2021-03-25,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces RELATIVITY-047, a -4-"
BMY,2021-03-25,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces RELATIVITY-047, a -5-"
BMY,2021-03-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,"Bristol-Myers Squibb Co.: RELATIVITY-047 (CA224-047) is a randomized, double-blind Phase 2/3 study",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival"
BMY,2021-03-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2021-03-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2021-03-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -5-
BMY,2021-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: The application is based on results from CheckMate -274, the first positive Phase 3 trial",PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2021-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2021-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2021-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2021-03-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-03-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Bristol-Myers Squibb Co.: The application is based on results from CheckMate -274, the first positive Phase 3 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-03-29,10:59:12,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,NEWS-FLASH,Dow Jones Newswires,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo as Adjuvant Treatment for Patients With Muscle-Invasive Urothelial Carcinoma
BMY,2021-03-30,12:05:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma
BMY,2021-03-30,12:05:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: Press Release: Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma
BMY,2021-04-02,17:15:46,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Mily Acquires 3,394 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Mily Acquires 3,394 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-04-07,07:00:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Psioxus Therapeutics Updates Agreement with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration
BMY,2021-04-07,07:00:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to,PRESS-RELEASE,Business Wire,PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration
BMY,2021-04-08,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo (nivolumab) -3-
BMY,2021-04-08,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo (nivolumab) -4-
BMY,2021-04-08,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo (nivolumab) -5-
BMY,2021-04-08,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo (nivolumab) -5-
BMY,2021-04-08,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2021-04-08,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2021-04-08,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -5-
BMY,2021-04-08,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -5-
BMY,2021-04-08,11:28:25,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Yervoy Show Positive Phase 3 Results,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb's Opdivo, Yervoy Show Positive Phase 3 Results for Additional Application"
BMY,2021-04-08,11:43:25,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Yervoy Show Positive Phase 3 Results,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb's Opdivo, Yervoy Show Positive Phase 3 Results for Additional Application"
BMY,2021-04-08,23:35:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,CORRECTING and REPLACING Bristol Myers Squibb -4-
BMY,2021-04-08,23:35:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,CORRECTING and REPLACING Bristol Myers Squibb -4-
BMY,2021-04-08,23:35:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,CORRECTING and REPLACING Bristol Myers Squibb -5-
BMY,2021-04-08,23:35:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,CORRECTING and REPLACING Bristol Myers Squibb -5-
BMY,2021-04-13,11:21:06,94637C,Bristol-Myers Squibb Co.,100,0.94,analyst-ratings,positive,Bristol Myers Squibb upgraded to buy from hold,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb upgraded to buy from hold at Truist
BMY,2021-04-13,12:11:12,94637C,Bristol-Myers Squibb Co.,100,0.94,analyst-ratings,positive,Bristol Myers Squibb Raised to Buy From Hold by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Raised to Buy From Hold by Truist Securities
BMY,2021-04-13,12:11:12,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol Myers Squibb Price Target Raised to $74.00/Share From $66.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Raised to $74.00/Share From $66.00 by Truist Securities
BMY,2021-04-14,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cabometyx(R) (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
BMY,2021-04-14,20:16:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2021-04-14,20:16:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2021-04-14,20:16:00,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2021-04-14,20:16:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -6-
BMY,2021-04-14,20:16:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination with Cabometyx(R) (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
BMY,2021-04-14,20:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-04-14,20:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-04-14,20:16:01,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-04-14,20:16:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -6-
BMY,2021-04-14,20:16:53,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab),NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) in Combination With Cabometyx(R) (cabozantinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
BMY,2021-04-14,20:28:54,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets EU Approval for Renal Cell Carcinoma Treatment,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets EU Approval for Renal Cell Carcinoma Treatment
BMY,2021-04-14,20:28:54,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Co. said Wednesday the European Commission has approved its drug nivolumab,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets EU Approval for Renal Cell Carcinoma Treatment
BMY,2021-04-14,20:43:54,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets EU Approval for Renal Cell Carcinoma Treatment,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets EU Approval for Renal Cell Carcinoma Treatment
BMY,2021-04-14,20:43:54,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Co. said Wednesday the European Commission has approved its drug nivolumab,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets EU Approval for Renal Cell Carcinoma Treatment
BMY,2021-04-16,17:10:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma...."
BMY,2021-04-16,17:11:57,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma...."
BMY,2021-04-16,17:14:33,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets FDA OK For Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA OK For Opdivo in First-Line Gastric Cancer Treatment >BMY
BMY,2021-04-16,17:29:32,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets FDA OK For Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA OK For Opdivo in First-Line Gastric Cancer Treatment
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-04-23,10:45:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-04-23,10:51:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg(R) (azacitidine tablets,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg(R) (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
BMY,2021-04-23,10:51:00,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: The study enrolled 472 patients,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg(R) (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
BMY,2021-04-23,10:51:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg(R) (azacitidine tablets,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg(R) (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
BMY,2021-04-23,10:51:01,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: The study enrolled 472 patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg(R) (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
BMY,2021-04-23,10:52:40,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg (Azacitidine Tablets,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg (Azacitidine Tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults With Acute Myeloid Leukemia in First Remission
BMY,2021-04-23,14:00:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla(R) (apremilast)
BMY,2021-04-23,14:00:01,94637C,Bristol-Myers Squibb Co.,99,0.31,corporate-responsibility,,Bristol Myers Squibb will host a virtual Investor Event on Friday,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Positive Data from -2-
BMY,2021-04-23,14:00:01,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Positive Data from -2-
BMY,2021-04-23,14:00:41,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Presents Positive Data From Two Pivotal Phase 3 Psoriasis Studies,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Presents Positive Data From Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla
BMY,2021-04-23,14:00:59,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Presents Positive Data From Two Pivotal Phase 3 Psoriasis Studies,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Presents Positive Data From Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla
BMY,2021-04-23,14:01:44,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla(R) (apremilast)
BMY,2021-04-23,14:01:44,94637C,Bristol-Myers Squibb Co.,99,0.31,corporate-responsibility,,Bristol Myers Squibb will host a virtual Investor Event on Friday,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2021-04-23,14:01:44,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2021-04-24,07:21:18,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2021 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2021 (BMY)"
BMY,2021-04-26,05:50:29,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Bristol MYERS SQUIBB EXTENDS COLLABORATION WITH EVOTEC IN,PRESS-RELEASE,DJ Global Press Release Wire,Bristol Myers Squibb Exercises Option to Extend Targeted Protein Degradation Partnership with Evotec
BMY,2021-04-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in the 7(th) Annual Truist Life Sciences Summit,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Take Part in the 7(th) Annual Truist Life Sciences Summit
BMY,2021-04-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in the 7th Annual Truist Life Sciences Summit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in the 7th Annual Truist Life Sciences Summit
BMY,2021-04-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will participate in a fireside chat at the 7(th) Annual Virtual Truist Life Sciences Summit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in the 7th Annual Truist Life Sciences Summit
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 1Q Adj EPS $1.74,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q Adj EPS $1.74 >BMY
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Sees FY EPS $3.18,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY EPS $3.18-EPS $3.38 >BMY
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 1Q EPS 89c,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q EPS 89c >BMY
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Sees FY Adj EPS $7.35,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY Adj EPS $7.35-Adj EPS $7.55 >BMY
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 1Q Net $2B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q Net $2B >BMY
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 1Q Rev $11.1B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q Rev $11.1B >BMY
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports First Quarter Financial Results for 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports First Quarter Revenues of $11.1 Billion, an Increase of 3% YoY",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts First Quarter Earnings Per Share of $0.89,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Presents Positive Results from POETYK-1 and POETYK-PSO-2 Phase 3 Trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Announces FDA Acceptance of New Drug Application,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.24,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 6% to $2.2 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced the FDA approved Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -274 is the first positive Phase 3 trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Fda has approved Breyanzi(R) (lisocabtagene maraleucel,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.31,credit,,Bristol-Myers Squibb Co.: the company purchased approximately $4.0 billion in aggregate purchase price of certain debt,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,-0.58,security,,Bristol-Myers Squibb Co.: cyber-attacks on the company's information systems,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2021-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports First Quarter Financial Results for 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports First Quarter Revenues of $11.1 Billion, an Increase of 3% YoY",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts First Quarter Earnings Per Share of $0.89,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Presents Positive Results from POETYK-1 and POETYK-PSO-2 Phase 3 Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Announces FDA Acceptance of New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.24,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 6% to $2.2 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced the FDA approved Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2021
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -274 is the first positive Phase 3 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Fda has approved Breyanzi(R) (lisocabtagene maraleucel,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.31,credit,,Bristol-Myers Squibb Co.: the company purchased approximately $4.0 billion in aggregate purchase price of certain debt,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.58,security,,Bristol-Myers Squibb Co.: cyber-attacks on the company's information systems,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2021-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2021-04-29,11:00:27,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb Sees 2021 Worldwide Revenues Up,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees 2021 Worldwide Revenues Up High-Single Digits
BMY,2021-04-29,11:00:46,94637C,Bristol-Myers Squibb Co.,100,0.88,earnings,up,Bristol Myers Squibb Q1 EPS 89 cents vs. per-share loss 34 cents a year ago,NEWS-FLASH,MarketWatch,Bristol Myers Squibb Q1 EPS 89 cents vs. per-share loss 34 cents a year ago
BMY,2021-04-29,11:01:12,94637C,Bristol-Myers Squibb Co.,100,0.4,earnings,up,Bristol Myers Q1 adj. EPS $1.74 vs. $1.72 a year ago,NEWS-FLASH,MarketWatch,Bristol Myers Q1 adj. EPS $1.74 vs. $1.72 a year ago; FactSet consensus $1.81
BMY,2021-04-29,11:01:31,94637C,Bristol-Myers Squibb Co.,100,-0.27,revenues,below-expectations,Bristol Myers Q1 revenue $11.07 bln vs. $10.78 bln a year ago; FactSet consensus $11.13 bln,NEWS-FLASH,MarketWatch,Bristol Myers Q1 revenue $11.07 bln vs. $10.78 bln a year ago; FactSet consensus $11.13 bln
BMY,2021-04-29,11:02:55,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,unchanged,Bristol Myers affirms 2021 adj. EPS outlook $7.35-$7.55,NEWS-FLASH,MarketWatch,Bristol Myers affirms 2021 adj. EPS outlook $7.35-$7.55
BMY,2021-04-29,11:11:22,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Revlimid sales rose 1%,FULL-ARTICLE,MarketWatch,"Bristol Myers Squibb stock falls, as profit and revenue rise but miss expectations"
BMY,2021-04-29,11:11:22,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Eliquis sales grew 9%,FULL-ARTICLE,MarketWatch,"Bristol Myers Squibb stock falls, as profit and revenue rise but miss expectations"
BMY,2021-04-29,11:11:22,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Revlimid sales rose 1%,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Stock Falls, As Profit And Revenue Rise But Miss Expectations -- MarketWatch"
BMY,2021-04-29,11:11:22,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Eliquis sales grew 9%,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Stock Falls, As Profit And Revenue Rise But Miss Expectations -- MarketWatch"
BMY,2021-04-29,11:20:27,94637C,Bristol-Myers Squibb Co.,94,0.65,revenues,up,Bristol-Myers Squibb Co. Thursday posted first-quarter revenue growth,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb 1Q Revenue, Profit Land Below Expectations"
BMY,2021-04-29,11:35:28,94637C,Bristol-Myers Squibb Co.,94,0.65,revenues,up,Bristol-Myers Squibb Co. Thursday posted first-quarter revenue growth,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb 1Q Revenue, Profit Land Below Expectations"
BMY,2021-04-29,13:04:56,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb reported earnings early Thursday,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Stock Fell After Earnings. Here's Why. -- Barrons.com
BMY,2021-04-29,13:04:56,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers (ticker: BMY) reported non-GAAP earnings of $1.74 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Stock Fell After Earnings. Here's Why. -- Barrons.com
BMY,2021-04-29,13:20:03,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb reported earnings early Thursday,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Stock Fell After Earnings. Here's Why.
BMY,2021-04-29,13:20:03,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers (ticker: BMY) reported non-GAAP earnings of $1.74 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Stock Fell After Earnings. Here's Why.
BMY,2021-04-29,20:49:03,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb's CEO Giovanni Caforio on Q1 2021 Results -- Earnings Call,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb's CEO Giovanni Caforio on Q1 2021 Results -- Earnings Call Transcript >BMY
BMY,2021-04-29,20:49:03,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-myers-squibbs-bmy-ceo-giovanni-caforio-on-q1-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb's CEO Giovanni Caforio on Q1 2021 Results -- Earnings Call Transcript >BMY
BMY,2021-04-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-04-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -274 is one of four positive Phase 3 trials,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-04-30,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-04-30,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -274 is one of four positive Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
BMY,2021-04-30,11:13:31,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Opdivo in Muscle-Invasive Urothelial Carcinoma
BMY,2021-04-30,11:28:30,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Opdivo in Muscle-Invasive Urothelial Carcinoma
BMY,2021-04-30,13:55:43,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol Myers Squibb bought the biotech Celgene for $80 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Deal Sweetener for Celgene Looked Good at the Time. Why Shareholders Missed Out on an Extra $6 Billion. -- Barrons.com
BMY,2021-04-30,13:55:43,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,"Celgene drugs, ozanimod, received FDA approval",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Deal Sweetener for Celgene Looked Good at the Time. Why Shareholders Missed Out on an Extra $6 Billion. -- Barrons.com
BMY,2021-05-03,13:11:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Findings from the interim analysis,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology's 70(th) Annual Scientific Session
BMY,2021-05-03,13:11:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Findings from the interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology's 70th Annual Scientific Session
BMY,2021-05-04,20:00:52,94637C,Bristol-Myers Squibb Co.,100,-0.57,credit-ratings,withdrawn,Fitch Plans to Withdraw Bristol-Myers Squibb 's Ratings,NEWS-FLASH,Dow Jones Newswires,Fitch Plans to Withdraw Bristol-Myers Squibb 's Ratings
BMY,2021-05-04,20:00:52,94637C,Bristol-Myers Squibb Co.,100,-0.57,credit-ratings,withdrawn,Fitch Plans to Withdraw Bristol-Myers Squibb 's Ratings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Fitch Plans to Withdraw Bristol-Myers Squibb 's Ratings
BMY,2021-05-05,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference
BMY,2021-05-05,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference
BMY,2021-05-06,12:03:22,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,Canadian News Wire,DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative
BMY,2021-05-06,12:03:22,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: PR) DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,(PR) DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative
BMY,2021-05-06,12:03:22,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: Press Release: DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative
BMY,2021-05-06,12:03:22,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: Press Release: DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative
BMY,2021-05-06,12:04:44,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Research Collaboration With Bristol Myers Squibb for,NEWS-FLASH,Dow Jones Newswires,DarwinHealth Announces a Research Collaboration With Bristol Myers Squibb for a Novel Cancer Target DiscoveryInitiative
BMY,2021-05-06,13:15:07,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,Apixaban was launched in China in 2013,PRESS-RELEASE,PR Newswire,"China Apixaban Market Report 2021-2025 Featuring BMS/Pfizer EEIG (ELIQUIS), Chia Tai Tianqing (Anbeining), Jiangsu Hansoh (Zexin), Sichuan Kelun (Pukesha), & Jiangsu Sinobiopharma (Yipaiping)"
BMY,2021-05-07,20:58:12,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Vessey Sells 30,546 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Sells 30,546 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-05-07,20:59:11,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Dubow Sells 3,119 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Dubow Sells 3,119 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-05-11,20:40:13,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 9,251 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Acquires 9,251 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-05-11,20:40:43,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Schmukler Sells 15,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Schmukler Sells 15,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-05-11,20:40:53,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Eid Sells 1,118 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Eid Sells 1,118 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-05-12,15:43:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: In collaboration with the community, we're working to",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders
BMY,2021-05-12,15:43:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Research at -6-
BMY,2021-05-12,15:43:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Research at -6-
BMY,2021-05-12,15:43:00,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Research at -8-
BMY,2021-05-12,15:43:00,94637C,Bristol-Myers Squibb Co.,90,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Research at -10-
BMY,2021-05-12,15:43:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Research at -11-
BMY,2021-05-12,15:45:17,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: In collaboration with the community, we're working to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders
BMY,2021-05-12,15:45:17,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: A Phase 3 Study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -3-
BMY,2021-05-12,15:45:17,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -6-
BMY,2021-05-12,15:45:17,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -6-
BMY,2021-05-12,15:45:17,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -8-
BMY,2021-05-12,15:45:17,94637C,Bristol-Myers Squibb Co.,90,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -10-
BMY,2021-05-12,15:45:17,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -11-
BMY,2021-05-18,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb Announce Exclusive Global License for Agenus,PRESS-RELEASE,GlobeNewswire,Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Pleased to partner with Bristol Myers Squibb to,PRESS-RELEASE,GlobeNewswire,Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb Announce Exclusive Global License for Agenus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Pleased to partner with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb Announce Exclusive Global License for Agenus,PRESS-RELEASE,Business Wire,Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Pleased to partner with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb Announce Exclusive Global License for Agenus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Pleased to partner with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:30:18,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb Announce Exclusive Global License for Agenus,NEWS-FLASH,Dow Jones Newswires,"Agenus, Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program"
BMY,2021-05-18,11:30:56,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb Announce Exclusive Global License for Agenus,NEWS-FLASH,Dow Jones Newswires,Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
BMY,2021-05-18,11:48:54,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol-Myers Licenses Agenus AGEN1777 Program >BMY,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Licenses Agenus AGEN1777 Program >BMY AGEN
BMY,2021-05-18,12:03:54,94637C,Bristol-Myers Squibb Co.,95,0.39,products-services,,Bristol Myers Squibb Co. and Agenus Inc. Tuesday said they signed a licensing agreement,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Licenses Agenus AGEN1777 Program
BMY,2021-05-19,08:00:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb",PRESS-RELEASE,Business Wire,"Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb"
BMY,2021-05-19,10:53:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Exscientia collaboration with Bristol Myers Squibb,PRESS-RELEASE,LSE Regulatory News Service (RNS),Frontier IP Group plc Exscientia collaboration with Bristol Myers Squibb
BMY,2021-05-19,21:00:02,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces LAG-3-Blocking -4-
BMY,2021-05-19,21:00:02,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces LAG-3-Blocking -4-
BMY,2021-05-19,21:00:02,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces LAG-3-Blocking -5-
BMY,2021-05-19,21:00:02,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces LAG-3-Blocking -6-
BMY,2021-05-19,21:01:30,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2021-05-19,21:01:30,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2021-05-19,21:01:30,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -5-
BMY,2021-05-19,21:01:30,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -6-
BMY,2021-05-20,10:59:31,94637C,Bristol-Myers Squibb Co.,100,0.47,labor-issues,,Bristol Myers Squibb Names Manuel Hidalgo Medina to Board,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Names Manuel Hidalgo Medina to Board
BMY,2021-05-20,17:26:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) as Adjuvant Treatment,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy
BMY,2021-05-20,17:26:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) has approved Opdivo(R) (nivolumab,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy
BMY,2021-05-20,17:27:18,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Opdivo as Adjuvant Treatment,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: FDA Approves Opdivo as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients Who Have Received Neoadjuvant Chemoradiotherapy
BMY,2021-05-20,17:40:49,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Gets FDA OK For Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Gets FDA OK For Opdivo as Adjuvant in Upper Gastrointestinal Cancers
BMY,2021-05-20,17:55:49,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Gets FDA OK For Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Gets FDA OK For Opdivo as Adjuvant in Upper Gastrointestinal Cancers
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Yervoy received approval from the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Yervoy was also approved in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,97,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,97,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Yervoy received approval from the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Yervoy was also approved in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,97,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-05-21,20:16:01,94637C,Bristol-Myers Squibb Co.,97,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-05-21,20:47:51,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,Yervoy was approved by the U.S. Food and Drug Administration in 2018,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: CHMP Recommends Approval of Opdivo Plus Yervoy for Colorectal Cancer
BMY,2021-05-21,21:02:52,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,Yervoy was approved by the U.S. Food and Drug Administration in 2018,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: CHMP Recommends Approval of Opdivo Plus Yervoy for Colorectal Cancer
BMY,2021-05-23,15:35:00,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Zeposia was approved by the U.S. Food and Drug Administration (FDA) for the treatment,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data at -2-
BMY,2021-05-23,15:35:00,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,European Medicines Agency validated Bristol Myers Squibb's Marketing Authorization Application,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data at -2-
BMY,2021-05-23,15:35:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Zeposia was approved by the U.S. Food and Drug Administration (FDA) for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -2-
BMY,2021-05-23,15:35:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,European Medicines Agency validated Bristol Myers Squibb's Marketing Authorization Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -2-
BMY,2021-05-25,12:01:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Xencor and Bristol Myers Squibb Enter License Agreement,PRESS-RELEASE,Business Wire,Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend(TM) XmAb(R) Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
BMY,2021-05-25,12:01:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Xencor and Bristol Myers Squibb Enter License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend(TM) XmAb(R) Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
BMY,2021-05-25,12:01:06,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Xencor and Bristol Myers Squibb Enter License Agreement,NEWS-FLASH,Dow Jones Newswires,Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend(TM) XmAb(R) Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
BMY,2021-05-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in Bernstein's 37(th) Annual Strategic Decisions Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Take Part in Bernstein's 37(th) Annual Strategic Decisions Conference
BMY,2021-05-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in Bernstein's 37th Annual Strategic Decisions Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in Bernstein's 37th Annual Strategic Decisions Conference
BMY,2021-05-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will participate in a fireside chat at Bernstein's 37(th) Annual Strategic Decisions Virtual Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in Bernstein's 37th Annual Strategic Decisions Conference
BMY,2021-05-27,20:13:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food And Drug Administration Approves Bristol Myers Squibb's Zeposia(R) (ozanimod),NEWS-FLASH,Dow Jones Newswires,"U.S. Food And Drug Administration Approves Bristol Myers Squibb's Zeposia(R) (ozanimod), An Oral Treatment For Adults With Moderately To Severely Active Ulcerative Colitis1 >BMY"
BMY,2021-05-27,20:13:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia(R) (ozanimod),PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia(R) (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis(1)"
BMY,2021-05-27,20:13:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia(R) (ozanimod),PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia(R) (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1"
BMY,2021-06-01,11:30:02,94637C,Bristol-Myers Squibb Co.,100,0.47,labor-issues,,"Bristol Myers Squibb, Joins Coya Therapeutics(TM) Board of Directors",PRESS-RELEASE,GlobeNewswire,"Ann Lee, Ph.D., SVP at Bristol Myers Squibb, Joins Coya Therapeutics(TM) Board of Directors"
BMY,2021-06-01,11:30:02,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Juno Therapeutics, which was acquired by BMS",PRESS-RELEASE,GlobeNewswire,"Ann Lee, Ph.D., SVP at Bristol Myers Squibb, Joins Coya Therapeutics(TM) Board of Directors"
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: the first positive Phase 3 trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -6-
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -6-
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Deucravacitinib: An analysis of musculoskeletal disease improvements from the Phase 2 trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,93,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at EULAR 2021 Highlight -2-
BMY,2021-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Immunosuppression: In clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at EULAR 2021 Highlight -3-
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Deucravacitinib: An analysis of musculoskeletal disease improvements from the Phase 2 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at EULAR -2-
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Immunosuppression: In clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at EULAR -3-
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: the first positive Phase 3 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -6-
BMY,2021-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -6-
BMY,2021-06-02,10:59:30,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo Plus Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:00:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab),PRESS-RELEASE,Canadian News Wire,Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:00:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab),PRESS-RELEASE,Canadian News Wire,Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:00:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:00:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Approves OPDIVO (nivolumab) plus YERVOY (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:01:07,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves Opdivo Plus Yervoy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: Health Canada Approves Opdivo Plus Yervoy as First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:01:07,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves Opdivo Plus Yervoy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: Health Canada Approves Opdivo Plus Yervoy as First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:02:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO Plus YERVOY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: Health Canada Approves OPDIVO Plus YERVOY as First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-02,12:02:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO Plus YERVOY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: Health Canada Approves OPDIVO Plus YERVOY as First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
BMY,2021-06-03,20:15:11,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol-Myers Squibb acquired these two companies,PRESS-RELEASE,PR Newswire,"China Nivolumab Markets Report, 2016-2020 & 2021-2025 Featuring Bristol-Myers Squibb, Medarex, & Ono Pharmaceuticals"
BMY,2021-06-03,20:15:11,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Nivolumab was launched in China in 2018,PRESS-RELEASE,PR Newswire,"China Nivolumab Markets Report, 2016-2020 & 2021-2025 Featuring Bristol-Myers Squibb, Medarex, & Ono Pharmaceuticals"
BMY,2021-06-03,21:01:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: Opdivo has now demonstrated superior first,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BMY,2021-06-03,21:01:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data from CheckMate -4-
BMY,2021-06-03,21:01:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data from CheckMate -4-
BMY,2021-06-03,21:01:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data from CheckMate -6-
BMY,2021-06-03,21:01:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data from CheckMate -6-
BMY,2021-06-03,21:01:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: Opdivo has now demonstrated superior first,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BMY,2021-06-03,21:01:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In separate Phase 3 trials of YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data -4-
BMY,2021-06-03,21:01:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data -4-
BMY,2021-06-03,21:01:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data -6-
BMY,2021-06-03,21:01:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data -6-
BMY,2021-06-04,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in Goldman Sachs 42(nd) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Take Part in Goldman Sachs 42(nd) Annual Global Healthcare Conference
BMY,2021-06-04,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference
BMY,2021-06-04,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will participate in a fireside chat at the Goldman Sachs 42(nd) Annual Global Healthcare Virtual Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference
BMY,2021-06-04,20:37:26,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Eid Acquires 1,416 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Eid Acquires 1,416 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-06-07,18:50:36,94637C,Bristol-Myers Squibb Co.,100,0.09,credit-ratings,affirmation,Fitch Affirms Bristol-Myers Squibb's IDR at 'A-,NEWS-FLASH,Dow Jones Newswires,Fitch Affirms Bristol-Myers Squibb's IDR at 'A-'; Withdraws Ratings; Outlook Revised to Stable
BMY,2021-06-07,18:50:40,94637C,Bristol-Myers Squibb Co.,100,0.09,credit-ratings,affirmation,Fitch Affirms Bristol-Myers Squibb's IDR at 'A-,PRESS-RELEASE,Dow Jones Newswires,Press Release: Fitch Affirms Bristol-Myers Squibb's IDR at 'A-'; Withdraws Ratings; Outlook Revised to Stable
BMY,2021-06-07,18:50:50,94637C,Bristol-Myers Squibb Co.,100,0.0,credit-ratings,affirmation,Fitch Affirms Bristol-Myers,PRESS-RELEASE,Dow Jones Newswires,Press Release: Fitch Affirms Bristol-Myers -2-
BMY,2021-06-10,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma
BMY,2021-06-10,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: All enrolled patients,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma
BMY,2021-06-10,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma
BMY,2021-06-10,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: All enrolled patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma
BMY,2021-06-10,10:59:37,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results From Phase 3 TRANSFORM Trial,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Positive Topline Results From Phase 3 TRANSFORM Trial Evaluating Breyanzi
BMY,2021-06-10,11:05:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021"
BMY,2021-06-10,11:05:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: During a conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021"
BMY,2021-06-10,11:07:19,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021"
BMY,2021-06-10,11:07:19,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: During a conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021"
BMY,2021-06-10,11:28:13,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol Myers Squibb said a Phase 3 study of,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says Phase 3 Lymphoma Study Meets Objectives
BMY,2021-06-10,11:43:14,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol Myers Squibb said a Phase 3 study of,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says Phase 3 Lymphoma Study Meets Objectives
BMY,2021-06-10,19:36:56,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 42nd Annual Global Healthcare Conference,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript) >BMY
BMY,2021-06-14,12:00:01,94637C,Bristol-Myers Squibb Co.,94,0.34,products-services,,Nektar Therapeutics (Nasdaq: NKTR) will supply bempegaldesleukin to Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
BMY,2021-06-14,12:00:01,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Successful collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
BMY,2021-06-14,12:00:01,94637C,Bristol-Myers Squibb Co.,95,0.34,products-services,,Nektar Therapeutics (Nasdaq: NKTR) will supply bempegaldesleukin to Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
BMY,2021-06-14,12:00:01,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,Successful collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
BMY,2021-06-14,12:46:52,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Exelixis in Clinical Trial Collaboration with Bristol Myers,FULL-ARTICLE,Dow Jones Newswires,Exelixis in Clinical Trial Collaboration with Bristol Myers
BMY,2021-06-14,12:46:52,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Nektar Therapeutics will supply bempegaldesleukin to Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Exelixis in Clinical Trial Collaboration with Bristol Myers
BMY,2021-06-14,13:01:52,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Exelixis in Clinical Trial Collaboration with Bristol Myers,FULL-ARTICLE,Dow Jones Newswires,Exelixis in Clinical Trial Collaboration with Bristol Myers
BMY,2021-06-14,13:01:52,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Nektar Therapeutics will supply bempegaldesleukin to Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Exelixis in Clinical Trial Collaboration with Bristol Myers
BMY,2021-06-14,15:00:08,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol-Myers Squibb Co.: Clinical trial activity in the pancreatic cancer,PRESS-RELEASE,PR Newswire,"World Pancreatic Cancer Market Report 2021-2031: Bristol Myers Squibb Leads Industry Sponsors with the Highest Overall Number of Clinical Trials, Followed by Roche"
BMY,2021-06-17,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2021-06-17,20:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on August 2, 2021 to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2021-06-17,22:30:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration,PRESS-RELEASE,Business Wire,Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate
BMY,2021-06-17,22:34:44,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration,NEWS-FLASH,Dow Jones Newswires,Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate
BMY,2021-06-17,22:38:27,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate
BMY,2021-06-18,00:13:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,It Inks Agreement With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Eisai Shares Rise 9.6% After It Inks Agreement With Bristol Myers Squibb for Cancer Drug Development
BMY,2021-06-18,13:34:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Onureg(R) (azacitidine tablets,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Onureg(R) (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
BMY,2021-06-18,13:34:01,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: The study enrolled 472 patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Onureg(R) (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
BMY,2021-06-18,14:00:07,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,Bristol Myers Squibb received approval from the US FDA for its product,PRESS-RELEASE,PR Newswire,"Global Regenerative Medicine Market Outlook 2021-2026: Major Players are Amgen, Bristol Myers Squibb, Dendreon, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Osiris, Organogenesis, and Vericel"
BMY,2021-06-24,12:30:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Continued collaboration with Bristol Myers Squibb on,PRESS-RELEASE,DJ Global Press Release Wire,Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
BMY,2021-06-24,12:30:01,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,Continued collaboration with Bristol Myers Squibb on,FULL-ARTICLE,Dow Jones Newswires,Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
BMY,2021-06-24,12:30:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Continued collaboration with Bristol Myers Squibb on,PRESS-RELEASE,GlobeNewswire,Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
BMY,2021-06-24,12:30:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Continued collaboration with Bristol Myers Squibb on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
BMY,2021-06-24,12:30:02,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Continued collaboration with Bristol Myers Squibb on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
BMY,2021-06-24,12:33:37,94637C,Bristol-Myers Squibb Co.,100,0.46,equity-actions,,Prothena to Get $80 M From Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Prothena to Get $80 M From Bristol Myers Squibb for Exclusive US License to PRX005 >PRTA
BMY,2021-06-25,10:50:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma
BMY,2021-06-25,10:50:01,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: The study enrolled 140 patients,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma
BMY,2021-06-25,10:50:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma
BMY,2021-06-25,10:50:01,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: The study enrolled 140 patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma
BMY,2021-06-25,10:51:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene Vicleucel) for Relapsed and Refractory Multiple Myeloma
BMY,2021-06-25,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-06-25,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2021-06-25,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-06-25,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-06-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-06-25,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-06-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-06-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-06-29,11:06:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Yervoy received approval from the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Yervoy was also approved in Japan by the Ministry of Health, Labour and Welfare (MHLW)",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2021-06-29,11:06:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2021-06-29,11:06:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2021-06-29,11:06:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Yervoy received approval from the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Yervoy was also approved in Japan by the Ministry of Health, Labour and Welfare (MHLW)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-06-29,11:06:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-06-29,11:06:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-06-29,11:06:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-06-29,11:09:43,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo Plus Yervoy for the Treatment of Mismatch Repair Deficient or Microsatellite Instability--High Metastatic Colorectal Cancer After Prior Chemotherapy
BMY,2021-07-06,13:20:10,94637C,Bristol-Myers Squibb Co.,91,0.39,products-services,,Agenus Inc.: the company said a licensing deal with Bristol Myers Squibb Co. (BMY),FULL-ARTICLE,MarketWatch,MW Agenus says its Bristol Myers Squibb licensing deal has up to $1.3 billion in milestone payments
BMY,2021-07-06,13:20:10,94637C,Bristol-Myers Squibb Co.,91,0.39,products-services,,Agenus Inc.: the company said a licensing deal with Bristol Myers Squibb Co. (BMY),FULL-ARTICLE,Dow Jones Newswires,Agenus Says Its Bristol Myers Squibb Licensing Deal Has Up To $1.3 Billion In Milestone Payments -- MarketWatch
BMY,2021-07-06,20:39:37,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Santiago Acquires 522 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Santiago Acquires 522 Of Bristol-Myers Squibb Co >BMY
BMY,2021-07-06,20:40:01,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 4,570 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Acquires 4,570 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-07-16,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -4-
BMY,2021-07-16,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -5-
BMY,2021-07-16,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -5-
BMY,2021-07-16,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -4-
BMY,2021-07-16,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -5-
BMY,2021-07-16,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -5-
BMY,2021-07-16,11:10:37,94637C,Bristol-Myers Squibb Co.,100,-0.65,products-services,negative,Bristol Myers says late-stage trial of head and neck cancer treatment failed,FULL-ARTICLE,MarketWatch,MW Bristol Myers says late-stage trial of head and neck cancer treatment failed to meet main goals
BMY,2021-07-16,11:10:37,94637C,Bristol-Myers Squibb Co.,100,-0.65,products-services,negative,Bristol Myers Says Late-stage Trial Of Head And Neck Cancer Treatment Failed,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says Late-stage Trial Of Head And Neck Cancer Treatment Failed To Meet Main Goals -- MarketWatch
BMY,2021-07-24,07:29:16,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2021 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2021 (BMY)"
BMY,2021-07-27,11:30:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Pleased to collaborate with Bristol Myers Squibb and advance BridgeBio,PRESS-RELEASE,PR Newswire,"BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO(R) (nivolumab) in Advanced Solid Tumors with KRAS Mutations"
BMY,2021-07-27,11:30:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Pleased to collaborate with Bristol Myers Squibb and advance BridgeBio,PRESS-RELEASE,Dow Jones Newswires,"Press Release: BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO(R) (nivolumab) in Advanced Solid Tumors with KRAS Mutations"
BMY,2021-07-27,11:32:28,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bridgebio Announces Clinical Collaboration With Bristol Myers Squibb to,NEWS-FLASH,Dow Jones Newswires,BridgeBio Announces Clinical Collaboration With Bristol Myers Squibb to Study BBP-398
BMY,2021-07-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Sees FY EPS $2.77,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY EPS $2.77-EPS $2.97 >BMY
BMY,2021-07-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 2Q EPS 47c,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q EPS 47c >BMY
BMY,2021-07-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Sees FY Adj EPS $7.35,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY Adj EPS $7.35-Adj EPS $7.55 >BMY
BMY,2021-07-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 2Q Adj EPS $1.93,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Adj EPS $1.93 >BMY
BMY,2021-07-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 2Q Net $1.1B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Net $1.1B >BMY
BMY,2021-07-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 2Q Rev $11.7B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Rev $11.7B >BMY
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports Second Quarter Revenues of $11.7 Billion, an Increase of 16% YoY",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Second Quarter Earnings Per Share of $0.47,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.4,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increased 30%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: FIRST HALF PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Commission (EC) has approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Commission (EC) has approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,products-services,positive,"Bristol-Myers Squibb Co.: the company announced positive topline results from TRANSFORM, a global, randomized, multicenter Phase 3 study",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the FDA approved Zeposia(R) (ozanimod),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: the company and Eisai Co., Ltd. announced that the companies have entered into an exclusive global strategic collaboration",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol-Myers Squibb Co.: the company and Agenus Inc. (NASDAQ: AGEN) announced that they have entered into a definitive agreement,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: the company's Annual Report on Form 10-K for the year ended December 31, 2020",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED JUNE 30, 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE SIX MONTHS ENDED JUNE 30, 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -6-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports Second Quarter Revenues of $11.7 Billion, an Increase of 16% YoY",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Second Quarter Earnings Per Share of $0.47,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.4,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increased 30%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: FIRST HALF PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Commission (EC) has approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Commission (EC) has approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,products-services,positive,"Bristol-Myers Squibb Co.: the company announced positive topline results from TRANSFORM, a global, randomized, multicenter Phase 3 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the FDA approved Zeposia(R) (ozanimod),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: the company and Eisai Co., Ltd. announced that the companies have entered into an exclusive global strategic collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol-Myers Squibb Co.: the company and Agenus Inc. (NASDAQ: AGEN) announced that they have entered into a definitive agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.48,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: the company's Annual Report on Form 10-K for the year ended December 31, 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED JUNE 30, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE SIX MONTHS ENDED JUNE 30, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2021-07-28,10:59:01,94637C,Bristol-Myers Squibb Co.,98,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2021-07-28,11:00:28,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb Sees FY21 Worldwide Revenues Up,NEWS-FLASH,Dow Jones Newswires,Correct: Bristol Myers Squibb Sees FY21 Worldwide Revenues Up in High-Single Digits
BMY,2021-07-28,11:00:58,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Q2 EPS 47 cents,NEWS-FLASH,MarketWatch,MW Bristol Myers Q2 EPS 47 cents vs. loss per share 4 cents a year ago
BMY,2021-07-28,11:01:12,94637C,Bristol-Myers Squibb Co.,100,0.46,earnings,above-expectations,Bristol Myers Q2 adj. EPS $1.93; FactSet consensus $1.89,NEWS-FLASH,MarketWatch,MW Bristol Myers Q2 adj. EPS $1.93; FactSet consensus $1.89
BMY,2021-07-28,11:01:47,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 2Q Opdivo Revenue $1.91 Billion,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Opdivo Revenue $1.91 Billion >BMY
BMY,2021-07-28,11:01:53,94637C,Bristol-Myers Squibb Co.,100,0.48,revenues,above-expectations,Bristol Myers Q2 revenue $11.703 bln vs. $10.129 bln a year ago; FactSet consensus $11.269 bln,NEWS-FLASH,MarketWatch,MW Bristol Myers Q2 revenue $11.703 bln vs. $10.129 bln a year ago; FactSet consensus $11.269 bln
BMY,2021-07-28,11:03:40,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers now sees full-year EPS of $2.77 to $2.97,NEWS-FLASH,MarketWatch,MW Bristol Myers now sees full-year EPS of $2.77 to $2.97 vs. prior $3.18 to $3.38
BMY,2021-07-28,11:04:05,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers still sees full-year adj. EPS of $7.35 to $7.55,NEWS-FLASH,MarketWatch,MW Bristol Myers still sees full-year adj. EPS of $7.35 to $7.55
BMY,2021-07-28,11:04:22,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers now sees full-year revenue up,NEWS-FLASH,MarketWatch,MW Bristol Myers now sees full-year revenue up in high-single-digits
BMY,2021-07-28,11:12:35,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers swings to profit,FULL-ARTICLE,MarketWatch,MW Bristol Myers swings to profit to beat second-quarter estimates as Opdivo returns to growth
BMY,2021-07-28,11:12:35,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers updated its full-year EPS guidance,FULL-ARTICLE,MarketWatch,MW Bristol Myers swings to profit to beat second-quarter estimates as Opdivo returns to growth
BMY,2021-07-28,11:12:35,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers Swings To Profit,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Swings To Profit To Beat Second-quarter Estimates As Opdivo Returns To Growth -- MarketWatch
BMY,2021-07-28,11:12:35,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers updated its full-year EPS guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Swings To Profit To Beat Second-quarter Estimates As Opdivo Returns To Growth -- MarketWatch
BMY,2021-07-28,14:08:55,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Ticker: BMY) markets in collaboration with Pfizer (PFE),FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Stock Rises After Modest Earnings Beat -- Barrons.com
BMY,2021-07-28,15:10:04,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Ticker: BMY) markets in collaboration with Pfizer,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Stock Rises After Modest Earnings Beat
BMY,2021-07-28,17:21:21,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol Myers Squibb CEO Giovanni Caforio on Q2 2021 Results -- Earnings Call,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb CEO Giovanni Caforio on Q2 2021 Results -- Earnings Call Transcript >BMY
BMY,2021-07-29,12:39:48,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol Myers Squibb Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Is Maintained at Equal-Weight by Morgan Stanley
BMY,2021-07-29,12:39:48,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol Myers Squibb Price Target Raised to $71.00/Share From $62.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Raised to $71.00/Share From $62.00 by Morgan Stanley
BMY,2021-07-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-07-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Approval is based on Phase 3 results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-07-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opdivo also received approval from the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-07-30,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2021-07-30,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2021-07-30,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2021-07-30,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-07-30,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Approval is based on Phase 3 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-07-30,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opdivo also received approval from the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-07-30,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-07-30,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-07-30,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-07-30,10:59:20,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab),NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients With Residual Pathologic Disease Following Chemoradiotherapy
BMY,2021-07-30,12:00:16,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Says EC Approves Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says EC Approves Opdivo as Adjuvant Treatment in Esophageal or Gastroesophageal Junction Cancer
BMY,2021-07-30,12:00:16,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opdivo received approval from the U.S. Food and Drug Administration,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says EC Approves Opdivo as Adjuvant Treatment in Esophageal or Gastroesophageal Junction Cancer
BMY,2021-07-30,12:15:16,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Says EC Approves Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says EC Approves Opdivo as Adjuvant Treatment in Esophageal or Gastroesophageal Junction Cancer
BMY,2021-07-30,12:15:16,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opdivo received approval from the U.S. Food and Drug Administration,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says EC Approves Opdivo as Adjuvant Treatment in Esophageal or Gastroesophageal Junction Cancer
BMY,2021-08-03,11:00:01,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland"
BMY,2021-08-03,11:00:01,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland"
BMY,2021-08-03,11:00:06,94637C,Bristol-Myers Squibb Co.,100,0.55,acquisitions-mergers,,"Bristol-Myers Squibb Co.: today announced that it has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland",PRESS-RELEASE,PR Newswire,"WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland"
BMY,2021-08-03,11:00:06,94637C,Bristol-Myers Squibb Co.,100,0.41,assets,open,"Bristol-Myers Squibb Co.: Opened in 2018, this facility",PRESS-RELEASE,PR Newswire,"WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland"
BMY,2021-08-03,11:00:13,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland"
BMY,2021-08-03,11:01:37,94637C,Bristol-Myers Squibb Co.,100,0.55,acquisitions-mergers,,"Bristol-Myers Squibb Co.: today announced that it has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland",PRESS-RELEASE,PR Newswire,"WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland"
BMY,2021-08-03,11:01:37,94637C,Bristol-Myers Squibb Co.,100,0.41,assets,open,"Bristol-Myers Squibb Co.: Opened in 2018, this facility",PRESS-RELEASE,PR Newswire,"WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland"
BMY,2021-08-03,20:50:05,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp von Autenried Sells 25,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP von Autenried Sells 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-03,20:53:53,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Vessey Sells 158,393 Of Bristol-Myers Squibb Co",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Sells 158,393 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-03,20:56:27,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Leung Sells 29,390 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Leung Sells 29,390 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-03,20:57:44,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Dubow Sells 2,466 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Dubow Sells 2,466 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-03,21:22:14,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 22,667 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Elkins Acquires 22,667 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-04,20:49:40,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Powell Sells 23,280 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Powell Sells 23,280 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-04,20:50:00,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 20,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Caforio Sells 20,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-09,20:34:17,94637C,Bristol-Myers Squibb Co.,100,-0.51,labor-issues,,Bonney Resigns From Board of Bristol-Myers Squibb,RNS-SEC8K,Dow Jones Newswires,Michael Bonney Resigns From Board of Bristol-Myers Squibb in Connection With Appointment as Executive Chairman of Alnylam Pharmaceuticals
BMY,2021-08-10,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol Myers Squibb (NYSE: BMY) announced its collaboration with Florida Agricultural and Mechanical University, Howard University, Morgan",PRESS-RELEASE,Business Wire,Bristol Myers Squibb and Five Leading Historically Black Colleges and Universities Launch Tomorrow's Innovators to Create Custom Biopharma Educational Programming and Increase Recruitment of Black Talent in the Biopharma Industry
BMY,2021-08-10,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol Myers Squibb (NYSE: BMY) announced its collaboration with Florida Agricultural and Mechanical University, Howard University, Morgan",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and Five Leading Historically Black Colleges and Universities Launch Tomorrow's Innovators to Create Custom Biopharma Educational Programming and Increase Recruitment of Black Talent in the Biopharma Industry
BMY,2021-08-16,21:53:42,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Cfo Elkins Sells 99,691 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Elkins Sells 99,691 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Bristol Myers Squibb's Applications,PRESS-RELEASE,Business Wire,"EMA Validates Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma"
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Bristol Myers Squibb's Applications,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -2-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Bristol Myers Squibb's Applications,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -3-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Bristol Myers Squibb's Applications,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -4-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -4-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Bristol Myers Squibb's Applications,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -5-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -5-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -5-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Bristol Myers Squibb's Applications,PRESS-RELEASE,Business Wire,EMA Validates Bristol Myers Squibb's Applications -6-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Bristol Myers Squibb's Applications,PRESS-RELEASE,Dow Jones Newswires,"Press Release: EMA Validates Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma"
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: EMA Validates Bristol Myers -4-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: EMA Validates Bristol Myers -5-
BMY,2021-08-17,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: EMA Validates Bristol Myers -5-
BMY,2021-08-17,11:00:19,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Applications for Opdivo,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: EMA Validates Applications for Opdivo + Yervoy, Opdivo + Chemotherapy as First-Line Treatments for Certain Carcinomas"
BMY,2021-08-17,11:34:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb: EMA Validates Two Opdivo Applications,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: EMA Validates Two Opdivo Applications
BMY,2021-08-17,11:34:36,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers said the applications based on positive results from a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: EMA Validates Two Opdivo Applications
BMY,2021-08-17,11:49:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb: EMA Validates Two Opdivo Applications,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: EMA Validates Two Opdivo Applications
BMY,2021-08-17,11:49:36,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers said the applications based on positive results from a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: EMA Validates Two Opdivo Applications
BMY,2021-08-18,11:00:03,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: our strategic collaboration with Exscientia.,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Exercises Option to Develop Exscientia's AI-designed, Immune-modulating Drug Candidate"
BMY,2021-08-19,13:34:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma"
BMY,2021-08-19,13:34:00,94637C,Bristol-Myers Squibb Co.,100,0.44,products-services,,Bristol-Myers Squibb Co.: Abecma expands upon,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma"
BMY,2021-08-19,13:34:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma"
BMY,2021-08-19,13:34:01,94637C,Bristol-Myers Squibb Co.,100,0.44,products-services,,Bristol-Myers Squibb Co.: Abecma expands upon,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma"
BMY,2021-08-20,15:45:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma
BMY,2021-08-23,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)
BMY,2021-08-23,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The sBLA submitted to the FDA is based on results from the,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)
BMY,2021-08-23,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)
BMY,2021-08-23,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: The sBLA submitted to the FDA is based on results from the,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)
BMY,2021-08-23,11:19:27,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Orencia,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Orencia in Acute Graft-Vs-Host Disease >BMY
BMY,2021-08-23,11:19:27,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Orencia in Acute Graft-Vs-Host Disease >BMY
BMY,2021-08-23,11:19:27,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Orencia is currently approved in the U.S.,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Orencia in Acute Graft-Vs-Host Disease >BMY
BMY,2021-08-23,11:34:27,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Orencia,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Orencia in Acute Graft-Vs-Host Disease
BMY,2021-08-23,11:34:27,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Orencia in Acute Graft-Vs-Host Disease
BMY,2021-08-23,11:34:27,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Orencia is currently approved in the U.S.,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Orencia in Acute Graft-Vs-Host Disease
BMY,2021-09-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Take Part in Morgan Stanley 19(th) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Take Part in Morgan Stanley 19(th) Annual Global Healthcare Conference
BMY,2021-09-08,10:59:00,94637C,Bristol-Myers Squibb Co.,98,0.0,products-services,,Bristol-Myers Squibb Co.: Phase 3 data,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage Cancers
BMY,2021-09-08,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO 2021 -4-
BMY,2021-09-08,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO 2021 -6-
BMY,2021-09-08,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO 2021 -6-
BMY,2021-09-08,10:59:09,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Phase 3 data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage Cancers
BMY,2021-09-08,10:59:09,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at -4-
BMY,2021-09-08,10:59:09,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at -6-
BMY,2021-09-08,10:59:09,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at -6-
BMY,2021-09-08,11:01:12,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers: Updated Phase 3 Data,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers: Updated Phase 3 Data From CheckMate -577 Reinforce Benefit of Opdivo in Earlier Stages of Esophageal, Gastroesophageal Cancers"
BMY,2021-09-08,11:10:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021"
BMY,2021-09-08,11:10:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: During a conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021"
BMY,2021-09-08,11:10:09,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021"
BMY,2021-09-08,11:10:09,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: During a conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021"
BMY,2021-09-08,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,GlobeNewswire,Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo(R) for Treatment of HER2-Expressing Solid Tumors
BMY,2021-09-08,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo(R) for Treatment of HER2-Expressing Solid Tumors
BMY,2021-09-08,11:30:11,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bolt Biotherapeutics Announces Clinical Collaboration With Bristol Myers Squibb to,NEWS-FLASH,Dow Jones Newswires,Bolt Biotherapeutics Announces Clinical Collaboration With Bristol Myers Squibb to Study BDC-1001 in Combination With Opdivo(R) for Treatment of HER2-Expressing Solid Tumors
BMY,2021-09-09,13:00:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Trial Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy CG0070 in Combination with OPDIVO(R) (nivolumab) in Metastatic Urothelial Cancer
BMY,2021-09-09,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2021-09-09,20:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on November 1, 2021 to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2021-09-17,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma whose Tumors Express PD-L1 with CPS >= 5"
BMY,2021-09-17,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2021-09-17,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-09-17,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2021-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma whose Tumors Express PD-L1 with CPS >= 5"
BMY,2021-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-09-17,10:59:51,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo + Chemotherapy for Patients With HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma Whose Tumors Express PD-L1 With CPS >= 5"
BMY,2021-09-17,11:15:03,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Gets Positive CHMP Opinion for Opdivo,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets Positive CHMP Opinion for Opdivo in Gastric, Esophageal Cancers >BMY"
BMY,2021-09-17,11:15:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers said the recommendation is based on results from a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets Positive CHMP Opinion for Opdivo in Gastric, Esophageal Cancers >BMY"
BMY,2021-09-17,11:30:03,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Gets Positive CHMP Opinion for Opdivo,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets Positive CHMP Opinion for Opdivo in Gastric, Esophageal Cancers"
BMY,2021-09-17,11:30:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers said the recommendation is based on results from a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets Positive CHMP Opinion for Opdivo in Gastric, Esophageal Cancers"
BMY,2021-09-20,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
BMY,2021-09-20,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: The BLA submission,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
BMY,2021-09-20,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
BMY,2021-09-20,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: The BLA submission,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
BMY,2021-09-20,11:37:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Relatlimab,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Relatlimab/Opdivo Combo in Melanoma >BMY
BMY,2021-09-20,11:37:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Relatlimab/Opdivo Combo in Melanoma >BMY
BMY,2021-09-20,11:52:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Relatlimab,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Relatlimab/Opdivo Combo in Melanoma
BMY,2021-09-20,11:52:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Relatlimab/Opdivo Combo in Melanoma
BMY,2021-09-22,21:20:47,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-09-27,11:06:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications,PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma"
BMY,2021-09-27,11:06:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -648 is one of four positive Phase 3 trials,PRESS-RELEASE,Business Wire,"U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma"
BMY,2021-09-27,11:06:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications,PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma"
BMY,2021-09-27,11:06:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -648 is one of four positive Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,"Press Release: U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma"
BMY,2021-09-27,11:13:30,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Accepts Applications for Opdivo (nivolumab),NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: FDA Accepts Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma >BMY"
BMY,2021-09-30,13:45:00,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at the EADV 30(th) -2-
BMY,2021-09-30,13:52:42,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at the -2-
BMY,2021-10-01,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
BMY,2021-10-01,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
BMY,2021-10-01,10:59:46,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Application for Mavacamten,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: European Medicines Agency Validates Application for Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy >BMY
BMY,2021-10-01,11:00:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma
BMY,2021-10-01,11:00:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2021-10-01,11:00:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2021-10-01,11:00:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2021-10-01,11:00:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma
BMY,2021-10-01,11:00:13,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application,NEWS-FLASH,Dow Jones Newswires,European Medicines Agency Validates Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients With Unresectable or Metastatic Melanoma
BMY,2021-10-01,11:05:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Hold Investor Event on November 16,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Hold Investor Event on November 16
BMY,2021-10-01,11:05:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Hold Investor Event on November 16,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Hold Investor Event on November 16
BMY,2021-10-01,11:37:51,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Relatlimab/Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: EMA Validates Relatlimab/Opdivo Combo Application in Melanoma >BMY
BMY,2021-10-01,11:37:51,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Relatlimab/Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: EMA Validates Relatlimab/Opdivo Combo Application in Melanoma >BMY
BMY,2021-10-01,11:52:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Relatlimab/Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: EMA Validates Relatlimab/Opdivo Combo Application in Melanoma
BMY,2021-10-01,11:52:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Ema Validates Relatlimab/Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: EMA Validates Relatlimab/Opdivo Combo Application in Melanoma
BMY,2021-10-06,22:44:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol Myers' $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Business Wire,Entwistle & Cappucci LLP Files a Securities Class Action Complaint Against Bristol-Myers Squibb Company
BMY,2021-10-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Provides Update on Phase 2 Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
BMY,2021-10-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
BMY,2021-10-07,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Provides Update on Phase 2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
BMY,2021-10-07,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,,Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
BMY,2021-10-07,10:59:36,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Provides Update on Phase 2 Study,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
BMY,2021-10-08,00:20:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Business Wire,"BRISTOL MYERS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-10-08,00:20:00,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,Business Wire,"BRISTOL MYERS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-10-08,05:30:33,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec expands neuroscience collaboration with Bristol Myers Squibb to,PRESS-RELEASE,DGAP News,PRESS RELEASE: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type
BMY,2021-10-08,05:30:33,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec expands neuroscience collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type
BMY,2021-10-08,05:31:25,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec expands neuroscience collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type
BMY,2021-10-08,05:31:25,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec expands neuroscience collaboration with Bristol Myers Squibb to,PRESS-RELEASE,DGAP News,PRESS RELEASE: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type
BMY,2021-10-08,05:50:31,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include Novel Cell Type
BMY,2021-10-08,12:56:04,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2021-10-08,12:56:04,94637C,Bristol-Myers Squibb Co.,100,-0.52,price-targets,downgrade,Bristol Myers Squibb Price Target Cut to $68.00/Share From $71.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Cut to $68.00/Share From $71.00 by Barclays
BMY,2021-10-09,02:50:01,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS APPH, BMY, EAR, HYZN, INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-11,13:07:22,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol Myers Squibb Is Maintained at Buy by Berenberg,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Is Maintained at Buy by Berenberg
BMY,2021-10-11,13:07:22,94637C,Bristol-Myers Squibb Co.,100,-0.62,price-targets,downgrade,Bristol Myers Squibb Price Target Cut to $71.00/Share From $75.00 by Berenberg,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Cut to $71.00/Share From $75.00 by Berenberg
BMY,2021-10-11,19:15:44,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, EAR Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-12,02:47:25,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANVS, BMY, HNST, PYPL INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-12,12:27:38,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol Myers Squibb Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Is Maintained at Equal-Weight by Morgan Stanley
BMY,2021-10-12,12:27:38,94637C,Bristol-Myers Squibb Co.,100,-0.68,price-targets,downgrade,Bristol Myers Squibb Price Target Cut to $66.00/Share From $71.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Cut to $66.00/Share From $71.00 by Morgan Stanley
BMY,2021-10-12,12:30:03,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody
BMY,2021-10-12,12:30:04,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody
BMY,2021-10-12,12:30:41,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Agenus to Receive $20M Milestone Payment From Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Agenus to Receive $20M Milestone Payment From Bristol Myers Squibb With Dosing of First Patient With Its TIGIT Bispecific Antibody
BMY,2021-10-12,17:02:39,94637C,Bristol-Myers Squibb Co.,100,-0.57,acquisitions-mergers,rumor-denied,Bristol Myers Didn't Bid for Acceleron,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Didn't Bid for Acceleron as Merck Circled -- Market Talk
BMY,2021-10-12,17:02:39,94637C,Bristol-Myers Squibb Co.,100,-0.59,acquisitions-mergers,rejected,Acceleron rejected the initial bid,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Didn't Bid for Acceleron as Merck Circled -- Market Talk
BMY,2021-10-12,20:30:40,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"BMY, EAR, SLQT SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced interim results from the Phase 3 open-label extension trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2021-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: U.S. FDA-APPROVED INDICATIONS FOR ZEPOSIA,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2021-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2021-10-13,11:08:29,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced interim results from the Phase 3 open-label extension trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2021-10-13,11:08:29,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: U.S. FDA-APPROVED INDICATIONS FOR ZEPOSIA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2021-10-13,11:08:29,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2021-10-13,23:46:11,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Bristol-Myers Squibb Co.: INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company,PRESS-RELEASE,DJ Global Press Release Wire,INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-13,23:46:11,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-14,02:36:12,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, HNST, PYPL INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-15,02:32:17,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"APPH, BMY, WDH SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-15,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Zeposia was approved by the FDA for the treatment of adults with relapsing forms of multiple sclerosis,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:13,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia as a Treatment for Adult Patients With Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Zeposia (ozanimod),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Zeposia was approved by the FDA for the treatment of adults with relapsing forms of multiple sclerosis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Zeposia (ozanimod),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration approved Zeposia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-15,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2021-10-16,02:50:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"APPH, BMY, EAR, HYZN SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-18,17:53:20,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS APPH, BMY, WDH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-19,02:50:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, HNST, HYZN, SAM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-19,04:19:58,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Dr. Reddy's Laboratories: Obtained FDA Approval for Lenalidomide,NEWS-FLASH,Dow Jones Newswires,Dr. Reddy's Laboratories: Obtained FDA Approval for Lenalidomide Capsules >RDY
BMY,2021-10-19,22:21:20,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of APPH, BMY, WDH Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-20,15:30:07,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,European Medicines Agency (EMA) approval of Bristol Myers Squibb's Zeposia,PRESS-RELEASE,PR Newswire,"Bristol Myers Squibb's Zeposia Launch Trajectories Diverge in Germany and the UK Following Negative NICE Decision; Janssen's Ponvory Could Likewise Stumble, According to Spherix Global Insights"
BMY,2021-10-20,20:17:23,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Bristol-Myers Squibb Co.: INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company,PRESS-RELEASE,DJ Global Press Release Wire,INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-20,20:17:23,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-21,03:02:32,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of APPH, BMY, EAR, HYZN Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma ..."
BMY,2021-10-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2021-10-21,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2021-10-21,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma ..."
BMY,2021-10-21,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2021-10-21,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2021-10-21,11:00:19,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb: European Commission Approves Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: European Commission Approves Opdivo Plus Chemotherapy for Certain Cancers
BMY,2021-10-22,02:41:12,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"APPH, BMY, EAR SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-22,19:55:00,94637C,Bristol-Myers Squibb Co.,99,-0.52,legal,,"Litigation has been filed against Bristol-Myers Squibb Company (""Bristol-Myers",PRESS-RELEASE,Business Wire,"BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action -- Contact Lieff Cabraser"
BMY,2021-10-22,19:55:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Business Wire,"BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action -- Contact Lieff Cabraser"
BMY,2021-10-23,14:15:24,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Class Action Lawsuit Filed Against Bristol-Myers Squibb Company,PRESS-RELEASE,DJ Global Press Release Wire,CELG Investor Alert: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-23,14:15:24,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,CELG Investor Alert: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-24,08:01:38,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2021 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2021 (BMY)"
BMY,2021-10-25,10:45:00,94637C,Bristol-Myers Squibb Co.,95,0.39,products-services,,Tcr(2) Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,TCR(2) Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo(R) and Yervoy(R) in Mesothelin-Expressing Solid Tumors
BMY,2021-10-25,10:45:00,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY),PRESS-RELEASE,GlobeNewswire,TCR(2) Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo(R) and Yervoy(R) in Mesothelin-Expressing Solid Tumors
BMY,2021-10-25,10:45:01,94637C,Bristol-Myers Squibb Co.,95,0.39,products-services,,Tcr(2) Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: TCR(2) Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo(R) and Yervoy(R) in Mesothelin-Expressing Solid Tumors
BMY,2021-10-25,10:45:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY),PRESS-RELEASE,Dow Jones Newswires,Press Release: TCR(2) Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo(R) and Yervoy(R) in Mesothelin-Expressing Solid Tumors
BMY,2021-10-25,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Third Quarter 2021 Earnings Call to,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)"
BMY,2021-10-25,11:03:15,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Press Release: Bristol Myers Squibb Announces Earnings,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)"
BMY,2021-10-25,11:03:15,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Third Quarter 2021 Earnings Call to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)"
BMY,2021-10-25,12:55:13,94637C,Bristol-Myers Squibb Co.,93,0.55,acquisitions-mergers,interest,Bristol Myers Squibb Co. has expressed interest in acquiring the smaller biopharmaceutical company,FULL-ARTICLE,Dow Jones Newswires,Aurinia Pharmaceuticals Shares Rally on Report of Bristol Myers Interest >AUPH
BMY,2021-10-25,13:10:13,94637C,Bristol-Myers Squibb Co.,93,0.55,acquisitions-mergers,interest,Bristol Myers Squibb Co. has expressed interest in acquiring the smaller biopharmaceutical company,FULL-ARTICLE,Dow Jones Newswires,Aurinia Pharmaceuticals Shares Rally on Report of Bristol Myers Interest
BMY,2021-10-25,18:15:36,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of APPH, BMY, EAR Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-26,02:28:32,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS APPH, BMY, EAR, HYZN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-26,13:00:02,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: our existing relationship with Bristol Myers Squibb in,PRESS-RELEASE,Business Wire,Ubiquigent Extends and Expands Drug Discovery Collaboration With Bristol Myers Squibb
BMY,2021-10-26,17:46:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bristol-Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Business Wire,"BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action -- Contact Lieff Cabraser"
BMY,2021-10-26,18:55:11,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Expected to Post Higher 3Q Sales,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb Expected to Post Higher 3Q Sales -- Earnings Preview
BMY,2021-10-26,18:55:11,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co. is set to report its third-quarter earnings on Wednesday morning,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb Expected to Post Higher 3Q Sales -- Earnings Preview
BMY,2021-10-26,19:50:08,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS APPH, BMY, EAR INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 3Q Adj EPS $2.00,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q Adj EPS $2.00 >BMY
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Sees FY EPS $2.68,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY EPS $2.68-EPS $2.83 >BMY
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Sees FY Adj EPS $7.40,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY Adj EPS $7.40-Adj EPS $7.55 >BMY
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 3Q EPS 69c,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q EPS 69c >BMY
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 3Q Net $1.5B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q Net $1.5B >BMY
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 3Q Rev $11.6B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q Rev $11.6B >BMY
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports Third Quarter Revenues of $11.6 Billion, an Increase of 10% YoY",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Third Quarter Earnings Per Share of $0.69,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: Achieves FDA Priority Review for Third,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Demand for Revlimid, Eliquis and",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Demand for Eliquis, Revlimid and",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.4,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increased 30%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: NINE-MONTH PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for mavacamten,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the European Commission (EC) has approved Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Applications (sBLA) for both Opdivo(R),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the EMA has validated its Type II Variation MAA for both Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Ema has recommended approval of Zeposia(R) (ozanimod),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the FDA has accepted its supplemental sBLA for Orencia(R) (abatacept),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: the company announced a collaboration with five Historically Black Colleges and Universities (HBCU) to,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,-0.49,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increasing,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -5-
BMY,2021-10-27,10:59:00,94637C,Bristol-Myers Squibb Co.,96,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.70 $ 0.83 $,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -5-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports Third Quarter Revenues of $11.6 Billion, an Increase of 10% YoY",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Third Quarter Earnings Per Share of $0.69,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: Achieves FDA Priority Review for Third,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Demand for Revlimid, Eliquis and",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Demand for Eliquis, Revlimid and",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.4,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increased 30%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: NINE-MONTH PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for mavacamten,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the European Commission (EC) has approved Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Applications (sBLA) for both Opdivo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the EMA has validated its Type II Variation MAA for both Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Ema has recommended approval of Zeposia(R) (ozanimod),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the FDA has accepted its supplemental sBLA for Orencia(R) (abatacept),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: the company announced a collaboration with five Historically Black Colleges and Universities (HBCU) to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Worldwide revenues increasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.49,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increasing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2021 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: For example, non-GAAP earnings",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -5-
BMY,2021-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.70 $ 0.83 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -5-
BMY,2021-10-27,11:00:36,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb Sees FY Worldwide Rev Increasing,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY Worldwide Rev Increasing in High-Single Digits >BMY
BMY,2021-10-27,11:00:55,94637C,Bristol-Myers Squibb Co.,100,-0.59,equity-actions,up,Bristol Myers Squibb Sees FY Research and Development Expenses Increasing,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees FY Research and Development Expenses Increasing in Low-Single Digits >BMY
BMY,2021-10-27,11:11:10,94637C,Bristol-Myers Squibb Co.,100,-0.32,earnings,down,Bristol Myers Squibb Q3 EPS 69 cents vs. 82 cents a year ago,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb Q3 EPS 69 cents vs. 82 cents a year ago
BMY,2021-10-27,11:11:26,94637C,Bristol-Myers Squibb Co.,100,0.46,earnings,above-expectations,Bristol Myers Squibb Q3 adj. EPS $2.00; FactSet consensus $1.92,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb Q3 adj. EPS $2.00; FactSet consensus $1.92
BMY,2021-10-27,11:11:52,94637C,Bristol-Myers Squibb Co.,100,0.48,revenues,above-expectations,Bristol Myers Squibb Q3 revenue $11.624 bln vs. $10.540 bln a year ago; FactSet consensus $11.612 bln,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb Q3 revenue $11.624 bln vs. $10.540 bln a year ago; FactSet consensus $11.612 bln
BMY,2021-10-27,11:13:13,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb lowers full-year guidance,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb lowers full-year guidance
BMY,2021-10-27,11:13:36,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb now sees full-year EPS of $2.68 to $2.83,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb now sees full-year EPS of $2.68 to $2.83 vs. prior $2.77 to $2.97
BMY,2021-10-27,11:14:03,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb now sees full-year adj. EPS of $7.40 to $7.55,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb now sees full-year adj. EPS of $7.40 to $7.55 vs. prior $7.35 to $7.55
BMY,2021-10-27,11:14:14,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb now sees full-year revenue up,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb now sees full-year revenue up in high-single digits
BMY,2021-10-27,11:18:10,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol-Myers Squibb Posts 3Q Sales Growth,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb Posts 3Q Sales Growth as R&D Spending Rises
BMY,2021-10-27,11:21:32,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb Narrows Full-Year Earnings Guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Narrows Full-Year Earnings Guidance
BMY,2021-10-27,11:33:11,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol-Myers Squibb Posts 3Q Sales Growth,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb Posts 3Q Sales Growth as R&D Spending Rises
BMY,2021-10-27,11:36:32,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb Narrows Full-Year Earnings Guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Narrows Full-Year Earnings Guidance
BMY,2021-10-27,11:49:55,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,"Bristol Myers Squibb says sales of Revlimid, Eliquis increased in the third quarter",FULL-ARTICLE,MarketWatch,"MW Bristol Myers Squibb says sales of Revlimid, Eliquis increased in the third quarter"
BMY,2021-10-27,11:49:55,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,"Bristol Myers Squibb Says Sales Of Revlimid, Eliquis Increased In The Third Quarter",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Says Sales Of Revlimid, Eliquis Increased In The Third Quarter -- MarketWatch"
BMY,2021-10-27,17:28:46,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol Myers Squibb CEO Giovanni Caforio on Q3 2021 Results -- Earnings Call,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb CEO Giovanni Caforio on Q3 2021 Results -- Earnings Call Transcript >BMY
BMY,2021-10-27,23:13:00,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company,PRESS-RELEASE,Business Wire,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-10-27,23:13:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol-Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Business Wire,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-10-28,03:05:03,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS APPH, BMY, EAR, HEPS INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-10-28,13:28:00,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company,PRESS-RELEASE,Business Wire,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-10-28,13:28:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol-Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Business Wire,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-10-28,13:53:47,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2021-10-28,13:53:47,94637C,Bristol-Myers Squibb Co.,100,-0.44,price-targets,downgrade,Bristol Myers Squibb Price Target Cut to $66.00/Share From $68.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Cut to $66.00/Share From $68.00 by Barclays
BMY,2021-10-28,21:15:24,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Bristol-Myers Squibb Co.: Investor Alert: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company,PRESS-RELEASE,DJ Global Press Release Wire,Investor Alert: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-28,21:15:24,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,Investor Alert: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-10-29,03:05:16,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"BMY, EAR, HYZN SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits Filed on Behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-10-30,02:50:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, EAR, HYZN, WDH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-01,12:52:21,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol Myers Squibb Cut to Hold From Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Cut to Hold From Buy by Argus Research
BMY,2021-11-01,16:43:03,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-11-01,16:43:03,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol-Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-11-01,16:43:03,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company,PRESS-RELEASE,Dow Jones Newswires,"Press Release: SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-11-01,16:43:03,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol-Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Dow Jones Newswires,"Press Release: SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BMY,2021-11-01,18:01:15,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, EAR, HYZN Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-02,02:44:41,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, HEPS, HMLP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-02,19:00:35,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, EAR, HYZN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-03,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Immunosuppression: In clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ACR Convergence 2021 -3-
BMY,2021-11-03,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,"Bristol-Myers Squibb Co.: However, abatacept was present",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ACR Convergence 2021 -3-
BMY,2021-11-03,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Immunosuppression: In clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ACR -3-
BMY,2021-11-03,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,"Bristol-Myers Squibb Co.: However, abatacept was present",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ACR -3-
BMY,2021-11-03,23:50:03,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-03,23:50:03,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-04,06:14:22,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, EAR, HYZN, WDH Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-04,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Inspirna Announces Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,Inspirna Announces Clinical Collaboration with Bristol Myers Squibb to Study RGX-104 in Combination with Yervoy(R) (ipilimumab) for Treatment of Metastatic Endometrial Cancer
BMY,2021-11-04,14:16:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First clinical results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight More than 80 Abstracts at ASH 2021 Demonstrating Strength of Innovative Therapeutic Platforms Improving Outcomes for a Broad Range of Hematologic Diseases
BMY,2021-11-04,14:16:00,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Efficacy Clinical Trials,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight More than 80 -2-
BMY,2021-11-04,14:16:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: Six-Year Results from the Phase 3,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight More than 80 -2-
BMY,2021-11-04,14:16:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,"Bristol-Myers Squibb Co.: First Results from a Phase 1, Open-Label Study",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight More than 80 -2-
BMY,2021-11-04,14:16:00,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,"Bristol-Myers Squibb Co.: Cellular Sunday, Life Results",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight More than 80 -3-
BMY,2021-11-04,14:16:00,94637C,Bristol-Myers Squibb Co.,97,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight More than 80 -3-
BMY,2021-11-04,14:16:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight More than 80 -4-
BMY,2021-11-04,14:16:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First clinical results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight More than 80 Abstracts at ASH 2021 Demonstrating Strength of Innovative Therapeutic Platforms Improving Outcomes for a Broad Range of Hematologic Diseases
BMY,2021-11-04,14:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: Six-Year Results from the Phase 3,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -2-
BMY,2021-11-04,14:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,"Bristol-Myers Squibb Co.: First Results from a Phase 1, Open-Label Study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -2-
BMY,2021-11-04,14:16:01,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,"Bristol-Myers Squibb Co.: Cellular Sunday, Life Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -3-
BMY,2021-11-04,14:16:01,94637C,Bristol-Myers Squibb Co.,97,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -3-
BMY,2021-11-04,14:16:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -4-
BMY,2021-11-05,01:25:03,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Bristol-Myers Squibb Company - BMY
BMY,2021-11-05,01:25:03,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Dow Jones Newswires,Press Release: FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Bristol-Myers Squibb Company - BMY
BMY,2021-11-05,15:02:59,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"BMY, HNST, WDH SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-06,02:50:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"BMY, HEPS, HMLP INVESTOR ALERT BY CLAIMSFILER: Pending Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-08,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Pfizer Alliance) ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
BMY,2021-11-08,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: The milvexian Phase 2 clinical trial program,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
BMY,2021-11-08,11:59:18,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Pfizer Alliance) ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
BMY,2021-11-08,11:59:18,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: The milvexian Phase 2 clinical trial program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
BMY,2021-11-08,18:41:49,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, HNST, WDH Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-09,04:28:34,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, EAR, HMLP, SAM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-09,14:16:28,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,Bristol-Myers Squibb Co.: INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company,PRESS-RELEASE,DJ Global Press Release Wire,INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-11-09,14:16:28,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,"Bristol Myers's $74 billion acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,INVESTOR-ALERT: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company
BMY,2021-11-09,17:45:43,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, HNST, WDH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-10,07:00:32,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,"Evotec SE: Chief Scientific Officer of Evotec, said: ""Our collaboration with BMS",PRESS-RELEASE,DJ Global Press Release Wire,Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2021-11-10,17:16:05,94637C,Bristol-Myers Squibb Co.,100,0.0,credit-ratings,action,Moody's Announces Completion Of A Periodic Review Of Ratings Of Bristol-Myers Squibb Company,NEWS-FLASH,Dow Jones Newswires,Moody's Announces Completion Of A Periodic Review Of Ratings Of Bristol-Myers Squibb Company
BMY,2021-11-10,20:41:03,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-10,20:41:03,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-11,03:50:01,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, EAR, HYZN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-11,12:00:07,94637C,Bristol-Myers Squibb Co.,98,0.22,acquisitions-mergers,,Bristol Myers Squibb's strategic investment in Compugen,PRESS-RELEASE,PR Newswire,Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment
BMY,2021-11-11,12:00:07,94637C,Bristol-Myers Squibb Co.,99,0.22,acquisitions-mergers,,Bristol Myers Squibb's strategic investment in Compugen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment
BMY,2021-11-12,00:47:30,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, HYZN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-12,00:47:30,94637C,Bristol-Myers Squibb Co.,94,0.59,equity-actions,,Bristol-Myers Squibb Co.: MISLEADING PROSPECTUS,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, HYZN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-12,12:00:11,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R),PRESS-RELEASE,PR Newswire,Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R) and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
BMY,2021-11-12,12:00:11,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R),PRESS-RELEASE,PR Newswire,Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R) and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
BMY,2021-11-12,12:00:11,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: our collaboration with Compugen to,PRESS-RELEASE,PR Newswire,Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R) and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
BMY,2021-11-12,12:04:21,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Compugen Presents Preliminary Results From Phase 1/2 Dose Escalation Study of COM701 With Opdivo,NEWS-FLASH,Dow Jones Newswires,"Compugen Presents Preliminary Results From Phase 1/2 Dose Escalation Study of COM701 With Opdivo, BMS-986207"
BMY,2021-11-12,12:04:21,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Compugen Presents Preliminary Results From Phase 1/2 Dose Escalation Study of COM701 With Opdivo,NEWS-FLASH,Dow Jones Newswires,"Compugen Presents Preliminary Results From Phase 1/2 Dose Escalation Study of COM701 With Opdivo, BMS-986207"
BMY,2021-11-12,12:15:20,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R) and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
BMY,2021-11-12,12:15:20,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R) and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
BMY,2021-11-12,12:15:20,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol-Myers Squibb Co.: our collaboration with Compugen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo(R) and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
BMY,2021-11-13,03:50:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"BMY, EAR, HMLP SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-15,19:00:51,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, HMLP, NVAX INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-16,03:50:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, EAR, HEPS, HMLP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-16,19:25:51,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, HMLP, NVAX Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-18,00:38:02,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-18,00:38:02,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-18,04:50:09,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, EAR, HMLP, NVAX Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-19,03:50:03,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Bristol-Myers Squibb Company - BMY
BMY,2021-11-19,03:50:03,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Dow Jones Newswires,Press Release: FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Bristol-Myers Squibb Company - BMY
BMY,2021-11-19,10:46:56,94637C,Bristol-Myers Squibb Co.,100,0.95,analyst-ratings,positive,Bristol Myers Squibb Initiated at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Initiated at Outperform by BMO Capital
BMY,2021-11-19,10:46:56,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol Myers Squibb Price Target Announced at $72.00/Share by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Announced at $72.00/Share by BMO Capital
BMY,2021-11-19,12:19:58,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Myokardia Inc., which Bristol-Myers bought last year",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers: FDA Extends Review of Heart-Drug Mavacamten by Three Months
BMY,2021-11-19,12:34:58,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Myokardia Inc., which Bristol-Myers bought last year",FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers: FDA Extends Review of Heart-Drug Mavacamten by Three Months
BMY,2021-11-19,13:49:35,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol Myers Squibb started at outperform with $72 stock price target at BMO Capital,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb started at outperform with $72 stock price target at BMO Capital
BMY,2021-11-20,03:00:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"BMY, EAR, HEPS, HMLP INVESTOR ALERT BY CLAIMSFILER: Pending Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-22,18:30:41,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,DJ Global Press Release Wire,"BMY, HMLP, NVAX SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-23,03:56:31,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, CTXS, OWLT INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-23,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
BMY,2021-11-23,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: More information about the open-label extension trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
BMY,2021-11-23,11:59:00,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration (FDA) approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -2-
BMY,2021-11-23,11:59:00,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -2-
BMY,2021-11-23,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
BMY,2021-11-23,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: More information about the open-label extension trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
BMY,2021-11-23,11:59:01,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration (FDA) approved Zeposia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -2-
BMY,2021-11-23,11:59:01,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -2-
BMY,2021-11-23,11:59:30,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval of Zeposia,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval of Zeposia for Use in Adults With Moderately to Severely Active Ulcerative Colitis
BMY,2021-11-23,12:14:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets Europe OK for Zeposia,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Europe OK for Zeposia in Ulcerative Colitis >BMY
BMY,2021-11-23,12:29:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets Europe OK for Zeposia,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Europe OK for Zeposia in Ulcerative Colitis
BMY,2021-11-24,05:06:04,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMY, HEPS, PTON and Z"
BMY,2021-11-24,21:16:04,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-24,21:16:04,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,PR Newswire,"BRISTOL MYERS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY"
BMY,2021-11-24,22:26:23,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp von Autenried Sells 51,134 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP von Autenried Sells 51,134 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-11-25,04:34:40,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, CTXS, STNE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-11-27,03:50:00,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, CTXS, OWLT, PTON Investors, Lead Plaintiff Deadlines Set"
BMY,2021-11-29,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
BMY,2021-11-29,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
BMY,2021-11-29,12:29:59,94637C,Bristol-Myers Squibb Co.,96,0.58,acquisitions-mergers,,Amgen bought Otezla from Celgene Corp. for $13.4 billion,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb: Deucravacitinib Applications Advance in U.S., Europe"
BMY,2021-11-29,12:29:59,94637C,Bristol-Myers Squibb Co.,96,0.6,acquisitions-mergers,approval,Regulatory approval Celgene's $74 billion acquisition,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb: Deucravacitinib Applications Advance in U.S., Europe"
BMY,2021-11-29,12:44:58,94637C,Bristol-Myers Squibb Co.,96,0.58,acquisitions-mergers,,Amgen bought Otezla from Celgene Corp. for $13.4 billion,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb: Deucravacitinib Applications Advance in U.S., Europe"
BMY,2021-11-29,12:44:58,94637C,Bristol-Myers Squibb Co.,96,0.6,acquisitions-mergers,approval,Regulatory approval Celgene's $74 billion acquisition,FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb: Deucravacitinib Applications Advance in U.S., Europe"
BMY,2021-11-30,04:44:09,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, OWLT, PTON, ZG INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits"
BMY,2021-12-01,04:34:02,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMY, CTXS, HEPS and STNE"
BMY,2021-12-02,00:53:02,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,PR Newswire,CLAIMSFILER ALERTS BRISTOL MYERS Investors to Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
BMY,2021-12-02,00:53:02,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,PR Newswire,CLAIMSFILER ALERTS BRISTOL MYERS Investors to Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
BMY,2021-12-02,00:53:02,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Dow Jones Newswires,Press Release: CLAIMSFILER ALERTS BRISTOL MYERS Investors to Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
BMY,2021-12-02,00:53:02,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,Dow Jones Newswires,Press Release: CLAIMSFILER ALERTS BRISTOL MYERS Investors to Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
BMY,2021-12-02,04:16:41,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,"Bristol-Myers' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, LSPD, PTON, ZG Investors, Lead Plaintiff Deadlines Set"
BMY,2021-12-03,12:16:15,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
BMY,2021-12-03,12:16:15,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted for priority review its supplemental Biologics License Application for Reblozyl luspatercept-aamt,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
BMY,2021-12-03,12:16:15,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers also said the European Medicines Agency has validated the Type II variation for Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
BMY,2021-12-03,12:31:15,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
BMY,2021-12-03,12:31:15,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted for priority review its supplemental Biologics License Application for Reblozyl luspatercept-aamt,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
BMY,2021-12-03,12:31:15,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers also said the European Medicines Agency has validated the Type II variation for Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
BMY,2021-12-04,03:50:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,"Bms' acquisition of Celgene on November 20, 2019",PRESS-RELEASE,Business Wire,"BRISTOL MYERS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Bristol-Myers Squibb Company - BMY"
BMY,2021-12-04,03:50:00,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Bms and Celgene agreed to a merger under,PRESS-RELEASE,Business Wire,"BRISTOL MYERS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Bristol-Myers Squibb Company - BMY"
BMY,2021-12-06,23:28:20,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Boerner Acquires 1,288 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Boerner Acquires 1,288 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-12-06,23:28:30,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 4,294 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Elkins Acquires 4,294 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-12-06,23:28:50,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 4,294 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Acquires 4,294 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-12-09,13:31:33,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol Myers Squibb Initiated at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Initiated at Equal-Weight by Wells Fargo
BMY,2021-12-09,13:31:33,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol Myers Squibb Price Target Announced at $58.00/Share by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Announced at $58.00/Share by Wells Fargo
BMY,2021-12-11,13:30:00,94637C,Bristol-Myers Squibb Co.,95,0.4,products-services,start,Bristol-Myers Squibb Co.: All enrolled patients,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results"
BMY,2021-12-11,13:30:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi (lisocabtagene -2-
BMY,2021-12-13,00:30:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Antengene Announces Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo(R) (nivolumab) in Advanced Solid Tumors
BMY,2021-12-13,00:30:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Antengene Announces Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo(R) (nivolumab) in Advanced Solid Tumors
BMY,2021-12-13,00:34:22,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Antengene, Bristol Myers Squibb to Collaborate on",NEWS-FLASH,Dow Jones Newswires,"Antengene, Bristol Myers Squibb to Collaborate on Clinical Evaluation of ATG-017 in Combination With Opdivo(R) (nivolumab) in Advanced Solid Tumors >6996.HK"
BMY,2021-12-13,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol Myers Squibb Announces Dividend Increase And Additional $15 Billion Share Repurchase Authorization,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Dividend Increase And Additional $15 Billion Share Repurchase Authorization >BMY
BMY,2021-12-13,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol-Myers Squibb Co.: Increase in 2022 Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Co.: The Board of Directors has declared a quarterly dividend of fifty-four cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Co.: This amount represents a 10.2% increase in the quarterly dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Co.: At this quarterly dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol-Myers Squibb Co.: Multi-Year Share Repurchase,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:03,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:03,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol-Myers Squibb Co.: Increase in 2022 Dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Co.: The Board of Directors has declared a quarterly dividend of fifty-four cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:03,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Co.: This amount represents a 10.2% increase in the quarterly dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Co.: At this quarterly dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:03,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol-Myers Squibb Co.: Multi-Year Share Repurchase,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
BMY,2021-12-13,11:59:42,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Declares Dividend of 54,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Declares Dividend of 54c >BMY
BMY,2021-12-13,12:01:03,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol Myers Squibb raises quarterly dividend by 10.2% to 54 cents,NEWS-FLASH,MarketWatch,"MW Bristol Myers Squibb raises quarterly dividend by 10.2% to 54 cents a share, adds $15 bln to share buybacks"
BMY,2021-12-13,12:01:06,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Declares Qtrly Div of 50c/Shr,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Declares Qtrly Div of 50c/Shr on $2 Convertible Preferred Stk >BMY
BMY,2021-12-13,12:06:38,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Raises Quarterly Dividend,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Raises Quarterly Dividend And Adds $15 Billion To Share Buyback Program -- MarketWatch
BMY,2021-12-13,12:06:38,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Co.: the company announced a 10.2% increase in its quarterly dividend,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Raises Quarterly Dividend And Adds $15 Billion To Share Buyback Program -- MarketWatch
BMY,2021-12-13,12:06:38,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb raises quarterly dividend,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb raises quarterly dividend and adds $15 billion to share buyback program
BMY,2021-12-13,12:06:38,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Co.: the company announced a 10.2% increase in its quarterly dividend,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb raises quarterly dividend and adds $15 billion to share buyback program
BMY,2021-12-13,12:11:28,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol-Myers Squibb adds $15 billion to stock buyback program,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb adds $15 billion to stock buyback program
BMY,2021-12-13,12:15:28,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,"Bristol-Myers Squibb Raises Dividend,",FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb Raises Dividend, Buyback Authorization"
BMY,2021-12-13,12:30:28,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,"Bristol-Myers Squibb Raises Dividend,",FULL-ARTICLE,Dow Jones Newswires,"Bristol-Myers Squibb Raises Dividend, Buyback Authorization"
BMY,2021-12-13,12:43:08,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Raises Its Dividend,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Raises Its Dividend and Adds $15 Billion to Its Buyback Plan. The Stock Jumps. -- Barrons.com
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Immatics N.V.: our existing collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb's global clinical development,PRESS-RELEASE,Business Wire,Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Immatics N.V.: our existing collaboration with Bristol Myers Squibb to,PRESS-RELEASE,GlobeNewswire,Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb's global clinical development,PRESS-RELEASE,GlobeNewswire,Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Immatics N.V.: our existing collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb's global clinical development,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Immatics N.V.: our existing collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb's global clinical development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Immatics N.V.: our existing collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb's global clinical development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,12:09:12,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Immatics N.V.: our existing collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,12:09:12,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb's global clinical development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
BMY,2021-12-14,12:24:40,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Bristol Myers, Immatics to Collaborate on",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers, Immatics to Collaborate on IMA401 >BMY IMTX"
BMY,2021-12-14,12:39:40,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Bristol Myers, Immatics to Collaborate on",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers, Immatics to Collaborate on IMA401"
BMY,2021-12-15,17:14:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda OKs Bristol Myers' Orencia,FULL-ARTICLE,Dow Jones Newswires,FDA OKs Bristol Myers' Orencia in Acute Graft-Vs-Host Disease >BMY
BMY,2021-12-15,17:14:22,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers reported revenue of $2.44 billion for the first nine months of the year,FULL-ARTICLE,Dow Jones Newswires,FDA OKs Bristol Myers' Orencia in Acute Graft-Vs-Host Disease >BMY
BMY,2021-12-15,17:29:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda OKs Bristol Myers' Orencia,FULL-ARTICLE,Dow Jones Newswires,FDA OKs Bristol Myers' Orencia in Acute Graft-Vs-Host Disease
BMY,2021-12-15,17:29:22,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers reported revenue of $2.44 billion for the first nine months of the year,FULL-ARTICLE,Dow Jones Newswires,FDA OKs Bristol Myers' Orencia in Acute Graft-Vs-Host Disease
BMY,2021-12-15,20:13:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Orencia(R) (abatacept) in,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Orencia(R) (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)...
BMY,2021-12-15,20:13:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Orencia(R) (abatacept) in,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Orencia(R) (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)...
BMY,2021-12-15,20:14:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Orencia in,NEWS-FLASH,Dow Jones Newswires,U.S. FDA Approves Orencia in Combination With Calcineurin Inhibitor and Methotrexate for Prevention of Acute Graft Versus Host Disease
BMY,2021-12-17,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022"
BMY,2021-12-17,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: During a conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022"
BMY,2021-12-17,12:47:24,94637C,Bristol-Myers Squibb Co.,100,0.95,analyst-ratings,positive,Bristol Myers Squibb Initiated at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Initiated at Buy by Goldman Sachs
BMY,2021-12-17,12:47:24,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol Myers Squibb Price Target Announced at $72.00/Share by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Price Target Announced at $72.00/Share by Goldman Sachs
BMY,2021-12-17,22:10:00,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Vessey Sells 19,298 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Sells 19,298 Of Bristol-Myers Squibb Co >BMY"
BMY,2021-12-20,13:58:46,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda OKs Bristol Myers' Orencia,FULL-ARTICLE,Dow Jones Newswires,Correction to FDA OKs Bristol Myers' Orencia Story
BMY,2021-12-20,14:13:46,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda OKs Bristol Myers' Orencia,FULL-ARTICLE,Dow Jones Newswires,Correction to FDA OKs Bristol Myers' Orencia Story
BMY,2021-12-23,17:54:16,94637C,Bristol-Myers Squibb Co.,100,-0.52,legal,,"C. Announces Investigations of Bristol-Myers Squibb Company (NYSE: BMY), Eargo, Inc.",PRESS-RELEASE,GlobeNewswire,"Lifshitz Law Firm, P.C. Announces Investigations of Bristol-Myers Squibb Company (NYSE: BMY), Eargo, Inc. (NASDAQGS: EAR), Hyzon Motors Inc. (NASDAQ: HYZN), Nano-X Imaging Ltd. (NASDAQ: NNOX), and View, Inc. (NASDAQGM: VIEW)"
BMY,2021-01-29,07:00:11,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: our preliminary results in June 2021,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2021-01-29,07:00:11,97C893,Bloomsbury Publishing PLC,99,-0.51,labor-issues,,Bloomsbury also announces that John Warren will step down from the Board,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2021-01-29,07:27:09,97C893,Bloomsbury Publishing PLC,100,0.79,revenues,above-expectations,"Bloomsbury Publishing Expects FY 2021 Revenue, Profit to Beat Market Views",FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Expects FY 2021 Revenue, Profit to Beat Market Views"
BMY,2021-03-24,07:00:21,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury announces that revenue is,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Further Trading Update
BMY,2021-03-24,07:00:21,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: our preliminary results in June 2021,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Further Trading Update
BMY,2021-03-24,07:13:04,97C893,Bloomsbury Publishing PLC,100,0.7,earnings,up,Bloomsbury Publishing Raises FY 2021 Expectations on,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Raises FY 2021 Expectations on Consumer Strength
BMY,2021-03-24,11:32:23,97C893,Bloomsbury Publishing PLC,100,-0.51,products-services,decrease,Bloomsbury Publishing Could See Demand Slowdown After February,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Could See Demand Slowdown After February Surge -- Market Talk
BMY,2021-03-24,12:00:00,97C893,Bloomsbury Publishing PLC,100,0.7,earnings,up,Bloomsbury Publishing Raises FY 2021 Expectations,FULL-ARTICLE,Dow Jones Newswires,Amigo: UK Regulator Not Planning Action on Scheme of Arrangement Process; Bloomsbury Publishing Raises FY 2021 Expectations
BMY,2021-04-23,06:33:15,97C893,Bloomsbury Publishing PLC,100,0.55,acquisitions-mergers,,Bloomsbury Publishing Buys Some Red Globe Press Assets for GBP3.7 Mln,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Buys Some Red Globe Press Assets for GBP3.7 Mln
BMY,2021-05-18,11:07:04,97C893,Bloomsbury Publishing PLC,100,0.49,partnerships,,Bloomsbury Publishing PLC: Connect For Education Partners with Bloomsbury,PRESS-RELEASE,PR Newswire,"Connect For Education Partners with Bloomsbury to Create, Distribute, and Support Interactive and Flexible Digital Courses"
BMY,2021-06-01,06:00:25,97C893,Bloomsbury Publishing PLC,100,0.57,acquisitions-mergers,completed,Bloomsbury Publishing PLC Completion of Acquisition,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Completion of Acquisition
BMY,2021-06-01,06:00:26,97C893,Bloomsbury Publishing PLC,100,0.57,acquisitions-mergers,completed,Bloomsbury Publishing PLC Completion of Acquisition,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing PLC Completion of Acquisition
BMY,2021-06-01,06:00:26,97C893,Bloomsbury Publishing PLC,100,0.57,acquisitions-mergers,completed,Bloomsbury Publishing PLC Completion of Acquisition,NEWS-FLASH,Dow Jones Newswires,Bloomsbury Publishing PLC Completion of Acquisition
BMY,2021-06-01,14:17:31,97C893,Bloomsbury Publishing PLC,93,0.0,earnings,,Bloomsbury Publishing PLC: the company's full-year results due,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Post-Lockdown Trade in Focus -- Market Talk
BMY,2021-06-01,14:17:31,97C893,Bloomsbury Publishing PLC,93,0.34,analyst-ratings,neutral,"Numis Securities, which has an add rating on Bloomsbury",FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Post-Lockdown Trade in Focus -- Market Talk
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Audited Preliminary Results for the year ended 28 February 2021,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Third profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: Special dividend,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: Revenues increased by 14% to GBP185.1 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.44,earnings,up,Bloomsbury Publishing PLC: Diluted earnings per share grew by 25%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.53,labor-issues,,Bloomsbury Publishing PLC: Appointment of Ian Hudson as Managing Director,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.34,products-services,,Bloomsbury Publishing PLC: Acquisition of Red,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.49,partnerships,,Bloomsbury Publishing PLC: BDR partnerships with Taylor & Francis and Human Kinetics launched and new,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.82,revenues,up,Bloomsbury Publishing PLC: Sarah J. Maas' sales grew by 129% compared to last year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.49,partnerships,,Bloomsbury Publishing PLC: o New partnerships with Yale University,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Special Interest revenue was GBP22.5 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.62,acquisitions-mergers,,"Bloomsbury Publishing PLC: In March 2020, we acquired certain assets of Zed Books Limited, the academic",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.46,equity-actions,,Bloomsbury Publishing PLC: we invested GBP1.1 million of,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: Together with the interim dividend,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.26,corporate-responsibility,,Bloomsbury Publishing PLC: our donation to Black Lives Matter,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,-0.51,labor-issues,,"Bloomsbury Publishing PLC: In addition, John Warren will step down from the Board",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 99,603",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,96,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,96,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,96,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year 13,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,96,0.0,dividends,,Bloomsbury Publishing PLC: 31) - Dividends,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -5-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,96,0.0,revenues,,Bloomsbury Publishing PLC: Print revenues are,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -5-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 37,471",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 10,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,93,0.0,revenues,,Bloomsbury Publishing PLC: During the year sales,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,93,0.0,assets,,Bloomsbury Publishing PLC: Total assets,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,93,-0.48,equity-actions,costs,Bloomsbury Publishing PLC: Restructuring costs,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,93,0.0,equity-actions,,"Bloomsbury Publishing PLC: Coronavirus onerous costs of GBP180,000",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,93,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,95,0.0,dividends,,Bloomsbury Publishing PLC: Total dividend payments in the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 16.71p 13.40p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 18.68p 16.23p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,95,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2021-06-02,06:27:21,97C893,Bloomsbury Publishing PLC,100,0.0,dividends,,Bloomsbury Publishing Declares Special Dividend,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Declares Special Dividend After Beating FY 2021 Views
BMY,2021-06-02,06:27:21,97C893,Bloomsbury Publishing PLC,100,0.48,earnings,up,Bloomsbury Publishing PLC: the company's pretax profit rose 31% to GBP17.3 million,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Declares Special Dividend After Beating FY 2021 Views
BMY,2021-06-02,07:57:58,97C893,Bloomsbury Publishing PLC,93,0.0,earnings,,Bloomsbury Publishing's fiscal 2021 results,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Entered FY 2022 With Strong Momentum -- Market Talk
BMY,2021-06-02,11:00:00,97C893,Bloomsbury Publishing PLC,100,0.0,dividends,,Bloomsbury Publishing Declares Special Dividend,FULL-ARTICLE,Dow Jones Newswires,Wizz Air Swung to FY 2021 Pretax Loss; Bloomsbury Publishing Declares Special Dividend
BMY,2021-06-02,11:44:28,97C893,Bloomsbury Publishing PLC,100,0.62,acquisitions-mergers,,Bloomsbury Acquires Publisher Head of Zeus for GBP8.5 Mln,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Acquires Publisher Head of Zeus for GBP8.5 Mln -- Deal Digest
BMY,2021-07-15,14:31:04,97C893,Bloomsbury Publishing PLC,100,0.0,investor-relations,,Bloomsbury Publishing PLC Annual General Meeting,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual General Meeting
BMY,2021-07-21,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.46,revenues,up,Bloomsbury Publishing PLC: Year-on-year revenue growth of 28%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2021-07-21,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: 4 months to June 4 months Revenue,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2021-07-21,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: UK Consumer print sales growth,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2021-07-21,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: The results for the six months,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2021-07-21,06:42:27,97C893,Bloomsbury Publishing PLC,100,0.65,revenues,up,Bloomsbury Four-Month Revenue Rose,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Four-Month Revenue Rose; Sees FY 2022 in Line
BMY,2021-07-21,15:52:59,97C893,Bloomsbury Publishing PLC,99,0.0,investor-relations,,Bloomsbury Publishing PLC: Results of the 2021 Annual General Meeting,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Results of the 2021 Annual General Meeting
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.64,earnings,up,Bloomsbury Publishing PLC: Record first half earnings,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.66,revenues,up,"Bloomsbury Publishing PLC: Strong Adult Trade performance, with revenue up 27% to GBP23.9 million",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.62,dividends,up,Bloomsbury Publishing PLC: 1.34 pence 1.28 pence Interim dividend,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.57,acquisitions-mergers,completed,Bloomsbury Publishing PLC: We completed two acquisitions,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 10.41 pence 2.87 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.4,products-services,,Bloomsbury won Trade Publisher of The Year at the Independent Publishing Awards,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Non-Consumer profit before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.46,revenues,up,Bloomsbury Publishing PLC: Revenue grew by 29% to GBP100.7 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation was GBP11.1 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.64,earnings,up,Bloomsbury Publishing PLC: Growth in organic profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.42,revenues,up,Bloomsbury Publishing PLC: Children's sales increased by 31% to GBP39.0 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.0,products-services,,Bloomsbury Publishing PLC: demand for our digital products,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.49,partnerships,,"Bloomsbury Publishing PLC: We extended our partnerships with Taylor & Francis and Human Kinetics, in addition to",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.52,products-services,,Bloomsbury Publishing PLC: we have delivered one new product,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.57,acquisitions-mergers,completed,"Bloomsbury Publishing PLC: In June 2021, we completed the acquisition of the issued share capital of HoZ, the independent",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.46,equity-actions,,Bloomsbury Publishing PLC: we invested GBP3.0 million in,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: The dividend will be paid on 3 December 2021,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.44,products-services,,"Bloomsbury Publishing PLC: In September, we strengthened our digital content by",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -4-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: Our first half revenues have therefore been boosted,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -4-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 56,689",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -4-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -4-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -4-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -4-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,97,0.0,dividends,,Bloomsbury Publishing PLC: 31) - Dividends,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,97,0.39,products-services,,"Bloomsbury Publishing PLC: Total transactions with owners of the Company 78 7,931 - - - 1",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,-0.52,revenues,down,Bloomsbury Publishing PLC: Print sales drop by 25% - 50%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 20,896",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 37,471",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 10,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.0,assets,,Bloomsbury Publishing PLC: Total assets 31 August 31,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.47,equity-actions,,Bloomsbury Publishing PLC: For the six months ended 31 August 2021 restructuring,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.0,dividends,,Bloomsbury Publishing PLC: The proposed interim dividend of 1.34 pence per ordinary share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,Bloomsbury Publishing PLC: Basic earnings per share 10.54p 2.89p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -10-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,97,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -10-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,97,0.0,equity-actions,,"Bloomsbury Publishing PLC: Transaction costs of GBP241,000",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -10-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,97,0.0,revenues,,"Bloomsbury Publishing PLC: From 2 June 2021, revenue of GBP2.7 million",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -10-
BMY,2021-10-27,07:33:12,97C893,Bloomsbury Publishing PLC,100,0.62,earnings,up,Bloomsbury 1H 2022 Pretax Profit Boosted,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury 1H 2022 Pretax Profit Boosted by Early Christmas Orders
BMY,2021-12-16,08:21:24,97C893,Bloomsbury Publishing PLC,100,0.62,acquisitions-mergers,,Bloomsbury Publishing Buys ABC-CLIO for $22.9 Mln,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Buys ABC-CLIO for $22.9 Mln
BMY,2021-01-29,07:00:11,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: our preliminary results in June 2021,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2021-01-29,07:00:11,97C893,Bloomsbury Publishing PLC,99,-0.51,labor-issues,,Bloomsbury also announces that John Warren will step down from the Board,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2021-01-29,07:27:09,97C893,Bloomsbury Publishing PLC,100,0.79,revenues,above-expectations,"Bloomsbury Publishing Expects FY 2021 Revenue, Profit to Beat Market Views",FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Expects FY 2021 Revenue, Profit to Beat Market Views"
BMY,2021-03-24,07:00:21,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury announces that revenue is,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Further Trading Update
BMY,2021-03-24,07:00:21,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: our preliminary results in June 2021,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Further Trading Update
BMY,2021-03-24,07:13:04,97C893,Bloomsbury Publishing PLC,100,0.7,earnings,up,Bloomsbury Publishing Raises FY 2021 Expectations on,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Raises FY 2021 Expectations on Consumer Strength
BMY,2021-03-24,11:32:23,97C893,Bloomsbury Publishing PLC,100,-0.51,products-services,decrease,Bloomsbury Publishing Could See Demand Slowdown After February,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Could See Demand Slowdown After February Surge -- Market Talk
BMY,2021-03-24,12:00:00,97C893,Bloomsbury Publishing PLC,100,0.7,earnings,up,Bloomsbury Publishing Raises FY 2021 Expectations,FULL-ARTICLE,Dow Jones Newswires,Amigo: UK Regulator Not Planning Action on Scheme of Arrangement Process; Bloomsbury Publishing Raises FY 2021 Expectations
BMY,2021-04-23,06:33:15,97C893,Bloomsbury Publishing PLC,100,0.55,acquisitions-mergers,,Bloomsbury Publishing Buys Some Red Globe Press Assets for GBP3.7 Mln,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Buys Some Red Globe Press Assets for GBP3.7 Mln
BMY,2021-05-18,11:07:04,97C893,Bloomsbury Publishing PLC,100,0.49,partnerships,,Bloomsbury Publishing PLC: Connect For Education Partners with Bloomsbury,PRESS-RELEASE,PR Newswire,"Connect For Education Partners with Bloomsbury to Create, Distribute, and Support Interactive and Flexible Digital Courses"
BMY,2021-06-01,06:00:25,97C893,Bloomsbury Publishing PLC,100,0.57,acquisitions-mergers,completed,Bloomsbury Publishing PLC Completion of Acquisition,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Completion of Acquisition
BMY,2021-06-01,06:00:26,97C893,Bloomsbury Publishing PLC,100,0.57,acquisitions-mergers,completed,Bloomsbury Publishing PLC Completion of Acquisition,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing PLC Completion of Acquisition
BMY,2021-06-01,06:00:26,97C893,Bloomsbury Publishing PLC,100,0.57,acquisitions-mergers,completed,Bloomsbury Publishing PLC Completion of Acquisition,NEWS-FLASH,Dow Jones Newswires,Bloomsbury Publishing PLC Completion of Acquisition
BMY,2021-06-01,14:17:31,97C893,Bloomsbury Publishing PLC,93,0.0,earnings,,Bloomsbury Publishing PLC: the company's full-year results due,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Post-Lockdown Trade in Focus -- Market Talk
BMY,2021-06-01,14:17:31,97C893,Bloomsbury Publishing PLC,93,0.34,analyst-ratings,neutral,"Numis Securities, which has an add rating on Bloomsbury",FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Post-Lockdown Trade in Focus -- Market Talk
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Audited Preliminary Results for the year ended 28 February 2021,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Third profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: Special dividend,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: Revenues increased by 14% to GBP185.1 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.44,earnings,up,Bloomsbury Publishing PLC: Diluted earnings per share grew by 25%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.53,labor-issues,,Bloomsbury Publishing PLC: Appointment of Ian Hudson as Managing Director,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.34,products-services,,Bloomsbury Publishing PLC: Acquisition of Red,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.49,partnerships,,Bloomsbury Publishing PLC: BDR partnerships with Taylor & Francis and Human Kinetics launched and new,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.82,revenues,up,Bloomsbury Publishing PLC: Sarah J. Maas' sales grew by 129% compared to last year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.49,partnerships,,Bloomsbury Publishing PLC: o New partnerships with Yale University,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Special Interest revenue was GBP22.5 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.62,acquisitions-mergers,,"Bloomsbury Publishing PLC: In March 2020, we acquired certain assets of Zed Books Limited, the academic",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.46,equity-actions,,Bloomsbury Publishing PLC: we invested GBP1.1 million of,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: Together with the interim dividend,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.26,corporate-responsibility,,Bloomsbury Publishing PLC: our donation to Black Lives Matter,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,-0.51,labor-issues,,"Bloomsbury Publishing PLC: In addition, John Warren will step down from the Board",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 99,603",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,96,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,96,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,96,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year 13,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,96,0.0,dividends,,Bloomsbury Publishing PLC: 31) - Dividends,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -5-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,96,0.0,revenues,,Bloomsbury Publishing PLC: Print revenues are,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -5-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 37,471",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 10,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,93,0.0,revenues,,Bloomsbury Publishing PLC: During the year sales,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,93,0.0,assets,,Bloomsbury Publishing PLC: Total assets,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,93,-0.48,equity-actions,costs,Bloomsbury Publishing PLC: Restructuring costs,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,93,0.0,equity-actions,,"Bloomsbury Publishing PLC: Coronavirus onerous costs of GBP180,000",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,93,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,95,0.0,dividends,,Bloomsbury Publishing PLC: Total dividend payments in the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 16.71p 13.40p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 18.68p 16.23p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2021-06-02,06:00:13,97C893,Bloomsbury Publishing PLC,95,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2021-06-02,06:27:21,97C893,Bloomsbury Publishing PLC,100,0.0,dividends,,Bloomsbury Publishing Declares Special Dividend,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Declares Special Dividend After Beating FY 2021 Views
BMY,2021-06-02,06:27:21,97C893,Bloomsbury Publishing PLC,100,0.48,earnings,up,Bloomsbury Publishing PLC: the company's pretax profit rose 31% to GBP17.3 million,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Declares Special Dividend After Beating FY 2021 Views
BMY,2021-06-02,07:57:58,97C893,Bloomsbury Publishing PLC,93,0.0,earnings,,Bloomsbury Publishing's fiscal 2021 results,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Entered FY 2022 With Strong Momentum -- Market Talk
BMY,2021-06-02,11:00:00,97C893,Bloomsbury Publishing PLC,100,0.0,dividends,,Bloomsbury Publishing Declares Special Dividend,FULL-ARTICLE,Dow Jones Newswires,Wizz Air Swung to FY 2021 Pretax Loss; Bloomsbury Publishing Declares Special Dividend
BMY,2021-06-02,11:44:28,97C893,Bloomsbury Publishing PLC,100,0.62,acquisitions-mergers,,Bloomsbury Acquires Publisher Head of Zeus for GBP8.5 Mln,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Acquires Publisher Head of Zeus for GBP8.5 Mln -- Deal Digest
BMY,2021-07-15,14:31:04,97C893,Bloomsbury Publishing PLC,100,0.0,investor-relations,,Bloomsbury Publishing PLC Annual General Meeting,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual General Meeting
BMY,2021-07-21,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.46,revenues,up,Bloomsbury Publishing PLC: Year-on-year revenue growth of 28%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2021-07-21,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: 4 months to June 4 months Revenue,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2021-07-21,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: UK Consumer print sales growth,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2021-07-21,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: The results for the six months,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2021-07-21,06:42:27,97C893,Bloomsbury Publishing PLC,100,0.65,revenues,up,Bloomsbury Four-Month Revenue Rose,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Four-Month Revenue Rose; Sees FY 2022 in Line
BMY,2021-07-21,15:52:59,97C893,Bloomsbury Publishing PLC,99,0.0,investor-relations,,Bloomsbury Publishing PLC: Results of the 2021 Annual General Meeting,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Results of the 2021 Annual General Meeting
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.64,earnings,up,Bloomsbury Publishing PLC: Record first half earnings,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.66,revenues,up,"Bloomsbury Publishing PLC: Strong Adult Trade performance, with revenue up 27% to GBP23.9 million",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.62,dividends,up,Bloomsbury Publishing PLC: 1.34 pence 1.28 pence Interim dividend,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.57,acquisitions-mergers,completed,Bloomsbury Publishing PLC: We completed two acquisitions,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 10.41 pence 2.87 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.4,products-services,,Bloomsbury won Trade Publisher of The Year at the Independent Publishing Awards,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Non-Consumer profit before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.46,revenues,up,Bloomsbury Publishing PLC: Revenue grew by 29% to GBP100.7 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation was GBP11.1 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.64,earnings,up,Bloomsbury Publishing PLC: Growth in organic profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.42,revenues,up,Bloomsbury Publishing PLC: Children's sales increased by 31% to GBP39.0 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.0,products-services,,Bloomsbury Publishing PLC: demand for our digital products,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.49,partnerships,,"Bloomsbury Publishing PLC: We extended our partnerships with Taylor & Francis and Human Kinetics, in addition to",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.52,products-services,,Bloomsbury Publishing PLC: we have delivered one new product,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.57,acquisitions-mergers,completed,"Bloomsbury Publishing PLC: In June 2021, we completed the acquisition of the issued share capital of HoZ, the independent",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.46,equity-actions,,Bloomsbury Publishing PLC: we invested GBP3.0 million in,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: The dividend will be paid on 3 December 2021,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.44,products-services,,"Bloomsbury Publishing PLC: In September, we strengthened our digital content by",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -4-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: Our first half revenues have therefore been boosted,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -4-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 56,689",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -4-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -4-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -4-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -4-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,97,0.0,dividends,,Bloomsbury Publishing PLC: 31) - Dividends,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,97,0.39,products-services,,"Bloomsbury Publishing PLC: Total transactions with owners of the Company 78 7,931 - - - 1",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,-0.52,revenues,down,Bloomsbury Publishing PLC: Print sales drop by 25% - 50%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 20,896",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 37,471",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 10,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.0,assets,,Bloomsbury Publishing PLC: Total assets 31 August 31,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.47,equity-actions,,Bloomsbury Publishing PLC: For the six months ended 31 August 2021 restructuring,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.0,dividends,,Bloomsbury Publishing PLC: The proposed interim dividend of 1.34 pence per ordinary share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,Bloomsbury Publishing PLC: Basic earnings per share 10.54p 2.89p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -10-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,97,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -10-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,97,0.0,equity-actions,,"Bloomsbury Publishing PLC: Transaction costs of GBP241,000",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -10-
BMY,2021-10-27,06:00:08,97C893,Bloomsbury Publishing PLC,97,0.0,revenues,,"Bloomsbury Publishing PLC: From 2 June 2021, revenue of GBP2.7 million",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -10-
BMY,2021-10-27,07:33:12,97C893,Bloomsbury Publishing PLC,100,0.62,earnings,up,Bloomsbury 1H 2022 Pretax Profit Boosted,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury 1H 2022 Pretax Profit Boosted by Early Christmas Orders
BMY,2021-12-16,08:21:24,97C893,Bloomsbury Publishing PLC,100,0.62,acquisitions-mergers,,Bloomsbury Publishing Buys ABC-CLIO for $22.9 Mln,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Buys ABC-CLIO for $22.9 Mln
BMY,2022-01-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 40(th) Annual Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present at J.P. Morgan's 40(th) Annual Healthcare Conference
BMY,2022-01-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 40th Annual Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present at J.P. Morgan's 40th Annual Healthcare Conference
BMY,2022-01-04,23:22:18,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 21,996 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Acquires 21,996 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-01-04,23:23:55,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 23,155 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Elkins Acquires 23,155 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-01-10,11:45:00,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,approved,Bristol-Myers Squibb Co.: the Company's previously disclosed multi-year $15 billion share repurchase authorization,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan's 40(th) Annual Healthcare Conference
BMY,2022-01-10,11:45:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Revlimid sales are expected to,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan's 40(th) Annual Healthcare Conference
BMY,2022-01-10,11:45:01,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,approved,Bristol-Myers Squibb Co.: the Company's previously disclosed multi-year $15 billion share repurchase authorization,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan's 40th Annual Healthcare Conference
BMY,2022-01-10,11:45:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Revlimid sales are expected to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan's 40th Annual Healthcare Conference
BMY,2022-01-10,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration,PRESS-RELEASE,Business Wire,Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
BMY,2022-01-10,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration,PRESS-RELEASE,GlobeNewswire,Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
BMY,2022-01-10,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
BMY,2022-01-10,11:59:49,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Century Therapeutics and Bristol Myers Squibb Enter Into a Strategic Collaboration,NEWS-FLASH,Dow Jones Newswires,Century Therapeutics and Bristol Myers Squibb Enter Into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
BMY,2022-01-10,12:13:17,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
BMY,2022-01-10,13:00:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Of Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors
BMY,2022-01-10,21:05:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bioatla Announces Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo(R) (nivolumab) for Treatment of Solid Tumors
BMY,2022-01-10,21:05:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bioatla Announces Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo(R) (nivolumab) for Treatment of Solid Tumors
BMY,2022-01-10,21:05:40,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bioatla Announces Clinical Collaboration With Bristol Myers Squibb to,NEWS-FLASH,Dow Jones Newswires,BioAtla Announces Clinical Collaboration With Bristol Myers Squibb to Study Mecbotamab Vedotin and Ozuriftamab Vedotin in Combination With Opdivo for Solid Tumors
BMY,2022-01-11,06:30:36,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec expands neuroscience collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach
BMY,2022-01-11,06:30:36,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec expands neuroscience collaboration with Bristol Myers Squibb to,PRESS-RELEASE,DGAP News,PRESS RELEASE: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach
BMY,2022-01-11,07:00:46,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach
BMY,2022-01-11,18:36:28,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach
BMY,2022-01-13,13:30:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb
BMY,2022-01-21,22:42:25,94637C,Bristol-Myers Squibb Co.,100,0.0,insider-trading,,Chmn Caforio Gifts 525 Of Bristol-Myers Squibb Co >BMY,TABULAR-MATERIAL,Dow Jones Newswires,Chmn Caforio Gifts 525 Of Bristol-Myers Squibb Co >BMY
BMY,2022-01-25,08:09:02,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2021 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2021 (BMY)"
BMY,2022-01-28,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B"
BMY,2022-01-28,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B"
BMY,2022-01-28,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B"
BMY,2022-01-28,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B"
BMY,2022-01-28,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B"
BMY,2022-01-28,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B"
BMY,2022-01-28,11:59:11,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene Maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B"
BMY,2022-01-28,12:23:41,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Gets Positive CHMP Opinion For Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Positive CHMP Opinion For Breyanzi in Lymphoma
BMY,2022-01-28,12:23:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency recommended approval of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Positive CHMP Opinion For Breyanzi in Lymphoma
BMY,2022-01-28,12:38:41,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Gets Positive CHMP Opinion For Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Positive CHMP Opinion For Breyanzi in Lymphoma
BMY,2022-01-28,12:38:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency recommended approval of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Positive CHMP Opinion For Breyanzi in Lymphoma
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Adj EPS $1.83,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Adj EPS $1.83 >BMY
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q EPS $1.07,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q EPS $1.07 >BMY
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Net $2.4B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Net $2.4B >BMY
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 4Q Rev $12B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Rev $12B >BMY
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers Squibb posted fourth quarter revenues of $12.0 billion, an increase of 8%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Full-Year Revenues of $46.4 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Fourth Quarter Earnings Per Share of $1.07,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Full-Year Earnings Per Share of $3.12,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,"Bristol-Myers Squibb Co.: Delivers Strong Revenues for Eliquis, Immuno-Oncology and New Product Portfolios",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol-Myers Squibb Co.: Announces $15 Billion Share Repurchase Authorization,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.38,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 30% to $2.6 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: TWELVE-MONTH PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi(R) (lisocabtagene maraleucel),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The EMA also validated the Type II variation for Reblozyl,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Orencia(R) (abatacept) was approved by the FDA,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the European Commission (EC) approved Zeposia(R) (ozanimod),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: the company and Century Therapeutics (NASDAQ: IPSC) announced a research collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.62,dividends,up,Bristol-Myers Squibb Co.: the company announced that its Board of Directors approved an increase in the quarterly dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Sales from key loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Revlimid sales,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating expenses,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers Squibb posted fourth quarter revenues of $12.0 billion, an increase of 8%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Full-Year Revenues of $46.4 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Fourth Quarter Earnings Per Share of $1.07,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Full-Year Earnings Per Share of $3.12,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,"Bristol-Myers Squibb Co.: Delivers Strong Revenues for Eliquis, Immuno-Oncology and New Product Portfolios",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol-Myers Squibb Co.: Announces $15 Billion Share Repurchase Authorization,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.38,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 30% to $2.6 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: TWELVE-MONTH PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi(R) (lisocabtagene maraleucel),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The EMA also validated the Type II variation for Reblozyl,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Orencia(R) (abatacept) was approved by the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the European Commission (EC) approved Zeposia(R) (ozanimod),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: the company and Century Therapeutics (NASDAQ: IPSC) announced a research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,dividends,up,Bristol-Myers Squibb Co.: the company announced that its Board of Directors approved an increase in the quarterly dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Sales from key loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Revlimid sales,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:33,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol-Myers Squibb Announces $15B Share Repurchase Authorization,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Announces $15B Share Repurchase Authorization >BMY
BMY,2022-02-04,11:59:59,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol-Myers Squibb Plans $5B Accelerated Repurchase,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Plans $5B Accelerated Repurchase in 1Q >BMY
BMY,2022-02-04,12:00:51,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2022 EPS $3.37,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2022 EPS $3.37-EPS $3.67 >BMY
BMY,2022-02-04,12:01:06,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2022 Adj EPS $7.65,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2022 Adj EPS $7.65-Adj EPS $7.95 >BMY
BMY,2022-02-04,12:01:28,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Sees 2022 Revenue About $47B,HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb Sees 2022 Revenue About $47B, Up Low-Single Digits >BMY"
BMY,2022-02-04,12:01:31,94637C,Bristol-Myers Squibb Co.,100,0.82,earnings,up,Bristol-Myers Squibb Q4 EPS $1.07 vs. loss $4.45 a year ago,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb Q4 EPS $1.07 vs. loss $4.45 a year ago
BMY,2022-02-04,12:01:58,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Sees 2022 Revlimid Sales $9.5B-$10B >BMY,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2022 Revlimid Sales $9.5B-$10B >BMY
BMY,2022-02-04,12:02:12,94637C,Bristol-Myers Squibb Co.,100,-0.27,revenues,below-expectations,Bristol-Myers Squibb Q4 revenue $11.985 bln vs. $11.068 bln a year ago; FactSet consensus $12.842 bln,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb Q4 revenue $11.985 bln vs. $11.068 bln a year ago; FactSet consensus $12.842 bln
BMY,2022-02-04,12:02:55,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb sees 2022 EPS of $3.37 to $3.67,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb sees 2022 EPS of $3.37 to $3.67
BMY,2022-02-04,12:03:05,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Sees 2022 Revenue,HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb Sees 2022 Revenue From In-Line, New Products About $36.5B >BMY"
BMY,2022-02-04,12:03:46,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb sees 2022 adj. EPS of $7.65 to $7.95,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb sees 2022 adj. EPS of $7.65 to $7.95; FactSet consensus $7.80
BMY,2022-02-04,12:04:15,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb now sees 2022 revenue of about $47 bln,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb now sees 2022 revenue of about $47 bln; FactSet consensus $47.2 bln
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers Squibb posted fourth quarter revenues of $12.0 billion, an increase of 8%",PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Full-Year Revenues of $46.4 Billion,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Fourth Quarter Earnings Per Share of $1.07,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Full-Year Earnings Per Share of $3.12,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,"Bristol-Myers Squibb Co.: Delivers Strong Revenues for Eliquis, Immuno-Oncology and New Product Portfolios",PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol-Myers Squibb Co.: Announces $15 Billion Share Repurchase Authorization,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.38,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 30% to $2.6 billion,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: TWELVE-MONTH PRODUCT REVENUE,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -2-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi(R) (lisocabtagene maraleucel),PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -2-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The EMA also validated the Type II variation for Reblozyl,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -2-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Orencia(R) (abatacept) was approved by the FDA,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -2-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the European Commission (EC) approved Zeposia(R) (ozanimod),PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -2-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Net $2.37B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Net $2.37B >BMY
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: the company and Century Therapeutics (NASDAQ: IPSC) announced a research collaboration,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.62,dividends,up,Bristol-Myers Squibb Co.: the company announced that its Board of Directors approved an increase in the quarterly dividend,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide revenues,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Sales from key loss,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Revlimid sales,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating expenses,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q EPS $1.07,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q EPS $1.07 >BMY
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: the company's Annual Report on Form 10-K for the year ended December 31, 2020",PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -5-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED DECEMBER 31, 2021",PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -5-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2021",PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -5-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Adj EPS $1.83,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Adj EPS $1.83 >BMY
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 4Q Rev $11.99B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Rev $11.99B >BMY
BMY,2022-02-04,13:49:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -6-
BMY,2022-02-04,19:01:36,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co CEO Giovanni Caforio on Q4 2021 Results -- Earnings Call,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Co CEO Giovanni Caforio on Q4 2021 Results -- Earnings Call Transcript >BMY
BMY,2022-02-05,09:13:17,94637C,Bristol-Myers Squibb Co.,100,0.82,earnings,up,Bristol-Myers Squibb Q4 EPS $1.07 vs. loss $4.45 a year ago,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb Q4 EPS $1.07 vs. loss $4.45 a year ago
BMY,2022-02-05,09:13:17,94637C,Bristol-Myers Squibb Co.,100,-0.27,revenues,below-expectations,Bristol-Myers Squibb Q4 revenue $11.985 bln vs. $11.068 bln a year ago; FactSet consensus $12.842 bln,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb Q4 revenue $11.985 bln vs. $11.068 bln a year ago; FactSet consensus $12.842 bln
BMY,2022-02-05,09:13:17,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb sees 2022 EPS of $3.37 to $3.67,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb sees 2022 EPS of $3.37 to $3.67
BMY,2022-02-05,09:13:17,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb sees 2022 adj. EPS of $7.65 to $7.95,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb sees 2022 adj. EPS of $7.65 to $7.95; FactSet consensus $7.80
BMY,2022-02-05,09:13:17,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb now sees 2022 revenue of about $47 bln,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb now sees 2022 revenue of about $47 bln; FactSet consensus $47.2 bln
BMY,2022-02-08,16:30:04,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,"Endari, and DROXIA have been launched recently",PRESS-RELEASE,PR Newswire,Sickle Cell Disease Treatment Market size to Record 10.83% Y-O-Y Growth Rate in 2021 | Addmedica SAS and Bristol-Myers Squibb Co. are the leading companies in the market | Technavio
BMY,2022-02-08,16:30:04,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,"Endari, and DROXIA have been launched recently",PRESS-RELEASE,PR Newswire,Sickle Cell Disease Treatment Market size to Record 10.83% Y-O-Y Growth Rate in 2021 | Addmedica SAS and Bristol-Myers Squibb Co. are the leading companies in the market | Technavio
BMY,2022-02-08,23:11:04,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 2,281 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Acquires 2,281 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-02-09,12:18:06,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers Squibb announces $5 billion accelerated share buyback program,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb announces $5 billion accelerated share buyback program
BMY,2022-02-09,12:18:06,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers Squibb Announces $5 Billion Accelerated Share Buyback Program,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Announces $5 Billion Accelerated Share Buyback Program -- MarketWatch
BMY,2022-02-09,12:21:39,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,Bristol Myers Squibb Co. on Wednesday said it plans to buy back $5 billion in common stock under,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Sets $5 Bln Accelerated Stock Buyback >BMY
BMY,2022-02-09,12:36:39,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Bristol Myers Squibb Co. on Wednesday said it plans to buy back $5 billion in common stock under,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Sets $5 Billion Accelerated Stock Buyback
BMY,2022-02-14,21:11:22,94637C,Bristol-Myers Squibb Co.,100,-0.34,equity-actions,decrease,Berkshire Hathaway Decreases Stake in Bristol Myers Squibb,RNS-SEC13F,Dow Jones Newswires,"Berkshire Hathaway Decreases Stake in Bristol Myers Squibb by 16,844,262 to 5,202,674 Shares -- 13F Filing"
BMY,2022-02-15,12:00:03,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Mavacamten Granted Breakthrough Therapy Designation in China,PRESS-RELEASE,GlobeNewswire,LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China
BMY,2022-02-15,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Mavacamten Granted Breakthrough Therapy Designation in China,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China
BMY,2022-02-15,12:03:00,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Mavacamten Granted Breakthrough Therapy Designation in China,NEWS-FLASH,Dow Jones Newswires,LianBio: Mavacamten Granted Breakthrough Therapy Designation in China >LIAN
BMY,2022-02-15,14:04:00,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $500,000,000",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
BMY,2022-02-15,14:04:00,94637C,Bristol-Myers Squibb Co.,98,0.0,credit,,Bristol Myers Squibb shall have completed an offering of debt,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Tender Offers for -2-
BMY,2022-02-15,14:04:00,94637C,Bristol-Myers Squibb Co.,97,0.48,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is available on Global Bondholder Services,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Tender Offers for -4-
BMY,2022-02-15,14:04:00,94637C,Bristol-Myers Squibb Co.,97,0.55,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is only addressed to Holders where they would,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Tender Offers for -4-
BMY,2022-02-15,14:04:01,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $500,000,000",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
BMY,2022-02-15,14:04:01,94637C,Bristol-Myers Squibb Co.,98,0.0,credit,,Bristol Myers Squibb shall have completed an offering of debt,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2022-02-15,14:04:01,94637C,Bristol-Myers Squibb Co.,97,0.48,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is available on Global Bondholder Services,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2022-02-15,14:04:01,94637C,Bristol-Myers Squibb Co.,97,0.55,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is only addressed to Holders where they would,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2022-02-15,16:56:33,94637C,Bristol-Myers Squibb Co.,100,0.36,credit-ratings,set,S&PGR Rates Bristol-Myers Squibb's Sr Unsecured Notes 'A+,NEWS-FLASH,Dow Jones Newswires,S&PGR Rates Bristol-Myers Squibb's Sr Unsecured Notes 'A+'
BMY,2022-02-15,16:56:33,94637C,Bristol-Myers Squibb Co.,100,0.36,credit-ratings,set,S&PGR Rates Bristol-Myers Squibb's Sr Unsecured Notes 'A+,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Rates Bristol-Myers Squibb's Sr Unsecured Notes 'A+'
BMY,2022-02-15,16:56:33,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,Bristol-Myers Squibb Co.: rising demand for the company's other leading products,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Rates Bristol-Myers Squibb's Sr Unsecured Notes 'A+'
BMY,2022-02-15,17:08:04,94637C,Bristol-Myers Squibb Co.,100,0.26,credit-ratings,set,Moody's Assigns A2 To Bristol-Myers Notes,NEWS-FLASH,Dow Jones Newswires,Moody's Assigns A2 To Bristol-Myers Notes; Stable Outlook
BMY,2022-02-15,21:39:00,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes
BMY,2022-02-15,21:39:01,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes
BMY,2022-02-15,21:39:05,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb Prices $6 B of Senior Unsecured Notes,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Prices $6 B of Senior Unsecured Notes
BMY,2022-02-16,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy"
BMY,2022-02-16,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy"
BMY,2022-02-16,11:59:31,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results From Phase 3 VALOR-HCM Trial,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Announces Positive Topline Results From Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy"
BMY,2022-02-17,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,U.S. Food And Drug Administration (FDA) Accepts For Priority Review Bristol Myers Squibb's Supplemental Biologics License Application For Breyanzi (lisocabtagene Maraleucel),NEWS-FLASH,Dow Jones Newswires,U.S. Food And Drug Administration (FDA) Accepts For Priority Review Bristol Myers Squibb's Supplemental Biologics License Application For Breyanzi (lisocabtagene Maraleucel) As A Second-Line Therapy For Relapsed Or Refractory Large B-cell Lymphoma >BMY
BMY,2022-02-17,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-02-17,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-02-17,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-02-17,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-02-17,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-02-17,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-02-17,11:59:38,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review for Breyanzi,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Breyanzi as Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-02-17,12:26:02,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review for Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Breyanzi as Second-Line Therapy >BMY
BMY,2022-02-17,12:26:02,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Thursday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Breyanzi as Second-Line Therapy >BMY
BMY,2022-02-17,12:26:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda last year approved Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Breyanzi as Second-Line Therapy >BMY
BMY,2022-02-17,12:41:02,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review for Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Breyanzi as Second-Line Therapy
BMY,2022-02-17,12:41:02,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Thursday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Breyanzi as Second-Line Therapy
BMY,2022-02-17,12:41:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda last year approved Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Breyanzi as Second-Line Therapy
BMY,2022-02-17,17:19:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: In the True North extension study, data from an interim analysis",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2022-02-17,17:19:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2022-02-17,17:19:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration (FDA) approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2022-02-22,12:15:01,94637C,Bristol-Myers Squibb Co.,97,0.49,partnerships,,National Cancer Institute in collaboration with Zenith and BMS,PRESS-RELEASE,GlobeNewswire,Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb's Immune Checkpoint Inhibitor OPDIVO
BMY,2022-02-22,12:15:26,94637C,Bristol-Myers Squibb Co.,97,0.49,partnerships,,National Cancer Institute in collaboration with Zenith and BMS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb's Immune Checkpoint Inhibitor OPDIVO
BMY,2022-02-22,22:12:35,94637C,Bristol-Myers Squibb Co.,100,0.0,credit-ratings,stable,S&P Sees Bristol-Myers Squibb Co. Outlk Stable,NEWS-FLASH,Dow Jones Newswires,S&P Sees Bristol-Myers Squibb Co. Outlk Stable
BMY,2022-02-22,22:13:43,94637C,Bristol-Myers Squibb Co.,100,0.0,credit-ratings,affirmation,S&PGR Afrms Bristol-Myers Squibb Rtg,NEWS-FLASH,Dow Jones Newswires,"S&PGR Afrms Bristol-Myers Squibb Rtg, Revises Otlk To Stable"
BMY,2022-02-22,22:13:43,94637C,Bristol-Myers Squibb Co.,100,0.0,credit-ratings,affirmation,S&PGR Afrms Bristol-Myers Squibb Rtg,PRESS-RELEASE,Dow Jones Newswires,"Press Release: S&PGR Afrms Bristol-Myers Squibb Rtg, Revises Otlk To Stable"
BMY,2022-02-22,22:13:43,94637C,Bristol-Myers Squibb Co.,100,-0.68,revenues,down,Revlimid revenues decline,PRESS-RELEASE,Dow Jones Newswires,"Press Release: S&PGR Afrms Bristol-Myers Squibb Rtg, Revises Otlk To Stable"
BMY,2022-02-22,22:13:53,94637C,Bristol-Myers Squibb Co.,100,0.0,credit-ratings,affirmation,S&PGR Afrms Bristol-Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Afrms Bristol-Myers Squibb -2-
BMY,2022-02-25,11:45:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-02-25,11:45:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: Opdivo received approval,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-02-25,11:45:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2022-02-25,11:45:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2022-02-25,11:45:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2022-02-25,11:45:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-02-25,11:45:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: Opdivo received approval,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-02-25,11:45:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2022-02-25,11:45:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-02-25,11:45:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-02-25,11:50:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma..."
BMY,2022-02-25,11:50:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2022-02-25,11:50:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2022-02-25,11:50:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2022-02-25,11:50:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma..."
BMY,2022-02-25,11:50:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2022-02-25,11:50:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-02-25,11:50:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-02-25,11:55:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1..."
BMY,2022-02-25,11:55:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1..."
BMY,2022-02-25,11:55:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2022-02-25,11:55:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2022-02-25,11:55:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2022-02-25,11:55:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1..."
BMY,2022-02-25,11:55:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1..."
BMY,2022-02-25,11:55:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2022-02-25,11:55:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-02-25,11:55:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-02-25,11:57:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo Plus Chemotherapy for First-Line Treatment of Patients With Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma With Tumor Cell PD-L1..."
BMY,2022-02-25,11:57:51,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,The U.S. Food and Drug Administration last year approved Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Opdivo in Bladder Cancer >BMY
BMY,2022-02-25,12:12:50,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,The U.S. Food and Drug Administration last year approved Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Opdivo in Bladder Cancer
BMY,2022-02-28,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -816 is one of four positive Phase 3 trials,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The FDA's acceptance of our application,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -816 is one of four positive Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The FDA's acceptance of our application,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,12:01:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Says FDA Accepts Supplemental Biologics License Application for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Says FDA Accepts Supplemental Biologics License Application for Opdivo Plus Chemotherapy for Neoadjuvant Treatment of Patients With Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,12:01:46,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb: FDA Grants Application Priority Review Status,NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb: FDA Grants Application Priority Review Status, Assigned Prescription Drug User Fee Act Goal Date of July 13 >BMY"
BMY,2022-02-28,12:30:08,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Added Opdivo Indication >BMY
BMY,2022-02-28,12:45:07,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Added Opdivo Indication
BMY,2022-02-28,22:11:07,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 30,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Caforio Sells 30,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-01,18:00:39,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb (NYSE:BMY) signed an exclusive worldwide license agreement with Dragonfly Therapeutics,PRESS-RELEASE,Canadian News Wire,Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
BMY,2022-03-01,18:00:39,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb (NYSE:BMY) signed an exclusive worldwide license agreement with Dragonfly Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
BMY,2022-03-01,18:00:40,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb (NYSE:BMY) signed an exclusive worldwide license agreement with Dragonfly Therapeutics,PRESS-RELEASE,PR Newswire,(PR) Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
BMY,2022-03-01,18:00:40,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb (NYSE:BMY) signed an exclusive worldwide license agreement with Dragonfly Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
BMY,2022-03-01,18:34:50,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb (NYSE:BMY) signed an exclusive worldwide license agreement with Dragonfly Therapeutics,PRESS-RELEASE,PR Newswire,Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
BMY,2022-03-01,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2022-03-01,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on May 2, 2022 to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2022-03-02,02:03:00,94637C,Bristol-Myers Squibb Co.,97,0.55,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: Offers to purchase for cash all of the aggregate principal amount,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender Offers"
BMY,2022-03-02,02:03:00,94637C,Bristol-Myers Squibb Co.,98,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $1,500,000",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Early -2-
BMY,2022-03-02,02:03:01,94637C,Bristol-Myers Squibb Co.,98,0.55,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: Offers to purchase for cash all of the aggregate principal amount,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender Offers"
BMY,2022-03-02,02:03:01,94637C,Bristol-Myers Squibb Co.,98,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $1,500,000",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2022-03-02,12:39:45,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
BMY,2022-03-02,12:39:45,94637C,Bristol-Myers Squibb Co.,100,0.72,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $65.00/Share From $60.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $65.00/Share From $60.00 by Wells Fargo
BMY,2022-03-02,13:30:03,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Strategically partnered with BMS to,PRESS-RELEASE,PR Newswire,"Alexandria Real Estate Equities, Inc. Announces Long-Term Lease With Bristol Myers Squibb for a New 427,000 RSF Innovative Research Hub at the Alexandria Point Mega Campus in the San Diego Cluster Market"
BMY,2022-03-02,13:30:04,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Strategically partnered with BMS to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Alexandria Real Estate Equities, Inc. Announces Long-Term Lease With Bristol Myers Squibb for a New 427,000 RSF Innovative Research Hub at the Alexandria Point Mega Campus in the San Diego Cluster Market"
BMY,2022-03-02,20:19:00,94637C,Bristol-Myers Squibb Co.,98,0.55,acquisitions-mergers,interest,"Offer to Purchase""), as amended by Bristol Myers Squibb",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
BMY,2022-03-02,20:19:00,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Offer to Purchase, as amended by Bristol Myers Squibb",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Accepted Amounts -2-
BMY,2022-03-02,20:19:00,94637C,Bristol-Myers Squibb Co.,95,0.55,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is only addressed to Holders where they would,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Accepted Amounts -3-
BMY,2022-03-02,20:19:01,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Offer to Purchase""), as amended by Bristol Myers Squibb",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
BMY,2022-03-02,20:19:01,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Offer to Purchase, as amended by Bristol Myers Squibb",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2022-03-02,20:19:01,94637C,Bristol-Myers Squibb Co.,95,0.55,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is only addressed to Holders where they would,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2022-03-03,22:44:44,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 14,196 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 14,196 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-03,22:46:44,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 13,047 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Acquires 13,047 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-04,22:44:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer
BMY,2022-03-04,22:44:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer
BMY,2022-03-04,22:48:14,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb: FDA Approves Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: FDA Approves Opdivo With Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients With Resectable Non-Small Cell Lung Cancer
BMY,2022-03-07,17:18:00,94637C,Bristol-Myers Squibb Co.,95,0.57,products-services,granted,Dasatinib was approved in China,PRESS-RELEASE,Business Wire,"Investigation Report on China's Dasatinib Markets, 2016-2020 & 2021-2025: An Anti-tumor Drug Developed by Bristol-Myers Squibb - ResearchAndMarkets.com"
BMY,2022-03-07,17:18:00,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: Prices of Dasatinib,PRESS-RELEASE,Business Wire,"Investigation Report on China's Dasatinib Markets, 2016-2020 & 2021-2025: An Anti-tumor Drug Developed by Bristol-Myers Squibb - ResearchAndMarkets.com"
BMY,2022-03-09,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16
BMY,2022-03-09,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16
BMY,2022-03-11,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022"
BMY,2022-03-11,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: To be directly connected to the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022"
BMY,2022-03-11,11:59:07,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022"
BMY,2022-03-11,11:59:07,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: To be directly connected to the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022"
BMY,2022-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,To collaborating with BMS to,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
BMY,2022-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and Nektar Announce Update -5-
BMY,2022-03-14,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,To collaborating with BMS to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
BMY,2022-03-14,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and Nektar -5-
BMY,2022-03-15,01:17:17,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Mily Acquires 2,130 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Mily Acquires 2,130 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:18:34,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 6,496 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Acquires 6,496 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:19:02,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 3,869 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Acquires 3,869 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:19:20,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Powell Acquires 15,317 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Powell Acquires 15,317 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:19:43,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 6,845 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 6,845 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:20:03,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Santiago Acquires 4,850 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Santiago Acquires 4,850 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:20:29,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Boerner Acquires 17,170 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Boerner Acquires 17,170 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:21:22,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Leung Acquires 15,372 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Leung Acquires 15,372 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:22:06,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Chmn Caforio Acquires 80,611 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Chmn Caforio Acquires 80,611 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,08:30:33,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Temedica announces cooperation with Bristol Myers Squibb for,PRESS-RELEASE,DGAP News,PRESS RELEASE: Temedica announces cooperation with Bristol Myers Squibb for the development of a digital companion for psoriasis patients
BMY,2022-03-15,08:30:33,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Temedica announces cooperation with Bristol Myers Squibb for,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: Temedica announces cooperation with Bristol Myers Squibb for the development of a digital companion for psoriasis patients
BMY,2022-03-16,22:50:25,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co (BMY) Presents at Barclays Global Healthcare Broker Conference,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Co (BMY) Presents at Barclays Global Healthcare Broker Conference Call - (Transcript) >BMY
BMY,2022-03-16,23:33:23,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Boerner Sells 29,532 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Boerner Sells 29,532 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-16,23:33:33,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Santiago Sells 6,577 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Santiago Sells 6,577 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-18,17:53:44,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp von Autenried Registers 25,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP von Autenried Registers 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-18,21:53:03,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Vessey Sells 74,559 Of Bristol-Myers Squibb Co",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Sells 74,559 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-18,23:02:46,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Melanoma Treatment Receives FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Melanoma Treatment Receives FDA Approval
BMY,2022-03-18,23:17:46,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Melanoma Treatment Receives FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Melanoma Treatment Receives FDA Approval
BMY,2022-03-21,09:00:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Today announced a collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb
BMY,2022-03-22,00:16:37,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo(R) in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer
BMY,2022-03-22,00:16:37,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,,Bristol Myers Squibb will supply Opdivo to Transcenta,PRESS-RELEASE,PR Newswire,Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo(R) in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer
BMY,2022-03-22,00:16:37,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo(R) in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer
BMY,2022-03-22,00:16:37,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,,Bristol Myers Squibb will supply Opdivo to Transcenta,PRESS-RELEASE,Dow Jones Newswires,Press Release: Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo(R) in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer
BMY,2022-03-23,23:46:10,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co",FULL-ARTICLE,Dow Jones Newswires,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-24,20:50:16,94637C,Bristol-Myers Squibb Co.,100,-0.1,labor-issues,decrease,"Bristol Myers Squibb CEO Giovanni Caforio 2021 Total Pay $19.8M, Down From $20.2M in 2020",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb CEO Giovanni Caforio 2021 Total Pay $19.8M, Down From $20.2M in 2020"
BMY,2022-03-25,05:00:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Roche announces collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,Roche announces collaboration with Bristol Myers Squibb to advance personalised healthcare through digital pathology solutions
BMY,2022-03-25,05:00:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Roche announces collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Roche announces collaboration with Bristol Myers Squibb to advance personalised healthcare through digital pathology solutions
BMY,2022-03-25,05:00:27,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Roche announces collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,Roche announces collaboration with Bristol Myers Squibb to advance personalised healthcare through digital pathology solutions
BMY,2022-03-25,05:03:33,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Roche, Bristol Myers Squibb Collaborate to",NEWS-FLASH,Dow Jones Newswires,"Roche, Bristol Myers Squibb Collaborate to Support Advancement of Two Assays in Clinical Trials With Use of Two New Digital Pathology Algorithms >RO.EB"
BMY,2022-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,"Bristol-Myers Squibb Co.: In the pivotal CheckMate -816 study, the first positive Phase 3 trial",PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"816, the U.S. Food and Drug Administration approved Opdivo",PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -4-
BMY,2022-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2022-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2022-03-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-03-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,"Bristol-Myers Squibb Co.: In the pivotal CheckMate -816 study, the first positive Phase 3 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-03-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"816, the U.S. Food and Drug Administration approved Opdivo",PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-03-30,14:55:56,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital
BMY,2022-03-30,14:55:56,94637C,Bristol-Myers Squibb Co.,100,0.76,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $81.00/Share From $74.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $81.00/Share From $74.00 by BMO Capital
BMY,2022-04-03,13:45:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Interim results were presented as a late-breaking clinical trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Receiving Mavacamten
BMY,2022-04-03,13:45:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Interim results were presented as a late-breaking clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Receiving Mavacamten
BMY,2022-04-04,22:15:21,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Mily Acquires 3,014 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Mily Acquires 3,014 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-04-05,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-04-05,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: Approval based on Phase 3 CheckMate -274 trial results,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-04-05,10:45:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2022-04-05,10:45:00,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2022-04-05,10:45:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -6-
BMY,2022-04-05,10:45:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-04-05,10:45:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: Approval based on Phase 3 CheckMate -274 trial results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-04-05,10:45:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2022-04-05,10:45:01,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-04-05,10:45:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -6-
BMY,2022-04-05,10:45:17,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo as,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Receives European Commission Approval for Opdivo as Adjuvant Treatment for Patients With Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma With Tumor Cell PD-L1 Expression >=1%"
BMY,2022-04-05,10:50:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...
BMY,2022-04-05,10:50:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...
BMY,2022-04-05,10:50:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2022-04-05,10:50:00,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2022-04-05,10:50:00,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2022-04-05,10:50:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...
BMY,2022-04-05,10:50:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...
BMY,2022-04-05,10:50:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2022-04-05,10:50:01,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-04-05,10:50:01,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-04-05,10:55:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
BMY,2022-04-05,10:55:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: We are eager to introduce this new treatment,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
BMY,2022-04-05,10:55:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2022-04-05,10:55:00,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2022-04-05,10:55:00,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2022-04-05,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
BMY,2022-04-05,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: We are eager to introduce this new treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
BMY,2022-04-05,10:55:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2022-04-05,10:55:01,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-04-05,10:55:01,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-04-05,10:55:45,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Gets EC OK For Opdivo,NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb Gets EC OK For Opdivo With Chemotherapy as First-Line Treatment for Patients With Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma With Tumor Cell PD-L1 Expression >= 1%"
BMY,2022-04-05,11:13:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets European OK for Three More Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European OK for Three More Opdivo Indications >BMY
BMY,2022-04-05,11:28:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets European OK for Three More Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European OK for Three More Opdivo Indications
BMY,2022-04-05,14:33:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-04-05,14:33:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-04-05,14:33:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-04-05,14:33:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -2-
BMY,2022-04-05,14:35:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for CAR,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-04-05,14:53:37,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol Myers Squibb Co. said the European Commission has approved marketing authorization for Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Breyanzi Receives European Commission Marketing Authorization
BMY,2022-04-05,15:08:37,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol Myers Squibb Co. said the European Commission has approved marketing authorization for Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Breyanzi Receives European Commission Marketing Authorization
BMY,2022-04-06,14:05:19,94637C,Bristol-Myers Squibb Co.,100,-0.98,analyst-ratings,negative,Bristol-Myers Squibb Cut to Underweight From Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Underweight From Equal-Weight by Morgan Stanley
BMY,2022-04-06,14:05:19,94637C,Bristol-Myers Squibb Co.,100,-0.44,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $64.00/Share From $66.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $64.00/Share From $66.00 by Morgan Stanley
BMY,2022-04-08,05:55:37,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Evotec SE: Our neuroscience collaboration with Bristol Myers Squibb,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2022-04-12,13:30:04,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bms) today announced that Health Canada has approved ZEPOSIA(R) (ozanimod),PRESS-RELEASE,Canadian News Wire,"Health Canada Has Approved ZEPOSIA (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis"
BMY,2022-04-14,20:30:05,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,PR Newswire,Nektar and Bristol Myers Squibb Announce Update -5-
BMY,2022-04-14,20:30:06,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Nektar and Bristol Myers Squibb -6-
BMY,2022-04-14,21:15:57,94637C,Bristol-Myers Squibb Co.,100,-0.54,products-services,suspended,Bristol Myers to Discontinue Bempeg Clinical Development Program,FULL-ARTICLE,Dow Jones Newswires,"Nektar, Bristol Myers to Discontinue Bempeg Clinical Development Program"
BMY,2022-04-14,21:15:57,94637C,Bristol-Myers Squibb Co.,100,-0.54,products-services,suspended,Nektar Therapeutics and Bristol Myers Squibb Co. are ending a clinical development program,FULL-ARTICLE,Dow Jones Newswires,"Nektar, Bristol Myers to Discontinue Bempeg Clinical Development Program"
BMY,2022-04-14,21:30:58,94637C,Bristol-Myers Squibb Co.,100,-0.54,products-services,suspended,Bristol Myers to Discontinue Bempeg Clinical Development Program,FULL-ARTICLE,Dow Jones Newswires,"Nektar, Bristol Myers to Discontinue Bempeg Clinical Development Program"
BMY,2022-04-14,21:30:58,94637C,Bristol-Myers Squibb Co.,100,-0.54,products-services,suspended,Nektar Therapeutics and Bristol Myers Squibb Co. are ending a clinical development program,FULL-ARTICLE,Dow Jones Newswires,"Nektar, Bristol Myers to Discontinue Bempeg Clinical Development Program"
BMY,2022-04-18,14:35:47,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Nektar, Bristol Myers Squibb End Clinical Development Of Combination Therapy",FULL-ARTICLE,Dow Jones Newswires,"Nektar, Bristol Myers Squibb End Clinical Development Of Combination Therapy Including Opdivo -- MarketWatch"
BMY,2022-04-18,14:35:47,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Nektar, Bristol Myers Squibb end clinical development of combination therapy",FULL-ARTICLE,MarketWatch,"MW Nektar, Bristol Myers Squibb end clinical development of combination therapy including Opdivo"
BMY,2022-04-18,14:39:36,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Nektar, Bristol Myers Squibb end clinical development of combination therapy",FULL-ARTICLE,MarketWatch,"MW Nektar, Bristol Myers Squibb end clinical development of combination therapy including Opdivo"
BMY,2022-04-18,14:39:36,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Nektar, Bristol Myers Squibb End Clinical Development Of Combination Therapy",FULL-ARTICLE,Dow Jones Newswires,"Update: Nektar, Bristol Myers Squibb End Clinical Development Of Combination Therapy Including Opdivo -- MarketWatch"
BMY,2022-04-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Edp Renewables and Bristol Myers Squibb Execute Power Purchase Agreement,PRESS-RELEASE,GlobeNewswire,EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park
BMY,2022-04-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Delighted to partner with Bristol Myers Squibb on,PRESS-RELEASE,GlobeNewswire,EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park
BMY,2022-04-21,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Edp Renewables and Bristol Myers Squibb Execute Power Purchase Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park
BMY,2022-04-21,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Delighted to partner with Bristol Myers Squibb on,PRESS-RELEASE,Dow Jones Newswires,Press Release: EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park
BMY,2022-04-21,10:59:20,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Edp Renewables and Bristol Myers Squibb Execute Power Purchase Agreement,NEWS-FLASH,Dow Jones Newswires,EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park
BMY,2022-04-21,11:03:02,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Merger of Bristol Myers Squibb and Celgene,PRESS-RELEASE,PR Newswire,Veeva Vault CTMS Launched at Bristol Myers Squibb to Simplify Clinical Trial Processes Globally
BMY,2022-04-21,11:03:02,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Merger of Bristol Myers Squibb and Celgene,PRESS-RELEASE,Dow Jones Newswires,Press Release: Veeva Vault CTMS Launched at Bristol Myers Squibb to Simplify Clinical Trial Processes Globally
BMY,2022-04-21,11:03:30,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Merger of Bristol Myers Squibb and Celgene,PRESS-RELEASE,PR Newswire,Veeva Vault CTMS Launched at Bristol Myers Squibb to Simplify Clinical Trial Processes Globally
BMY,2022-04-21,12:30:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Platform, Announces Collaboration with Bristol Myers Squibb",PRESS-RELEASE,Business Wire,"Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key Appointments"
BMY,2022-04-21,12:30:00,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,Bristol-Myers Squibb Co.: Appoints Industry Veteran Rick Artis as Chief,PRESS-RELEASE,Business Wire,"Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key Appointments"
BMY,2022-04-25,07:16:25,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2022 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2022 (BMY)"
BMY,2022-04-29,00:26:06,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Bristol-Myers Drug for,NEWS-FLASH,Dow Jones Newswires,FDA Approves Bristol-Myers Drug for Most Common Genetic Heart Condition -- WSJ
BMY,2022-04-29,00:26:06,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves New Bristol-Myers Drug,FULL-ARTICLE,Dow Jones Newswires,FDA Approves New Bristol-Myers Drug for Common Inherited Heart Disease -- WSJ
BMY,2022-04-29,00:26:06,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: the company's $13.1 billion acquisition of MyoKardia in 2020,FULL-ARTICLE,Dow Jones Newswires,FDA Approves New Bristol-Myers Drug for Common Inherited Heart Disease -- WSJ
BMY,2022-04-29,10:00:04,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves New Bristol-Myers Drug,FULL-ARTICLE,Dow Jones Newswires,FDA Approves New Bristol-Myers Drug for Common Inherited Heart Disease
BMY,2022-04-29,10:00:04,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: the company's $13.1 billion acquisition of MyoKardia in 2020,FULL-ARTICLE,Dow Jones Newswires,FDA Approves New Bristol-Myers Drug for Common Inherited Heart Disease
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q Adj EPS $1.96,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Adj EPS $1.96 >BMY
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q EPS 59c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q EPS 59c >BMY
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q Net $1.3B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Net $1.3B >BMY
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 1Q Rev $11.6B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Rev $11.6B >BMY
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,"Bristol-Myers Squibb Co.: Eliquis revenues, which grew 11%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.1 billion compared to $1.9 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.18,revenues,,Bristol-Myers Squibb Co.: International revenues were $1.1 billion compared to $963 million,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 12%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.48,revenues,down,Bristol-Myers Squibb Co.: Abraxane revenues declined 32%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Bristol-Myers Squibb Co.: The EC approved Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Bristol-Myers Squibb Co.: The FDA approved Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,96,0.0,products-services,,Bristol-Myers Squibb Co.: Two-year follow-up results from the Phase 3,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,96,0.59,equity-actions,,"Bristol-Myers Squibb Co.: In February, the company entered into accelerated share repurchase (ASR) transactions to",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,96,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $3.37-$3.67,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today at 8 a.m. EDT,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -6-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.60 $ 0.90,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -6-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,98,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Loss on,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -7-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports First Quarter Financial Results for 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports First Quarter Revenues of $11.6 Billion, an Increase of 5% YoY",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts First Quarter Earnings Per Share of $0.59,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts GAAP 2022 EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 3% to $4.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.13,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increased 2%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD increased to $333 million in the quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol-Myers Squibb Co.: For purposes of comparability, the non-GAAP financial results for the first quarter of 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,"Bristol-Myers Squibb Co.: Eliquis revenues, which grew 11%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.1 billion compared to $1.9 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.18,revenues,,Bristol-Myers Squibb Co.: International revenues were $1.1 billion compared to $963 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 12%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.48,revenues,down,Bristol-Myers Squibb Co.: Abraxane revenues declined 32%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Bristol-Myers Squibb Co.: The EC approved Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Bristol-Myers Squibb Co.: The FDA approved Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,products-services,,Bristol-Myers Squibb Co.: Two-year follow-up results from the Phase 3,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.59,equity-actions,,"Bristol-Myers Squibb Co.: In February, the company entered into accelerated share repurchase (ASR) transactions to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $3.37-$3.67,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today at 8 a.m. EDT,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -6-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.60 $ 0.90,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -6-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,97,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Loss on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -7-
BMY,2022-04-29,11:00:22,94637C,Bristol-Myers Squibb Co.,100,-0.5,earnings,down,Bristol Myers Squibb Q1 EPS 59 cents vs. 89 cents a year ago,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb Q1 EPS 59 cents vs. 89 cents a year ago
BMY,2022-04-29,11:00:43,94637C,Bristol-Myers Squibb Co.,100,0.46,earnings,above-expectations,Bristol Myers Q1 adj. EPS $1.96; FactSet consensus $1.91,NEWS-FLASH,MarketWatch,MW Bristol Myers Q1 adj. EPS $1.96; FactSet consensus $1.91
BMY,2022-04-29,11:01:02,94637C,Bristol-Myers Squibb Co.,100,0.48,revenues,above-expectations,Bristol Myers Q1 revenue $11.65 bln vs. $11.07 bln a year ago; FactSet consensus $11.35 bln,NEWS-FLASH,MarketWatch,MW Bristol Myers Q1 revenue $11.65 bln vs. $11.07 bln a year ago; FactSet consensus $11.35 bln
BMY,2022-04-29,11:01:49,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb Cuts 2022 View To EPS $2.92,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cuts 2022 View To EPS $2.92-EPS $3.22 >BMY
BMY,2022-04-29,11:01:56,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Q1 Eliquis revenue $3.21 bln vs. $2.89 bln,NEWS-FLASH,MarketWatch,MW Bristol Myers Q1 Eliquis revenue $3.21 bln vs. $2.89 bln a year ago; FactSet consensus $3.18 bln
BMY,2022-04-29,11:02:21,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb Cuts 2022 View To Adj EPS $7.44,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cuts 2022 View To Adj EPS $7.44-Adj EPS $7.74 >BMY
BMY,2022-04-29,11:02:34,94637C,Bristol-Myers Squibb Co.,100,0.48,revenues,above-expectations,Bristol Myers Q1 Revlimid revenue $2.78 bln vs. $2.94 bln; FactSet consensus $2.52 bln,NEWS-FLASH,MarketWatch,MW Bristol Myers Q1 Revlimid revenue $2.78 bln vs. $2.94 bln; FactSet consensus $2.52 bln
BMY,2022-04-29,11:03:33,94637C,Bristol-Myers Squibb Co.,100,-0.26,earnings,down,Bristol Myers cuts 2022 adj. EPS outlook to $7.44-$7.74 from $7.65-$7.95,NEWS-FLASH,MarketWatch,MW Bristol Myers cuts 2022 adj. EPS outlook to $7.44-$7.74 from $7.65-$7.95
BMY,2022-04-29,11:53:10,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb Co. said its revenue rose 5.2% in the first quarter,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb 1Q Sales Rise on In-Line Product Growth
BMY,2022-04-29,12:08:10,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb Co. said its revenue rose 5.2% in the first quarter,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb 1Q Sales Rise on In-Line Product Growth
BMY,2022-04-29,17:30:45,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Company CEO Giovanni Caforio on Q1 2022 Results -- Earnings Call,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Company CEO Giovanni Caforio on Q1 2022 Results -- Earnings Call Transcript >BMY
BMY,2022-05-02,11:39:11,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2022-05-02,11:39:11,94637C,Bristol-Myers Squibb Co.,100,0.44,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $68.00/Share From $66.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $68.00/Share From $66.00 by Barclays
BMY,2022-05-02,12:38:51,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2022-05-02,12:38:51,94637C,Bristol-Myers Squibb Co.,100,-0.32,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $63.00/Share From $64.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $63.00/Share From $64.00 by Morgan Stanley
BMY,2022-05-02,14:25:22,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital
BMY,2022-05-02,14:25:22,94637C,Bristol-Myers Squibb Co.,100,0.6,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $92.00/Share From $87.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $92.00/Share From $87.00 by BMO Capital
BMY,2022-05-02,19:43:34,94637C,Bristol-Myers Squibb Co.,100,-0.8,products-services,negative,Bristol-Myers Covid Drug Failed Phase 2 Study,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Covid Drug Failed Phase 2 Study -- Market Talk
BMY,2022-05-02,19:43:34,94637C,Bristol-Myers Squibb Co.,100,-0.8,products-services,negative,Bristol-Myers Covid Drug Failed Phase 2 Study,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Covid Drug Failed Phase 2 Study -- Market Talk
BMY,2022-05-04,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference
BMY,2022-05-04,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference
BMY,2022-05-04,12:00:12,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Enters Strategic Collaboration with Bristol Myers Squibb for,PRESS-RELEASE,PR Newswire,Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
BMY,2022-05-04,12:02:10,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Enters Strategic Collaboration with Bristol Myers Squibb for,PRESS-RELEASE,PR Newswire,Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
BMY,2022-05-04,12:08:07,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Enters Strategic Collaboration with Bristol Myers Squibb for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
BMY,2022-05-10,11:12:23,94637C,Bristol-Myers Squibb Co.,100,0.41,products-services,start,Ima401 Phase 1 Trial Started at First,NEWS-FLASH,Dow Jones Newswires,Immatics Patient Enrollment for IMA401 Phase 1 Trial Started at First Clinical Site in Germany >IMTX
BMY,2022-05-10,14:29:46,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb extend and expand strategic partnership,PRESS-RELEASE,DGAP News,DGAP-Adhoc: Evotec and Bristol Myers Squibb extend and expand strategic partnership
BMY,2022-05-10,14:29:46,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb extend and expand strategic partnership,PRESS-RELEASE,Dow Jones Newswires,DGAP-Adhoc: Evotec and Bristol Myers Squibb extend and expand strategic partnership
BMY,2022-05-10,14:31:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb extend and expand strategic partnership,PRESS-RELEASE,DGAP News,PRESS RELEASE: Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
BMY,2022-05-10,14:31:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb extend and expand strategic partnership,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
BMY,2022-05-10,14:45:54,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership,PRESS-RELEASE,DJ Global Press Release Wire,Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
BMY,2022-05-10,14:55:54,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership,PRESS-RELEASE,DJ Global Press Release Wire,Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership
BMY,2022-05-12,11:30:02,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bridgebio Announces Exclusive License Agreement with Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,"BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology"
BMY,2022-05-12,11:30:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"In July 2021, BridgeBio initially announced a non-exclusive, co-funded clinical collaboration with Bristol Myers Squibb",PRESS-RELEASE,GlobeNewswire,"BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology"
BMY,2022-05-12,11:30:02,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bridgebio Announces Exclusive License Agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,"Press Release: BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology"
BMY,2022-05-12,11:30:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"In July 2021, BridgeBio initially announced a non-exclusive, co-funded clinical collaboration with Bristol Myers Squibb",PRESS-RELEASE,Dow Jones Newswires,"Press Release: BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology"
BMY,2022-05-12,11:31:25,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bridgebio Announces Exclusive License Agreement With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,"BridgeBio Announces Exclusive License Agreement With Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology"
BMY,2022-05-13,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.58,acquisitions-mergers,,"Lotte to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York",PRESS-RELEASE,Business Wire,"LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York"
BMY,2022-05-13,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Agreed to purchase Bristol Myers Squibb's manufacturing facility in East Syracuse, New York",PRESS-RELEASE,Business Wire,"LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York"
BMY,2022-05-13,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.58,acquisitions-mergers,,"Lotte to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York",PRESS-RELEASE,Dow Jones Newswires,"Press Release: LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York"
BMY,2022-05-13,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Agreed to purchase Bristol Myers Squibb's manufacturing facility in East Syracuse, New York",PRESS-RELEASE,Dow Jones Newswires,"Press Release: LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York"
BMY,2022-05-13,11:00:39,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Lotte to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, NY",NEWS-FLASH,Dow Jones Newswires,"LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, NY"
BMY,2022-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.62,products-services,positive,Opdivo has shown clinical benefit,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2022-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -4-
BMY,2022-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -5-
BMY,2022-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -5-
BMY,2022-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,products-services,positive,Opdivo has shown clinical benefit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2022-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -4-
BMY,2022-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -5-
BMY,2022-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -5-
BMY,2022-05-16,21:35:22,94637C,Bristol-Myers Squibb Co.,100,-0.34,equity-actions,decrease,Berkshire Hathaway Eliminates Stakes in Bristol Myers Squibb,RNS-SEC13F,Dow Jones Newswires,Berkshire Hathaway Eliminates Stakes in Bristol Myers Squibb and AbbVie -- 13F Filing
BMY,2022-05-17,10:51:16,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
BMY,2022-05-17,10:51:16,94637C,Bristol-Myers Squibb Co.,100,0.68,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $70.00/Share From $65.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $70.00/Share From $65.00 by Wells Fargo
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Data from Phase 1 studies of CC-99282,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,earnings,,"Bristol-Myers Squibb Co.: Long-term Safety Vip Viprakasit Poster Friday, June 10, Results",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 -3-
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,97,0.0,products-services,,Bristol-Myers Squibb Co.: First Clinical Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 -4-
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 -6-
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 -8-
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 -10-
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 -11-
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 -13-
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Data from Phase 1 studies of CC-99282,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,earnings,,"Bristol-Myers Squibb Co.: Long-term Safety Vip Viprakasit Poster Friday, June 10, Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -3-
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,products-services,,Bristol-Myers Squibb Co.: First Clinical Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -4-
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -6-
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -8-
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -10-
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -11-
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -13-
BMY,2022-05-26,04:29:31,94637C,Bristol-Myers Squibb Co.,96,0.0,investor-relations,,Bristol-Myers Squibb Co.: the company's earnings call for the first quarter of 2022,FULL-ARTICLE,Dow Jones Newswires,Why Bristol Myers Stock Is Still a Buy -- Barrons.com
BMY,2022-05-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Bernstein's 38(th) Annual Strategic Decisions Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Bernstein's 38(th) Annual Strategic Decisions Conference
BMY,2022-05-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Bernstein's 38th Annual Strategic Decisions Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Bernstein's 38th Annual Strategic Decisions Conference
BMY,2022-05-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will take part in a fireside chat at Bernstein's 38(th) Annual Strategic Decisions Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Bernstein's 38th Annual Strategic Decisions Conference
BMY,2022-05-26,11:09:51,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Buy by Citigroup
BMY,2022-05-26,11:09:51,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $90.00/Share From $75.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $90.00/Share From $75.00 by Citigroup
BMY,2022-05-26,21:00:00,94637C,Bristol-Myers Squibb Co.,96,0.4,products-services,start,Bristol-Myers Squibb Co.: All enrolled patients,PRESS-RELEASE,Business Wire,Data from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy
BMY,2022-05-26,21:00:00,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Data from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy
BMY,2022-05-26,21:29:33,94637C,Bristol-Myers Squibb Co.,97,0.4,products-services,start,Bristol-Myers Squibb Co.: All enrolled patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy
BMY,2022-05-26,21:29:33,94637C,Bristol-Myers Squibb Co.,97,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy
BMY,2022-05-27,22:11:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Two Opdivo(R) (nivolumab)-Based Regimens as First-Line Treatments for Unresectable,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Two Opdivo(R) (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BMY,2022-05-27,22:11:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Two Opdivo(R) (nivolumab)-Based Regimens as First-Line Treatments for Unresectable,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Two Opdivo(R) (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BMY,2022-05-27,22:13:12,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Two Opdivo-Based Regimens as First-Line Treatments for Unresectable,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: FDA Approves Two Opdivo-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BMY,2022-05-27,22:30:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Two Opdivo-Based Regimens,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says FDA Approves Two Opdivo-Based Regimens
BMY,2022-05-27,22:45:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Two Opdivo-Based Regimens,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says FDA Approves Two Opdivo-Based Regimens
BMY,2022-05-28,01:30:18,94637C,Bristol-Myers Squibb Co.,97,0.0,investor-relations,,Bristol-Myers Squibb Co.: the company's earnings call for the first quarter of 2022,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Looks Like The Right Medicine
BMY,2022-05-28,01:30:18,94637C,Bristol-Myers Squibb Co.,97,0.0,investor-relations,,Bristol-Myers Squibb Co.: the company's earnings call for the first quarter of 2022,FULL-ARTICLE,Barrons,Bristol Myers Looks Like The Right Medicine -- Barron's
BMY,2022-06-01,00:30:02,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Antengene to Present Clinical Results of ATG-008 (Onatasertib),PRESS-RELEASE,PR Newswire,Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting
BMY,2022-06-01,00:30:02,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Antengene to Present Clinical Results of ATG-008 (Onatasertib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting
BMY,2022-06-01,11:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb: Advancing Deucravacitinib Into Phase 3 Studies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: Advancing Deucravacitinib Into Phase 3 Studies for Systemic Lupus Erythematosus >BMY
BMY,2022-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics and Bristol Myers Squibb Expand Strategic Alliance to,PRESS-RELEASE,Business Wire,Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
BMY,2022-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics and Bristol Myers Squibb Expand Strategic Alliance to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
BMY,2022-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics and Bristol Myers Squibb Expand Strategic Alliance to,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
BMY,2022-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics and Bristol Myers Squibb Expand Strategic Alliance to,PRESS-RELEASE,GlobeNewswire,Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
BMY,2022-06-02,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics and Bristol Myers Squibb Expand Strategic Alliance to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
BMY,2022-06-02,10:59:08,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics and Bristol Myers Squibb Expand Strategic Alliance to,NEWS-FLASH,Dow Jones Newswires,Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
BMY,2022-06-02,11:00:35,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics and Bristol Myers Squibb Expand Strategic Alliance to,NEWS-FLASH,Dow Jones Newswires,Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
BMY,2022-06-02,11:33:50,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics in 2019 teamed with Celgene,FULL-ARTICLE,Dow Jones Newswires,"Immatics, Bristol Myers Squibb Expand Alliance"
BMY,2022-06-02,11:44:26,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,"Bristol Myers Squibb, Immatics expand CAR-T agreement",FULL-ARTICLE,MarketWatch,"MW Bristol Myers Squibb, Immatics expand CAR-T agreement"
BMY,2022-06-02,11:44:26,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,"Bristol Myers Squibb, Immatics Expand CAR-T Agreement",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb, Immatics Expand CAR-T Agreement -- MarketWatch"
BMY,2022-06-02,11:48:50,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics in 2019 teamed with Celgene,FULL-ARTICLE,Dow Jones Newswires,"Immatics, Bristol Myers Squibb Expand Alliance"
BMY,2022-06-02,15:01:00,94637C,Bristol-Myers Squibb Co.,97,0.0,products-services,,Bristol-Myers Squibb Co.: Immunosuppression: In clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19
BMY,2022-06-02,15:01:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,"Bristol-Myers Squibb Co.: However, abatacept was present",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Topline Results -2-
BMY,2022-06-02,15:01:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,"Bristol-Myers Squibb Co.: However, abatacept was present",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2022-06-03,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb To Acquire Turning Point Therapeutics,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb To Acquire Turning Point Therapeutics, A Leading Precision Oncology Company >BMY"
BMY,2022-06-03,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Acquire Turning Point Therapeutics,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company"
BMY,2022-06-03,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.63,acquisitions-mergers,,"Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company"
BMY,2022-06-03,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Acquire Turning Point,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Acquire Turning Point -2-
BMY,2022-06-03,10:59:30,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company"
BMY,2022-06-03,10:59:30,94637C,Bristol-Myers Squibb Co.,100,0.63,acquisitions-mergers,,"Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company"
BMY,2022-06-03,10:59:30,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Acquire -2-
BMY,2022-06-03,11:03:05,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to buy Turning Point Therapeutics in a deal,NEWS-FLASH,MarketWatch,MW Bristol Myers to buy Turning Point Therapeutics in a deal valuing Turning Point at about $3.8 bln
BMY,2022-06-03,11:13:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Turning Point Therapeutics for $4.1 Billion >BMY,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Buy Turning Point Therapeutics for $4.1 Billion >BMY TPTX
BMY,2022-06-03,11:28:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Turning Point Therapeutics for $4.1 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Buy Turning Point Therapeutics for $4.1 Billion
BMY,2022-06-03,11:40:03,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Turning Point Therapeutics for $4.1 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Buy Turning Point Therapeutics for $4.1 Billion
BMY,2022-06-03,14:06:16,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Agreed to be acquired by Bristol Myers Squibb Co. for $4.1 billion,FULL-ARTICLE,Dow Jones Newswires,Turning Point Therapeutics Shares Surge on Bristol Myers Deal >TPTX
BMY,2022-06-03,14:10:24,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion -- Update
BMY,2022-06-03,14:21:17,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Agreed to be acquired by Bristol Myers Squibb Co. for $4.1 billion,FULL-ARTICLE,Dow Jones Newswires,Turning Point Therapeutics Shares Surge on Bristol Myers Deal
BMY,2022-06-03,14:53:42,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Market Perform From Outperform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Market Perform From Outperform by Raymond James
BMY,2022-06-03,15:46:49,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Acquire HBM Portfolio Company Turning Point Therapeutics for USD 4.1 billion,PRESS-RELEASE,Dow Jones Newswires,Bristol Myers Squibb to Acquire HBM Portfolio Company Turning Point Therapeutics for USD 4.1 billion in cash
BMY,2022-06-03,15:46:49,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Acquire HBM Portfolio Company Turning Point Therapeutics for USD 4.1 billion,PRESS-RELEASE,DGAP News,Bristol Myers Squibb to Acquire HBM Portfolio Company Turning Point Therapeutics for USD 4.1 billion in cash
BMY,2022-06-03,17:49:10,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion -- 2nd,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion -- 2nd Update
BMY,2022-06-03,20:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.45,products-services,withdrawn,Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl(R) (luspatercept-aamt),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl(R) (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia
BMY,2022-06-03,20:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.45,products-services,withdrawn,Bristol-Myers Squibb Co.: the company has withdrawn a supplemental biologics license application (sBLA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl(R) (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia
BMY,2022-06-03,20:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.45,products-services,withdrawn,Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl(R) (luspatercept-aamt),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl(R) (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia
BMY,2022-06-03,20:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.45,products-services,withdrawn,Bristol-Myers Squibb Co.: the company has withdrawn a supplemental biologics license application (sBLA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl(R) (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia
BMY,2022-06-03,21:03:22,94637C,Bristol-Myers Squibb Co.,100,-0.45,products-services,withdrawn,Bristol Myers Squibb: Withdraws Supplemental Biologics License Application for Reblozyl,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: Withdraws Supplemental Biologics License Application for Reblozyl for Non-Transfusion Dependent Beta Thalassemia
BMY,2022-06-04,06:10:12,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co. said it would acquire biotechnology company Turning Point Therapeutics Inc. for $4.1 billion,FULL-ARTICLE,Dow Jones Newswires,EXCHANGE  ---  Bristol-Myers Agrees to Buy  Biotech Firm Turning Point  ----  By Jared S. Hopkins and Colin Kellaher
BMY,2022-06-04,06:32:11,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co. said it would acquire biotechnology company Turning Point Therapeutics Inc. for $4.1 billion,FULL-ARTICLE,Wall Street Journal,Bristol-Myers Agrees to Buy Biotech Firm Turning Point -- WSJ
BMY,2022-06-06,08:47:39,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Market Perform From Outperform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Market Perform From Outperform by Raymond James
BMY,2022-06-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Goldman Sachs 43(rd) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Goldman Sachs 43(rd) Annual Global Healthcare Conference
BMY,2022-06-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will take part in a fireside chat at Goldman Sachs' 43(rd) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Goldman Sachs 43(rd) Annual Global Healthcare Conference
BMY,2022-06-07,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
BMY,2022-06-07,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will take part in a fireside chat at Goldman Sachs' 43(rd) Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
BMY,2022-06-07,21:51:03,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Leung Sells 65,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Leung Sells 65,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-06-08,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022"
BMY,2022-06-08,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: To be directly connected to the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022"
BMY,2022-06-08,10:59:42,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022"
BMY,2022-06-08,10:59:42,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: To be directly connected to the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022"
BMY,2022-06-14,21:59:53,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 30,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Caforio Sells 30,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-06-15,19:30:23,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp Leung Registers 65,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP Leung Registers 65,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-06-15,19:58:13,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Company Management presents at Goldman Sachs 43rd Annual Global Healthcare Conference,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Company Management presents at Goldman Sachs 43rd Annual Global Healthcare Conference >BMY
BMY,2022-06-15,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2022-06-15,20:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2022-06-20,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
BMY,2022-06-20,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
BMY,2022-06-20,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
BMY,2022-06-20,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
BMY,2022-06-20,19:37:13,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Eliquis Now Available in Canada,PRESS-RELEASE,Canadian News Wire,First Generic Alternative to Eliquis Now Available in Canada
BMY,2022-06-22,17:44:33,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Chmn Caforio Registers 30,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"Chmn Caforio Registers 30,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-06-24,16:52:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
BMY,2022-06-24,16:52:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
BMY,2022-06-24,16:52:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration (FDA) approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
BMY,2022-06-24,16:52:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
BMY,2022-06-24,16:52:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
BMY,2022-06-24,16:52:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration (FDA) approved Zeposia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
BMY,2022-06-24,23:05:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's CAR,NEWS-FLASH,Dow Jones Newswires,U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi(R) For Relapsed Or Refractory Large B-cell Lymphoma After One Prior Therapy >BMY
BMY,2022-06-24,23:05:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's CAR,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi(R) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2022-06-24,23:05:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi(R) (lisocabtagene maraleucel),PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi(R) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2022-06-24,23:05:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's CAR,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's CAR T -2-
BMY,2022-06-24,23:05:00,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: All enrolled patients,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's CAR T -2-
BMY,2022-06-24,23:05:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's CAR T -2-
BMY,2022-06-24,23:05:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's CAR,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's CAR T -3-
BMY,2022-06-24,23:41:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's CAR,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi(R) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2022-06-24,23:41:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi(R) (lisocabtagene maraleucel),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi(R) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2022-06-24,23:41:22,94637C,Bristol-Myers Squibb Co.,92,0.4,products-services,start,Bristol-Myers Squibb Co.: All enrolled patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers -2-
BMY,2022-06-24,23:41:22,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers -2-
BMY,2022-06-28,15:25:53,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO (nivolumab) as,PRESS-RELEASE,Canadian News Wire,Health Canada Approves OPDIVO (nivolumab) as Monotherapy for the Adjuvant treatment of Adults with Urothelial Carcinoma (UC) at High Risk of Recurrence after Undergoing Radical Resection of UC
BMY,2022-06-28,15:25:54,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO(R) (nivolumab) as,PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Approves OPDIVO (nivolumab) as Monotherapy for the Adjuvant treatment of Adults with Urothelial Carcinoma (UC) at High Risk of Recurrence after Undergoing Radical Resection of UC
BMY,2022-06-28,15:26:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb: Health Canada Approves OPDIVO as Monotherapy for Adjuvant Treatment of Adults With Urothelial Carcinoma,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: Health Canada Approves OPDIVO as Monotherapy for Adjuvant Treatment of Adults With Urothelial Carcinoma at High Risk of Recurrence After Radical Resection
BMY,2022-07-05,20:28:51,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 4,570 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Hirawat Acquires 4,570 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-07-05,20:31:11,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Weese Acquires 1,203 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Weese Acquires 1,203 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-07-06,17:29:43,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,Vp Santiago Registers 700 Of Bristol-Myers Squibb Co >BMY,RNS-SEC144,Dow Jones Newswires,VP Santiago Registers 700 Of Bristol-Myers Squibb Co >BMY
BMY,2022-07-12,12:15:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Celgene (which was acquired by Bristol Myers Squibb in 2019,PRESS-RELEASE,Business Wire,"Sampled Appoints Sarah Hersey, VP, Head of Translational Sciences & Diagnostics at Bristol Myers Squibb, as its First Independent Director"
BMY,2022-07-21,06:00:26,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Oxford Biomedica PLC Expanded Agreement with BMS,PRESS-RELEASE,LSE Regulatory News Service (RNS),Oxford Biomedica PLC Expanded Agreement with BMS's Juno in CAR-T
BMY,2022-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol Myers Squibb Teams Up with Jack and Jill of,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Teams Up with Jack and Jill of America Inc. to Expand Tomorrow's Innovators Program to Increase Black Representation in the Healthcare Industry
BMY,2022-07-21,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb Teams Up with Jack and Jill of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Teams Up with Jack and Jill of America Inc. to Expand Tomorrow's Innovators Program to Increase Black Representation in the Healthcare Industry
BMY,2022-07-22,01:32:13,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lenalidomide Is Conditionally Approved by FDA,NEWS-FLASH,Dow Jones Newswires,"InnoCare: Tafasitamab in Combination With Lenalidomide Is Conditionally Approved by FDA, EMA for Treatment of Relapsed or Refractory DLBCL Patients Not Eligible for ASCT >09969.HK"
BMY,2022-07-22,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Recommendation based on results from the Phase 2/3 RELATIVITY-047 trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma
BMY,2022-07-22,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2022-07-22,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -7-
BMY,2022-07-22,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Recommendation based on results from the Phase 2/3 RELATIVITY-047 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma
BMY,2022-07-22,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-07-22,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -7-
BMY,2022-07-25,07:17:04,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2022 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2022 (BMY)"
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q Adj EPS $1.93,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Adj EPS $1.93 >BMY
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q EPS 66c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q EPS 66c >BMY
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q Net $1.4B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Net $1.4B >BMY
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 2Q Rev $11.9B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Rev $11.9B >BMY
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports Second Quarter Revenues of $11.9 Billion, an Increase of 2% YoY",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Second Quarter Earnings Per Share of $0.66,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts 2022 GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Reaffirms Non-GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2022,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.32,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 16% to $3.6 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.24,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 6% to $2.3 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD decreased from $793 million,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol-Myers Squibb Co.: For purposes of comparability, the non-GAAP financial results for the second quarter of 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.04,revenues,,Bristol-Myers Squibb Co.: International revenues were $858 million compared to $834 million,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Eliquis revenues grew 16%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.46,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.2 billion compared to $1.7 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 8%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 2%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.38,revenues,down,Bristol-Myers Squibb Co.: Abraxane revenues declined 19%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Administration (FDA) approved Opdivo (injection for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Fda approved Breyanzi (lisocabtagene maraleucel,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,withdrawn,Bristol-Myers Squibb Co.: The company withdrew a (luspatercept-aamt) supplemental biologics license application,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Two-year results from the Phase 3,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Which Bristol Myers Squibb will acquire Turning Point pursuant to,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: the company, in collaboration with Disability Solutions, announced the launch of the Disability",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Sales,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusting GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS(3) $2.92-$3.22,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: July guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today at 8 a.m. EDT,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: the company's Annual Report on Form 10-K for the year ended December 31, 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -7-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -7-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE SIX MONTHS ENDED JUNE 30, 2022",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -7-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,96,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.67 $ 0.47 $,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -8-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports Second Quarter Revenues of $11.9 Billion, an Increase of 2% YoY",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Second Quarter Earnings Per Share of $0.66,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts 2022 GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Reaffirms Non-GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.32,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 16% to $3.6 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.24,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 6% to $2.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD decreased from $793 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol-Myers Squibb Co.: For purposes of comparability, the non-GAAP financial results for the second quarter of 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.04,revenues,,Bristol-Myers Squibb Co.: International revenues were $858 million compared to $834 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Eliquis revenues grew 16%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.46,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.2 billion compared to $1.7 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 8%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 2%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.38,revenues,down,Bristol-Myers Squibb Co.: Abraxane revenues declined 19%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Administration (FDA) approved Opdivo (injection for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Fda approved Breyanzi (lisocabtagene maraleucel,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,withdrawn,Bristol-Myers Squibb Co.: The company withdrew a (luspatercept-aamt) supplemental biologics license application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Two-year results from the Phase 3,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Which Bristol Myers Squibb will acquire Turning Point pursuant to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: the company, in collaboration with Disability Solutions, announced the launch of the Disability",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Sales,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusting GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS(3) $2.92-$3.22,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: July guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today at 8 a.m. EDT,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: the company's Annual Report on Form 10-K for the year ended December 31, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE SIX MONTHS ENDED JUNE 30, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.67 $ 0.47 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2022-07-27,11:00:44,94637C,Bristol-Myers Squibb Co.,100,0.54,earnings,up,Bristol-Myers Squibb Q2 EPS 66 cents vs. 47 cents a year ago,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb Q2 EPS 66 cents vs. 47 cents a year ago
BMY,2022-07-27,11:00:59,94637C,Bristol-Myers Squibb Co.,100,0.46,earnings,above-expectations,Bristol-Myers Squibb Q2 adj. EPs $1.93; FactSet consensus $1.77,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb Q2 adj. EPs $1.93; FactSet consensus $1.77
BMY,2022-07-27,11:01:27,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Q2 revenue $11.9 bln, up 2% from a year ago",NEWS-FLASH,MarketWatch,"MW Bristol-Myers Squibb Q2 revenue $11.9 bln, up 2% from a year ago; FactSet consensus $11.4 bln"
BMY,2022-07-27,11:01:53,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Sees 2022 Sales $46B >BMY,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2022 Sales $46B >BMY
BMY,2022-07-27,11:02:33,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,unchanged,Bristol-Myers Squibb Backs 2022 View of Adj EPS $7.44,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Backs 2022 View of Adj EPS $7.44-Adj EPS $7.74 >BMY
BMY,2022-07-27,11:04:16,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb lowers full-year GAAP EPS guidance to $2.71 to $3.01,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb lowers full-year GAAP EPS guidance to $2.71 to $3.01 vs. prior $2.92 to $3.22
BMY,2022-07-27,11:04:35,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb still sees full-year adj. EPS of $7.44 to $7.74,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb still sees full-year adj. EPS of $7.44 to $7.74
BMY,2022-07-27,11:29:32,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb Beats Earnings Estimates,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Beats Earnings Estimates, but Shares Fall -- Barrons.com"
BMY,2022-07-27,11:29:32,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb announced second quarter earnings early Wednesday,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Beats Earnings Estimates, but Shares Fall -- Barrons.com"
BMY,2022-07-27,11:29:32,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Ticker: BMY) revenue were $11.9 billion for the quarter,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Beats Earnings Estimates, but Shares Fall -- Barrons.com"
BMY,2022-07-27,11:33:28,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb says Eliquis revenue jumped 16% in the second quarter,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb says Eliquis revenue jumped 16% in the second quarter
BMY,2022-07-27,11:33:28,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb Co.: the company lowered guidance,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb says Eliquis revenue jumped 16% in the second quarter
BMY,2022-07-27,11:33:28,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb Says Eliquis Revenue Jumped 16% In The Second Quarter,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says Eliquis Revenue Jumped 16% In The Second Quarter -- MarketWatch
BMY,2022-07-27,11:33:28,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb Co.: the company lowered guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says Eliquis Revenue Jumped 16% In The Second Quarter -- MarketWatch
BMY,2022-07-27,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb Beats Earnings Estimates,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Beats Earnings Estimates, but Shares Fall"
BMY,2022-07-27,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb announced second quarter earnings early Wednesday,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Beats Earnings Estimates, but Shares Fall"
BMY,2022-07-27,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Ticker: BMY) revenue were $11.9 billion for the quarter,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Beats Earnings Estimates, but Shares Fall"
BMY,2022-07-27,15:21:53,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Company CEO Giovanni Caforio on Q2 2022 Results -- Earnings Call,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Company CEO Giovanni Caforio on Q2 2022 Results -- Earnings Call Transcript >BMY
BMY,2022-07-28,10:15:34,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities
BMY,2022-07-28,10:15:34,94637C,Bristol-Myers Squibb Co.,100,0.3,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $83.00/Share From $82.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $83.00/Share From $82.00 by Atlantic Equities
BMY,2022-07-28,13:28:55,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by UBS
BMY,2022-07-28,13:28:55,94637C,Bristol-Myers Squibb Co.,100,0.42,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $75.00/Share From $73.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $75.00/Share From $73.00 by UBS
BMY,2022-07-28,14:25:15,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2022-07-28,14:25:15,94637C,Bristol-Myers Squibb Co.,100,-0.46,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $61.00/Share From $63.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $61.00/Share From $63.00 by Morgan Stanley
BMY,2022-07-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -4-
BMY,2022-07-29,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -5-
BMY,2022-07-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -6-
BMY,2022-07-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -4-
BMY,2022-07-29,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -5-
BMY,2022-07-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -6-
BMY,2022-08-10,10:45:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Results of a pre-specified interim analysis,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
BMY,2022-08-10,10:45:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
BMY,2022-08-10,10:49:02,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Results of a pre-specified interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
BMY,2022-08-10,10:49:02,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
BMY,2022-08-10,11:00:06,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Gentibio Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases
BMY,2022-08-17,12:31:00,94637C,Bristol-Myers Squibb Co.,100,0.5,acquisitions-mergers,completed,Bristol Myers Squibb completed the acquisition of Turning Point through the merger of its wholly owned subsidiary,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio"
BMY,2022-08-17,12:31:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers Squibb's previously announced tender offer for all outstanding shares of common stock,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio"
BMY,2022-08-17,12:31:00,94637C,Bristol-Myers Squibb Co.,100,0.5,acquisitions-mergers,completed,Bristol Myers Squibb completed the acquisition of Turning Point through the merger of its wholly owned subsidiary,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio"
BMY,2022-08-17,12:31:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers Squibb's previously announced tender offer for all outstanding shares of common stock,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio"
BMY,2022-08-17,12:31:10,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio"
BMY,2022-08-23,12:30:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO (nivolumab) with,PRESS-RELEASE,Canadian News Wire,Health Canada Approves OPDIVO (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Adult Patients with Resectable Non-Small Cell Lung Cancer
BMY,2022-08-23,12:30:06,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bms) announced Health Canada's approval of OPDIVO(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Approves OPDIVO (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Adult Patients with Resectable Non-Small Cell Lung Cancer
BMY,2022-08-23,12:30:35,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO (nivolumab) With,NEWS-FLASH,Dow Jones Newswires,Health Canada Approves OPDIVO (nivolumab) With Chemotherapy as Neoadjuvant Treatment for Adult Patients With Resectable Non-Small Cell Lung Cancer
BMY,2022-08-23,13:00:36,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bio Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,A-Alpha Bio Announces Collaboration with Bristol Myers Squibb to Discover Molecular Glue Targets for Protein Degradation
BMY,2022-08-25,13:00:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: we have entered into a long-term collaboration with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,PathAI Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
BMY,2022-08-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Citi's 17(th) Annual BioPharma Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Citi's 17(th) Annual BioPharma Conference
BMY,2022-08-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will take part in a fireside chat at Citi's 17(th) Annual BioPharma Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Citi's 17(th) Annual BioPharma Conference
BMY,2022-08-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Citi's 17th Annual BioPharma Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Citi's 17th Annual BioPharma Conference
BMY,2022-08-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will take part in a fireside chat at Citi's 17(th) Annual BioPharma Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Citi's 17th Annual BioPharma Conference
BMY,2022-09-05,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Long-term data continue to reinforce benefits of Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
BMY,2022-09-05,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Safety, efficacy, pharmacokinetic and pharmacodynamic data from the Phase 1/2 study",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
BMY,2022-09-05,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Phase 3 study of cabozantinib,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
BMY,2022-09-05,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO Congress -6-
BMY,2022-09-05,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO Congress -8-
BMY,2022-09-05,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Long-term data continue to reinforce benefits of Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
BMY,2022-09-05,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Safety, efficacy, pharmacokinetic and pharmacodynamic data from the Phase 1/2 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
BMY,2022-09-05,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Phase 3 study of cabozantinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
BMY,2022-09-05,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at -6-
BMY,2022-09-05,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at -8-
BMY,2022-09-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
BMY,2022-09-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will take part in a fireside chat at the Morgan Stanley 20(th) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
BMY,2022-09-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
BMY,2022-09-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will take part in a fireside chat at the Morgan Stanley 20(th) Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
BMY,2022-09-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022"
BMY,2022-09-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: To be directly connected to the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022"
BMY,2022-09-07,11:17:13,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022"
BMY,2022-09-07,11:17:13,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: To be directly connected to the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022"
BMY,2022-09-07,11:45:35,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Cipla receives USFDA approval for generic version of Revlimid(R) (Lenalidomide,PRESS-RELEASE,PR Newswire,Cipla receives USFDA approval for generic version of Revlimid(R) (Lenalidomide capsules)
BMY,2022-09-07,11:45:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Cipla receives USFDA approval for generic version of Revlimid(R) (Lenalidomide,PRESS-RELEASE,Dow Jones Newswires,Press Release: Cipla receives USFDA approval for generic version of Revlimid(R) (Lenalidomide capsules)
BMY,2022-09-08,23:39:00,94637C,Bristol-Myers Squibb Co.,100,0.41,products-services,start,Innocare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide,PRESS-RELEASE,Business Wire,InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
BMY,2022-09-08,23:39:00,94637C,Bristol-Myers Squibb Co.,100,0.41,products-services,start,Innocare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide,PRESS-RELEASE,Business Wire,InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
BMY,2022-09-08,23:39:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lenalidomide has been approved by the Health Commission,PRESS-RELEASE,Business Wire,InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
BMY,2022-09-08,23:39:00,94637C,Bristol-Myers Squibb Co.,100,0.41,products-services,start,Innocare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide,PRESS-RELEASE,Dow Jones Newswires,Press Release: InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
BMY,2022-09-08,23:39:00,94637C,Bristol-Myers Squibb Co.,100,0.41,products-services,start,Innocare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide,PRESS-RELEASE,Dow Jones Newswires,Press Release: InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
BMY,2022-09-08,23:39:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lenalidomide has been approved by the Health Commission,PRESS-RELEASE,Dow Jones Newswires,Press Release: InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
BMY,2022-09-10,06:30:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration approved Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces New -2-
BMY,2022-09-10,06:30:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration approved Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces New Sotyktu(TM) -2-
BMY,2022-09-12,08:42:55,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities
BMY,2022-09-12,08:42:55,94637C,Bristol-Myers Squibb Co.,100,0.56,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $87.00/Share From $83.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $87.00/Share From $83.00 by Atlantic Equities
BMY,2022-09-12,14:36:11,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Wins FDA Nod for Otezla,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Wins FDA Nod for Otezla Competitor
BMY,2022-09-12,12:00:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol Myers Squibb, presented updated Phase 1 results with BMS-986249",PRESS-RELEASE,GlobeNewswire,CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody(R) Therapeutic BMS-986249
BMY,2022-09-12,12:00:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bms-986288, partnered with Bristol Myers Squibb, as well as",PRESS-RELEASE,GlobeNewswire,CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody(R) Therapeutic BMS-986249
BMY,2022-09-12,12:00:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol Myers Squibb, presented updated Phase 1 results with BMS-986249",PRESS-RELEASE,Dow Jones Newswires,Press Release: CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody(R) Therapeutic BMS-986249
BMY,2022-09-12,12:00:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bms-986288, partnered with Bristol Myers Squibb, as well as",PRESS-RELEASE,Dow Jones Newswires,Press Release: CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody(R) Therapeutic BMS-986249
BMY,2022-09-12,12:29:06,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital
BMY,2022-09-12,12:29:06,94637C,Bristol-Myers Squibb Co.,100,0.4,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $94.00/Share From $92.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $94.00/Share From $92.00 by BMO Capital
BMY,2022-09-12,14:20:50,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Wins FDA Nod for Otezla,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Wins FDA Nod for Otezla Competitor
BMY,2022-09-12,14:21:11,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Wins FDA Nod for Otezla,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Wins FDA Nod for Otezla Competitor
BMY,2022-09-12,14:35:50,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Wins FDA Nod for Otezla,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Wins FDA Nod for Otezla Competitor
BMY,2022-09-14,08:53:26,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Hold From Buy by Berenberg,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Hold From Buy by Berenberg
BMY,2022-09-14,08:53:26,94637C,Bristol-Myers Squibb Co.,100,-0.7,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $76.00/Share From $82.00 by Berenberg,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $76.00/Share From $82.00 by Berenberg
BMY,2022-09-14,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2022-09-14,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2022-09-14,20:33:24,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Cfo Elkins Registers 133,951 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"CFO Elkins Registers 133,951 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-15,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2022-09-15,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -5-
BMY,2022-09-15,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Adjuvant Treatment -3-
BMY,2022-09-15,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Adjuvant Treatment -5-
BMY,2022-09-15,11:15:27,94637C,Bristol-Myers Squibb Co.,94,0.0,products-services,,Bristol Myers Squibb Co. said its Phase 3 trial of Opdivo as an adjuvant treatment for patients,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Trial for Certain Type of Skin Cancer Meets Primary Endpoint
BMY,2022-09-15,11:30:27,94637C,Bristol-Myers Squibb Co.,94,0.0,products-services,,Bristol Myers Squibb Co. said its Phase 3 trial of Opdivo as an adjuvant treatment for patients,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Trial for Certain Type of Skin Cancer Meets Primary Endpoint
BMY,2022-09-15,18:56:32,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp Powell Registers 25,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP Powell Registers 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-15,23:31:09,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Powell Sells 25,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Powell Sells 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-15,23:32:50,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Cfo Elkins Sells 133,951 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Elkins Sells 133,951 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-16,20:15:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%"
BMY,2022-09-16,20:15:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-09-16,20:15:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%"
BMY,2022-09-16,20:15:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2022-09-16,20:24:50,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb: Receives European Commission Approval for LAG-3-Blocking Antibody,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag for the Treatment of Unresectable or Metastatic Melanoma With Tumor Cell PD-L1 Expression < 1%"
BMY,2022-09-16,20:39:41,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol Myers Squibb Co. said Friday that the European Commission approved the fixed-dose,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Skin Cancer Treatment Opdualag Gets Approval from European Commission
BMY,2022-09-16,20:54:41,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol Myers Squibb Co. said Friday that the European Commission approved the fixed-dose,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Skin Cancer Treatment Opdualag Gets Approval from European Commission
BMY,2022-09-16,21:13:39,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 50,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Caforio Sells 50,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-16,21:14:33,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Chmn Caforio Registers 50,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"Chmn Caforio Registers 50,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-20,20:56:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"In Collaboration with Bristol Myers Squibb, to",PRESS-RELEASE,PR Newswire,"Lyfebulb Seeks Applicants for the Global 2022 Innovation Challenge, in Collaboration with Bristol Myers Squibb, to Address Unmet Needs in Inflammatory Bowel Disease"
BMY,2022-09-21,15:38:30,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Chmn Caforio Registers 25,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"Chmn Caforio Registers 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-22,21:14:18,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co",FULL-ARTICLE,Dow Jones Newswires,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-29,10:30:03,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: The first Fully Digital, Clinical Trial Solution",PRESS-RELEASE,PR Newswire,Bristol Myers Squibb and ConcertAI Advance Novel Oncology Accelerated Digital Clinical Trial Solution
BMY,2022-09-29,10:32:31,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: The first Fully Digital, Clinical Trial Solution",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and ConcertAI Advance Novel Oncology Accelerated Digital Clinical Trial Solution
BMY,2022-10-04,11:00:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for,PRESS-RELEASE,GlobeNewswire,Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus' Proprietary Safety Switch System
BMY,2022-10-04,11:00:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus' Proprietary Safety Switch System
BMY,2022-10-04,11:03:10,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Autolus Therapeutics Announces Collaboration With Bristol Myers Squibb for,NEWS-FLASH,Dow Jones Newswires,Autolus Therapeutics Announces Collaboration With Bristol Myers Squibb for Use of Autolus' Proprietary Safety Switch System
BMY,2022-10-04,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial
BMY,2022-10-04,12:00:25,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Exelixis Expands Clinical Trial Collaboration and Supply Agreement With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Exelixis Expands Clinical Trial Collaboration and Supply Agreement With Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination With XL092 in Phase 1b STELLAR-002 Trial
BMY,2022-10-04,12:00:30,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial
BMY,2022-10-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol Myers Squibb Announces Change to Earnings Conference Call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022"
BMY,2022-10-07,10:59:19,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol Myers Squibb Announces Change to Earnings Conference Call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022"
BMY,2022-10-10,11:55:50,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Neutral From Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Neutral From Buy by Guggenheim
BMY,2022-10-10,12:00:10,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Nmpa Approval of Relmacabtagene Autoleucel Injection,PRESS-RELEASE,PR Newswire,JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
BMY,2022-10-10,12:01:32,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Nmpa Approval of Relmacabtagene Autoleucel Injection,PRESS-RELEASE,Dow Jones Newswires,Press Release: JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
BMY,2022-10-12,10:55:30,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2022-10-12,10:55:30,94637C,Bristol-Myers Squibb Co.,100,-0.54,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $66.00/Share From $69.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $66.00/Share From $69.00 by Barclays
BMY,2022-10-19,20:30:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data from CheckMate -3-
BMY,2022-10-19,20:30:00,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data from CheckMate -5-
BMY,2022-10-19,20:30:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data -4-
BMY,2022-10-19,20:30:01,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data -5-
BMY,2022-10-21,11:22:29,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,Bristol Myers' roughly $13 billion acquisition of MyoKardia Inc.,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: FDA to Review Camzyos to Reduce Septal-Reduction Therapy Need
BMY,2022-10-21,11:37:29,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,Bristol Myers' roughly $13 billion acquisition of MyoKardia Inc.,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: FDA to Review Camzyos to Reduce Septal-Reduction Therapy Need
BMY,2022-10-25,07:15:13,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2022 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2022 (BMY)"
BMY,2022-10-25,23:31:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q Adj EPS $1.99,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Adj EPS $1.99 >BMY
BMY,2022-10-25,23:31:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 3Q Rev $11.2B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Rev $11.2B >BMY
BMY,2022-10-25,23:31:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q Net $1.6B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Net $1.6B >BMY
BMY,2022-10-25,23:31:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q EPS 75c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q EPS 75c >BMY
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol-Myers Squibb Co.: Reports Third Quarter Revenues of $11.2 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Third Quarter Earnings Per Share of $0.75,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol-Myers Squibb Co.: Completes Acquisition of Turning Point Therapeutics,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts 2022 GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Reaffirms Non-GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2022,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,-0.42,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 24% to $3.3 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.32,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 19% to $2.4 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD decreased from $271 million,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol-Myers Squibb Co.: For purposes of comparability, the non-GAAP financial results for the third quarter of 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenue $11,218 $11,624",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.14,revenues,,Bristol-Myers Squibb Co.: Eliquis revenues grew 10%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.48,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.7 billion compared to $1.3 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 7%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,"Bristol-Myers Squibb Co.: When adjusted for foreign exchange impacts, Opdivo's international revenues increased 8%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,92,-0.46,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 6% to $2.2 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: Welfare approved Sotyktu for the treatment of patients with plaque psoriasis,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusting GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Sales $46.0 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS(3) $2.71-$3.01,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call tomorrow, Wednesday, October 26, 2022 at 8 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol-Myers Squibb Co.: Reports Third Quarter Revenues of $11.2 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Third Quarter Earnings Per Share of $0.75,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol-Myers Squibb Co.: Completes Acquisition of Turning Point Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts 2022 GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Reaffirms Non-GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,-0.42,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 24% to $3.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.32,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 19% to $2.4 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD decreased from $271 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol-Myers Squibb Co.: For purposes of comparability, the non-GAAP financial results for the third quarter of 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenue $11,218 $11,624",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.14,revenues,,Bristol-Myers Squibb Co.: Eliquis revenues grew 10%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.48,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.7 billion compared to $1.3 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 7%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,"Bristol-Myers Squibb Co.: When adjusted for foreign exchange impacts, Opdivo's international revenues increased 8%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2022",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -6-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -6-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,92,-0.46,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 6% to $2.2 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $34,753 $34,400",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -7-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,96,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.75 $ 0.70 $,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -7-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: Welfare approved Sotyktu for the treatment of patients with plaque psoriasis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusting GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Sales $46.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS(3) $2.71-$3.01,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call tomorrow, Wednesday, October 26, 2022 at 8 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -6-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -6-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $34,753 $34,400",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -7-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,96,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.75 $ 0.70 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -7-
BMY,2022-10-25,23:40:26,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2022 EPS $2.54,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2022 EPS $2.54-EPS $2.84 >BMY
BMY,2022-10-26,02:05:54,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers's Third-Quarter Profit Rose,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers's Third-Quarter Profit Rose, Revenue Declined"
BMY,2022-10-26,02:20:54,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers's Third-Quarter Profit Rose,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers's Third-Quarter Profit Rose, Revenue Declined"
BMY,2022-10-26,02:40:04,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers's Third-Quarter Profit Rose Slightly,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers's Third-Quarter Profit Rose Slightly
BMY,2022-10-26,06:16:06,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers: Retrospective Analyses of Phase 3 Study of Covid,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: Retrospective Analyses of Phase 3 Study of Covid Vaccine Responses in Takers of MS Drug Zeposia Show Over 90% of Participants Had Immune Response >BMY
BMY,2022-10-26,09:01:57,94637C,Bristol-Myers Squibb Co.,100,-0.68,revenues,down,Bristol Myers Sales Fall on,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Sales Fall on Strong Dollar. But Earnings Beat Expectations. -- Barrons.com
BMY,2022-10-26,09:01:57,94637C,Bristol-Myers Squibb Co.,100,0.46,earnings,above-expectations,"Bristol-Myers Squibb Co.: The company reported adjusted earnings per share of $1.99, beating analyst estimates of $1.83",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Sales Fall on Strong Dollar. But Earnings Beat Expectations. -- Barrons.com
BMY,2022-10-26,12:22:17,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: the company's $13.1B acquisition of MyoKardia in 2020,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says New Heart Drug Camzyos Off to Strong Start -- Market Talk
BMY,2022-10-26,12:22:17,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: the company's $13.1B acquisition of MyoKardia in 2020,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says New Heart Drug Camzyos Off to Strong Start -- Market Talk
BMY,2022-10-26,12:24:34,94637C,Bristol-Myers Squibb Co.,97,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: the company's $13.1B acquisition of MyoKardia in 2020,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says Inflation is Manageable -- Market Talk
BMY,2022-10-26,12:28:28,94637C,Bristol-Myers Squibb Co.,100,-0.46,revenues,down,Revlimid Sales Fall 28%,FULL-ARTICLE,Dow Jones Newswires,"As Generics Arrive, Bristol's Revlimid Sales Fall 28% -- Market Talk"
BMY,2022-10-26,12:28:28,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: the company maintained its annual sales guidance,FULL-ARTICLE,Dow Jones Newswires,"As Generics Arrive, Bristol's Revlimid Sales Fall 28% -- Market Talk"
BMY,2022-10-26,12:28:28,94637C,Bristol-Myers Squibb Co.,100,-0.46,revenues,down,Revlimid Sales Fall 28%,FULL-ARTICLE,Dow Jones Newswires,"As Generics Arrive, Bristol's Revlimid Sales Fall 28% -- Market Talk"
BMY,2022-10-26,12:28:28,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: the company maintained its annual sales guidance,FULL-ARTICLE,Dow Jones Newswires,"As Generics Arrive, Bristol's Revlimid Sales Fall 28% -- Market Talk"
BMY,2022-10-26,12:28:28,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: the company's $13.1B acquisition of MyoKardia in 2020,FULL-ARTICLE,Dow Jones Newswires,"As Generics Arrive, Bristol's Revlimid Sales Fall 28% -- Market Talk"
BMY,2022-10-26,20:59:29,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Myers Squibb 3Q Results Better Than Expected,FULL-ARTICLE,Dow Jones Newswires,Trending: Britsol Myers Squibb 3Q Results Better Than Expected
BMY,2022-10-26,20:59:29,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: The company reported third-quarter financial results after the bell Tuesday,FULL-ARTICLE,Dow Jones Newswires,Trending: Britsol Myers Squibb 3Q Results Better Than Expected
BMY,2022-10-26,20:59:29,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: The company reported third-quarter earnings per share of 75 cents,FULL-ARTICLE,Dow Jones Newswires,Trending: Britsol Myers Squibb 3Q Results Better Than Expected
BMY,2022-10-26,20:59:41,94637C,Bristol-Myers Squibb Co.,91,0.64,earnings,up,Bristol-Myers Squibb's net profit rose,FULL-ARTICLE,Dow Jones Newswires,Health Care Up After Bristol Myers Earnings -- Health Care Roundup
BMY,2022-10-26,21:14:30,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Myers Squibb 3Q Results Better Than Expected,FULL-ARTICLE,Dow Jones Newswires,Trending: Britsol Myers Squibb 3Q Results Better Than Expected
BMY,2022-10-26,21:14:30,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: The company reported third-quarter financial results after the bell Tuesday,FULL-ARTICLE,Dow Jones Newswires,Trending: Britsol Myers Squibb 3Q Results Better Than Expected
BMY,2022-10-26,21:14:30,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: The company reported third-quarter earnings per share of 75 cents,FULL-ARTICLE,Dow Jones Newswires,Trending: Britsol Myers Squibb 3Q Results Better Than Expected
BMY,2022-10-26,21:14:41,94637C,Bristol-Myers Squibb Co.,91,0.64,earnings,up,Bristol-Myers Squibb's net profit rose,FULL-ARTICLE,Dow Jones Newswires,Health Care Up After Bristol Myers Earnings -- Health Care Roundup
BMY,2022-10-27,08:57:18,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities
BMY,2022-10-27,08:57:18,94637C,Bristol-Myers Squibb Co.,100,-0.4,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $85.00/Share From $87.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $85.00/Share From $87.00 by Atlantic Equities
BMY,2022-10-27,11:54:18,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2022-10-27,11:54:18,94637C,Bristol-Myers Squibb Co.,100,-0.32,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $60.00/Share From $61.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $60.00/Share From $61.00 by Morgan Stanley
BMY,2022-10-27,12:30:10,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals,PRESS-RELEASE,PR Newswire,Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
BMY,2022-10-27,12:30:10,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: The Phase I FIH clinical trial,PRESS-RELEASE,PR Newswire,Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
BMY,2022-10-27,12:30:10,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
BMY,2022-10-27,12:30:10,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: The Phase I FIH clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
BMY,2022-10-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial
BMY,2022-10-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial
BMY,2022-11-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol Myers Squibb-Pfizer Alliance, on",PRESS-RELEASE,Business Wire,Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022
BMY,2022-11-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"In 2007, Pfizer and Bristol Myers Squibb entered into a worldwide collaboration",PRESS-RELEASE,Business Wire,Data Reinforcing Impact of Bristol Myers Squibb -4-
BMY,2022-11-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol Myers Squibb-Pfizer Alliance, on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022
BMY,2022-11-03,11:00:03,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Kura Oncology Announces Financing Transactions with Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,"Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million"
BMY,2022-11-03,11:00:03,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Kura Oncology Announces Financing Transactions with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million"
BMY,2022-11-03,11:19:42,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Kura Oncology Announces Financing Transactions With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,"Kura Oncology Announces Financing Transactions With Bristol Myers Squibb and Hercules Cap, Providing Access to Up to $150M"
BMY,2022-11-08,21:03:46,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp Vessey Registers 45,910 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP Vessey Registers 45,910 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-11-09,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference
BMY,2022-11-09,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference
BMY,2022-11-10,01:43:44,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 6,694 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Acquires 6,694 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-11-10,13:16:34,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities
BMY,2022-11-10,13:16:34,94637C,Bristol-Myers Squibb Co.,100,0.48,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $88.00/Share From $85.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $88.00/Share From $85.00 by Atlantic Equities
BMY,2022-11-10,14:00:03,94637C,Bristol-Myers Squibb Co.,95,0.57,products-services,granted,"Mavacamten), approved by the U.S. Food and Drug Administration (FDA) for the treatment",PRESS-RELEASE,Business Wire,PicnicHealth Announces Engagement with Bristol Myers Squibb to Leverage Real-World Evidence to Study Symptomatic Obstructive Hypertrophic Cardiomyopathy Patients
BMY,2022-11-10,14:03:44,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Ikena Oncology Program in Collaboration With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Ikena Oncology Program in Collaboration With Bristol Myers Squibb and Eligible for Opt-In Through Early 2024 >IKNA
BMY,2022-11-10,19:03:31,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp Powell Registers 16,250 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP Powell Registers 16,250 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-11-14,23:58:49,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Powell Sells 16,250 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Powell Sells 16,250 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-11-18,10:06:17,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Initiated at Neutral by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Neutral by Credit Suisse
BMY,2022-11-18,10:06:17,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $78.00/Share by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $78.00/Share by Credit Suisse
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: First results from a Phase 1/2 study evaluating BMS-986158,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Five-Year Results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: Phase 2 Study of,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight -2-
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.0,earnings,,Bristol-Myers Squibb Co.: Results From the First,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight -2-
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight -3-
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight -4-
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight -6-
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Onureg(R) (azacitidine tablets) is approved in the U.S.,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight -7-
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: First results from a Phase 1/2 study evaluating BMS-986158,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Five-Year Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,"Bristol-Myers Squibb Co.: Cellular Monday, Phase 2 Study of",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH -2-
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,earnings,,Bristol-Myers Squibb Co.: Results From the First,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH -2-
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH -3-
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH -4-
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH -6-
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Onureg(R) (azacitidine tablets) is approved in the U.S.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH -7-
BMY,2022-11-27,23:00:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients
BMY,2022-11-29,13:00:15,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Envisagenics Announces Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,Envisagenics Announces Research Collaboration with Bristol Myers Squibb
BMY,2022-11-29,13:00:15,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Envisagenics Announces Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Envisagenics Announces Research Collaboration with Bristol Myers Squibb
BMY,2022-12-06,23:45:11,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 4,294 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Acquires 4,294 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-12-06,23:45:36,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 4,294 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Elkins Acquires 4,294 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-12-07,00:33:27,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Boerner Acquires 1,288 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Boerner Acquires 1,288 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-12-08,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Announces Dividend Increase,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Dividend Increase >BMY
BMY,2022-12-08,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Co.: This quarterly dividend represents a 5.6% increase over last year's quarterly dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2022-12-08,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2022-12-08,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on February 1, 2023 to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2022-12-08,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Co.: This quarterly dividend represents a 5.6% increase over last year's quarterly dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2022-12-08,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2022-12-08,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on February 1, 2023 to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2022-12-08,21:16:50,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol-Myers Squibb Raises Dividend to 57c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raises Dividend to 57c >BMY
BMY,2022-12-09,14:32:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"In Collaboration with Bristol Myers Squibb, to",PRESS-RELEASE,PR Newswire,"Lyfebulb Announces Finalists for the 2022 Innovation Challenge, in Collaboration with Bristol Myers Squibb, to Address Unmet Needs in Inflammatory Bowel Disease"
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: First multicenter results from the Phase 1 study,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio"
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First results,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio"
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: First multicenter results from the Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio"
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio"
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: Novel CELMoD(TM) agents mezigdomide (CC-92480) and iberdomide (CC-220) Phase 1/2 Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces First Disclosures -2-
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: Novel CELMoD(TM) agents mezigdomide (CC-92480) and iberdomide (CC-220) Phase 1/2 Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces First Disclosures -2-
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces First Disclosures -3-
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: Novel CELMoD(TM) agents mezigdomide (CC-92480) and iberdomide (CC-220) Phase 1/2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: Novel CELMoD(TM) agents mezigdomide (CC-92480) and iberdomide (CC-220) Phase 1/2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2022-12-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023"
BMY,2022-12-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023"
BMY,2022-12-15,12:08:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023"
BMY,2022-12-15,12:08:01,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023"
BMY,2022-12-16,08:40:23,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Evotec SE: after six years our neuroscience collaboration with Bristol Myers Squibb,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2022-12-16,08:40:23,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Evotec SE: after six years our neuroscience collaboration with Bristol Myers Squibb,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2022-12-16,12:27:52,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec to Receive $26 Mln in Expanded Bristol Myers Squibb Collaboration,FULL-ARTICLE,Dow Jones Newswires,Evotec to Receive $26 Mln in Expanded Bristol Myers Squibb Collaboration
BMY,2022-12-16,12:42:52,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec to Receive $26 Million in Expanded Bristol Myers Squibb Collaboration,FULL-ARTICLE,Dow Jones Newswires,Evotec to Receive $26 Million in Expanded Bristol Myers Squibb Collaboration
BMY,2022-01-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 40(th) Annual Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present at J.P. Morgan's 40(th) Annual Healthcare Conference
BMY,2022-01-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 40th Annual Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present at J.P. Morgan's 40th Annual Healthcare Conference
BMY,2022-01-04,23:22:18,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 21,996 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Acquires 21,996 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-01-04,23:23:55,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 23,155 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Elkins Acquires 23,155 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-01-10,11:45:00,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,approved,Bristol-Myers Squibb Co.: the Company's previously disclosed multi-year $15 billion share repurchase authorization,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan's 40(th) Annual Healthcare Conference
BMY,2022-01-10,11:45:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Revlimid sales are expected to,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan's 40(th) Annual Healthcare Conference
BMY,2022-01-10,11:45:01,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,approved,Bristol-Myers Squibb Co.: the Company's previously disclosed multi-year $15 billion share repurchase authorization,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan's 40th Annual Healthcare Conference
BMY,2022-01-10,11:45:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Revlimid sales are expected to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan's 40th Annual Healthcare Conference
BMY,2022-01-10,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration,PRESS-RELEASE,Business Wire,Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
BMY,2022-01-10,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration,PRESS-RELEASE,GlobeNewswire,Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
BMY,2022-01-10,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
BMY,2022-01-10,11:59:49,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Century Therapeutics and Bristol Myers Squibb Enter Into a Strategic Collaboration,NEWS-FLASH,Dow Jones Newswires,Century Therapeutics and Bristol Myers Squibb Enter Into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
BMY,2022-01-10,12:13:17,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
BMY,2022-01-10,13:00:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Of Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors
BMY,2022-01-10,21:05:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bioatla Announces Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo(R) (nivolumab) for Treatment of Solid Tumors
BMY,2022-01-10,21:05:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bioatla Announces Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo(R) (nivolumab) for Treatment of Solid Tumors
BMY,2022-01-10,21:05:40,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bioatla Announces Clinical Collaboration With Bristol Myers Squibb to,NEWS-FLASH,Dow Jones Newswires,BioAtla Announces Clinical Collaboration With Bristol Myers Squibb to Study Mecbotamab Vedotin and Ozuriftamab Vedotin in Combination With Opdivo for Solid Tumors
BMY,2022-01-11,06:30:36,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec expands neuroscience collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach
BMY,2022-01-11,06:30:36,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec expands neuroscience collaboration with Bristol Myers Squibb to,PRESS-RELEASE,DGAP News,PRESS RELEASE: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach
BMY,2022-01-11,07:00:46,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach
BMY,2022-01-11,18:36:28,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach
BMY,2022-01-13,13:30:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb
BMY,2022-01-21,22:42:25,94637C,Bristol-Myers Squibb Co.,100,0.0,insider-trading,,Chmn Caforio Gifts 525 Of Bristol-Myers Squibb Co >BMY,TABULAR-MATERIAL,Dow Jones Newswires,Chmn Caforio Gifts 525 Of Bristol-Myers Squibb Co >BMY
BMY,2022-01-25,08:09:02,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2021 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2021 (BMY)"
BMY,2022-01-28,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B"
BMY,2022-01-28,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B"
BMY,2022-01-28,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B"
BMY,2022-01-28,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B"
BMY,2022-01-28,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B"
BMY,2022-01-28,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B"
BMY,2022-01-28,11:59:11,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene Maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B"
BMY,2022-01-28,12:23:41,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Gets Positive CHMP Opinion For Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Positive CHMP Opinion For Breyanzi in Lymphoma
BMY,2022-01-28,12:23:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency recommended approval of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Positive CHMP Opinion For Breyanzi in Lymphoma
BMY,2022-01-28,12:38:41,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Gets Positive CHMP Opinion For Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Positive CHMP Opinion For Breyanzi in Lymphoma
BMY,2022-01-28,12:38:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency recommended approval of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Positive CHMP Opinion For Breyanzi in Lymphoma
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Adj EPS $1.83,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Adj EPS $1.83 >BMY
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q EPS $1.07,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q EPS $1.07 >BMY
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Net $2.4B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Net $2.4B >BMY
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 4Q Rev $12B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Rev $12B >BMY
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers Squibb posted fourth quarter revenues of $12.0 billion, an increase of 8%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Full-Year Revenues of $46.4 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Fourth Quarter Earnings Per Share of $1.07,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Full-Year Earnings Per Share of $3.12,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,"Bristol-Myers Squibb Co.: Delivers Strong Revenues for Eliquis, Immuno-Oncology and New Product Portfolios",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol-Myers Squibb Co.: Announces $15 Billion Share Repurchase Authorization,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.38,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 30% to $2.6 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: TWELVE-MONTH PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi(R) (lisocabtagene maraleucel),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The EMA also validated the Type II variation for Reblozyl,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Orencia(R) (abatacept) was approved by the FDA,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the European Commission (EC) approved Zeposia(R) (ozanimod),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: the company and Century Therapeutics (NASDAQ: IPSC) announced a research collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.62,dividends,up,Bristol-Myers Squibb Co.: the company announced that its Board of Directors approved an increase in the quarterly dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Sales from key loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Revlimid sales,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating expenses,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers Squibb posted fourth quarter revenues of $12.0 billion, an increase of 8%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Full-Year Revenues of $46.4 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Fourth Quarter Earnings Per Share of $1.07,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Full-Year Earnings Per Share of $3.12,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,"Bristol-Myers Squibb Co.: Delivers Strong Revenues for Eliquis, Immuno-Oncology and New Product Portfolios",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol-Myers Squibb Co.: Announces $15 Billion Share Repurchase Authorization,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.38,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 30% to $2.6 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: TWELVE-MONTH PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi(R) (lisocabtagene maraleucel),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The EMA also validated the Type II variation for Reblozyl,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Orencia(R) (abatacept) was approved by the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the European Commission (EC) approved Zeposia(R) (ozanimod),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: the company and Century Therapeutics (NASDAQ: IPSC) announced a research collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,dividends,up,Bristol-Myers Squibb Co.: the company announced that its Board of Directors approved an increase in the quarterly dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Sales from key loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Revlimid sales,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-02-04,11:59:33,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol-Myers Squibb Announces $15B Share Repurchase Authorization,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Announces $15B Share Repurchase Authorization >BMY
BMY,2022-02-04,11:59:59,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol-Myers Squibb Plans $5B Accelerated Repurchase,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Plans $5B Accelerated Repurchase in 1Q >BMY
BMY,2022-02-04,12:00:51,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2022 EPS $3.37,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2022 EPS $3.37-EPS $3.67 >BMY
BMY,2022-02-04,12:01:06,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2022 Adj EPS $7.65,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2022 Adj EPS $7.65-Adj EPS $7.95 >BMY
BMY,2022-02-04,12:01:28,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Sees 2022 Revenue About $47B,HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb Sees 2022 Revenue About $47B, Up Low-Single Digits >BMY"
BMY,2022-02-04,12:01:31,94637C,Bristol-Myers Squibb Co.,100,0.82,earnings,up,Bristol-Myers Squibb Q4 EPS $1.07 vs. loss $4.45 a year ago,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb Q4 EPS $1.07 vs. loss $4.45 a year ago
BMY,2022-02-04,12:01:58,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Sees 2022 Revlimid Sales $9.5B-$10B >BMY,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2022 Revlimid Sales $9.5B-$10B >BMY
BMY,2022-02-04,12:02:12,94637C,Bristol-Myers Squibb Co.,100,-0.27,revenues,below-expectations,Bristol-Myers Squibb Q4 revenue $11.985 bln vs. $11.068 bln a year ago; FactSet consensus $12.842 bln,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb Q4 revenue $11.985 bln vs. $11.068 bln a year ago; FactSet consensus $12.842 bln
BMY,2022-02-04,12:02:55,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb sees 2022 EPS of $3.37 to $3.67,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb sees 2022 EPS of $3.37 to $3.67
BMY,2022-02-04,12:03:05,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Sees 2022 Revenue,HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb Sees 2022 Revenue From In-Line, New Products About $36.5B >BMY"
BMY,2022-02-04,12:03:46,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb sees 2022 adj. EPS of $7.65 to $7.95,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb sees 2022 adj. EPS of $7.65 to $7.95; FactSet consensus $7.80
BMY,2022-02-04,12:04:15,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb now sees 2022 revenue of about $47 bln,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb now sees 2022 revenue of about $47 bln; FactSet consensus $47.2 bln
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers Squibb posted fourth quarter revenues of $12.0 billion, an increase of 8%",PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Full-Year Revenues of $46.4 Billion,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Fourth Quarter Earnings Per Share of $1.07,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Full-Year Earnings Per Share of $3.12,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,"Bristol-Myers Squibb Co.: Delivers Strong Revenues for Eliquis, Immuno-Oncology and New Product Portfolios",PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol-Myers Squibb Co.: Announces $15 Billion Share Repurchase Authorization,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.38,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 30% to $2.6 billion,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: TWELVE-MONTH PRODUCT REVENUE,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -2-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi(R) (lisocabtagene maraleucel),PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -2-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The EMA also validated the Type II variation for Reblozyl,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -2-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Orencia(R) (abatacept) was approved by the FDA,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -2-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company announced that the European Commission (EC) approved Zeposia(R) (ozanimod),PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -2-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Net $2.37B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Net $2.37B >BMY
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: the company and Century Therapeutics (NASDAQ: IPSC) announced a research collaboration,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.62,dividends,up,Bristol-Myers Squibb Co.: the company announced that its Board of Directors approved an increase in the quarterly dividend,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide revenues,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Sales from key loss,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Revlimid sales,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating expenses,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol-Myers Squibb Co.: Company and Conference Call,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -3-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q EPS $1.07,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q EPS $1.07 >BMY
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: the company's Annual Report on Form 10-K for the year ended December 31, 2020",PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -5-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED DECEMBER 31, 2021",PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -5-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2021",PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -5-
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Adj EPS $1.83,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Adj EPS $1.83 >BMY
BMY,2022-02-04,13:49:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 4Q Rev $11.99B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Rev $11.99B >BMY
BMY,2022-02-04,13:49:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,ADDING and REPLACING Bristol Myers Squibb Reports -6-
BMY,2022-02-04,19:01:36,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co CEO Giovanni Caforio on Q4 2021 Results -- Earnings Call,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Co CEO Giovanni Caforio on Q4 2021 Results -- Earnings Call Transcript >BMY
BMY,2022-02-05,09:13:17,94637C,Bristol-Myers Squibb Co.,100,0.82,earnings,up,Bristol-Myers Squibb Q4 EPS $1.07 vs. loss $4.45 a year ago,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb Q4 EPS $1.07 vs. loss $4.45 a year ago
BMY,2022-02-05,09:13:17,94637C,Bristol-Myers Squibb Co.,100,-0.27,revenues,below-expectations,Bristol-Myers Squibb Q4 revenue $11.985 bln vs. $11.068 bln a year ago; FactSet consensus $12.842 bln,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb Q4 revenue $11.985 bln vs. $11.068 bln a year ago; FactSet consensus $12.842 bln
BMY,2022-02-05,09:13:17,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb sees 2022 EPS of $3.37 to $3.67,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb sees 2022 EPS of $3.37 to $3.67
BMY,2022-02-05,09:13:17,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb sees 2022 adj. EPS of $7.65 to $7.95,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb sees 2022 adj. EPS of $7.65 to $7.95; FactSet consensus $7.80
BMY,2022-02-05,09:13:17,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb now sees 2022 revenue of about $47 bln,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb now sees 2022 revenue of about $47 bln; FactSet consensus $47.2 bln
BMY,2022-02-08,16:30:04,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,"Endari, and DROXIA have been launched recently",PRESS-RELEASE,PR Newswire,Sickle Cell Disease Treatment Market size to Record 10.83% Y-O-Y Growth Rate in 2021 | Addmedica SAS and Bristol-Myers Squibb Co. are the leading companies in the market | Technavio
BMY,2022-02-08,16:30:04,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,"Endari, and DROXIA have been launched recently",PRESS-RELEASE,PR Newswire,Sickle Cell Disease Treatment Market size to Record 10.83% Y-O-Y Growth Rate in 2021 | Addmedica SAS and Bristol-Myers Squibb Co. are the leading companies in the market | Technavio
BMY,2022-02-08,23:11:04,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 2,281 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Acquires 2,281 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-02-09,12:18:06,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers Squibb announces $5 billion accelerated share buyback program,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb announces $5 billion accelerated share buyback program
BMY,2022-02-09,12:18:06,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers Squibb Announces $5 Billion Accelerated Share Buyback Program,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Announces $5 Billion Accelerated Share Buyback Program -- MarketWatch
BMY,2022-02-09,12:21:39,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,Bristol Myers Squibb Co. on Wednesday said it plans to buy back $5 billion in common stock under,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Sets $5 Bln Accelerated Stock Buyback >BMY
BMY,2022-02-09,12:36:39,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Bristol Myers Squibb Co. on Wednesday said it plans to buy back $5 billion in common stock under,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Sets $5 Billion Accelerated Stock Buyback
BMY,2022-02-14,21:11:22,94637C,Bristol-Myers Squibb Co.,100,-0.34,equity-actions,decrease,Berkshire Hathaway Decreases Stake in Bristol Myers Squibb,RNS-SEC13F,Dow Jones Newswires,"Berkshire Hathaway Decreases Stake in Bristol Myers Squibb by 16,844,262 to 5,202,674 Shares -- 13F Filing"
BMY,2022-02-15,12:00:03,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Mavacamten Granted Breakthrough Therapy Designation in China,PRESS-RELEASE,GlobeNewswire,LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China
BMY,2022-02-15,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Mavacamten Granted Breakthrough Therapy Designation in China,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China
BMY,2022-02-15,12:03:00,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Mavacamten Granted Breakthrough Therapy Designation in China,NEWS-FLASH,Dow Jones Newswires,LianBio: Mavacamten Granted Breakthrough Therapy Designation in China >LIAN
BMY,2022-02-15,14:04:00,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $500,000,000",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
BMY,2022-02-15,14:04:00,94637C,Bristol-Myers Squibb Co.,98,0.0,credit,,Bristol Myers Squibb shall have completed an offering of debt,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Tender Offers for -2-
BMY,2022-02-15,14:04:00,94637C,Bristol-Myers Squibb Co.,97,0.48,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is available on Global Bondholder Services,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Tender Offers for -4-
BMY,2022-02-15,14:04:00,94637C,Bristol-Myers Squibb Co.,97,0.55,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is only addressed to Holders where they would,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Tender Offers for -4-
BMY,2022-02-15,14:04:01,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $500,000,000",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
BMY,2022-02-15,14:04:01,94637C,Bristol-Myers Squibb Co.,98,0.0,credit,,Bristol Myers Squibb shall have completed an offering of debt,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2022-02-15,14:04:01,94637C,Bristol-Myers Squibb Co.,97,0.48,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is available on Global Bondholder Services,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2022-02-15,14:04:01,94637C,Bristol-Myers Squibb Co.,97,0.55,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is only addressed to Holders where they would,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2022-02-15,16:56:33,94637C,Bristol-Myers Squibb Co.,100,0.36,credit-ratings,set,S&PGR Rates Bristol-Myers Squibb's Sr Unsecured Notes 'A+,NEWS-FLASH,Dow Jones Newswires,S&PGR Rates Bristol-Myers Squibb's Sr Unsecured Notes 'A+'
BMY,2022-02-15,16:56:33,94637C,Bristol-Myers Squibb Co.,100,0.36,credit-ratings,set,S&PGR Rates Bristol-Myers Squibb's Sr Unsecured Notes 'A+,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Rates Bristol-Myers Squibb's Sr Unsecured Notes 'A+'
BMY,2022-02-15,16:56:33,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,Bristol-Myers Squibb Co.: rising demand for the company's other leading products,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Rates Bristol-Myers Squibb's Sr Unsecured Notes 'A+'
BMY,2022-02-15,17:08:04,94637C,Bristol-Myers Squibb Co.,100,0.26,credit-ratings,set,Moody's Assigns A2 To Bristol-Myers Notes,NEWS-FLASH,Dow Jones Newswires,Moody's Assigns A2 To Bristol-Myers Notes; Stable Outlook
BMY,2022-02-15,21:39:00,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes
BMY,2022-02-15,21:39:01,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes
BMY,2022-02-15,21:39:05,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb Prices $6 B of Senior Unsecured Notes,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Prices $6 B of Senior Unsecured Notes
BMY,2022-02-16,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy"
BMY,2022-02-16,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy"
BMY,2022-02-16,11:59:31,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results From Phase 3 VALOR-HCM Trial,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Announces Positive Topline Results From Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy"
BMY,2022-02-17,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,U.S. Food And Drug Administration (FDA) Accepts For Priority Review Bristol Myers Squibb's Supplemental Biologics License Application For Breyanzi (lisocabtagene Maraleucel),NEWS-FLASH,Dow Jones Newswires,U.S. Food And Drug Administration (FDA) Accepts For Priority Review Bristol Myers Squibb's Supplemental Biologics License Application For Breyanzi (lisocabtagene Maraleucel) As A Second-Line Therapy For Relapsed Or Refractory Large B-cell Lymphoma >BMY
BMY,2022-02-17,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-02-17,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-02-17,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-02-17,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-02-17,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-02-17,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-02-17,11:59:38,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review for Breyanzi,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Breyanzi as Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-02-17,12:26:02,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review for Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Breyanzi as Second-Line Therapy >BMY
BMY,2022-02-17,12:26:02,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Thursday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Breyanzi as Second-Line Therapy >BMY
BMY,2022-02-17,12:26:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda last year approved Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Breyanzi as Second-Line Therapy >BMY
BMY,2022-02-17,12:41:02,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review for Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Breyanzi as Second-Line Therapy
BMY,2022-02-17,12:41:02,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Thursday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Breyanzi as Second-Line Therapy
BMY,2022-02-17,12:41:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda last year approved Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Breyanzi as Second-Line Therapy
BMY,2022-02-17,17:19:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: In the True North extension study, data from an interim analysis",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2022-02-17,17:19:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2022-02-17,17:19:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration (FDA) approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis
BMY,2022-02-22,12:15:01,94637C,Bristol-Myers Squibb Co.,97,0.49,partnerships,,National Cancer Institute in collaboration with Zenith and BMS,PRESS-RELEASE,GlobeNewswire,Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb's Immune Checkpoint Inhibitor OPDIVO
BMY,2022-02-22,12:15:26,94637C,Bristol-Myers Squibb Co.,97,0.49,partnerships,,National Cancer Institute in collaboration with Zenith and BMS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb's Immune Checkpoint Inhibitor OPDIVO
BMY,2022-02-22,22:12:35,94637C,Bristol-Myers Squibb Co.,100,0.0,credit-ratings,stable,S&P Sees Bristol-Myers Squibb Co. Outlk Stable,NEWS-FLASH,Dow Jones Newswires,S&P Sees Bristol-Myers Squibb Co. Outlk Stable
BMY,2022-02-22,22:13:43,94637C,Bristol-Myers Squibb Co.,100,0.0,credit-ratings,affirmation,S&PGR Afrms Bristol-Myers Squibb Rtg,NEWS-FLASH,Dow Jones Newswires,"S&PGR Afrms Bristol-Myers Squibb Rtg, Revises Otlk To Stable"
BMY,2022-02-22,22:13:43,94637C,Bristol-Myers Squibb Co.,100,0.0,credit-ratings,affirmation,S&PGR Afrms Bristol-Myers Squibb Rtg,PRESS-RELEASE,Dow Jones Newswires,"Press Release: S&PGR Afrms Bristol-Myers Squibb Rtg, Revises Otlk To Stable"
BMY,2022-02-22,22:13:43,94637C,Bristol-Myers Squibb Co.,100,-0.68,revenues,down,Revlimid revenues decline,PRESS-RELEASE,Dow Jones Newswires,"Press Release: S&PGR Afrms Bristol-Myers Squibb Rtg, Revises Otlk To Stable"
BMY,2022-02-22,22:13:53,94637C,Bristol-Myers Squibb Co.,100,0.0,credit-ratings,affirmation,S&PGR Afrms Bristol-Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Afrms Bristol-Myers Squibb -2-
BMY,2022-02-25,11:45:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-02-25,11:45:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: Opdivo received approval,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-02-25,11:45:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2022-02-25,11:45:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2022-02-25,11:45:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2022-02-25,11:45:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-02-25,11:45:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: Opdivo received approval,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-02-25,11:45:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2022-02-25,11:45:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-02-25,11:45:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-02-25,11:50:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma..."
BMY,2022-02-25,11:50:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2022-02-25,11:50:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2022-02-25,11:50:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2022-02-25,11:50:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma..."
BMY,2022-02-25,11:50:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2022-02-25,11:50:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-02-25,11:50:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-02-25,11:55:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1..."
BMY,2022-02-25,11:55:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1..."
BMY,2022-02-25,11:55:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2022-02-25,11:55:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2022-02-25,11:55:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2022-02-25,11:55:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1..."
BMY,2022-02-25,11:55:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1..."
BMY,2022-02-25,11:55:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2022-02-25,11:55:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-02-25,11:55:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-02-25,11:57:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo Plus Chemotherapy for First-Line Treatment of Patients With Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma With Tumor Cell PD-L1..."
BMY,2022-02-25,11:57:51,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,The U.S. Food and Drug Administration last year approved Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Opdivo in Bladder Cancer >BMY
BMY,2022-02-25,12:12:50,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,The U.S. Food and Drug Administration last year approved Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Opdivo in Bladder Cancer
BMY,2022-02-28,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -816 is one of four positive Phase 3 trials,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The FDA's acceptance of our application,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: CheckMate -816 is one of four positive Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The FDA's acceptance of our application,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,12:01:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Says FDA Accepts Supplemental Biologics License Application for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Says FDA Accepts Supplemental Biologics License Application for Opdivo Plus Chemotherapy for Neoadjuvant Treatment of Patients With Resectable Non-Small Cell Lung Cancer
BMY,2022-02-28,12:01:46,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb: FDA Grants Application Priority Review Status,NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb: FDA Grants Application Priority Review Status, Assigned Prescription Drug User Fee Act Goal Date of July 13 >BMY"
BMY,2022-02-28,12:30:08,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Added Opdivo Indication >BMY
BMY,2022-02-28,12:45:07,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Added Opdivo Indication
BMY,2022-02-28,22:11:07,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 30,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Caforio Sells 30,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-01,18:00:39,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb (NYSE:BMY) signed an exclusive worldwide license agreement with Dragonfly Therapeutics,PRESS-RELEASE,Canadian News Wire,Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
BMY,2022-03-01,18:00:39,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb (NYSE:BMY) signed an exclusive worldwide license agreement with Dragonfly Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
BMY,2022-03-01,18:00:40,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb (NYSE:BMY) signed an exclusive worldwide license agreement with Dragonfly Therapeutics,PRESS-RELEASE,PR Newswire,(PR) Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
BMY,2022-03-01,18:00:40,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb (NYSE:BMY) signed an exclusive worldwide license agreement with Dragonfly Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
BMY,2022-03-01,18:34:50,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb (NYSE:BMY) signed an exclusive worldwide license agreement with Dragonfly Therapeutics,PRESS-RELEASE,PR Newswire,Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
BMY,2022-03-01,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2022-03-01,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on May 2, 2022 to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2022-03-02,02:03:00,94637C,Bristol-Myers Squibb Co.,97,0.55,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: Offers to purchase for cash all of the aggregate principal amount,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender Offers"
BMY,2022-03-02,02:03:00,94637C,Bristol-Myers Squibb Co.,98,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $1,500,000",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Early -2-
BMY,2022-03-02,02:03:01,94637C,Bristol-Myers Squibb Co.,98,0.55,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: Offers to purchase for cash all of the aggregate principal amount,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender Offers"
BMY,2022-03-02,02:03:01,94637C,Bristol-Myers Squibb Co.,98,0.55,acquisitions-mergers,interest,"Bristol-Myers Squibb Co.: Offers to purchase for cash up to $1,500,000",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2022-03-02,12:39:45,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
BMY,2022-03-02,12:39:45,94637C,Bristol-Myers Squibb Co.,100,0.72,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $65.00/Share From $60.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $65.00/Share From $60.00 by Wells Fargo
BMY,2022-03-02,13:30:03,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Strategically partnered with BMS to,PRESS-RELEASE,PR Newswire,"Alexandria Real Estate Equities, Inc. Announces Long-Term Lease With Bristol Myers Squibb for a New 427,000 RSF Innovative Research Hub at the Alexandria Point Mega Campus in the San Diego Cluster Market"
BMY,2022-03-02,13:30:04,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Strategically partnered with BMS to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Alexandria Real Estate Equities, Inc. Announces Long-Term Lease With Bristol Myers Squibb for a New 427,000 RSF Innovative Research Hub at the Alexandria Point Mega Campus in the San Diego Cluster Market"
BMY,2022-03-02,20:19:00,94637C,Bristol-Myers Squibb Co.,98,0.55,acquisitions-mergers,interest,"Offer to Purchase""), as amended by Bristol Myers Squibb",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
BMY,2022-03-02,20:19:00,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Offer to Purchase, as amended by Bristol Myers Squibb",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Accepted Amounts -2-
BMY,2022-03-02,20:19:00,94637C,Bristol-Myers Squibb Co.,95,0.55,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is only addressed to Holders where they would,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Accepted Amounts -3-
BMY,2022-03-02,20:19:01,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Offer to Purchase""), as amended by Bristol Myers Squibb",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
BMY,2022-03-02,20:19:01,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,"Offer to Purchase, as amended by Bristol Myers Squibb",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2022-03-02,20:19:01,94637C,Bristol-Myers Squibb Co.,95,0.55,acquisitions-mergers,interest,Bristol-Myers Squibb Co.: The Offer to Purchase is only addressed to Holders where they would,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2022-03-03,22:44:44,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 14,196 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 14,196 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-03,22:46:44,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 13,047 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Acquires 13,047 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-04,22:44:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer
BMY,2022-03-04,22:44:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer
BMY,2022-03-04,22:48:14,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb: FDA Approves Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: FDA Approves Opdivo With Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients With Resectable Non-Small Cell Lung Cancer
BMY,2022-03-07,17:18:00,94637C,Bristol-Myers Squibb Co.,95,0.57,products-services,granted,Dasatinib was approved in China,PRESS-RELEASE,Business Wire,"Investigation Report on China's Dasatinib Markets, 2016-2020 & 2021-2025: An Anti-tumor Drug Developed by Bristol-Myers Squibb - ResearchAndMarkets.com"
BMY,2022-03-07,17:18:00,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: Prices of Dasatinib,PRESS-RELEASE,Business Wire,"Investigation Report on China's Dasatinib Markets, 2016-2020 & 2021-2025: An Anti-tumor Drug Developed by Bristol-Myers Squibb - ResearchAndMarkets.com"
BMY,2022-03-09,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16
BMY,2022-03-09,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16
BMY,2022-03-11,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022"
BMY,2022-03-11,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: To be directly connected to the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022"
BMY,2022-03-11,11:59:07,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022"
BMY,2022-03-11,11:59:07,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: To be directly connected to the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022"
BMY,2022-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,To collaborating with BMS to,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
BMY,2022-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and Nektar Announce Update -5-
BMY,2022-03-14,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,To collaborating with BMS to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
BMY,2022-03-14,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and Nektar -5-
BMY,2022-03-15,01:17:17,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Mily Acquires 2,130 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Mily Acquires 2,130 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:18:34,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 6,496 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Acquires 6,496 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:19:02,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 3,869 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Acquires 3,869 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:19:20,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Powell Acquires 15,317 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Powell Acquires 15,317 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:19:43,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 6,845 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 6,845 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:20:03,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Santiago Acquires 4,850 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Santiago Acquires 4,850 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:20:29,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Boerner Acquires 17,170 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Boerner Acquires 17,170 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:21:22,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Leung Acquires 15,372 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Leung Acquires 15,372 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,01:22:06,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Chmn Caforio Acquires 80,611 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Chmn Caforio Acquires 80,611 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-15,08:30:33,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Temedica announces cooperation with Bristol Myers Squibb for,PRESS-RELEASE,DGAP News,PRESS RELEASE: Temedica announces cooperation with Bristol Myers Squibb for the development of a digital companion for psoriasis patients
BMY,2022-03-15,08:30:33,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Temedica announces cooperation with Bristol Myers Squibb for,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: Temedica announces cooperation with Bristol Myers Squibb for the development of a digital companion for psoriasis patients
BMY,2022-03-16,22:50:25,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co (BMY) Presents at Barclays Global Healthcare Broker Conference,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Co (BMY) Presents at Barclays Global Healthcare Broker Conference Call - (Transcript) >BMY
BMY,2022-03-16,23:33:23,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Boerner Sells 29,532 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Boerner Sells 29,532 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-16,23:33:33,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Santiago Sells 6,577 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Santiago Sells 6,577 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-18,17:53:44,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp von Autenried Registers 25,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP von Autenried Registers 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-18,21:53:03,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Vessey Sells 74,559 Of Bristol-Myers Squibb Co",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Sells 74,559 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-18,23:02:46,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Melanoma Treatment Receives FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Melanoma Treatment Receives FDA Approval
BMY,2022-03-18,23:17:46,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Melanoma Treatment Receives FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Melanoma Treatment Receives FDA Approval
BMY,2022-03-21,09:00:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Today announced a collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb
BMY,2022-03-22,00:16:37,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo(R) in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer
BMY,2022-03-22,00:16:37,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,,Bristol Myers Squibb will supply Opdivo to Transcenta,PRESS-RELEASE,PR Newswire,Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo(R) in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer
BMY,2022-03-22,00:16:37,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo(R) in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer
BMY,2022-03-22,00:16:37,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,,Bristol Myers Squibb will supply Opdivo to Transcenta,PRESS-RELEASE,Dow Jones Newswires,Press Release: Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo(R) in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer
BMY,2022-03-23,23:46:10,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co",FULL-ARTICLE,Dow Jones Newswires,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-03-24,20:50:16,94637C,Bristol-Myers Squibb Co.,100,-0.1,labor-issues,decrease,"Bristol Myers Squibb CEO Giovanni Caforio 2021 Total Pay $19.8M, Down From $20.2M in 2020",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb CEO Giovanni Caforio 2021 Total Pay $19.8M, Down From $20.2M in 2020"
BMY,2022-03-25,05:00:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Roche announces collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,Roche announces collaboration with Bristol Myers Squibb to advance personalised healthcare through digital pathology solutions
BMY,2022-03-25,05:00:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Roche announces collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Roche announces collaboration with Bristol Myers Squibb to advance personalised healthcare through digital pathology solutions
BMY,2022-03-25,05:00:27,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Roche announces collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,Roche announces collaboration with Bristol Myers Squibb to advance personalised healthcare through digital pathology solutions
BMY,2022-03-25,05:03:33,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Roche, Bristol Myers Squibb Collaborate to",NEWS-FLASH,Dow Jones Newswires,"Roche, Bristol Myers Squibb Collaborate to Support Advancement of Two Assays in Clinical Trials With Use of Two New Digital Pathology Algorithms >RO.EB"
BMY,2022-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,"Bristol-Myers Squibb Co.: In the pivotal CheckMate -816 study, the first positive Phase 3 trial",PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"816, the U.S. Food and Drug Administration approved Opdivo",PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -4-
BMY,2022-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2022-03-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2022-03-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-03-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,"Bristol-Myers Squibb Co.: In the pivotal CheckMate -816 study, the first positive Phase 3 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-03-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"816, the U.S. Food and Drug Administration approved Opdivo",PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
BMY,2022-03-30,14:55:56,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital
BMY,2022-03-30,14:55:56,94637C,Bristol-Myers Squibb Co.,100,0.76,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $81.00/Share From $74.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $81.00/Share From $74.00 by BMO Capital
BMY,2022-04-03,13:45:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Interim results were presented as a late-breaking clinical trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Receiving Mavacamten
BMY,2022-04-03,13:45:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Interim results were presented as a late-breaking clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Receiving Mavacamten
BMY,2022-04-04,22:15:21,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Mily Acquires 3,014 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Mily Acquires 3,014 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-04-05,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-04-05,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: Approval based on Phase 3 CheckMate -274 trial results,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-04-05,10:45:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2022-04-05,10:45:00,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2022-04-05,10:45:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -6-
BMY,2022-04-05,10:45:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-04-05,10:45:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: Approval based on Phase 3 CheckMate -274 trial results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression >=1%"
BMY,2022-04-05,10:45:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2022-04-05,10:45:01,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-04-05,10:45:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -6-
BMY,2022-04-05,10:45:17,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo as,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Receives European Commission Approval for Opdivo as Adjuvant Treatment for Patients With Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma With Tumor Cell PD-L1 Expression >=1%"
BMY,2022-04-05,10:50:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...
BMY,2022-04-05,10:50:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...
BMY,2022-04-05,10:50:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2022-04-05,10:50:00,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2022-04-05,10:50:00,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2022-04-05,10:50:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...
BMY,2022-04-05,10:50:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...
BMY,2022-04-05,10:50:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2022-04-05,10:50:01,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-04-05,10:50:01,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-04-05,10:55:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
BMY,2022-04-05,10:55:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: We are eager to introduce this new treatment,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
BMY,2022-04-05,10:55:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2022-04-05,10:55:00,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2022-04-05,10:55:00,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2022-04-05,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
BMY,2022-04-05,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: We are eager to introduce this new treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
BMY,2022-04-05,10:55:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2022-04-05,10:55:01,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-04-05,10:55:01,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-04-05,10:55:45,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Gets EC OK For Opdivo,NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb Gets EC OK For Opdivo With Chemotherapy as First-Line Treatment for Patients With Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma With Tumor Cell PD-L1 Expression >= 1%"
BMY,2022-04-05,11:13:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets European OK for Three More Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European OK for Three More Opdivo Indications >BMY
BMY,2022-04-05,11:28:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets European OK for Three More Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European OK for Three More Opdivo Indications
BMY,2022-04-05,14:33:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-04-05,14:33:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-04-05,14:33:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-04-05,14:33:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -2-
BMY,2022-04-05,14:35:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for CAR,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
BMY,2022-04-05,14:53:37,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol Myers Squibb Co. said the European Commission has approved marketing authorization for Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Breyanzi Receives European Commission Marketing Authorization
BMY,2022-04-05,15:08:37,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol Myers Squibb Co. said the European Commission has approved marketing authorization for Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Breyanzi Receives European Commission Marketing Authorization
BMY,2022-04-06,14:05:19,94637C,Bristol-Myers Squibb Co.,100,-0.98,analyst-ratings,negative,Bristol-Myers Squibb Cut to Underweight From Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Underweight From Equal-Weight by Morgan Stanley
BMY,2022-04-06,14:05:19,94637C,Bristol-Myers Squibb Co.,100,-0.44,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $64.00/Share From $66.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $64.00/Share From $66.00 by Morgan Stanley
BMY,2022-04-08,05:55:37,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Evotec SE: Our neuroscience collaboration with Bristol Myers Squibb,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2022-04-12,13:30:04,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bms) today announced that Health Canada has approved ZEPOSIA(R) (ozanimod),PRESS-RELEASE,Canadian News Wire,"Health Canada Has Approved ZEPOSIA (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis"
BMY,2022-04-14,20:30:05,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,PR Newswire,Nektar and Bristol Myers Squibb Announce Update -5-
BMY,2022-04-14,20:30:06,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Nektar and Bristol Myers Squibb -6-
BMY,2022-04-14,21:15:57,94637C,Bristol-Myers Squibb Co.,100,-0.54,products-services,suspended,Bristol Myers to Discontinue Bempeg Clinical Development Program,FULL-ARTICLE,Dow Jones Newswires,"Nektar, Bristol Myers to Discontinue Bempeg Clinical Development Program"
BMY,2022-04-14,21:15:57,94637C,Bristol-Myers Squibb Co.,100,-0.54,products-services,suspended,Nektar Therapeutics and Bristol Myers Squibb Co. are ending a clinical development program,FULL-ARTICLE,Dow Jones Newswires,"Nektar, Bristol Myers to Discontinue Bempeg Clinical Development Program"
BMY,2022-04-14,21:30:58,94637C,Bristol-Myers Squibb Co.,100,-0.54,products-services,suspended,Bristol Myers to Discontinue Bempeg Clinical Development Program,FULL-ARTICLE,Dow Jones Newswires,"Nektar, Bristol Myers to Discontinue Bempeg Clinical Development Program"
BMY,2022-04-14,21:30:58,94637C,Bristol-Myers Squibb Co.,100,-0.54,products-services,suspended,Nektar Therapeutics and Bristol Myers Squibb Co. are ending a clinical development program,FULL-ARTICLE,Dow Jones Newswires,"Nektar, Bristol Myers to Discontinue Bempeg Clinical Development Program"
BMY,2022-04-18,14:35:47,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Nektar, Bristol Myers Squibb End Clinical Development Of Combination Therapy",FULL-ARTICLE,Dow Jones Newswires,"Nektar, Bristol Myers Squibb End Clinical Development Of Combination Therapy Including Opdivo -- MarketWatch"
BMY,2022-04-18,14:35:47,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Nektar, Bristol Myers Squibb end clinical development of combination therapy",FULL-ARTICLE,MarketWatch,"MW Nektar, Bristol Myers Squibb end clinical development of combination therapy including Opdivo"
BMY,2022-04-18,14:39:36,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Nektar, Bristol Myers Squibb end clinical development of combination therapy",FULL-ARTICLE,MarketWatch,"MW Nektar, Bristol Myers Squibb end clinical development of combination therapy including Opdivo"
BMY,2022-04-18,14:39:36,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Nektar, Bristol Myers Squibb End Clinical Development Of Combination Therapy",FULL-ARTICLE,Dow Jones Newswires,"Update: Nektar, Bristol Myers Squibb End Clinical Development Of Combination Therapy Including Opdivo -- MarketWatch"
BMY,2022-04-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Edp Renewables and Bristol Myers Squibb Execute Power Purchase Agreement,PRESS-RELEASE,GlobeNewswire,EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park
BMY,2022-04-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Delighted to partner with Bristol Myers Squibb on,PRESS-RELEASE,GlobeNewswire,EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park
BMY,2022-04-21,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Edp Renewables and Bristol Myers Squibb Execute Power Purchase Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park
BMY,2022-04-21,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Delighted to partner with Bristol Myers Squibb on,PRESS-RELEASE,Dow Jones Newswires,Press Release: EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park
BMY,2022-04-21,10:59:20,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Edp Renewables and Bristol Myers Squibb Execute Power Purchase Agreement,NEWS-FLASH,Dow Jones Newswires,EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park
BMY,2022-04-21,11:03:02,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Merger of Bristol Myers Squibb and Celgene,PRESS-RELEASE,PR Newswire,Veeva Vault CTMS Launched at Bristol Myers Squibb to Simplify Clinical Trial Processes Globally
BMY,2022-04-21,11:03:02,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Merger of Bristol Myers Squibb and Celgene,PRESS-RELEASE,Dow Jones Newswires,Press Release: Veeva Vault CTMS Launched at Bristol Myers Squibb to Simplify Clinical Trial Processes Globally
BMY,2022-04-21,11:03:30,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,Merger of Bristol Myers Squibb and Celgene,PRESS-RELEASE,PR Newswire,Veeva Vault CTMS Launched at Bristol Myers Squibb to Simplify Clinical Trial Processes Globally
BMY,2022-04-21,12:30:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"Platform, Announces Collaboration with Bristol Myers Squibb",PRESS-RELEASE,Business Wire,"Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key Appointments"
BMY,2022-04-21,12:30:00,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,Bristol-Myers Squibb Co.: Appoints Industry Veteran Rick Artis as Chief,PRESS-RELEASE,Business Wire,"Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key Appointments"
BMY,2022-04-25,07:16:25,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2022 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2022 (BMY)"
BMY,2022-04-29,00:26:06,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Bristol-Myers Drug for,NEWS-FLASH,Dow Jones Newswires,FDA Approves Bristol-Myers Drug for Most Common Genetic Heart Condition -- WSJ
BMY,2022-04-29,00:26:06,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves New Bristol-Myers Drug,FULL-ARTICLE,Dow Jones Newswires,FDA Approves New Bristol-Myers Drug for Common Inherited Heart Disease -- WSJ
BMY,2022-04-29,00:26:06,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: the company's $13.1 billion acquisition of MyoKardia in 2020,FULL-ARTICLE,Dow Jones Newswires,FDA Approves New Bristol-Myers Drug for Common Inherited Heart Disease -- WSJ
BMY,2022-04-29,10:00:04,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves New Bristol-Myers Drug,FULL-ARTICLE,Dow Jones Newswires,FDA Approves New Bristol-Myers Drug for Common Inherited Heart Disease
BMY,2022-04-29,10:00:04,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: the company's $13.1 billion acquisition of MyoKardia in 2020,FULL-ARTICLE,Dow Jones Newswires,FDA Approves New Bristol-Myers Drug for Common Inherited Heart Disease
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q Adj EPS $1.96,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Adj EPS $1.96 >BMY
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q EPS 59c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q EPS 59c >BMY
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q Net $1.3B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Net $1.3B >BMY
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 1Q Rev $11.6B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Rev $11.6B >BMY
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,"Bristol-Myers Squibb Co.: Eliquis revenues, which grew 11%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.1 billion compared to $1.9 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.18,revenues,,Bristol-Myers Squibb Co.: International revenues were $1.1 billion compared to $963 million,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 12%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.48,revenues,down,Bristol-Myers Squibb Co.: Abraxane revenues declined 32%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Bristol-Myers Squibb Co.: The EC approved Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Bristol-Myers Squibb Co.: The FDA approved Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,96,0.0,products-services,,Bristol-Myers Squibb Co.: Two-year follow-up results from the Phase 3,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,96,0.59,equity-actions,,"Bristol-Myers Squibb Co.: In February, the company entered into accelerated share repurchase (ASR) transactions to",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,96,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $3.37-$3.67,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today at 8 a.m. EDT,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -6-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.60 $ 0.90,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -6-
BMY,2022-04-29,10:59:00,94637C,Bristol-Myers Squibb Co.,98,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Loss on,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -7-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports First Quarter Financial Results for 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports First Quarter Revenues of $11.6 Billion, an Increase of 5% YoY",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts First Quarter Earnings Per Share of $0.59,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts GAAP 2022 EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 3% to $4.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.13,equity-actions,up,Bristol-Myers Squibb Co.: Research and development expenses increased 2%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD increased to $333 million in the quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol-Myers Squibb Co.: For purposes of comparability, the non-GAAP financial results for the first quarter of 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2022
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,"Bristol-Myers Squibb Co.: Eliquis revenues, which grew 11%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.1 billion compared to $1.9 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.18,revenues,,Bristol-Myers Squibb Co.: International revenues were $1.1 billion compared to $963 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 12%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.48,revenues,down,Bristol-Myers Squibb Co.: Abraxane revenues declined 32%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Bristol-Myers Squibb Co.: The EC approved Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Bristol-Myers Squibb Co.: The FDA approved Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,products-services,,Bristol-Myers Squibb Co.: Two-year follow-up results from the Phase 3,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.59,equity-actions,,"Bristol-Myers Squibb Co.: In February, the company entered into accelerated share repurchase (ASR) transactions to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $3.37-$3.67,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today at 8 a.m. EDT,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -6-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.60 $ 0.90,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -6-
BMY,2022-04-29,10:59:01,94637C,Bristol-Myers Squibb Co.,97,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Loss on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -7-
BMY,2022-04-29,11:00:22,94637C,Bristol-Myers Squibb Co.,100,-0.5,earnings,down,Bristol Myers Squibb Q1 EPS 59 cents vs. 89 cents a year ago,NEWS-FLASH,MarketWatch,MW Bristol Myers Squibb Q1 EPS 59 cents vs. 89 cents a year ago
BMY,2022-04-29,11:00:43,94637C,Bristol-Myers Squibb Co.,100,0.46,earnings,above-expectations,Bristol Myers Q1 adj. EPS $1.96; FactSet consensus $1.91,NEWS-FLASH,MarketWatch,MW Bristol Myers Q1 adj. EPS $1.96; FactSet consensus $1.91
BMY,2022-04-29,11:01:02,94637C,Bristol-Myers Squibb Co.,100,0.48,revenues,above-expectations,Bristol Myers Q1 revenue $11.65 bln vs. $11.07 bln a year ago; FactSet consensus $11.35 bln,NEWS-FLASH,MarketWatch,MW Bristol Myers Q1 revenue $11.65 bln vs. $11.07 bln a year ago; FactSet consensus $11.35 bln
BMY,2022-04-29,11:01:49,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb Cuts 2022 View To EPS $2.92,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cuts 2022 View To EPS $2.92-EPS $3.22 >BMY
BMY,2022-04-29,11:01:56,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Q1 Eliquis revenue $3.21 bln vs. $2.89 bln,NEWS-FLASH,MarketWatch,MW Bristol Myers Q1 Eliquis revenue $3.21 bln vs. $2.89 bln a year ago; FactSet consensus $3.18 bln
BMY,2022-04-29,11:02:21,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb Cuts 2022 View To Adj EPS $7.44,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cuts 2022 View To Adj EPS $7.44-Adj EPS $7.74 >BMY
BMY,2022-04-29,11:02:34,94637C,Bristol-Myers Squibb Co.,100,0.48,revenues,above-expectations,Bristol Myers Q1 Revlimid revenue $2.78 bln vs. $2.94 bln; FactSet consensus $2.52 bln,NEWS-FLASH,MarketWatch,MW Bristol Myers Q1 Revlimid revenue $2.78 bln vs. $2.94 bln; FactSet consensus $2.52 bln
BMY,2022-04-29,11:03:33,94637C,Bristol-Myers Squibb Co.,100,-0.26,earnings,down,Bristol Myers cuts 2022 adj. EPS outlook to $7.44-$7.74 from $7.65-$7.95,NEWS-FLASH,MarketWatch,MW Bristol Myers cuts 2022 adj. EPS outlook to $7.44-$7.74 from $7.65-$7.95
BMY,2022-04-29,11:53:10,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb Co. said its revenue rose 5.2% in the first quarter,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb 1Q Sales Rise on In-Line Product Growth
BMY,2022-04-29,12:08:10,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb Co. said its revenue rose 5.2% in the first quarter,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb 1Q Sales Rise on In-Line Product Growth
BMY,2022-04-29,17:30:45,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Company CEO Giovanni Caforio on Q1 2022 Results -- Earnings Call,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Company CEO Giovanni Caforio on Q1 2022 Results -- Earnings Call Transcript >BMY
BMY,2022-05-02,11:39:11,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2022-05-02,11:39:11,94637C,Bristol-Myers Squibb Co.,100,0.44,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $68.00/Share From $66.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $68.00/Share From $66.00 by Barclays
BMY,2022-05-02,12:38:51,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2022-05-02,12:38:51,94637C,Bristol-Myers Squibb Co.,100,-0.32,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $63.00/Share From $64.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $63.00/Share From $64.00 by Morgan Stanley
BMY,2022-05-02,14:25:22,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital
BMY,2022-05-02,14:25:22,94637C,Bristol-Myers Squibb Co.,100,0.6,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $92.00/Share From $87.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $92.00/Share From $87.00 by BMO Capital
BMY,2022-05-02,19:43:34,94637C,Bristol-Myers Squibb Co.,100,-0.8,products-services,negative,Bristol-Myers Covid Drug Failed Phase 2 Study,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Covid Drug Failed Phase 2 Study -- Market Talk
BMY,2022-05-02,19:43:34,94637C,Bristol-Myers Squibb Co.,100,-0.8,products-services,negative,Bristol-Myers Covid Drug Failed Phase 2 Study,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Covid Drug Failed Phase 2 Study -- Market Talk
BMY,2022-05-04,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference
BMY,2022-05-04,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference
BMY,2022-05-04,12:00:12,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Enters Strategic Collaboration with Bristol Myers Squibb for,PRESS-RELEASE,PR Newswire,Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
BMY,2022-05-04,12:02:10,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Enters Strategic Collaboration with Bristol Myers Squibb for,PRESS-RELEASE,PR Newswire,Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
BMY,2022-05-04,12:08:07,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Enters Strategic Collaboration with Bristol Myers Squibb for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
BMY,2022-05-10,11:12:23,94637C,Bristol-Myers Squibb Co.,100,0.41,products-services,start,Ima401 Phase 1 Trial Started at First,NEWS-FLASH,Dow Jones Newswires,Immatics Patient Enrollment for IMA401 Phase 1 Trial Started at First Clinical Site in Germany >IMTX
BMY,2022-05-10,14:29:46,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb extend and expand strategic partnership,PRESS-RELEASE,DGAP News,DGAP-Adhoc: Evotec and Bristol Myers Squibb extend and expand strategic partnership
BMY,2022-05-10,14:29:46,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb extend and expand strategic partnership,PRESS-RELEASE,Dow Jones Newswires,DGAP-Adhoc: Evotec and Bristol Myers Squibb extend and expand strategic partnership
BMY,2022-05-10,14:31:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb extend and expand strategic partnership,PRESS-RELEASE,DGAP News,PRESS RELEASE: Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
BMY,2022-05-10,14:31:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb extend and expand strategic partnership,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
BMY,2022-05-10,14:45:54,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership,PRESS-RELEASE,DJ Global Press Release Wire,Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
BMY,2022-05-10,14:55:54,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership,PRESS-RELEASE,DJ Global Press Release Wire,Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership
BMY,2022-05-12,11:30:02,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bridgebio Announces Exclusive License Agreement with Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,"BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology"
BMY,2022-05-12,11:30:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"In July 2021, BridgeBio initially announced a non-exclusive, co-funded clinical collaboration with Bristol Myers Squibb",PRESS-RELEASE,GlobeNewswire,"BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology"
BMY,2022-05-12,11:30:02,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bridgebio Announces Exclusive License Agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,"Press Release: BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology"
BMY,2022-05-12,11:30:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"In July 2021, BridgeBio initially announced a non-exclusive, co-funded clinical collaboration with Bristol Myers Squibb",PRESS-RELEASE,Dow Jones Newswires,"Press Release: BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology"
BMY,2022-05-12,11:31:25,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bridgebio Announces Exclusive License Agreement With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,"BridgeBio Announces Exclusive License Agreement With Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology"
BMY,2022-05-13,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.58,acquisitions-mergers,,"Lotte to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York",PRESS-RELEASE,Business Wire,"LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York"
BMY,2022-05-13,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Agreed to purchase Bristol Myers Squibb's manufacturing facility in East Syracuse, New York",PRESS-RELEASE,Business Wire,"LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York"
BMY,2022-05-13,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.58,acquisitions-mergers,,"Lotte to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York",PRESS-RELEASE,Dow Jones Newswires,"Press Release: LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York"
BMY,2022-05-13,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Agreed to purchase Bristol Myers Squibb's manufacturing facility in East Syracuse, New York",PRESS-RELEASE,Dow Jones Newswires,"Press Release: LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York"
BMY,2022-05-13,11:00:39,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Lotte to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, NY",NEWS-FLASH,Dow Jones Newswires,"LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, NY"
BMY,2022-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.62,products-services,positive,Opdivo has shown clinical benefit,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2022-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -4-
BMY,2022-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -5-
BMY,2022-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -5-
BMY,2022-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,products-services,positive,Opdivo has shown clinical benefit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2022-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -4-
BMY,2022-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -5-
BMY,2022-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -5-
BMY,2022-05-16,21:35:22,94637C,Bristol-Myers Squibb Co.,100,-0.34,equity-actions,decrease,Berkshire Hathaway Eliminates Stakes in Bristol Myers Squibb,RNS-SEC13F,Dow Jones Newswires,Berkshire Hathaway Eliminates Stakes in Bristol Myers Squibb and AbbVie -- 13F Filing
BMY,2022-05-17,10:51:16,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
BMY,2022-05-17,10:51:16,94637C,Bristol-Myers Squibb Co.,100,0.68,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $70.00/Share From $65.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $70.00/Share From $65.00 by Wells Fargo
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Data from Phase 1 studies of CC-99282,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,earnings,,"Bristol-Myers Squibb Co.: Long-term Safety Vip Viprakasit Poster Friday, June 10, Results",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 -3-
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,97,0.0,products-services,,Bristol-Myers Squibb Co.: First Clinical Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 -4-
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 -6-
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 -8-
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 -10-
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 -11-
BMY,2022-05-19,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASCO and EHA 2022 -13-
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Data from Phase 1 studies of CC-99282,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,earnings,,"Bristol-Myers Squibb Co.: Long-term Safety Vip Viprakasit Poster Friday, June 10, Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -3-
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,products-services,,Bristol-Myers Squibb Co.: First Clinical Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -4-
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -6-
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -8-
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -10-
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -11-
BMY,2022-05-19,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASCO -13-
BMY,2022-05-26,04:29:31,94637C,Bristol-Myers Squibb Co.,96,0.0,investor-relations,,Bristol-Myers Squibb Co.: the company's earnings call for the first quarter of 2022,FULL-ARTICLE,Dow Jones Newswires,Why Bristol Myers Stock Is Still a Buy -- Barrons.com
BMY,2022-05-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Bernstein's 38(th) Annual Strategic Decisions Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Bernstein's 38(th) Annual Strategic Decisions Conference
BMY,2022-05-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Bernstein's 38th Annual Strategic Decisions Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Bernstein's 38th Annual Strategic Decisions Conference
BMY,2022-05-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will take part in a fireside chat at Bernstein's 38(th) Annual Strategic Decisions Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Bernstein's 38th Annual Strategic Decisions Conference
BMY,2022-05-26,11:09:51,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Buy by Citigroup
BMY,2022-05-26,11:09:51,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $90.00/Share From $75.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $90.00/Share From $75.00 by Citigroup
BMY,2022-05-26,21:00:00,94637C,Bristol-Myers Squibb Co.,96,0.4,products-services,start,Bristol-Myers Squibb Co.: All enrolled patients,PRESS-RELEASE,Business Wire,Data from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy
BMY,2022-05-26,21:00:00,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Data from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy
BMY,2022-05-26,21:29:33,94637C,Bristol-Myers Squibb Co.,97,0.4,products-services,start,Bristol-Myers Squibb Co.: All enrolled patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy
BMY,2022-05-26,21:29:33,94637C,Bristol-Myers Squibb Co.,97,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy
BMY,2022-05-27,22:11:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Two Opdivo(R) (nivolumab)-Based Regimens as First-Line Treatments for Unresectable,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Two Opdivo(R) (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BMY,2022-05-27,22:11:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Two Opdivo(R) (nivolumab)-Based Regimens as First-Line Treatments for Unresectable,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Two Opdivo(R) (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BMY,2022-05-27,22:13:12,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Two Opdivo-Based Regimens as First-Line Treatments for Unresectable,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: FDA Approves Two Opdivo-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BMY,2022-05-27,22:30:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Two Opdivo-Based Regimens,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says FDA Approves Two Opdivo-Based Regimens
BMY,2022-05-27,22:45:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Two Opdivo-Based Regimens,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says FDA Approves Two Opdivo-Based Regimens
BMY,2022-05-28,01:30:18,94637C,Bristol-Myers Squibb Co.,97,0.0,investor-relations,,Bristol-Myers Squibb Co.: the company's earnings call for the first quarter of 2022,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Looks Like The Right Medicine
BMY,2022-05-28,01:30:18,94637C,Bristol-Myers Squibb Co.,97,0.0,investor-relations,,Bristol-Myers Squibb Co.: the company's earnings call for the first quarter of 2022,FULL-ARTICLE,Barrons,Bristol Myers Looks Like The Right Medicine -- Barron's
BMY,2022-06-01,00:30:02,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Antengene to Present Clinical Results of ATG-008 (Onatasertib),PRESS-RELEASE,PR Newswire,Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting
BMY,2022-06-01,00:30:02,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Antengene to Present Clinical Results of ATG-008 (Onatasertib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting
BMY,2022-06-01,11:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb: Advancing Deucravacitinib Into Phase 3 Studies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: Advancing Deucravacitinib Into Phase 3 Studies for Systemic Lupus Erythematosus >BMY
BMY,2022-06-02,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics and Bristol Myers Squibb Expand Strategic Alliance to,PRESS-RELEASE,Business Wire,Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
BMY,2022-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics and Bristol Myers Squibb Expand Strategic Alliance to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
BMY,2022-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics and Bristol Myers Squibb Expand Strategic Alliance to,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
BMY,2022-06-02,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics and Bristol Myers Squibb Expand Strategic Alliance to,PRESS-RELEASE,GlobeNewswire,Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
BMY,2022-06-02,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics and Bristol Myers Squibb Expand Strategic Alliance to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
BMY,2022-06-02,10:59:08,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics and Bristol Myers Squibb Expand Strategic Alliance to,NEWS-FLASH,Dow Jones Newswires,Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
BMY,2022-06-02,11:00:35,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics and Bristol Myers Squibb Expand Strategic Alliance to,NEWS-FLASH,Dow Jones Newswires,Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
BMY,2022-06-02,11:33:50,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics in 2019 teamed with Celgene,FULL-ARTICLE,Dow Jones Newswires,"Immatics, Bristol Myers Squibb Expand Alliance"
BMY,2022-06-02,11:44:26,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,"Bristol Myers Squibb, Immatics expand CAR-T agreement",FULL-ARTICLE,MarketWatch,"MW Bristol Myers Squibb, Immatics expand CAR-T agreement"
BMY,2022-06-02,11:44:26,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,"Bristol Myers Squibb, Immatics Expand CAR-T Agreement",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb, Immatics Expand CAR-T Agreement -- MarketWatch"
BMY,2022-06-02,11:48:50,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Immatics in 2019 teamed with Celgene,FULL-ARTICLE,Dow Jones Newswires,"Immatics, Bristol Myers Squibb Expand Alliance"
BMY,2022-06-02,15:01:00,94637C,Bristol-Myers Squibb Co.,97,0.0,products-services,,Bristol-Myers Squibb Co.: Immunosuppression: In clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19
BMY,2022-06-02,15:01:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,"Bristol-Myers Squibb Co.: However, abatacept was present",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Topline Results -2-
BMY,2022-06-02,15:01:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,"Bristol-Myers Squibb Co.: However, abatacept was present",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2022-06-03,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb To Acquire Turning Point Therapeutics,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb To Acquire Turning Point Therapeutics, A Leading Precision Oncology Company >BMY"
BMY,2022-06-03,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Acquire Turning Point Therapeutics,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company"
BMY,2022-06-03,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.63,acquisitions-mergers,,"Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company"
BMY,2022-06-03,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Acquire Turning Point,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Acquire Turning Point -2-
BMY,2022-06-03,10:59:30,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company"
BMY,2022-06-03,10:59:30,94637C,Bristol-Myers Squibb Co.,100,0.63,acquisitions-mergers,,"Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company"
BMY,2022-06-03,10:59:30,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Acquire -2-
BMY,2022-06-03,11:03:05,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to buy Turning Point Therapeutics in a deal,NEWS-FLASH,MarketWatch,MW Bristol Myers to buy Turning Point Therapeutics in a deal valuing Turning Point at about $3.8 bln
BMY,2022-06-03,11:13:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Turning Point Therapeutics for $4.1 Billion >BMY,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Buy Turning Point Therapeutics for $4.1 Billion >BMY TPTX
BMY,2022-06-03,11:28:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Turning Point Therapeutics for $4.1 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Buy Turning Point Therapeutics for $4.1 Billion
BMY,2022-06-03,11:40:03,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Turning Point Therapeutics for $4.1 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Buy Turning Point Therapeutics for $4.1 Billion
BMY,2022-06-03,14:06:16,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Agreed to be acquired by Bristol Myers Squibb Co. for $4.1 billion,FULL-ARTICLE,Dow Jones Newswires,Turning Point Therapeutics Shares Surge on Bristol Myers Deal >TPTX
BMY,2022-06-03,14:10:24,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion -- Update
BMY,2022-06-03,14:21:17,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Agreed to be acquired by Bristol Myers Squibb Co. for $4.1 billion,FULL-ARTICLE,Dow Jones Newswires,Turning Point Therapeutics Shares Surge on Bristol Myers Deal
BMY,2022-06-03,14:53:42,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Market Perform From Outperform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Market Perform From Outperform by Raymond James
BMY,2022-06-03,15:46:49,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Acquire HBM Portfolio Company Turning Point Therapeutics for USD 4.1 billion,PRESS-RELEASE,Dow Jones Newswires,Bristol Myers Squibb to Acquire HBM Portfolio Company Turning Point Therapeutics for USD 4.1 billion in cash
BMY,2022-06-03,15:46:49,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Acquire HBM Portfolio Company Turning Point Therapeutics for USD 4.1 billion,PRESS-RELEASE,DGAP News,Bristol Myers Squibb to Acquire HBM Portfolio Company Turning Point Therapeutics for USD 4.1 billion in cash
BMY,2022-06-03,17:49:10,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion -- 2nd,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion -- 2nd Update
BMY,2022-06-03,20:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.45,products-services,withdrawn,Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl(R) (luspatercept-aamt),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl(R) (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia
BMY,2022-06-03,20:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.45,products-services,withdrawn,Bristol-Myers Squibb Co.: the company has withdrawn a supplemental biologics license application (sBLA),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl(R) (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia
BMY,2022-06-03,20:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.45,products-services,withdrawn,Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl(R) (luspatercept-aamt),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl(R) (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia
BMY,2022-06-03,20:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.45,products-services,withdrawn,Bristol-Myers Squibb Co.: the company has withdrawn a supplemental biologics license application (sBLA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl(R) (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia
BMY,2022-06-03,21:03:22,94637C,Bristol-Myers Squibb Co.,100,-0.45,products-services,withdrawn,Bristol Myers Squibb: Withdraws Supplemental Biologics License Application for Reblozyl,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: Withdraws Supplemental Biologics License Application for Reblozyl for Non-Transfusion Dependent Beta Thalassemia
BMY,2022-06-04,06:10:12,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co. said it would acquire biotechnology company Turning Point Therapeutics Inc. for $4.1 billion,FULL-ARTICLE,Dow Jones Newswires,EXCHANGE  ---  Bristol-Myers Agrees to Buy  Biotech Firm Turning Point  ----  By Jared S. Hopkins and Colin Kellaher
BMY,2022-06-04,06:32:11,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co. said it would acquire biotechnology company Turning Point Therapeutics Inc. for $4.1 billion,FULL-ARTICLE,Wall Street Journal,Bristol-Myers Agrees to Buy Biotech Firm Turning Point -- WSJ
BMY,2022-06-06,08:47:39,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Market Perform From Outperform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Market Perform From Outperform by Raymond James
BMY,2022-06-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Goldman Sachs 43(rd) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Goldman Sachs 43(rd) Annual Global Healthcare Conference
BMY,2022-06-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will take part in a fireside chat at Goldman Sachs' 43(rd) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Goldman Sachs 43(rd) Annual Global Healthcare Conference
BMY,2022-06-07,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
BMY,2022-06-07,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will take part in a fireside chat at Goldman Sachs' 43(rd) Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
BMY,2022-06-07,21:51:03,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Leung Sells 65,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Leung Sells 65,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-06-08,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022"
BMY,2022-06-08,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: To be directly connected to the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022"
BMY,2022-06-08,10:59:42,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022"
BMY,2022-06-08,10:59:42,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: To be directly connected to the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022"
BMY,2022-06-14,21:59:53,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 30,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Caforio Sells 30,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-06-15,19:30:23,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp Leung Registers 65,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP Leung Registers 65,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-06-15,19:58:13,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Company Management presents at Goldman Sachs 43rd Annual Global Healthcare Conference,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Company Management presents at Goldman Sachs 43rd Annual Global Healthcare Conference >BMY
BMY,2022-06-15,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2022-06-15,20:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2022-06-20,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
BMY,2022-06-20,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
BMY,2022-06-20,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for CAR,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
BMY,2022-06-20,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
BMY,2022-06-20,19:37:13,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Eliquis Now Available in Canada,PRESS-RELEASE,Canadian News Wire,First Generic Alternative to Eliquis Now Available in Canada
BMY,2022-06-22,17:44:33,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Chmn Caforio Registers 30,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"Chmn Caforio Registers 30,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-06-24,16:52:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
BMY,2022-06-24,16:52:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
BMY,2022-06-24,16:52:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration (FDA) approved Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
BMY,2022-06-24,16:52:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
BMY,2022-06-24,16:52:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Zeposia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
BMY,2022-06-24,16:52:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration (FDA) approved Zeposia,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
BMY,2022-06-24,23:05:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's CAR,NEWS-FLASH,Dow Jones Newswires,U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi(R) For Relapsed Or Refractory Large B-cell Lymphoma After One Prior Therapy >BMY
BMY,2022-06-24,23:05:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's CAR,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi(R) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2022-06-24,23:05:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi(R) (lisocabtagene maraleucel),PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi(R) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2022-06-24,23:05:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's CAR,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's CAR T -2-
BMY,2022-06-24,23:05:00,94637C,Bristol-Myers Squibb Co.,100,0.4,products-services,start,Bristol-Myers Squibb Co.: All enrolled patients,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's CAR T -2-
BMY,2022-06-24,23:05:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's CAR T -2-
BMY,2022-06-24,23:05:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's CAR,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's CAR T -3-
BMY,2022-06-24,23:41:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's CAR,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi(R) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2022-06-24,23:41:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi(R) (lisocabtagene maraleucel),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi(R) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2022-06-24,23:41:22,94637C,Bristol-Myers Squibb Co.,92,0.4,products-services,start,Bristol-Myers Squibb Co.: All enrolled patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers -2-
BMY,2022-06-24,23:41:22,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers -2-
BMY,2022-06-28,15:25:53,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO (nivolumab) as,PRESS-RELEASE,Canadian News Wire,Health Canada Approves OPDIVO (nivolumab) as Monotherapy for the Adjuvant treatment of Adults with Urothelial Carcinoma (UC) at High Risk of Recurrence after Undergoing Radical Resection of UC
BMY,2022-06-28,15:25:54,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO(R) (nivolumab) as,PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Approves OPDIVO (nivolumab) as Monotherapy for the Adjuvant treatment of Adults with Urothelial Carcinoma (UC) at High Risk of Recurrence after Undergoing Radical Resection of UC
BMY,2022-06-28,15:26:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb: Health Canada Approves OPDIVO as Monotherapy for Adjuvant Treatment of Adults With Urothelial Carcinoma,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: Health Canada Approves OPDIVO as Monotherapy for Adjuvant Treatment of Adults With Urothelial Carcinoma at High Risk of Recurrence After Radical Resection
BMY,2022-07-05,20:28:51,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 4,570 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Hirawat Acquires 4,570 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-07-05,20:31:11,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Weese Acquires 1,203 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Weese Acquires 1,203 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-07-06,17:29:43,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,Vp Santiago Registers 700 Of Bristol-Myers Squibb Co >BMY,RNS-SEC144,Dow Jones Newswires,VP Santiago Registers 700 Of Bristol-Myers Squibb Co >BMY
BMY,2022-07-12,12:15:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Celgene (which was acquired by Bristol Myers Squibb in 2019,PRESS-RELEASE,Business Wire,"Sampled Appoints Sarah Hersey, VP, Head of Translational Sciences & Diagnostics at Bristol Myers Squibb, as its First Independent Director"
BMY,2022-07-21,06:00:26,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Oxford Biomedica PLC Expanded Agreement with BMS,PRESS-RELEASE,LSE Regulatory News Service (RNS),Oxford Biomedica PLC Expanded Agreement with BMS's Juno in CAR-T
BMY,2022-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol Myers Squibb Teams Up with Jack and Jill of,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Teams Up with Jack and Jill of America Inc. to Expand Tomorrow's Innovators Program to Increase Black Representation in the Healthcare Industry
BMY,2022-07-21,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb Teams Up with Jack and Jill of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Teams Up with Jack and Jill of America Inc. to Expand Tomorrow's Innovators Program to Increase Black Representation in the Healthcare Industry
BMY,2022-07-22,01:32:13,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lenalidomide Is Conditionally Approved by FDA,NEWS-FLASH,Dow Jones Newswires,"InnoCare: Tafasitamab in Combination With Lenalidomide Is Conditionally Approved by FDA, EMA for Treatment of Relapsed or Refractory DLBCL Patients Not Eligible for ASCT >09969.HK"
BMY,2022-07-22,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Recommendation based on results from the Phase 2/3 RELATIVITY-047 trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma
BMY,2022-07-22,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2022-07-22,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -7-
BMY,2022-07-22,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Recommendation based on results from the Phase 2/3 RELATIVITY-047 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma
BMY,2022-07-22,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-07-22,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -7-
BMY,2022-07-25,07:17:04,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2022 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2022 (BMY)"
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q Adj EPS $1.93,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Adj EPS $1.93 >BMY
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q EPS 66c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q EPS 66c >BMY
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q Net $1.4B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Net $1.4B >BMY
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 2Q Rev $11.9B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Rev $11.9B >BMY
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports Second Quarter Revenues of $11.9 Billion, an Increase of 2% YoY",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Second Quarter Earnings Per Share of $0.66,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts 2022 GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Reaffirms Non-GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2022,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.32,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 16% to $3.6 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.24,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 6% to $2.3 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD decreased from $793 million,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol-Myers Squibb Co.: For purposes of comparability, the non-GAAP financial results for the second quarter of 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.04,revenues,,Bristol-Myers Squibb Co.: International revenues were $858 million compared to $834 million,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Eliquis revenues grew 16%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.46,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.2 billion compared to $1.7 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 8%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 2%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.38,revenues,down,Bristol-Myers Squibb Co.: Abraxane revenues declined 19%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Administration (FDA) approved Opdivo (injection for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Fda approved Breyanzi (lisocabtagene maraleucel,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,withdrawn,Bristol-Myers Squibb Co.: The company withdrew a (luspatercept-aamt) supplemental biologics license application,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Two-year results from the Phase 3,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Which Bristol Myers Squibb will acquire Turning Point pursuant to,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: the company, in collaboration with Disability Solutions, announced the launch of the Disability",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Sales,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusting GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS(3) $2.92-$3.22,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: July guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today at 8 a.m. EDT,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: the company's Annual Report on Form 10-K for the year ended December 31, 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -7-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -7-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE SIX MONTHS ENDED JUNE 30, 2022",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -7-
BMY,2022-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,96,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.67 $ 0.47 $,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -8-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Reports Second Quarter Revenues of $11.9 Billion, an Increase of 2% YoY",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Second Quarter Earnings Per Share of $0.66,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts 2022 GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Reaffirms Non-GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.32,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 16% to $3.6 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.24,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 6% to $2.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD decreased from $793 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol-Myers Squibb Co.: For purposes of comparability, the non-GAAP financial results for the second quarter of 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.04,revenues,,Bristol-Myers Squibb Co.: International revenues were $858 million compared to $834 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Eliquis revenues grew 16%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.46,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.2 billion compared to $1.7 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 8%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 2%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.38,revenues,down,Bristol-Myers Squibb Co.: Abraxane revenues declined 19%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Administration (FDA) approved Opdivo (injection for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Fda approved Breyanzi (lisocabtagene maraleucel,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,withdrawn,Bristol-Myers Squibb Co.: The company withdrew a (luspatercept-aamt) supplemental biologics license application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Two-year results from the Phase 3,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Which Bristol Myers Squibb will acquire Turning Point pursuant to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: the company, in collaboration with Disability Solutions, announced the launch of the Disability",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Sales,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusting GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS(3) $2.92-$3.22,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: July guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today at 8 a.m. EDT,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: the company's Annual Report on Form 10-K for the year ended December 31, 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE SIX MONTHS ENDED JUNE 30, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2022-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.67 $ 0.47 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2022-07-27,11:00:44,94637C,Bristol-Myers Squibb Co.,100,0.54,earnings,up,Bristol-Myers Squibb Q2 EPS 66 cents vs. 47 cents a year ago,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb Q2 EPS 66 cents vs. 47 cents a year ago
BMY,2022-07-27,11:00:59,94637C,Bristol-Myers Squibb Co.,100,0.46,earnings,above-expectations,Bristol-Myers Squibb Q2 adj. EPs $1.93; FactSet consensus $1.77,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb Q2 adj. EPs $1.93; FactSet consensus $1.77
BMY,2022-07-27,11:01:27,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Q2 revenue $11.9 bln, up 2% from a year ago",NEWS-FLASH,MarketWatch,"MW Bristol-Myers Squibb Q2 revenue $11.9 bln, up 2% from a year ago; FactSet consensus $11.4 bln"
BMY,2022-07-27,11:01:53,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Sees 2022 Sales $46B >BMY,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2022 Sales $46B >BMY
BMY,2022-07-27,11:02:33,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,unchanged,Bristol-Myers Squibb Backs 2022 View of Adj EPS $7.44,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Backs 2022 View of Adj EPS $7.44-Adj EPS $7.74 >BMY
BMY,2022-07-27,11:04:16,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb lowers full-year GAAP EPS guidance to $2.71 to $3.01,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb lowers full-year GAAP EPS guidance to $2.71 to $3.01 vs. prior $2.92 to $3.22
BMY,2022-07-27,11:04:35,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb still sees full-year adj. EPS of $7.44 to $7.74,NEWS-FLASH,MarketWatch,MW Bristol-Myers Squibb still sees full-year adj. EPS of $7.44 to $7.74
BMY,2022-07-27,11:29:32,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb Beats Earnings Estimates,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Beats Earnings Estimates, but Shares Fall -- Barrons.com"
BMY,2022-07-27,11:29:32,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb announced second quarter earnings early Wednesday,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Beats Earnings Estimates, but Shares Fall -- Barrons.com"
BMY,2022-07-27,11:29:32,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Ticker: BMY) revenue were $11.9 billion for the quarter,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Beats Earnings Estimates, but Shares Fall -- Barrons.com"
BMY,2022-07-27,11:33:28,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb says Eliquis revenue jumped 16% in the second quarter,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb says Eliquis revenue jumped 16% in the second quarter
BMY,2022-07-27,11:33:28,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb Co.: the company lowered guidance,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb says Eliquis revenue jumped 16% in the second quarter
BMY,2022-07-27,11:33:28,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb Says Eliquis Revenue Jumped 16% In The Second Quarter,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says Eliquis Revenue Jumped 16% In The Second Quarter -- MarketWatch
BMY,2022-07-27,11:33:28,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb Co.: the company lowered guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Says Eliquis Revenue Jumped 16% In The Second Quarter -- MarketWatch
BMY,2022-07-27,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb Beats Earnings Estimates,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Beats Earnings Estimates, but Shares Fall"
BMY,2022-07-27,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb announced second quarter earnings early Wednesday,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Beats Earnings Estimates, but Shares Fall"
BMY,2022-07-27,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Ticker: BMY) revenue were $11.9 billion for the quarter,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Beats Earnings Estimates, but Shares Fall"
BMY,2022-07-27,15:21:53,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Company CEO Giovanni Caforio on Q2 2022 Results -- Earnings Call,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Company CEO Giovanni Caforio on Q2 2022 Results -- Earnings Call Transcript >BMY
BMY,2022-07-28,10:15:34,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities
BMY,2022-07-28,10:15:34,94637C,Bristol-Myers Squibb Co.,100,0.3,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $83.00/Share From $82.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $83.00/Share From $82.00 by Atlantic Equities
BMY,2022-07-28,13:28:55,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by UBS
BMY,2022-07-28,13:28:55,94637C,Bristol-Myers Squibb Co.,100,0.42,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $75.00/Share From $73.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $75.00/Share From $73.00 by UBS
BMY,2022-07-28,14:25:15,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2022-07-28,14:25:15,94637C,Bristol-Myers Squibb Co.,100,-0.46,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $61.00/Share From $63.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $61.00/Share From $63.00 by Morgan Stanley
BMY,2022-07-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -4-
BMY,2022-07-29,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -5-
BMY,2022-07-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on CheckMate -6-
BMY,2022-07-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -4-
BMY,2022-07-29,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -5-
BMY,2022-07-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Ono and Bristol Myers Squibb further expanded the companies' strategic collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -6-
BMY,2022-08-10,10:45:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Results of a pre-specified interim analysis,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
BMY,2022-08-10,10:45:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
BMY,2022-08-10,10:49:02,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Results of a pre-specified interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
BMY,2022-08-10,10:49:02,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
BMY,2022-08-10,11:00:06,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Gentibio Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases
BMY,2022-08-17,12:31:00,94637C,Bristol-Myers Squibb Co.,100,0.5,acquisitions-mergers,completed,Bristol Myers Squibb completed the acquisition of Turning Point through the merger of its wholly owned subsidiary,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio"
BMY,2022-08-17,12:31:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers Squibb's previously announced tender offer for all outstanding shares of common stock,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio"
BMY,2022-08-17,12:31:00,94637C,Bristol-Myers Squibb Co.,100,0.5,acquisitions-mergers,completed,Bristol Myers Squibb completed the acquisition of Turning Point through the merger of its wholly owned subsidiary,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio"
BMY,2022-08-17,12:31:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers Squibb's previously announced tender offer for all outstanding shares of common stock,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio"
BMY,2022-08-17,12:31:10,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio"
BMY,2022-08-23,12:30:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO (nivolumab) with,PRESS-RELEASE,Canadian News Wire,Health Canada Approves OPDIVO (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Adult Patients with Resectable Non-Small Cell Lung Cancer
BMY,2022-08-23,12:30:06,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bms) announced Health Canada's approval of OPDIVO(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Approves OPDIVO (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Adult Patients with Resectable Non-Small Cell Lung Cancer
BMY,2022-08-23,12:30:35,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Health Canada Approves OPDIVO (nivolumab) With,NEWS-FLASH,Dow Jones Newswires,Health Canada Approves OPDIVO (nivolumab) With Chemotherapy as Neoadjuvant Treatment for Adult Patients With Resectable Non-Small Cell Lung Cancer
BMY,2022-08-23,13:00:36,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bio Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,A-Alpha Bio Announces Collaboration with Bristol Myers Squibb to Discover Molecular Glue Targets for Protein Degradation
BMY,2022-08-25,13:00:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: we have entered into a long-term collaboration with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,PathAI Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
BMY,2022-08-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Citi's 17(th) Annual BioPharma Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Citi's 17(th) Annual BioPharma Conference
BMY,2022-08-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will take part in a fireside chat at Citi's 17(th) Annual BioPharma Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Citi's 17(th) Annual BioPharma Conference
BMY,2022-08-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Citi's 17th Annual BioPharma Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Citi's 17th Annual BioPharma Conference
BMY,2022-08-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will take part in a fireside chat at Citi's 17(th) Annual BioPharma Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Citi's 17th Annual BioPharma Conference
BMY,2022-09-05,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Long-term data continue to reinforce benefits of Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
BMY,2022-09-05,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Safety, efficacy, pharmacokinetic and pharmacodynamic data from the Phase 1/2 study",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
BMY,2022-09-05,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Phase 3 study of cabozantinib,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
BMY,2022-09-05,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO Congress -6-
BMY,2022-09-05,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Research at ESMO Congress -8-
BMY,2022-09-05,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Long-term data continue to reinforce benefits of Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
BMY,2022-09-05,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: Safety, efficacy, pharmacokinetic and pharmacodynamic data from the Phase 1/2 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
BMY,2022-09-05,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Phase 3 study of cabozantinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
BMY,2022-09-05,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at -6-
BMY,2022-09-05,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Research at -8-
BMY,2022-09-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
BMY,2022-09-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will take part in a fireside chat at the Morgan Stanley 20(th) Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
BMY,2022-09-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
BMY,2022-09-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol-Myers Squibb Co.: the company will take part in a fireside chat at the Morgan Stanley 20(th) Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
BMY,2022-09-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022"
BMY,2022-09-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: To be directly connected to the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022"
BMY,2022-09-07,11:17:13,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022"
BMY,2022-09-07,11:17:13,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: To be directly connected to the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022"
BMY,2022-09-07,11:45:35,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Cipla receives USFDA approval for generic version of Revlimid(R) (Lenalidomide,PRESS-RELEASE,PR Newswire,Cipla receives USFDA approval for generic version of Revlimid(R) (Lenalidomide capsules)
BMY,2022-09-07,11:45:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Cipla receives USFDA approval for generic version of Revlimid(R) (Lenalidomide,PRESS-RELEASE,Dow Jones Newswires,Press Release: Cipla receives USFDA approval for generic version of Revlimid(R) (Lenalidomide capsules)
BMY,2022-09-08,23:39:00,94637C,Bristol-Myers Squibb Co.,100,0.41,products-services,start,Innocare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide,PRESS-RELEASE,Business Wire,InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
BMY,2022-09-08,23:39:00,94637C,Bristol-Myers Squibb Co.,100,0.41,products-services,start,Innocare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide,PRESS-RELEASE,Business Wire,InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
BMY,2022-09-08,23:39:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lenalidomide has been approved by the Health Commission,PRESS-RELEASE,Business Wire,InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
BMY,2022-09-08,23:39:00,94637C,Bristol-Myers Squibb Co.,100,0.41,products-services,start,Innocare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide,PRESS-RELEASE,Dow Jones Newswires,Press Release: InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
BMY,2022-09-08,23:39:00,94637C,Bristol-Myers Squibb Co.,100,0.41,products-services,start,Innocare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide,PRESS-RELEASE,Dow Jones Newswires,Press Release: InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
BMY,2022-09-08,23:39:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lenalidomide has been approved by the Health Commission,PRESS-RELEASE,Dow Jones Newswires,Press Release: InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
BMY,2022-09-10,06:30:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration approved Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces New -2-
BMY,2022-09-10,06:30:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration approved Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces New Sotyktu(TM) -2-
BMY,2022-09-12,08:42:55,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities
BMY,2022-09-12,08:42:55,94637C,Bristol-Myers Squibb Co.,100,0.56,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $87.00/Share From $83.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $87.00/Share From $83.00 by Atlantic Equities
BMY,2022-09-12,14:36:11,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Wins FDA Nod for Otezla,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Wins FDA Nod for Otezla Competitor
BMY,2022-09-12,12:00:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol Myers Squibb, presented updated Phase 1 results with BMS-986249",PRESS-RELEASE,GlobeNewswire,CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody(R) Therapeutic BMS-986249
BMY,2022-09-12,12:00:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bms-986288, partnered with Bristol Myers Squibb, as well as",PRESS-RELEASE,GlobeNewswire,CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody(R) Therapeutic BMS-986249
BMY,2022-09-12,12:00:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol Myers Squibb, presented updated Phase 1 results with BMS-986249",PRESS-RELEASE,Dow Jones Newswires,Press Release: CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody(R) Therapeutic BMS-986249
BMY,2022-09-12,12:00:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bms-986288, partnered with Bristol Myers Squibb, as well as",PRESS-RELEASE,Dow Jones Newswires,Press Release: CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody(R) Therapeutic BMS-986249
BMY,2022-09-12,12:29:06,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital
BMY,2022-09-12,12:29:06,94637C,Bristol-Myers Squibb Co.,100,0.4,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $94.00/Share From $92.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $94.00/Share From $92.00 by BMO Capital
BMY,2022-09-12,14:20:50,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Wins FDA Nod for Otezla,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Wins FDA Nod for Otezla Competitor
BMY,2022-09-12,14:21:11,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Wins FDA Nod for Otezla,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Wins FDA Nod for Otezla Competitor
BMY,2022-09-12,14:35:50,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Wins FDA Nod for Otezla,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Wins FDA Nod for Otezla Competitor
BMY,2022-09-14,08:53:26,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Hold From Buy by Berenberg,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Hold From Buy by Berenberg
BMY,2022-09-14,08:53:26,94637C,Bristol-Myers Squibb Co.,100,-0.7,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $76.00/Share From $82.00 by Berenberg,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $76.00/Share From $82.00 by Berenberg
BMY,2022-09-14,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2022-09-14,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2022-09-14,20:33:24,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Cfo Elkins Registers 133,951 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"CFO Elkins Registers 133,951 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-15,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2022-09-15,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -5-
BMY,2022-09-15,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Adjuvant Treatment -3-
BMY,2022-09-15,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Adjuvant Treatment -5-
BMY,2022-09-15,11:15:27,94637C,Bristol-Myers Squibb Co.,94,0.0,products-services,,Bristol Myers Squibb Co. said its Phase 3 trial of Opdivo as an adjuvant treatment for patients,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Trial for Certain Type of Skin Cancer Meets Primary Endpoint
BMY,2022-09-15,11:30:27,94637C,Bristol-Myers Squibb Co.,94,0.0,products-services,,Bristol Myers Squibb Co. said its Phase 3 trial of Opdivo as an adjuvant treatment for patients,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb: Opdivo Trial for Certain Type of Skin Cancer Meets Primary Endpoint
BMY,2022-09-15,18:56:32,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp Powell Registers 25,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP Powell Registers 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-15,23:31:09,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Powell Sells 25,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Powell Sells 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-15,23:32:50,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Cfo Elkins Sells 133,951 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Elkins Sells 133,951 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-16,20:15:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%"
BMY,2022-09-16,20:15:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2022-09-16,20:15:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%"
BMY,2022-09-16,20:15:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2022-09-16,20:24:50,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb: Receives European Commission Approval for LAG-3-Blocking Antibody,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag for the Treatment of Unresectable or Metastatic Melanoma With Tumor Cell PD-L1 Expression < 1%"
BMY,2022-09-16,20:39:41,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol Myers Squibb Co. said Friday that the European Commission approved the fixed-dose,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Skin Cancer Treatment Opdualag Gets Approval from European Commission
BMY,2022-09-16,20:54:41,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol Myers Squibb Co. said Friday that the European Commission approved the fixed-dose,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Skin Cancer Treatment Opdualag Gets Approval from European Commission
BMY,2022-09-16,21:13:39,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 50,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Caforio Sells 50,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-16,21:14:33,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Chmn Caforio Registers 50,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"Chmn Caforio Registers 50,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-20,20:56:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"In Collaboration with Bristol Myers Squibb, to",PRESS-RELEASE,PR Newswire,"Lyfebulb Seeks Applicants for the Global 2022 Innovation Challenge, in Collaboration with Bristol Myers Squibb, to Address Unmet Needs in Inflammatory Bowel Disease"
BMY,2022-09-21,15:38:30,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Chmn Caforio Registers 25,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"Chmn Caforio Registers 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-22,21:14:18,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co",FULL-ARTICLE,Dow Jones Newswires,"Chmn Caforio Sells 25,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-09-29,10:30:03,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: The first Fully Digital, Clinical Trial Solution",PRESS-RELEASE,PR Newswire,Bristol Myers Squibb and ConcertAI Advance Novel Oncology Accelerated Digital Clinical Trial Solution
BMY,2022-09-29,10:32:31,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: The first Fully Digital, Clinical Trial Solution",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and ConcertAI Advance Novel Oncology Accelerated Digital Clinical Trial Solution
BMY,2022-10-04,11:00:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for,PRESS-RELEASE,GlobeNewswire,Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus' Proprietary Safety Switch System
BMY,2022-10-04,11:00:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus' Proprietary Safety Switch System
BMY,2022-10-04,11:03:10,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Autolus Therapeutics Announces Collaboration With Bristol Myers Squibb for,NEWS-FLASH,Dow Jones Newswires,Autolus Therapeutics Announces Collaboration With Bristol Myers Squibb for Use of Autolus' Proprietary Safety Switch System
BMY,2022-10-04,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial
BMY,2022-10-04,12:00:25,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Exelixis Expands Clinical Trial Collaboration and Supply Agreement With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Exelixis Expands Clinical Trial Collaboration and Supply Agreement With Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination With XL092 in Phase 1b STELLAR-002 Trial
BMY,2022-10-04,12:00:30,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial
BMY,2022-10-07,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol Myers Squibb Announces Change to Earnings Conference Call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022"
BMY,2022-10-07,10:59:19,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol Myers Squibb Announces Change to Earnings Conference Call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022"
BMY,2022-10-10,11:55:50,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Neutral From Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Neutral From Buy by Guggenheim
BMY,2022-10-10,12:00:10,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Nmpa Approval of Relmacabtagene Autoleucel Injection,PRESS-RELEASE,PR Newswire,JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
BMY,2022-10-10,12:01:32,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Nmpa Approval of Relmacabtagene Autoleucel Injection,PRESS-RELEASE,Dow Jones Newswires,Press Release: JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
BMY,2022-10-12,10:55:30,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2022-10-12,10:55:30,94637C,Bristol-Myers Squibb Co.,100,-0.54,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $66.00/Share From $69.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $66.00/Share From $69.00 by Barclays
BMY,2022-10-19,20:30:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data from CheckMate -3-
BMY,2022-10-19,20:30:00,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data from CheckMate -5-
BMY,2022-10-19,20:30:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data -4-
BMY,2022-10-19,20:30:01,94637C,Bristol-Myers Squibb Co.,91,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data -5-
BMY,2022-10-21,11:22:29,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,Bristol Myers' roughly $13 billion acquisition of MyoKardia Inc.,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: FDA to Review Camzyos to Reduce Septal-Reduction Therapy Need
BMY,2022-10-21,11:37:29,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,Bristol Myers' roughly $13 billion acquisition of MyoKardia Inc.,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers: FDA to Review Camzyos to Reduce Septal-Reduction Therapy Need
BMY,2022-10-25,07:15:13,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2022 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2022 (BMY)"
BMY,2022-10-25,23:31:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q Adj EPS $1.99,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Adj EPS $1.99 >BMY
BMY,2022-10-25,23:31:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 3Q Rev $11.2B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Rev $11.2B >BMY
BMY,2022-10-25,23:31:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q Net $1.6B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Net $1.6B >BMY
BMY,2022-10-25,23:31:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q EPS 75c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q EPS 75c >BMY
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol-Myers Squibb Co.: Reports Third Quarter Revenues of $11.2 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Third Quarter Earnings Per Share of $0.75,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol-Myers Squibb Co.: Completes Acquisition of Turning Point Therapeutics,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts 2022 GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Reaffirms Non-GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2022,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,-0.42,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 24% to $3.3 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.32,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 19% to $2.4 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD decreased from $271 million,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol-Myers Squibb Co.: For purposes of comparability, the non-GAAP financial results for the third quarter of 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenue $11,218 $11,624",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.14,revenues,,Bristol-Myers Squibb Co.: Eliquis revenues grew 10%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.48,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.7 billion compared to $1.3 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 7%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,"Bristol-Myers Squibb Co.: When adjusted for foreign exchange impacts, Opdivo's international revenues increased 8%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,92,-0.46,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 6% to $2.2 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: Welfare approved Sotyktu for the treatment of patients with plaque psoriasis,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusting GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Sales $46.0 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS(3) $2.71-$3.01,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call tomorrow, Wednesday, October 26, 2022 at 8 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol-Myers Squibb Co.: Reports Third Quarter Revenues of $11.2 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Third Quarter Earnings Per Share of $0.75,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol-Myers Squibb Co.: Completes Acquisition of Turning Point Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts 2022 GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Reaffirms Non-GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,-0.42,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 24% to $3.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.32,equity-actions,down,Bristol-Myers Squibb Co.: Research and development expenses decreased 19% to $2.4 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD decreased from $271 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol-Myers Squibb Co.: For purposes of comparability, the non-GAAP financial results for the third quarter of 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenue $11,218 $11,624",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.14,revenues,,Bristol-Myers Squibb Co.: Eliquis revenues grew 10%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.48,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.7 billion compared to $1.3 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 7%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,90,0.41,revenues,up,"Bristol-Myers Squibb Co.: When adjusted for foreign exchange impacts, Opdivo's international revenues increased 8%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2022",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -6-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -6-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,92,-0.46,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 6% to $2.2 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $34,753 $34,400",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -7-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,96,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.75 $ 0.70 $,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -7-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: Welfare approved Sotyktu for the treatment of patients with plaque psoriasis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusting GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Sales $46.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS(3) $2.71-$3.01,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2022 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call tomorrow, Wednesday, October 26, 2022 at 8 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -6-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -6-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $34,753 $34,400",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -7-
BMY,2022-10-25,23:31:01,94637C,Bristol-Myers Squibb Co.,96,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.75 $ 0.70 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -7-
BMY,2022-10-25,23:40:26,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2022 EPS $2.54,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2022 EPS $2.54-EPS $2.84 >BMY
BMY,2022-10-26,02:05:54,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers's Third-Quarter Profit Rose,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers's Third-Quarter Profit Rose, Revenue Declined"
BMY,2022-10-26,02:20:54,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers's Third-Quarter Profit Rose,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers's Third-Quarter Profit Rose, Revenue Declined"
BMY,2022-10-26,02:40:04,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers's Third-Quarter Profit Rose Slightly,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers's Third-Quarter Profit Rose Slightly
BMY,2022-10-26,06:16:06,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers: Retrospective Analyses of Phase 3 Study of Covid,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: Retrospective Analyses of Phase 3 Study of Covid Vaccine Responses in Takers of MS Drug Zeposia Show Over 90% of Participants Had Immune Response >BMY
BMY,2022-10-26,09:01:57,94637C,Bristol-Myers Squibb Co.,100,-0.68,revenues,down,Bristol Myers Sales Fall on,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Sales Fall on Strong Dollar. But Earnings Beat Expectations. -- Barrons.com
BMY,2022-10-26,09:01:57,94637C,Bristol-Myers Squibb Co.,100,0.46,earnings,above-expectations,"Bristol-Myers Squibb Co.: The company reported adjusted earnings per share of $1.99, beating analyst estimates of $1.83",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Sales Fall on Strong Dollar. But Earnings Beat Expectations. -- Barrons.com
BMY,2022-10-26,12:22:17,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: the company's $13.1B acquisition of MyoKardia in 2020,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says New Heart Drug Camzyos Off to Strong Start -- Market Talk
BMY,2022-10-26,12:22:17,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: the company's $13.1B acquisition of MyoKardia in 2020,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says New Heart Drug Camzyos Off to Strong Start -- Market Talk
BMY,2022-10-26,12:24:34,94637C,Bristol-Myers Squibb Co.,97,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: the company's $13.1B acquisition of MyoKardia in 2020,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says Inflation is Manageable -- Market Talk
BMY,2022-10-26,12:28:28,94637C,Bristol-Myers Squibb Co.,100,-0.46,revenues,down,Revlimid Sales Fall 28%,FULL-ARTICLE,Dow Jones Newswires,"As Generics Arrive, Bristol's Revlimid Sales Fall 28% -- Market Talk"
BMY,2022-10-26,12:28:28,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: the company maintained its annual sales guidance,FULL-ARTICLE,Dow Jones Newswires,"As Generics Arrive, Bristol's Revlimid Sales Fall 28% -- Market Talk"
BMY,2022-10-26,12:28:28,94637C,Bristol-Myers Squibb Co.,100,-0.46,revenues,down,Revlimid Sales Fall 28%,FULL-ARTICLE,Dow Jones Newswires,"As Generics Arrive, Bristol's Revlimid Sales Fall 28% -- Market Talk"
BMY,2022-10-26,12:28:28,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: the company maintained its annual sales guidance,FULL-ARTICLE,Dow Jones Newswires,"As Generics Arrive, Bristol's Revlimid Sales Fall 28% -- Market Talk"
BMY,2022-10-26,12:28:28,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: the company's $13.1B acquisition of MyoKardia in 2020,FULL-ARTICLE,Dow Jones Newswires,"As Generics Arrive, Bristol's Revlimid Sales Fall 28% -- Market Talk"
BMY,2022-10-26,20:59:29,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Myers Squibb 3Q Results Better Than Expected,FULL-ARTICLE,Dow Jones Newswires,Trending: Britsol Myers Squibb 3Q Results Better Than Expected
BMY,2022-10-26,20:59:29,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: The company reported third-quarter financial results after the bell Tuesday,FULL-ARTICLE,Dow Jones Newswires,Trending: Britsol Myers Squibb 3Q Results Better Than Expected
BMY,2022-10-26,20:59:29,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: The company reported third-quarter earnings per share of 75 cents,FULL-ARTICLE,Dow Jones Newswires,Trending: Britsol Myers Squibb 3Q Results Better Than Expected
BMY,2022-10-26,20:59:41,94637C,Bristol-Myers Squibb Co.,91,0.64,earnings,up,Bristol-Myers Squibb's net profit rose,FULL-ARTICLE,Dow Jones Newswires,Health Care Up After Bristol Myers Earnings -- Health Care Roundup
BMY,2022-10-26,21:14:30,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Myers Squibb 3Q Results Better Than Expected,FULL-ARTICLE,Dow Jones Newswires,Trending: Britsol Myers Squibb 3Q Results Better Than Expected
BMY,2022-10-26,21:14:30,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: The company reported third-quarter financial results after the bell Tuesday,FULL-ARTICLE,Dow Jones Newswires,Trending: Britsol Myers Squibb 3Q Results Better Than Expected
BMY,2022-10-26,21:14:30,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: The company reported third-quarter earnings per share of 75 cents,FULL-ARTICLE,Dow Jones Newswires,Trending: Britsol Myers Squibb 3Q Results Better Than Expected
BMY,2022-10-26,21:14:41,94637C,Bristol-Myers Squibb Co.,91,0.64,earnings,up,Bristol-Myers Squibb's net profit rose,FULL-ARTICLE,Dow Jones Newswires,Health Care Up After Bristol Myers Earnings -- Health Care Roundup
BMY,2022-10-27,08:57:18,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities
BMY,2022-10-27,08:57:18,94637C,Bristol-Myers Squibb Co.,100,-0.4,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $85.00/Share From $87.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $85.00/Share From $87.00 by Atlantic Equities
BMY,2022-10-27,11:54:18,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2022-10-27,11:54:18,94637C,Bristol-Myers Squibb Co.,100,-0.32,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $60.00/Share From $61.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $60.00/Share From $61.00 by Morgan Stanley
BMY,2022-10-27,12:30:10,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals,PRESS-RELEASE,PR Newswire,Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
BMY,2022-10-27,12:30:10,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: The Phase I FIH clinical trial,PRESS-RELEASE,PR Newswire,Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
BMY,2022-10-27,12:30:10,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
BMY,2022-10-27,12:30:10,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: The Phase I FIH clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
BMY,2022-10-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial
BMY,2022-10-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial
BMY,2022-11-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol Myers Squibb-Pfizer Alliance, on",PRESS-RELEASE,Business Wire,Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022
BMY,2022-11-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"In 2007, Pfizer and Bristol Myers Squibb entered into a worldwide collaboration",PRESS-RELEASE,Business Wire,Data Reinforcing Impact of Bristol Myers Squibb -4-
BMY,2022-11-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol Myers Squibb-Pfizer Alliance, on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022
BMY,2022-11-03,11:00:03,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Kura Oncology Announces Financing Transactions with Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,"Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million"
BMY,2022-11-03,11:00:03,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Kura Oncology Announces Financing Transactions with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million"
BMY,2022-11-03,11:19:42,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Kura Oncology Announces Financing Transactions With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,"Kura Oncology Announces Financing Transactions With Bristol Myers Squibb and Hercules Cap, Providing Access to Up to $150M"
BMY,2022-11-08,21:03:46,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp Vessey Registers 45,910 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP Vessey Registers 45,910 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-11-09,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference
BMY,2022-11-09,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference
BMY,2022-11-10,01:43:44,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 6,694 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Acquires 6,694 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-11-10,13:16:34,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities
BMY,2022-11-10,13:16:34,94637C,Bristol-Myers Squibb Co.,100,0.48,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $88.00/Share From $85.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $88.00/Share From $85.00 by Atlantic Equities
BMY,2022-11-10,14:00:03,94637C,Bristol-Myers Squibb Co.,95,0.57,products-services,granted,"Mavacamten), approved by the U.S. Food and Drug Administration (FDA) for the treatment",PRESS-RELEASE,Business Wire,PicnicHealth Announces Engagement with Bristol Myers Squibb to Leverage Real-World Evidence to Study Symptomatic Obstructive Hypertrophic Cardiomyopathy Patients
BMY,2022-11-10,14:03:44,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Ikena Oncology Program in Collaboration With Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Ikena Oncology Program in Collaboration With Bristol Myers Squibb and Eligible for Opt-In Through Early 2024 >IKNA
BMY,2022-11-10,19:03:31,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp Powell Registers 16,250 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP Powell Registers 16,250 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-11-14,23:58:49,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Powell Sells 16,250 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Powell Sells 16,250 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-11-18,10:06:17,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Initiated at Neutral by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Neutral by Credit Suisse
BMY,2022-11-18,10:06:17,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $78.00/Share by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $78.00/Share by Credit Suisse
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: First results from a Phase 1/2 study evaluating BMS-986158,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Five-Year Results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: Phase 2 Study of,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight -2-
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.0,earnings,,Bristol-Myers Squibb Co.: Results From the First,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight -2-
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight -3-
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight -4-
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight -6-
BMY,2022-11-21,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Onureg(R) (azacitidine tablets) is approved in the U.S.,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Data at ASH 2022 Highlight -7-
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: First results from a Phase 1/2 study evaluating BMS-986158,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Five-Year Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,"Bristol-Myers Squibb Co.: Cellular Monday, Phase 2 Study of",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH -2-
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,earnings,,Bristol-Myers Squibb Co.: Results From the First,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH -2-
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH -3-
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH -4-
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH -6-
BMY,2022-11-21,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Onureg(R) (azacitidine tablets) is approved in the U.S.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Data at ASH -7-
BMY,2022-11-27,23:00:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Clinical Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients
BMY,2022-11-29,13:00:15,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Envisagenics Announces Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,Envisagenics Announces Research Collaboration with Bristol Myers Squibb
BMY,2022-11-29,13:00:15,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Envisagenics Announces Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Envisagenics Announces Research Collaboration with Bristol Myers Squibb
BMY,2022-12-06,23:45:11,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 4,294 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Vessey Acquires 4,294 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-12-06,23:45:36,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 4,294 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Elkins Acquires 4,294 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-12-07,00:33:27,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Boerner Acquires 1,288 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Boerner Acquires 1,288 Of Bristol-Myers Squibb Co >BMY"
BMY,2022-12-08,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Announces Dividend Increase,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Dividend Increase >BMY
BMY,2022-12-08,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Co.: This quarterly dividend represents a 5.6% increase over last year's quarterly dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2022-12-08,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2022-12-08,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on February 1, 2023 to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2022-12-08,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Co.: This quarterly dividend represents a 5.6% increase over last year's quarterly dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2022-12-08,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2022-12-08,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on February 1, 2023 to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2022-12-08,21:16:50,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol-Myers Squibb Raises Dividend to 57c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raises Dividend to 57c >BMY
BMY,2022-12-09,14:32:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"In Collaboration with Bristol Myers Squibb, to",PRESS-RELEASE,PR Newswire,"Lyfebulb Announces Finalists for the 2022 Innovation Challenge, in Collaboration with Bristol Myers Squibb, to Address Unmet Needs in Inflammatory Bowel Disease"
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: First multicenter results from the Phase 1 study,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio"
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First results,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio"
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: First multicenter results from the Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio"
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio"
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: Novel CELMoD(TM) agents mezigdomide (CC-92480) and iberdomide (CC-220) Phase 1/2 Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces First Disclosures -2-
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: Novel CELMoD(TM) agents mezigdomide (CC-92480) and iberdomide (CC-220) Phase 1/2 Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces First Disclosures -2-
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces First Disclosures -3-
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: Novel CELMoD(TM) agents mezigdomide (CC-92480) and iberdomide (CC-220) Phase 1/2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: Novel CELMoD(TM) agents mezigdomide (CC-92480) and iberdomide (CC-220) Phase 1/2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2022-12-12,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2022-12-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023"
BMY,2022-12-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023"
BMY,2022-12-15,12:08:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023"
BMY,2022-12-15,12:08:01,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023"
BMY,2022-12-16,08:40:23,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Evotec SE: after six years our neuroscience collaboration with Bristol Myers Squibb,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2022-12-16,08:40:23,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Evotec SE: after six years our neuroscience collaboration with Bristol Myers Squibb,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2022-12-16,12:27:52,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec to Receive $26 Mln in Expanded Bristol Myers Squibb Collaboration,FULL-ARTICLE,Dow Jones Newswires,Evotec to Receive $26 Mln in Expanded Bristol Myers Squibb Collaboration
BMY,2022-12-16,12:42:52,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec to Receive $26 Million in Expanded Bristol Myers Squibb Collaboration,FULL-ARTICLE,Dow Jones Newswires,Evotec to Receive $26 Million in Expanded Bristol Myers Squibb Collaboration
BMY,2022-01-26,07:00:24,97C893,Bloomsbury Publishing PLC,99,0.57,acquisitions-mergers,completed,"Bloomsbury completed the purchase of ABC-CLIO on 16 December 2021, for GBP17.3 million",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2022-01-26,07:00:24,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: our preliminary results in May 2022,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2022-01-26,07:37:47,97C893,Bloomsbury Publishing PLC,100,0.72,revenues,above-expectations,"Bloomsbury Publishing Says FY 2022 Revenue, Profit to Beat Expectations",FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Says FY 2022 Revenue, Profit to Beat Expectations"
BMY,2022-01-26,07:37:47,97C893,Bloomsbury Publishing PLC,100,0.0,revenues,,Bloomsbury Publishing PLC said Wednesday that it expects to report revenue and profit ahead of market expectations for fiscal 2022,FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Says FY 2022 Revenue, Profit to Beat Expectations"
BMY,2022-03-30,06:00:31,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Revenue is,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2022-03-30,06:00:31,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: our preliminary results in May 2022,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2022-03-30,06:00:31,97C893,Bloomsbury Publishing PLC,99,0.47,labor-issues,,Bloomsbury Publishing PLC: Steven joined the Board in 2017,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2022-03-30,06:00:31,97C893,Bloomsbury Publishing PLC,99,-0.51,labor-issues,,Bloomsbury Publishing PLC: Steven Hall will step down from the Board,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Audited Preliminary Results for the year ended 28 February 2022,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.54,revenues,up,Bloomsbury Publishing PLC: Non-Consumer revenue growth of 23% to GBP81.9 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.44,revenues,up,Bloomsbury Publishing PLC: The Consumer division revenue grew by 25%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: our final dividend to 9.40 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: GBP13.2 Profit before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 25.94 pence 18.68 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 20.33 pence 16.71 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.62,acquisitions-mergers,,"Bloomsbury Publishing PLC: Acquisition of Head of Zeus Ltd (""HoZ"") in June 2021",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: 2) Organic revenue for 2021/22,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.46,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 28% to GBP22.2 million (2020/21: GBP17.3 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.62,revenues,up,"Bloomsbury Publishing PLC: 2021/22: delivered GBP18.6 million revenue, up 50%",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.62,acquisitions-mergers,,Bloomsbury Publishing PLC: We have strengthened BDR with the acquisitions of RGP and ABC-CLIO,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: US revenues increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: Sarah J. Maas' sales grew by 86% compared to last year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation was GBP6.7 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.74,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 81% to GBP6.6 million (2020/21: GBP3.6 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.0,products-services,,Bloomsbury Publishing PLC: demand for our digital products,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.57,acquisitions-mergers,completed,"Bloomsbury Publishing PLC: In June 2021, we completed the acquisition of the issued share capital of HoZ, the independent",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.39,products-services,,"Bloomsbury Publishing PLC: In December 2021, we completed the purchase",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.46,equity-actions,,Bloomsbury Publishing PLC: we invested GBP26.6 million in,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,-0.51,labor-issues,,Bloomsbury Publishing PLC: Steven Hall will step down from the Board,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.47,labor-issues,,Bloomsbury Publishing PLC: Steven joined the Board in 2017,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 122,162",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year 16,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,94,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -5-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,94,0.0,dividends,,Bloomsbury Publishing PLC: 31) - Dividends,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -5-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,93,0.0,revenues,,Bloomsbury Publishing PLC: Print revenues are,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,93,-0.26,equity-actions,up,Bloomsbury Publishing PLC: Print costs are increased by 15% from 2022/2023,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,93,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 46,280",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,93,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,93,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 15,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 37,471",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 10,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,90,0.0,revenues,,Bloomsbury Publishing PLC: During the year sales,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,90,0.0,assets,,Bloomsbury Publishing PLC: Total assets,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,-0.48,equity-actions,costs,Bloomsbury Publishing PLC: Restructuring costs,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.0,equity-actions,,Bloomsbury Publishing PLC: Factors affecting tax charge for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.0,dividends,,Bloomsbury Publishing PLC: Total dividend payments in the year 15,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 20.33p 16.71p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 25.94p 18.68p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.0,equity-actions,,"Bloomsbury Publishing PLC: Transaction costs of GBP242,000",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -9-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.0,revenues,,"Bloomsbury Publishing PLC: From 2 June 2021, revenue of GBP9.0 million",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -9-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.0,revenues,,"Bloomsbury Publishing PLC: From 16 December 2021, revenue of GBP2.2 million",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -9-
BMY,2022-06-15,06:27:23,97C893,Bloomsbury Publishing PLC,100,0.62,earnings,up,"Bloomsbury Publishing FY 2022 Pretax Profit, Revenue Rose",FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing FY 2022 Pretax Profit, Revenue Rose on Strong Consumer, Non-Consumer Divisions"
BMY,2022-06-15,06:27:23,97C893,Bloomsbury Publishing PLC,100,0.59,earnings,positive,Bloomsbury Publishing PLC said Wednesday that pretax profit,FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing FY 2022 Pretax Profit, Revenue Rose on Strong Consumer, Non-Consumer Divisions"
BMY,2022-06-28,15:42:34,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: we operate Increased Sales,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report
BMY,2022-06-28,15:42:34,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Global staff turnover,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -4-
BMY,2022-07-01,06:00:40,97C893,Bloomsbury Publishing PLC,100,0.4,products-services,,Bloomsbury wins Small Cap Award,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Bloomsbury wins Small Cap Award
BMY,2022-07-04,14:52:05,97C893,Bloomsbury Publishing PLC,99,0.0,investor-relations,,Bloomsbury Publishing PLC: Notice of AGM,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Notice of AGM Clarification
BMY,2022-07-20,06:00:11,97C893,Bloomsbury Publishing PLC,99,0.44,revenues,up,Bloomsbury Publishing PLC: Sales growth of 27% for the first,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2022-07-20,06:00:11,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: 4 months to June 4 months Revenue,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2022-07-20,06:00:11,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: The results for the six months,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2022-07-20,06:43:59,97C893,Bloomsbury Publishing PLC,100,0.44,revenues,up,Bloomsbury Publishing Four-Month Revenue Rose 27%,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Four-Month Revenue Rose 27% After Record 1H UK Book Sales
BMY,2022-07-20,11:04:25,97C893,Bloomsbury Publishing PLC,100,0.65,revenues,up,Bloomsbury Publishing Four-Month Revenue Boosted,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Four-Month Revenue Boosted by Record Book Sales; Finsbury Food FY 2022 Sales Rose on Year
BMY,2022-07-20,15:32:46,97C893,Bloomsbury Publishing PLC,99,0.0,investor-relations,,Bloomsbury Publishing PLC: Results of the 2022 Annual General Meeting,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Results of the 2022 Annual General Meeting
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.64,earnings,up,Bloomsbury Publishing PLC: Record first half earnings,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.62,dividends,up,Bloomsbury Publishing PLC: Interim dividend increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: GBP11.1 Profit before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 12.30 pence 10.41 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.64,revenues,up,Bloomsbury Publishing PLC: Non-Consumer revenue growth of 24% to GBP46.6 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.42,revenues,up,Bloomsbury Publishing PLC: Revenue grew by 22% to GBP122.9 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Profit before taxation was GBP12.9 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: US revenues increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.51,products-services,increase,Bloomsbury Publishing PLC: increased demand for our existing digital products,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.46,revenues,up,Bloomsbury Publishing PLC: Children's revenue increased by 30% to GBP50.6 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.46,equity-actions,,Bloomsbury Publishing PLC: we invested GBP0.9 million of,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: The Board has declared an interim dividend of 1.41 pence per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: The dividend will be paid on 2 December 2022,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.62,acquisitions-mergers,,Bloomsbury Publishing PLC: The acquisition of ABC-CLIO expands Bloomsbury,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 66,106",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,-0.4,revenues,down,Bloomsbury Publishing PLC: Sales drop by 20%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 24,154",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 46,280",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 15,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.0,assets,,Bloomsbury Publishing PLC: Total assets 31 August 31,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.47,equity-actions,,Bloomsbury Publishing PLC: For the six months ended 31 August 2021 integration and restructuring,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.0,dividends,,Bloomsbury Publishing PLC: The proposed interim dividend of 1.41 pence per ordinary share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,Bloomsbury Publishing PLC: Basic earnings per share 12.49p 10.54p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2022-10-26,06:27:07,97C893,Bloomsbury Publishing PLC,100,0.62,earnings,up,Bloomsbury Publishing 1H Pretax Profit Rose,FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing 1H Pretax Profit Rose on Strategy Execution, Digital Revenue"
BMY,2022-01-26,07:00:24,97C893,Bloomsbury Publishing PLC,99,0.57,acquisitions-mergers,completed,"Bloomsbury completed the purchase of ABC-CLIO on 16 December 2021, for GBP17.3 million",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2022-01-26,07:00:24,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: our preliminary results in May 2022,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2022-01-26,07:37:47,97C893,Bloomsbury Publishing PLC,100,0.72,revenues,above-expectations,"Bloomsbury Publishing Says FY 2022 Revenue, Profit to Beat Expectations",FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Says FY 2022 Revenue, Profit to Beat Expectations"
BMY,2022-01-26,07:37:47,97C893,Bloomsbury Publishing PLC,100,0.0,revenues,,Bloomsbury Publishing PLC said Wednesday that it expects to report revenue and profit ahead of market expectations for fiscal 2022,FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Says FY 2022 Revenue, Profit to Beat Expectations"
BMY,2022-03-30,06:00:31,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Revenue is,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2022-03-30,06:00:31,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: our preliminary results in May 2022,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2022-03-30,06:00:31,97C893,Bloomsbury Publishing PLC,99,0.47,labor-issues,,Bloomsbury Publishing PLC: Steven joined the Board in 2017,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2022-03-30,06:00:31,97C893,Bloomsbury Publishing PLC,99,-0.51,labor-issues,,Bloomsbury Publishing PLC: Steven Hall will step down from the Board,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Audited Preliminary Results for the year ended 28 February 2022,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.54,revenues,up,Bloomsbury Publishing PLC: Non-Consumer revenue growth of 23% to GBP81.9 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.44,revenues,up,Bloomsbury Publishing PLC: The Consumer division revenue grew by 25%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: our final dividend to 9.40 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: GBP13.2 Profit before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 25.94 pence 18.68 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 20.33 pence 16.71 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.62,acquisitions-mergers,,"Bloomsbury Publishing PLC: Acquisition of Head of Zeus Ltd (""HoZ"") in June 2021",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: 2) Organic revenue for 2021/22,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.46,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 28% to GBP22.2 million (2020/21: GBP17.3 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.62,revenues,up,"Bloomsbury Publishing PLC: 2021/22: delivered GBP18.6 million revenue, up 50%",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.62,acquisitions-mergers,,Bloomsbury Publishing PLC: We have strengthened BDR with the acquisitions of RGP and ABC-CLIO,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: US revenues increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: Sarah J. Maas' sales grew by 86% compared to last year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation was GBP6.7 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.74,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 81% to GBP6.6 million (2020/21: GBP3.6 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.0,products-services,,Bloomsbury Publishing PLC: demand for our digital products,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.57,acquisitions-mergers,completed,"Bloomsbury Publishing PLC: In June 2021, we completed the acquisition of the issued share capital of HoZ, the independent",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.39,products-services,,"Bloomsbury Publishing PLC: In December 2021, we completed the purchase",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.46,equity-actions,,Bloomsbury Publishing PLC: we invested GBP26.6 million in,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -3-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,-0.51,labor-issues,,Bloomsbury Publishing PLC: Steven Hall will step down from the Board,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.47,labor-issues,,Bloomsbury Publishing PLC: Steven joined the Board in 2017,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 122,162",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year 16,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,94,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -5-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,94,0.0,dividends,,Bloomsbury Publishing PLC: 31) - Dividends,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -5-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,93,0.0,revenues,,Bloomsbury Publishing PLC: Print revenues are,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,93,-0.26,equity-actions,up,Bloomsbury Publishing PLC: Print costs are increased by 15% from 2022/2023,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,93,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 46,280",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,93,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,93,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 15,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 37,471",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 10,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,90,0.0,revenues,,Bloomsbury Publishing PLC: During the year sales,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,90,0.0,assets,,Bloomsbury Publishing PLC: Total assets,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,-0.48,equity-actions,costs,Bloomsbury Publishing PLC: Restructuring costs,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.0,equity-actions,,Bloomsbury Publishing PLC: Factors affecting tax charge for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.0,dividends,,Bloomsbury Publishing PLC: Total dividend payments in the year 15,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 20.33p 16.71p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 25.94p 18.68p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.0,equity-actions,,"Bloomsbury Publishing PLC: Transaction costs of GBP242,000",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -9-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.0,revenues,,"Bloomsbury Publishing PLC: From 2 June 2021, revenue of GBP9.0 million",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -9-
BMY,2022-06-15,06:00:29,97C893,Bloomsbury Publishing PLC,96,0.0,revenues,,"Bloomsbury Publishing PLC: From 16 December 2021, revenue of GBP2.2 million",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -9-
BMY,2022-06-15,06:27:23,97C893,Bloomsbury Publishing PLC,100,0.62,earnings,up,"Bloomsbury Publishing FY 2022 Pretax Profit, Revenue Rose",FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing FY 2022 Pretax Profit, Revenue Rose on Strong Consumer, Non-Consumer Divisions"
BMY,2022-06-15,06:27:23,97C893,Bloomsbury Publishing PLC,100,0.59,earnings,positive,Bloomsbury Publishing PLC said Wednesday that pretax profit,FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing FY 2022 Pretax Profit, Revenue Rose on Strong Consumer, Non-Consumer Divisions"
BMY,2022-06-28,15:42:34,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: we operate Increased Sales,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report
BMY,2022-06-28,15:42:34,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Global staff turnover,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -4-
BMY,2022-07-01,06:00:40,97C893,Bloomsbury Publishing PLC,100,0.4,products-services,,Bloomsbury wins Small Cap Award,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Bloomsbury wins Small Cap Award
BMY,2022-07-04,14:52:05,97C893,Bloomsbury Publishing PLC,99,0.0,investor-relations,,Bloomsbury Publishing PLC: Notice of AGM,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Notice of AGM Clarification
BMY,2022-07-20,06:00:11,97C893,Bloomsbury Publishing PLC,99,0.44,revenues,up,Bloomsbury Publishing PLC: Sales growth of 27% for the first,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2022-07-20,06:00:11,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: 4 months to June 4 months Revenue,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2022-07-20,06:00:11,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: The results for the six months,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2022-07-20,06:43:59,97C893,Bloomsbury Publishing PLC,100,0.44,revenues,up,Bloomsbury Publishing Four-Month Revenue Rose 27%,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Four-Month Revenue Rose 27% After Record 1H UK Book Sales
BMY,2022-07-20,11:04:25,97C893,Bloomsbury Publishing PLC,100,0.65,revenues,up,Bloomsbury Publishing Four-Month Revenue Boosted,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Four-Month Revenue Boosted by Record Book Sales; Finsbury Food FY 2022 Sales Rose on Year
BMY,2022-07-20,15:32:46,97C893,Bloomsbury Publishing PLC,99,0.0,investor-relations,,Bloomsbury Publishing PLC: Results of the 2022 Annual General Meeting,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Results of the 2022 Annual General Meeting
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.64,earnings,up,Bloomsbury Publishing PLC: Record first half earnings,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.62,dividends,up,Bloomsbury Publishing PLC: Interim dividend increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: GBP11.1 Profit before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 12.30 pence 10.41 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.64,revenues,up,Bloomsbury Publishing PLC: Non-Consumer revenue growth of 24% to GBP46.6 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.42,revenues,up,Bloomsbury Publishing PLC: Revenue grew by 22% to GBP122.9 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Profit before taxation was GBP12.9 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: US revenues increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.51,products-services,increase,Bloomsbury Publishing PLC: increased demand for our existing digital products,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.46,revenues,up,Bloomsbury Publishing PLC: Children's revenue increased by 30% to GBP50.6 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.46,equity-actions,,Bloomsbury Publishing PLC: we invested GBP0.9 million of,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: The Board has declared an interim dividend of 1.41 pence per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: The dividend will be paid on 2 December 2022,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.62,acquisitions-mergers,,Bloomsbury Publishing PLC: The acquisition of ABC-CLIO expands Bloomsbury,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 66,106",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,-0.4,revenues,down,Bloomsbury Publishing PLC: Sales drop by 20%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 24,154",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 46,280",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 15,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.0,assets,,Bloomsbury Publishing PLC: Total assets 31 August 31,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.47,equity-actions,,Bloomsbury Publishing PLC: For the six months ended 31 August 2021 integration and restructuring,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.0,dividends,,Bloomsbury Publishing PLC: The proposed interim dividend of 1.41 pence per ordinary share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,Bloomsbury Publishing PLC: Basic earnings per share 12.49p 10.54p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2022-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2022-10-26,06:27:07,97C893,Bloomsbury Publishing PLC,100,0.62,earnings,up,Bloomsbury Publishing 1H Pretax Profit Rose,FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing 1H Pretax Profit Rose on Strategy Execution, Digital Revenue"
BMY,2023-01-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York"
BMY,2023-01-03,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York"
BMY,2023-01-03,11:59:10,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, NY",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, NY"
BMY,2023-01-03,12:05:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 41(st) Annual Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present at J.P. Morgan's 41(st) Annual Healthcare Conference
BMY,2023-01-03,12:05:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 41st Annual Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present at J.P. Morgan's 41st Annual Healthcare Conference
BMY,2023-01-03,14:23:36,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
BMY,2023-01-03,14:23:36,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $78.00/Share From $70.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $78.00/Share From $70.00 by Wells Fargo
BMY,2023-01-05,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide,PRESS-RELEASE,Dow Jones Newswires,Press Release: Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
BMY,2023-01-05,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
BMY,2023-01-05,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide,PRESS-RELEASE,GlobeNewswire,Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
BMY,2023-01-05,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide,PRESS-RELEASE,Dow Jones Newswires,Press Release: Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
BMY,2023-01-05,12:03:46,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Amryt Announces Positive Top Line Results From Phase 3 Pediatric Trial of Lomitapide,NEWS-FLASH,Dow Jones Newswires,Amryt Announces Positive Top Line Results From Phase 3 Pediatric Trial of Lomitapide in HoFH
BMY,2023-01-17,13:27:44,94637C,Bristol-Myers Squibb Co.,100,0.95,analyst-ratings,positive,Bristol-Myers Squibb Initiated at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Overweight by Cantor Fitzgerald
BMY,2023-01-17,13:27:44,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $95.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $95.00/Share by Cantor Fitzgerald
BMY,2023-01-19,13:30:00,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol-Myers Squibb Co.: we are honored to have Amgen serve as a supporter of the Winn Award,PRESS-RELEASE,Dow Jones Newswires,Press Release: The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen's Commitment of $8 Million
BMY,2023-01-19,13:30:01,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol-Myers Squibb Co.: we are honored to have Amgen serve as a supporter of the Winn Award,PRESS-RELEASE,Business Wire,The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen's Commitment of $8 Million
BMY,2023-01-19,17:56:07,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol-Myers Squibb Co.: we are honored to have Amgen serve as a supporter of the Winn Award,PRESS-RELEASE,DJ Global Press Release Wire,The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation To Expand With Amgen's Commitment of $8 Million
BMY,2023-01-19,17:56:07,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol-Myers Squibb Co.: we are honored to have Amgen serve as a supporter of the Winn Award,PRESS-RELEASE,DJ Global Press Release Wire,The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation To Expand With Amgen's Commitment of $8 Million
BMY,2023-01-24,09:09:17,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2022 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2022 (BMY)"
BMY,2023-01-26,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi(R) (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-01-26,11:59:01,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi(R) (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-01-26,14:32:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"In Collaboration with Bristol Myers Squibb, to",PRESS-RELEASE,PR Newswire,"OstoBuddy and South Asian IBD Alliance Named Winners of Innovation Challenge, in Collaboration with Bristol Myers Squibb, to Address Unmet Needs in Inflammatory Bowel Disease"
BMY,2023-01-27,07:00:08,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,2022 Innovation Challenge in collaboration with Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Genetic Analysis AS: Genetic Analysis' CTO finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD
BMY,2023-01-27,07:00:08,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,2022 Innovation Challenge in collaboration with Bristol Myers Squibb,PRESS-RELEASE,Cision News,Genetic Analysis AS: Genetic Analysis' CTO finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD
BMY,2023-01-27,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration (FDA) approved Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
BMY,2023-01-27,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration (FDA) approved Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
BMY,2023-01-27,12:05:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia"
BMY,2023-01-27,12:05:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia"
BMY,2023-01-27,12:05:20,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl for Adults With Anemia-Associated, Non-Transfusion-Dependent Beta Thalassemia"
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Net $2.02B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Net $2.02B >BMY
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.06,revenues,,Bristol-Myers Squibb Co.: Reports Fourth Quarter Revenues of $11.4 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Full-Year Revenues of $46.2 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Fourth Quarter GAAP EPS of $0.95,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Reports Full-Year GAAP EPS of $2.95,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD in 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Provides GAAP and Non-GAAP Financial Guidance for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD expenses decreased from $89 million in 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.14,revenues,,Bristol-Myers Squibb Co.: International revenues were $951 million compared to $868 million,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.7 billion compared to $1.5 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.02,revenues,,Bristol-Myers Squibb Co.: Eliquis revenues grew 1%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 11%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: The approval is based on the results of clinical trials,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,97,0.0,assets,,Bristol-Myers Squibb Co.: Pipeline Multiple Myeloma Portfolio In December,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,97,0.0,products-services,,Bristol-Myers Squibb Co.: alnuctamab First multicenter results from the Phase 1 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: FULL YEAR FINANCIAL RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,97,0.04,revenues,,Bristol Myers Squibb posted revenues of $46.2 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD in 2022,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.0,earnings,,"Bristol-Myers Squibb Co.: For purposes of comparability, the non-GAAP financial results for the fourth quarter of 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.06,revenues,,Bristol-Myers Squibb Co.: FULL YEAR PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $7.8 billion compared to $6.5 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.41,revenues,up,Bristol-Myers Squibb Co.: Eliquis revenues grew 10%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 10%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating expenses,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today at 9:00 a.m. ET,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -6-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -7-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 4Q Rev $11.41B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Rev $11.41B >BMY
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q EPS 95c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q EPS 95c >BMY
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.06,revenues,,Bristol-Myers Squibb Co.: Reports Fourth Quarter Revenues of $11.4 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Full-Year Revenues of $46.2 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Fourth Quarter GAAP EPS of $0.95,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Reports Full-Year GAAP EPS of $2.95,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Provides GAAP and Non-GAAP Financial Guidance for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD expenses decreased from $89 million in 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.14,revenues,,Bristol-Myers Squibb Co.: International revenues were $951 million compared to $868 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.7 billion compared to $1.5 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.02,revenues,,Bristol-Myers Squibb Co.: Eliquis revenues grew 1%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 11%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: The approval is based on the results of clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,assets,,Bristol-Myers Squibb Co.: Pipeline Multiple Myeloma Portfolio In December,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,products-services,,Bristol-Myers Squibb Co.: alnuctamab First multicenter results from the Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: FULL YEAR FINANCIAL RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.04,revenues,,Bristol Myers Squibb posted revenues of $46.2 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD in 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD in 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,earnings,,"Bristol-Myers Squibb Co.: For purposes of comparability, the non-GAAP financial results for the fourth quarter of 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,Bristol-Myers Squibb Co.: FULL YEAR PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $7.8 billion compared to $6.5 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.41,revenues,up,Bristol-Myers Squibb Co.: Eliquis revenues grew 10%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.41,revenues,up,Bristol-Myers Squibb Co.: International revenues were $3.4 billion compared to $3.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 10%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.42,revenues,down,Bristol-Myers Squibb Co.: Revlimid revenues declined by 22%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today at 9:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Adj EPS $1.82,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Adj EPS $1.82 >BMY
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Adj EPS $1.82,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Adj EPS $1.82 >BMY
BMY,2023-02-02,12:04:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2023 Adj EPS $7.95,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 Adj EPS $7.95-Adj EPS $8.25 >BMY
BMY,2023-02-02,12:04:13,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2023 EPS $4.03,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 EPS $4.03-EPS $4.33 >BMY
BMY,2023-02-02,12:04:29,94637C,Bristol-Myers Squibb Co.,100,0.48,revenues,up,Bristol-Myers Squibb Sees 2023 Revenue Up About 2%,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 Revenue Up About 2% >BMY
BMY,2023-02-02,12:05:10,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Sees 2023 Revenue From Revlimid About $6.5B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 Revenue From Revlimid About $6.5B >BMY
BMY,2023-02-02,12:21:07,94637C,Bristol-Myers Squibb Co.,100,-0.68,revenues,down,Bristol Myers Squibb had revenue of $11.4 billion for the quarter,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb sees revenue fall in Q4
BMY,2023-02-02,12:21:07,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers Squibb Co.: the company announced better-than-expected earnings for the fourth quarter of 2022,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb sees revenue fall in Q4
BMY,2023-02-02,12:21:07,94637C,Bristol-Myers Squibb Co.,100,-0.68,revenues,down,Bristol Myers Squibb had revenue of $11.4 billion for the quarter,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Sees Revenue Fall In Q4 -- MarketWatch
BMY,2023-02-02,12:21:07,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers Squibb Co.: the company announced better-than-expected earnings for the fourth quarter of 2022,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Sees Revenue Fall In Q4 -- MarketWatch
BMY,2023-02-02,12:39:24,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb reported fourth-quarter earnings that beat Wall Street expectations,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Rises as Revenue Falls on Lower Revlimid Sales but Profit Tops Estimates -- Barrons.com
BMY,2023-02-02,12:39:24,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers (ticker: BMY) posted fourth-quarter earnings of $1.82 a share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Rises as Revenue Falls on Lower Revlimid Sales but Profit Tops Estimates -- Barrons.com
BMY,2023-02-02,12:39:24,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers expects adjusted earnings to be between $7.95 and $8.25 a share for 2023,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Rises as Revenue Falls on Lower Revlimid Sales but Profit Tops Estimates -- Barrons.com
BMY,2023-02-02,13:00:03,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb and Exscientia expanded the collaboration in,PRESS-RELEASE,Business Wire,"Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318"
BMY,2023-02-02,13:01:30,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb and Exscientia expanded the collaboration in,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318"
BMY,2023-02-02,13:56:38,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb reported adjusted earnings of $1.82 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Jumps On Fourth-Quarter Beat Strong Earnings Outlook -- IBD
BMY,2023-02-02,15:29:57,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,above-expectations,Bristol Myers Squibb Beats 4Q Sales Expectations,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb Beats 4Q Sales Expectations
BMY,2023-02-02,15:44:57,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,above-expectations,Bristol Myers Squibb Beats 4Q Sales Expectations,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb Beats 4Q Sales Expectations
BMY,2023-02-02,15:45:19,94637C,Bristol-Myers Squibb Co.,93,0.41,revenues,up,Opdivo sales ramped up 11%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Revlimid Takes A 32% Hit As Generics Keep Coming -- IBD
BMY,2023-02-02,16:21:38,94637C,Bristol-Myers Squibb Co.,93,0.41,revenues,up,Opdivo sales ramped up 11%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Revlimid Takes A 32% Hit As Generics Keep Coming -- IBD
BMY,2023-02-02,21:13:55,94637C,Bristol-Myers Squibb Co.,93,0.41,revenues,up,Opdivo sales ramped up 11%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Revlimid Takes A 32% Hit As Generics Keep Coming -- IBD
BMY,2023-02-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
BMY,2023-02-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
BMY,2023-02-03,12:05:34,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities
BMY,2023-02-03,12:05:34,94637C,Bristol-Myers Squibb Co.,100,0.4,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $90.00/Share From $88.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $90.00/Share From $88.00 by Atlantic Equities
BMY,2023-02-03,13:18:15,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2023-02-03,13:18:15,94637C,Bristol-Myers Squibb Co.,100,0.46,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $62.00/Share From $60.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $62.00/Share From $60.00 by Morgan Stanley
BMY,2023-02-04,00:19:47,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Meyers Acquires 1,812 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Meyers Acquires 1,812 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-02-07,21:27:38,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Chmn Caforio Registers 240,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"Chmn Caforio Registers 240,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-02-07,21:39:55,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp Powell Registers 11,183 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP Powell Registers 11,183 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-02-09,01:10:41,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Powell Sells 11,183 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Powell Sells 11,183 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-02-09,01:12:01,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 240,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Caforio Sells 240,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-02-09,20:15:08,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,The FDA approved Zeposia for use in Ulcerative Colitis,PRESS-RELEASE,PR Newswire,"Can BMS' Zeposia Cement a Defensible Market Position in Ulcerative Colitis Ahead of Pfizer's Potential Rival S1P treatment, etrasimod? According to Spherix Global Insights"
BMY,2023-02-17,03:46:07,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Glenmark Pharmaceuticals Inc., USA Gets Second Tentative Approval From FDA for Saxagliptin",NEWS-FLASH,Dow Jones Newswires,"Glenmark Pharmaceuticals Inc., USA Gets Second Tentative Approval From FDA for Saxagliptin Tablets"
BMY,2023-02-23,16:00:07,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Forces Partners with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,Friendly Forces Partners with Bristol Myers Squibb to Promote Pro-Reservist Policies and Hiring
BMY,2023-02-27,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Findings from clinical studies,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology
BMY,2023-02-27,12:08:52,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Findings from clinical studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology
BMY,2023-03-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,start,Bristol-Myers Squibb Co.: First patient has been enrolled,PRESS-RELEASE,Business Wire,"The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor"
BMY,2023-03-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol Myers Squibb (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc.",PRESS-RELEASE,Business Wire,"The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor"
BMY,2023-03-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Important Phase 2 proof-of-concept data for milvexian,PRESS-RELEASE,Business Wire,"The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor"
BMY,2023-03-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,start,Bristol-Myers Squibb Co.: First patient has been enrolled,PRESS-RELEASE,Dow Jones Newswires,"Press Release: The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor"
BMY,2023-03-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol Myers Squibb (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,"Press Release: The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor"
BMY,2023-03-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Important Phase 2 proof-of-concept data for milvexian,PRESS-RELEASE,Dow Jones Newswires,"Press Release: The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor"
BMY,2023-03-02,12:01:15,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,"Bristol Myers, J&J Launch Phase 3 Program",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers, J&J Launch Phase 3 Program Evaluating Milvexian Factor XIa Inhibitor"
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,13:00:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Viz.ai Announces Agreement with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,11:59:09,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval of Reblozyl,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval of Reblozyl for Anemia in Adult Patients With Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,12:17:21,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol Myers Squibb wins expanded European Commission approval of the anemia drug,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Adds an Arrow to Reblozyl European Quiver -- Market Talk
BMY,2023-03-03,12:17:21,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol Myers Squibb wins expanded European Commission approval of the anemia drug,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Adds an Arrow to Reblozyl European Quiver -- Market Talk
BMY,2023-03-03,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2023-03-03,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2023-03-03,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on May 1, 2023, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2023-03-06,10:47:22,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Initiated at Hold by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Hold by Jefferies
BMY,2023-03-06,10:47:22,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $62.00/Share by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $62.00/Share by Jefferies
BMY,2023-03-09,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023"
BMY,2023-03-09,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023"
BMY,2023-03-09,11:59:27,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023"
BMY,2023-03-09,11:59:27,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023"
BMY,2023-03-15,00:14:43,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Chmn Caforio Acquires 96,687 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Chmn Caforio Acquires 96,687 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:14:51,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 30,540 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 30,540 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:15:15,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Boerner Acquires 24,491 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Boerner Acquires 24,491 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:15:17,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Shanahan Acquires 1,533 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Shanahan Acquires 1,533 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:15:28,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Meyers Acquires 1,593 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Meyers Acquires 1,593 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:15:30,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Weese Acquires 996 Of Bristol-Myers Squibb Co >BMY,TABULAR-MATERIAL,Dow Jones Newswires,VP Weese Acquires 996 Of Bristol-Myers Squibb Co >BMY
BMY,2023-03-15,00:19:36,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Powell Acquires 17,637 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Powell Acquires 17,637 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:20:01,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 16,583 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Acquires 16,583 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:30:38,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Leung Acquires 23,886 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Leung Acquires 23,886 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:35:48,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 28,437 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Acquires 28,437 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:41:51,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Mily Acquires 15,596 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Mily Acquires 15,596 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.22,acquisitions-mergers,,Bristol-Myers Squibb Co.: Investing in diverse suppliers enables BMS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments
BMY,2023-03-15,11:06:06,94637C,Bristol-Myers Squibb Co.,99,0.22,acquisitions-mergers,,Bristol-Myers Squibb Co.: Investing in diverse suppliers enables BMS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments
BMY,2023-03-16,07:05:32,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Evotec SE: the Company has further extended and expanded its partnership with Bristol Myers Squibb,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
BMY,2023-03-16,08:41:54,94637C,Bristol-Myers Squibb Co.,92,0.49,partnerships,,"Evotec, which in May of last year extended its partnership with Bristol Myers Squibb",FULL-ARTICLE,Dow Jones Newswires,Evotec Shares Rise After Drug Progress Earns Payment From Bristol Myers Squibb
BMY,2023-03-16,08:56:53,94637C,Bristol-Myers Squibb Co.,92,0.49,partnerships,,"Evotec, which in May of last year extended its partnership with Bristol Myers Squibb",FULL-ARTICLE,Dow Jones Newswires,Evotec Shares Rise After Drug Progress Earns Payment From Bristol Myers Squibb
BMY,2023-03-20,11:00:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Therapeutics Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs
BMY,2023-03-20,11:03:23,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Therapeutics Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs
BMY,2023-03-23,11:30:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,By partnering with Bristol Myers Squibb on,PRESS-RELEASE,GlobeNewswire,BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb's OPDIVO(R) (nivolumab)
BMY,2023-03-23,11:30:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,"In May 2022, BridgeBio entered into an exclusive license agreement with Bristol Myers Squibb",PRESS-RELEASE,GlobeNewswire,BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb's OPDIVO(R) (nivolumab)
BMY,2023-03-23,11:30:02,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,By partnering with Bristol Myers Squibb on,PRESS-RELEASE,Dow Jones Newswires,Press Release: BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb's OPDIVO(R) (nivolumab)
BMY,2023-03-23,11:30:02,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,"In May 2022, BridgeBio entered into an exclusive license agreement with Bristol Myers Squibb",PRESS-RELEASE,Dow Jones Newswires,Press Release: BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb's OPDIVO(R) (nivolumab)
BMY,2023-03-23,21:13:49,94637C,Bristol-Myers Squibb Co.,100,0.44,labor-issues,,Bristol-Myers Squibb CEO Giovanni Caforio 2022 Total Pay Valued at $20.1M,NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb CEO Giovanni Caforio 2022 Total Pay Valued at $20.1M, Compared With $19.8M in 2021"
BMY,2023-03-28,09:01:57,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership 28-March-2023,PRESS-RELEASE,Dow Jones Newswires,EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
BMY,2023-03-28,09:01:57,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership 28-March-2023,PRESS-RELEASE,DGAP News,EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
BMY,2023-03-28,09:03:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership,PRESS-RELEASE,DGAP News,EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
BMY,2023-03-28,09:03:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
BMY,2023-03-28,09:20:38,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec SE: our strategic neurodegeneration partnership with Bristol Myers Squibb.,PRESS-RELEASE,DJ Global Press Release Wire,Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
BMY,2023-03-28,09:57:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec Extends Partnership With Bristol Myers Squibb for,FULL-ARTICLE,Dow Jones Newswires,Evotec Extends Partnership With Bristol Myers Squibb for Potential $4 Bln
BMY,2023-03-28,10:12:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec Extends Partnership With Bristol Myers Squibb for,FULL-ARTICLE,Dow Jones Newswires,Evotec Extends Partnership With Bristol Myers Squibb for Potential $4 Billion
BMY,2023-03-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission has approved Sotyktu (deucravacitinib),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis"
BMY,2023-03-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The Phase 3 POETYK-PSO clinical trials,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis"
BMY,2023-03-28,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2023-03-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission has approved Sotyktu (deucravacitinib),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis"
BMY,2023-03-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The Phase 3 POETYK-PSO clinical trials,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis"
BMY,2023-03-28,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-03-28,10:59:09,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval of Sotyktu,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval of Sotyktu Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
BMY,2023-03-28,11:24:21,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets European Green Light for Otezla,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Green Light for Otezla Rival -- Market Talk
BMY,2023-03-28,11:24:21,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb wins European Commission approval of Sotyktu,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Green Light for Otezla Rival -- Market Talk
BMY,2023-03-28,11:24:21,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers to complete its $74B acquisition of Celgene,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Green Light for Otezla Rival -- Market Talk
BMY,2023-03-28,11:24:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets European Green Light for Otezla,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Green Light for Otezla Rival -- Market Talk
BMY,2023-03-28,11:24:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb wins European Commission approval of Sotyktu,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Green Light for Otezla Rival -- Market Talk
BMY,2023-03-28,11:24:22,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers to complete its $74B acquisition of Celgene,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Green Light for Otezla Rival -- Market Talk
BMY,2023-03-31,12:07:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-03-31,12:07:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-03-31,12:07:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-03-31,12:07:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-03-31,12:07:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-03-31,12:07:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-03-31,12:07:34,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-Cell Lymphoma After One Prior Therapy
BMY,2023-03-31,12:42:33,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,Breyanzi is already approved in Europe,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Second-Line Breyanzi >BMY
BMY,2023-03-31,12:42:33,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,Bristol Myers reported 2022 Breyanzi revenue of $182 million,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Second-Line Breyanzi >BMY
BMY,2023-03-31,12:57:33,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,Breyanzi is already approved in Europe,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Second-Line Breyanzi
BMY,2023-03-31,12:57:33,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,Bristol Myers reported 2022 Breyanzi revenue of $182 million,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Second-Line Breyanzi
BMY,2023-04-05,00:41:28,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Shanahan Acquires 1,614 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Shanahan Acquires 1,614 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-04-05,00:42:09,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Mily Acquires 3,148 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Mily Acquires 3,148 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-04-11,11:04:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Foundation Medicine and Bristol Myers Squibb Expand Partnership to,PRESS-RELEASE,Business Wire,Foundation Medicine and Bristol Myers Squibb Expand Partnership to Focus on Companion Diagnostic Development
BMY,2023-04-20,09:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Tubulis Announces Strategic License Agreement with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
BMY,2023-04-21,12:00:03,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten,PRESS-RELEASE,GlobeNewswire,LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
BMY,2023-04-21,12:00:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Lianbio's Phase 1 pharmacokinetic study of mavacamten,PRESS-RELEASE,GlobeNewswire,LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
BMY,2023-04-21,12:00:03,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Mavacamten was granted Breakthrough Therapy Designation in China,PRESS-RELEASE,GlobeNewswire,LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
BMY,2023-04-21,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
BMY,2023-04-21,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Lianbio's Phase 1 pharmacokinetic study of mavacamten,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
BMY,2023-04-21,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Mavacamten was granted Breakthrough Therapy Designation in China,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
BMY,2023-04-21,12:01:27,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Admin Acceptance With Priority Review of New Drug Application for Mavacamten,NEWS-FLASH,Dow Jones Newswires,LianBio Announces China National Medical Products Admin Acceptance With Priority Review of New Drug Application for Mavacamten for the Treatment of Patients With Obstructive Hypertrophic Cardiomyopathy
BMY,2023-04-21,12:20:38,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lianbio Gets China Approval for Priority Review of Mavacamten,FULL-ARTICLE,Dow Jones Newswires,LianBio Gets China Approval for Priority Review of Mavacamten New Drug App
BMY,2023-04-21,12:20:38,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,China's National Medical Products Administration has accepted with priority review its new drug application for mavacamten,FULL-ARTICLE,Dow Jones Newswires,LianBio Gets China Approval for Priority Review of Mavacamten New Drug App
BMY,2023-04-21,12:20:38,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Phase 3 trial, which evaluated the safety and efficacy of mavacamten",FULL-ARTICLE,Dow Jones Newswires,LianBio Gets China Approval for Priority Review of Mavacamten New Drug App
BMY,2023-04-21,14:20:11,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Buy by B of A Securities
BMY,2023-04-21,14:20:11,94637C,Bristol-Myers Squibb Co.,100,0.48,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $85.00/Share From $82.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $85.00/Share From $82.00 by B of A Securities
BMY,2023-04-24,07:28:11,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2023 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2023 (BMY)"
BMY,2023-04-26,18:42:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,18:42:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of CAMZYOS(R) (mavacamten),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,18:42:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Results from the Phase 3 VALOR-HCM study evaluated CAMZYOS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,18:42:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"2022, the U.S. Food and Drug Administration (FDA) approved CAMZYOS",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,18:42:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,18:42:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of CAMZYOS(R) (mavacamten),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,18:42:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Results from the Phase 3 VALOR-HCM study evaluated CAMZYOS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,18:42:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"2022, the U.S. Food and Drug Administration (FDA) approved CAMZYOS",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,20:14:00,94637C,Bristol-Myers Squibb Co.,99,-0.49,labor-issues,,"Bristol Myers Squibb Chairman and CEO, to Retire",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Leadership Transition Plan
BMY,2023-04-26,20:14:00,94637C,Bristol-Myers Squibb Co.,99,0.53,labor-issues,,"Bristol-Myers Squibb Co.: to Succeed Giovanni Caforio, MD, as CEO",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Leadership Transition Plan
BMY,2023-04-26,20:14:00,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol Myers Squibb has nearly tripled its revenue,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Leadership Transition Plan
BMY,2023-04-26,20:14:01,94637C,Bristol-Myers Squibb Co.,99,-0.49,labor-issues,,"Bristol Myers Squibb Chairman and CEO, to Retire",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Leadership Transition Plan
BMY,2023-04-26,20:14:01,94637C,Bristol-Myers Squibb Co.,99,0.53,labor-issues,,"Bristol-Myers Squibb Co.: to Succeed Giovanni Caforio, MD, as CEO",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Leadership Transition Plan
BMY,2023-04-26,20:14:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol Myers Squibb has nearly tripled its revenue,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Leadership Transition Plan
BMY,2023-04-26,20:14:31,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,"Chmn and CEO, to Retire as CEO, Effective Nov 1",HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb : Giovanni Caforio, MD, Chmn and CEO, to Retire as CEO, Effective Nov 1 >BMY"
BMY,2023-04-26,20:15:22,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Christopher Boerner Appointed EVP, Oper Chief, Effective Immediately",HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb: Christopher Boerner Appointed EVP, Oper Chief, Effective Immediately >BMY"
BMY,2023-04-26,20:15:44,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,Bristol-Myers Squibb: Boerner to Succeed Giovanni Caforio as CEO,HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb: Boerner to Succeed Giovanni Caforio as CEO, Effective Nov 1 >BMY"
BMY,2023-04-26,20:15:54,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Appointed EVP, Chief Commercialization Officer, Effective Immediately >BMY",HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb: Adam Lenkowsky Appointed EVP, Chief Commercialization Officer, Effective Immediately >BMY"
BMY,2023-04-26,20:23:30,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,Bristol-Myers Squibb CEO to Retire Nov. 1,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb CEO to Retire Nov. 1 -- WSJ
BMY,2023-04-26,20:23:30,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,Bristol-Myers Squibb Co. Chief Executive Giovanni Caforio is planning to retire,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers CEO Giovanni Caforio to Leave Drugmaker -- WSJ
BMY,2023-04-26,20:29:11,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,Bristol-Myers Squibb Co. Chief Executive Giovanni Caforio is planning to retire,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers CEO Giovanni Caforio to Leave Drugmaker -- Update
BMY,2023-04-26,20:30:11,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,Bristol-Myers Squibb Co. Chief Executive Giovanni Caforio is planning to retire,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers CEO Giovanni Caforio to Leave Drugmaker
BMY,2023-04-26,20:35:21,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,Bristol-Myers Squibb Co. Chief Executive Giovanni Caforio is planning to retire,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers CEO Giovanni Caforio to Leave Drugmaker -- 2nd Update
BMY,2023-04-27,06:14:42,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,Bristol-Myers's Caforio to Retire As Drugmaker's Chief Executive,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers's Caforio to Retire  As Drugmaker's Chief Executive  ----  By Jared S. Hopkins and Laura Cooper
BMY,2023-04-27,06:32:14,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,Bristol-Myers's Caforio to Retire As Drugmaker's Chief Executive,FULL-ARTICLE,Wall Street Journal,Bristol-Myers's Caforio to Retire As Drugmaker's Chief Executive -- WSJ
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 1Q Rev $11.3B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Rev $11.3B >BMY
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q Net $2.26B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Net $2.26B >BMY
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q EPS $1.07,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q EPS $1.07 >BMY
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q Adj EPS $2.05,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Adj EPS $2.05 >BMY
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports First Quarter Financial Results for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol-Myers Squibb Co.: Reports First Quarter Revenues of $11.3 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts First Quarter GAAP Earnings Per Share of $1.07,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts GAAP 2023 EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Affirms Non-GAAP Financial Guidance for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.32,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 16% to $3.3 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.6 billion compared to $2.1 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.14,revenues,,Bristol-Myers Squibb Co.: International revenues were $912 million compared to $824 million,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Camzyos,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.49,partnerships,,"Bristol-Myers Squibb Co.: The company, in collaboration with Janssen Pharmaceuticals, Inc.",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: The submissions were based on results from the Phase 3 CheckMate-76K clinical trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,93,0.62,products-services,positive,Bristol-Myers Squibb Co.: The positive opinion was based on results from the pivotal Phase 3 TRANSFORM clinical trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusting GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $4.03-$4.33,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, April 27, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 1.08 $ 0.60,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -6-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2023",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -6-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,98,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $ 11,337 $11,648",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -7-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Full Year 2023 Pre-tax Tax After-tax Projected Diluted Earnings,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -8-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: the company's 2023 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -8-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The GAAP financial results for the full year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -8-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -8-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol Myers Squibb Reports First Quarter Financial Results for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -8-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports First Quarter Financial Results for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol-Myers Squibb Co.: Reports First Quarter Revenues of $11.3 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts First Quarter GAAP Earnings Per Share of $1.07,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts GAAP 2023 EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Affirms Non-GAAP Financial Guidance for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.32,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 16% to $3.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.6 billion compared to $2.1 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.14,revenues,,Bristol-Myers Squibb Co.: International revenues were $912 million compared to $824 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Camzyos,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.49,partnerships,,"Bristol-Myers Squibb Co.: The company, in collaboration with Janssen Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: The submissions were based on results from the Phase 3 CheckMate-76K clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.62,products-services,positive,Bristol-Myers Squibb Co.: The positive opinion was based on results from the pivotal Phase 3 TRANSFORM clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusting GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $4.03-$4.33,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, April 27, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 1.08 $ 0.60,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -6-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -6-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,98,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $ 11,337 $11,648",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -7-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Full Year 2023 Pre-tax Tax After-tax Projected Diluted Earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -8-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: the company's 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -8-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The GAAP financial results for the full year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -8-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -8-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol Myers Squibb Reports First Quarter Financial Results for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -8-
BMY,2023-04-27,11:01:08,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,unchanged,Bristol-Myers Squibb Backs 2023 View of Adj EPS $7.95,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Backs 2023 View of Adj EPS $7.95-Adj EPS $8.25 >BMY
BMY,2023-04-27,11:02:56,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb 1Q Revenue From In-Line Products, New Product Portfolio Up 10%",NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb 1Q Revenue From In-Line Products, New Product Portfolio Up 10% Ex-Forex >BMY"
BMY,2023-04-27,11:09:24,94637C,Bristol-Myers Squibb Co.,100,0.74,earnings,up,Bristol Myers Squibb Q1 EPS $1.07 vs. 59 cents a year ago,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb Q1 EPS $1.07 vs. 59 cents a year ago
BMY,2023-04-27,11:09:24,94637C,Bristol-Myers Squibb Co.,100,0.46,earnings,above-expectations,Bristol Myers Squibb Q1 adj. EPS $2.05; FactSet consensus $1.97,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb Q1 adj. EPS $2.05; FactSet consensus $1.97
BMY,2023-04-27,11:10:24,94637C,Bristol-Myers Squibb Co.,100,-0.27,revenues,below-expectations,Bristol Myers Squibb Q1 revenue $11.337 bln vs. $11.648 bln a year ago; FactSet consensus $11.496 bln,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb Q1 revenue $11.337 bln vs. $11.648 bln a year ago; FactSet consensus $11.496 bln
BMY,2023-04-27,11:11:24,94637C,Bristol-Myers Squibb Co.,100,0.48,revenues,up,Bristol Myers Squibb still sees full-year revenue up 2%,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb still sees full-year revenue up 2%
BMY,2023-04-27,11:12:24,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb now sees full-year EPS of $4.10 to $4.40,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb now sees full-year EPS of $4.10 to $4.40 vs. prior $4.03 to $4.33
BMY,2023-04-27,11:12:25,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb still sees full-year adj. EPS of $7.85 to $8.25,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb still sees full-year adj. EPS of $7.85 to $8.25
BMY,2023-04-27,11:22:24,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Q1 Profit Beats,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Q1 Profit Beats While Revenue Falls Slightly Short Of Estimates -- MarketWatch
BMY,2023-04-27,11:22:24,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb Co. (BMY) posted net income of $2.262 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Q1 Profit Beats While Revenue Falls Slightly Short Of Estimates -- MarketWatch
BMY,2023-04-27,11:22:24,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Q1 profit beats,FULL-ARTICLE,MarketWatch,MW Bristol Myers Q1 profit beats while revenue falls slightly short of estimates
BMY,2023-04-27,11:22:24,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb Co. (BMY) posted net income of $2.262 billion,FULL-ARTICLE,MarketWatch,MW Bristol Myers Q1 profit beats while revenue falls slightly short of estimates
BMY,2023-04-28,12:51:10,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by Credit Suisse
BMY,2023-04-28,12:51:10,94637C,Bristol-Myers Squibb Co.,100,-0.7,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $72.00/Share From $78.00 by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $72.00/Share From $78.00 by Credit Suisse
BMY,2023-05-01,10:02:16,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2023-05-01,10:02:16,94637C,Bristol-Myers Squibb Co.,100,-0.3,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $65.00/Share From $66.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $65.00/Share From $66.00 by Barclays
BMY,2023-05-01,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate
BMY,2023-05-01,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate
BMY,2023-05-01,11:05:50,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Reblozylas First-Line Treatment of Anemia in Adults With Lower-Risk Myelodysplastic Syndromes
BMY,2023-05-01,11:20:38,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Expanded Reblozyl Use >BMY
BMY,2023-05-01,11:35:38,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Expanded Reblozyl Use
BMY,2023-05-01,18:02:33,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review for Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Gets FDA Priority Review for Reblozyl Expanded Use
BMY,2023-05-01,18:17:33,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review for Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Gets FDA Priority Review for Reblozyl Expanded Use
BMY,2023-05-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,marketing,,Bristol-Myers Squibb Co.: the company will participate in the Bank of America Securities 2023 Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare Conference
BMY,2023-05-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,marketing,,Bristol-Myers Squibb Co.: the company will participate in the Bank of America Securities 2023 Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare Conference
BMY,2023-05-03,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-05-03,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: TRANSFORM Clinical Trial Results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-05-03,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-05-03,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-05-03,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: TRANSFORM Clinical Trial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-05-03,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-05-03,10:59:11,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene Maraleucel),NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene Maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-05-03,17:48:27,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp Vessey Registers 50,385 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP Vessey Registers 50,385 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-05-03,23:38:38,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Greenlees Acquires 671 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Greenlees Acquires 671 Of Bristol-Myers Squibb Co >BMY
BMY,2023-05-04,07:00:47,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: our collaboration with BMS.,PRESS-RELEASE,PR Newswire,Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb
BMY,2023-05-04,12:00:09,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: our collaboration with BMS.,PRESS-RELEASE,PR Newswire,Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb
BMY,2023-05-04,21:52:26,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Vessey Sells 50,385 Of Bristol-Myers Squibb Co",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Sells 50,385 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-05-11,17:41:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: phase 1 study of,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight Diversified -3-
BMY,2023-05-11,17:41:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight Diversified -10-
BMY,2023-05-11,17:41:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight Diversified -10-
BMY,2023-05-11,17:41:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight Diversified -10-
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,99,0.0,marketing,,Bristol Myers Squibb to Host Virtual Investor Event,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023"
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Results from the dose-escalation components of a Phase 1/2 study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023"
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023"
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: A phase 2/3 trial of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -4-
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -7-
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -10-
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -10-
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -10-
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,90,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -13-
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -13-
BMY,2023-05-22,15:01:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Data demonstrate potential of BMS-986278,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Investigational LPA(1) Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
BMY,2023-05-22,15:01:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced results from a Phase 2 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Investigational LPA(1) Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
BMY,2023-05-22,15:01:36,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Data demonstrate potential of BMS-986278,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
BMY,2023-05-22,15:01:36,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced results from a Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
BMY,2023-05-25,11:06:41,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Bristol Myers/J&J Get FDA Fast-Track Designation,NEWS-FLASH,Dow Jones Newswires,Bristol Myers/J&J Get FDA Fast-Track Designation for Milvexian in Three Indications in Phase 3
BMY,2023-05-25,21:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb to Present First Results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl(R) (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
BMY,2023-05-25,21:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Results from Phase 3 COMMANDS study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl(R) (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
BMY,2023-05-25,21:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb to Present First Results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present First Results at -2-
BMY,2023-05-25,21:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Reblozyl,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present First Results at -2-
BMY,2023-05-25,21:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb to Present First Results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present First Results at -3-
BMY,2023-05-25,21:02:24,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb to Present First Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl(R) (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
BMY,2023-05-25,21:02:24,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Results from Phase 3 COMMANDS study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl(R) (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
BMY,2023-05-25,21:02:24,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Reblozyl,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -2-
BMY,2023-05-25,21:05:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi (lisocabtagene -2-
BMY,2023-05-25,21:05:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Breyanzi -2-
BMY,2023-05-26,12:10:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...
BMY,2023-05-26,12:10:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...
BMY,2023-05-26,12:10:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2023-05-26,12:10:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2023-05-26,12:10:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2023-05-26,12:10:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...
BMY,2023-05-26,12:10:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...
BMY,2023-05-26,12:10:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-05-26,12:10:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-05-26,12:10:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2023-05-26,12:11:20,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo With Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients With Tumor Cell PD-L1 Expression >1%
BMY,2023-05-26,12:28:15,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,Committee for Medicinal Products for Human Use has recommended approval of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets CHMP Recommendation for Opdivo With Chemotherapy to Treat Lung Cancer
BMY,2023-05-26,12:43:14,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,Committee for Medicinal Products for Human Use has recommended approval of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets CHMP Recommendation for Opdivo With Chemotherapy to Treat Lung Cancer
BMY,2023-05-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
BMY,2023-05-30,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
BMY,2023-05-30,10:59:35,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Repotrectinib,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Repotrectinib in Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
BMY,2023-05-30,11:19:37,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Repotrectinib,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Repotrectinib in Certain Non-Small Cell Lung Cancer
BMY,2023-05-30,11:19:37,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb on Tuesday said the Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Repotrectinib in Certain Non-Small Cell Lung Cancer
BMY,2023-05-30,11:19:37,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers's $4.1 billion acquisition of Turning Point Therapeutics,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Repotrectinib in Certain Non-Small Cell Lung Cancer
BMY,2023-05-30,11:34:37,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Repotrectinib,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Repotrectinib in Certain Non-Small Cell Lung Cancer
BMY,2023-05-30,11:34:37,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb on Tuesday said the Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Repotrectinib in Certain Non-Small Cell Lung Cancer
BMY,2023-05-30,11:34:37,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers's $4.1 billion acquisition of Turning Point Therapeutics,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Repotrectinib in Certain Non-Small Cell Lung Cancer
BMY,2023-05-30,13:24:00,94637C,Bristol-Myers Squibb Co.,95,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant Lymphoma
BMY,2023-05-30,13:24:00,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant Lymphoma
BMY,2023-06-01,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2023-06-01,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2023-06-05,16:12:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Sciences Announces Collaboration with Bristol Myers Squibb on,PRESS-RELEASE,Business Wire,MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on Tumor Target Discovery
BMY,2023-06-05,16:12:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The company is developing internal drug programs for hepatocellular carcinoma,PRESS-RELEASE,Business Wire,MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on Tumor Target Discovery
BMY,2023-06-05,16:40:55,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Sciences Announces Collaboration with Bristol Myers Squibb on,PRESS-RELEASE,Dow Jones Newswires,Press Release: MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on Tumor Target Discovery
BMY,2023-06-05,16:40:55,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The company is developing internal drug programs for hepatocellular carcinoma,PRESS-RELEASE,Dow Jones Newswires,Press Release: MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on Tumor Target Discovery
BMY,2023-06-06,23:40:54,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Lenkowsky Acquires 526 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Lenkowsky Acquires 526 Of Bristol-Myers Squibb Co >BMY
BMY,2023-06-08,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023"
BMY,2023-06-08,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023"
BMY,2023-06-08,11:05:51,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023"
BMY,2023-06-08,11:05:51,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023"
BMY,2023-06-08,20:16:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the U.S. Food and Drug Administration (FDA) has approved commercial production at the company's newest cell therapy,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts"
BMY,2023-06-08,20:16:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the U.S. Food and Drug Administration (FDA) has approved commercial production at the company's newest cell therapy,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts"
BMY,2023-06-14,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2023-06-14,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on August 1, 2023, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2023-06-14,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2023-06-14,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on August 1, 2023, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2023-06-16,21:03:01,94637C,Bristol-Myers Squibb Co.,100,-0.48,legal,,Bristol Myers Squibb sues federal government over,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb sues federal government over Medicare drug negotiations: report
BMY,2023-06-16,21:03:01,94637C,Bristol-Myers Squibb Co.,100,-0.48,legal,,Bristol Myers Squibb Sues Federal Government Over,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Sues Federal Government Over Medicare Drug Negotiations: Report -- MarketWatch
BMY,2023-06-17,09:30:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi (lisocabtagene -2-
BMY,2023-06-17,09:30:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Breyanzi -2-
BMY,2023-06-26,12:01:35,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lianbio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in Singapore,PRESS-RELEASE,GlobeNewswire,LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in Singapore
BMY,2023-06-26,12:01:35,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Mavacamten was granted Breakthrough Therapy Designation in China,PRESS-RELEASE,GlobeNewswire,LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in Singapore
BMY,2023-06-26,12:01:35,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lianbio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in Singapore,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in Singapore
BMY,2023-06-26,12:01:35,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Mavacamten was granted Breakthrough Therapy Designation in China,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in Singapore
BMY,2023-06-26,12:01:53,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lianbio Announces Marketing Approval of CAMZYOS (Mavacamten) in Singapore,NEWS-FLASH,Dow Jones Newswires,LianBio Announces Marketing Approval of CAMZYOS (Mavacamten) in Singapore
BMY,2023-06-26,12:09:46,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lianbio: CAMZYOS Gets Singapore Marketing Approval,NEWS-FLASH,Dow Jones Newswires,LianBio: CAMZYOS Gets Singapore Marketing Approval for Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
BMY,2023-06-26,20:01:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved CAMZYOS(R),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval of CAMZYOS(R) (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)"
BMY,2023-06-26,20:01:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: The positive results of both Phase 3 clinical trials showed that CAMZYOS,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval of CAMZYOS(R) (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)"
BMY,2023-06-26,20:01:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved CAMZYOS(R),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval of CAMZYOS(R) (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)"
BMY,2023-06-26,20:01:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: The positive results of both Phase 3 clinical trials showed that CAMZYOS,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval of CAMZYOS(R) (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)"
BMY,2023-06-26,20:01:27,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval of CAMZYOS,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval of CAMZYOS to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy
BMY,2023-06-26,20:08:27,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers' Heart Treatment Camzyos Gets EU Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Heart Treatment Camzyos Gets EU Approval
BMY,2023-06-26,20:23:27,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers' Heart Treatment Camzyos Gets EU Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Heart Treatment Camzyos Gets EU Approval
BMY,2023-06-26,21:59:35,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval -- Market Talk
BMY,2023-06-26,21:59:35,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb's European-Commission approval for its heart-disease drug,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval -- Market Talk
BMY,2023-06-26,21:59:35,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers acquired Camzyos when it took over MyoKardia for $13.1B,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval -- Market Talk
BMY,2023-06-26,21:59:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval -- Market Talk
BMY,2023-06-26,21:59:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb's European-Commission approval for its heart-disease drug,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval -- Market Talk
BMY,2023-06-26,21:59:36,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers acquired Camzyos when it took over MyoKardia for $13.1B,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval -- Market Talk
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression >=1%
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The importance of the approval of nivolumab combined with chemotherapy for the treatment of certain patients with non-metastatic NSCLC,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression >=1%
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -6-
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression >=1%
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The importance of the approval of nivolumab combined with chemotherapy for the treatment of certain patients with non-metastatic NSCLC,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression >=1%
BMY,2023-06-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2023-06-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2023-06-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2023-06-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -6-
BMY,2023-06-29,10:59:27,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo With Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients With Tumor Cell PD-L1 Expression
BMY,2023-07-05,21:25:19,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 4,570 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Acquires 4,570 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-07-05,21:28:08,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Weese Acquires 1,203 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Weese Acquires 1,203 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-07-10,13:58:42,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Initiated at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Market Perform by SVB Leerink
BMY,2023-07-10,13:58:42,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $66.00/Share by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $66.00/Share by SVB Leerink
BMY,2023-07-11,05:30:32,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership,PRESS-RELEASE,DGAP News,EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
BMY,2023-07-11,05:30:32,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Evotec and Bristol Myers Squibb enter licence agreement,PRESS-RELEASE,DGAP News,EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
BMY,2023-07-11,05:30:32,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
BMY,2023-07-11,05:30:32,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Evotec and Bristol Myers Squibb enter licence agreement,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
BMY,2023-07-11,05:50:37,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership,PRESS-RELEASE,DJ Global Press Release Wire,Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership
BMY,2023-07-11,10:34:15,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2023-07-11,10:34:15,94637C,Bristol-Myers Squibb Co.,100,-0.3,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $64.00/Share From $65.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $64.00/Share From $65.00 by Barclays
BMY,2023-07-12,10:59:00,94637C,Bristol-Myers Squibb Co.,95,0.57,products-services,granted,Zeposia was approved by the U.S. Food and Drug Administration (FDA) for the treatment,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Launches Supporting You with UC, with Women's World Cup Commentator, Former Professional Soccer Player and Ulcerative Colitis Patient, Rosie White"
BMY,2023-07-12,10:59:00,94637C,Bristol-Myers Squibb Co.,95,0.57,products-services,granted,Bristol-Myers Squibb Co.: Zeposia was approved by the FDA for the treatment of moderate to severe ulcerative colitis,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Launches Supporting You with UC, with Women's World Cup Commentator, Former Professional Soccer Player and Ulcerative Colitis Patient, Rosie White"
BMY,2023-07-12,10:59:00,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: sudden loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Launches Supporting You with -2-
BMY,2023-07-14,08:57:56,94637C,Bristol-Myers Squibb Co.,100,-0.99,analyst-ratings,negative,Bristol-Myers Squibb Initiated at Reduce by HSBC,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Reduce by HSBC
BMY,2023-07-14,08:57:56,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $56.00/Share by HSBC,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $56.00/Share by HSBC
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opdivo was approved by the European Commission,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opdivo was approved by the European Commission,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2023-07-21,10:59:16,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo as an Adjuvant Treatment for Patients With Completely Resected Stage IIB or IIC Melanoma
BMY,2023-07-24,11:00:00,94637C,Bristol-Myers Squibb Co.,93,0.22,acquisitions-mergers,,"Bristol Myers Squibb purchased 2,419,818 ordinary shares in a private placement transaction at a subscription price",PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
BMY,2023-07-24,11:00:00,94637C,Bristol-Myers Squibb Co.,93,0.22,acquisitions-mergers,,"Bristol Myers Squibb purchased 2,419,818 ordinary shares in a private placement transaction at a subscription price",PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
BMY,2023-07-24,11:00:01,94637C,Bristol-Myers Squibb Co.,94,0.22,acquisitions-mergers,,Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
BMY,2023-07-24,11:00:01,94637C,Bristol-Myers Squibb Co.,94,0.22,acquisitions-mergers,,Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
BMY,2023-07-24,11:11:22,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Bristol Myers Buys 2.42M Ordinary Shrs in Private Placement Transaction at Subscription Price of $14,NEWS-FLASH,Dow Jones Newswires,Immatics: Bristol Myers Buys 2.42M Ordinary Shrs in Private Placement Transaction at Subscription Price of $14.46/Shr
BMY,2023-07-24,11:26:20,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Bristol Myers Squibb Invests $35 Million in Immatics,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Invests $35 Million in Immatics
BMY,2023-07-24,11:41:20,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Bristol Myers Squibb Invests $35 Million in Immatics,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Invests $35 Million in Immatics
BMY,2023-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q Adj EPS $1.75,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Adj EPS $1.75 >BMY
BMY,2023-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q EPS 99c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q EPS 99c >BMY
BMY,2023-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q Net $2.1B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Net $2.1B >BMY
BMY,2023-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 2Q Rev $11.2B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Rev $11.2B >BMY
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol-Myers Squibb Co.: Reports Second Quarter Revenues of $11.2 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Second Quarter GAAP Earnings Per Share of $0.99,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol-Myers Squibb Co.: Announces $4 Billion Accelerated Share Repurchase,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.75,revenues,down,Expected decline in Revlimid sales in the quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: our financial guidance for the year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 5% to $7.9 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: The EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.3 billion compared to $2.2 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues increased 2% to $1.2 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,"European Commission (EC) approved Camzyos, the first",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,products-services,,Bristol-Myers Squibb Co.: The approval is based upon results from two Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,"Bristol-Myers Squibb Co.: The company in collaboration with Janssen Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,European Medicines Agency (EMA) recommended approval of Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: The approval was based on results from the pivotal Phase 3 TRANSFORM clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Clinical & LPA(1) Results from the Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.16,revenues,,Bristol-Myers Squibb Co.: International revenues decreased 12% to $6.6 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: FIRST HALF FINANCIAL RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,unchanged,Bristol-Myers Squibb Co.: U.S. revenues remained consistent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.5 billion compared to $2.3 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $4.9 billion compared to $4.3 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.68,revenues,down,Bristol-Myers Squibb Co.: Revlimid worldwide revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,,Bristol-Myers Squibb Co.: the company is announcing a $4 billion accelerated share repurchase program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $4.10-$4.40,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, July 27, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: the company's Annual Report on Form 10-K for the year ended December 31, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED JUNE 30, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.99 $ 0.67 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $7,891 $3,335",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,226 $11,887",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -9-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: the company's 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -10-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The GAAP financial results for the full year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -10-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -10-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol-Myers Squibb Co.: Reports Second Quarter Revenues of $11.2 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Second Quarter GAAP Earnings Per Share of $0.99,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol-Myers Squibb Co.: Announces $4 Billion Accelerated Share Repurchase,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.75,revenues,down,Expected decline in Revlimid sales in the quarter,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: our financial guidance for the year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 5% to $7.9 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: The EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.3 billion compared to $2.2 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues increased 2% to $1.2 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,"European Commission (EC) approved Camzyos, the first",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,products-services,,Bristol-Myers Squibb Co.: The approval is based upon results from two Phase 3 trials,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,"Bristol-Myers Squibb Co.: The company in collaboration with Janssen Pharmaceuticals, Inc.",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,European Medicines Agency (EMA) recommended approval of Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: The approval was based on results from the pivotal Phase 3 TRANSFORM clinical trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Clinical & LPA(1) Results from the Phase 2 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.16,revenues,,Bristol-Myers Squibb Co.: International revenues decreased 12% to $6.6 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: FIRST HALF FINANCIAL RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,unchanged,Bristol-Myers Squibb Co.: U.S. revenues remained consistent,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.5 billion compared to $2.3 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $4.9 billion compared to $4.3 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.68,revenues,down,Bristol-Myers Squibb Co.: Revlimid worldwide revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,,Bristol-Myers Squibb Co.: the company is announcing a $4 billion accelerated share repurchase program,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $4.10-$4.40,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, July 27, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: the company's Annual Report on Form 10-K for the year ended December 31, 2022",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -7-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED JUNE 30, 2023",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -7-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.99 $ 0.67 $,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -7-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $7,891 $3,335",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -8-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,226 $11,887",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -9-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: the company's 2023 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -10-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The GAAP financial results for the full year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -10-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -10-
BMY,2023-07-27,10:59:46,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2023 Adj EPS $7.35,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 Adj EPS $7.35-Adj EPS $7.65 >BMY
BMY,2023-07-27,11:00:12,94637C,Bristol-Myers Squibb Co.,100,-0.75,revenues,down,Bristol-Myers Squibb Sees 2023 Revenue Down,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 Revenue Down Low-Single Digits >BMY
BMY,2023-07-27,11:07:27,94637C,Bristol-Myers Squibb Co.,100,-0.26,earnings,below-expectations,Bristol-Myers Squibb Q2 adj. EPS $1.75; FactSet consensus $1.98,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb Q2 adj. EPS $1.75; FactSet consensus $1.98
BMY,2023-07-27,11:07:28,94637C,Bristol-Myers Squibb Co.,100,-0.27,revenues,below-expectations,Bristol-Myers Squibb Q2 revenue $11.226 bln vs. $11.887 bln a year ago; FactSet consensus $11.806 bln,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb Q2 revenue $11.226 bln vs. $11.887 bln a year ago; FactSet consensus $11.806 bln
BMY,2023-07-27,11:08:28,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb lowers guidance,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb lowers guidance to reflect lower-than-expected revlimid sales
BMY,2023-07-27,11:09:28,94637C,Bristol-Myers Squibb Co.,100,-0.75,revenues,down,Bristol-Myers Squibb now sees 2023 revenue down,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb now sees 2023 revenue down by low single-digits vs. prior guidance o up 2%
BMY,2023-07-27,11:10:27,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb now sees 2023 adj. EPS of $7.35 to $7.65,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb now sees 2023 adj. EPS of $7.35 to $7.65 vs. prior $8.95 to $8.25
BMY,2023-07-27,11:17:28,94637C,Bristol-Myers Squibb Co.,91,-0.54,revenues,down,Revlimid sales dropped 41%,FULL-ARTICLE,MarketWatch,MW Bristol Myers stock takes a hit from earnings miss and lower outlook amid disappointing Revlimid sales
BMY,2023-07-27,11:17:28,94637C,Bristol-Myers Squibb Co.,91,0.0,revenues,,Revlimid sales are now expected to,FULL-ARTICLE,MarketWatch,MW Bristol Myers stock takes a hit from earnings miss and lower outlook amid disappointing Revlimid sales
BMY,2023-07-27,11:17:28,94637C,Bristol-Myers Squibb Co.,91,-0.54,revenues,down,Revlimid sales dropped 41%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Takes A Hit From Earnings Miss And Lower Outlook Amid Disappointing Revlimid Sales -- MarketWatch
BMY,2023-07-27,11:17:28,94637C,Bristol-Myers Squibb Co.,91,0.0,revenues,,Revlimid sales are now expected to,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Takes A Hit From Earnings Miss And Lower Outlook Amid Disappointing Revlimid Sales -- MarketWatch
BMY,2023-07-27,12:13:49,94637C,Bristol-Myers Squibb Co.,93,-0.75,revenues,down,Bristol Myers now estimates 2023 revenue to fall,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Slashes Forecast on Tumbling Revlimid Sales -- Barrons.com
BMY,2023-07-27,12:13:49,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,Revlimid sales were forecast at,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Slashes Forecast on Tumbling Revlimid Sales -- Barrons.com
BMY,2023-07-27,13:50:04,94637C,Bristol-Myers Squibb Co.,93,-0.75,revenues,down,Bristol Myers now estimates 2023 revenue to fall,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Slashes Forecast on Tumbling Revlimid Sales
BMY,2023-07-27,13:50:04,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,Revlimid sales were forecast at,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Slashes Forecast on Tumbling Revlimid Sales
BMY,2023-07-28,10:25:19,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2023-07-28,10:25:19,94637C,Bristol-Myers Squibb Co.,100,-0.46,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $62.00/Share From $64.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $62.00/Share From $64.00 by Barclays
BMY,2023-07-28,10:33:59,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities
BMY,2023-07-28,10:33:59,94637C,Bristol-Myers Squibb Co.,100,-0.62,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $85.00/Share From $90.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $85.00/Share From $90.00 by Atlantic Equities
BMY,2023-07-28,13:09:10,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Buy by B of A Securities
BMY,2023-07-28,13:09:10,94637C,Bristol-Myers Squibb Co.,100,-0.64,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $80.00/Share From $85.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $80.00/Share From $85.00 by B of A Securities
BMY,2023-07-28,14:12:40,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital
BMY,2023-07-28,14:12:40,94637C,Bristol-Myers Squibb Co.,100,-0.76,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $79.00/Share From $87.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $79.00/Share From $87.00 by BMO Capital
BMY,2023-07-28,16:05:10,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
BMY,2023-07-28,16:05:10,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $65.00/Share From $78.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $65.00/Share From $78.00 by Wells Fargo
BMY,2023-08-03,19:57:32,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,Vp Plenge Registers 732 Of Bristol-Myers Squibb Co >BMY,RNS-SEC144,Dow Jones Newswires,VP Plenge Registers 732 Of Bristol-Myers Squibb Co >BMY
BMY,2023-08-07,21:25:27,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,Vp Plenge Sells 732 Of Bristol-Myers Squibb Co,FULL-ARTICLE,Dow Jones Newswires,VP Plenge Sells 732 Of Bristol-Myers Squibb Co >BMY
BMY,2023-08-10,11:01:00,94637C,Bristol-Myers Squibb Co.,99,0.53,equity-actions,,Bristol-Myers Squibb Co.: Achieves $1 billion investment,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts"
BMY,2023-08-10,11:01:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms actively collaborates with renowned organizations such as,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts"
BMY,2023-08-10,11:01:01,94637C,Bristol-Myers Squibb Co.,99,0.53,equity-actions,,Bristol-Myers Squibb Co.: Achieves $1 billion investment,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts"
BMY,2023-08-10,11:01:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms actively collaborates with renowned organizations such as,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts"
BMY,2023-08-10,11:23:20,94637C,Bristol-Myers Squibb Co.,94,0.59,equity-actions,,Bristol Myers Squibb is buying back $4 billion worth of stock,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Sets $4 Billion Accelerated Stock Buyback >BMY
BMY,2023-08-10,11:38:20,94637C,Bristol-Myers Squibb Co.,93,0.59,equity-actions,,Bristol Myers Squibb is buying back $4 billion worth of stock,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Sets $4 Billion Accelerated Stock Buyback
BMY,2023-08-19,07:18:34,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2023 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2023 (BMY)"
BMY,2023-08-21,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Data from clinical studies,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023
BMY,2023-08-21,10:59:00,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data Across its -3-
BMY,2023-08-21,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data Across its -4-
BMY,2023-08-21,11:13:06,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Data from clinical studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023
BMY,2023-08-21,11:13:06,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase -3-
BMY,2023-08-21,11:13:06,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase -4-
BMY,2023-08-22,20:18:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-08-22,20:18:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2023-08-22,20:18:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2023-08-22,20:18:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2023-08-22,20:18:00,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2023-08-22,20:18:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-08-22,20:18:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-08-22,20:18:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-08-22,20:18:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2023-08-22,20:18:01,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2023-08-22,20:18:42,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo as,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo as Adjuvant Treatment for Patients With Completely Resected Stage IIB or IIC Melanoma >BMY
BMY,2023-08-22,20:38:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb said Tuesday it had received European Commission approval for Opdivo,FULL-ARTICLE,Dow Jones Newswires,BMY Gets European Approval for Opdivo as Treatment for Some Melanoma Patients
BMY,2023-08-22,20:53:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb said Tuesday it had received European Commission approval for Opdivo,FULL-ARTICLE,Dow Jones Newswires,BMY Gets European Approval for Opdivo as Treatment for Some Melanoma Patients
BMY,2023-08-23,11:55:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company obtained 18 approvals for new medicines,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments"
BMY,2023-08-23,11:55:00,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb also executed a 15-year virtual power purchase agreement,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments"
BMY,2023-08-23,11:55:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company obtained 18 approvals for new medicines,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments"
BMY,2023-08-23,11:55:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb also executed a 15-year virtual power purchase agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments"
BMY,2023-08-24,18:21:35,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp Powell Registers 17,986 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP Powell Registers 17,986 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-08-28,12:00:09,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: during pre-clinical development, in",PRESS-RELEASE,PR Newswire,Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
BMY,2023-08-28,12:00:09,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Partnering with Cellares enables academics, biotechs, and pharma companies to",PRESS-RELEASE,PR Newswire,Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
BMY,2023-08-28,12:00:09,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: during pre-clinical development, in",PRESS-RELEASE,Dow Jones Newswires,Press Release: Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
BMY,2023-08-28,12:00:09,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Partnering with Cellares enables academics, biotechs, and pharma companies to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
BMY,2023-08-28,12:01:27,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: during pre-clinical development, in",PRESS-RELEASE,PR Newswire,Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
BMY,2023-08-28,12:01:27,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Partnering with Cellares enables academics, biotechs, and pharma companies to",PRESS-RELEASE,PR Newswire,Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
BMY,2023-08-28,21:29:43,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Powell Sells 17,986 Of Bristol-Myers Squibb Co",FULL-ARTICLE,Dow Jones Newswires,"VP Powell Sells 17,986 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-08-29,02:00:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's Reblozyl(R) (luspatercept-aamt),NEWS-FLASH,Dow Jones Newswires,U.S. FDA Approves Bristol Myers Squibb's Reblozyl(R) (luspatercept-aamt) As First-Line Treatment Of Anemia In Adults With Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions >BMY
BMY,2023-08-29,02:00:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Reblozyl(R) (luspatercept-aamt),PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's Reblozyl(R) (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
BMY,2023-08-29,02:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: This expanded indication to,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's Reblozyl(R) (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
BMY,2023-08-29,02:18:26,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb: FDA Approved Reblozyl,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: FDA Approved Reblozyl as First-Line Treatment of Anemia in Adults With Lower-Risk Myelodysplastic Syndromes Who May Require Transfusions >BMY
BMY,2023-08-29,09:29:42,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Reblozyl(R) (luspatercept-aamt),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers Squibb's Reblozyl(R) (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
BMY,2023-08-29,09:29:42,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: This expanded indication to,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers Squibb's Reblozyl(R) (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
BMY,2023-09-01,11:01:49,94637C,Bristol-Myers Squibb Co.,99,0.0,marketing,,Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
BMY,2023-09-05,10:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,"Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia"
BMY,2023-09-05,10:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,"Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia"
BMY,2023-09-05,10:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,DJ Global Press Release Wire,"Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia"
BMY,2023-09-05,10:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia"
BMY,2023-09-09,22:01:16,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced results from a Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study
BMY,2023-09-09,22:01:52,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced results from a Phase 2 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Investigational LPA(1) Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study
BMY,2023-09-14,12:30:01,94637C,Bristol-Myers Squibb Co.,99,0.0,assets,,Bristol-Myers Squibb Co.: The first asset,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
BMY,2023-09-14,12:30:01,94637C,Bristol-Myers Squibb Co.,99,0.0,assets,,Bristol-Myers Squibb Co.: The first asset,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
BMY,2023-09-15,15:20:46,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Market Perform by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Market Perform by TD Cowen
BMY,2023-09-15,15:20:46,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $66.00/Share From $80.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $66.00/Share From $80.00 by TD Cowen
BMY,2023-09-17,23:57:50,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
BMY,2023-09-17,23:57:51,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
BMY,2023-09-20,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2023-09-20,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on November 1, 2023, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2023-09-20,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2023-09-20,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on November 1, 2023, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2023-09-22,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Positive results reinforce improved efficacy now seen in six Phase 3 trials,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
BMY,2023-09-22,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Perioperative -3-
BMY,2023-09-22,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Perioperative -3-
BMY,2023-09-22,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Perioperative -3-
BMY,2023-09-22,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Perioperative -5-
BMY,2023-09-22,10:59:03,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Positive results reinforce improved efficacy now seen in six Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
BMY,2023-09-22,10:59:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2023-09-22,10:59:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2023-09-22,10:59:03,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2023-09-22,10:59:03,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -5-
BMY,2023-09-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023"
BMY,2023-09-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023"
BMY,2023-09-26,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023"
BMY,2023-09-26,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023"
BMY,2023-09-26,13:30:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: our ongoing collaboration with the company and we,PRESS-RELEASE,GlobeNewswire,Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
BMY,2023-09-26,13:30:02,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: our ongoing collaboration with the company and we,PRESS-RELEASE,Dow Jones Newswires,Press Release: Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
BMY,2023-09-26,13:30:02,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: our ongoing collaboration with the company and we,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
BMY,2023-10-06,10:30:03,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,A collaboration with Bristol Myers Squibb (NYSE: BMY) to,PRESS-RELEASE,PR Newswire,Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials
BMY,2023-10-06,10:30:03,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,A collaboration with Bristol Myers Squibb (NYSE: BMY) to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials
BMY,2023-10-08,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
BMY,2023-10-08,21:16:00,94637C,Bristol-Myers Squibb Co.,99,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens and Diversifies -2-
BMY,2023-10-08,21:16:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens and Diversifies -3-
BMY,2023-10-08,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
BMY,2023-10-08,21:16:01,94637C,Bristol-Myers Squibb Co.,99,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens -2-
BMY,2023-10-08,21:16:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens -3-
BMY,2023-10-08,21:25:07,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics >BMY MRTX
BMY,2023-10-08,21:25:29,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb To Acquire Mirati for $58 Per Shr in Cash,NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb To Acquire Mirati for $58 Per Shr in Cash, for a Total Equity Value of $4.8B >BMY MRTX"
BMY,2023-10-08,21:26:24,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Acquire Mirati for $58/Share in Cash,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb to Acquire Mirati for $58/Share in Cash
BMY,2023-10-08,22:02:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share,PRESS-RELEASE,Business Wire,CORRECTING AND REPLACING/ Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
BMY,2023-10-08,22:02:00,94637C,Bristol-Myers Squibb Co.,99,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Business Wire,CORRECTING AND REPLACING/ Bristol Myers Squibb -2-
BMY,2023-10-08,22:02:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Business Wire,CORRECTING AND REPLACING/ Bristol Myers Squibb -3-
BMY,2023-10-08,22:12:29,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion -- WSJ
BMY,2023-10-08,22:12:29,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb acquired Turning Point Therapeutics for $4.1 billion in cash,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion -- WSJ
BMY,2023-10-08,23:34:41,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion
BMY,2023-10-08,23:36:53,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion
BMY,2023-10-09,08:28:17,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Agreement to be acquired by Bristol Myers Squibb (BMY) for $58,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Exxon, Chevron, Mirati, Bristol Myers, Disney, Lockheed, and More -- Barrons.com"
BMY,2023-10-09,08:38:45,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Bristol Myers Squibb agreed to buy the oncology developer Mirati,FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Monday: RTX, Disney, Bristol Myers Squibb -- WSJ"
BMY,2023-10-09,09:27:39,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Oncology Developer,FULL-ARTICLE,Dow Jones Newswires,Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 Billion -- Barrons.com
BMY,2023-10-09,09:27:39,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol Myers boost revenue,FULL-ARTICLE,Dow Jones Newswires,Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 Billion -- Barrons.com
BMY,2023-10-09,12:04:11,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion
BMY,2023-10-09,14:00:30,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Bristol Myers Squibb is buying Mirati Therapeutics in,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb Buying Mirati Therapeutics
BMY,2023-10-09,14:15:30,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Bristol Myers Squibb is buying Mirati Therapeutics in,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb Buying Mirati Therapeutics
BMY,2023-10-11,06:01:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol Myers Squibb Presents New Zeposia (ozanimod),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2023-10-11,06:01:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol Myers Squibb Presents New Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Zeposia -2-
BMY,2023-10-11,06:01:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol Myers Squibb Presents New Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Zeposia -3-
BMY,2023-10-11,06:01:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol Myers Squibb Presents New Zeposia (ozanimod),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2023-10-11,11:01:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Cellares Announces Expanded Agreement with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares' Technology Adoption Partnership Program
BMY,2023-10-11,11:01:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Excited to expand our relationship with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares' Technology Adoption Partnership Program
BMY,2023-10-11,13:38:52,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2023-10-11,13:38:52,94637C,Bristol-Myers Squibb Co.,100,-0.34,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $56.00/Share From $57.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $56.00/Share From $57.00 by Morgan Stanley
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Additional data demonstrate potential of repotrectinib,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023"
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Seven-year efficacy results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023"
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,99,0.62,products-services,positive,Bristol-Myers Squibb Co.: Updated results from the registrational TRIDENT-1 trial demonstrating clinical benefit,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023"
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Seven-year efficacy results,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023"
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: CheckMate 77T: Phase 3 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data -2-
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data -5-
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data -5-
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data -5-
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data -7-
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Additional data demonstrate potential of repotrectinib,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023"
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,99,0.62,products-services,positive,Bristol-Myers Squibb Co.: Updated results from the registrational TRIDENT-1 trial demonstrating clinical benefit,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023"
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: CheckMate 77T: Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase -2-
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase -5-
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase -5-
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase -5-
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase -7-
BMY,2023-10-12,23:14:17,94637C,Bristol-Myers Squibb Co.,100,0.0,insider-trading,,Chmn Caforio Gifts 440 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,Chmn Caforio Gifts 440 Of Bristol-Myers Squibb Co >BMY
BMY,2023-10-13,11:10:38,94637C,Bristol-Myers Squibb Co.,100,-0.66,price-targets,downgrade,Bristol-Myers Squibb price target cut to $75 from $80 at JPMorgan,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb price target cut to $75 from $80 at JPMorgan
BMY,2023-10-14,01:18:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) as,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma(1)
BMY,2023-10-14,01:18:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma1
BMY,2023-10-20,12:05:15,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Coverage Assumed by UBS at Neutral,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Coverage Assumed by UBS at Neutral
BMY,2023-10-20,12:05:15,94637C,Bristol-Myers Squibb Co.,100,-0.8,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $60.00/Share From $70.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $60.00/Share From $70.00 by UBS
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Lianbio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China,PRESS-RELEASE,GlobeNewswire,LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,China National Medical Products Administration (NMPA) accepted with Priority Review a New Drug Application (NDA) for mavacamten,PRESS-RELEASE,GlobeNewswire,LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lianbio received approval in Macau and Singapore for mavacamten,PRESS-RELEASE,GlobeNewswire,LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Close collaboration with BMS to,PRESS-RELEASE,GlobeNewswire,LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Phase 2 study assessing the safety and efficacy of BMS-986278,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA(1) Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.7,products-services,,The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for BMS-986278,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA(1) Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: The Breakthrough Therapy Designation is based on results from the global, randomized Phase 2 study",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA(1) Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.69,products-services,,Fda has also previously granted BMS-986278 fast-track designation,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA(1) Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Phase 2 study assessing the safety and efficacy of BMS-986278,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.7,products-services,,The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for BMS-986278,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: The Breakthrough Therapy Designation is based on results from the global, randomized Phase 2 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.69,products-services,,Fda has also previously granted BMS-986278 fast-track designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Lianbio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,China National Medical Products Administration (NMPA) accepted with Priority Review a New Drug Application (NDA) for mavacamten,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lianbio received approval in Macau and Singapore for mavacamten,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Close collaboration with BMS to,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:44,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Lianbio Enters Into Agreement With Bristol Myers Squibb for Mavacamten in China,NEWS-FLASH,Dow Jones Newswires,LianBio Enters Into Agreement With Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,11:00:02,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Phase 2 Study Assessing the Safety and Efficacy of BMS-986278,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: Designation Is Based on Results From the Progressive Pulmonary Fibrosis Cohort of the Phase 2 Study Assessing the Safety and Efficacy of BMS-986278 Treatment Versus Placebo >BMY
BMY,2023-10-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 3Q Rev $11B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Rev $11B >BMY
BMY,2023-10-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q Net $1.93B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Net $1.93B >BMY
BMY,2023-10-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q EPS 93c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q EPS 93c >BMY
BMY,2023-10-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q Adj EPS $2.00,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Adj EPS $2.00 >BMY
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol-Myers Squibb Co.: Reports Third Quarter Revenues of $11.0 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Third Quarter GAAP Earnings Per Share of $0.93,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts 2023 GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 4% to $7.6 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,Bristol-Myers Squibb Co.: Revlimid worldwide revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.8 billion compared to $1.7 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues increased 9% to $1.4 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.84,products-services,positive,"Bristol-Myers Squibb Co.: In addition, the company achieved strong results from a Phase 3 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,"Trial, evaluating Opdivo as an adjuvant treatment for patients with localized renal cell carcinoma",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted Priority Review of the New Drug Application for repotrectinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: Clinical & Research LPA(1) antagonist Results from the Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Adjusting total revenues for Revlimid to be approximately $6.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $3.72-$4.02,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.68,revenues,down,Bristol-Myers Squibb Co.: Low Low Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -5-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 Non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -5-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, October 26, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -5-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -6-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.94 $ 0.75 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -7-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -7-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -7-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $23,552 $9,977",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -8-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $10,966 $11,218",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -9-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: the company's 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -10-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The GAAP financial results for the full year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -10-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -10-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol-Myers Squibb Co.: Reports Third Quarter Revenues of $11.0 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Third Quarter GAAP Earnings Per Share of $0.93,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts 2023 GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 4% to $7.6 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,Bristol-Myers Squibb Co.: Revlimid worldwide revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.8 billion compared to $1.7 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues increased 9% to $1.4 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.84,products-services,positive,"Bristol-Myers Squibb Co.: In addition, the company achieved strong results from a Phase 3 study",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,"Trial, evaluating Opdivo as an adjuvant treatment for patients with localized renal cell carcinoma",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted Priority Review of the New Drug Application for repotrectinib,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: Clinical & Research LPA(1) antagonist Results from the Phase 2 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Adjusting total revenues for Revlimid to be approximately $6.0 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $3.72-$4.02,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.68,revenues,down,Bristol-Myers Squibb Co.: Low Low Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -5-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 Non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -5-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, October 26, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -5-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -6-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.94 $ 0.75 $,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -7-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2023",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -7-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -7-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $23,552 $9,977",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -8-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $10,966 $11,218",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -9-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: the company's 2023 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -10-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The GAAP financial results for the full year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -10-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -10-
BMY,2023-10-26,11:03:36,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Sees 2023 Revenues for Revlimid to Be Approximately $6B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 Revenues for Revlimid to Be Approximately $6B >BMY
BMY,2023-10-26,11:04:22,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2023 EPS $3.68,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 EPS $3.68-EPS $3.83 >BMY
BMY,2023-10-26,11:04:50,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2023 Adj EPS $7.50,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 Adj EPS $7.50-Adj EPS $7.65 >BMY
BMY,2023-10-26,11:08:15,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers Squibb earnings top estimates,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb earnings top estimates
BMY,2023-10-26,11:08:15,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co. (BMY) on Thursday posted net income of $1.928 billion,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb earnings top estimates
BMY,2023-10-26,11:08:15,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers Squibb Earnings Top Estimates,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb Earnings Top Estimates -- MarketWatch
BMY,2023-10-26,11:08:15,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co. (BMY) on Thursday posted net income of $1.928 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb Earnings Top Estimates -- MarketWatch
BMY,2023-10-26,11:45:45,94637C,Bristol-Myers Squibb Co.,100,-0.68,revenues,down,Bristol Myers Revenue Declines,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Revenue Declines but Beats Expectations as Revlimid Sales Drop -- Barrons.com
BMY,2023-10-26,11:45:45,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb posted third-quarter earnings and revenue that beat Wall Street estimates,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Revenue Declines but Beats Expectations as Revlimid Sales Drop -- Barrons.com
BMY,2023-10-26,11:45:45,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers (ticker: BMY) posted third-quarter earnings of $2 a share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Revenue Declines but Beats Expectations as Revlimid Sales Drop -- Barrons.com
BMY,2023-10-26,11:45:45,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: The company previously expected earnings to be between $7.35,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Revenue Declines but Beats Expectations as Revlimid Sales Drop -- Barrons.com
BMY,2023-10-26,13:04:46,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol Myers raised its guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Skids 5% After Pushing Back A Key Sales Milestone By A Year -- IBD
BMY,2023-10-26,14:17:53,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers earned $2 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone -- IBD
BMY,2023-10-26,14:17:53,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Eliquis sales edged up 2%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone -- IBD
BMY,2023-10-26,14:17:53,94637C,Bristol-Myers Squibb Co.,100,-0.54,revenues,down,Revlimid sales also plummeted 41% to $1.43 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone -- IBD
BMY,2023-10-26,20:04:15,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers earned $2 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone -- IBD
BMY,2023-10-26,20:04:15,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Eliquis sales edged up 2%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone -- IBD
BMY,2023-10-26,20:04:15,94637C,Bristol-Myers Squibb Co.,100,-0.54,revenues,down,Revlimid sales also plummeted 41% to $1.43 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone -- IBD
BMY,2023-10-27,09:46:01,94637C,Bristol-Myers Squibb Co.,100,0.62,analyst-ratings,positive,Bristol-Myers Squibb Raised to Hold From Reduce by HSBC,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raised to Hold From Reduce by HSBC
BMY,2023-10-27,09:46:01,94637C,Bristol-Myers Squibb Co.,100,-0.48,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $53.00/Share From $55.00 by HSBC,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $53.00/Share From $55.00 by HSBC
BMY,2023-10-27,10:49:21,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Market Perform From Outperform by William Blair,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Market Perform From Outperform by William Blair
BMY,2023-10-27,10:50:31,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Market Perform From Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Market Perform From Outperform by BMO Capital
BMY,2023-10-27,10:50:31,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $60.00/Share by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $60.00/Share by BMO Capital
BMY,2023-10-27,11:57:31,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2023-10-27,11:57:31,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $51.00/Share From $60.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $51.00/Share From $60.00 by Barclays
BMY,2023-10-27,13:05:11,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2023-10-27,13:05:11,94637C,Bristol-Myers Squibb Co.,100,-0.8,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $50.00/Share From $56.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $50.00/Share From $56.00 by Morgan Stanley
BMY,2023-10-27,14:38:05,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol Myers Squibb downgraded to market perform at BMO Capital,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb downgraded to market perform at BMO Capital
BMY,2023-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2023-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2023-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2023-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -4-
BMY,2023-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2023-10-30,12:00:22,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Trial Collaboration With Bristol Myers Squibb to,NEWS-FLASH,Dow Jones Newswires,Karyopharm Announces Clinical Trial Collaboration With Bristol Myers Squibb to Evaluate Novel CELMoD(TM) Agent CC- 92480 Mezigdomide in Combination With Selinexor in Patients With Relapsed/Refractory Multiple Myeloma
BMY,2023-10-30,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2023-10-30,11:03:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo,NEWS-FLASH,Dow Jones Newswires,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo in Combination With Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients With Unresectable or Metastatic Urothelial Carcinoma
BMY,2023-10-30,12:00:15,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Trial Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD(TM) Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
BMY,2023-10-30,12:00:15,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol-Myers Squibb (NYSE: BMY),PRESS-RELEASE,PR Newswire,Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD(TM) Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
BMY,2023-10-30,12:00:15,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Trial Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD(TM) Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
BMY,2023-10-30,12:00:15,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol-Myers Squibb (NYSE: BMY),PRESS-RELEASE,Dow Jones Newswires,Press Release: Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD(TM) Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
BMY,2023-10-30,12:06:19,94637C,Bristol-Myers Squibb Co.,100,0.41,products-services,start,Bristol Myers to Launch Phase 1b/2 Trial in 1st Half of 2024,NEWS-FLASH,Dow Jones Newswires,"Karyopharm, Bristol Myers to Launch Phase 1b/2 Trial in 1st Half of 2024 >KPTI BMY"
BMY,2023-10-30,12:53:52,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Buy by Goldman Sachs
BMY,2023-10-30,12:53:52,94637C,Bristol-Myers Squibb Co.,100,-0.8,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $69.00/Share From $81.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $69.00/Share From $81.00 by Goldman Sachs
BMY,2023-10-31,00:19:00,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
BMY,2023-10-31,00:19:01,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
BMY,2023-10-31,22:25:01,94637C,Bristol-Myers Squibb Co.,99,-0.43,labor-issues,,Bristol-Myers Squibb Co.: Giovanni Caforio to Retire as Chair After 23 Years,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024"
BMY,2023-10-31,22:25:01,94637C,Bristol-Myers Squibb Co.,99,0.53,labor-issues,,Bristol-Myers Squibb Co.: Boerner was named Executive Vice President,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024"
BMY,2023-10-31,22:25:01,94637C,Bristol-Myers Squibb Co.,99,-0.43,labor-issues,,Bristol-Myers Squibb Co.: Giovanni Caforio to Retire as Chair After 23 Years,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024"
BMY,2023-10-31,22:25:01,94637C,Bristol-Myers Squibb Co.,99,0.53,labor-issues,,Bristol-Myers Squibb Co.: Boerner was named Executive Vice President,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024"
BMY,2023-10-31,22:26:21,94637C,Bristol-Myers Squibb Co.,100,-0.43,labor-issues,,Bristol-Myers Squibb Chair Giovanni Caforio to Retire April 1,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Chair Giovanni Caforio to Retire April 1
BMY,2023-10-31,22:39:15,94637C,Bristol-Myers Squibb Co.,100,0.47,labor-issues,,Bristol Myers Names Incoming CEO Boerner as Next Chairman,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Names Incoming CEO Boerner as Next Chairman
BMY,2023-10-31,22:54:15,94637C,Bristol-Myers Squibb Co.,100,0.47,labor-issues,,Bristol Myers Names Incoming CEO Boerner as Next Chairman,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Names Incoming CEO Boerner as Next Chairman
BMY,2023-11-02,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference
BMY,2023-11-02,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference
BMY,2023-11-02,15:34:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Updated safety and efficacy data from the Phase 1 study,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology"
BMY,2023-11-02,15:34:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First results from the Phase 1/2,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology"
BMY,2023-11-02,15:34:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's First Disclosures and New -5-
BMY,2023-11-02,15:34:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's First Disclosures and New -7-
BMY,2023-11-02,15:34:01,94637C,Bristol-Myers Squibb Co.,99,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's First Disclosures and New -9-
BMY,2023-11-02,15:37:10,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Updated safety and efficacy data from the Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology"
BMY,2023-11-02,15:37:10,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First results from the Phase 1/2,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology"
BMY,2023-11-02,15:37:11,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's First -6-
BMY,2023-11-02,15:37:11,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's First -7-
BMY,2023-11-02,15:37:11,94637C,Bristol-Myers Squibb Co.,94,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's First -9-
BMY,2023-11-02,15:38:24,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Neutral From Outperform by Daiwa Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Neutral From Outperform by Daiwa Capital
BMY,2023-11-02,15:38:24,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $54.00/Share From $68.00 by Daiwa Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $54.00/Share From $68.00 by Daiwa Capital
BMY,2023-11-06,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Clinical trial data,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
BMY,2023-11-06,11:59:00,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data from -3-
BMY,2023-11-06,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,"Bristol-Myers Squibb Co.: APPRAISE-2, a placebo-controlled clinical trial of apixaban",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data from -3-
BMY,2023-11-06,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data from -4-
BMY,2023-11-06,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Clinical trial data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
BMY,2023-11-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2023-11-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,"Bristol-Myers Squibb Co.: APPRAISE-2, a placebo-controlled clinical trial of apixaban",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2023-11-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2023-11-06,12:00:01,94637C,Bristol-Myers Squibb Co.,94,0.34,products-services,,Bristol Myers Squibb has acquired Orum's ORM-6151,PRESS-RELEASE,Business Wire,Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb
BMY,2023-11-06,12:10:49,94637C,Bristol-Myers Squibb Co.,95,0.34,products-services,,Bristol Myers Squibb has acquired Orum's ORM-6151,PRESS-RELEASE,Dow Jones Newswires,Press Release: Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb
BMY,2023-11-08,14:00:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Tempus Announces Research Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches
BMY,2023-11-09,10:25:09,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Initiated at Hold by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Hold by Deutsche Bank
BMY,2023-11-09,10:25:09,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $55.00/Share by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $55.00/Share by Deutsche Bank
BMY,2023-11-09,15:14:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2023-11-09,15:14:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2023-11-09,15:14:01,94637C,Bristol-Myers Squibb Co.,96,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2023-11-09,15:14:01,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2023-11-09,15:14:53,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Breyanzi,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Breyanzi) for Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BMY,2023-11-09,15:27:10,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol Myers started at hold with $55 stock price target at Deutsche Bank,FULL-ARTICLE,MarketWatch,MW Bristol Myers started at hold with $55 stock price target at Deutsche Bank
BMY,2023-11-09,15:38:32,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Expanded Breyanzi Label
BMY,2023-11-09,15:53:32,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Expanded Breyanzi Label
BMY,2023-11-15,14:01:42,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Neutral From Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Neutral From Overweight by Cantor Fitzgerald
BMY,2023-11-15,14:01:42,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $55.00/Share From $68.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $55.00/Share From $68.00 by Cantor Fitzgerald
BMY,2023-11-15,18:00:05,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb Sign Power Purchase Agreements with National Grid,PRESS-RELEASE,PR Newswire,Fujifilm and Bristol Myers Squibb Sign Power Purchase Agreements with National Grid Renewables
BMY,2023-11-16,10:57:35,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Bristol Myers's $4.1 billion acquisition of Turning Point Therapeutics,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Bet on Turning Point Pays Off -- Market Talk
BMY,2023-11-17,15:46:12,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol-Myers Squibb Co.: Virtual power purchase agreements,PRESS-RELEASE,DJ Global Press Release Wire,How Is BMS Making Progress on Its Renewable Energy Goals?
BMY,2023-11-17,15:46:12,94637C,Bristol-Myers Squibb Co.,99,0.46,equity-actions,,Bms' VPPAs invest in solar power,PRESS-RELEASE,DJ Global Press Release Wire,How Is BMS Making Progress on Its Renewable Energy Goals?
BMY,2023-11-19,08:35:17,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2023 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2023 (BMY)"
BMY,2023-11-20,13:35:52,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb and 2seventy bio are jointly developing the cell therapy,FULL-ARTICLE,MarketWatch,"MW Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment"
BMY,2023-11-20,13:35:52,94637C,Bristol-Myers Squibb Co.,100,-0.11,products-services,,"Abecma is facing increasing competition, including from Johnson & Johnson (JNJ)",FULL-ARTICLE,MarketWatch,"MW Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment"
BMY,2023-11-20,19:01:25,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA
BMY,2023-11-20,19:16:25,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA
BMY,2023-11-22,00:02:15,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Dir Samuels II Buys 8,500 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Dir Samuels II Buys 8,500 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-11-28,11:30:05,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"In 2021, Avidity announced a research collaboration with MyoKardia",PRESS-RELEASE,PR Newswire,Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC(TM) Platform Technology
BMY,2023-11-28,11:30:05,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"In 2021, Avidity announced a research collaboration with MyoKardia",PRESS-RELEASE,Dow Jones Newswires,Press Release: Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC(TM) Platform Technology
BMY,2023-11-28,11:33:41,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Cardiovascular Collaboration With Bristol Myers Squibb for,NEWS-FLASH,Dow Jones Newswires,Avidity Biosciences Announces Expansion of Cardiovascular Collaboration With Bristol Myers Squibb for Up to Five Targets Utilizing Avidity's Proprietary AOC Platform Technology
BMY,2023-11-28,11:37:32,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol Myers Squibb and Avidity to expand cardiovascular collaboration,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb and Avidity to expand cardiovascular collaboration
BMY,2023-11-28,11:46:13,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Of expanded collaboration with Bristol Myers,FULL-ARTICLE,MarketWatch,MW Avidity's stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments
BMY,2023-11-28,11:46:13,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Of Expanded Collaboration With Bristol Myers,FULL-ARTICLE,Dow Jones Newswires,Avidity's Stock Soars On News Of Expanded Collaboration With Bristol Myers That Includes Potential To Receive Up To $2.2 Billion In Milestone Payments -- MarketWatch
BMY,2023-11-28,11:51:03,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Bristol Myers Squibb to Take Stake in Avidity Biosciences,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb to Take Stake in Avidity Biosciences, Expand Partnership"
BMY,2023-11-28,12:06:03,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Bristol Myers Squibb to Take Stake in Avidity Biosciences,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb to Take Stake in Avidity Biosciences, Expand Partnership"
BMY,2023-11-28,13:33:17,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,Cardiovascular collaboration with Bristol Myers Squibb Co. in,FULL-ARTICLE,MarketWatch,MW Avidity's stock rockets on Bristol Myers deal that could mean $2.2 billion in milestone payments
BMY,2023-11-30,23:33:05,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Ceo Boerner Buys 3,071 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Boerner Buys 3,071 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-12-01,08:00:03,94637C,Bristol-Myers Squibb Co.,100,-0.57,labor-issues,,Bristol Myers announced CEO Giovanni Caforio would step down,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Is Slumping. One Director Bought Up Shares. -- Barrons.com
BMY,2023-12-01,18:56:42,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Bristol Myers Squibb CEO Chris Boerner Buys Up Stock,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb CEO Chris Boerner Buys Up Stock -- Barrons.com
BMY,2023-12-02,02:30:24,94637C,Bristol-Myers Squibb Co.,99,-0.57,labor-issues,,Bristol Myers announced CEO Giovanni Caforio would step down,FULL-ARTICLE,Barron's,Bristol Myers Director Buys the Slumping Stock -- Barron's
BMY,2023-12-02,02:30:24,94637C,Bristol-Myers Squibb Co.,99,-0.57,labor-issues,,Bristol Myers announced CEO Giovanni Caforio would step down,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Director Buys the Slumping Stock
BMY,2023-12-05,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
BMY,2023-12-05,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
BMY,2023-12-05,12:02:48,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Opdivo Plus Chemotherapy for First-Line Unresectable or Metastatic Urothelial Carcinoma >BMY
BMY,2023-12-05,12:25:40,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Opdivo-Chemotherapy Combo in Bladder Cancer
BMY,2023-12-05,12:40:40,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Opdivo-Chemotherapy Combo in Bladder Cancer
BMY,2023-12-05,23:22:21,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Ceo Boerner Acquires 1,288 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CEO Boerner Acquires 1,288 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-12-05,23:23:35,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 5,062 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 5,062 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-12-05,23:24:24,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Plenge Acquires 342 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Plenge Acquires 342 Of Bristol-Myers Squibb Co >BMY
BMY,2023-12-06,13:30:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Is expanding its strategic collaboration with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research and Development
BMY,2023-12-06,13:38:14,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,A strategic partnership with BMS to,PRESS-RELEASE,Dow Jones Newswires,Press Release: IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research and Development
BMY,2023-12-06,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Announces Dividend Increase,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Dividend Increase >BMY
BMY,2023-12-06,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Announces Dividend Increase,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2023-12-06,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2023-12-06,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on February 1, 2024, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2023-12-06,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Announces Dividend Increase,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2023-12-06,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2023-12-06,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on February 1, 2024, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2023-12-06,21:16:44,94637C,Bristol-Myers Squibb Co.,100,0.4,dividends,up,Bristol-Myers Squibb Raises Quarterly Dividend to 60c Vs. 50c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raises Quarterly Dividend to 60c Vs. 50c >BMY
BMY,2023-12-06,21:28:11,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Raises Quarterly Dividend to 60c Vs. 57c,NEWS-FLASH,Dow Jones Newswires,"Correct: Bristol-Myers Squibb Raises Quarterly Dividend to 60c Vs. 57c, Not 50c >BMY"
BMY,2023-12-06,21:37:12,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,"Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents"
BMY,2023-12-06,21:37:12,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Co.: The company also declared a quarterly dividend of 50 cents per share,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents"
BMY,2023-12-06,21:52:11,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,"Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents"
BMY,2023-12-06,21:52:11,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Co.: The company also declared a quarterly dividend of 50 cents per share,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents"
BMY,2023-12-06,22:14:21,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol Myers Squibb raises dividend by 5.3%,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb raises dividend by 5.3%
BMY,2023-12-06,22:14:21,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Co. (BMY) said late Wednesday that its board has declared a quarterly dividend of 60 cents,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb raises dividend by 5.3%
BMY,2023-12-06,22:14:21,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol Myers Squibb Raises Dividend By 5.3%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Raises Dividend By 5.3% -- MarketWatch
BMY,2023-12-06,22:14:21,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Co. (BMY) said late Wednesday that its board has declared a quarterly dividend of 60 cents,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Raises Dividend By 5.3% -- MarketWatch
BMY,2023-12-07,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization >BMY
BMY,2023-12-07,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
BMY,2023-12-07,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
BMY,2023-12-07,11:32:11,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers announces additional $3 bln share buyback program,FULL-ARTICLE,MarketWatch,MW Bristol Myers announces additional $3 bln share buyback program
BMY,2023-12-07,11:34:46,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers adds $3 billion to share buyback program,FULL-ARTICLE,MarketWatch,MW Bristol Myers adds $3 billion to share buyback program to boost total to about $5 billion
BMY,2023-12-07,11:34:46,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers Adds $3 Billion To Share Buyback Program,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Adds $3 Billion To Share Buyback Program To Boost Total To About $5 Billion -- MarketWatch
BMY,2023-12-07,11:41:19,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers Adds $3 Billion to Stock Buyback Program,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Adds $3 Billion to Stock Buyback Program
BMY,2023-12-07,11:56:19,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers Adds $3 Billion to Stock Buyback Program,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Adds $3 Billion to Stock Buyback Program
BMY,2023-12-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Phase 3 CheckMate -3-
BMY,2023-12-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Phase 3 CheckMate -3-
BMY,2023-12-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Phase 3 CheckMate -4-
BMY,2023-12-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2023-12-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2023-12-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2023-12-07,17:01:24,94637C,Bristol-Myers Squibb Co.,98,0.0,investor-relations,,Bristol-Myers Squibb Co.: the company's Q3 earnings call,PRESS-RELEASE,GlobeNewswire,"BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights' Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake"
BMY,2023-12-07,17:01:24,94637C,Bristol-Myers Squibb Co.,98,0.57,products-services,granted,Sotyktu received FDA approval in September 2022,PRESS-RELEASE,GlobeNewswire,"BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights' Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake"
BMY,2023-12-07,23:07:31,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Ceo Boerner Buys 2,000 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Boerner Buys 2,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-12-09,22:00:00,94637C,Bristol-Myers Squibb Co.,92,0.84,products-services,positive,Bristol-Myers Squibb Co.: New data confirm findings consistent with interim analysis,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Nave Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
BMY,2023-12-11,02:26:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Breyanzi,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-12-11,02:26:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: TRANSCEND FL is the largest clinical trial evaluating a CAR,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-12-11,02:26:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Results from the third,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-12-11,02:26:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data at ASH -2-
BMY,2023-12-11,02:26:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-12-11,02:26:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: TRANSCEND FL is the largest clinical trial evaluating a CAR,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-12-11,02:26:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Results from the third,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-12-11,02:26:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -2-
BMY,2023-12-11,02:45:44,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers: Phase 2 Study Evaluating Breyanzi,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: Phase 2 Study Evaluating Breyanzi in Patients With Relapsed or Refractory Follicular Lymphoma >BMY
BMY,2023-12-11,12:30:00,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
BMY,2023-12-11,12:30:10,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
BMY,2023-12-11,12:30:12,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Agenus to Receive $25 M Milestone Payment From Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Agenus to Receive $25 M Milestone Payment From Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
BMY,2023-12-11,21:15:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Systimmune and Bristol Myers Squibb Announce a Global Strategic Collaboration,PRESS-RELEASE,Business Wire,SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
BMY,2023-12-11,21:15:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Systimmune and Bristol Myers Squibb Announce a Global Strategic Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
BMY,2023-12-11,21:15:24,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Systimmune and Bristol Myers Squibb Announce Global Strategic Collaboration,NEWS-FLASH,Dow Jones Newswires,SystImmune and Bristol Myers Squibb Announce Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
BMY,2023-12-12,01:04:49,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers: Phase 3 Study of Abecma Shows,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: Phase 3 Study of Abecma Shows Sustained Progression-Free Survival Vs Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma >BMY
BMY,2023-12-12,01:30:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Updated data from the Phase 1 study,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs"
BMY,2023-12-12,01:30:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Updated results of the Phase 1 study of alnuctamab,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs"
BMY,2023-12-12,01:30:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Phase 1/2 study evaluating the safety and efficacy of mezigdomide,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs"
BMY,2023-12-12,01:30:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: A Phase 3 study of alnuctamab,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Data at ASH 2023 -2-
BMY,2023-12-12,01:30:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Updated data from the Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs"
BMY,2023-12-12,01:30:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Updated results of the Phase 1 study of alnuctamab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs"
BMY,2023-12-12,01:30:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Phase 1/2 study evaluating the safety and efficacy of mezigdomide,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs"
BMY,2023-12-12,01:30:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: A Phase 3 study of alnuctamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2023-12-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024"
BMY,2023-12-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024"
BMY,2023-12-15,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024"
BMY,2023-12-15,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024"
BMY,2023-12-22,11:32:11,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb Reaches Deal to Buy Karuna Therapeutics for $14 Billion,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Reaches Deal to Buy Karuna Therapeutics for $14 Billion -- WSJ
BMY,2023-12-22,11:32:11,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Karuna Therapeutics for $14 Billion -- WSJ,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Buy Karuna Therapeutics for $14 Billion -- WSJ
BMY,2023-12-22,11:55:26,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,Bristol Myers Squibb Co. (BMY) has reached an agreement to buy the drug developer in a deal valued at $14 billion,FULL-ARTICLE,Dow Jones Newswires,Karuna Therapeutics' Stock Rockets Into Record Territory After Report Bristol Myers' $14 Billion Buyout Agreement -- MarketWatch
BMY,2023-12-22,11:55:26,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,Bristol Myers Squibb Co. (BMY) has reached an agreement to buy the drug developer in a deal valued at $14 billion,FULL-ARTICLE,MarketWatch,MW Karuna Therapeutics' stock rockets into record territory after report Bristol Myers' $14 billion buyout agreement
BMY,2023-12-22,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,Proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience -2-
BMY,2023-12-22,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience -2-
BMY,2023-12-22,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 42(nd) Annual Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present at J.P. Morgan's 42(nd) Annual Healthcare Conference
BMY,2023-12-22,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 42nd Annual Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present at J.P. Morgan's 42nd Annual Healthcare Conference
BMY,2023-12-22,12:02:23,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:02:23,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:05:01,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,Proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens -2-
BMY,2023-12-22,12:02:23,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:02:23,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,Proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens -2-
BMY,2023-12-22,12:02:23,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens -2-
BMY,2023-12-22,12:05:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:05:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:05:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:05:00,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,Proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience -2-
BMY,2023-12-22,12:05:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience -2-
BMY,2023-12-22,12:05:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:05:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:05:01,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:05:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens -2-
BMY,2023-12-22,12:05:16,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buys Karuna Therapeutics in $14 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Buys Karuna Therapeutics in $14 Billion Pharma Deal: Report -- Barrons.com
BMY,2023-12-22,13:31:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bmy Acquires PRTC Founded Entity Karuna for $14B,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC BMY Acquires PRTC Founded Entity Karuna for $14B
BMY,2023-12-22,13:31:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC BMY Acquires PRTC Founded Entity Karuna for $14B
BMY,2023-12-22,13:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC BMY Acquires PRTC Founded Entity Karuna for $14B
BMY,2023-12-22,13:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET",PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC BMY Acquires PRTC Founded Entity Karuna for $14B
BMY,2023-12-22,13:31:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bmy Acquires PRTC,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC BMY Acquires PRTC Founded -2-
BMY,2023-12-22,13:31:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bmy Acquires PRTC,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC BMY Acquires PRTC Founded -3-
BMY,2023-12-22,14:06:53,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Bristol Myers Squibb announced its $14 billion acquisition of Karuna Therapeutics on,FULL-ARTICLE,Dow Jones Newswires,Karuna Stock Soars On Bristol Myers' $14 Billion Takeover -- IBD
BMY,2023-12-22,14:13:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Karuna Therapeutics To Be Acquired By Bristol Myers Squibb For $14 Billion,NEWS-FLASH,Dow Jones Newswires,PureTech Founded Entity Karuna Therapeutics To Be Acquired By Bristol Myers Squibb For $14 Billion >PRTC.LN
BMY,2023-12-22,14:13:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion,PRESS-RELEASE,Business Wire,PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
BMY,2023-12-22,14:13:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
BMY,2023-12-22,14:13:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
BMY,2023-12-22,14:13:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
BMY,2023-12-22,14:13:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
BMY,2023-12-22,14:13:01,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
BMY,2023-12-22,15:21:56,94637C,Bristol-Myers Squibb Co.,96,0.62,acquisitions-mergers,,Bristol Myers Squibb announced its $14 billion acquisition of Karuna Therapeutics on,FULL-ARTICLE,Dow Jones Newswires,Karuna Stock Catapults 47% And Breaks Out On Bristol Myers' $14 Billion Buyout -- IBD
BMY,2023-12-22,15:45:13,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Karuna Therapeutics for $14 Billion,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers to Buy Karuna Therapeutics for $14 Billion
BMY,2023-12-22,16:00:13,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Karuna Therapeutics for $14 Billion,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers to Buy Karuna Therapeutics for $14 Billion
BMY,2023-12-23,07:16:33,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers To Buy Karuna For $14 Billion,FULL-ARTICLE,Dow Jones Newswires,EXCHANGE --- Bristol-Myers To Buy Karuna For $14 Billion ---- By Jonathan D. Rockoff
BMY,2023-12-23,07:32:08,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers To Buy Karuna For $14 Billion -- WSJ,FULL-ARTICLE,Wall Street Journal,Bristol-Myers To Buy Karuna For $14 Billion -- WSJ
BMY,2023-12-26,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,"Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Adds Premier -2-
BMY,2023-12-26,12:00:13,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb to Acquire RayzeBio for $62.50 Per Shr in Cash,NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb to Acquire RayzeBio for $62.50 Per Shr in Cash, for a Total Equity Value of Approximately $4.1 B >BMY"
BMY,2023-12-26,12:05:08,94637C,Bristol-Myers Squibb Co.,100,0.55,acquisitions-mergers,interest,Bristol Myers Squibb bid to buy RayzeBio,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb bid to buy RayzeBio represents a premium of more than 100%
BMY,2023-12-26,12:11:24,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to buy RayzeBio for,FULL-ARTICLE,MarketWatch,"MW Bristol Myers to buy RayzeBio for more than 100% premium, in a deal valued at $4.1 billion"
BMY,2023-12-26,12:11:24,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers To Buy RayzeBio For,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers To Buy RayzeBio For More Than 100% Premium, In A Deal Valued At $4.1 Billion -- MarketWatch"
BMY,2023-12-26,12:11:42,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,"Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,12:11:42,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,12:11:42,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Adds Premier -2-
BMY,2023-12-26,12:13:25,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,"Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement",PRESS-RELEASE,GlobeNewswire,Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,12:13:25,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash,PRESS-RELEASE,GlobeNewswire,Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,12:13:25,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,GlobeNewswire,Bristol Myers Squibb Adds Premier -2-
BMY,2023-12-26,12:13:26,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,"Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,12:13:26,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,12:13:26,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Adds Premier -2-
BMY,2023-12-26,12:16:27,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion -- Barrons.com
BMY,2023-12-26,12:16:29,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Buy RayzeBio for $4.1 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb to Buy RayzeBio for $4.1 Billion
BMY,2023-12-26,12:31:29,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Buy RayzeBio for $4.1 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb to Buy RayzeBio for $4.1 Billion
BMY,2023-12-26,12:34:01,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Bristol Myers will pay $62.50 a share for RayzeBio,FULL-ARTICLE,Dow Jones Newswires,RayzeBio Shares Soar Premarket on Takeover by Bristol Myers
BMY,2023-12-26,12:49:01,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Bristol Myers will pay $62.50 a share for RayzeBio,FULL-ARTICLE,Dow Jones Newswires,RayzeBio Shares Soar Premarket on Takeover by Bristol Myers
BMY,2023-12-26,14:58:56,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Buy RayzeBio,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb to Buy RayzeBio
BMY,2023-12-26,15:13:56,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Buy RayzeBio,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb to Buy RayzeBio
BMY,2023-12-26,15:47:48,94637C,Bristol-Myers Squibb Co.,98,0.62,acquisitions-mergers,,Bristol Myers Squibb said Tuesday it would acquire cancer drug developer RayzeBio in a deal valued at $4.1 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100% -- IBD
BMY,2023-12-26,17:33:30,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion -- WSJ,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion -- WSJ
BMY,2023-12-26,23:56:56,94637C,Bristol-Myers Squibb Co.,98,0.62,acquisitions-mergers,,Bristol Myers Squibb said Tuesday it would acquire cancer drug developer RayzeBio in a deal valued at $4.1 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100% -- IBD
BMY,2023-12-27,07:08:13,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Acquires RayzeBio ---- By,FULL-ARTICLE,Dow Jones Newswires,Business News: Bristol-Myers Acquires RayzeBio ---- By Jared S. Hopkins and Colin Kellaher
BMY,2023-12-27,07:32:10,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Acquires RayzeBio -- WSJ,FULL-ARTICLE,Wall Street Journal,Bristol-Myers Acquires RayzeBio -- WSJ
BMY,2023-12-27,11:00:40,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Buy by B of A Securities
BMY,2023-12-27,11:00:40,94637C,Bristol-Myers Squibb Co.,100,-0.62,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $68.00/Share From $72.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $68.00/Share From $72.00 by B of A Securities
BMY,2023-12-27,20:54:23,94637C,Bristol-Myers Squibb Co.,100,-0.38,credit-ratings,downgrade,S&PGR Downgrades Bristol-Myers To 'A,NEWS-FLASH,Dow Jones Newswires,S&PGR Downgrades Bristol-Myers To 'A'; Outlook Stable
BMY,2023-12-27,20:54:23,94637C,Bristol-Myers Squibb Co.,100,-0.38,credit-ratings,downgrade,S&PGR Downgrades Bristol-Myers To 'A,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Downgrades Bristol-Myers To 'A'; Outlook Stable
BMY,2023-12-27,20:54:23,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co. (BMY) announced the acquisition of Karuna Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Downgrades Bristol-Myers To 'A'; Outlook Stable
BMY,2023-12-27,20:54:25,94637C,Bristol-Myers Squibb Co.,100,-0.38,credit-ratings,downgrade,S&P Cuts Bristol-Myers Squibb Co. Rtg To A From A+,NEWS-FLASH,Dow Jones Newswires,S&P Cuts Bristol-Myers Squibb Co. Rtg To A From A+; Outlk Stable
BMY,2023-12-27,20:54:33,94637C,Bristol-Myers Squibb Co.,100,-0.61,credit-ratings,downgrade,S&PGR Downgrades Bristol-Myers To,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Downgrades Bristol-Myers To -2-
BMY,2023-12-27,21:27:37,94637C,Bristol-Myers Squibb Co.,100,-0.38,credit-ratings,downgrade,S&P Cuts Bristol Myers Squibb to A,FULL-ARTICLE,Dow Jones Newswires,S&P Cuts Bristol Myers Squibb to A With Stable Outlook -- Market Talk
BMY,2023-12-27,21:27:37,94637C,Bristol-Myers Squibb Co.,100,-0.38,credit-ratings,downgrade,S&P Cuts Bristol Myers Squibb to A,FULL-ARTICLE,Dow Jones Newswires,S&P Cuts Bristol Myers Squibb to A With Stable Outlook -- Market Talk
BMY,2023-01-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York"
BMY,2023-01-03,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York"
BMY,2023-01-03,11:59:10,94637C,Bristol-Myers Squibb Co.,100,-0.44,assets,sale,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, NY",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, NY"
BMY,2023-01-03,12:05:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 41(st) Annual Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present at J.P. Morgan's 41(st) Annual Healthcare Conference
BMY,2023-01-03,12:05:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 41st Annual Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present at J.P. Morgan's 41st Annual Healthcare Conference
BMY,2023-01-03,14:23:36,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
BMY,2023-01-03,14:23:36,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $78.00/Share From $70.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $78.00/Share From $70.00 by Wells Fargo
BMY,2023-01-05,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide,PRESS-RELEASE,Dow Jones Newswires,Press Release: Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
BMY,2023-01-05,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
BMY,2023-01-05,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide,PRESS-RELEASE,GlobeNewswire,Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
BMY,2023-01-05,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide,PRESS-RELEASE,Dow Jones Newswires,Press Release: Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
BMY,2023-01-05,12:03:46,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Amryt Announces Positive Top Line Results From Phase 3 Pediatric Trial of Lomitapide,NEWS-FLASH,Dow Jones Newswires,Amryt Announces Positive Top Line Results From Phase 3 Pediatric Trial of Lomitapide in HoFH
BMY,2023-01-17,13:27:44,94637C,Bristol-Myers Squibb Co.,100,0.95,analyst-ratings,positive,Bristol-Myers Squibb Initiated at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Overweight by Cantor Fitzgerald
BMY,2023-01-17,13:27:44,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $95.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $95.00/Share by Cantor Fitzgerald
BMY,2023-01-19,13:30:00,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol-Myers Squibb Co.: we are honored to have Amgen serve as a supporter of the Winn Award,PRESS-RELEASE,Dow Jones Newswires,Press Release: The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen's Commitment of $8 Million
BMY,2023-01-19,13:30:01,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol-Myers Squibb Co.: we are honored to have Amgen serve as a supporter of the Winn Award,PRESS-RELEASE,Business Wire,The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen's Commitment of $8 Million
BMY,2023-01-19,17:56:07,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol-Myers Squibb Co.: we are honored to have Amgen serve as a supporter of the Winn Award,PRESS-RELEASE,DJ Global Press Release Wire,The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation To Expand With Amgen's Commitment of $8 Million
BMY,2023-01-19,17:56:07,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,,Bristol-Myers Squibb Co.: we are honored to have Amgen serve as a supporter of the Winn Award,PRESS-RELEASE,DJ Global Press Release Wire,The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation To Expand With Amgen's Commitment of $8 Million
BMY,2023-01-24,09:09:17,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2022 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2022 (BMY)"
BMY,2023-01-26,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi(R) (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-01-26,11:59:01,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi(R) (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-01-26,14:32:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"In Collaboration with Bristol Myers Squibb, to",PRESS-RELEASE,PR Newswire,"OstoBuddy and South Asian IBD Alliance Named Winners of Innovation Challenge, in Collaboration with Bristol Myers Squibb, to Address Unmet Needs in Inflammatory Bowel Disease"
BMY,2023-01-27,07:00:08,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,2022 Innovation Challenge in collaboration with Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,Genetic Analysis AS: Genetic Analysis' CTO finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD
BMY,2023-01-27,07:00:08,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,2022 Innovation Challenge in collaboration with Bristol Myers Squibb,PRESS-RELEASE,Cision News,Genetic Analysis AS: Genetic Analysis' CTO finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD
BMY,2023-01-27,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration (FDA) approved Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
BMY,2023-01-27,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: The U.S. Food and Drug Administration (FDA) approved Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
BMY,2023-01-27,12:05:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia"
BMY,2023-01-27,12:05:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(R) (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia"
BMY,2023-01-27,12:05:20,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl for Adults With Anemia-Associated, Non-Transfusion-Dependent Beta Thalassemia"
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Net $2.02B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Net $2.02B >BMY
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.06,revenues,,Bristol-Myers Squibb Co.: Reports Fourth Quarter Revenues of $11.4 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Full-Year Revenues of $46.2 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Fourth Quarter GAAP EPS of $0.95,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Reports Full-Year GAAP EPS of $2.95,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD in 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Provides GAAP and Non-GAAP Financial Guidance for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD expenses decreased from $89 million in 2021,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.14,revenues,,Bristol-Myers Squibb Co.: International revenues were $951 million compared to $868 million,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.7 billion compared to $1.5 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.02,revenues,,Bristol-Myers Squibb Co.: Eliquis revenues grew 1%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 11%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: The approval is based on the results of clinical trials,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,97,0.0,assets,,Bristol-Myers Squibb Co.: Pipeline Multiple Myeloma Portfolio In December,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,97,0.0,products-services,,Bristol-Myers Squibb Co.: alnuctamab First multicenter results from the Phase 1 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: FULL YEAR FINANCIAL RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,97,0.04,revenues,,Bristol Myers Squibb posted revenues of $46.2 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD in 2022,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.0,earnings,,"Bristol-Myers Squibb Co.: For purposes of comparability, the non-GAAP financial results for the fourth quarter of 2021",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.06,revenues,,Bristol-Myers Squibb Co.: FULL YEAR PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $7.8 billion compared to $6.5 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.41,revenues,up,Bristol-Myers Squibb Co.: Eliquis revenues grew 10%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 10%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating expenses,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today at 9:00 a.m. ET,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -5-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -6-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -7-
BMY,2023-02-02,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 4Q Rev $11.41B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Rev $11.41B >BMY
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q EPS 95c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q EPS 95c >BMY
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.06,revenues,,Bristol-Myers Squibb Co.: Reports Fourth Quarter Revenues of $11.4 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: Full-Year Revenues of $46.2 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Fourth Quarter GAAP EPS of $0.95,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Reports Full-Year GAAP EPS of $2.95,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Provides GAAP and Non-GAAP Financial Guidance for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD expenses decreased from $89 million in 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.14,revenues,,Bristol-Myers Squibb Co.: International revenues were $951 million compared to $868 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.7 billion compared to $1.5 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.02,revenues,,Bristol-Myers Squibb Co.: Eliquis revenues grew 1%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 11%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: The approval is based on the results of clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,assets,,Bristol-Myers Squibb Co.: Pipeline Multiple Myeloma Portfolio In December,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,products-services,,Bristol-Myers Squibb Co.: alnuctamab First multicenter results from the Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.0,earnings,,Bristol-Myers Squibb Co.: FULL YEAR FINANCIAL RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,97,0.04,revenues,,Bristol Myers Squibb posted revenues of $46.2 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD in 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co.: Acquired IPRD in 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,earnings,,"Bristol-Myers Squibb Co.: For purposes of comparability, the non-GAAP financial results for the fourth quarter of 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,Bristol-Myers Squibb Co.: FULL YEAR PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $7.8 billion compared to $6.5 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.41,revenues,up,Bristol-Myers Squibb Co.: Eliquis revenues grew 10%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.41,revenues,up,Bristol-Myers Squibb Co.: International revenues were $3.4 billion compared to $3.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.41,revenues,up,Bristol-Myers Squibb Co.: Opdivo revenues increased 10%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.42,revenues,down,Bristol-Myers Squibb Co.: Revlimid revenues declined by 22%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today at 9:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,Bristol-Myers Squibb Co.: Worldwide Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Adj EPS $1.82,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Adj EPS $1.82 >BMY
BMY,2023-02-02,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Adj EPS $1.82,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Adj EPS $1.82 >BMY
BMY,2023-02-02,12:04:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2023 Adj EPS $7.95,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 Adj EPS $7.95-Adj EPS $8.25 >BMY
BMY,2023-02-02,12:04:13,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2023 EPS $4.03,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 EPS $4.03-EPS $4.33 >BMY
BMY,2023-02-02,12:04:29,94637C,Bristol-Myers Squibb Co.,100,0.48,revenues,up,Bristol-Myers Squibb Sees 2023 Revenue Up About 2%,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 Revenue Up About 2% >BMY
BMY,2023-02-02,12:05:10,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Sees 2023 Revenue From Revlimid About $6.5B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 Revenue From Revlimid About $6.5B >BMY
BMY,2023-02-02,12:21:07,94637C,Bristol-Myers Squibb Co.,100,-0.68,revenues,down,Bristol Myers Squibb had revenue of $11.4 billion for the quarter,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb sees revenue fall in Q4
BMY,2023-02-02,12:21:07,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers Squibb Co.: the company announced better-than-expected earnings for the fourth quarter of 2022,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb sees revenue fall in Q4
BMY,2023-02-02,12:21:07,94637C,Bristol-Myers Squibb Co.,100,-0.68,revenues,down,Bristol Myers Squibb had revenue of $11.4 billion for the quarter,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Sees Revenue Fall In Q4 -- MarketWatch
BMY,2023-02-02,12:21:07,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers Squibb Co.: the company announced better-than-expected earnings for the fourth quarter of 2022,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Sees Revenue Fall In Q4 -- MarketWatch
BMY,2023-02-02,12:39:24,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb reported fourth-quarter earnings that beat Wall Street expectations,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Rises as Revenue Falls on Lower Revlimid Sales but Profit Tops Estimates -- Barrons.com
BMY,2023-02-02,12:39:24,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers (ticker: BMY) posted fourth-quarter earnings of $1.82 a share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Rises as Revenue Falls on Lower Revlimid Sales but Profit Tops Estimates -- Barrons.com
BMY,2023-02-02,12:39:24,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers expects adjusted earnings to be between $7.95 and $8.25 a share for 2023,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Rises as Revenue Falls on Lower Revlimid Sales but Profit Tops Estimates -- Barrons.com
BMY,2023-02-02,13:00:03,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb and Exscientia expanded the collaboration in,PRESS-RELEASE,Business Wire,"Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318"
BMY,2023-02-02,13:01:30,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb and Exscientia expanded the collaboration in,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318"
BMY,2023-02-02,13:56:38,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb reported adjusted earnings of $1.82 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Jumps On Fourth-Quarter Beat Strong Earnings Outlook -- IBD
BMY,2023-02-02,15:29:57,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,above-expectations,Bristol Myers Squibb Beats 4Q Sales Expectations,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb Beats 4Q Sales Expectations
BMY,2023-02-02,15:44:57,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,above-expectations,Bristol Myers Squibb Beats 4Q Sales Expectations,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb Beats 4Q Sales Expectations
BMY,2023-02-02,15:45:19,94637C,Bristol-Myers Squibb Co.,93,0.41,revenues,up,Opdivo sales ramped up 11%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Revlimid Takes A 32% Hit As Generics Keep Coming -- IBD
BMY,2023-02-02,16:21:38,94637C,Bristol-Myers Squibb Co.,93,0.41,revenues,up,Opdivo sales ramped up 11%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Revlimid Takes A 32% Hit As Generics Keep Coming -- IBD
BMY,2023-02-02,21:13:55,94637C,Bristol-Myers Squibb Co.,93,0.41,revenues,up,Opdivo sales ramped up 11%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Revlimid Takes A 32% Hit As Generics Keep Coming -- IBD
BMY,2023-02-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
BMY,2023-02-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
BMY,2023-02-03,12:05:34,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities
BMY,2023-02-03,12:05:34,94637C,Bristol-Myers Squibb Co.,100,0.4,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $90.00/Share From $88.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $90.00/Share From $88.00 by Atlantic Equities
BMY,2023-02-03,13:18:15,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2023-02-03,13:18:15,94637C,Bristol-Myers Squibb Co.,100,0.46,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $62.00/Share From $60.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $62.00/Share From $60.00 by Morgan Stanley
BMY,2023-02-04,00:19:47,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Meyers Acquires 1,812 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Meyers Acquires 1,812 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-02-07,21:27:38,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Chmn Caforio Registers 240,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"Chmn Caforio Registers 240,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-02-07,21:39:55,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp Powell Registers 11,183 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP Powell Registers 11,183 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-02-09,01:10:41,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Powell Sells 11,183 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"VP Powell Sells 11,183 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-02-09,01:12:01,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Chmn Caforio Sells 240,000 Of Bristol-Myers Squibb Co",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Caforio Sells 240,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-02-09,20:15:08,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,The FDA approved Zeposia for use in Ulcerative Colitis,PRESS-RELEASE,PR Newswire,"Can BMS' Zeposia Cement a Defensible Market Position in Ulcerative Colitis Ahead of Pfizer's Potential Rival S1P treatment, etrasimod? According to Spherix Global Insights"
BMY,2023-02-17,03:46:07,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Glenmark Pharmaceuticals Inc., USA Gets Second Tentative Approval From FDA for Saxagliptin",NEWS-FLASH,Dow Jones Newswires,"Glenmark Pharmaceuticals Inc., USA Gets Second Tentative Approval From FDA for Saxagliptin Tablets"
BMY,2023-02-23,16:00:07,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Forces Partners with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,Friendly Forces Partners with Bristol Myers Squibb to Promote Pro-Reservist Policies and Hiring
BMY,2023-02-27,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Findings from clinical studies,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology
BMY,2023-02-27,12:08:52,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Findings from clinical studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology
BMY,2023-03-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,start,Bristol-Myers Squibb Co.: First patient has been enrolled,PRESS-RELEASE,Business Wire,"The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor"
BMY,2023-03-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol Myers Squibb (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc.",PRESS-RELEASE,Business Wire,"The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor"
BMY,2023-03-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Important Phase 2 proof-of-concept data for milvexian,PRESS-RELEASE,Business Wire,"The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor"
BMY,2023-03-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.4,products-services,start,Bristol-Myers Squibb Co.: First patient has been enrolled,PRESS-RELEASE,Dow Jones Newswires,"Press Release: The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor"
BMY,2023-03-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol Myers Squibb (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,"Press Release: The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor"
BMY,2023-03-02,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Important Phase 2 proof-of-concept data for milvexian,PRESS-RELEASE,Dow Jones Newswires,"Press Release: The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor"
BMY,2023-03-02,12:01:15,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,"Bristol Myers, J&J Launch Phase 3 Program",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers, J&J Launch Phase 3 Program Evaluating Milvexian Factor XIa Inhibitor"
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,13:00:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Viz.ai Announces Agreement with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Bristol-Myers Squibb Co.: Reblozyl is currently approved in the European Union (EU), United States",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval of Reblozyl(R) (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,11:59:09,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval of Reblozyl,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval of Reblozyl for Anemia in Adult Patients With Non-Transfusion-Dependent Beta Thalassemia
BMY,2023-03-03,12:17:21,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol Myers Squibb wins expanded European Commission approval of the anemia drug,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Adds an Arrow to Reblozyl European Quiver -- Market Talk
BMY,2023-03-03,12:17:21,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Bristol Myers Squibb wins expanded European Commission approval of the anemia drug,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Adds an Arrow to Reblozyl European Quiver -- Market Talk
BMY,2023-03-03,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Announces Dividend,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2023-03-03,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2023-03-03,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on May 1, 2023, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2023-03-06,10:47:22,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Initiated at Hold by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Hold by Jefferies
BMY,2023-03-06,10:47:22,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $62.00/Share by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $62.00/Share by Jefferies
BMY,2023-03-09,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023"
BMY,2023-03-09,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023"
BMY,2023-03-09,11:59:27,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023"
BMY,2023-03-09,11:59:27,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: A replay of the conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023"
BMY,2023-03-15,00:14:43,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Chmn Caforio Acquires 96,687 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Chmn Caforio Acquires 96,687 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:14:51,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 30,540 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 30,540 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:15:15,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Boerner Acquires 24,491 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Boerner Acquires 24,491 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:15:17,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Shanahan Acquires 1,533 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Shanahan Acquires 1,533 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:15:28,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Meyers Acquires 1,593 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Meyers Acquires 1,593 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:15:30,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Weese Acquires 996 Of Bristol-Myers Squibb Co >BMY,TABULAR-MATERIAL,Dow Jones Newswires,VP Weese Acquires 996 Of Bristol-Myers Squibb Co >BMY
BMY,2023-03-15,00:19:36,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Powell Acquires 17,637 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Powell Acquires 17,637 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:20:01,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 16,583 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Acquires 16,583 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:30:38,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Leung Acquires 23,886 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Leung Acquires 23,886 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:35:48,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Vessey Acquires 28,437 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Acquires 28,437 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,00:41:51,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Mily Acquires 15,596 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Mily Acquires 15,596 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-03-15,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.22,acquisitions-mergers,,Bristol-Myers Squibb Co.: Investing in diverse suppliers enables BMS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments
BMY,2023-03-15,11:06:06,94637C,Bristol-Myers Squibb Co.,99,0.22,acquisitions-mergers,,Bristol-Myers Squibb Co.: Investing in diverse suppliers enables BMS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments
BMY,2023-03-16,07:05:32,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Evotec SE: the Company has further extended and expanded its partnership with Bristol Myers Squibb,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
BMY,2023-03-16,08:41:54,94637C,Bristol-Myers Squibb Co.,92,0.49,partnerships,,"Evotec, which in May of last year extended its partnership with Bristol Myers Squibb",FULL-ARTICLE,Dow Jones Newswires,Evotec Shares Rise After Drug Progress Earns Payment From Bristol Myers Squibb
BMY,2023-03-16,08:56:53,94637C,Bristol-Myers Squibb Co.,92,0.49,partnerships,,"Evotec, which in May of last year extended its partnership with Bristol Myers Squibb",FULL-ARTICLE,Dow Jones Newswires,Evotec Shares Rise After Drug Progress Earns Payment From Bristol Myers Squibb
BMY,2023-03-20,11:00:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Therapeutics Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs
BMY,2023-03-20,11:03:23,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Therapeutics Announces Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs
BMY,2023-03-23,11:30:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,By partnering with Bristol Myers Squibb on,PRESS-RELEASE,GlobeNewswire,BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb's OPDIVO(R) (nivolumab)
BMY,2023-03-23,11:30:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,"In May 2022, BridgeBio entered into an exclusive license agreement with Bristol Myers Squibb",PRESS-RELEASE,GlobeNewswire,BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb's OPDIVO(R) (nivolumab)
BMY,2023-03-23,11:30:02,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,By partnering with Bristol Myers Squibb on,PRESS-RELEASE,Dow Jones Newswires,Press Release: BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb's OPDIVO(R) (nivolumab)
BMY,2023-03-23,11:30:02,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,"In May 2022, BridgeBio entered into an exclusive license agreement with Bristol Myers Squibb",PRESS-RELEASE,Dow Jones Newswires,Press Release: BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb's OPDIVO(R) (nivolumab)
BMY,2023-03-23,21:13:49,94637C,Bristol-Myers Squibb Co.,100,0.44,labor-issues,,Bristol-Myers Squibb CEO Giovanni Caforio 2022 Total Pay Valued at $20.1M,NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb CEO Giovanni Caforio 2022 Total Pay Valued at $20.1M, Compared With $19.8M in 2021"
BMY,2023-03-28,09:01:57,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership 28-March-2023,PRESS-RELEASE,Dow Jones Newswires,EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
BMY,2023-03-28,09:01:57,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership 28-March-2023,PRESS-RELEASE,DGAP News,EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
BMY,2023-03-28,09:03:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership,PRESS-RELEASE,DGAP News,EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
BMY,2023-03-28,09:03:03,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
BMY,2023-03-28,09:20:38,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec SE: our strategic neurodegeneration partnership with Bristol Myers Squibb.,PRESS-RELEASE,DJ Global Press Release Wire,Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
BMY,2023-03-28,09:57:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec Extends Partnership With Bristol Myers Squibb for,FULL-ARTICLE,Dow Jones Newswires,Evotec Extends Partnership With Bristol Myers Squibb for Potential $4 Bln
BMY,2023-03-28,10:12:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec Extends Partnership With Bristol Myers Squibb for,FULL-ARTICLE,Dow Jones Newswires,Evotec Extends Partnership With Bristol Myers Squibb for Potential $4 Billion
BMY,2023-03-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission has approved Sotyktu (deucravacitinib),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis"
BMY,2023-03-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The Phase 3 POETYK-PSO clinical trials,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis"
BMY,2023-03-28,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2023-03-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission has approved Sotyktu (deucravacitinib),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis"
BMY,2023-03-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The Phase 3 POETYK-PSO clinical trials,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis"
BMY,2023-03-28,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-03-28,10:59:09,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval of Sotyktu,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval of Sotyktu Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
BMY,2023-03-28,11:24:21,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets European Green Light for Otezla,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Green Light for Otezla Rival -- Market Talk
BMY,2023-03-28,11:24:21,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb wins European Commission approval of Sotyktu,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Green Light for Otezla Rival -- Market Talk
BMY,2023-03-28,11:24:21,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers to complete its $74B acquisition of Celgene,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Green Light for Otezla Rival -- Market Talk
BMY,2023-03-28,11:24:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets European Green Light for Otezla,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Green Light for Otezla Rival -- Market Talk
BMY,2023-03-28,11:24:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb wins European Commission approval of Sotyktu,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Green Light for Otezla Rival -- Market Talk
BMY,2023-03-28,11:24:22,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers to complete its $74B acquisition of Celgene,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Green Light for Otezla Rival -- Market Talk
BMY,2023-03-31,12:07:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-03-31,12:07:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-03-31,12:07:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-03-31,12:07:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-03-31,12:07:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-03-31,12:07:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-03-31,12:07:34,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-Cell Lymphoma After One Prior Therapy
BMY,2023-03-31,12:42:33,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,Breyanzi is already approved in Europe,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Second-Line Breyanzi >BMY
BMY,2023-03-31,12:42:33,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,Bristol Myers reported 2022 Breyanzi revenue of $182 million,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Second-Line Breyanzi >BMY
BMY,2023-03-31,12:57:33,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,Breyanzi is already approved in Europe,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Second-Line Breyanzi
BMY,2023-03-31,12:57:33,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,Bristol Myers reported 2022 Breyanzi revenue of $182 million,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets CHMP Backing for Second-Line Breyanzi
BMY,2023-04-05,00:41:28,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Shanahan Acquires 1,614 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Shanahan Acquires 1,614 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-04-05,00:42:09,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Mily Acquires 3,148 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Mily Acquires 3,148 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-04-11,11:04:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Foundation Medicine and Bristol Myers Squibb Expand Partnership to,PRESS-RELEASE,Business Wire,Foundation Medicine and Bristol Myers Squibb Expand Partnership to Focus on Companion Diagnostic Development
BMY,2023-04-20,09:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Tubulis Announces Strategic License Agreement with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
BMY,2023-04-21,12:00:03,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten,PRESS-RELEASE,GlobeNewswire,LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
BMY,2023-04-21,12:00:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Lianbio's Phase 1 pharmacokinetic study of mavacamten,PRESS-RELEASE,GlobeNewswire,LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
BMY,2023-04-21,12:00:03,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Mavacamten was granted Breakthrough Therapy Designation in China,PRESS-RELEASE,GlobeNewswire,LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
BMY,2023-04-21,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
BMY,2023-04-21,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Lianbio's Phase 1 pharmacokinetic study of mavacamten,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
BMY,2023-04-21,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Mavacamten was granted Breakthrough Therapy Designation in China,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
BMY,2023-04-21,12:01:27,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Admin Acceptance With Priority Review of New Drug Application for Mavacamten,NEWS-FLASH,Dow Jones Newswires,LianBio Announces China National Medical Products Admin Acceptance With Priority Review of New Drug Application for Mavacamten for the Treatment of Patients With Obstructive Hypertrophic Cardiomyopathy
BMY,2023-04-21,12:20:38,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lianbio Gets China Approval for Priority Review of Mavacamten,FULL-ARTICLE,Dow Jones Newswires,LianBio Gets China Approval for Priority Review of Mavacamten New Drug App
BMY,2023-04-21,12:20:38,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,China's National Medical Products Administration has accepted with priority review its new drug application for mavacamten,FULL-ARTICLE,Dow Jones Newswires,LianBio Gets China Approval for Priority Review of Mavacamten New Drug App
BMY,2023-04-21,12:20:38,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Phase 3 trial, which evaluated the safety and efficacy of mavacamten",FULL-ARTICLE,Dow Jones Newswires,LianBio Gets China Approval for Priority Review of Mavacamten New Drug App
BMY,2023-04-21,14:20:11,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Buy by B of A Securities
BMY,2023-04-21,14:20:11,94637C,Bristol-Myers Squibb Co.,100,0.48,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $85.00/Share From $82.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $85.00/Share From $82.00 by B of A Securities
BMY,2023-04-24,07:28:11,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2023 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2023 (BMY)"
BMY,2023-04-26,18:42:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,18:42:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of CAMZYOS(R) (mavacamten),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,18:42:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Results from the Phase 3 VALOR-HCM study evaluated CAMZYOS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,18:42:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"2022, the U.S. Food and Drug Administration (FDA) approved CAMZYOS",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,18:42:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,18:42:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of CAMZYOS(R) (mavacamten),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,18:42:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Results from the Phase 3 VALOR-HCM study evaluated CAMZYOS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,18:42:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"2022, the U.S. Food and Drug Administration (FDA) approved CAMZYOS",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS(R) (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
BMY,2023-04-26,20:14:00,94637C,Bristol-Myers Squibb Co.,99,-0.49,labor-issues,,"Bristol Myers Squibb Chairman and CEO, to Retire",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Leadership Transition Plan
BMY,2023-04-26,20:14:00,94637C,Bristol-Myers Squibb Co.,99,0.53,labor-issues,,"Bristol-Myers Squibb Co.: to Succeed Giovanni Caforio, MD, as CEO",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Leadership Transition Plan
BMY,2023-04-26,20:14:00,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol Myers Squibb has nearly tripled its revenue,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Leadership Transition Plan
BMY,2023-04-26,20:14:01,94637C,Bristol-Myers Squibb Co.,99,-0.49,labor-issues,,"Bristol Myers Squibb Chairman and CEO, to Retire",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Leadership Transition Plan
BMY,2023-04-26,20:14:01,94637C,Bristol-Myers Squibb Co.,99,0.53,labor-issues,,"Bristol-Myers Squibb Co.: to Succeed Giovanni Caforio, MD, as CEO",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Leadership Transition Plan
BMY,2023-04-26,20:14:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol Myers Squibb has nearly tripled its revenue,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Leadership Transition Plan
BMY,2023-04-26,20:14:31,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,"Chmn and CEO, to Retire as CEO, Effective Nov 1",HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb : Giovanni Caforio, MD, Chmn and CEO, to Retire as CEO, Effective Nov 1 >BMY"
BMY,2023-04-26,20:15:22,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Christopher Boerner Appointed EVP, Oper Chief, Effective Immediately",HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb: Christopher Boerner Appointed EVP, Oper Chief, Effective Immediately >BMY"
BMY,2023-04-26,20:15:44,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,Bristol-Myers Squibb: Boerner to Succeed Giovanni Caforio as CEO,HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb: Boerner to Succeed Giovanni Caforio as CEO, Effective Nov 1 >BMY"
BMY,2023-04-26,20:15:54,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Appointed EVP, Chief Commercialization Officer, Effective Immediately >BMY",HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb: Adam Lenkowsky Appointed EVP, Chief Commercialization Officer, Effective Immediately >BMY"
BMY,2023-04-26,20:23:30,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,Bristol-Myers Squibb CEO to Retire Nov. 1,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb CEO to Retire Nov. 1 -- WSJ
BMY,2023-04-26,20:23:30,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,Bristol-Myers Squibb Co. Chief Executive Giovanni Caforio is planning to retire,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers CEO Giovanni Caforio to Leave Drugmaker -- WSJ
BMY,2023-04-26,20:29:11,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,Bristol-Myers Squibb Co. Chief Executive Giovanni Caforio is planning to retire,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers CEO Giovanni Caforio to Leave Drugmaker -- Update
BMY,2023-04-26,20:30:11,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,Bristol-Myers Squibb Co. Chief Executive Giovanni Caforio is planning to retire,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers CEO Giovanni Caforio to Leave Drugmaker
BMY,2023-04-26,20:35:21,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,Bristol-Myers Squibb Co. Chief Executive Giovanni Caforio is planning to retire,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers CEO Giovanni Caforio to Leave Drugmaker -- 2nd Update
BMY,2023-04-27,06:14:42,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,Bristol-Myers's Caforio to Retire As Drugmaker's Chief Executive,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers's Caforio to Retire  As Drugmaker's Chief Executive  ----  By Jared S. Hopkins and Laura Cooper
BMY,2023-04-27,06:32:14,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,Bristol-Myers's Caforio to Retire As Drugmaker's Chief Executive,FULL-ARTICLE,Wall Street Journal,Bristol-Myers's Caforio to Retire As Drugmaker's Chief Executive -- WSJ
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 1Q Rev $11.3B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Rev $11.3B >BMY
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q Net $2.26B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Net $2.26B >BMY
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q EPS $1.07,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q EPS $1.07 >BMY
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q Adj EPS $2.05,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Adj EPS $2.05 >BMY
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports First Quarter Financial Results for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol-Myers Squibb Co.: Reports First Quarter Revenues of $11.3 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts First Quarter GAAP Earnings Per Share of $1.07,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts GAAP 2023 EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Affirms Non-GAAP Financial Guidance for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.32,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 16% to $3.3 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.6 billion compared to $2.1 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.14,revenues,,Bristol-Myers Squibb Co.: International revenues were $912 million compared to $824 million,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Camzyos,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.49,partnerships,,"Bristol-Myers Squibb Co.: The company, in collaboration with Janssen Pharmaceuticals, Inc.",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: The submissions were based on results from the Phase 3 CheckMate-76K clinical trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,93,0.62,products-services,positive,Bristol-Myers Squibb Co.: The positive opinion was based on results from the pivotal Phase 3 TRANSFORM clinical trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusting GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $4.03-$4.33,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, April 27, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 1.08 $ 0.60,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -6-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2023",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -6-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,98,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $ 11,337 $11,648",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -7-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Full Year 2023 Pre-tax Tax After-tax Projected Diluted Earnings,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -8-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: the company's 2023 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -8-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The GAAP financial results for the full year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -8-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -8-
BMY,2023-04-27,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol Myers Squibb Reports First Quarter Financial Results for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -8-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports First Quarter Financial Results for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol-Myers Squibb Co.: Reports First Quarter Revenues of $11.3 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts First Quarter GAAP Earnings Per Share of $1.07,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts GAAP 2023 EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Affirms Non-GAAP Financial Guidance for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.32,revenues,down,Bristol-Myers Squibb Co.: International revenues decreased 16% to $3.3 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2023
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.6 billion compared to $2.1 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.14,revenues,,Bristol-Myers Squibb Co.: International revenues were $912 million compared to $824 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Camzyos,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.49,partnerships,,"Bristol-Myers Squibb Co.: The company, in collaboration with Janssen Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: The submissions were based on results from the Phase 3 CheckMate-76K clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.62,products-services,positive,Bristol-Myers Squibb Co.: The positive opinion was based on results from the pivotal Phase 3 TRANSFORM clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusting GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $4.03-$4.33,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, April 27, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 1.08 $ 0.60,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -6-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -6-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,98,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $ 11,337 $11,648",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -7-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Full Year 2023 Pre-tax Tax After-tax Projected Diluted Earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -8-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: the company's 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -8-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The GAAP financial results for the full year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -8-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -8-
BMY,2023-04-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol Myers Squibb Reports First Quarter Financial Results for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -8-
BMY,2023-04-27,11:01:08,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,unchanged,Bristol-Myers Squibb Backs 2023 View of Adj EPS $7.95,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Backs 2023 View of Adj EPS $7.95-Adj EPS $8.25 >BMY
BMY,2023-04-27,11:02:56,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb 1Q Revenue From In-Line Products, New Product Portfolio Up 10%",NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb 1Q Revenue From In-Line Products, New Product Portfolio Up 10% Ex-Forex >BMY"
BMY,2023-04-27,11:09:24,94637C,Bristol-Myers Squibb Co.,100,0.74,earnings,up,Bristol Myers Squibb Q1 EPS $1.07 vs. 59 cents a year ago,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb Q1 EPS $1.07 vs. 59 cents a year ago
BMY,2023-04-27,11:09:24,94637C,Bristol-Myers Squibb Co.,100,0.46,earnings,above-expectations,Bristol Myers Squibb Q1 adj. EPS $2.05; FactSet consensus $1.97,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb Q1 adj. EPS $2.05; FactSet consensus $1.97
BMY,2023-04-27,11:10:24,94637C,Bristol-Myers Squibb Co.,100,-0.27,revenues,below-expectations,Bristol Myers Squibb Q1 revenue $11.337 bln vs. $11.648 bln a year ago; FactSet consensus $11.496 bln,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb Q1 revenue $11.337 bln vs. $11.648 bln a year ago; FactSet consensus $11.496 bln
BMY,2023-04-27,11:11:24,94637C,Bristol-Myers Squibb Co.,100,0.48,revenues,up,Bristol Myers Squibb still sees full-year revenue up 2%,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb still sees full-year revenue up 2%
BMY,2023-04-27,11:12:24,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb now sees full-year EPS of $4.10 to $4.40,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb now sees full-year EPS of $4.10 to $4.40 vs. prior $4.03 to $4.33
BMY,2023-04-27,11:12:25,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb still sees full-year adj. EPS of $7.85 to $8.25,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb still sees full-year adj. EPS of $7.85 to $8.25
BMY,2023-04-27,11:22:24,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Q1 Profit Beats,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Q1 Profit Beats While Revenue Falls Slightly Short Of Estimates -- MarketWatch
BMY,2023-04-27,11:22:24,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb Co. (BMY) posted net income of $2.262 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Q1 Profit Beats While Revenue Falls Slightly Short Of Estimates -- MarketWatch
BMY,2023-04-27,11:22:24,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Q1 profit beats,FULL-ARTICLE,MarketWatch,MW Bristol Myers Q1 profit beats while revenue falls slightly short of estimates
BMY,2023-04-27,11:22:24,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb Co. (BMY) posted net income of $2.262 billion,FULL-ARTICLE,MarketWatch,MW Bristol Myers Q1 profit beats while revenue falls slightly short of estimates
BMY,2023-04-28,12:51:10,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by Credit Suisse
BMY,2023-04-28,12:51:10,94637C,Bristol-Myers Squibb Co.,100,-0.7,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $72.00/Share From $78.00 by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $72.00/Share From $78.00 by Credit Suisse
BMY,2023-05-01,10:02:16,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2023-05-01,10:02:16,94637C,Bristol-Myers Squibb Co.,100,-0.3,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $65.00/Share From $66.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $65.00/Share From $66.00 by Barclays
BMY,2023-05-01,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate
BMY,2023-05-01,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate
BMY,2023-05-01,11:05:50,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Reblozylas First-Line Treatment of Anemia in Adults With Lower-Risk Myelodysplastic Syndromes
BMY,2023-05-01,11:20:38,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Expanded Reblozyl Use >BMY
BMY,2023-05-01,11:35:38,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb Co. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Expanded Reblozyl Use
BMY,2023-05-01,18:02:33,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review for Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Gets FDA Priority Review for Reblozyl Expanded Use
BMY,2023-05-01,18:17:33,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review for Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Gets FDA Priority Review for Reblozyl Expanded Use
BMY,2023-05-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,marketing,,Bristol-Myers Squibb Co.: the company will participate in the Bank of America Securities 2023 Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare Conference
BMY,2023-05-02,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,marketing,,Bristol-Myers Squibb Co.: the company will participate in the Bank of America Securities 2023 Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare Conference
BMY,2023-05-03,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-05-03,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: TRANSFORM Clinical Trial Results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-05-03,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-05-03,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-05-03,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: TRANSFORM Clinical Trial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-05-03,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-05-03,10:59:11,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene Maraleucel),NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene Maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
BMY,2023-05-03,17:48:27,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp Vessey Registers 50,385 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP Vessey Registers 50,385 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-05-03,23:38:38,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Greenlees Acquires 671 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Greenlees Acquires 671 Of Bristol-Myers Squibb Co >BMY
BMY,2023-05-04,07:00:47,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: our collaboration with BMS.,PRESS-RELEASE,PR Newswire,Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb
BMY,2023-05-04,12:00:09,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: our collaboration with BMS.,PRESS-RELEASE,PR Newswire,Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb
BMY,2023-05-04,21:52:26,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Vessey Sells 50,385 Of Bristol-Myers Squibb Co",FULL-ARTICLE,Dow Jones Newswires,"VP Vessey Sells 50,385 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-05-11,17:41:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: phase 1 study of,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight Diversified -3-
BMY,2023-05-11,17:41:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight Diversified -10-
BMY,2023-05-11,17:41:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight Diversified -10-
BMY,2023-05-11,17:41:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Highlight Diversified -10-
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,99,0.0,marketing,,Bristol Myers Squibb to Host Virtual Investor Event,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023"
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Results from the dose-escalation components of a Phase 1/2 study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023"
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023"
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: A phase 2/3 trial of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -4-
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -7-
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -10-
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -10-
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -10-
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,90,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -13-
BMY,2023-05-11,17:42:28,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Highlight -13-
BMY,2023-05-22,15:01:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Data demonstrate potential of BMS-986278,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Investigational LPA(1) Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
BMY,2023-05-22,15:01:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced results from a Phase 2 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Investigational LPA(1) Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
BMY,2023-05-22,15:01:36,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Data demonstrate potential of BMS-986278,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
BMY,2023-05-22,15:01:36,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced results from a Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
BMY,2023-05-25,11:06:41,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Bristol Myers/J&J Get FDA Fast-Track Designation,NEWS-FLASH,Dow Jones Newswires,Bristol Myers/J&J Get FDA Fast-Track Designation for Milvexian in Three Indications in Phase 3
BMY,2023-05-25,21:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb to Present First Results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl(R) (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
BMY,2023-05-25,21:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Results from Phase 3 COMMANDS study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl(R) (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
BMY,2023-05-25,21:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb to Present First Results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present First Results at -2-
BMY,2023-05-25,21:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Reblozyl,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present First Results at -2-
BMY,2023-05-25,21:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb to Present First Results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present First Results at -3-
BMY,2023-05-25,21:02:24,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb to Present First Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl(R) (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
BMY,2023-05-25,21:02:24,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Results from Phase 3 COMMANDS study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl(R) (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
BMY,2023-05-25,21:02:24,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Reblozyl,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -2-
BMY,2023-05-25,21:05:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi (lisocabtagene -2-
BMY,2023-05-25,21:05:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Breyanzi -2-
BMY,2023-05-26,12:10:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...
BMY,2023-05-26,12:10:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...
BMY,2023-05-26,12:10:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2023-05-26,12:10:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2023-05-26,12:10:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2023-05-26,12:10:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...
BMY,2023-05-26,12:10:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...
BMY,2023-05-26,12:10:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-05-26,12:10:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-05-26,12:10:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2023-05-26,12:11:20,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo With Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients With Tumor Cell PD-L1 Expression >1%
BMY,2023-05-26,12:28:15,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,Committee for Medicinal Products for Human Use has recommended approval of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets CHMP Recommendation for Opdivo With Chemotherapy to Treat Lung Cancer
BMY,2023-05-26,12:43:14,94637C,Bristol-Myers Squibb Co.,93,0.57,products-services,granted,Committee for Medicinal Products for Human Use has recommended approval of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Gets CHMP Recommendation for Opdivo With Chemotherapy to Treat Lung Cancer
BMY,2023-05-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
BMY,2023-05-30,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
BMY,2023-05-30,10:59:35,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Repotrectinib,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Repotrectinib in Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
BMY,2023-05-30,11:19:37,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Repotrectinib,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Repotrectinib in Certain Non-Small Cell Lung Cancer
BMY,2023-05-30,11:19:37,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb on Tuesday said the Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Repotrectinib in Certain Non-Small Cell Lung Cancer
BMY,2023-05-30,11:19:37,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers's $4.1 billion acquisition of Turning Point Therapeutics,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Repotrectinib in Certain Non-Small Cell Lung Cancer
BMY,2023-05-30,11:34:37,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Repotrectinib,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Repotrectinib in Certain Non-Small Cell Lung Cancer
BMY,2023-05-30,11:34:37,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Squibb on Tuesday said the Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Repotrectinib in Certain Non-Small Cell Lung Cancer
BMY,2023-05-30,11:34:37,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers's $4.1 billion acquisition of Turning Point Therapeutics,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Repotrectinib in Certain Non-Small Cell Lung Cancer
BMY,2023-05-30,13:24:00,94637C,Bristol-Myers Squibb Co.,95,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant Lymphoma
BMY,2023-05-30,13:24:00,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant Lymphoma
BMY,2023-06-01,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2023-06-01,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2023-06-05,16:12:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Sciences Announces Collaboration with Bristol Myers Squibb on,PRESS-RELEASE,Business Wire,MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on Tumor Target Discovery
BMY,2023-06-05,16:12:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The company is developing internal drug programs for hepatocellular carcinoma,PRESS-RELEASE,Business Wire,MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on Tumor Target Discovery
BMY,2023-06-05,16:40:55,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Sciences Announces Collaboration with Bristol Myers Squibb on,PRESS-RELEASE,Dow Jones Newswires,Press Release: MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on Tumor Target Discovery
BMY,2023-06-05,16:40:55,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The company is developing internal drug programs for hepatocellular carcinoma,PRESS-RELEASE,Dow Jones Newswires,Press Release: MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on Tumor Target Discovery
BMY,2023-06-06,23:40:54,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Lenkowsky Acquires 526 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Lenkowsky Acquires 526 Of Bristol-Myers Squibb Co >BMY
BMY,2023-06-08,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023"
BMY,2023-06-08,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023"
BMY,2023-06-08,11:05:51,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023"
BMY,2023-06-08,11:05:51,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023"
BMY,2023-06-08,20:16:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the U.S. Food and Drug Administration (FDA) has approved commercial production at the company's newest cell therapy,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts"
BMY,2023-06-08,20:16:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the U.S. Food and Drug Administration (FDA) has approved commercial production at the company's newest cell therapy,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts"
BMY,2023-06-14,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2023-06-14,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on August 1, 2023, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2023-06-14,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2023-06-14,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on August 1, 2023, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2023-06-16,21:03:01,94637C,Bristol-Myers Squibb Co.,100,-0.48,legal,,Bristol Myers Squibb sues federal government over,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb sues federal government over Medicare drug negotiations: report
BMY,2023-06-16,21:03:01,94637C,Bristol-Myers Squibb Co.,100,-0.48,legal,,Bristol Myers Squibb Sues Federal Government Over,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Sues Federal Government Over Medicare Drug Negotiations: Report -- MarketWatch
BMY,2023-06-17,09:30:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Breyanzi (lisocabtagene -2-
BMY,2023-06-17,09:30:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Breyanzi -2-
BMY,2023-06-26,12:01:35,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lianbio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in Singapore,PRESS-RELEASE,GlobeNewswire,LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in Singapore
BMY,2023-06-26,12:01:35,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Mavacamten was granted Breakthrough Therapy Designation in China,PRESS-RELEASE,GlobeNewswire,LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in Singapore
BMY,2023-06-26,12:01:35,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lianbio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in Singapore,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in Singapore
BMY,2023-06-26,12:01:35,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Mavacamten was granted Breakthrough Therapy Designation in China,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in Singapore
BMY,2023-06-26,12:01:53,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lianbio Announces Marketing Approval of CAMZYOS (Mavacamten) in Singapore,NEWS-FLASH,Dow Jones Newswires,LianBio Announces Marketing Approval of CAMZYOS (Mavacamten) in Singapore
BMY,2023-06-26,12:09:46,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lianbio: CAMZYOS Gets Singapore Marketing Approval,NEWS-FLASH,Dow Jones Newswires,LianBio: CAMZYOS Gets Singapore Marketing Approval for Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
BMY,2023-06-26,20:01:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved CAMZYOS(R),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval of CAMZYOS(R) (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)"
BMY,2023-06-26,20:01:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: The positive results of both Phase 3 clinical trials showed that CAMZYOS,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval of CAMZYOS(R) (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)"
BMY,2023-06-26,20:01:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved CAMZYOS(R),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval of CAMZYOS(R) (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)"
BMY,2023-06-26,20:01:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: The positive results of both Phase 3 clinical trials showed that CAMZYOS,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval of CAMZYOS(R) (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)"
BMY,2023-06-26,20:01:27,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval of CAMZYOS,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval of CAMZYOS to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy
BMY,2023-06-26,20:08:27,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers' Heart Treatment Camzyos Gets EU Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Heart Treatment Camzyos Gets EU Approval
BMY,2023-06-26,20:23:27,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers' Heart Treatment Camzyos Gets EU Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' Heart Treatment Camzyos Gets EU Approval
BMY,2023-06-26,21:59:35,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval -- Market Talk
BMY,2023-06-26,21:59:35,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb's European-Commission approval for its heart-disease drug,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval -- Market Talk
BMY,2023-06-26,21:59:35,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers acquired Camzyos when it took over MyoKardia for $13.1B,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval -- Market Talk
BMY,2023-06-26,21:59:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval -- Market Talk
BMY,2023-06-26,21:59:36,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb's European-Commission approval for its heart-disease drug,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval -- Market Talk
BMY,2023-06-26,21:59:36,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers acquired Camzyos when it took over MyoKardia for $13.1B,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers' Heart Treatment Camzyos Gets EU Approval -- Market Talk
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression >=1%
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The importance of the approval of nivolumab combined with chemotherapy for the treatment of certain patients with non-metastatic NSCLC,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression >=1%
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -6-
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression >=1%
BMY,2023-06-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb Co.: The importance of the approval of nivolumab combined with chemotherapy for the treatment of certain patients with non-metastatic NSCLC,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression >=1%
BMY,2023-06-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2023-06-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2023-06-29,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2023-06-29,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -6-
BMY,2023-06-29,10:59:27,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo With Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients With Tumor Cell PD-L1 Expression
BMY,2023-07-05,21:25:19,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 4,570 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Acquires 4,570 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-07-05,21:28:08,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Weese Acquires 1,203 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Weese Acquires 1,203 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-07-10,13:58:42,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Initiated at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Market Perform by SVB Leerink
BMY,2023-07-10,13:58:42,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $66.00/Share by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $66.00/Share by SVB Leerink
BMY,2023-07-11,05:30:32,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership,PRESS-RELEASE,DGAP News,EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
BMY,2023-07-11,05:30:32,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Evotec and Bristol Myers Squibb enter licence agreement,PRESS-RELEASE,DGAP News,EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
BMY,2023-07-11,05:30:32,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
BMY,2023-07-11,05:30:32,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Evotec and Bristol Myers Squibb enter licence agreement,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
BMY,2023-07-11,05:50:37,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership,PRESS-RELEASE,DJ Global Press Release Wire,Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership
BMY,2023-07-11,10:34:15,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2023-07-11,10:34:15,94637C,Bristol-Myers Squibb Co.,100,-0.3,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $64.00/Share From $65.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $64.00/Share From $65.00 by Barclays
BMY,2023-07-12,10:59:00,94637C,Bristol-Myers Squibb Co.,95,0.57,products-services,granted,Zeposia was approved by the U.S. Food and Drug Administration (FDA) for the treatment,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Launches Supporting You with UC, with Women's World Cup Commentator, Former Professional Soccer Player and Ulcerative Colitis Patient, Rosie White"
BMY,2023-07-12,10:59:00,94637C,Bristol-Myers Squibb Co.,95,0.57,products-services,granted,Bristol-Myers Squibb Co.: Zeposia was approved by the FDA for the treatment of moderate to severe ulcerative colitis,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Launches Supporting You with UC, with Women's World Cup Commentator, Former Professional Soccer Player and Ulcerative Colitis Patient, Rosie White"
BMY,2023-07-12,10:59:00,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: sudden loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Launches Supporting You with -2-
BMY,2023-07-14,08:57:56,94637C,Bristol-Myers Squibb Co.,100,-0.99,analyst-ratings,negative,Bristol-Myers Squibb Initiated at Reduce by HSBC,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Reduce by HSBC
BMY,2023-07-14,08:57:56,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $56.00/Share by HSBC,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $56.00/Share by HSBC
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opdivo was approved by the European Commission,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -5-
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Opdivo was approved by the European Commission,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2023-07-21,10:59:16,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo as an Adjuvant Treatment for Patients With Completely Resected Stage IIB or IIC Melanoma
BMY,2023-07-24,11:00:00,94637C,Bristol-Myers Squibb Co.,93,0.22,acquisitions-mergers,,"Bristol Myers Squibb purchased 2,419,818 ordinary shares in a private placement transaction at a subscription price",PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
BMY,2023-07-24,11:00:00,94637C,Bristol-Myers Squibb Co.,93,0.22,acquisitions-mergers,,"Bristol Myers Squibb purchased 2,419,818 ordinary shares in a private placement transaction at a subscription price",PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
BMY,2023-07-24,11:00:01,94637C,Bristol-Myers Squibb Co.,94,0.22,acquisitions-mergers,,Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
BMY,2023-07-24,11:00:01,94637C,Bristol-Myers Squibb Co.,94,0.22,acquisitions-mergers,,Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
BMY,2023-07-24,11:11:22,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Bristol Myers Buys 2.42M Ordinary Shrs in Private Placement Transaction at Subscription Price of $14,NEWS-FLASH,Dow Jones Newswires,Immatics: Bristol Myers Buys 2.42M Ordinary Shrs in Private Placement Transaction at Subscription Price of $14.46/Shr
BMY,2023-07-24,11:26:20,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Bristol Myers Squibb Invests $35 Million in Immatics,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Invests $35 Million in Immatics
BMY,2023-07-24,11:41:20,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Bristol Myers Squibb Invests $35 Million in Immatics,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Invests $35 Million in Immatics
BMY,2023-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q Adj EPS $1.75,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Adj EPS $1.75 >BMY
BMY,2023-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q EPS 99c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q EPS 99c >BMY
BMY,2023-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 2Q Net $2.1B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Net $2.1B >BMY
BMY,2023-07-27,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 2Q Rev $11.2B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 2Q Rev $11.2B >BMY
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol-Myers Squibb Co.: Reports Second Quarter Revenues of $11.2 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Second Quarter GAAP Earnings Per Share of $0.99,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol-Myers Squibb Co.: Announces $4 Billion Accelerated Share Repurchase,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.75,revenues,down,Expected decline in Revlimid sales in the quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: our financial guidance for the year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 5% to $7.9 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: The EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.3 billion compared to $2.2 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues increased 2% to $1.2 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,"European Commission (EC) approved Camzyos, the first",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,products-services,,Bristol-Myers Squibb Co.: The approval is based upon results from two Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,"Bristol-Myers Squibb Co.: The company in collaboration with Janssen Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,European Medicines Agency (EMA) recommended approval of Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: The approval was based on results from the pivotal Phase 3 TRANSFORM clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Clinical & LPA(1) Results from the Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.16,revenues,,Bristol-Myers Squibb Co.: International revenues decreased 12% to $6.6 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: FIRST HALF FINANCIAL RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,unchanged,Bristol-Myers Squibb Co.: U.S. revenues remained consistent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.5 billion compared to $2.3 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $4.9 billion compared to $4.3 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.68,revenues,down,Bristol-Myers Squibb Co.: Revlimid worldwide revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,,Bristol-Myers Squibb Co.: the company is announcing a $4 billion accelerated share repurchase program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $4.10-$4.40,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, July 27, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: the company's Annual Report on Form 10-K for the year ended December 31, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED JUNE 30, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.99 $ 0.67 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $7,891 $3,335",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,226 $11,887",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -9-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: the company's 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -10-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The GAAP financial results for the full year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -10-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -10-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol-Myers Squibb Co.: Reports Second Quarter Revenues of $11.2 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Second Quarter GAAP Earnings Per Share of $0.99,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol-Myers Squibb Co.: Announces $4 Billion Accelerated Share Repurchase,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.75,revenues,down,Expected decline in Revlimid sales in the quarter,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: our financial guidance for the year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 5% to $7.9 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: The EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.3 billion compared to $2.2 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues increased 2% to $1.2 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,"European Commission (EC) approved Camzyos, the first",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,products-services,,Bristol-Myers Squibb Co.: The approval is based upon results from two Phase 3 trials,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,"Bristol-Myers Squibb Co.: The company in collaboration with Janssen Pharmaceuticals, Inc.",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.57,products-services,granted,European Medicines Agency (EMA) recommended approval of Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -2-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: The approval was based on results from the pivotal Phase 3 TRANSFORM clinical trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -3-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Clinical & LPA(1) Results from the Phase 2 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.16,revenues,,Bristol-Myers Squibb Co.: International revenues decreased 12% to $6.6 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: FIRST HALF FINANCIAL RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,unchanged,Bristol-Myers Squibb Co.: U.S. revenues remained consistent,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $2.5 billion compared to $2.3 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -4-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $4.9 billion compared to $4.3 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.68,revenues,down,Bristol-Myers Squibb Co.: Revlimid worldwide revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.59,equity-actions,,Bristol-Myers Squibb Co.: the company is announcing a $4 billion accelerated share repurchase program,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $4.10-$4.40,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, July 27, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -5-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,"Bristol-Myers Squibb Co.: the company's Annual Report on Form 10-K for the year ended December 31, 2022",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -7-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED JUNE 30, 2023",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -7-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.99 $ 0.67 $,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -7-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $7,891 $3,335",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -8-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,226 $11,887",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -9-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: the company's 2023 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -10-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The GAAP financial results for the full year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -10-
BMY,2023-07-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter -10-
BMY,2023-07-27,10:59:46,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2023 Adj EPS $7.35,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 Adj EPS $7.35-Adj EPS $7.65 >BMY
BMY,2023-07-27,11:00:12,94637C,Bristol-Myers Squibb Co.,100,-0.75,revenues,down,Bristol-Myers Squibb Sees 2023 Revenue Down,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 Revenue Down Low-Single Digits >BMY
BMY,2023-07-27,11:07:27,94637C,Bristol-Myers Squibb Co.,100,-0.26,earnings,below-expectations,Bristol-Myers Squibb Q2 adj. EPS $1.75; FactSet consensus $1.98,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb Q2 adj. EPS $1.75; FactSet consensus $1.98
BMY,2023-07-27,11:07:28,94637C,Bristol-Myers Squibb Co.,100,-0.27,revenues,below-expectations,Bristol-Myers Squibb Q2 revenue $11.226 bln vs. $11.887 bln a year ago; FactSet consensus $11.806 bln,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb Q2 revenue $11.226 bln vs. $11.887 bln a year ago; FactSet consensus $11.806 bln
BMY,2023-07-27,11:08:28,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol-Myers Squibb lowers guidance,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb lowers guidance to reflect lower-than-expected revlimid sales
BMY,2023-07-27,11:09:28,94637C,Bristol-Myers Squibb Co.,100,-0.75,revenues,down,Bristol-Myers Squibb now sees 2023 revenue down,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb now sees 2023 revenue down by low single-digits vs. prior guidance o up 2%
BMY,2023-07-27,11:10:27,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb now sees 2023 adj. EPS of $7.35 to $7.65,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb now sees 2023 adj. EPS of $7.35 to $7.65 vs. prior $8.95 to $8.25
BMY,2023-07-27,11:17:28,94637C,Bristol-Myers Squibb Co.,91,-0.54,revenues,down,Revlimid sales dropped 41%,FULL-ARTICLE,MarketWatch,MW Bristol Myers stock takes a hit from earnings miss and lower outlook amid disappointing Revlimid sales
BMY,2023-07-27,11:17:28,94637C,Bristol-Myers Squibb Co.,91,0.0,revenues,,Revlimid sales are now expected to,FULL-ARTICLE,MarketWatch,MW Bristol Myers stock takes a hit from earnings miss and lower outlook amid disappointing Revlimid sales
BMY,2023-07-27,11:17:28,94637C,Bristol-Myers Squibb Co.,91,-0.54,revenues,down,Revlimid sales dropped 41%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Takes A Hit From Earnings Miss And Lower Outlook Amid Disappointing Revlimid Sales -- MarketWatch
BMY,2023-07-27,11:17:28,94637C,Bristol-Myers Squibb Co.,91,0.0,revenues,,Revlimid sales are now expected to,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Takes A Hit From Earnings Miss And Lower Outlook Amid Disappointing Revlimid Sales -- MarketWatch
BMY,2023-07-27,12:13:49,94637C,Bristol-Myers Squibb Co.,93,-0.75,revenues,down,Bristol Myers now estimates 2023 revenue to fall,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Slashes Forecast on Tumbling Revlimid Sales -- Barrons.com
BMY,2023-07-27,12:13:49,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,Revlimid sales were forecast at,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Slashes Forecast on Tumbling Revlimid Sales -- Barrons.com
BMY,2023-07-27,13:50:04,94637C,Bristol-Myers Squibb Co.,93,-0.75,revenues,down,Bristol Myers now estimates 2023 revenue to fall,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Slashes Forecast on Tumbling Revlimid Sales
BMY,2023-07-27,13:50:04,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,Revlimid sales were forecast at,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Slashes Forecast on Tumbling Revlimid Sales
BMY,2023-07-28,10:25:19,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2023-07-28,10:25:19,94637C,Bristol-Myers Squibb Co.,100,-0.46,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $62.00/Share From $64.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $62.00/Share From $64.00 by Barclays
BMY,2023-07-28,10:33:59,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Overweight by Atlantic Equities
BMY,2023-07-28,10:33:59,94637C,Bristol-Myers Squibb Co.,100,-0.62,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $85.00/Share From $90.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $85.00/Share From $90.00 by Atlantic Equities
BMY,2023-07-28,13:09:10,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Buy by B of A Securities
BMY,2023-07-28,13:09:10,94637C,Bristol-Myers Squibb Co.,100,-0.64,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $80.00/Share From $85.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $80.00/Share From $85.00 by B of A Securities
BMY,2023-07-28,14:12:40,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Outperform by BMO Capital
BMY,2023-07-28,14:12:40,94637C,Bristol-Myers Squibb Co.,100,-0.76,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $79.00/Share From $87.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $79.00/Share From $87.00 by BMO Capital
BMY,2023-07-28,16:05:10,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
BMY,2023-07-28,16:05:10,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $65.00/Share From $78.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $65.00/Share From $78.00 by Wells Fargo
BMY,2023-08-03,19:57:32,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,Vp Plenge Registers 732 Of Bristol-Myers Squibb Co >BMY,RNS-SEC144,Dow Jones Newswires,VP Plenge Registers 732 Of Bristol-Myers Squibb Co >BMY
BMY,2023-08-07,21:25:27,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,Vp Plenge Sells 732 Of Bristol-Myers Squibb Co,FULL-ARTICLE,Dow Jones Newswires,VP Plenge Sells 732 Of Bristol-Myers Squibb Co >BMY
BMY,2023-08-10,11:01:00,94637C,Bristol-Myers Squibb Co.,99,0.53,equity-actions,,Bristol-Myers Squibb Co.: Achieves $1 billion investment,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts"
BMY,2023-08-10,11:01:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms actively collaborates with renowned organizations such as,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts"
BMY,2023-08-10,11:01:01,94637C,Bristol-Myers Squibb Co.,99,0.53,equity-actions,,Bristol-Myers Squibb Co.: Achieves $1 billion investment,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts"
BMY,2023-08-10,11:01:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms actively collaborates with renowned organizations such as,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts"
BMY,2023-08-10,11:23:20,94637C,Bristol-Myers Squibb Co.,94,0.59,equity-actions,,Bristol Myers Squibb is buying back $4 billion worth of stock,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Sets $4 Billion Accelerated Stock Buyback >BMY
BMY,2023-08-10,11:38:20,94637C,Bristol-Myers Squibb Co.,93,0.59,equity-actions,,Bristol Myers Squibb is buying back $4 billion worth of stock,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Sets $4 Billion Accelerated Stock Buyback
BMY,2023-08-19,07:18:34,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2023 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2023 (BMY)"
BMY,2023-08-21,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Data from clinical studies,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023
BMY,2023-08-21,10:59:00,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data Across its -3-
BMY,2023-08-21,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data Across its -4-
BMY,2023-08-21,11:13:06,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Data from clinical studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023
BMY,2023-08-21,11:13:06,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase -3-
BMY,2023-08-21,11:13:06,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase -4-
BMY,2023-08-22,20:18:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-08-22,20:18:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2023-08-22,20:18:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2023-08-22,20:18:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2023-08-22,20:18:00,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -5-
BMY,2023-08-22,20:18:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
BMY,2023-08-22,20:18:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-08-22,20:18:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2023-08-22,20:18:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2023-08-22,20:18:01,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -5-
BMY,2023-08-22,20:18:42,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo as,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Receives European Commission Approval for Opdivo as Adjuvant Treatment for Patients With Completely Resected Stage IIB or IIC Melanoma >BMY
BMY,2023-08-22,20:38:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb said Tuesday it had received European Commission approval for Opdivo,FULL-ARTICLE,Dow Jones Newswires,BMY Gets European Approval for Opdivo as Treatment for Some Melanoma Patients
BMY,2023-08-22,20:53:22,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb said Tuesday it had received European Commission approval for Opdivo,FULL-ARTICLE,Dow Jones Newswires,BMY Gets European Approval for Opdivo as Treatment for Some Melanoma Patients
BMY,2023-08-23,11:55:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company obtained 18 approvals for new medicines,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments"
BMY,2023-08-23,11:55:00,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb also executed a 15-year virtual power purchase agreement,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments"
BMY,2023-08-23,11:55:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: the company obtained 18 approvals for new medicines,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments"
BMY,2023-08-23,11:55:01,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol Myers Squibb also executed a 15-year virtual power purchase agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments"
BMY,2023-08-24,18:21:35,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Vp Powell Registers 17,986 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"VP Powell Registers 17,986 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-08-28,12:00:09,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: during pre-clinical development, in",PRESS-RELEASE,PR Newswire,Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
BMY,2023-08-28,12:00:09,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Partnering with Cellares enables academics, biotechs, and pharma companies to",PRESS-RELEASE,PR Newswire,Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
BMY,2023-08-28,12:00:09,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: during pre-clinical development, in",PRESS-RELEASE,Dow Jones Newswires,Press Release: Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
BMY,2023-08-28,12:00:09,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Partnering with Cellares enables academics, biotechs, and pharma companies to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
BMY,2023-08-28,12:01:27,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: during pre-clinical development, in",PRESS-RELEASE,PR Newswire,Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
BMY,2023-08-28,12:01:27,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Partnering with Cellares enables academics, biotechs, and pharma companies to",PRESS-RELEASE,PR Newswire,Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
BMY,2023-08-28,21:29:43,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Vp Powell Sells 17,986 Of Bristol-Myers Squibb Co",FULL-ARTICLE,Dow Jones Newswires,"VP Powell Sells 17,986 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-08-29,02:00:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. FDA Approves Bristol Myers Squibb's Reblozyl(R) (luspatercept-aamt),NEWS-FLASH,Dow Jones Newswires,U.S. FDA Approves Bristol Myers Squibb's Reblozyl(R) (luspatercept-aamt) As First-Line Treatment Of Anemia In Adults With Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions >BMY
BMY,2023-08-29,02:00:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Reblozyl(R) (luspatercept-aamt),PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's Reblozyl(R) (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
BMY,2023-08-29,02:00:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: This expanded indication to,PRESS-RELEASE,Business Wire,U.S. FDA Approves Bristol Myers Squibb's Reblozyl(R) (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
BMY,2023-08-29,02:18:26,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb: FDA Approved Reblozyl,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: FDA Approved Reblozyl as First-Line Treatment of Anemia in Adults With Lower-Risk Myelodysplastic Syndromes Who May Require Transfusions >BMY
BMY,2023-08-29,09:29:42,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Reblozyl(R) (luspatercept-aamt),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers Squibb's Reblozyl(R) (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
BMY,2023-08-29,09:29:42,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: This expanded indication to,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. FDA Approves Bristol Myers Squibb's Reblozyl(R) (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
BMY,2023-09-01,11:01:49,94637C,Bristol-Myers Squibb Co.,99,0.0,marketing,,Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
BMY,2023-09-05,10:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,GlobeNewswire,"Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia"
BMY,2023-09-05,10:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,"Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia"
BMY,2023-09-05,10:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,DJ Global Press Release Wire,"Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia"
BMY,2023-09-05,10:00:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia"
BMY,2023-09-09,22:01:16,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced results from a Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study
BMY,2023-09-09,22:01:52,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced results from a Phase 2 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Investigational LPA(1) Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study
BMY,2023-09-14,12:30:01,94637C,Bristol-Myers Squibb Co.,99,0.0,assets,,Bristol-Myers Squibb Co.: The first asset,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
BMY,2023-09-14,12:30:01,94637C,Bristol-Myers Squibb Co.,99,0.0,assets,,Bristol-Myers Squibb Co.: The first asset,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
BMY,2023-09-15,15:20:46,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Market Perform by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Market Perform by TD Cowen
BMY,2023-09-15,15:20:46,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $66.00/Share From $80.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $66.00/Share From $80.00 by TD Cowen
BMY,2023-09-17,23:57:50,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
BMY,2023-09-17,23:57:51,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
BMY,2023-09-20,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2023-09-20,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on November 1, 2023, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2023-09-20,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2023-09-20,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on November 1, 2023, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2023-09-22,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Positive results reinforce improved efficacy now seen in six Phase 3 trials,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
BMY,2023-09-22,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Perioperative -3-
BMY,2023-09-22,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Perioperative -3-
BMY,2023-09-22,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Perioperative -3-
BMY,2023-09-22,10:59:00,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Perioperative -5-
BMY,2023-09-22,10:59:03,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Positive results reinforce improved efficacy now seen in six Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
BMY,2023-09-22,10:59:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2023-09-22,10:59:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2023-09-22,10:59:03,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2023-09-22,10:59:03,94637C,Bristol-Myers Squibb Co.,94,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -5-
BMY,2023-09-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023"
BMY,2023-09-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023"
BMY,2023-09-26,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023"
BMY,2023-09-26,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023"
BMY,2023-09-26,13:30:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: our ongoing collaboration with the company and we,PRESS-RELEASE,GlobeNewswire,Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
BMY,2023-09-26,13:30:02,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: our ongoing collaboration with the company and we,PRESS-RELEASE,Dow Jones Newswires,Press Release: Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
BMY,2023-09-26,13:30:02,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: our ongoing collaboration with the company and we,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
BMY,2023-10-06,10:30:03,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,A collaboration with Bristol Myers Squibb (NYSE: BMY) to,PRESS-RELEASE,PR Newswire,Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials
BMY,2023-10-06,10:30:03,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,A collaboration with Bristol Myers Squibb (NYSE: BMY) to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials
BMY,2023-10-08,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
BMY,2023-10-08,21:16:00,94637C,Bristol-Myers Squibb Co.,99,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens and Diversifies -2-
BMY,2023-10-08,21:16:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens and Diversifies -3-
BMY,2023-10-08,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
BMY,2023-10-08,21:16:01,94637C,Bristol-Myers Squibb Co.,99,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens -2-
BMY,2023-10-08,21:16:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens -3-
BMY,2023-10-08,21:25:07,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics >BMY MRTX
BMY,2023-10-08,21:25:29,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb To Acquire Mirati for $58 Per Shr in Cash,NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb To Acquire Mirati for $58 Per Shr in Cash, for a Total Equity Value of $4.8B >BMY MRTX"
BMY,2023-10-08,21:26:24,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Acquire Mirati for $58/Share in Cash,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb to Acquire Mirati for $58/Share in Cash
BMY,2023-10-08,22:02:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share,PRESS-RELEASE,Business Wire,CORRECTING AND REPLACING/ Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
BMY,2023-10-08,22:02:00,94637C,Bristol-Myers Squibb Co.,99,-0.45,products-services,,Bristol-Myers Squibb Co.: KRAZATI was discontinued,PRESS-RELEASE,Business Wire,CORRECTING AND REPLACING/ Bristol Myers Squibb -2-
BMY,2023-10-08,22:02:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Business Wire,CORRECTING AND REPLACING/ Bristol Myers Squibb -3-
BMY,2023-10-08,22:12:29,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion -- WSJ
BMY,2023-10-08,22:12:29,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb acquired Turning Point Therapeutics for $4.1 billion in cash,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion -- WSJ
BMY,2023-10-08,23:34:41,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion
BMY,2023-10-08,23:36:53,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion
BMY,2023-10-09,08:28:17,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Agreement to be acquired by Bristol Myers Squibb (BMY) for $58,FULL-ARTICLE,Dow Jones Newswires,"These Stocks Are Moving the Most Today: Exxon, Chevron, Mirati, Bristol Myers, Disney, Lockheed, and More -- Barrons.com"
BMY,2023-10-09,08:38:45,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Bristol Myers Squibb agreed to buy the oncology developer Mirati,FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch Monday: RTX, Disney, Bristol Myers Squibb -- WSJ"
BMY,2023-10-09,09:27:39,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Oncology Developer,FULL-ARTICLE,Dow Jones Newswires,Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 Billion -- Barrons.com
BMY,2023-10-09,09:27:39,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol Myers boost revenue,FULL-ARTICLE,Dow Jones Newswires,Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 Billion -- Barrons.com
BMY,2023-10-09,12:04:11,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion
BMY,2023-10-09,14:00:30,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Bristol Myers Squibb is buying Mirati Therapeutics in,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb Buying Mirati Therapeutics
BMY,2023-10-09,14:15:30,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Bristol Myers Squibb is buying Mirati Therapeutics in,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb Buying Mirati Therapeutics
BMY,2023-10-11,06:01:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol Myers Squibb Presents New Zeposia (ozanimod),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2023-10-11,06:01:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol Myers Squibb Presents New Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Zeposia -2-
BMY,2023-10-11,06:01:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol Myers Squibb Presents New Zeposia,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Zeposia -3-
BMY,2023-10-11,06:01:01,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol Myers Squibb Presents New Zeposia (ozanimod),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
BMY,2023-10-11,11:01:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Cellares Announces Expanded Agreement with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares' Technology Adoption Partnership Program
BMY,2023-10-11,11:01:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Excited to expand our relationship with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares' Technology Adoption Partnership Program
BMY,2023-10-11,13:38:52,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2023-10-11,13:38:52,94637C,Bristol-Myers Squibb Co.,100,-0.34,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $56.00/Share From $57.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $56.00/Share From $57.00 by Morgan Stanley
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Additional data demonstrate potential of repotrectinib,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023"
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Seven-year efficacy results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023"
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,99,0.62,products-services,positive,Bristol-Myers Squibb Co.: Updated results from the registrational TRIDENT-1 trial demonstrating clinical benefit,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023"
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Seven-year efficacy results,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023"
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: CheckMate 77T: Phase 3 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data -2-
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data -5-
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data -5-
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data -5-
BMY,2023-10-12,11:15:00,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Showcase Data -7-
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Additional data demonstrate potential of repotrectinib,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023"
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,99,0.62,products-services,positive,Bristol-Myers Squibb Co.: Updated results from the registrational TRIDENT-1 trial demonstrating clinical benefit,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023"
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: CheckMate 77T: Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase -2-
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase -5-
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase -5-
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase -5-
BMY,2023-10-12,11:15:01,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Showcase -7-
BMY,2023-10-12,23:14:17,94637C,Bristol-Myers Squibb Co.,100,0.0,insider-trading,,Chmn Caforio Gifts 440 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,Chmn Caforio Gifts 440 Of Bristol-Myers Squibb Co >BMY
BMY,2023-10-13,11:10:38,94637C,Bristol-Myers Squibb Co.,100,-0.66,price-targets,downgrade,Bristol-Myers Squibb price target cut to $75 from $80 at JPMorgan,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb price target cut to $75 from $80 at JPMorgan
BMY,2023-10-14,01:18:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) as,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma(1)
BMY,2023-10-14,01:18:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma1
BMY,2023-10-20,12:05:15,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Coverage Assumed by UBS at Neutral,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Coverage Assumed by UBS at Neutral
BMY,2023-10-20,12:05:15,94637C,Bristol-Myers Squibb Co.,100,-0.8,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $60.00/Share From $70.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $60.00/Share From $70.00 by UBS
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Lianbio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China,PRESS-RELEASE,GlobeNewswire,LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,China National Medical Products Administration (NMPA) accepted with Priority Review a New Drug Application (NDA) for mavacamten,PRESS-RELEASE,GlobeNewswire,LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lianbio received approval in Macau and Singapore for mavacamten,PRESS-RELEASE,GlobeNewswire,LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Close collaboration with BMS to,PRESS-RELEASE,GlobeNewswire,LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Phase 2 study assessing the safety and efficacy of BMS-986278,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA(1) Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.7,products-services,,The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for BMS-986278,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA(1) Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: The Breakthrough Therapy Designation is based on results from the global, randomized Phase 2 study",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA(1) Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.69,products-services,,Fda has also previously granted BMS-986278 fast-track designation,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA(1) Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Phase 2 study assessing the safety and efficacy of BMS-986278,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.7,products-services,,The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for BMS-986278,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bristol-Myers Squibb Co.: The Breakthrough Therapy Designation is based on results from the global, randomized Phase 2 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.69,products-services,,Fda has also previously granted BMS-986278 fast-track designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Lianbio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,China National Medical Products Administration (NMPA) accepted with Priority Review a New Drug Application (NDA) for mavacamten,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Lianbio received approval in Macau and Singapore for mavacamten,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Close collaboration with BMS to,PRESS-RELEASE,Dow Jones Newswires,Press Release: LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,10:59:44,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Lianbio Enters Into Agreement With Bristol Myers Squibb for Mavacamten in China,NEWS-FLASH,Dow Jones Newswires,LianBio Enters Into Agreement With Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
BMY,2023-10-24,11:00:02,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Phase 2 Study Assessing the Safety and Efficacy of BMS-986278,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: Designation Is Based on Results From the Progressive Pulmonary Fibrosis Cohort of the Phase 2 Study Assessing the Safety and Efficacy of BMS-986278 Treatment Versus Placebo >BMY
BMY,2023-10-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 3Q Rev $11B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Rev $11B >BMY
BMY,2023-10-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q Net $1.93B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Net $1.93B >BMY
BMY,2023-10-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q EPS 93c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q EPS 93c >BMY
BMY,2023-10-26,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 3Q Adj EPS $2.00,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 3Q Adj EPS $2.00 >BMY
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol-Myers Squibb Co.: Reports Third Quarter Revenues of $11.0 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Third Quarter GAAP Earnings Per Share of $0.93,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts 2023 GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 4% to $7.6 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,Bristol-Myers Squibb Co.: Revlimid worldwide revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.8 billion compared to $1.7 billion in the prior year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues increased 9% to $1.4 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.84,products-services,positive,"Bristol-Myers Squibb Co.: In addition, the company achieved strong results from a Phase 3 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,"Trial, evaluating Opdivo as an adjuvant treatment for patients with localized renal cell carcinoma",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted Priority Review of the New Drug Application for repotrectinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: Clinical & Research LPA(1) antagonist Results from the Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -3-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Adjusting total revenues for Revlimid to be approximately $6.0 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $3.72-$4.02,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.68,revenues,down,Bristol-Myers Squibb Co.: Low Low Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -5-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 Non-GAAP EPS guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -5-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, October 26, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -5-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -6-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.94 $ 0.75 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -7-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -7-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -7-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $23,552 $9,977",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -8-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $10,966 $11,218",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -9-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: the company's 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -10-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The GAAP financial results for the full year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -10-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third -10-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2023,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol-Myers Squibb Co.: Reports Third Quarter Revenues of $11.0 Billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Posts Third Quarter GAAP Earnings Per Share of $0.93,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Adjusts 2023 GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol-Myers Squibb Co.: U.S. revenues decreased 4% to $7.6 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,Bristol-Myers Squibb Co.: Revlimid worldwide revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues were $1.8 billion compared to $1.7 billion in the prior year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.41,revenues,up,Bristol-Myers Squibb Co.: U.S. revenues increased 9% to $1.4 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: Recent LOE Products,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.84,products-services,positive,"Bristol-Myers Squibb Co.: In addition, the company achieved strong results from a Phase 3 study",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.57,products-services,granted,Bristol-Myers Squibb Co.: The European Commission approved Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,earnings,,Bristol-Myers Squibb Co.: Three-year follow-up results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -2-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,"Trial, evaluating Opdivo as an adjuvant treatment for patients with localized renal cell carcinoma",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA granted Priority Review of the New Drug Application for repotrectinib,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: Clinical & Research LPA(1) antagonist Results from the Phase 2 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -3-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Adjusting total revenues for Revlimid to be approximately $6.0 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $3.72-$4.02,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.68,revenues,down,Bristol-Myers Squibb Co.: Low Low Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -4-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -5-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 Non-GAAP EPS guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -5-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Thursday, October 26, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -5-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -6-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.61,earnings,positive,Bristol-Myers Squibb Co.: Earnings per Common Share: Basic $ 0.94 $ 0.75 $,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -7-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2023",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -7-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,94,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -7-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,93,0.0,revenues,,"Bristol-Myers Squibb Co.: Total Revenues $23,552 $9,977",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -8-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $10,966 $11,218",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -9-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: the company's 2023 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -10-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The GAAP financial results for the full year,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -10-
BMY,2023-10-26,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2023 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter -10-
BMY,2023-10-26,11:03:36,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Sees 2023 Revenues for Revlimid to Be Approximately $6B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 Revenues for Revlimid to Be Approximately $6B >BMY
BMY,2023-10-26,11:04:22,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2023 EPS $3.68,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 EPS $3.68-EPS $3.83 >BMY
BMY,2023-10-26,11:04:50,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees 2023 Adj EPS $7.50,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees 2023 Adj EPS $7.50-Adj EPS $7.65 >BMY
BMY,2023-10-26,11:08:15,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers Squibb earnings top estimates,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb earnings top estimates
BMY,2023-10-26,11:08:15,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co. (BMY) on Thursday posted net income of $1.928 billion,FULL-ARTICLE,MarketWatch,MW Bristol-Myers Squibb earnings top estimates
BMY,2023-10-26,11:08:15,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol-Myers Squibb Earnings Top Estimates,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb Earnings Top Estimates -- MarketWatch
BMY,2023-10-26,11:08:15,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co. (BMY) on Thursday posted net income of $1.928 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb Earnings Top Estimates -- MarketWatch
BMY,2023-10-26,11:45:45,94637C,Bristol-Myers Squibb Co.,100,-0.68,revenues,down,Bristol Myers Revenue Declines,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Revenue Declines but Beats Expectations as Revlimid Sales Drop -- Barrons.com
BMY,2023-10-26,11:45:45,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb posted third-quarter earnings and revenue that beat Wall Street estimates,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Revenue Declines but Beats Expectations as Revlimid Sales Drop -- Barrons.com
BMY,2023-10-26,11:45:45,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers (ticker: BMY) posted third-quarter earnings of $2 a share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Revenue Declines but Beats Expectations as Revlimid Sales Drop -- Barrons.com
BMY,2023-10-26,11:45:45,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: The company previously expected earnings to be between $7.35,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Revenue Declines but Beats Expectations as Revlimid Sales Drop -- Barrons.com
BMY,2023-10-26,13:04:46,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol Myers raised its guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Skids 5% After Pushing Back A Key Sales Milestone By A Year -- IBD
BMY,2023-10-26,14:17:53,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers earned $2 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone -- IBD
BMY,2023-10-26,14:17:53,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Eliquis sales edged up 2%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone -- IBD
BMY,2023-10-26,14:17:53,94637C,Bristol-Myers Squibb Co.,100,-0.54,revenues,down,Revlimid sales also plummeted 41% to $1.43 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone -- IBD
BMY,2023-10-26,20:04:15,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers earned $2 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone -- IBD
BMY,2023-10-26,20:04:15,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Eliquis sales edged up 2%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone -- IBD
BMY,2023-10-26,20:04:15,94637C,Bristol-Myers Squibb Co.,100,-0.54,revenues,down,Revlimid sales also plummeted 41% to $1.43 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone -- IBD
BMY,2023-10-27,09:46:01,94637C,Bristol-Myers Squibb Co.,100,0.62,analyst-ratings,positive,Bristol-Myers Squibb Raised to Hold From Reduce by HSBC,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raised to Hold From Reduce by HSBC
BMY,2023-10-27,09:46:01,94637C,Bristol-Myers Squibb Co.,100,-0.48,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $53.00/Share From $55.00 by HSBC,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $53.00/Share From $55.00 by HSBC
BMY,2023-10-27,10:49:21,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Market Perform From Outperform by William Blair,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Market Perform From Outperform by William Blair
BMY,2023-10-27,10:50:31,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Market Perform From Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Market Perform From Outperform by BMO Capital
BMY,2023-10-27,10:50:31,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $60.00/Share by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $60.00/Share by BMO Capital
BMY,2023-10-27,11:57:31,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Barclays
BMY,2023-10-27,11:57:31,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $51.00/Share From $60.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $51.00/Share From $60.00 by Barclays
BMY,2023-10-27,13:05:11,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2023-10-27,13:05:11,94637C,Bristol-Myers Squibb Co.,100,-0.8,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $50.00/Share From $56.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $50.00/Share From $56.00 by Morgan Stanley
BMY,2023-10-27,14:38:05,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol Myers Squibb downgraded to market perform at BMO Capital,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb downgraded to market perform at BMO Capital
BMY,2023-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab),PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2023-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2023-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -3-
BMY,2023-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -4-
BMY,2023-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.84,products-services,positive,Bristol-Myers Squibb Co.: Clinical Trials and Patient,PRESS-RELEASE,Business Wire,European Medicines Agency Validates Bristol Myers -5-
BMY,2023-10-30,12:00:22,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Trial Collaboration With Bristol Myers Squibb to,NEWS-FLASH,Dow Jones Newswires,Karyopharm Announces Clinical Trial Collaboration With Bristol Myers Squibb to Evaluate Novel CELMoD(TM) Agent CC- 92480 Mezigdomide in Combination With Selinexor in Patients With Relapsed/Refractory Multiple Myeloma
BMY,2023-10-30,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY,2023-10-30,11:03:41,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo,NEWS-FLASH,Dow Jones Newswires,European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo in Combination With Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients With Unresectable or Metastatic Urothelial Carcinoma
BMY,2023-10-30,12:00:15,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Trial Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,PR Newswire,Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD(TM) Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
BMY,2023-10-30,12:00:15,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol-Myers Squibb (NYSE: BMY),PRESS-RELEASE,PR Newswire,Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD(TM) Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
BMY,2023-10-30,12:00:15,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Trial Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD(TM) Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
BMY,2023-10-30,12:00:15,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Clinical trial collaboration and supply agreement with Bristol-Myers Squibb (NYSE: BMY),PRESS-RELEASE,Dow Jones Newswires,Press Release: Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD(TM) Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
BMY,2023-10-30,12:06:19,94637C,Bristol-Myers Squibb Co.,100,0.41,products-services,start,Bristol Myers to Launch Phase 1b/2 Trial in 1st Half of 2024,NEWS-FLASH,Dow Jones Newswires,"Karyopharm, Bristol Myers to Launch Phase 1b/2 Trial in 1st Half of 2024 >KPTI BMY"
BMY,2023-10-30,12:53:52,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Buy by Goldman Sachs
BMY,2023-10-30,12:53:52,94637C,Bristol-Myers Squibb Co.,100,-0.8,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $69.00/Share From $81.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $69.00/Share From $81.00 by Goldman Sachs
BMY,2023-10-31,00:19:00,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
BMY,2023-10-31,00:19:01,94637C,Bristol-Myers Squibb Co.,100,0.0,credit,,Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
BMY,2023-10-31,22:25:01,94637C,Bristol-Myers Squibb Co.,99,-0.43,labor-issues,,Bristol-Myers Squibb Co.: Giovanni Caforio to Retire as Chair After 23 Years,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024"
BMY,2023-10-31,22:25:01,94637C,Bristol-Myers Squibb Co.,99,0.53,labor-issues,,Bristol-Myers Squibb Co.: Boerner was named Executive Vice President,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024"
BMY,2023-10-31,22:25:01,94637C,Bristol-Myers Squibb Co.,99,-0.43,labor-issues,,Bristol-Myers Squibb Co.: Giovanni Caforio to Retire as Chair After 23 Years,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024"
BMY,2023-10-31,22:25:01,94637C,Bristol-Myers Squibb Co.,99,0.53,labor-issues,,Bristol-Myers Squibb Co.: Boerner was named Executive Vice President,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024"
BMY,2023-10-31,22:26:21,94637C,Bristol-Myers Squibb Co.,100,-0.43,labor-issues,,Bristol-Myers Squibb Chair Giovanni Caforio to Retire April 1,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Chair Giovanni Caforio to Retire April 1
BMY,2023-10-31,22:39:15,94637C,Bristol-Myers Squibb Co.,100,0.47,labor-issues,,Bristol Myers Names Incoming CEO Boerner as Next Chairman,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Names Incoming CEO Boerner as Next Chairman
BMY,2023-10-31,22:54:15,94637C,Bristol-Myers Squibb Co.,100,0.47,labor-issues,,Bristol Myers Names Incoming CEO Boerner as Next Chairman,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Names Incoming CEO Boerner as Next Chairman
BMY,2023-11-02,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference
BMY,2023-11-02,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference
BMY,2023-11-02,15:34:01,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Updated safety and efficacy data from the Phase 1 study,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology"
BMY,2023-11-02,15:34:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First results from the Phase 1/2,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology"
BMY,2023-11-02,15:34:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's First Disclosures and New -5-
BMY,2023-11-02,15:34:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's First Disclosures and New -7-
BMY,2023-11-02,15:34:01,94637C,Bristol-Myers Squibb Co.,99,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's First Disclosures and New -9-
BMY,2023-11-02,15:37:10,94637C,Bristol-Myers Squibb Co.,99,0.84,products-services,positive,Bristol-Myers Squibb Co.: Updated safety and efficacy data from the Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology"
BMY,2023-11-02,15:37:10,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: First results from the Phase 1/2,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 Highlight Company's Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology"
BMY,2023-11-02,15:37:11,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's First -6-
BMY,2023-11-02,15:37:11,94637C,Bristol-Myers Squibb Co.,90,0.52,products-services,,Bristol-Myers Squibb Co.: ABECMA is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's First -7-
BMY,2023-11-02,15:37:11,94637C,Bristol-Myers Squibb Co.,94,0.42,products-services,,Bristol-Myers Squibb Co.: Restart dose,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's First -9-
BMY,2023-11-02,15:38:24,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Neutral From Outperform by Daiwa Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Neutral From Outperform by Daiwa Capital
BMY,2023-11-02,15:38:24,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $54.00/Share From $68.00 by Daiwa Capital,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $54.00/Share From $68.00 by Daiwa Capital
BMY,2023-11-06,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Clinical trial data,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
BMY,2023-11-06,11:59:00,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data from -3-
BMY,2023-11-06,11:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,"Bristol-Myers Squibb Co.: APPRAISE-2, a placebo-controlled clinical trial of apixaban",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data from -3-
BMY,2023-11-06,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data from -4-
BMY,2023-11-06,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Clinical trial data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
BMY,2023-11-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2023-11-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,"Bristol-Myers Squibb Co.: APPRAISE-2, a placebo-controlled clinical trial of apixaban",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2023-11-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Bristol-Myers Squibb Co.: Through collaborations with non-profit organizations, the Alliance aims to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2023-11-06,12:00:01,94637C,Bristol-Myers Squibb Co.,94,0.34,products-services,,Bristol Myers Squibb has acquired Orum's ORM-6151,PRESS-RELEASE,Business Wire,Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb
BMY,2023-11-06,12:10:49,94637C,Bristol-Myers Squibb Co.,95,0.34,products-services,,Bristol Myers Squibb has acquired Orum's ORM-6151,PRESS-RELEASE,Dow Jones Newswires,Press Release: Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb
BMY,2023-11-08,14:00:02,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Tempus Announces Research Collaboration with Bristol Myers Squibb to,PRESS-RELEASE,Business Wire,Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches
BMY,2023-11-09,10:25:09,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Initiated at Hold by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Hold by Deutsche Bank
BMY,2023-11-09,10:25:09,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $55.00/Share by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $55.00/Share by Deutsche Bank
BMY,2023-11-09,15:14:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2023-11-09,15:14:00,94637C,Bristol-Myers Squibb Co.,100,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2023-11-09,15:14:01,94637C,Bristol-Myers Squibb Co.,96,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2023-11-09,15:14:01,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
BMY,2023-11-09,15:14:53,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Breyanzi,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Breyanzi) for Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BMY,2023-11-09,15:27:10,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol Myers started at hold with $55 stock price target at Deutsche Bank,FULL-ARTICLE,MarketWatch,MW Bristol Myers started at hold with $55 stock price target at Deutsche Bank
BMY,2023-11-09,15:38:32,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Expanded Breyanzi Label
BMY,2023-11-09,15:53:32,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Expanded Breyanzi Label
BMY,2023-11-15,14:01:42,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Neutral From Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Neutral From Overweight by Cantor Fitzgerald
BMY,2023-11-15,14:01:42,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $55.00/Share From $68.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $55.00/Share From $68.00 by Cantor Fitzgerald
BMY,2023-11-15,18:00:05,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers Squibb Sign Power Purchase Agreements with National Grid,PRESS-RELEASE,PR Newswire,Fujifilm and Bristol Myers Squibb Sign Power Purchase Agreements with National Grid Renewables
BMY,2023-11-16,10:57:35,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Bristol Myers's $4.1 billion acquisition of Turning Point Therapeutics,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Bet on Turning Point Pays Off -- Market Talk
BMY,2023-11-17,15:46:12,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bristol-Myers Squibb Co.: Virtual power purchase agreements,PRESS-RELEASE,DJ Global Press Release Wire,How Is BMS Making Progress on Its Renewable Energy Goals?
BMY,2023-11-17,15:46:12,94637C,Bristol-Myers Squibb Co.,99,0.46,equity-actions,,Bms' VPPAs invest in solar power,PRESS-RELEASE,DJ Global Press Release Wire,How Is BMS Making Progress on Its Renewable Energy Goals?
BMY,2023-11-19,08:35:17,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2023 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 3Q 2023 (BMY)"
BMY,2023-11-20,13:35:52,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb and 2seventy bio are jointly developing the cell therapy,FULL-ARTICLE,MarketWatch,"MW Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment"
BMY,2023-11-20,13:35:52,94637C,Bristol-Myers Squibb Co.,100,-0.11,products-services,,"Abecma is facing increasing competition, including from Johnson & Johnson (JNJ)",FULL-ARTICLE,MarketWatch,"MW Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment"
BMY,2023-11-20,19:01:25,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA
BMY,2023-11-20,19:16:25,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA
BMY,2023-11-22,00:02:15,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Dir Samuels II Buys 8,500 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Dir Samuels II Buys 8,500 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-11-28,11:30:05,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"In 2021, Avidity announced a research collaboration with MyoKardia",PRESS-RELEASE,PR Newswire,Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC(TM) Platform Technology
BMY,2023-11-28,11:30:05,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,"In 2021, Avidity announced a research collaboration with MyoKardia",PRESS-RELEASE,Dow Jones Newswires,Press Release: Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC(TM) Platform Technology
BMY,2023-11-28,11:33:41,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Cardiovascular Collaboration With Bristol Myers Squibb for,NEWS-FLASH,Dow Jones Newswires,Avidity Biosciences Announces Expansion of Cardiovascular Collaboration With Bristol Myers Squibb for Up to Five Targets Utilizing Avidity's Proprietary AOC Platform Technology
BMY,2023-11-28,11:37:32,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Bristol Myers Squibb and Avidity to expand cardiovascular collaboration,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb and Avidity to expand cardiovascular collaboration
BMY,2023-11-28,11:46:13,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Of expanded collaboration with Bristol Myers,FULL-ARTICLE,MarketWatch,MW Avidity's stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments
BMY,2023-11-28,11:46:13,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Of Expanded Collaboration With Bristol Myers,FULL-ARTICLE,Dow Jones Newswires,Avidity's Stock Soars On News Of Expanded Collaboration With Bristol Myers That Includes Potential To Receive Up To $2.2 Billion In Milestone Payments -- MarketWatch
BMY,2023-11-28,11:51:03,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Bristol Myers Squibb to Take Stake in Avidity Biosciences,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb to Take Stake in Avidity Biosciences, Expand Partnership"
BMY,2023-11-28,12:06:03,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Bristol Myers Squibb to Take Stake in Avidity Biosciences,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb to Take Stake in Avidity Biosciences, Expand Partnership"
BMY,2023-11-28,13:33:17,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,Cardiovascular collaboration with Bristol Myers Squibb Co. in,FULL-ARTICLE,MarketWatch,MW Avidity's stock rockets on Bristol Myers deal that could mean $2.2 billion in milestone payments
BMY,2023-11-30,23:33:05,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Ceo Boerner Buys 3,071 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Boerner Buys 3,071 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-12-01,08:00:03,94637C,Bristol-Myers Squibb Co.,100,-0.57,labor-issues,,Bristol Myers announced CEO Giovanni Caforio would step down,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Stock Is Slumping. One Director Bought Up Shares. -- Barrons.com
BMY,2023-12-01,18:56:42,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Bristol Myers Squibb CEO Chris Boerner Buys Up Stock,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb CEO Chris Boerner Buys Up Stock -- Barrons.com
BMY,2023-12-02,02:30:24,94637C,Bristol-Myers Squibb Co.,99,-0.57,labor-issues,,Bristol Myers announced CEO Giovanni Caforio would step down,FULL-ARTICLE,Barron's,Bristol Myers Director Buys the Slumping Stock -- Barron's
BMY,2023-12-02,02:30:24,94637C,Bristol-Myers Squibb Co.,99,-0.57,labor-issues,,Bristol Myers announced CEO Giovanni Caforio would step down,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Director Buys the Slumping Stock
BMY,2023-12-05,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
BMY,2023-12-05,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,products-services,,Bristol-Myers Squibb Co.: U.S. Food and Drug Administration Accepts for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
BMY,2023-12-05,12:02:48,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review for Opdivo Plus Chemotherapy for First-Line Unresectable or Metastatic Urothelial Carcinoma >BMY
BMY,2023-12-05,12:25:40,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Opdivo-Chemotherapy Combo in Bladder Cancer
BMY,2023-12-05,12:40:40,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Opdivo-Chemotherapy Combo in Bladder Cancer
BMY,2023-12-05,23:22:21,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Ceo Boerner Acquires 1,288 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CEO Boerner Acquires 1,288 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-12-05,23:23:35,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 5,062 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 5,062 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-12-05,23:24:24,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Plenge Acquires 342 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Plenge Acquires 342 Of Bristol-Myers Squibb Co >BMY
BMY,2023-12-06,13:30:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Is expanding its strategic collaboration with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research and Development
BMY,2023-12-06,13:38:14,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,A strategic partnership with BMS to,PRESS-RELEASE,Dow Jones Newswires,Press Release: IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research and Development
BMY,2023-12-06,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Announces Dividend Increase,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Dividend Increase >BMY
BMY,2023-12-06,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Announces Dividend Increase,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2023-12-06,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2023-12-06,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on February 1, 2024, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend Increase
BMY,2023-12-06,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.62,dividends,up,Bristol Myers Squibb Announces Dividend Increase,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2023-12-06,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2023-12-06,21:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on February 1, 2024, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend Increase
BMY,2023-12-06,21:16:44,94637C,Bristol-Myers Squibb Co.,100,0.4,dividends,up,Bristol-Myers Squibb Raises Quarterly Dividend to 60c Vs. 50c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Raises Quarterly Dividend to 60c Vs. 50c >BMY
BMY,2023-12-06,21:28:11,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol-Myers Squibb Raises Quarterly Dividend to 60c Vs. 57c,NEWS-FLASH,Dow Jones Newswires,"Correct: Bristol-Myers Squibb Raises Quarterly Dividend to 60c Vs. 57c, Not 50c >BMY"
BMY,2023-12-06,21:37:12,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,"Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents"
BMY,2023-12-06,21:37:12,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Co.: The company also declared a quarterly dividend of 50 cents per share,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents"
BMY,2023-12-06,21:52:11,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,"Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents"
BMY,2023-12-06,21:52:11,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol-Myers Squibb Co.: The company also declared a quarterly dividend of 50 cents per share,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents"
BMY,2023-12-06,22:14:21,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol Myers Squibb raises dividend by 5.3%,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb raises dividend by 5.3%
BMY,2023-12-06,22:14:21,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Co. (BMY) said late Wednesday that its board has declared a quarterly dividend of 60 cents,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb raises dividend by 5.3%
BMY,2023-12-06,22:14:21,94637C,Bristol-Myers Squibb Co.,100,0.38,dividends,up,Bristol Myers Squibb Raises Dividend By 5.3%,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Raises Dividend By 5.3% -- MarketWatch
BMY,2023-12-06,22:14:21,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb Co. (BMY) said late Wednesday that its board has declared a quarterly dividend of 60 cents,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Raises Dividend By 5.3% -- MarketWatch
BMY,2023-12-07,11:30:00,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization >BMY
BMY,2023-12-07,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
BMY,2023-12-07,11:30:01,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,approved,Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
BMY,2023-12-07,11:32:11,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,,Bristol Myers announces additional $3 bln share buyback program,FULL-ARTICLE,MarketWatch,MW Bristol Myers announces additional $3 bln share buyback program
BMY,2023-12-07,11:34:46,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers adds $3 billion to share buyback program,FULL-ARTICLE,MarketWatch,MW Bristol Myers adds $3 billion to share buyback program to boost total to about $5 billion
BMY,2023-12-07,11:34:46,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers Adds $3 Billion To Share Buyback Program,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Adds $3 Billion To Share Buyback Program To Boost Total To About $5 Billion -- MarketWatch
BMY,2023-12-07,11:41:19,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers Adds $3 Billion to Stock Buyback Program,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Adds $3 Billion to Stock Buyback Program
BMY,2023-12-07,11:56:19,94637C,Bristol-Myers Squibb Co.,100,0.59,equity-actions,extended,Bristol Myers Adds $3 Billion to Stock Buyback Program,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Adds $3 Billion to Stock Buyback Program
BMY,2023-12-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Phase 3 CheckMate -3-
BMY,2023-12-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Phase 3 CheckMate -3-
BMY,2023-12-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Phase 3 CheckMate -4-
BMY,2023-12-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2023-12-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2023-12-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -4-
BMY,2023-12-07,17:01:24,94637C,Bristol-Myers Squibb Co.,98,0.0,investor-relations,,Bristol-Myers Squibb Co.: the company's Q3 earnings call,PRESS-RELEASE,GlobeNewswire,"BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights' Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake"
BMY,2023-12-07,17:01:24,94637C,Bristol-Myers Squibb Co.,98,0.57,products-services,granted,Sotyktu received FDA approval in September 2022,PRESS-RELEASE,GlobeNewswire,"BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights' Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake"
BMY,2023-12-07,23:07:31,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Ceo Boerner Buys 2,000 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Boerner Buys 2,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2023-12-09,22:00:00,94637C,Bristol-Myers Squibb Co.,92,0.84,products-services,positive,Bristol-Myers Squibb Co.: New data confirm findings consistent with interim analysis,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Nave Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
BMY,2023-12-11,02:26:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Breyanzi,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-12-11,02:26:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: TRANSCEND FL is the largest clinical trial evaluating a CAR,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-12-11,02:26:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Results from the third,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-12-11,02:26:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents New Data at ASH -2-
BMY,2023-12-11,02:26:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,filed,Bristol-Myers Squibb Co.: A supplemental Biologics License Application for Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-12-11,02:26:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: TRANSCEND FL is the largest clinical trial evaluating a CAR,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-12-11,02:26:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Results from the third,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
BMY,2023-12-11,02:26:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents New -2-
BMY,2023-12-11,02:45:44,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers: Phase 2 Study Evaluating Breyanzi,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: Phase 2 Study Evaluating Breyanzi in Patients With Relapsed or Refractory Follicular Lymphoma >BMY
BMY,2023-12-11,12:30:00,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
BMY,2023-12-11,12:30:10,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
BMY,2023-12-11,12:30:12,94637C,Bristol-Myers Squibb Co.,100,0.34,products-services,,Agenus to Receive $25 M Milestone Payment From Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,Agenus to Receive $25 M Milestone Payment From Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
BMY,2023-12-11,21:15:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Systimmune and Bristol Myers Squibb Announce a Global Strategic Collaboration,PRESS-RELEASE,Business Wire,SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
BMY,2023-12-11,21:15:01,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Systimmune and Bristol Myers Squibb Announce a Global Strategic Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
BMY,2023-12-11,21:15:24,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Systimmune and Bristol Myers Squibb Announce Global Strategic Collaboration,NEWS-FLASH,Dow Jones Newswires,SystImmune and Bristol Myers Squibb Announce Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
BMY,2023-12-12,01:04:49,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers: Phase 3 Study of Abecma Shows,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: Phase 3 Study of Abecma Shows Sustained Progression-Free Survival Vs Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma >BMY
BMY,2023-12-12,01:30:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Updated data from the Phase 1 study,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs"
BMY,2023-12-12,01:30:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Updated results of the Phase 1 study of alnuctamab,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs"
BMY,2023-12-12,01:30:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Phase 1/2 study evaluating the safety and efficacy of mezigdomide,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs"
BMY,2023-12-12,01:30:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: A Phase 3 study of alnuctamab,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Data at ASH 2023 -2-
BMY,2023-12-12,01:30:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Updated data from the Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs"
BMY,2023-12-12,01:30:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Updated results of the Phase 1 study of alnuctamab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs"
BMY,2023-12-12,01:30:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Phase 1/2 study evaluating the safety and efficacy of mezigdomide,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs"
BMY,2023-12-12,01:30:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: A Phase 3 study of alnuctamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2023-12-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024"
BMY,2023-12-15,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024"
BMY,2023-12-15,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024"
BMY,2023-12-15,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,Bristol-Myers Squibb Co.: Those unable to register can access the live conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024"
BMY,2023-12-22,11:32:11,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb Reaches Deal to Buy Karuna Therapeutics for $14 Billion,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Reaches Deal to Buy Karuna Therapeutics for $14 Billion -- WSJ
BMY,2023-12-22,11:32:11,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Karuna Therapeutics for $14 Billion -- WSJ,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Buy Karuna Therapeutics for $14 Billion -- WSJ
BMY,2023-12-22,11:55:26,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,Bristol Myers Squibb Co. (BMY) has reached an agreement to buy the drug developer in a deal valued at $14 billion,FULL-ARTICLE,Dow Jones Newswires,Karuna Therapeutics' Stock Rockets Into Record Territory After Report Bristol Myers' $14 Billion Buyout Agreement -- MarketWatch
BMY,2023-12-22,11:55:26,94637C,Bristol-Myers Squibb Co.,94,0.62,acquisitions-mergers,,Bristol Myers Squibb Co. (BMY) has reached an agreement to buy the drug developer in a deal valued at $14 billion,FULL-ARTICLE,MarketWatch,MW Karuna Therapeutics' stock rockets into record territory after report Bristol Myers' $14 billion buyout agreement
BMY,2023-12-22,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,Proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience -2-
BMY,2023-12-22,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience -2-
BMY,2023-12-22,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 42(nd) Annual Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present at J.P. Morgan's 42(nd) Annual Healthcare Conference
BMY,2023-12-22,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 42nd Annual Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present at J.P. Morgan's 42nd Annual Healthcare Conference
BMY,2023-12-22,12:02:23,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:02:23,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:05:01,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,Proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens -2-
BMY,2023-12-22,12:02:23,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:02:23,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,Proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens -2-
BMY,2023-12-22,12:02:23,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens -2-
BMY,2023-12-22,12:05:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:05:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:05:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:05:00,94637C,Bristol-Myers Squibb Co.,99,0.55,acquisitions-mergers,interest,Proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience -2-
BMY,2023-12-22,12:05:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens Neuroscience -2-
BMY,2023-12-22,12:05:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:05:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:05:01,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BMY,2023-12-22,12:05:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens -2-
BMY,2023-12-22,12:05:16,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buys Karuna Therapeutics in $14 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Buys Karuna Therapeutics in $14 Billion Pharma Deal: Report -- Barrons.com
BMY,2023-12-22,13:31:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bmy Acquires PRTC Founded Entity Karuna for $14B,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC BMY Acquires PRTC Founded Entity Karuna for $14B
BMY,2023-12-22,13:31:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC BMY Acquires PRTC Founded Entity Karuna for $14B
BMY,2023-12-22,13:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC BMY Acquires PRTC Founded Entity Karuna for $14B
BMY,2023-12-22,13:31:01,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET",PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC BMY Acquires PRTC Founded Entity Karuna for $14B
BMY,2023-12-22,13:31:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bmy Acquires PRTC,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC BMY Acquires PRTC Founded -2-
BMY,2023-12-22,13:31:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bmy Acquires PRTC,PRESS-RELEASE,LSE Regulatory News Service (RNS),PureTech Health PLC BMY Acquires PRTC Founded -3-
BMY,2023-12-22,14:06:53,94637C,Bristol-Myers Squibb Co.,93,0.62,acquisitions-mergers,,Bristol Myers Squibb announced its $14 billion acquisition of Karuna Therapeutics on,FULL-ARTICLE,Dow Jones Newswires,Karuna Stock Soars On Bristol Myers' $14 Billion Takeover -- IBD
BMY,2023-12-22,14:13:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Karuna Therapeutics To Be Acquired By Bristol Myers Squibb For $14 Billion,NEWS-FLASH,Dow Jones Newswires,PureTech Founded Entity Karuna Therapeutics To Be Acquired By Bristol Myers Squibb For $14 Billion >PRTC.LN
BMY,2023-12-22,14:13:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion,PRESS-RELEASE,Business Wire,PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
BMY,2023-12-22,14:13:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
BMY,2023-12-22,14:13:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
BMY,2023-12-22,14:13:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
BMY,2023-12-22,14:13:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
BMY,2023-12-22,14:13:01,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
BMY,2023-12-22,15:21:56,94637C,Bristol-Myers Squibb Co.,96,0.62,acquisitions-mergers,,Bristol Myers Squibb announced its $14 billion acquisition of Karuna Therapeutics on,FULL-ARTICLE,Dow Jones Newswires,Karuna Stock Catapults 47% And Breaks Out On Bristol Myers' $14 Billion Buyout -- IBD
BMY,2023-12-22,15:45:13,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Karuna Therapeutics for $14 Billion,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers to Buy Karuna Therapeutics for $14 Billion
BMY,2023-12-22,16:00:13,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Karuna Therapeutics for $14 Billion,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers to Buy Karuna Therapeutics for $14 Billion
BMY,2023-12-23,07:16:33,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers To Buy Karuna For $14 Billion,FULL-ARTICLE,Dow Jones Newswires,EXCHANGE --- Bristol-Myers To Buy Karuna For $14 Billion ---- By Jonathan D. Rockoff
BMY,2023-12-23,07:32:08,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers To Buy Karuna For $14 Billion -- WSJ,FULL-ARTICLE,Wall Street Journal,Bristol-Myers To Buy Karuna For $14 Billion -- WSJ
BMY,2023-12-26,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,"Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,11:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Adds Premier -2-
BMY,2023-12-26,12:00:13,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb to Acquire RayzeBio for $62.50 Per Shr in Cash,NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Squibb to Acquire RayzeBio for $62.50 Per Shr in Cash, for a Total Equity Value of Approximately $4.1 B >BMY"
BMY,2023-12-26,12:05:08,94637C,Bristol-Myers Squibb Co.,100,0.55,acquisitions-mergers,interest,Bristol Myers Squibb bid to buy RayzeBio,FULL-ARTICLE,MarketWatch,MW Bristol Myers Squibb bid to buy RayzeBio represents a premium of more than 100%
BMY,2023-12-26,12:11:24,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to buy RayzeBio for,FULL-ARTICLE,MarketWatch,"MW Bristol Myers to buy RayzeBio for more than 100% premium, in a deal valued at $4.1 billion"
BMY,2023-12-26,12:11:24,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers To Buy RayzeBio For,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers To Buy RayzeBio For More Than 100% Premium, In A Deal Valued At $4.1 Billion -- MarketWatch"
BMY,2023-12-26,12:11:42,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,"Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,12:11:42,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,12:11:42,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Adds Premier -2-
BMY,2023-12-26,12:13:25,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,"Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement",PRESS-RELEASE,GlobeNewswire,Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,12:13:25,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash,PRESS-RELEASE,GlobeNewswire,Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,12:13:25,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,GlobeNewswire,Bristol Myers Squibb Adds Premier -2-
BMY,2023-12-26,12:13:26,94637C,Bristol-Myers Squibb Co.,99,0.63,acquisitions-mergers,,"Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,12:13:26,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
BMY,2023-12-26,12:13:26,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Non-GAAP earnings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Adds Premier -2-
BMY,2023-12-26,12:16:27,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion -- Barrons.com
BMY,2023-12-26,12:16:29,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Buy RayzeBio for $4.1 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb to Buy RayzeBio for $4.1 Billion
BMY,2023-12-26,12:31:29,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Buy RayzeBio for $4.1 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb to Buy RayzeBio for $4.1 Billion
BMY,2023-12-26,12:34:01,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Bristol Myers will pay $62.50 a share for RayzeBio,FULL-ARTICLE,Dow Jones Newswires,RayzeBio Shares Soar Premarket on Takeover by Bristol Myers
BMY,2023-12-26,12:49:01,94637C,Bristol-Myers Squibb Co.,92,0.62,acquisitions-mergers,,Bristol Myers will pay $62.50 a share for RayzeBio,FULL-ARTICLE,Dow Jones Newswires,RayzeBio Shares Soar Premarket on Takeover by Bristol Myers
BMY,2023-12-26,14:58:56,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Buy RayzeBio,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb to Buy RayzeBio
BMY,2023-12-26,15:13:56,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb to Buy RayzeBio,FULL-ARTICLE,Dow Jones Newswires,Trending: Bristol Myers Squibb to Buy RayzeBio
BMY,2023-12-26,15:47:48,94637C,Bristol-Myers Squibb Co.,98,0.62,acquisitions-mergers,,Bristol Myers Squibb said Tuesday it would acquire cancer drug developer RayzeBio in a deal valued at $4.1 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100% -- IBD
BMY,2023-12-26,17:33:30,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion -- WSJ,FULL-ARTICLE,Dow Jones Newswires,Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion -- WSJ
BMY,2023-12-26,23:56:56,94637C,Bristol-Myers Squibb Co.,98,0.62,acquisitions-mergers,,Bristol Myers Squibb said Tuesday it would acquire cancer drug developer RayzeBio in a deal valued at $4.1 billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100% -- IBD
BMY,2023-12-27,07:08:13,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Acquires RayzeBio ---- By,FULL-ARTICLE,Dow Jones Newswires,Business News: Bristol-Myers Acquires RayzeBio ---- By Jared S. Hopkins and Colin Kellaher
BMY,2023-12-27,07:32:10,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Acquires RayzeBio -- WSJ,FULL-ARTICLE,Wall Street Journal,Bristol-Myers Acquires RayzeBio -- WSJ
BMY,2023-12-27,11:00:40,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Buy by B of A Securities
BMY,2023-12-27,11:00:40,94637C,Bristol-Myers Squibb Co.,100,-0.62,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $68.00/Share From $72.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $68.00/Share From $72.00 by B of A Securities
BMY,2023-12-27,20:54:23,94637C,Bristol-Myers Squibb Co.,100,-0.38,credit-ratings,downgrade,S&PGR Downgrades Bristol-Myers To 'A,NEWS-FLASH,Dow Jones Newswires,S&PGR Downgrades Bristol-Myers To 'A'; Outlook Stable
BMY,2023-12-27,20:54:23,94637C,Bristol-Myers Squibb Co.,100,-0.38,credit-ratings,downgrade,S&PGR Downgrades Bristol-Myers To 'A,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Downgrades Bristol-Myers To 'A'; Outlook Stable
BMY,2023-12-27,20:54:23,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol-Myers Squibb Co. (BMY) announced the acquisition of Karuna Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Downgrades Bristol-Myers To 'A'; Outlook Stable
BMY,2023-12-27,20:54:25,94637C,Bristol-Myers Squibb Co.,100,-0.38,credit-ratings,downgrade,S&P Cuts Bristol-Myers Squibb Co. Rtg To A From A+,NEWS-FLASH,Dow Jones Newswires,S&P Cuts Bristol-Myers Squibb Co. Rtg To A From A+; Outlk Stable
BMY,2023-12-27,20:54:33,94637C,Bristol-Myers Squibb Co.,100,-0.61,credit-ratings,downgrade,S&PGR Downgrades Bristol-Myers To,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Downgrades Bristol-Myers To -2-
BMY,2023-12-27,21:27:37,94637C,Bristol-Myers Squibb Co.,100,-0.38,credit-ratings,downgrade,S&P Cuts Bristol Myers Squibb to A,FULL-ARTICLE,Dow Jones Newswires,S&P Cuts Bristol Myers Squibb to A With Stable Outlook -- Market Talk
BMY,2023-12-27,21:27:37,94637C,Bristol-Myers Squibb Co.,100,-0.38,credit-ratings,downgrade,S&P Cuts Bristol Myers Squibb to A,FULL-ARTICLE,Dow Jones Newswires,S&P Cuts Bristol Myers Squibb to A With Stable Outlook -- Market Talk
BMY,2023-03-15,07:00:12,97C893,Bloomsbury Publishing PLC,99,0.46,equity-actions,,Bloomsbury Publishing PLC: our investment in high quality content,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2023-03-15,07:00:12,97C893,Bloomsbury Publishing PLC,99,0.61,products-services,increase,Bloomsbury Publishing PLC: We have seen strong demand,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2023-03-15,07:00:12,97C893,Bloomsbury Publishing PLC,99,0.52,products-services,,Bloomsbury Publishing PLC: We have launched a new platform for,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2023-03-15,07:00:12,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: our preliminary results,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2023-03-15,07:28:00,97C893,Bloomsbury Publishing PLC,100,0.79,revenues,above-expectations,"Bloomsbury Publishing Sees FY 2023 Revenue, Profit Ahead of Views",FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Sees FY 2023 Revenue, Profit Ahead of Views"
BMY,2023-03-15,07:28:00,97C893,Bloomsbury Publishing PLC,100,0.0,revenues,,Bloomsbury Publishing PLC said Wednesday that it expects to report revenue and profit materially ahead of views for fiscal 2023,FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Sees FY 2023 Revenue, Profit Ahead of Views"
BMY,2023-03-15,12:00:00,97C893,Bloomsbury Publishing PLC,100,0.79,revenues,above-expectations,"Bloomsbury Publishing Sees FY 2023 Revenue, Profit Ahead of Views",FULL-ARTICLE,Dow Jones Newswires,"Trainline FY 2023 Boosted by International Ticket Sales; Bloomsbury Publishing Sees FY 2023 Revenue, Profit Ahead of Views"
BMY,2023-03-15,12:00:00,97C893,Bloomsbury Publishing PLC,100,0.0,revenues,,Bloomsbury PUBLISHING PLC said it expects to report revenue and profit materially ahead of views for fiscal 2023,FULL-ARTICLE,Dow Jones Newswires,"Trainline FY 2023 Boosted by International Ticket Sales; Bloomsbury Publishing Sees FY 2023 Revenue, Profit Ahead of Views"
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Audited Preliminary Results for the year ended 28 February 2023,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.56,revenues,up,Bloomsbury Publishing PLC: Our international revenues have increased to 73% of,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.38,dividends,up,Bloomsbury Publishing PLC: Final dividend up 10%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 30.56p 25.94p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 24.54p 20.33p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: 3) Organic revenue for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.38,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 15% to GBP25.4 million (2021/22: GBP22.2 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: o Goal: Expand international revenues.,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: US revenues increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.44,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 25% to GBP8.2 million (2021/22: GBP6.6 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.62,acquisitions-mergers,,Bloomsbury Publishing PLC: The acquisition of ABC-CLIO increased the depth and breadth of,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,97,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year - - - - - -,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,97,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year 20,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,94,-0.13,equity-actions,up,Bloomsbury Publishing PLC: Print costs are increased by 3% from 2023/2024,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -5-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 52,692",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 17,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 15,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,93,0.0,revenues,,Bloomsbury Publishing PLC: During the year sales,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,93,0.0,assets,,Bloomsbury Publishing PLC: Total assets,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,93,0.0,equity-actions,,Bloomsbury Publishing PLC: Factors affecting tax charge for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,93,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 24.54p 20.33p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 30.56p 25.94p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,95,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2023-05-31,06:28:29,97C893,Bloomsbury Publishing PLC,100,0.7,earnings,above-expectations,"Bloomsbury Publishing FY 2023 Profit, Revenue Beat Expectations",FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing FY 2023 Profit, Revenue Beat Expectations"
BMY,2023-05-31,11:00:00,97C893,Bloomsbury Publishing PLC,100,0.7,earnings,above-expectations,"Bloomsbury Publishing FY 2023 Profit, Revenue Beat Views",FULL-ARTICLE,Dow Jones Newswires,"WH Smith Raises FY 2023 Guidance On Revenue Jump; Bloomsbury Publishing FY 2023 Profit, Revenue Beat Views"
BMY,2023-05-31,11:00:00,97C893,Bloomsbury Publishing PLC,100,0.59,earnings,positive,Bloomsbury PUBLISHING said fiscal 2023 pretax profit,FULL-ARTICLE,Dow Jones Newswires,"WH Smith Raises FY 2023 Guidance On Revenue Jump; Bloomsbury Publishing FY 2023 Profit, Revenue Beat Views"
BMY,2023-05-31,13:04:37,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: the Company's Preliminary Results for the year ended 28 February 2023,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Investor Presentation
BMY,2023-06-02,10:50:10,97C893,Bloomsbury Publishing PLC,99,0.52,insider-trading,,"Bloomsbury Publishing PLC: The Company announces that John Bason, Non-Executive Director, has purchased 10,526 ordinary shares of GBP0.0125",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Director/PDMR Shareholding
BMY,2023-06-23,13:29:02,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Global staff turnover,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -4-
BMY,2023-07-18,06:00:07,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: Sales growth of 9% in the first,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2023-07-18,06:00:07,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: The results for the six months,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2023-07-18,06:16:18,97C893,Bloomsbury Publishing PLC,100,0.41,revenues,up,Bloomsbury Publishing Four-Month Sales Rose 9%,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Four-Month Sales Rose 9%
BMY,2023-07-18,16:13:34,97C893,Bloomsbury Publishing PLC,99,0.0,investor-relations,,Bloomsbury Publishing PLC: Results of the 2023 Annual General Meeting,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Results of the 2023 Annual General Meeting
BMY,2023-08-22,07:00:04,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury reported record annual revenues,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Bloomsbury enjoys bestseller success
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.64,earnings,up,Bloomsbury Publishing PLC: Record first half earnings,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.62,dividends,up,Bloomsbury Publishing PLC: Interim dividend increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: The Consumer division revenue grew by 17%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: our overall dividend guidance for the full year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: GBP12.9 GBP11.1 Profit before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 13.66 pence 12.30 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.63,revenues,up,Bloomsbury Publishing PLC: Strong Consumer revenue growth of 17%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.38,earnings,up,Bloomsbury Publishing PLC: Profit before taxation grew by 8% to GBP14.0 million (2022: GBP12.9 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.72,revenues,up,Bloomsbury Publishing PLC: Special Interest revenue increased by 7% to GBP10.9 million (2022: GBP10.1 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: US revenues increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation was GBP3.7 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Academic & Professional revenues were GBP36.4 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.44,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 27% to GBP11.0 million (2022: GBP8.7 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,-0.65,earnings,negative,Bloomsbury Publishing PLC: Loss before taxation was GBP0.1 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.42,revenues,up,Bloomsbury Publishing PLC: Children's revenue increased by 22% to GBP61.7 million (2022: GBP50.6 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.46,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 29% to GBP11.1 million (2022: GBP8.7 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,"Bloomsbury Publishing PLC: In line with this rebalancing, the Board has declared an interim dividend of 3.70 pence per share",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 77,700",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,-0.13,equity-actions,up,Bloomsbury Publishing PLC: Print costs are increased by 3% from 2023/2024,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 33,876",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 24,154",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 17,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Basic earnings per share 13.81p 12.49p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.0,earnings,,Bloomsbury Publishing PLC: Adjusted basic earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2023-10-26,08:53:00,97C893,Bloomsbury Publishing PLC,100,0.64,earnings,up,Bloomsbury Publishing Pretax Profit Rose on,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Pretax Profit Rose on Higher International sales
BMY,2023-03-15,07:00:12,97C893,Bloomsbury Publishing PLC,99,0.46,equity-actions,,Bloomsbury Publishing PLC: our investment in high quality content,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2023-03-15,07:00:12,97C893,Bloomsbury Publishing PLC,99,0.61,products-services,increase,Bloomsbury Publishing PLC: We have seen strong demand,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2023-03-15,07:00:12,97C893,Bloomsbury Publishing PLC,99,0.52,products-services,,Bloomsbury Publishing PLC: We have launched a new platform for,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2023-03-15,07:00:12,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: our preliminary results,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update
BMY,2023-03-15,07:28:00,97C893,Bloomsbury Publishing PLC,100,0.79,revenues,above-expectations,"Bloomsbury Publishing Sees FY 2023 Revenue, Profit Ahead of Views",FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Sees FY 2023 Revenue, Profit Ahead of Views"
BMY,2023-03-15,07:28:00,97C893,Bloomsbury Publishing PLC,100,0.0,revenues,,Bloomsbury Publishing PLC said Wednesday that it expects to report revenue and profit materially ahead of views for fiscal 2023,FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Sees FY 2023 Revenue, Profit Ahead of Views"
BMY,2023-03-15,12:00:00,97C893,Bloomsbury Publishing PLC,100,0.79,revenues,above-expectations,"Bloomsbury Publishing Sees FY 2023 Revenue, Profit Ahead of Views",FULL-ARTICLE,Dow Jones Newswires,"Trainline FY 2023 Boosted by International Ticket Sales; Bloomsbury Publishing Sees FY 2023 Revenue, Profit Ahead of Views"
BMY,2023-03-15,12:00:00,97C893,Bloomsbury Publishing PLC,100,0.0,revenues,,Bloomsbury PUBLISHING PLC said it expects to report revenue and profit materially ahead of views for fiscal 2023,FULL-ARTICLE,Dow Jones Newswires,"Trainline FY 2023 Boosted by International Ticket Sales; Bloomsbury Publishing Sees FY 2023 Revenue, Profit Ahead of Views"
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Audited Preliminary Results for the year ended 28 February 2023,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.56,revenues,up,Bloomsbury Publishing PLC: Our international revenues have increased to 73% of,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.38,dividends,up,Bloomsbury Publishing PLC: Final dividend up 10%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 30.56p 25.94p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 24.54p 20.33p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: 3) Organic revenue for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.38,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 15% to GBP25.4 million (2021/22: GBP22.2 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary Results
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: o Goal: Expand international revenues.,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: US revenues increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.44,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 25% to GBP8.2 million (2021/22: GBP6.6 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,99,0.62,acquisitions-mergers,,Bloomsbury Publishing PLC: The acquisition of ABC-CLIO increased the depth and breadth of,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -2-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,97,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year - - - - - -,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,97,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year 20,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -4-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,94,-0.13,equity-actions,up,Bloomsbury Publishing PLC: Print costs are increased by 3% from 2023/2024,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -5-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 52,692",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 17,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 15,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -6-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,93,0.0,revenues,,Bloomsbury Publishing PLC: During the year sales,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,93,0.0,assets,,Bloomsbury Publishing PLC: Total assets,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,93,0.0,equity-actions,,Bloomsbury Publishing PLC: Factors affecting tax charge for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,93,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -7-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 24.54p 20.33p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 30.56p 25.94p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2023-05-31,06:00:17,97C893,Bloomsbury Publishing PLC,95,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Audited Preliminary -8-
BMY,2023-05-31,06:28:29,97C893,Bloomsbury Publishing PLC,100,0.7,earnings,above-expectations,"Bloomsbury Publishing FY 2023 Profit, Revenue Beat Expectations",FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing FY 2023 Profit, Revenue Beat Expectations"
BMY,2023-05-31,11:00:00,97C893,Bloomsbury Publishing PLC,100,0.7,earnings,above-expectations,"Bloomsbury Publishing FY 2023 Profit, Revenue Beat Views",FULL-ARTICLE,Dow Jones Newswires,"WH Smith Raises FY 2023 Guidance On Revenue Jump; Bloomsbury Publishing FY 2023 Profit, Revenue Beat Views"
BMY,2023-05-31,11:00:00,97C893,Bloomsbury Publishing PLC,100,0.59,earnings,positive,Bloomsbury PUBLISHING said fiscal 2023 pretax profit,FULL-ARTICLE,Dow Jones Newswires,"WH Smith Raises FY 2023 Guidance On Revenue Jump; Bloomsbury Publishing FY 2023 Profit, Revenue Beat Views"
BMY,2023-05-31,13:04:37,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: the Company's Preliminary Results for the year ended 28 February 2023,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Investor Presentation
BMY,2023-06-02,10:50:10,97C893,Bloomsbury Publishing PLC,99,0.52,insider-trading,,"Bloomsbury Publishing PLC: The Company announces that John Bason, Non-Executive Director, has purchased 10,526 ordinary shares of GBP0.0125",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Director/PDMR Shareholding
BMY,2023-06-23,13:29:02,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Global staff turnover,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -4-
BMY,2023-07-18,06:00:07,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: Sales growth of 9% in the first,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2023-07-18,06:00:07,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: The results for the six months,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2023-07-18,06:16:18,97C893,Bloomsbury Publishing PLC,100,0.41,revenues,up,Bloomsbury Publishing Four-Month Sales Rose 9%,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Four-Month Sales Rose 9%
BMY,2023-07-18,16:13:34,97C893,Bloomsbury Publishing PLC,99,0.0,investor-relations,,Bloomsbury Publishing PLC: Results of the 2023 Annual General Meeting,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Results of the 2023 Annual General Meeting
BMY,2023-08-22,07:00:04,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury reported record annual revenues,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Bloomsbury enjoys bestseller success
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.64,earnings,up,Bloomsbury Publishing PLC: Record first half earnings,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.62,dividends,up,Bloomsbury Publishing PLC: Interim dividend increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: The Consumer division revenue grew by 17%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: our overall dividend guidance for the full year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: GBP12.9 GBP11.1 Profit before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 13.66 pence 12.30 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.63,revenues,up,Bloomsbury Publishing PLC: Strong Consumer revenue growth of 17%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.38,earnings,up,Bloomsbury Publishing PLC: Profit before taxation grew by 8% to GBP14.0 million (2022: GBP12.9 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.72,revenues,up,Bloomsbury Publishing PLC: Special Interest revenue increased by 7% to GBP10.9 million (2022: GBP10.1 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: US revenues increased,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation was GBP3.7 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Academic & Professional revenues were GBP36.4 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.44,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 27% to GBP11.0 million (2022: GBP8.7 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,-0.65,earnings,negative,Bloomsbury Publishing PLC: Loss before taxation was GBP0.1 million,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.42,revenues,up,Bloomsbury Publishing PLC: Children's revenue increased by 22% to GBP61.7 million (2022: GBP50.6 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.46,earnings,up,Bloomsbury Publishing PLC: Profit before taxation increased by 29% to GBP11.1 million (2022: GBP8.7 million),PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,"Bloomsbury Publishing PLC: In line with this rebalancing, the Board has declared an interim dividend of 3.70 pence per share",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 77,700",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,-0.13,equity-actions,up,Bloomsbury Publishing PLC: Print costs are increased by 3% from 2023/2024,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 33,876",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,92,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,"Bloomsbury Publishing PLC: Gross profit 24,154",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,90,-0.65,earnings,negative,Bloomsbury Publishing PLC: Profit/(loss) for the year 17,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Basic earnings per share 13.81p 12.49p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.0,earnings,,Bloomsbury Publishing PLC: Adjusted basic earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2023-10-26,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -9-
BMY,2023-10-26,08:53:00,97C893,Bloomsbury Publishing PLC,100,0.64,earnings,up,Bloomsbury Publishing Pretax Profit Rose on,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Pretax Profit Rose on Higher International sales
BMY,2025-01-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference
BMY,2025-01-03,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference
BMY,2025-01-08,11:51:27,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Buy by Truist Securities
BMY,2025-01-08,11:51:27,94637C,Bristol-Myers Squibb Co.,100,0.56,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $65.00/Share From $62.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $65.00/Share From $62.00 by Truist Securities
BMY,2025-01-13,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Discovery collaboration with Bristol Myers Squibb in,PRESS-RELEASE,GlobeNewswire,ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
BMY,2025-01-17,12:30:33,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,China's Acceptance of New Drug Application for KarXT,NEWS-FLASH,Dow Jones Newswires,Zai Lab Announces China's Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
BMY,2025-01-25,15:02:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Results from -4-
BMY,2025-01-25,15:02:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Results from -4-
BMY,2025-01-25,15:02:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Results from -4-
BMY,2025-01-27,10:36:31,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2025-01-27,10:36:31,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2025-01-27,10:36:31,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2025-01-28,12:33:41,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by Citigroup
BMY,2025-01-28,12:33:41,94637C,Bristol-Myers Squibb Co.,100,0.72,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $65.00/Share From $60.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $65.00/Share From $60.00 by Citigroup
BMY,2025-01-28,13:45:02,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept,PRESS-RELEASE,Business Wire,"Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept Biosimilar Candidate, KSHB002"
BMY,2025-01-28,13:45:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Eu-authorized reference product, ORENCIA(R)",PRESS-RELEASE,Business Wire,"Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept Biosimilar Candidate, KSHB002"
BMY,2025-01-31,11:50:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-01-31,11:50:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi(R) (lisocabtagene maraleucel; Bristol-Myers Squibb Co.:,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-01-31,11:50:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -2-
BMY,2025-01-31,11:50:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -2-
BMY,2025-01-31,11:50:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-01-31,11:50:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi(R) (lisocabtagene maraleucel; Bristol-Myers Squibb Co.:,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-01-31,11:50:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -2-
BMY,2025-01-31,11:50:01,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -2-
BMY,2025-01-31,11:50:20,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Gets Positive CHMP Opinion for CAR T Cell Therapy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Gets Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma >BMY
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Recommendation based on results of Phase 3 CheckMate -9DW clinical trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: the Company's supplemental Biologics License Application (sBLA) for Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Yervoy was granted accelerated approval by the U.S. FDA in 2020,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Recommendation based on results of Phase 3 CheckMate -9DW clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: the Company's supplemental Biologics License Application (sBLA) for Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Yervoy was granted accelerated approval by the U.S. FDA in 2020,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2025-01-31,11:59:33,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Gets Positive CHMP Opinion for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Gets Positive CHMP Opinion for Opdivo Plus Yervoy as First-Line Treatment Option for Adults With Unresectable or Advanced Hepatocellular Carcinoma >BMY
BMY,2025-01-31,12:52:43,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses"
BMY,2025-01-31,12:52:43,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses"
BMY,2025-01-31,12:52:43,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Chmp also recommended approval of Opdivo,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses"
BMY,2025-01-31,13:07:43,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses"
BMY,2025-01-31,13:07:43,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses"
BMY,2025-01-31,13:07:43,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Chmp also recommended approval of Opdivo,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses"
BMY,2025-02-04,14:15:27,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by Cantor Fitzgerald
BMY,2025-02-04,14:15:27,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $55.00/Share From $50.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $55.00/Share From $50.00 by Cantor Fitzgerald
BMY,2025-02-05,00:05:21,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Meyers Acquires 1,710 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Meyers Acquires 1,710 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-02-05,00:06:13,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Officer Hickey Acquires 6,353 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Officer Hickey Acquires 6,353 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 4Q EPS 4c,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 4Q EPS 4c >BMY
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 4Q Rev $12.34B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 4Q Rev $12.34B >BMY
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 4Q Adj EPS $1.67,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 4Q Adj EPS $1.67 >BMY
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb Sees 2025 Rev $45.5B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees 2025 Rev $45.5B >BMY
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb: 2025 Rev Outlook,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: 2025 Rev Outlook Reflects Near-Term Impact of Generics Across Revlimid, Pomalyst, Sprycel and Abraxane >BMY"
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb: 2025 Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: 2025 Rev Guidance Also Reflects an About $500 Million Expected Negative Impact to Revenue Due to Foreign Exchange >BMY
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers Squibb 4Q Growth Portfolio Revenue $6.36B, Up 21%",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb 4Q Growth Portfolio Revenue $6.36B, Up 21% >BMY"
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,"Bristol Myers Squibb 4Q Legacy Portfolio Revenue $5.98B, Down 4%",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb 4Q Legacy Portfolio Revenue $5.98B, Down 4% >BMY"
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.68,revenues,down,Bristol Myers Squibb: 4Q Legacy Portfolio Revenue Lower,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: 4Q Legacy Portfolio Revenue Lower Vs Yr-Ago Primarily Due to Impact of Generics on Sprycel, Revlimid, Abraxane and Pomalyst, Partially Offset by Higher Demand for Eliquis >BMY"
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 4Q U.S. Revenue Rose 9% to $8.6B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 4Q U.S. Revenue Rose 9% to $8.6B >BMY
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.7B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.7B >BMY
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb's 4Q Beats Forecasts,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol Myers Squibb posted higher quarterly revenue,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,"Opdivo posted fourth-quarter net income of $72 million, or 4 cents a share",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,Higher demand for Opdivo and other growth-portfolio drugs,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Fourth Quarter Revenues were $12.3 Billion, Increasing 8%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: GAAP Loss Per Share was $(4.41),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Full-Year Revenues were $48.3 Billion, Increasing 7%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"The Fourth Quarter, Including U.S. Approval of Opdivo",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Provides 2025 Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Non-GAAP EPS Range of $6.55 to $6.85,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,"Higher demand for Eliquis, partially offset by the impact of generics",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,revenues,,Bristol-Myers Squibb Co.: FOURTH QUARTER PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.65,revenues,up,Bristol-Myers Squibb Co.: Growth Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,European Medicines Agency (EMA) recommended approval of Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,"Ec approved Augtyro, a next-generation tyrosine kinase inhibitor",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Administration (FDA) approved Opdivo Qvantig injection for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Ema recommended approval of Breyanzi,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: FULL-YEAR FINANCIAL RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,"Bristol Myers Squibb posted revenues of $48.3 billion, an increase of 7%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.51,products-services,increase,"Higher demand for Eliquis, partially offset by the impact of generics",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,"Bristol-Myers Squibb Co.: On a GAAP basis, income tax expense was $554 million",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: FULL-YEAR PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: FULL-YEAR PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Growth Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.51,products-services,increase,"Higher demand for Eliquis, offset by the impact of generics",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: We estimate total revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating Expenses,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $6.55-$6.85,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED DECEMBER 31, 2024",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -6-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -6-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,92,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2024",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -7-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $12,342 $11,477",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -8-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Adj EPS $1.67,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Adj EPS $1.67 >BMY
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Net $72M,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Net $72M >BMY
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q EPS 4c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q EPS 4c >BMY
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 4Q Rev $12.3B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Rev $12.3B >BMY
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Fourth Quarter Revenues were $12.3 Billion, Increasing 8%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: GAAP Loss Per Share was $(4.41),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Full-Year Revenues were $48.3 Billion, Increasing 7%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"The Fourth Quarter, Including U.S. Approval of Opdivo",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Provides 2025 Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Non-GAAP EPS Range of $6.55 to $6.85,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,"Higher demand for Eliquis, partially offset by the impact of generics",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.0,revenues,,Bristol-Myers Squibb Co.: FOURTH QUARTER PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.65,revenues,up,Bristol-Myers Squibb Co.: Growth Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,European Medicines Agency (EMA) recommended approval of Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,"Ec approved Augtyro, a next-generation tyrosine kinase inhibitor",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Administration (FDA) approved Opdivo Qvantig injection for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Ema recommended approval of Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: FULL-YEAR FINANCIAL RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,"Bristol Myers Squibb posted revenues of $48.3 billion, an increase of 7%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.51,products-services,increase,"Higher demand for Eliquis, partially offset by the impact of generics",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,"Bristol-Myers Squibb Co.: On a GAAP basis, income tax expense was $554 million",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: FULL-YEAR PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: FULL-YEAR PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Growth Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.51,products-services,increase,"Higher demand for Eliquis, offset by the impact of generics",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: We estimate total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $6.55-$6.85,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED DECEMBER 31, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,92,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $12,342 $11,477",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2025-02-06,12:13:41,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb's 4Q Beats Forecasts,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,12:13:41,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol Myers Squibb posted higher quarterly revenue,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,12:13:41,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,"Opdivo posted fourth-quarter net income of $72 million, or 4 cents a share",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,12:13:41,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,Higher demand for Opdivo and other growth-portfolio drugs,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,13:56:37,94637C,Bristol-Myers Squibb Co.,96,0.61,earnings,positive,Bristol Myers to earn $1.46 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. -- IBD
BMY,2025-02-06,15:35:37,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol Myers forecast $45.5 billion in sales,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD"
BMY,2025-02-06,15:35:37,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol Myers earned $1.67 per share,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD"
BMY,2025-02-06,15:35:37,94637C,Bristol-Myers Squibb Co.,99,0.65,acquisitions-mergers,,Company's $14 billion takeover of Karuna Therapeutics,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD"
BMY,2025-02-06,21:03:37,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol Myers forecast $45.5 billion in sales,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD"
BMY,2025-02-06,21:03:37,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol Myers earned $1.67 per share,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD"
BMY,2025-02-06,21:03:37,94637C,Bristol-Myers Squibb Co.,99,0.65,acquisitions-mergers,,Company's $14 billion takeover of Karuna Therapeutics,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD"
BMY,2025-02-07,14:38:44,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
BMY,2025-02-07,14:38:44,94637C,Bristol-Myers Squibb Co.,100,0.46,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $62.00/Share From $60.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $62.00/Share From $60.00 by Wells Fargo
BMY,2025-02-10,11:59:00,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results for Breyanzi(R) (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
BMY,2025-02-10,11:59:00,94637C,Bristol-Myers Squibb Co.,96,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results for Breyanzi(R) (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
BMY,2025-02-10,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline -2-
BMY,2025-02-10,11:59:01,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results for Breyanzi(R) (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
BMY,2025-02-10,11:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results for Breyanzi(R) (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
BMY,2025-02-10,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2025-02-10,13:04:02,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Sees Positive Results for Breyanzi in Lymphoma Trials
BMY,2025-02-10,13:19:02,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Sees Positive Results for Breyanzi in Lymphoma Trials
BMY,2025-02-11,13:00:03,94637C,Bristol-Myers Squibb Co.,100,0.47,labor-issues,,Biomedicines Appoints Elizabeth Mily to Board of Directors,PRESS-RELEASE,GlobeNewswire,Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors
BMY,2025-02-13,21:16:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 3 -4-
BMY,2025-02-13,21:16:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 3 -4-
BMY,2025-02-13,21:16:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 3 -5-
BMY,2025-02-13,21:16:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 3 -8-
BMY,2025-02-13,21:16:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -4-
BMY,2025-02-13,21:16:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -4-
BMY,2025-02-13,21:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -5-
BMY,2025-02-13,21:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -8-
BMY,2025-02-19,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo(R) Plus -3-
BMY,2025-02-19,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo(R) Plus -3-
BMY,2025-02-19,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo(R) Plus -3-
BMY,2025-02-19,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2025-02-19,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2025-02-19,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2025-02-19,13:00:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,And Receives U.S. FDA Approval For Lenalidomide,NEWS-FLASH,Dow Jones Newswires,Amneal Launches Mesalamine And Receives U.S. FDA Approval For Lenalidomide >AMRX
BMY,2025-02-19,13:00:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,And Receives U.S. FDA Approval for Lenalidomide,PRESS-RELEASE,Business Wire,Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
BMY,2025-02-19,13:00:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,And Receives U.S. FDA Approval for Lenalidomide,PRESS-RELEASE,Dow Jones Newswires,Press Release: Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
BMY,2025-02-20,00:20:51,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Buys 1,823 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Buys 1,823 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-02-20,05:30:13,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bioarctic had entered into a global license agreement with Bristol Myers Squibb,PRESS-RELEASE,Cision News,BioArctic: BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
BMY,2025-02-20,05:30:13,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bioarctic had entered into a global license agreement with Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,BioArctic: BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
BMY,2025-02-20,05:50:02,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bioarctic had entered into a global license agreement with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
BMY,2025-02-20,05:50:03,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bioarctic had entered into a global license agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
BMY,2025-02-20,05:52:52,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bioarctic had entered into a global license agreement with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
BMY,2025-02-22,00:10:40,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Chmn Boerner Buys 2,000 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Boerner Buys 2,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-02-23,08:05:50,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2024 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2024 (BMY)"
BMY,2025-02-23,23:51:02,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Innovent Biologics Inc.: NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab,PRESS-RELEASE,PR Newswire,"NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-23,23:51:02,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Innovent Biologics Inc.: The NDA for ipilimumab in combination with sintilimab,PRESS-RELEASE,PR Newswire,"NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-23,23:51:02,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Innovent Biologics Inc.: The NDA for ipilimumab in combination with sintilimab,PRESS-RELEASE,PR Newswire,"NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-23,23:51:02,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Cde has granted Breakthrough Therapy Designation (BTD) for ipilimumab,PRESS-RELEASE,PR Newswire,"NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-23,23:51:03,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Nmpa Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-23,23:51:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Innovent Biologics Inc.: The NDA for ipilimumab in combination with sintilimab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-23,23:51:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Innovent Biologics Inc.: The NDA for ipilimumab in combination with sintilimab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-23,23:51:03,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Cde has granted Breakthrough Therapy Designation (BTD) for ipilimumab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-24,11:59:00,94637C,Bristol-Myers Squibb Co.,98,0.7,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Breakthrough Therapy Designation,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application for Opdivo(R) Plus Yervoy(R) for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
BMY,2025-02-24,11:59:00,94637C,Bristol-Myers Squibb Co.,98,0.57,products-services,granted,Yervoy received approval from the U.S. FDA in July 2018,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application for Opdivo(R) Plus Yervoy(R) for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
BMY,2025-02-24,11:59:01,94637C,Bristol-Myers Squibb Co.,98,0.7,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Breakthrough Therapy Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application for Opdivo(R) Plus Yervoy(R) for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
BMY,2025-02-24,11:59:01,94637C,Bristol-Myers Squibb Co.,98,0.57,products-services,granted,Yervoy received approval from the U.S. FDA in July 2018,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application for Opdivo(R) Plus Yervoy(R) for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
BMY,2025-02-24,12:03:13,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Opdivo Plus Yervoy in Certain Patients With Colorectal Cancer >BMY
BMY,2025-02-25,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2025-02-25,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2025-03-03,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2025-03-03,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on May 1, 2025, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2025-03-03,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2025-03-03,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on May 1, 2025, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2025-03-04,06:31:03,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Evotec SE: our collaboration with Bristol Myers Squibb and the impact it has for jointly building a,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2025-03-04,06:31:03,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Evotec SE: our collaboration with Bristol Myers Squibb and the impact it has for jointly building a,PRESS-RELEASE,DGAP News,EQS-News: Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2025-03-04,06:32:03,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Evotec SE: our collaboration with Bristol Myers Squibb and the impact it has for jointly building a,PRESS-RELEASE,DGAP News,EQS-News: Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2025-03-04,06:32:03,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Evotec SE: our collaboration with Bristol Myers Squibb and the impact it has for jointly building a,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2025-03-04,06:45:35,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Evotec and Bristol Myers Squibb have been working together to,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2025-03-04,23:07:56,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Officer Hickey Acquires 1,656 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Officer Hickey Acquires 1,656 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Approval based on results of Phase 3 CheckMate -9DW clinical trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: the Company's supplemental Biologics License Application (sBLA) for Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Yervoy was granted accelerated approval,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2025-03-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-03-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-03-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2025-03-07,11:59:33,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets European Commission Approval for Opdivo Plus Yervoy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Gets European Commission Approval for Opdivo Plus Yervoy for First-Line Treatment of Adults With Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-03-07,11:59:33,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets European Commission Approval for Opdivo Plus Yervoy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Gets European Commission Approval for Opdivo Plus Yervoy for First-Line Treatment of Adults With Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-03-07,12:12:44,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets Expanded Europe OK of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Expanded Europe OK of Opdivo/Yervoy Combo in Liver Cancer
BMY,2025-03-07,12:27:44,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets Expanded Europe OK of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Expanded Europe OK of Opdivo/Yervoy Combo in Liver Cancer
BMY,2025-03-08,14:01:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
BMY,2025-03-08,14:01:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Late-Breaking Data -2-
BMY,2025-03-08,14:01:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
BMY,2025-03-08,14:01:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2025-03-11,02:17:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,2seventy Bio Enters Into Definitive Agreement To Be Acquired By Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,2seventy Bio Enters Into Definitive Agreement To Be Acquired By Bristol Myers Squibb >TSVT
BMY,2025-03-11,02:17:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb,PRESS-RELEASE,Business Wire,2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
BMY,2025-03-11,02:17:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: 2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
BMY,2025-03-11,02:19:25,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,2seventy Bio Enters Into Definitive Agreement to Be Acquired by Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,2seventy Bio Enters Into Definitive Agreement to Be Acquired by Bristol Myers Squibb
BMY,2025-03-11,02:21:07,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Bristol Myers to Acquire 2seventy Bio Shares at $5.00,NEWS-FLASH,Dow Jones Newswires,Bristol Myers to Acquire 2seventy Bio Shares at $5.00 Each in All-Cash Deal for Equity Value of About $286M >TSVT
BMY,2025-03-11,09:58:05,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,"Bristol Myers and 2seventy are partners on the gene therapy Abecma, which is approved in",FULL-ARTICLE,Dow Jones Newswires,2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers
BMY,2025-03-11,09:58:06,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,"Bristol Myers and 2seventy are partners on the gene therapy Abecma, which is approved in",FULL-ARTICLE,Dow Jones Newswires,2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers
BMY,2025-03-11,10:13:05,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,"Bristol Myers and 2seventy are partners on the gene therapy Abecma, which is approved in",FULL-ARTICLE,Dow Jones Newswires,2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers
BMY,2025-03-11,10:13:06,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,"Bristol Myers and 2seventy are partners on the gene therapy Abecma, which is approved in",FULL-ARTICLE,Dow Jones Newswires,2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers
BMY,2025-03-13,01:29:41,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Chmn Boerner Acquires 38,237 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Chmn Boerner Acquires 38,237 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:30:00,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 48,582 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 48,582 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:30:17,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Gallman Acquires 5,648 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Gallman Acquires 5,648 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:32:30,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 28,042 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Acquires 28,042 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:32:55,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Holzer Acquires 5,320 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Holzer Acquires 5,320 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:33:09,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Officer Hoch Acquires 5,198 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Officer Hoch Acquires 5,198 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:35:31,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Leung Acquires 31,008 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Leung Acquires 31,008 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:38:31,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Poole Acquires 4,891 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Poole Acquires 4,891 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:39:03,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Lenkowsky Acquires 10,619 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Lenkowsky Acquires 10,619 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:39:16,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Shanahan Acquires 13,250 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Shanahan Acquires 13,250 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:39:30,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Meyers Acquires 16,439 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Meyers Acquires 16,439 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:42:07,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Plenge Acquires 7,645 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Plenge Acquires 7,645 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025"
BMY,2025-03-13,11:11:39,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025"
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,95,0.62,products-services,positive,Breyanzi demonstrated sustained clinical benefit,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,95,0.57,products-services,granted,Breyanzi is also approved in the EU for the treatment,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Approval from the -2-
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Approval from the -2-
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,95,0.62,products-services,positive,Breyanzi demonstrated sustained clinical benefit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,95,0.57,products-services,granted,Breyanzi is also approved in the EU for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -2-
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -2-
BMY,2025-03-14,11:00:06,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets Expanded Europe Approval For Breyanzi,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets Expanded Europe Approval For Breyanzi for Relapsed or Refractory Follicular Lymphoma >BMY
BMY,2025-03-14,11:16:26,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets Expanded European Approval for Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Expanded European Approval for Breyanzi
BMY,2025-03-14,11:31:26,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets Expanded European Approval for Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Expanded European Approval for Breyanzi
BMY,2025-03-20,06:33:46,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,Bristol Myers Squibb Appoints Osama Braiwish as General Manager for,PRESS-RELEASE,PR Newswire,Bristol Myers Squibb Appoints Osama Braiwish as General Manager for Saudi Arabia & Gulf Countries
BMY,2025-03-20,06:37:14,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,Bristol Myers Squibb Appoints Osama Braiwish as General Manager for,PRESS-RELEASE,PR Newswire,Bristol Myers Squibb Appoints Osama Braiwish as General Manager for Saudi Arabia & Gulf Countries
BMY,2025-03-28,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-03-28,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig, was approved by the U.S. Food and Drug Administration (FDA)",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-03-28,12:00:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2025-03-28,12:00:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2025-03-28,12:00:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2025-03-28,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-03-28,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig, was approved by the U.S. Food and Drug Administration (FDA)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-03-28,12:00:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-03-28,12:00:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-03-28,12:00:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-03-28,12:00:28,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Gets Positive CHMP Opinion for Subcutaneous Formulation,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Gets Positive CHMP Opinion for Subcutaneous Formulation of Opdivo Across Multiple Solid Tumor Indications >BMY
BMY,2025-03-28,12:53:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo(R) (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
BMY,2025-03-28,12:53:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2025-03-28,12:53:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2025-03-28,12:53:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2025-03-28,12:53:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo(R) (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
BMY,2025-03-28,12:53:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-03-28,12:53:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-03-28,12:53:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2025-03-31,12:30:04,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation,PRESS-RELEASE,PR Newswire,Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-03-31,12:30:04,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig, was approved by the U.S. Food and Drug Administration",PRESS-RELEASE,PR Newswire,Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-03-31,12:30:05,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-03-31,12:30:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig, was approved by the U.S. Food and Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-03-31,12:33:13,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Halozyme: Bristol Myers Squibb Received Positive CHMP Opinion for Subcutaneous Formulation,NEWS-FLASH,Dow Jones Newswires,Halozyme: Bristol Myers Squibb Received Positive CHMP Opinion for Subcutaneous Formulation of Opdivo With ENHANZE Across Multiple Solid Tumor Indications
BMY,2025-04-03,21:16:40,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Shanahan Acquires 1,614 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Shanahan Acquires 1,614 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-04-08,16:12:56,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Neutral From Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Neutral From Buy by Goldman Sachs
BMY,2025-04-08,16:12:57,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $55.00/Share From $67.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $55.00/Share From $67.00 by Goldman Sachs
BMY,2025-04-08,19:36:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
BMY,2025-04-08,19:36:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
BMY,2025-04-08,19:36:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,"Yervoy, was previously granted accelerated approval",PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
BMY,2025-04-08,19:36:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
BMY,2025-04-08,19:36:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
BMY,2025-04-08,19:36:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,"Yervoy, was previously granted accelerated approval",PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
BMY,2025-04-08,19:36:34,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb: FDA Approves Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Approves Opdivo Plus Yervoy as Treatment for Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer
BMY,2025-04-11,14:45:37,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by UBS
BMY,2025-04-11,14:45:37,94637C,Bristol-Myers Squibb Co.,100,-0.8,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $54.00/Share From $60.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $54.00/Share From $60.00 by UBS
BMY,2025-04-11,19:49:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
BMY,2025-04-11,19:49:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
BMY,2025-04-11,19:49:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Yervoy was previously granted accelerated approval by the U.S. FDA in 2020,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
BMY,2025-04-11,19:49:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
BMY,2025-04-11,19:49:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
BMY,2025-04-11,19:49:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Yervoy was previously granted accelerated approval by the U.S. FDA in 2020,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
BMY,2025-04-11,19:54:18,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb: FDA Approves Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Approves Opdivo Plus Yervoy as First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma >BMY
BMY,2025-04-11,20:33:08,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Bristol Myers Squibb's Opdivo,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some Carcinomas
BMY,2025-04-11,20:33:08,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb said the Food and Drug Administration approved Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some Carcinomas
BMY,2025-04-11,20:33:08,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The company also said Phase 3 trial results showed Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some Carcinomas
BMY,2025-04-11,20:48:09,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Bristol Myers Squibb's Opdivo,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some Carcinomas
BMY,2025-04-11,20:48:09,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb said the Food and Drug Administration approved Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some Carcinomas
BMY,2025-04-11,20:48:09,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The company also said Phase 3 trial results showed Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some Carcinomas
BMY,2025-04-14,22:16:08,94637C,Bristol-Myers Squibb Co.,95,-0.65,products-services,negative,"Drug, Camzyos, failed in a final-phase study",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Slumps On Heart Drug Failure -- Taking Cytokinetics With It -- IBD
BMY,2025-04-15,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol-Myers Squibb Co.: Optellum Announces Agreement with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis
BMY,2025-04-15,14:58:09,94637C,Bristol-Myers Squibb Co.,98,-0.65,products-services,negative,"Drug, Camzyos, failed in a final-phase study",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Slumps On Heart Drug Failure -- Taking Cytokinetics With It -- IBD
BMY,2025-04-15,20:05:08,94637C,Bristol-Myers Squibb Co.,98,-0.65,products-services,negative,"Drug, Camzyos, failed in a final-phase study",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Slumps On Heart Drug Failure -- Taking Cytokinetics With It -- IBD
BMY,2025-04-22,11:45:52,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Coverage Assumed by Cantor Fitzgerald at Neutral,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Coverage Assumed by Cantor Fitzgerald at Neutral
BMY,2025-04-22,11:45:52,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $55.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $55.00/Share by Cantor Fitzgerald
BMY,2025-04-22,15:53:53,94637C,Bristol-Myers Squibb Co.,100,0.95,analyst-ratings,positive,Bristol-Myers Squibb Initiated at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Overweight by Piper Sandler
BMY,2025-04-22,15:53:53,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $65.00/Share by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $65.00/Share by Piper Sandler
BMY,2025-04-22,20:15:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced topline results from the Phase 3 ARISE trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
BMY,2025-04-22,20:15:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced topline results from the Phase 3 ARISE trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
BMY,2025-04-22,21:00:08,94637C,Bristol-Myers Squibb Co.,94,0.0,products-services,,Bristol-Myers Squibb Co.: The company said Tuesday a Phase 3 trial of,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Schizophrenia Treatment Falls Flat
BMY,2025-04-22,21:15:08,94637C,Bristol-Myers Squibb Co.,94,0.0,products-services,,Bristol-Myers Squibb Co.: The company said Tuesday a Phase 3 trial of,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Schizophrenia Treatment Falls Flat
BMY,2025-04-22,21:26:06,94637C,Bristol-Myers Squibb Co.,100,-0.65,products-services,negative,"Bristol-Myers Squibb Co.: the company's schizophrenia drug, Cobenfy, failed in a highly anticipated Phase 3 study",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test -- IBD
BMY,2025-04-23,12:56:55,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Buy by Jefferies
BMY,2025-04-23,12:56:55,94637C,Bristol-Myers Squibb Co.,100,-0.44,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $68.00/Share From $70.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $68.00/Share From $70.00 by Jefferies
BMY,2025-04-23,14:00:35,94637C,Bristol-Myers Squibb Co.,99,-0.65,products-services,negative,"Bristol-Myers Squibb Co.: the company's schizophrenia drug, Cobenfy, failed in a highly anticipated Phase 3 study",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test -- IBD
BMY,2025-04-23,15:08:45,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,unchanged,Bristol-Myers Squibb Price Target Maintained With a $55.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Maintained With a $55.00/Share by Cantor Fitzgerald
BMY,2025-04-23,20:09:05,94637C,Bristol-Myers Squibb Co.,99,-0.65,products-services,negative,"Bristol-Myers Squibb Co.: the company's schizophrenia drug, Cobenfy, failed in a highly anticipated Phase 3 study",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test -- IBD
BMY,2025-04-24,05:31:23,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Its collaboration with Bristol Myers Squibb for,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces significant progress in strategic protein degradation collaboration with Bristol Myers Squibb
BMY,2025-04-24,05:31:23,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Its collaboration with Bristol Myers Squibb for,PRESS-RELEASE,DGAP News,EQS-News: Evotec announces significant progress in strategic protein degradation collaboration with Bristol Myers Squibb
BMY,2025-04-24,05:52:43,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Its collaboration with Bristol Myers Squibb for,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb
BMY,2025-04-24,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees FY Adj EPS $6.70,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees FY Adj EPS $6.70-Adj EPS $7.00 >BMY
BMY,2025-04-24,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q Net $2.46B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Net $2.46B >BMY
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q EPS $1.20,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q EPS $1.20 >BMY
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q Adj EPS $1.80,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Adj EPS $1.80 >BMY
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 1Q Rev $11.2B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Rev $11.2B >BMY
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: FIRST QUARTER RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.08,revenues,,Bristol-Myers Squibb Co.: Total revenues of $11.2 billion decreased 6%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS was $1.20,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Co.: Raising 2025 revenue guidance to a range of $45.8 billion to $46.8 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol-Myers Squibb Co.: Increasing non-GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the first quarter of 2025.,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,equity-actions,,"Bristol-Myers Squibb Co.: Selling, general and administrative expenses of $1.6 billion",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,April 11 The FDA approved Opdivo plus Yervoy(R) (ipilimumab) Yervoy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,April 11 The FDA approved Opdivo plus Yervoy(R) (ipilimumab) Yervoy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) maraleucel) granted approval to Breyanzi,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: The company now anticipates other income and expense in 2025,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating Expenses,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $6.55-$6.85,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2025 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2025",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,201 $11,865",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -6-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: FIRST QUARTER RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.08,revenues,,Bristol-Myers Squibb Co.: Total revenues of $11.2 billion decreased 6%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS was $1.20,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Co.: Raising 2025 revenue guidance to a range of $45.8 billion to $46.8 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol-Myers Squibb Co.: Increasing non-GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the first quarter of 2025.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,equity-actions,,"Bristol-Myers Squibb Co.: Selling, general and administrative expenses of $1.6 billion",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,April 11 The FDA approved Opdivo plus Yervoy(R) (ipilimumab) Yervoy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,April 11 The FDA approved Opdivo plus Yervoy(R) (ipilimumab) Yervoy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) maraleucel) granted approval to Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: The company now anticipates other income and expense in 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $6.55-$6.85,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2025 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2025",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,201 $11,865",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -6-
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 1Q EPS $1.20,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q EPS $1.20 >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 1Q Rev $11.2B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q Rev $11.2B >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 1Q Adj EPS $1.80,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q Adj EPS $1.80 >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol Myers Squibb Raises 2025 View To Adj EPS $6.70,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Raises 2025 View To Adj EPS $6.70-Adj EPS $7.00 Vs Prior View $6.55-$6.85 >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb Raises 2025 View To Rev $45.8B-$46.8B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Raises 2025 View To Rev $45.8B-$46.8B Vs Prior View $45.5B >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol Myers Squibb: Growth Portfolio Revenue Increase,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY"
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,-0.4,revenues,down,Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 20%,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 20% to $5.64B >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb: Raised 1Q Rev Outlook,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY"
BMY,2025-04-24,11:13:16,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb reported better-than-expected earnings for the first quarter,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com"
BMY,2025-04-24,11:17:23,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers Squibb Swings to Profit in 1Q,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance"
BMY,2025-04-24,11:17:23,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol Myers Squibb upgraded its guidance for the year,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance"
BMY,2025-04-24,11:32:23,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers Squibb Swings to Profit in 1Q,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance"
BMY,2025-04-24,11:32:23,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol Myers Squibb upgraded its guidance for the year,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance"
BMY,2025-04-24,12:37:40,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol Myers Squibb Raises Guidance,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk"
BMY,2025-04-24,12:37:40,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb reports better-than-expected 1Q earnings,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk"
BMY,2025-04-24,12:37:41,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol Myers Squibb Raises Guidance,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk"
BMY,2025-04-24,12:37:41,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb reports better-than-expected 1Q earnings,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk"
BMY,2025-04-24,14:35:35,94637C,Bristol-Myers Squibb Co.,97,-0.56,revenues,down,Revlimid sales dropped 44% to $936 million,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Continues A Two-Day Losing Spree Despite Walloping Earnings Estimates -- IBD
BMY,2025-04-24,14:35:35,94637C,Bristol-Myers Squibb Co.,97,0.72,revenues,up,Bristol Myers Squibb raised its sales guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Continues A Two-Day Losing Spree Despite Walloping Earnings Estimates -- IBD
BMY,2025-04-24,20:12:37,94637C,Bristol-Myers Squibb Co.,97,-0.56,revenues,down,Revlimid sales dropped 44% to $936 million,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Reverses Its Losing Spree On First-Quarter Beat -- IBD
BMY,2025-04-24,20:12:37,94637C,Bristol-Myers Squibb Co.,97,0.72,revenues,up,Bristol Myers Squibb raised its sales guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Reverses Its Losing Spree On First-Quarter Beat -- IBD
BMY,2025-04-24,21:24:49,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Reports Better-Than-Expected Earnings,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com
BMY,2025-04-29,22:15:04,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Buys 4,250 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Hirawat Buys 4,250 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-04-30,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914),NEWS-FLASH,Dow Jones Newswires,Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914) For The Treatment Of Alopecia Areata >QTTB
BMY,2025-04-30,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914),PRESS-RELEASE,PR Newswire,Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
BMY,2025-04-30,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914),PRESS-RELEASE,Dow Jones Newswires,Press Release: Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
BMY,2025-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cari Gallman as Executive Vice President,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,"Bristol-Myers Squibb Co.: Sandra Leung, Executive Vice President, General Counsel Retires",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,"Bristol-Myers Squibb Co.: Sandra Leung, Executive Vice President, General Counsel Retires",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:18,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol Myers Appoints Cari Gallman EVP, General Counsel and Chief",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Appoints Cari Gallman EVP, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:18,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol Myers Appoints Cari Gallman EVP, General Counsel and Chief",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Appoints Cari Gallman EVP, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:46,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cari Gallman as Executive Vice President,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:46,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:46,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,"Bristol-Myers Squibb Co.: Sandra Leung, Executive Vice President, General Counsel Retires",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:46,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,"Bristol-Myers Squibb Co.: Sandra Leung, Executive Vice President, General Counsel Retires",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-07,20:05:08,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,The collaboration with BMS for,PRESS-RELEASE,Business Wire,2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb
BMY,2025-05-07,20:05:08,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bms will acquire all remaining shares of 2seventy bio,PRESS-RELEASE,Business Wire,2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb
BMY,2025-05-07,20:05:08,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,The collaboration with BMS for,PRESS-RELEASE,Dow Jones Newswires,Press Release: 2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb
BMY,2025-05-07,20:05:08,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bms will acquire all remaining shares of 2seventy bio,PRESS-RELEASE,Dow Jones Newswires,Press Release: 2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb
BMY,2025-05-13,16:48:08,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of 2seventy,RNS-SEC8K,Dow Jones Newswires,2seventy bio: Bristol Myers Squibb Completes Acquisition of 2seventy
BMY,2025-05-13,23:05:17,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,Officer Hickey Sells 97 Of Bristol-Myers Squibb Co,FULL-ARTICLE,Dow Jones Newswires,Officer Hickey Sells 97 Of Bristol-Myers Squibb Co >BMY
BMY,2025-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo(R) (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression >=1%"
BMY,2025-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2025-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2025-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2025-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo(R) (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression >=1%"
BMY,2025-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2025-05-22,07:04:41,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2025 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2025 (BMY)"
BMY,2025-05-22,21:05:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: 5-year OS results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO(R) 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
BMY,2025-05-22,21:05:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Results from two Phase 1 studies,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO(R) 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO(R) -6-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO(R) -6-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO(R) -6-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO(R) -9-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO(R) -9-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: 5-year OS results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data at ASCO(R) 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Results from two Phase 1 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data at ASCO(R) 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,94,0.0,products-services,,Bristol-Myers Squibb Co.: Phase I study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -6-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -6-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -6-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -9-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -9-
BMY,2025-05-23,07:12:52,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"2SEVENTY BIO INC COM, Inst Holders, 1Q 2025 (TSVT)",RNS-SEC13F,Dow Jones Newswires,"2SEVENTY BIO INC  COM, Inst Holders, 1Q 2025 (TSVT)"
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Approval is based on results from the Phase 3 CheckMate -67T clinical trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig(TM) , was approved by the U.S. Food and Drug Administration (FDA)",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Approval is based on results from the Phase 3 CheckMate -67T clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig(TM) , was approved by the U.S. Food and Drug Administration (FDA)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-05-28,10:55:43,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets European Approval for Subcutaneous Formulation of Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Gets European Approval for Subcutaneous Formulation of Opdivo Across Multiple Solid Tumor Indications >BMY
BMY,2025-05-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
BMY,2025-05-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
BMY,2025-05-28,11:31:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets European Approval for Subcutaneous Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Approval for Subcutaneous Opdivo
BMY,2025-05-28,11:31:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb has won European approval of a formulation,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Approval for Subcutaneous Opdivo
BMY,2025-05-28,11:46:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets European Approval for Subcutaneous Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Approval for Subcutaneous Opdivo
BMY,2025-05-28,11:46:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb has won European approval of a formulation,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Approval for Subcutaneous Opdivo
BMY,2025-05-28,12:30:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo(R) (nivolumab),PRESS-RELEASE,PR Newswire,Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo(R) (nivolumab) Co-Formulated with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-05-28,12:30:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig(TM) , was approved by the U.S. Food and Drug Administration",PRESS-RELEASE,PR Newswire,Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo(R) (nivolumab) Co-Formulated with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-05-28,12:30:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo(R) (nivolumab) Co-Formulated with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-05-28,12:30:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig(TM) , was approved by the U.S. Food and Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo(R) (nivolumab) Co-Formulated with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-06-02,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,PRESS-RELEASE,GlobeNewswire,BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,PRESS-RELEASE,Business Wire,(BW) BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,10:45:08,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,NEWS-FLASH,Dow Jones Newswires,BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,10:45:18,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,NEWS-FLASH,Dow Jones Newswires,BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,10:58:59,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,12:56:35,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers strikes $11 billion deal with BioNTech,FULL-ARTICLE,MarketWatch,MW Bristol Myers strikes $11 billion deal with BioNTech to join cancer-drug race
BMY,2025-06-04,21:42:47,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Short Acquires 4,706 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Short Acquires 4,706 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-06-11,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
BMY,2025-06-11,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: These positive Phase 3 data,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
BMY,2025-06-11,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Late-Breaking Data -3-
BMY,2025-06-11,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
BMY,2025-06-11,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: These positive Phase 3 data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
BMY,2025-06-11,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -3-
BMY,2025-06-12,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025"
BMY,2025-06-12,10:57:52,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025"
BMY,2025-06-12,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Results from the dose-expansion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD(TM) Agents and BCL6 Ligand-Directed Degrader at EHA 2025
BMY,2025-06-12,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Golcadomide are being evaluated in multiple phase 3 studies,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD(TM) Agents and BCL6 Ligand-Directed Degrader at EHA 2025
BMY,2025-06-12,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Results from the dose-expansion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD(TM) Agents and BCL6 Ligand-Directed Degrader at EHA 2025
BMY,2025-06-12,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Golcadomide are being evaluated in multiple phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD(TM) Agents and BCL6 Ligand-Directed Degrader at EHA 2025
BMY,2025-06-16,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents First Data from the -2-
BMY,2025-06-16,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents First Data from the -2-
BMY,2025-06-16,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2025-06-16,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2025-06-17,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2025-06-17,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on August 1, 2025, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2025-06-17,20:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2025-06-17,20:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on August 1, 2025, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2025-07-10,16:24:42,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2025-07-10,16:24:42,94637C,Bristol-Myers Squibb Co.,100,-0.62,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $34.00/Share From $36.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $34.00/Share From $36.00 by Morgan Stanley
BMY,2025-07-18,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl(R) (luspatercept-aamt),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl(R) (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
BMY,2025-07-18,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 INDEPENDENCE trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl(R) (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
BMY,2025-07-18,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl(R) (luspatercept-aamt),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl(R) (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
BMY,2025-07-18,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 INDEPENDENCE trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl(R) (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
BMY,2025-07-18,10:59:49,94637C,Bristol-Myers Squibb Co.,100,-0.8,products-services,negative,Bristol Myers: Phase 3 Study of Reblozyl in Adults With Myelofibrosis-Associated Anemia Misses,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: Phase 3 Study of Reblozyl in Adults With Myelofibrosis-Associated Anemia Misses Primary Endpoint >BMY
BMY,2025-07-18,11:29:54,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol Myers on Friday said the Phase 3 study of Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Posts Mixed Reblozyl Results in Myelofibrosis-Associated Anemia
BMY,2025-07-18,11:44:54,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol Myers on Friday said the Phase 3 study of Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Posts Mixed Reblozyl Results in Myelofibrosis-Associated Anemia
BMY,2025-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: Sotyktu received approval from the FDA,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
BMY,2025-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Supplemental New Drug -2-
BMY,2025-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: Sotyktu received approval from the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
BMY,2025-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's -2-
BMY,2025-07-21,11:14:24,94637C,Bristol-Myers Squibb Co.,100,-0.47,regulatory,,Fda to Review Sotyktu for,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:14:24,94637C,Bristol-Myers Squibb Co.,100,-0.47,regulatory,,China and Japan are also reviewing Sotyktu for,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:14:24,94637C,Bristol-Myers Squibb Co.,100,-0.47,regulatory,,China and Japan are also reviewing Sotyktu for,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:14:24,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda in September 2022 approved Sotyktu,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:14:24,94637C,Bristol-Myers Squibb Co.,100,0.56,revenues,up,"Bristol Myers reported 2024 Sotyktu sales of $246 million, up 45%",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:29:24,94637C,Bristol-Myers Squibb Co.,100,-0.47,regulatory,,Fda to Review Sotyktu for,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:29:24,94637C,Bristol-Myers Squibb Co.,100,-0.47,regulatory,,China and Japan are also reviewing Sotyktu for,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:29:24,94637C,Bristol-Myers Squibb Co.,100,-0.47,regulatory,,China and Japan are also reviewing Sotyktu for,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:29:24,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda in September 2022 approved Sotyktu,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:29:24,94637C,Bristol-Myers Squibb Co.,100,0.56,revenues,up,"Bristol Myers reported 2024 Sotyktu sales of $246 million, up 45%",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-25,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President",PRESS-RELEASE,Business Wire,"Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development"
BMY,2025-07-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development"
BMY,2025-07-25,10:59:33,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol-Myers Names Cristian Massacesi Exec VP, Chief Medical Officer",NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Names Cristian Massacesi Exec VP, Chief Medical Officer, Head of Development >BMY"
BMY,2025-07-25,10:59:33,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol-Myers Names Cristian Massacesi Exec VP, Chief Medical Officer",NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Names Cristian Massacesi Exec VP, Chief Medical Officer, Head of Development >BMY"
BMY,2025-07-25,11:30:05,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Will succeed Hirawat as executive vice president, chief medical officer",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs
BMY,2025-07-25,11:30:05,94637C,Bristol-Myers Squibb Co.,100,-0.57,labor-issues,,"Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs
BMY,2025-07-25,11:45:05,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Will succeed Hirawat as executive vice president, chief medical officer",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs
BMY,2025-07-25,11:45:05,94637C,Bristol-Myers Squibb Co.,100,-0.57,labor-issues,,"Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs
BMY,2025-07-25,20:43:45,94637C,Bristol-Myers Squibb Co.,99,-0.57,labor-issues,,"Bristol-Myers Squibb Co.: Chief Medical Officer and Head of Development, will leave the Company by November 1, 2025",RNS-SEC8K,Dow Jones Newswires,"Bristol-Myers Squibb Files 8K - Director, Officer or Compensation Filing >BMY"
BMY,2025-07-28,20:16:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: excited to partner with BMS and we,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
BMY,2025-07-28,20:16:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: excited to partner with BMS and we,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
BMY,2025-07-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2025,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
BMY,2025-07-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reported second quarter 2025 financial results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
BMY,2025-07-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Co.: The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, July 31, 2025",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
BMY,2025-07-31,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
BMY,2025-07-31,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reported second quarter 2025 financial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
BMY,2025-07-31,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Co.: The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, July 31, 2025",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
BMY,2025-07-31,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 2Q EPS 64c,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q EPS 64c >BMY
BMY,2025-07-31,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 2Q Rev $12.27B >BMY,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Rev $12.27B >BMY
BMY,2025-07-31,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 2Q Adj EPS $1.46,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Adj EPS $1.46 >BMY
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb Cuts 2025 View To Adj EPS $6.35,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Cuts 2025 View To Adj EPS $6.35-Adj EPS $6.65 Vs Prior View $6.70-$7.00 >BMY
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 2Q Growth Portfolio Revenue Rose 18% to $6.6B,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Growth Portfolio Revenue Rose 18% to $6.6B >BMY
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol Myers Squibb: Growth Portfolio Revenue Increase,HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Immuno-Oncology Portfolio, Breyanzi, Reblozyl and Camzyos, and Reflects Continued Strength of Cobenfy >BMY"
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,-0.28,revenues,down,Bristol Myers Squibb 2Q Legacy Portfolio Rev Fell 14%,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Legacy Portfolio Rev Fell 14% to $5.67B >BMY
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol Myers Squibb 2Q U.S. Revenue Fell 3% to $8.52B,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q U.S. Revenue Fell 3% to $8.52B >BMY
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 2Q International Revenue Rose 10% to $3.75B,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q International Revenue Rose 10% to $3.75B >BMY
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb Raises 2025 View To Rev $46.5B-$47.5B,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Raises 2025 View To Rev $46.5B-$47.5B From Prior View $45.8B-$46.8B >BMY
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb: Raised 2025 Rev Guidance,HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: Raised 2025 Rev Guidance Reflecting Strength of Growth Portfolio, Better-Than-Expected Legacy Portfolio Sales in 2Q and Favorable Impact of About $200M Related to Foreign Exchange Rates >BMY"
BMY,2025-07-31,10:59:08,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb Cuts Full-Year Adjusted View,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q"
BMY,2025-07-31,10:59:08,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers said its growth portfolio revenue rose 18%, to $6.6 billion, in the quarter",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q"
BMY,2025-07-31,10:59:08,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers said it is raising its revenue guidance,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q"
BMY,2025-07-31,10:59:22,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Beats Earnings Expectations,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Beats Earnings Expectations. It's Still Optimistic About New Schizophrenia Drug. -- Barrons.com
BMY,2025-07-31,10:59:22,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: the company reported sales of Cobenfy for the second quarter,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Beats Earnings Expectations. It's Still Optimistic About New Schizophrenia Drug. -- Barrons.com
BMY,2025-07-31,10:59:22,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Co.: The company also raised its full-year revenue guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Beats Earnings Expectations. It's Still Optimistic About New Schizophrenia Drug. -- Barrons.com
BMY,2025-07-31,11:14:08,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb Cuts Full-Year Adjusted View,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q"
BMY,2025-07-31,11:14:08,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers said its growth portfolio revenue rose 18%, to $6.6 billion, in the quarter",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q"
BMY,2025-07-31,11:14:08,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers said it is raising its revenue guidance,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q"
BMY,2025-07-31,11:54:39,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Cuts Full-Year Adjusted View,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update"
BMY,2025-07-31,11:54:39,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers said its growth portfolio revenue rose 18%, to $6.6 billion, in the quarter",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update"
BMY,2025-07-31,11:54:39,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers said it is raising its revenue guidance,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update"
BMY,2025-08-01,20:28:03,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by Citigroup
BMY,2025-08-01,20:28:03,94637C,Bristol-Myers Squibb Co.,100,-0.72,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $47.00/Share From $51.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $47.00/Share From $51.00 by Citigroup
BMY,2025-08-04,20:16:00,94637C,Bristol-Myers Squibb Co.,95,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
BMY,2025-08-04,20:16:00,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
BMY,2025-08-04,20:16:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Application for Breyanzi -2-
BMY,2025-08-04,20:16:01,94637C,Bristol-Myers Squibb Co.,95,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
BMY,2025-08-04,20:16:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
BMY,2025-08-04,20:16:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Application -2-
BMY,2025-08-05,22:00:27,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Short Acquires 360 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Short Acquires 360 Of Bristol-Myers Squibb Co >BMY
BMY,2025-08-05,22:05:11,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Gallman Acquires 518 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Gallman Acquires 518 Of Bristol-Myers Squibb Co >BMY
BMY,2025-08-22,07:04:34,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2025 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2025 (BMY)"
BMY,2025-08-25,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance on Eliquis (apixaban),PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
BMY,2025-08-25,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Pfizer Alliance ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
BMY,2025-08-25,10:59:00,94637C,Bristol-Myers Squibb Co.,92,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present New Clinical and -3-
BMY,2025-08-25,10:59:00,94637C,Bristol-Myers Squibb Co.,99,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present New Clinical and -4-
BMY,2025-08-25,11:12:31,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance on Eliquis (apixaban),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
BMY,2025-08-25,11:12:31,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Pfizer Alliance ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
BMY,2025-08-25,11:12:31,94637C,Bristol-Myers Squibb Co.,92,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2025-08-25,11:12:31,94637C,Bristol-Myers Squibb Co.,99,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2025-08-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
BMY,2025-08-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
BMY,2025-09-02,15:21:30,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Cfo Elkins Registers 56,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"CFO Elkins Registers 56,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-09-03,22:43:29,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Short Acquires 603 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Short Acquires 603 Of Bristol-Myers Squibb Co >BMY
BMY,2025-09-03,22:47:10,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Cfo Elkins Sells 56,000 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Sells 56,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-09-08,15:00:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bms"") today presented interim data from a global randomized Phase 2 trial",PRESS-RELEASE,GlobeNewswire,First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
BMY,2025-09-08,15:00:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bms"") today presented interim data from a global randomized Phase 2 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
BMY,2025-09-08,15:00:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bms"") today presented interim data from a global randomized Phase 2 trial",PRESS-RELEASE,Hugin GlobeNewswire,Press Release: First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
BMY,2025-09-08,15:00:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bms"") today presented interim data from a global randomized Phase 2 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
BMY,2025-09-15,13:00:11,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: We are proud to partner with BMS to,PRESS-RELEASE,PR Newswire,"Trialbee and BMS Session ""From Click to Clinic"" at DPHARM to Showcase How the Honey Platform(TM) Reinvents the Last Mile of Patient Recruitment for Trial Finder Websites"
BMY,2025-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2025-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on November 3, 2025, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2025-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2025-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on November 3, 2025, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2025-09-19,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025"
BMY,2025-09-19,11:01:16,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025"
BMY,2025-09-22,14:03:03,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Bristol-Myers Squibb Co.: our long-standing relationship with Veeva by,PRESS-RELEASE,PR Newswire,Bristol Myers Squibb Commits to Veeva Vault CRM
BMY,2025-09-22,14:03:04,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Bristol-Myers Squibb Co.: our long-standing relationship with Veeva by,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Commits to Veeva Vault CRM
BMY,2025-09-22,14:03:30,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Bristol-Myers Squibb Co.: our long-standing relationship with Veeva by,PRESS-RELEASE,PR Newswire,Bristol Myers Squibb Commits to Veeva Vault CRM
BMY,2025-09-23,10:59:59,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers: Phase 3 Study of Iberdomide,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: Phase 3 Study of Iberdomide in Combination With Standard Therapies Shows Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma >BMY
BMY,2025-09-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Builds on Eliquis(R) -2-
BMY,2025-09-25,10:59:07,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Builds on -2-
BMY,2025-10-01,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,"Bms-986446, Granted Fast Track Designation By U.S. FDA",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation By U.S. FDA For The Treatment Of Alzheimer's Disease >BMY"
BMY,2025-10-01,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease"
BMY,2025-10-01,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,complete,Bristol-Myers Squibb Co.: The ongoing Phase 2 study is fully enrolled,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease"
BMY,2025-10-01,10:59:06,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease"
BMY,2025-10-01,10:59:06,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,complete,Bristol-Myers Squibb Co.: The ongoing Phase 2 study is fully enrolled,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease"
BMY,2025-10-01,11:24:29,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Bristol Myers Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Fast-Track Designation for BMS-986446 in Alzheimer's
BMY,2025-10-01,11:39:29,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Bristol Myers Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Fast-Track Designation for BMS-986446 in Alzheimer's
BMY,2025-10-01,20:45:00,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Partner Bristol Myers Squibb Obtains Fast Track Designation From The U.S. FDA,NEWS-FLASH,Dow Jones Newswires,"Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation From The U.S. FDA For BMS-986446 (PRX005), An Anti-MTBR-Tau-Targeting Antibody, For The Treatment Of Alzheimer's Disease >PRTA"
BMY,2025-10-01,20:45:00,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA,PRESS-RELEASE,Business Wire,"Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease"
BMY,2025-10-01,20:45:03,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease"
BMY,2025-10-06,21:23:31,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Gallman Acquires 2,226 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Gallman Acquires 2,226 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-10-10,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
BMY,2025-10-10,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
BMY,2025-10-10,11:00:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,In partnership with BMS to,PRESS-RELEASE,DJ Global Press Release Wire,Bristol Myers Squibb and National Community Pharmacists Association Pilot Rural Heart Health Care Initiatives
BMY,2025-10-10,11:01:47,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio With Acquisition of Orbital Therapeutics,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio With Acquisition of Orbital Therapeutics
BMY,2025-10-10,12:17:44,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion
BMY,2025-10-10,12:32:44,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion
BMY,2025-10-10,16:19:19,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,It closed a $4.1 billion acquisition of RayzeBio,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com
BMY,2025-10-10,16:19:19,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,It closed a $4.1 billion acquisition of RayzeBio,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com
BMY,2025-10-13,09:00:32,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Systimmune, in collaboration with BMS outside of",PRESS-RELEASE,PR Newswire,SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
BMY,2025-10-13,09:00:36,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Systimmune, in collaboration with BMS outside of",PRESS-RELEASE,Dow Jones Newswires,Press Release: SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
BMY,2025-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,98,0.0,products-services,,Bristol-Myers Squibb Co.: First disclosure of results from a global Phase 1 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO(R) 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
BMY,2025-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,98,0.0,earnings,,"Bristol-Myers Squibb Co.: Final, 9-year results",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO(R) 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
BMY,2025-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: Phase II Study of,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO(R) -2-
BMY,2025-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO(R) -4-
BMY,2025-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO(R) -4-
BMY,2025-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO(R) -4-
BMY,2025-10-13,10:59:03,94637C,Bristol-Myers Squibb Co.,98,0.0,products-services,,Bristol-Myers Squibb Co.: First disclosure of results from a global Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data at ESMO(R) 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
BMY,2025-10-13,10:59:03,94637C,Bristol-Myers Squibb Co.,98,0.0,earnings,,"Bristol-Myers Squibb Co.: Final, 9-year results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data at ESMO(R) 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
BMY,2025-10-13,10:59:03,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: Phase II Study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -2-
BMY,2025-10-13,10:59:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2025-10-13,10:59:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2025-10-13,10:59:03,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2025-10-14,20:00:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Insitro Extends Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro's ChemML Discovery Platform
BMY,2025-10-14,20:10:26,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Insitro Extends Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro's ChemML Discovery Platform
BMY,2025-10-15,11:00:01,94637C,Bristol-Myers Squibb Co.,99,0.26,corporate-responsibility,,Bms Foundation's donation to the Patient Advocate Foundation,PRESS-RELEASE,DJ Global Press Release Wire,Bristol Myers Squibb Foundation Announces $1 Million Donation to Patient Advocate Foundation
BMY,2025-10-15,13:03:15,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: Providing teams with access to,PRESS-RELEASE,PR Newswire,Deck Bio and ReTrax Therapeutics Awarded 2025 Bristol Myers Squibb Golden Tickets
BMY,2025-10-16,11:00:02,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: First HopeHealth Clinical Trial,PRESS-RELEASE,DJ Global Press Release Wire,HopeHealth Launches Phase 3 Clinical Trial Site To Advance Lupus Research With Support From Bristol Myers Squibb
BMY,2025-10-17,14:00:14,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Systimmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results",PRESS-RELEASE,PR Newswire,"SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025"
BMY,2025-10-17,14:00:14,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,OrbiMed Advisors LLC: our global collaboration with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,"SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025"
BMY,2025-10-17,14:00:57,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Systimmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results",PRESS-RELEASE,Dow Jones Newswires,"Press Release: SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025"
BMY,2025-10-17,14:00:57,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,OrbiMed Advisors LLC: our global collaboration with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,"Press Release: SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025"
BMY,2025-10-17,14:03:30,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Systimmune and Bristol Myers Squibb Announce First Global Phase I Results,NEWS-FLASH,Dow Jones Newswires,"SystImmune and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR X HER3 Bispecific Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors"
BMY,2025-10-25,15:00:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T(TM) CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
BMY,2025-10-25,15:00:03,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T(TM) CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
BMY,2025-10-27,06:30:24,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,Evotec SE: our collaboration with Bristol Myers Squibb.,PRESS-RELEASE,DGAP News,EQS-News: Evotec announces progress in preclinical neuroscience partnership with Bristol Myers Squibb
BMY,2025-10-27,06:30:24,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,Evotec SE: our collaboration with Bristol Myers Squibb.,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces progress in preclinical neuroscience partnership with Bristol Myers Squibb
BMY,2025-10-27,06:50:01,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Evotec SE: our collaboration with Bristol Myers Squibb.,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
BMY,2025-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Initial Week 16 results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
BMY,2025-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Two Late-Breaking -3-
BMY,2025-10-27,10:59:04,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Initial Week 16 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
BMY,2025-10-27,10:59:04,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Two -3-
BMY,2025-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2025,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
BMY,2025-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reported third quarter 2025 financial results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
BMY,2025-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Co.: The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, October 30, 2025",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
BMY,2025-10-30,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
BMY,2025-10-30,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reported third quarter 2025 financial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
BMY,2025-10-30,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Co.: The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, October 30, 2025",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 3Q EPS $1.08,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q EPS $1.08 >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 3Q Rev $12.22B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q Rev $12.22B >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 3Q Adj EPS $1.63,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q Adj EPS $1.63 >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Adjusts 2025 View,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Adjusts 2025 View To Adj EPS $6.40-Adj EPS $6.60 Vs Prior Outlook $6.35-$6.65 >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 3Q Growth Portfolio Revenue Rose 18% to $6.86B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q Growth Portfolio Revenue Rose 18% to $6.86B >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol Myers Squibb 3Q Legacy Portfolio Rev Fell 12%,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q Legacy Portfolio Rev Fell 12% to $5.37B >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 3Q U.S. Revenue Rose 1% to $8.33B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q U.S. Revenue Rose 1% to $8.33B >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 3Q International Revenue Rose 6% to $3.89B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q International Revenue Rose 6% to $3.89B >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb Raises 2025 Rev Guidance to $47.5B-$48B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Raises 2025 Rev Guidance to $47.5B-$48B Vs Prior Outlook $46.5B-$47.5B >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb: Raised 2025 Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: Raised 2025 Rev Guidance Primarily Reflects Continued Strong Performance of Growth Portfolio >BMY
BMY,2025-10-30,10:59:17,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers Squibb 3Q Profit Soars,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb 3Q Profit Soars, Raises Revenue Guidance"
BMY,2025-10-30,11:14:17,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers Squibb 3Q Profit Soars,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb 3Q Profit Soars, Raises Revenue Guidance"
BMY,2025-10-30,11:32:34,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol Myers Squibb hiked its full-year guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain. -- Barrons.com
BMY,2025-01-03,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference
BMY,2025-01-03,12:00:02,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference
BMY,2025-01-08,11:51:27,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Buy by Truist Securities
BMY,2025-01-08,11:51:27,94637C,Bristol-Myers Squibb Co.,100,0.56,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $65.00/Share From $62.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $65.00/Share From $62.00 by Truist Securities
BMY,2025-01-13,12:00:03,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Discovery collaboration with Bristol Myers Squibb in,PRESS-RELEASE,GlobeNewswire,ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
BMY,2025-01-17,12:30:33,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,China's Acceptance of New Drug Application for KarXT,NEWS-FLASH,Dow Jones Newswires,Zai Lab Announces China's Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
BMY,2025-01-25,15:02:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Results from -4-
BMY,2025-01-25,15:02:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Results from -4-
BMY,2025-01-25,15:02:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Results from -4-
BMY,2025-01-27,10:36:31,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2025-01-27,10:36:31,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2025-01-27,10:36:31,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -4-
BMY,2025-01-28,12:33:41,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by Citigroup
BMY,2025-01-28,12:33:41,94637C,Bristol-Myers Squibb Co.,100,0.72,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $65.00/Share From $60.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $65.00/Share From $60.00 by Citigroup
BMY,2025-01-28,13:45:02,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept,PRESS-RELEASE,Business Wire,"Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept Biosimilar Candidate, KSHB002"
BMY,2025-01-28,13:45:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Eu-authorized reference product, ORENCIA(R)",PRESS-RELEASE,Business Wire,"Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept Biosimilar Candidate, KSHB002"
BMY,2025-01-31,11:50:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-01-31,11:50:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi(R) (lisocabtagene maraleucel; Bristol-Myers Squibb Co.:,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-01-31,11:50:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -2-
BMY,2025-01-31,11:50:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -2-
BMY,2025-01-31,11:50:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-01-31,11:50:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Breyanzi(R) (lisocabtagene maraleucel; Bristol-Myers Squibb Co.:,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-01-31,11:50:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -2-
BMY,2025-01-31,11:50:01,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -2-
BMY,2025-01-31,11:50:20,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Gets Positive CHMP Opinion for CAR T Cell Therapy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Gets Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma >BMY
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Recommendation based on results of Phase 3 CheckMate -9DW clinical trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: the Company's supplemental Biologics License Application (sBLA) for Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Yervoy was granted accelerated approval by the U.S. FDA in 2020,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Recommendation based on results of Phase 3 CheckMate -9DW clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: the Company's supplemental Biologics License Application (sBLA) for Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Yervoy was granted accelerated approval by the U.S. FDA in 2020,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-01-31,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2025-01-31,11:59:33,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Gets Positive CHMP Opinion for Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Gets Positive CHMP Opinion for Opdivo Plus Yervoy as First-Line Treatment Option for Adults With Unresectable or Advanced Hepatocellular Carcinoma >BMY
BMY,2025-01-31,12:52:43,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses"
BMY,2025-01-31,12:52:43,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses"
BMY,2025-01-31,12:52:43,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Chmp also recommended approval of Opdivo,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses"
BMY,2025-01-31,13:07:43,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses"
BMY,2025-01-31,13:07:43,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses"
BMY,2025-01-31,13:07:43,94637C,Bristol-Myers Squibb Co.,92,0.57,products-services,granted,Chmp also recommended approval of Opdivo,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses"
BMY,2025-02-04,14:15:27,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by Cantor Fitzgerald
BMY,2025-02-04,14:15:27,94637C,Bristol-Myers Squibb Co.,100,0.78,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $55.00/Share From $50.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $55.00/Share From $50.00 by Cantor Fitzgerald
BMY,2025-02-05,00:05:21,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Meyers Acquires 1,710 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Meyers Acquires 1,710 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-02-05,00:06:13,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Officer Hickey Acquires 6,353 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Officer Hickey Acquires 6,353 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 4Q EPS 4c,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 4Q EPS 4c >BMY
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 4Q Rev $12.34B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 4Q Rev $12.34B >BMY
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 4Q Adj EPS $1.67,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 4Q Adj EPS $1.67 >BMY
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb Sees 2025 Rev $45.5B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Sees 2025 Rev $45.5B >BMY
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb: 2025 Rev Outlook,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: 2025 Rev Outlook Reflects Near-Term Impact of Generics Across Revlimid, Pomalyst, Sprycel and Abraxane >BMY"
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb: 2025 Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: 2025 Rev Guidance Also Reflects an About $500 Million Expected Negative Impact to Revenue Due to Foreign Exchange >BMY
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers Squibb 4Q Growth Portfolio Revenue $6.36B, Up 21%",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb 4Q Growth Portfolio Revenue $6.36B, Up 21% >BMY"
BMY,2025-02-06,11:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,"Bristol Myers Squibb 4Q Legacy Portfolio Revenue $5.98B, Down 4%",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb 4Q Legacy Portfolio Revenue $5.98B, Down 4% >BMY"
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.68,revenues,down,Bristol Myers Squibb: 4Q Legacy Portfolio Revenue Lower,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: 4Q Legacy Portfolio Revenue Lower Vs Yr-Ago Primarily Due to Impact of Generics on Sprycel, Revlimid, Abraxane and Pomalyst, Partially Offset by Higher Demand for Eliquis >BMY"
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 4Q U.S. Revenue Rose 9% to $8.6B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 4Q U.S. Revenue Rose 9% to $8.6B >BMY
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.7B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.7B >BMY
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb's 4Q Beats Forecasts,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol Myers Squibb posted higher quarterly revenue,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,"Opdivo posted fourth-quarter net income of $72 million, or 4 cents a share",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,Higher demand for Opdivo and other growth-portfolio drugs,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Fourth Quarter Revenues were $12.3 Billion, Increasing 8%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: GAAP Loss Per Share was $(4.41),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Full-Year Revenues were $48.3 Billion, Increasing 7%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"The Fourth Quarter, Including U.S. Approval of Opdivo",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Provides 2025 Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Non-GAAP EPS Range of $6.55 to $6.85,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,"Higher demand for Eliquis, partially offset by the impact of generics",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,revenues,,Bristol-Myers Squibb Co.: FOURTH QUARTER PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.65,revenues,up,Bristol-Myers Squibb Co.: Growth Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,European Medicines Agency (EMA) recommended approval of Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,"Ec approved Augtyro, a next-generation tyrosine kinase inhibitor",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Administration (FDA) approved Opdivo Qvantig injection for,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -2-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Ema recommended approval of Breyanzi,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: FULL-YEAR FINANCIAL RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,"Bristol Myers Squibb posted revenues of $48.3 billion, an increase of 7%",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.51,products-services,increase,"Higher demand for Eliquis, partially offset by the impact of generics",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,"Bristol-Myers Squibb Co.: On a GAAP basis, income tax expense was $554 million",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: FULL-YEAR PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -3-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: FULL-YEAR PRODUCT REVENUE,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Growth Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.51,products-services,increase,"Higher demand for Eliquis, offset by the impact of generics",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: We estimate total revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating Expenses,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $6.55-$6.85,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -4-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED DECEMBER 31, 2024",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -6-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -6-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,92,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2024",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -7-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $12,342 $11,477",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Fourth Quarter and -8-
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Adj EPS $1.67,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Adj EPS $1.67 >BMY
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q Net $72M,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Net $72M >BMY
BMY,2025-02-06,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 4Q EPS 4c,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q EPS 4c >BMY
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 4Q Rev $12.3B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 4Q Rev $12.3B >BMY
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Fourth Quarter Revenues were $12.3 Billion, Increasing 8%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,-0.65,earnings,negative,Bristol-Myers Squibb Co.: GAAP Loss Per Share was $(4.41),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol-Myers Squibb Co.: Full-Year Revenues were $48.3 Billion, Increasing 7%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"The Fourth Quarter, Including U.S. Approval of Opdivo",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: Provides 2025 Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: Non-GAAP EPS Range of $6.55 to $6.85,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,"Higher demand for Eliquis, partially offset by the impact of generics",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.0,revenues,,Bristol-Myers Squibb Co.: FOURTH QUARTER PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.65,revenues,up,Bristol-Myers Squibb Co.: Growth Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,European Medicines Agency (EMA) recommended approval of Opdivo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,"Ec approved Augtyro, a next-generation tyrosine kinase inhibitor",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Administration (FDA) approved Opdivo Qvantig injection for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,91,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -2-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Ema recommended approval of Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: FULL-YEAR FINANCIAL RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.41,revenues,up,"Bristol Myers Squibb posted revenues of $48.3 billion, an increase of 7%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.51,products-services,increase,"Higher demand for Eliquis, partially offset by the impact of generics",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,"Bristol-Myers Squibb Co.: On a GAAP basis, income tax expense was $554 million",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: FULL-YEAR PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -3-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: FULL-YEAR PRODUCT REVENUE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.65,revenues,up,Bristol-Myers Squibb Co.: Growth Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Legacy Portfolio revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.51,products-services,increase,"Higher demand for Eliquis, offset by the impact of generics",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: We estimate total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $6.55-$6.85,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -4-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED DECEMBER 31, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,99,-0.65,earnings,negative,Bristol-Myers Squibb Co.: Net (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -6-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,92,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -7-
BMY,2025-02-06,11:59:02,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $12,342 $11,477",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports -8-
BMY,2025-02-06,12:13:41,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb's 4Q Beats Forecasts,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,12:13:41,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol Myers Squibb posted higher quarterly revenue,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,12:13:41,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,"Opdivo posted fourth-quarter net income of $72 million, or 4 cents a share",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,12:13:41,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,increase,Higher demand for Opdivo and other growth-portfolio drugs,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
BMY,2025-02-06,13:56:37,94637C,Bristol-Myers Squibb Co.,96,0.61,earnings,positive,Bristol Myers to earn $1.46 per share,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. -- IBD
BMY,2025-02-06,15:35:37,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol Myers forecast $45.5 billion in sales,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD"
BMY,2025-02-06,15:35:37,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol Myers earned $1.67 per share,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD"
BMY,2025-02-06,15:35:37,94637C,Bristol-Myers Squibb Co.,99,0.65,acquisitions-mergers,,Company's $14 billion takeover of Karuna Therapeutics,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD"
BMY,2025-02-06,21:03:37,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol Myers forecast $45.5 billion in sales,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD"
BMY,2025-02-06,21:03:37,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol Myers earned $1.67 per share,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD"
BMY,2025-02-06,21:03:37,94637C,Bristol-Myers Squibb Co.,99,0.65,acquisitions-mergers,,Company's $14 billion takeover of Karuna Therapeutics,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD"
BMY,2025-02-07,14:38:44,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
BMY,2025-02-07,14:38:44,94637C,Bristol-Myers Squibb Co.,100,0.46,price-targets,upgrade,Bristol-Myers Squibb Price Target Raised to $62.00/Share From $60.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Raised to $62.00/Share From $60.00 by Wells Fargo
BMY,2025-02-10,11:59:00,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results for Breyanzi(R) (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
BMY,2025-02-10,11:59:00,94637C,Bristol-Myers Squibb Co.,96,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline Results for Breyanzi(R) (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
BMY,2025-02-10,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Positive Topline -2-
BMY,2025-02-10,11:59:01,94637C,Bristol-Myers Squibb Co.,96,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results for Breyanzi(R) (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
BMY,2025-02-10,11:59:01,94637C,Bristol-Myers Squibb Co.,96,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Positive Topline Results for Breyanzi(R) (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
BMY,2025-02-10,11:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -2-
BMY,2025-02-10,13:04:02,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Sees Positive Results for Breyanzi in Lymphoma Trials
BMY,2025-02-10,13:19:02,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Sees Positive Results for Breyanzi in Lymphoma Trials
BMY,2025-02-11,13:00:03,94637C,Bristol-Myers Squibb Co.,100,0.47,labor-issues,,Biomedicines Appoints Elizabeth Mily to Board of Directors,PRESS-RELEASE,GlobeNewswire,Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors
BMY,2025-02-13,21:16:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 3 -4-
BMY,2025-02-13,21:16:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 3 -4-
BMY,2025-02-13,21:16:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 3 -5-
BMY,2025-02-13,21:16:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Provides Update on Phase 3 -8-
BMY,2025-02-13,21:16:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -4-
BMY,2025-02-13,21:16:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -4-
BMY,2025-02-13,21:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -5-
BMY,2025-02-13,21:16:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Provides -8-
BMY,2025-02-19,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo(R) Plus -3-
BMY,2025-02-19,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo(R) Plus -3-
BMY,2025-02-19,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Opdivo(R) Plus -3-
BMY,2025-02-19,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2025-02-19,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2025-02-19,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces -3-
BMY,2025-02-19,13:00:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,And Receives U.S. FDA Approval For Lenalidomide,NEWS-FLASH,Dow Jones Newswires,Amneal Launches Mesalamine And Receives U.S. FDA Approval For Lenalidomide >AMRX
BMY,2025-02-19,13:00:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,And Receives U.S. FDA Approval for Lenalidomide,PRESS-RELEASE,Business Wire,Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
BMY,2025-02-19,13:00:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,And Receives U.S. FDA Approval for Lenalidomide,PRESS-RELEASE,Dow Jones Newswires,Press Release: Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
BMY,2025-02-20,00:20:51,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Buys 1,823 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Buys 1,823 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-02-20,05:30:13,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bioarctic had entered into a global license agreement with Bristol Myers Squibb,PRESS-RELEASE,Cision News,BioArctic: BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
BMY,2025-02-20,05:30:13,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bioarctic had entered into a global license agreement with Bristol Myers Squibb,FULL-ARTICLE,Dow Jones Newswires,BioArctic: BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
BMY,2025-02-20,05:50:02,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bioarctic had entered into a global license agreement with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
BMY,2025-02-20,05:50:03,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bioarctic had entered into a global license agreement with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
BMY,2025-02-20,05:52:52,94637C,Bristol-Myers Squibb Co.,99,0.39,products-services,,Bioarctic had entered into a global license agreement with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
BMY,2025-02-22,00:10:40,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Chmn Boerner Buys 2,000 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Boerner Buys 2,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-02-23,08:05:50,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2024 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 4Q 2024 (BMY)"
BMY,2025-02-23,23:51:02,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Innovent Biologics Inc.: NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab,PRESS-RELEASE,PR Newswire,"NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-23,23:51:02,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Innovent Biologics Inc.: The NDA for ipilimumab in combination with sintilimab,PRESS-RELEASE,PR Newswire,"NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-23,23:51:02,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Innovent Biologics Inc.: The NDA for ipilimumab in combination with sintilimab,PRESS-RELEASE,PR Newswire,"NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-23,23:51:02,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Cde has granted Breakthrough Therapy Designation (BTD) for ipilimumab,PRESS-RELEASE,PR Newswire,"NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-23,23:51:03,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Nmpa Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-23,23:51:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Innovent Biologics Inc.: The NDA for ipilimumab in combination with sintilimab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-23,23:51:03,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Innovent Biologics Inc.: The NDA for ipilimumab in combination with sintilimab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-23,23:51:03,94637C,Bristol-Myers Squibb Co.,100,0.7,products-services,,Cde has granted Breakthrough Therapy Designation (BTD) for ipilimumab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer"
BMY,2025-02-24,11:59:00,94637C,Bristol-Myers Squibb Co.,98,0.7,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Breakthrough Therapy Designation,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application for Opdivo(R) Plus Yervoy(R) for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
BMY,2025-02-24,11:59:00,94637C,Bristol-Myers Squibb Co.,98,0.57,products-services,granted,Yervoy received approval from the U.S. FDA in July 2018,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application for Opdivo(R) Plus Yervoy(R) for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
BMY,2025-02-24,11:59:01,94637C,Bristol-Myers Squibb Co.,98,0.7,products-services,,Bristol-Myers Squibb Co.: The FDA granted the application Breakthrough Therapy Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application for Opdivo(R) Plus Yervoy(R) for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
BMY,2025-02-24,11:59:01,94637C,Bristol-Myers Squibb Co.,98,0.57,products-services,granted,Yervoy received approval from the U.S. FDA in July 2018,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application for Opdivo(R) Plus Yervoy(R) for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
BMY,2025-02-24,12:03:13,94637C,Bristol-Myers Squibb Co.,100,0.65,products-services,,Bristol Myers Gets FDA Priority Review of Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets FDA Priority Review of Opdivo Plus Yervoy in Certain Patients With Colorectal Cancer >BMY
BMY,2025-02-25,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2025-02-25,11:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY,2025-03-03,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2025-03-03,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on May 1, 2025, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2025-03-03,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2025-03-03,21:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on May 1, 2025, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2025-03-04,06:31:03,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Evotec SE: our collaboration with Bristol Myers Squibb and the impact it has for jointly building a,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2025-03-04,06:31:03,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Evotec SE: our collaboration with Bristol Myers Squibb and the impact it has for jointly building a,PRESS-RELEASE,DGAP News,EQS-News: Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2025-03-04,06:32:03,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Evotec SE: our collaboration with Bristol Myers Squibb and the impact it has for jointly building a,PRESS-RELEASE,DGAP News,EQS-News: Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2025-03-04,06:32:03,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Evotec SE: our collaboration with Bristol Myers Squibb and the impact it has for jointly building a,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2025-03-04,06:45:35,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Evotec and Bristol Myers Squibb have been working together to,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY,2025-03-04,23:07:56,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Officer Hickey Acquires 1,656 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Officer Hickey Acquires 1,656 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Approval based on results of Phase 3 CheckMate -9DW clinical trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,filed,Bristol-Myers Squibb Co.: the Company's supplemental Biologics License Application (sBLA) for Opdivo,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Yervoy was granted accelerated approval,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2025-03-07,11:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2025-03-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-03-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-03-07,11:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2025-03-07,11:59:33,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets European Commission Approval for Opdivo Plus Yervoy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Gets European Commission Approval for Opdivo Plus Yervoy for First-Line Treatment of Adults With Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-03-07,11:59:33,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets European Commission Approval for Opdivo Plus Yervoy,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Gets European Commission Approval for Opdivo Plus Yervoy for First-Line Treatment of Adults With Unresectable or Advanced Hepatocellular Carcinoma
BMY,2025-03-07,12:12:44,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets Expanded Europe OK of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Expanded Europe OK of Opdivo/Yervoy Combo in Liver Cancer
BMY,2025-03-07,12:27:44,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets Expanded Europe OK of Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Expanded Europe OK of Opdivo/Yervoy Combo in Liver Cancer
BMY,2025-03-08,14:01:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
BMY,2025-03-08,14:01:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Late-Breaking Data -2-
BMY,2025-03-08,14:01:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
BMY,2025-03-08,14:01:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2025-03-11,02:17:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,2seventy Bio Enters Into Definitive Agreement To Be Acquired By Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,2seventy Bio Enters Into Definitive Agreement To Be Acquired By Bristol Myers Squibb >TSVT
BMY,2025-03-11,02:17:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb,PRESS-RELEASE,Business Wire,2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
BMY,2025-03-11,02:17:01,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: 2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
BMY,2025-03-11,02:19:25,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,2seventy Bio Enters Into Definitive Agreement to Be Acquired by Bristol Myers Squibb,NEWS-FLASH,Dow Jones Newswires,2seventy Bio Enters Into Definitive Agreement to Be Acquired by Bristol Myers Squibb
BMY,2025-03-11,02:21:07,94637C,Bristol-Myers Squibb Co.,100,0.22,acquisitions-mergers,,Bristol Myers to Acquire 2seventy Bio Shares at $5.00,NEWS-FLASH,Dow Jones Newswires,Bristol Myers to Acquire 2seventy Bio Shares at $5.00 Each in All-Cash Deal for Equity Value of About $286M >TSVT
BMY,2025-03-11,09:58:05,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,"Bristol Myers and 2seventy are partners on the gene therapy Abecma, which is approved in",FULL-ARTICLE,Dow Jones Newswires,2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers
BMY,2025-03-11,09:58:06,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,"Bristol Myers and 2seventy are partners on the gene therapy Abecma, which is approved in",FULL-ARTICLE,Dow Jones Newswires,2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers
BMY,2025-03-11,10:13:05,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,"Bristol Myers and 2seventy are partners on the gene therapy Abecma, which is approved in",FULL-ARTICLE,Dow Jones Newswires,2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers
BMY,2025-03-11,10:13:06,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,"Bristol Myers and 2seventy are partners on the gene therapy Abecma, which is approved in",FULL-ARTICLE,Dow Jones Newswires,2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers
BMY,2025-03-13,01:29:41,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Chmn Boerner Acquires 38,237 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Chmn Boerner Acquires 38,237 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:30:00,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Cfo Elkins Acquires 48,582 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Acquires 48,582 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:30:17,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Gallman Acquires 5,648 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Gallman Acquires 5,648 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:32:30,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Acquires 28,042 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Hirawat Acquires 28,042 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:32:55,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Holzer Acquires 5,320 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Holzer Acquires 5,320 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:33:09,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Officer Hoch Acquires 5,198 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"Officer Hoch Acquires 5,198 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:35:31,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Leung Acquires 31,008 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Leung Acquires 31,008 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:38:31,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Poole Acquires 4,891 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Poole Acquires 4,891 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:39:03,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Lenkowsky Acquires 10,619 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Lenkowsky Acquires 10,619 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:39:16,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Shanahan Acquires 13,250 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Shanahan Acquires 13,250 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:39:30,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Meyers Acquires 16,439 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Meyers Acquires 16,439 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,01:42:07,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Plenge Acquires 7,645 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Plenge Acquires 7,645 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-03-13,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025"
BMY,2025-03-13,11:11:39,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025"
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,95,0.62,products-services,positive,Breyanzi demonstrated sustained clinical benefit,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,95,0.57,products-services,granted,Breyanzi is also approved in the EU for the treatment,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Approval from the -2-
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Approval from the -2-
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,95,0.62,products-services,positive,Breyanzi demonstrated sustained clinical benefit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,95,0.57,products-services,granted,Breyanzi is also approved in the EU for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -2-
BMY,2025-03-14,10:59:00,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -2-
BMY,2025-03-14,11:00:06,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets Expanded Europe Approval For Breyanzi,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Gets Expanded Europe Approval For Breyanzi for Relapsed or Refractory Follicular Lymphoma >BMY
BMY,2025-03-14,11:16:26,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets Expanded European Approval for Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Expanded European Approval for Breyanzi
BMY,2025-03-14,11:31:26,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets Expanded European Approval for Breyanzi,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets Expanded European Approval for Breyanzi
BMY,2025-03-20,06:33:46,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,Bristol Myers Squibb Appoints Osama Braiwish as General Manager for,PRESS-RELEASE,PR Newswire,Bristol Myers Squibb Appoints Osama Braiwish as General Manager for Saudi Arabia & Gulf Countries
BMY,2025-03-20,06:37:14,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,Bristol Myers Squibb Appoints Osama Braiwish as General Manager for,PRESS-RELEASE,PR Newswire,Bristol Myers Squibb Appoints Osama Braiwish as General Manager for Saudi Arabia & Gulf Countries
BMY,2025-03-28,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-03-28,12:00:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig, was approved by the U.S. Food and Drug Administration (FDA)",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-03-28,12:00:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2025-03-28,12:00:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2025-03-28,12:00:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2025-03-28,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-03-28,12:00:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig, was approved by the U.S. Food and Drug Administration (FDA)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-03-28,12:00:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-03-28,12:00:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-03-28,12:00:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-03-28,12:00:28,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Bristol Myers Squibb Gets Positive CHMP Opinion for Subcutaneous Formulation,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Gets Positive CHMP Opinion for Subcutaneous Formulation of Opdivo Across Multiple Solid Tumor Indications >BMY
BMY,2025-03-28,12:53:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo(R) (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
BMY,2025-03-28,12:53:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2025-03-28,12:53:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -3-
BMY,2025-03-28,12:53:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives Positive CHMP -4-
BMY,2025-03-28,12:53:01,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,European Medicines Agency (EMA) has recommended approval of Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo(R) (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
BMY,2025-03-28,12:53:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-03-28,12:53:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-03-28,12:53:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2025-03-31,12:30:04,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation,PRESS-RELEASE,PR Newswire,Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-03-31,12:30:04,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig, was approved by the U.S. Food and Drug Administration",PRESS-RELEASE,PR Newswire,Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-03-31,12:30:05,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-03-31,12:30:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig, was approved by the U.S. Food and Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo(R) (nivolumab) with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-03-31,12:33:13,94637C,Bristol-Myers Squibb Co.,100,0.82,products-services,positive,Halozyme: Bristol Myers Squibb Received Positive CHMP Opinion for Subcutaneous Formulation,NEWS-FLASH,Dow Jones Newswires,Halozyme: Bristol Myers Squibb Received Positive CHMP Opinion for Subcutaneous Formulation of Opdivo With ENHANZE Across Multiple Solid Tumor Indications
BMY,2025-04-03,21:16:40,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Shanahan Acquires 1,614 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Shanahan Acquires 1,614 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-04-08,16:12:56,94637C,Bristol-Myers Squibb Co.,100,-0.58,analyst-ratings,negative,Bristol-Myers Squibb Cut to Neutral From Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Cut to Neutral From Buy by Goldman Sachs
BMY,2025-04-08,16:12:57,94637C,Bristol-Myers Squibb Co.,100,-0.82,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $55.00/Share From $67.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $55.00/Share From $67.00 by Goldman Sachs
BMY,2025-04-08,19:36:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
BMY,2025-04-08,19:36:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
BMY,2025-04-08,19:36:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,"Yervoy, was previously granted accelerated approval",PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
BMY,2025-04-08,19:36:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
BMY,2025-04-08,19:36:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
BMY,2025-04-08,19:36:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,"Yervoy, was previously granted accelerated approval",PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
BMY,2025-04-08,19:36:34,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb: FDA Approves Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Approves Opdivo Plus Yervoy as Treatment for Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer
BMY,2025-04-11,14:45:37,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by UBS
BMY,2025-04-11,14:45:37,94637C,Bristol-Myers Squibb Co.,100,-0.8,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $54.00/Share From $60.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $54.00/Share From $60.00 by UBS
BMY,2025-04-11,19:49:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
BMY,2025-04-11,19:49:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
BMY,2025-04-11,19:49:00,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Yervoy was previously granted accelerated approval by the U.S. FDA in 2020,PRESS-RELEASE,Business Wire,U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
BMY,2025-04-11,19:49:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
BMY,2025-04-11,19:49:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
BMY,2025-04-11,19:49:01,94637C,Bristol-Myers Squibb Co.,100,0.71,products-services,,Yervoy was previously granted accelerated approval by the U.S. FDA in 2020,PRESS-RELEASE,Dow Jones Newswires,Press Release: U.S. Food and Drug Administration Approves Opdivo(R) (nivolumab) plus Yervoy(R) (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
BMY,2025-04-11,19:54:18,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol-Myers Squibb: FDA Approves Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb: FDA Approves Opdivo Plus Yervoy as First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma >BMY
BMY,2025-04-11,20:33:08,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Bristol Myers Squibb's Opdivo,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some Carcinomas
BMY,2025-04-11,20:33:08,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb said the Food and Drug Administration approved Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some Carcinomas
BMY,2025-04-11,20:33:08,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The company also said Phase 3 trial results showed Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some Carcinomas
BMY,2025-04-11,20:48:09,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda Approves Bristol Myers Squibb's Opdivo,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some Carcinomas
BMY,2025-04-11,20:48:09,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb said the Food and Drug Administration approved Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some Carcinomas
BMY,2025-04-11,20:48:09,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: The company also said Phase 3 trial results showed Opdivo plus Yervoy,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Bristol Myers Squibb's Opdivo Plus Yervoy to Treat Some Carcinomas
BMY,2025-04-14,22:16:08,94637C,Bristol-Myers Squibb Co.,95,-0.65,products-services,negative,"Drug, Camzyos, failed in a final-phase study",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Slumps On Heart Drug Failure -- Taking Cytokinetics With It -- IBD
BMY,2025-04-15,12:00:04,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol-Myers Squibb Co.: Optellum Announces Agreement with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis
BMY,2025-04-15,14:58:09,94637C,Bristol-Myers Squibb Co.,98,-0.65,products-services,negative,"Drug, Camzyos, failed in a final-phase study",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Slumps On Heart Drug Failure -- Taking Cytokinetics With It -- IBD
BMY,2025-04-15,20:05:08,94637C,Bristol-Myers Squibb Co.,98,-0.65,products-services,negative,"Drug, Camzyos, failed in a final-phase study",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Slumps On Heart Drug Failure -- Taking Cytokinetics With It -- IBD
BMY,2025-04-22,11:45:52,94637C,Bristol-Myers Squibb Co.,100,0.01,analyst-ratings,neutral,Bristol-Myers Squibb Coverage Assumed by Cantor Fitzgerald at Neutral,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Coverage Assumed by Cantor Fitzgerald at Neutral
BMY,2025-04-22,11:45:52,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $55.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $55.00/Share by Cantor Fitzgerald
BMY,2025-04-22,15:53:53,94637C,Bristol-Myers Squibb Co.,100,0.95,analyst-ratings,positive,Bristol-Myers Squibb Initiated at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Initiated at Overweight by Piper Sandler
BMY,2025-04-22,15:53:53,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,set,Bristol-Myers Squibb Price Target Announced at $65.00/Share by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Announced at $65.00/Share by Piper Sandler
BMY,2025-04-22,20:15:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced topline results from the Phase 3 ARISE trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
BMY,2025-04-22,20:15:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced topline results from the Phase 3 ARISE trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
BMY,2025-04-22,21:00:08,94637C,Bristol-Myers Squibb Co.,94,0.0,products-services,,Bristol-Myers Squibb Co.: The company said Tuesday a Phase 3 trial of,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Schizophrenia Treatment Falls Flat
BMY,2025-04-22,21:15:08,94637C,Bristol-Myers Squibb Co.,94,0.0,products-services,,Bristol-Myers Squibb Co.: The company said Tuesday a Phase 3 trial of,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb's Schizophrenia Treatment Falls Flat
BMY,2025-04-22,21:26:06,94637C,Bristol-Myers Squibb Co.,100,-0.65,products-services,negative,"Bristol-Myers Squibb Co.: the company's schizophrenia drug, Cobenfy, failed in a highly anticipated Phase 3 study",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test -- IBD
BMY,2025-04-23,12:56:55,94637C,Bristol-Myers Squibb Co.,100,0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Buy by Jefferies
BMY,2025-04-23,12:56:55,94637C,Bristol-Myers Squibb Co.,100,-0.44,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $68.00/Share From $70.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $68.00/Share From $70.00 by Jefferies
BMY,2025-04-23,14:00:35,94637C,Bristol-Myers Squibb Co.,99,-0.65,products-services,negative,"Bristol-Myers Squibb Co.: the company's schizophrenia drug, Cobenfy, failed in a highly anticipated Phase 3 study",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test -- IBD
BMY,2025-04-23,15:08:45,94637C,Bristol-Myers Squibb Co.,100,0.0,price-targets,unchanged,Bristol-Myers Squibb Price Target Maintained With a $55.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Maintained With a $55.00/Share by Cantor Fitzgerald
BMY,2025-04-23,20:09:05,94637C,Bristol-Myers Squibb Co.,99,-0.65,products-services,negative,"Bristol-Myers Squibb Co.: the company's schizophrenia drug, Cobenfy, failed in a highly anticipated Phase 3 study",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test -- IBD
BMY,2025-04-24,05:31:23,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Its collaboration with Bristol Myers Squibb for,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces significant progress in strategic protein degradation collaboration with Bristol Myers Squibb
BMY,2025-04-24,05:31:23,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Its collaboration with Bristol Myers Squibb for,PRESS-RELEASE,DGAP News,EQS-News: Evotec announces significant progress in strategic protein degradation collaboration with Bristol Myers Squibb
BMY,2025-04-24,05:52:43,94637C,Bristol-Myers Squibb Co.,98,0.49,partnerships,,Its collaboration with Bristol Myers Squibb for,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb
BMY,2025-04-24,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Sees FY Adj EPS $6.70,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Sees FY Adj EPS $6.70-Adj EPS $7.00 >BMY
BMY,2025-04-24,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q Net $2.46B,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Net $2.46B >BMY
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q EPS $1.20,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q EPS $1.20 >BMY
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb 1Q Adj EPS $1.80,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Adj EPS $1.80 >BMY
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb 1Q Rev $11.2B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb 1Q Rev $11.2B >BMY
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: FIRST QUARTER RESULTS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.08,revenues,,Bristol-Myers Squibb Co.: Total revenues of $11.2 billion decreased 6%,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS was $1.20,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Co.: Raising 2025 revenue guidance to a range of $45.8 billion to $46.8 billion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol-Myers Squibb Co.: Increasing non-GAAP EPS,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the first quarter of 2025.,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,equity-actions,,"Bristol-Myers Squibb Co.: Selling, general and administrative expenses of $1.6 billion",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,April 11 The FDA approved Opdivo plus Yervoy(R) (ipilimumab) Yervoy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,April 11 The FDA approved Opdivo plus Yervoy(R) (ipilimumab) Yervoy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) maraleucel) granted approval to Breyanzi,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: The company now anticipates other income and expense in 2025,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating Expenses,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $6.55-$6.85,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2025 financial guidance,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -4-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2025",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -5-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,201 $11,865",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports First Quarter -6-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol-Myers Squibb Co.: FIRST QUARTER RESULTS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,-0.08,revenues,,Bristol-Myers Squibb Co.: Total revenues of $11.2 billion decreased 6%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol-Myers Squibb Co.: GAAP EPS was $1.20,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Co.: Raising 2025 revenue guidance to a range of $45.8 billion to $46.8 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol-Myers Squibb Co.: Increasing non-GAAP EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reports results for the first quarter of 2025.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,equity-actions,,"Bristol-Myers Squibb Co.: Selling, general and administrative expenses of $1.6 billion",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First Quarter Financial Results for 2025
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,April 11 The FDA approved Opdivo plus Yervoy(R) (ipilimumab) Yervoy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,April 11 The FDA approved Opdivo plus Yervoy(R) (ipilimumab) Yervoy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,European Commission (EC) maraleucel) granted approval to Breyanzi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.57,products-services,granted,Ec approved Opdivo plus Yervoy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,earnings,,Bristol-Myers Squibb Co.: Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -2-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: The company now anticipates other income and expense in 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,equity-actions,,Bristol-Myers Squibb Co.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.61,earnings,positive,Bristol-Myers Squibb Co.: Diluted EPS $6.55-$6.85,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: The 2025 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,investor-relations,,Bristol Myers Squibb will host a conference call today,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -3-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,Bristol-Myers Squibb Co.: Total Revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -4-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,95,0.0,revenues,,"Bristol-MYERS SQUIBB COMPANY PRODUCT REVENUES FOR THE THREE MONTHS ENDED MARCH 31, 2025",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -5-
BMY,2025-04-24,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,revenues,,"Bristol-Myers Squibb Co.: Revenues $11,201 $11,865",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports First -6-
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 1Q EPS $1.20,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q EPS $1.20 >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 1Q Rev $11.2B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q Rev $11.2B >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 1Q Adj EPS $1.80,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q Adj EPS $1.80 >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol Myers Squibb Raises 2025 View To Adj EPS $6.70,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Raises 2025 View To Adj EPS $6.70-Adj EPS $7.00 Vs Prior View $6.55-$6.85 >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb Raises 2025 View To Rev $45.8B-$46.8B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Raises 2025 View To Rev $45.8B-$46.8B Vs Prior View $45.5B >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol Myers Squibb: Growth Portfolio Revenue Increase,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY"
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,-0.4,revenues,down,Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 20%,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 20% to $5.64B >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY
BMY,2025-04-24,10:59:05,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb: Raised 1Q Rev Outlook,NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY"
BMY,2025-04-24,11:13:16,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb reported better-than-expected earnings for the first quarter,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com"
BMY,2025-04-24,11:17:23,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers Squibb Swings to Profit in 1Q,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance"
BMY,2025-04-24,11:17:23,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol Myers Squibb upgraded its guidance for the year,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance"
BMY,2025-04-24,11:32:23,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers Squibb Swings to Profit in 1Q,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance"
BMY,2025-04-24,11:32:23,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol Myers Squibb upgraded its guidance for the year,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance"
BMY,2025-04-24,12:37:40,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol Myers Squibb Raises Guidance,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk"
BMY,2025-04-24,12:37:40,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb reports better-than-expected 1Q earnings,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk"
BMY,2025-04-24,12:37:41,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol Myers Squibb Raises Guidance,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk"
BMY,2025-04-24,12:37:41,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Squibb reports better-than-expected 1Q earnings,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk"
BMY,2025-04-24,14:35:35,94637C,Bristol-Myers Squibb Co.,97,-0.56,revenues,down,Revlimid sales dropped 44% to $936 million,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Continues A Two-Day Losing Spree Despite Walloping Earnings Estimates -- IBD
BMY,2025-04-24,14:35:35,94637C,Bristol-Myers Squibb Co.,97,0.72,revenues,up,Bristol Myers Squibb raised its sales guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Continues A Two-Day Losing Spree Despite Walloping Earnings Estimates -- IBD
BMY,2025-04-24,20:12:37,94637C,Bristol-Myers Squibb Co.,97,-0.56,revenues,down,Revlimid sales dropped 44% to $936 million,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Reverses Its Losing Spree On First-Quarter Beat -- IBD
BMY,2025-04-24,20:12:37,94637C,Bristol-Myers Squibb Co.,97,0.72,revenues,up,Bristol Myers Squibb raised its sales guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Reverses Its Losing Spree On First-Quarter Beat -- IBD
BMY,2025-04-24,21:24:49,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Reports Better-Than-Expected Earnings,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com
BMY,2025-04-29,22:15:04,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Hirawat Buys 4,250 Of Bristol-Myers Squibb Co >BMY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Hirawat Buys 4,250 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-04-30,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914),NEWS-FLASH,Dow Jones Newswires,Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914) For The Treatment Of Alopecia Areata >QTTB
BMY,2025-04-30,10:59:02,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914),PRESS-RELEASE,PR Newswire,Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
BMY,2025-04-30,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914),PRESS-RELEASE,Dow Jones Newswires,Press Release: Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
BMY,2025-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cari Gallman as Executive Vice President,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,"Bristol-Myers Squibb Co.: Sandra Leung, Executive Vice President, General Counsel Retires",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:00,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,"Bristol-Myers Squibb Co.: Sandra Leung, Executive Vice President, General Counsel Retires",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:18,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol Myers Appoints Cari Gallman EVP, General Counsel and Chief",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Appoints Cari Gallman EVP, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:18,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol Myers Appoints Cari Gallman EVP, General Counsel and Chief",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Appoints Cari Gallman EVP, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:46,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cari Gallman as Executive Vice President,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:46,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:46,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,"Bristol-Myers Squibb Co.: Sandra Leung, Executive Vice President, General Counsel Retires",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-06,10:59:46,94637C,Bristol-Myers Squibb Co.,100,-0.49,labor-issues,,"Bristol-Myers Squibb Co.: Sandra Leung, Executive Vice President, General Counsel Retires",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer"
BMY,2025-05-07,20:05:08,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,The collaboration with BMS for,PRESS-RELEASE,Business Wire,2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb
BMY,2025-05-07,20:05:08,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bms will acquire all remaining shares of 2seventy bio,PRESS-RELEASE,Business Wire,2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb
BMY,2025-05-07,20:05:08,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,The collaboration with BMS for,PRESS-RELEASE,Dow Jones Newswires,Press Release: 2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb
BMY,2025-05-07,20:05:08,94637C,Bristol-Myers Squibb Co.,99,0.62,acquisitions-mergers,,Bms will acquire all remaining shares of 2seventy bio,PRESS-RELEASE,Dow Jones Newswires,Press Release: 2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb
BMY,2025-05-13,16:48:08,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,Bristol Myers Squibb Completes Acquisition of 2seventy,RNS-SEC8K,Dow Jones Newswires,2seventy bio: Bristol Myers Squibb Completes Acquisition of 2seventy
BMY,2025-05-13,23:05:17,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,Officer Hickey Sells 97 Of Bristol-Myers Squibb Co,FULL-ARTICLE,Dow Jones Newswires,Officer Hickey Sells 97 Of Bristol-Myers Squibb Co >BMY
BMY,2025-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,"Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo(R) (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression >=1%"
BMY,2025-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2025-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2025-05-16,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -4-
BMY,2025-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo(R) (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression >=1%"
BMY,2025-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-05-16,10:59:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -4-
BMY,2025-05-22,07:04:41,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2025 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 1Q 2025 (BMY)"
BMY,2025-05-22,21:05:00,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: 5-year OS results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO(R) 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
BMY,2025-05-22,21:05:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Results from two Phase 1 studies,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO(R) 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO(R) -6-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO(R) -6-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO(R) -6-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO(R) -9-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ASCO(R) -9-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: 5-year OS results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data at ASCO(R) 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Results from two Phase 1 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data at ASCO(R) 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,94,0.0,products-services,,Bristol-Myers Squibb Co.: Phase I study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -6-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -6-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -6-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,92,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -9-
BMY,2025-05-22,21:05:01,94637C,Bristol-Myers Squibb Co.,92,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -9-
BMY,2025-05-23,07:12:52,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"2SEVENTY BIO INC COM, Inst Holders, 1Q 2025 (TSVT)",RNS-SEC13F,Dow Jones Newswires,"2SEVENTY BIO INC  COM, Inst Holders, 1Q 2025 (TSVT)"
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Approval is based on results from the Phase 3 CheckMate -67T clinical trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig(TM) , was approved by the U.S. Food and Drug Administration (FDA)",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Receives European Commission -3-
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol-Myers Squibb Co.: Approval is based on results from the Phase 3 CheckMate -67T clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig(TM) , was approved by the U.S. Food and Drug Administration (FDA)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(R) (nivolumab) Across Multiple Solid Tumor Indications
BMY,2025-05-28,10:55:01,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Receives -3-
BMY,2025-05-28,10:55:43,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Gets European Approval for Subcutaneous Formulation of Opdivo,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Gets European Approval for Subcutaneous Formulation of Opdivo Across Multiple Solid Tumor Indications >BMY
BMY,2025-05-28,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
BMY,2025-05-28,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
BMY,2025-05-28,11:31:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets European Approval for Subcutaneous Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Approval for Subcutaneous Opdivo
BMY,2025-05-28,11:31:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb has won European approval of a formulation,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Approval for Subcutaneous Opdivo
BMY,2025-05-28,11:46:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Gets European Approval for Subcutaneous Opdivo,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Approval for Subcutaneous Opdivo
BMY,2025-05-28,11:46:52,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb has won European approval of a formulation,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets European Approval for Subcutaneous Opdivo
BMY,2025-05-28,12:30:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo(R) (nivolumab),PRESS-RELEASE,PR Newswire,Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo(R) (nivolumab) Co-Formulated with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-05-28,12:30:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig(TM) , was approved by the U.S. Food and Drug Administration",PRESS-RELEASE,PR Newswire,Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo(R) (nivolumab) Co-Formulated with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-05-28,12:30:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo(R) (nivolumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo(R) (nivolumab) Co-Formulated with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-05-28,12:30:05,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,"Opdivo Qvantig(TM) , was approved by the U.S. Food and Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo(R) (nivolumab) Co-Formulated with ENHANZE(R) Across Multiple Solid Tumor Indications
BMY,2025-06-02,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,PRESS-RELEASE,GlobeNewswire,BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,PRESS-RELEASE,Business Wire,(BW) BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,10:45:08,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,NEWS-FLASH,Dow Jones Newswires,BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,10:45:18,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,NEWS-FLASH,Dow Jones Newswires,BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,10:58:59,94637C,Bristol-Myers Squibb Co.,100,0.7,partnerships,,Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY,2025-06-02,12:56:35,94637C,Bristol-Myers Squibb Co.,100,0.39,products-services,,Bristol Myers strikes $11 billion deal with BioNTech,FULL-ARTICLE,MarketWatch,MW Bristol Myers strikes $11 billion deal with BioNTech to join cancer-drug race
BMY,2025-06-04,21:42:47,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Short Acquires 4,706 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Short Acquires 4,706 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-06-11,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
BMY,2025-06-11,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: These positive Phase 3 data,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
BMY,2025-06-11,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Late-Breaking Data -3-
BMY,2025-06-11,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
BMY,2025-06-11,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol-Myers Squibb Co.: These positive Phase 3 data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
BMY,2025-06-11,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -3-
BMY,2025-06-12,10:45:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025"
BMY,2025-06-12,10:57:52,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025"
BMY,2025-06-12,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Results from the dose-expansion,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD(TM) Agents and BCL6 Ligand-Directed Degrader at EHA 2025
BMY,2025-06-12,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Golcadomide are being evaluated in multiple phase 3 studies,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD(TM) Agents and BCL6 Ligand-Directed Degrader at EHA 2025
BMY,2025-06-12,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: Results from the dose-expansion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD(TM) Agents and BCL6 Ligand-Directed Degrader at EHA 2025
BMY,2025-06-12,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Golcadomide are being evaluated in multiple phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD(TM) Agents and BCL6 Ligand-Directed Degrader at EHA 2025
BMY,2025-06-16,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents First Data from the -2-
BMY,2025-06-16,10:59:00,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents First Data from the -2-
BMY,2025-06-16,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.52,products-services,,Bristol-Myers Squibb Co.: BREYANZI is available,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2025-06-16,10:59:01,94637C,Bristol-Myers Squibb Co.,91,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents -2-
BMY,2025-06-17,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2025-06-17,20:16:00,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on August 1, 2025, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2025-06-17,20:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2025-06-17,20:16:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on August 1, 2025, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2025-07-10,16:24:42,94637C,Bristol-Myers Squibb Co.,100,-0.34,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Underweight by Morgan Stanley
BMY,2025-07-10,16:24:42,94637C,Bristol-Myers Squibb Co.,100,-0.62,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $34.00/Share From $36.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $34.00/Share From $36.00 by Morgan Stanley
BMY,2025-07-18,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl(R) (luspatercept-aamt),PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl(R) (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
BMY,2025-07-18,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 INDEPENDENCE trial,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl(R) (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
BMY,2025-07-18,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl(R) (luspatercept-aamt),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl(R) (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
BMY,2025-07-18,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 INDEPENDENCE trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl(R) (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
BMY,2025-07-18,10:59:49,94637C,Bristol-Myers Squibb Co.,100,-0.8,products-services,negative,Bristol Myers: Phase 3 Study of Reblozyl in Adults With Myelofibrosis-Associated Anemia Misses,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: Phase 3 Study of Reblozyl in Adults With Myelofibrosis-Associated Anemia Misses Primary Endpoint >BMY
BMY,2025-07-18,11:29:54,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol Myers on Friday said the Phase 3 study of Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Posts Mixed Reblozyl Results in Myelofibrosis-Associated Anemia
BMY,2025-07-18,11:44:54,94637C,Bristol-Myers Squibb Co.,93,0.0,products-services,,Bristol Myers on Friday said the Phase 3 study of Reblozyl,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Posts Mixed Reblozyl Results in Myelofibrosis-Associated Anemia
BMY,2025-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: Sotyktu received approval from the FDA,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
BMY,2025-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Supplemental New Drug -2-
BMY,2025-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.57,products-services,granted,Bristol-Myers Squibb Co.: Sotyktu received approval from the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
BMY,2025-07-21,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's -2-
BMY,2025-07-21,11:14:24,94637C,Bristol-Myers Squibb Co.,100,-0.47,regulatory,,Fda to Review Sotyktu for,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:14:24,94637C,Bristol-Myers Squibb Co.,100,-0.47,regulatory,,China and Japan are also reviewing Sotyktu for,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:14:24,94637C,Bristol-Myers Squibb Co.,100,-0.47,regulatory,,China and Japan are also reviewing Sotyktu for,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:14:24,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda in September 2022 approved Sotyktu,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:14:24,94637C,Bristol-Myers Squibb Co.,100,0.56,revenues,up,"Bristol Myers reported 2024 Sotyktu sales of $246 million, up 45%",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:29:24,94637C,Bristol-Myers Squibb Co.,100,-0.47,regulatory,,Fda to Review Sotyktu for,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:29:24,94637C,Bristol-Myers Squibb Co.,100,-0.47,regulatory,,China and Japan are also reviewing Sotyktu for,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:29:24,94637C,Bristol-Myers Squibb Co.,100,-0.47,regulatory,,China and Japan are also reviewing Sotyktu for,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:29:24,94637C,Bristol-Myers Squibb Co.,100,0.57,products-services,granted,Fda in September 2022 approved Sotyktu,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-21,11:29:24,94637C,Bristol-Myers Squibb Co.,100,0.56,revenues,up,"Bristol Myers reported 2024 Sotyktu sales of $246 million, up 45%",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis
BMY,2025-07-25,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President",PRESS-RELEASE,Business Wire,"Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development"
BMY,2025-07-25,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development"
BMY,2025-07-25,10:59:33,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol-Myers Names Cristian Massacesi Exec VP, Chief Medical Officer",NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Names Cristian Massacesi Exec VP, Chief Medical Officer, Head of Development >BMY"
BMY,2025-07-25,10:59:33,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Bristol-Myers Names Cristian Massacesi Exec VP, Chief Medical Officer",NEWS-FLASH,Dow Jones Newswires,"Bristol-Myers Names Cristian Massacesi Exec VP, Chief Medical Officer, Head of Development >BMY"
BMY,2025-07-25,11:30:05,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Will succeed Hirawat as executive vice president, chief medical officer",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs
BMY,2025-07-25,11:30:05,94637C,Bristol-Myers Squibb Co.,100,-0.57,labor-issues,,"Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs
BMY,2025-07-25,11:45:05,94637C,Bristol-Myers Squibb Co.,100,0.53,labor-issues,,"Will succeed Hirawat as executive vice president, chief medical officer",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs
BMY,2025-07-25,11:45:05,94637C,Bristol-Myers Squibb Co.,100,-0.57,labor-issues,,"Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker",FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs
BMY,2025-07-25,20:43:45,94637C,Bristol-Myers Squibb Co.,99,-0.57,labor-issues,,"Bristol-Myers Squibb Co.: Chief Medical Officer and Head of Development, will leave the Company by November 1, 2025",RNS-SEC8K,Dow Jones Newswires,"Bristol-Myers Squibb Files 8K - Director, Officer or Compensation Filing >BMY"
BMY,2025-07-28,20:16:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: excited to partner with BMS and we,PRESS-RELEASE,Business Wire,Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
BMY,2025-07-28,20:16:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: excited to partner with BMS and we,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
BMY,2025-07-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2025,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
BMY,2025-07-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reported second quarter 2025 financial results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
BMY,2025-07-31,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Co.: The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, July 31, 2025",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
BMY,2025-07-31,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Second Quarter Financial Results for 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
BMY,2025-07-31,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reported second quarter 2025 financial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
BMY,2025-07-31,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Co.: The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, July 31, 2025",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
BMY,2025-07-31,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 2Q EPS 64c,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q EPS 64c >BMY
BMY,2025-07-31,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 2Q Rev $12.27B >BMY,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Rev $12.27B >BMY
BMY,2025-07-31,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 2Q Adj EPS $1.46,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Adj EPS $1.46 >BMY
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb Cuts 2025 View To Adj EPS $6.35,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Cuts 2025 View To Adj EPS $6.35-Adj EPS $6.65 Vs Prior View $6.70-$7.00 >BMY
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 2Q Growth Portfolio Revenue Rose 18% to $6.6B,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Growth Portfolio Revenue Rose 18% to $6.6B >BMY
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,0.65,revenues,up,Bristol Myers Squibb: Growth Portfolio Revenue Increase,HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Immuno-Oncology Portfolio, Breyanzi, Reblozyl and Camzyos, and Reflects Continued Strength of Cobenfy >BMY"
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,-0.28,revenues,down,Bristol Myers Squibb 2Q Legacy Portfolio Rev Fell 14%,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q Legacy Portfolio Rev Fell 14% to $5.67B >BMY
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol Myers Squibb 2Q U.S. Revenue Fell 3% to $8.52B,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q U.S. Revenue Fell 3% to $8.52B >BMY
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 2Q International Revenue Rose 10% to $3.75B,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 2Q International Revenue Rose 10% to $3.75B >BMY
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb Raises 2025 View To Rev $46.5B-$47.5B,HOT-NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Raises 2025 View To Rev $46.5B-$47.5B From Prior View $45.8B-$46.8B >BMY
BMY,2025-07-31,10:59:04,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb: Raised 2025 Rev Guidance,HOT-NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb: Raised 2025 Rev Guidance Reflecting Strength of Growth Portfolio, Better-Than-Expected Legacy Portfolio Sales in 2Q and Favorable Impact of About $200M Related to Foreign Exchange Rates >BMY"
BMY,2025-07-31,10:59:08,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb Cuts Full-Year Adjusted View,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q"
BMY,2025-07-31,10:59:08,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers said its growth portfolio revenue rose 18%, to $6.6 billion, in the quarter",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q"
BMY,2025-07-31,10:59:08,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers said it is raising its revenue guidance,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q"
BMY,2025-07-31,10:59:22,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,above-expectations,Bristol Myers Beats Earnings Expectations,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Beats Earnings Expectations. It's Still Optimistic About New Schizophrenia Drug. -- Barrons.com
BMY,2025-07-31,10:59:22,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol-Myers Squibb Co.: the company reported sales of Cobenfy for the second quarter,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Beats Earnings Expectations. It's Still Optimistic About New Schizophrenia Drug. -- Barrons.com
BMY,2025-07-31,10:59:22,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol-Myers Squibb Co.: The company also raised its full-year revenue guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Beats Earnings Expectations. It's Still Optimistic About New Schizophrenia Drug. -- Barrons.com
BMY,2025-07-31,11:14:08,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Squibb Cuts Full-Year Adjusted View,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q"
BMY,2025-07-31,11:14:08,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers said its growth portfolio revenue rose 18%, to $6.6 billion, in the quarter",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q"
BMY,2025-07-31,11:14:08,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers said it is raising its revenue guidance,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q"
BMY,2025-07-31,11:54:39,94637C,Bristol-Myers Squibb Co.,100,-0.74,earnings,down,Bristol Myers Cuts Full-Year Adjusted View,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update"
BMY,2025-07-31,11:54:39,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,"Bristol Myers said its growth portfolio revenue rose 18%, to $6.6 billion, in the quarter",FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update"
BMY,2025-07-31,11:54:39,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers said it is raising its revenue guidance,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update"
BMY,2025-08-01,20:28:03,94637C,Bristol-Myers Squibb Co.,100,0.0,analyst-ratings,neutral,Bristol-Myers Squibb Is Maintained at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Is Maintained at Neutral by Citigroup
BMY,2025-08-01,20:28:03,94637C,Bristol-Myers Squibb Co.,100,-0.72,price-targets,downgrade,Bristol-Myers Squibb Price Target Cut to $47.00/Share From $51.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Bristol-Myers Squibb Price Target Cut to $47.00/Share From $51.00 by Citigroup
BMY,2025-08-04,20:16:00,94637C,Bristol-Myers Squibb Co.,95,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
BMY,2025-08-04,20:16:00,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
BMY,2025-08-04,20:16:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Business Wire,Bristol Myers Squibb's Application for Breyanzi -2-
BMY,2025-08-04,20:16:01,94637C,Bristol-Myers Squibb Co.,95,0.65,products-services,,Bristol-Myers Squibb Co.: The FDA has granted the application Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
BMY,2025-08-04,20:16:01,94637C,Bristol-Myers Squibb Co.,95,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
BMY,2025-08-04,20:16:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: In clinical trials of BREYANZI,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb's Application -2-
BMY,2025-08-05,22:00:27,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Short Acquires 360 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Short Acquires 360 Of Bristol-Myers Squibb Co >BMY
BMY,2025-08-05,22:05:11,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Gallman Acquires 518 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Gallman Acquires 518 Of Bristol-Myers Squibb Co >BMY
BMY,2025-08-22,07:04:34,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2025 (BMY)",RNS-SEC13F,Dow Jones Newswires,"Bristol-Myers Squibb Company, Inst Holders, 2Q 2025 (BMY)"
BMY,2025-08-25,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance on Eliquis (apixaban),PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
BMY,2025-08-25,10:59:00,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Pfizer Alliance ------,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
BMY,2025-08-25,10:59:00,94637C,Bristol-Myers Squibb Co.,92,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present New Clinical and -3-
BMY,2025-08-25,10:59:00,94637C,Bristol-Myers Squibb Co.,99,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present New Clinical and -4-
BMY,2025-08-25,11:12:31,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bms-Pfizer Alliance on Eliquis (apixaban),PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
BMY,2025-08-25,11:12:31,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol Myers Squibb-Pfizer Alliance ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
BMY,2025-08-25,11:12:31,94637C,Bristol-Myers Squibb Co.,92,-0.45,products-services,,Bristol-Myers Squibb Co.: If ELIQUIS is discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -3-
BMY,2025-08-25,11:12:31,94637C,Bristol-Myers Squibb Co.,99,-0.45,products-services,,Bristol-Myers Squibb Co.: ELIQUIS should be discontinued,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2025-08-29,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
BMY,2025-08-29,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,marketing,,Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
BMY,2025-09-02,15:21:30,94637C,Bristol-Myers Squibb Co.,100,-0.48,insider-trading,,"Cfo Elkins Registers 56,000 Of Bristol-Myers Squibb Co >BMY",RNS-SEC144,Dow Jones Newswires,"CFO Elkins Registers 56,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-09-03,22:43:29,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,Vp Short Acquires 603 Of Bristol-Myers Squibb Co >BMY,FULL-ARTICLE,Dow Jones Newswires,VP Short Acquires 603 Of Bristol-Myers Squibb Co >BMY
BMY,2025-09-03,22:47:10,94637C,Bristol-Myers Squibb Co.,100,-0.49,insider-trading,,"Cfo Elkins Sells 56,000 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"CFO Elkins Sells 56,000 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-09-08,15:00:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bms"") today presented interim data from a global randomized Phase 2 trial",PRESS-RELEASE,GlobeNewswire,First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
BMY,2025-09-08,15:00:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bms"") today presented interim data from a global randomized Phase 2 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
BMY,2025-09-08,15:00:00,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bms"") today presented interim data from a global randomized Phase 2 trial",PRESS-RELEASE,Hugin GlobeNewswire,Press Release: First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
BMY,2025-09-08,15:00:01,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,"Bms"") today presented interim data from a global randomized Phase 2 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
BMY,2025-09-15,13:00:11,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: We are proud to partner with BMS to,PRESS-RELEASE,PR Newswire,"Trialbee and BMS Session ""From Click to Clinic"" at DPHARM to Showcase How the Honey Platform(TM) Reinvents the Last Mile of Patient Recruitment for Trial Finder Websites"
BMY,2025-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2025-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on November 3, 2025, to stockholders",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Announces Dividend
BMY,2025-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2025-09-17,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,dividends,,"Bristol-Myers Squibb Co.: The dividend is payable on November 3, 2025, to stockholders",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Announces Dividend
BMY,2025-09-19,10:59:01,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025",PRESS-RELEASE,Business Wire,"Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025"
BMY,2025-09-19,11:01:16,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,"Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025"
BMY,2025-09-22,14:03:03,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Bristol-Myers Squibb Co.: our long-standing relationship with Veeva by,PRESS-RELEASE,PR Newswire,Bristol Myers Squibb Commits to Veeva Vault CRM
BMY,2025-09-22,14:03:04,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Bristol-Myers Squibb Co.: our long-standing relationship with Veeva by,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Commits to Veeva Vault CRM
BMY,2025-09-22,14:03:30,94637C,Bristol-Myers Squibb Co.,96,0.49,partnerships,,Bristol-Myers Squibb Co.: our long-standing relationship with Veeva by,PRESS-RELEASE,PR Newswire,Bristol Myers Squibb Commits to Veeva Vault CRM
BMY,2025-09-23,10:59:59,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Bristol Myers: Phase 3 Study of Iberdomide,NEWS-FLASH,Dow Jones Newswires,Bristol Myers: Phase 3 Study of Iberdomide in Combination With Standard Therapies Shows Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma >BMY
BMY,2025-09-25,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Builds on Eliquis(R) -2-
BMY,2025-09-25,10:59:07,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Builds on -2-
BMY,2025-10-01,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,"Bms-986446, Granted Fast Track Designation By U.S. FDA",NEWS-FLASH,Dow Jones Newswires,"Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation By U.S. FDA For The Treatment Of Alzheimer's Disease >BMY"
BMY,2025-10-01,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease"
BMY,2025-10-01,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,complete,Bristol-Myers Squibb Co.: The ongoing Phase 2 study is fully enrolled,PRESS-RELEASE,Business Wire,"Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease"
BMY,2025-10-01,10:59:06,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease"
BMY,2025-10-01,10:59:06,94637C,Bristol-Myers Squibb Co.,100,0.51,products-services,complete,Bristol-Myers Squibb Co.: The ongoing Phase 2 study is fully enrolled,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease"
BMY,2025-10-01,11:24:29,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Bristol Myers Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Fast-Track Designation for BMS-986446 in Alzheimer's
BMY,2025-10-01,11:39:29,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Bristol Myers Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Gets FDA Fast-Track Designation for BMS-986446 in Alzheimer's
BMY,2025-10-01,20:45:00,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Partner Bristol Myers Squibb Obtains Fast Track Designation From The U.S. FDA,NEWS-FLASH,Dow Jones Newswires,"Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation From The U.S. FDA For BMS-986446 (PRX005), An Anti-MTBR-Tau-Targeting Antibody, For The Treatment Of Alzheimer's Disease >PRTA"
BMY,2025-10-01,20:45:00,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA,PRESS-RELEASE,Business Wire,"Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease"
BMY,2025-10-01,20:45:03,94637C,Bristol-Myers Squibb Co.,100,0.69,products-services,,Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease"
BMY,2025-10-06,21:23:31,94637C,Bristol-Myers Squibb Co.,100,0.52,insider-trading,,"Vp Gallman Acquires 2,226 Of Bristol-Myers Squibb Co >BMY",FULL-ARTICLE,Dow Jones Newswires,"VP Gallman Acquires 2,226 Of Bristol-Myers Squibb Co >BMY"
BMY,2025-10-10,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
BMY,2025-10-10,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
BMY,2025-10-10,11:00:01,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,In partnership with BMS to,PRESS-RELEASE,DJ Global Press Release Wire,Bristol Myers Squibb and National Community Pharmacists Association Pilot Rural Heart Health Care Initiatives
BMY,2025-10-10,11:01:47,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio With Acquisition of Orbital Therapeutics,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio With Acquisition of Orbital Therapeutics
BMY,2025-10-10,12:17:44,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion
BMY,2025-10-10,12:32:44,94637C,Bristol-Myers Squibb Co.,100,0.62,acquisitions-mergers,,Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion
BMY,2025-10-10,16:19:19,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,It closed a $4.1 billion acquisition of RayzeBio,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com
BMY,2025-10-10,16:19:19,94637C,Bristol-Myers Squibb Co.,100,0.57,acquisitions-mergers,completed,It closed a $4.1 billion acquisition of RayzeBio,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com
BMY,2025-10-13,09:00:32,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Systimmune, in collaboration with BMS outside of",PRESS-RELEASE,PR Newswire,SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
BMY,2025-10-13,09:00:36,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,"Systimmune, in collaboration with BMS outside of",PRESS-RELEASE,Dow Jones Newswires,Press Release: SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
BMY,2025-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,98,0.0,products-services,,Bristol-Myers Squibb Co.: First disclosure of results from a global Phase 1 study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO(R) 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
BMY,2025-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,98,0.0,earnings,,"Bristol-Myers Squibb Co.: Final, 9-year results",PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO(R) 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
BMY,2025-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: Phase II Study of,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO(R) -2-
BMY,2025-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO(R) -4-
BMY,2025-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO(R) -4-
BMY,2025-10-13,10:59:00,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Business Wire,Bristol Myers Squibb to Present Data at ESMO(R) -4-
BMY,2025-10-13,10:59:03,94637C,Bristol-Myers Squibb Co.,98,0.0,products-services,,Bristol-Myers Squibb Co.: First disclosure of results from a global Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data at ESMO(R) 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
BMY,2025-10-13,10:59:03,94637C,Bristol-Myers Squibb Co.,98,0.0,earnings,,"Bristol-Myers Squibb Co.: Final, 9-year results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present Data at ESMO(R) 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
BMY,2025-10-13,10:59:03,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: Phase II Study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -2-
BMY,2025-10-13,10:59:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2025-10-13,10:59:03,94637C,Bristol-Myers Squibb Co.,90,-0.45,products-services,,Bristol-Myers Squibb Co.: Discontinue OPDIVO and YERVOY,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2025-10-13,10:59:03,94637C,Bristol-Myers Squibb Co.,90,0.0,products-services,,Bristol-Myers Squibb Co.: In randomized clinical trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb to Present -4-
BMY,2025-10-14,20:00:00,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Insitro Extends Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,Business Wire,insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro's ChemML Discovery Platform
BMY,2025-10-14,20:10:26,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,Insitro Extends Research Collaboration with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,Press Release: insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro's ChemML Discovery Platform
BMY,2025-10-15,11:00:01,94637C,Bristol-Myers Squibb Co.,99,0.26,corporate-responsibility,,Bms Foundation's donation to the Patient Advocate Foundation,PRESS-RELEASE,DJ Global Press Release Wire,Bristol Myers Squibb Foundation Announces $1 Million Donation to Patient Advocate Foundation
BMY,2025-10-15,13:03:15,94637C,Bristol-Myers Squibb Co.,99,0.49,partnerships,,Bristol-Myers Squibb Co.: Providing teams with access to,PRESS-RELEASE,PR Newswire,Deck Bio and ReTrax Therapeutics Awarded 2025 Bristol Myers Squibb Golden Tickets
BMY,2025-10-16,11:00:02,94637C,Bristol-Myers Squibb Co.,99,0.0,products-services,,Bristol-Myers Squibb Co.: First HopeHealth Clinical Trial,PRESS-RELEASE,DJ Global Press Release Wire,HopeHealth Launches Phase 3 Clinical Trial Site To Advance Lupus Research With Support From Bristol Myers Squibb
BMY,2025-10-17,14:00:14,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Systimmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results",PRESS-RELEASE,PR Newswire,"SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025"
BMY,2025-10-17,14:00:14,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,OrbiMed Advisors LLC: our global collaboration with Bristol Myers Squibb,PRESS-RELEASE,PR Newswire,"SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025"
BMY,2025-10-17,14:00:57,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,"Systimmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results",PRESS-RELEASE,Dow Jones Newswires,"Press Release: SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025"
BMY,2025-10-17,14:00:57,94637C,Bristol-Myers Squibb Co.,100,0.49,partnerships,,OrbiMed Advisors LLC: our global collaboration with Bristol Myers Squibb,PRESS-RELEASE,Dow Jones Newswires,"Press Release: SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025"
BMY,2025-10-17,14:03:30,94637C,Bristol-Myers Squibb Co.,100,0.0,products-services,,Systimmune and Bristol Myers Squibb Announce First Global Phase I Results,NEWS-FLASH,Dow Jones Newswires,"SystImmune and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR X HER3 Bispecific Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors"
BMY,2025-10-25,15:00:00,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T(TM) CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
BMY,2025-10-25,15:00:03,94637C,Bristol-Myers Squibb Co.,100,0.84,products-services,positive,Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T(TM) CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
BMY,2025-10-27,06:30:24,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,Evotec SE: our collaboration with Bristol Myers Squibb.,PRESS-RELEASE,DGAP News,EQS-News: Evotec announces progress in preclinical neuroscience partnership with Bristol Myers Squibb
BMY,2025-10-27,06:30:24,94637C,Bristol-Myers Squibb Co.,95,0.49,partnerships,,Evotec SE: our collaboration with Bristol Myers Squibb.,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Evotec announces progress in preclinical neuroscience partnership with Bristol Myers Squibb
BMY,2025-10-27,06:50:01,94637C,Bristol-Myers Squibb Co.,94,0.49,partnerships,,Evotec SE: our collaboration with Bristol Myers Squibb.,PRESS-RELEASE,DJ Global Press Release Wire,Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
BMY,2025-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Initial Week 16 results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
BMY,2025-10-27,10:59:01,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Presents Two Late-Breaking -3-
BMY,2025-10-27,10:59:04,94637C,Bristol-Myers Squibb Co.,99,0.0,earnings,,Bristol-Myers Squibb Co.: Initial Week 16 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
BMY,2025-10-27,10:59:04,94637C,Bristol-Myers Squibb Co.,99,0.52,products-services,,Bristol-Myers Squibb Co.: SOTYKTU is present,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Presents Two -3-
BMY,2025-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2025,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
BMY,2025-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reported third quarter 2025 financial results,PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
BMY,2025-10-30,10:59:00,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Co.: The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, October 30, 2025",PRESS-RELEASE,Business Wire,Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
BMY,2025-10-30,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Reports Third Quarter Financial Results for 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
BMY,2025-10-30,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb (NYSE: BMY) today reported third quarter 2025 financial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
BMY,2025-10-30,10:59:03,94637C,Bristol-Myers Squibb Co.,100,0.0,investor-relations,,"Bristol-Myers Squibb Co.: The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, October 30, 2025",PRESS-RELEASE,Dow Jones Newswires,Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 3Q EPS $1.08,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q EPS $1.08 >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.0,revenues,,Bristol Myers Squibb 3Q Rev $12.22B >BMY,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q Rev $12.22B >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.61,earnings,positive,Bristol Myers Squibb 3Q Adj EPS $1.63,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q Adj EPS $1.63 >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.0,earnings,,Bristol Myers Squibb Adjusts 2025 View,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Adjusts 2025 View To Adj EPS $6.40-Adj EPS $6.60 Vs Prior Outlook $6.35-$6.65 >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 3Q Growth Portfolio Revenue Rose 18% to $6.86B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q Growth Portfolio Revenue Rose 18% to $6.86B >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,-0.24,revenues,down,Bristol Myers Squibb 3Q Legacy Portfolio Rev Fell 12%,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q Legacy Portfolio Rev Fell 12% to $5.37B >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 3Q U.S. Revenue Rose 1% to $8.33B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q U.S. Revenue Rose 1% to $8.33B >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.41,revenues,up,Bristol Myers Squibb 3Q International Revenue Rose 6% to $3.89B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb 3Q International Revenue Rose 6% to $3.89B >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb Raises 2025 Rev Guidance to $47.5B-$48B,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb Raises 2025 Rev Guidance to $47.5B-$48B Vs Prior Outlook $46.5B-$47.5B >BMY
BMY,2025-10-30,10:59:07,94637C,Bristol-Myers Squibb Co.,100,0.72,revenues,up,Bristol Myers Squibb: Raised 2025 Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Bristol Myers Squibb: Raised 2025 Rev Guidance Primarily Reflects Continued Strong Performance of Growth Portfolio >BMY
BMY,2025-10-30,10:59:17,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers Squibb 3Q Profit Soars,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb 3Q Profit Soars, Raises Revenue Guidance"
BMY,2025-10-30,11:14:17,94637C,Bristol-Myers Squibb Co.,100,0.64,earnings,up,Bristol Myers Squibb 3Q Profit Soars,FULL-ARTICLE,Dow Jones Newswires,"Bristol Myers Squibb 3Q Profit Soars, Raises Revenue Guidance"
BMY,2025-10-30,11:32:34,94637C,Bristol-Myers Squibb Co.,100,0.7,earnings,up,Bristol Myers Squibb hiked its full-year guidance,FULL-ARTICLE,Dow Jones Newswires,Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain. -- Barrons.com
BMY,2025-01-24,07:09:15,97C893,Bloomsbury Publishing PLC,100,0.39,products-services,,Bloomsbury Signs Long-Term Supply Deal with Amazon,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Signs Long-Term Supply Deal with Amazon
BMY,2025-01-24,07:24:15,97C893,Bloomsbury Publishing PLC,100,0.39,products-services,,Bloomsbury Signs Long-Term Supply Deal with Amazon,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Signs Long-Term Supply Deal with Amazon
BMY,2025-01-24,09:10:45,97C893,Bloomsbury Publishing PLC,100,0.95,analyst-ratings,positive,Bloomsbury Started at Buy by Peel Hunt,NEWS-FLASH,Dow Jones Newswires,Bloomsbury Started at Buy by Peel Hunt
BMY,2025-01-24,09:10:49,97C893,Bloomsbury Publishing PLC,100,0.0,price-targets,set,Bloomsbury Target Started at 815p by Peel Hunt,NEWS-FLASH,Dow Jones Newswires,Bloomsbury Target Started at 815p by Peel Hunt
BMY,2025-03-20,07:00:19,97C893,Bloomsbury Publishing PLC,100,0.47,labor-issues,,Bloomsbury Publishing PLC Trading Update and Board Appointment,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update and Board Appointment
BMY,2025-03-20,07:00:19,97C893,Bloomsbury Publishing PLC,100,0.0,earnings,,Bloomsbury Publishing PLC: our Preliminary Results,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update and Board Appointment
BMY,2025-03-20,07:47:16,97C893,Bloomsbury Publishing PLC,100,0.7,earnings,above-expectations,Bloomsbury Publishing Beats Expectations After,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Beats Expectations After Strong End to Year
BMY,2025-03-20,07:47:16,97C893,Bloomsbury Publishing PLC,100,0.47,labor-issues,,Bloomsbury also named Heather Rabbatts to its board,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Beats Expectations After Strong End to Year
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: GBP41m revenue in 2027/28,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.64,revenues,up,Bloomsbury Publishing PLC: BDR revenues were GBP27.0m with growth of 2%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.41,assets,open,Bloomsbury Publishing PLC: our business in Asia by opening an office,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.41,assets,open,Bloomsbury Publishing PLC: our established offices in India,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.53,labor-issues,,Bloomsbury Publishing PLC: We have hired a Head of,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation was GBP4.8m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,"Bloomsbury Publishing PLC: Diluted earnings per share, excluding highlighted items, were 41.45 pence",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: our full year dividend to 15.43 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.47,labor-issues,,Bloomsbury Publishing PLC: Penny Scott-Bayfield was appointed Group Finance Director,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -3-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 203.9,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -3-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -3-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -3-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -3-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year 25,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -3-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year - - - - - -,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -4-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,93,-0.13,equity-actions,up,Bloomsbury Publishing PLC: print costs are increased by 2% from 2025/2026,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -5-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,93,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 133.6,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -5-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,93,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -5-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 133.9,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -6-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -6-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -6-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.0,revenues,,Bloomsbury Publishing PLC: During the year sales,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -6-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.0,assets,,Bloomsbury Publishing PLC: Total assets,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -6-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.0,equity-actions,,Bloomsbury Publishing PLC: Factors affecting tax charge for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -6-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -7-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.0,equity-actions,,Bloomsbury Publishing PLC: Tax charge for the year before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -7-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.0,dividends,,Bloomsbury Publishing PLC: Total dividend,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -7-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 30.71p 39.11 p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -7-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -7-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 41.45p 46.62 p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -7-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,94,0.0,equity-actions,,Bloomsbury Publishing PLC: Transaction costs of GBP0.7m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -8-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,94,0.0,revenues,,"Bloomsbury Publishing PLC: From 28 May 2024, revenue of GBP19.8m",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -8-
BMY,2025-05-22,08:33:14,97C893,Bloomsbury Publishing PLC,100,0.41,revenues,up,Bloomsbury Digital Resources sales increased 2% to 27.0 million pounds,FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Shares Fall on Pretax Profit Decline, Finance Chief's Departure"
BMY,2025-06-13,16:33:37,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Global staff turnover,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -4-
BMY,2025-06-13,16:33:37,97C893,Bloomsbury Publishing PLC,99,-0.49,equity-actions,up,Bloomsbury Publishing PLC: staff costs mitigate cost increases,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -4-
BMY,2025-07-16,06:00:10,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Results for the full year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2025-07-16,06:44:46,97C893,Bloomsbury Publishing PLC,93,0.0,revenues,,Bloomsbury Publishing PLC: on May 22 the company had guided for consensus revenue of 349.2 million pounds,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing to Meet Lowered Market Forecasts
BMY,2025-07-16,14:16:31,97C893,Bloomsbury Publishing PLC,99,0.0,investor-relations,,Bloomsbury Publishing PLC: The Company held its Annual General Meeting on Wednesday 16 July 2025,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Results of the 2025 Annual General Meeting
BMY,2025-08-29,14:39:48,97C893,Bloomsbury Publishing PLC,99,0.52,insider-trading,,"Bloomsbury Publishing PLC: the Company's Non-executive Chairman, purchased 253 ordinary shares of GBP0.0125",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Director/PDMR Shareholding
BMY,2025-09-18,06:00:19,97C893,Bloomsbury Publishing PLC,100,0.47,labor-issues,,Bloomsbury Publishing PLC Appointment of Chief Financial & Operating Officer,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Appointment of Chief Financial & Operating Officer
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Full year profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: A&P revenue up 20% to GBP46.1m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Group profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.38,dividends,up,Bloomsbury Publishing PLC: Interim dividend increased by 5%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.53,labor-issues,,Bloomsbury Publishing PLC: Appointment of Keith Underwood as Chief,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.39,products-services,,Bloomsbury Publishing PLC: IP value of academic content enabled us to sign our first non-exclusive AI licensing agreement,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: First Half Results 2025/26,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 22.98p 24.68p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 16.79p 20.10p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation was GBP13.1m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.0,equity-actions,,Bloomsbury Publishing PLC: Net finance costs were GBP0.7m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,"Bloomsbury Publishing PLC: Diluted earnings per share, excluding highlighted items, were 22.98p",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.38,dividends,up,Bloomsbury Publishing PLC: The interim dividend will increase by 5%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.39,products-services,,Bloomsbury Publishing PLC: we had signed our first non-exclusive AI licensing agreement,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.41,assets,open,Bloomsbury Publishing PLC: our business in Asia by opening an office,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.41,assets,open,Bloomsbury Publishing PLC: our established offices in Australia,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: Consumer revenue of GBP113.4m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.38,dividends,up,Bloomsbury Publishing PLC: The interim dividend will increase by 5%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.47,labor-issues,,Bloomsbury Publishing PLC: Board changes,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.53,labor-issues,,Be joining Bloomsbury as Chief Financial and Operating Officer on 2 February 2026,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 94.6,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,94,-0.13,equity-actions,up,Bloomsbury Publishing PLC: Print costs are increased by 2% from 2026/2027,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -5-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 59.8,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,90,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,90,0.47,equity-actions,,"Bloomsbury Publishing PLC: For the six months ended 31 August 2025, integration and restructuring",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,90,0.0,dividends,,Bloomsbury Publishing PLC: The proposed interim dividend of 4.08 pence per ordinary share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,90,0.0,earnings,,Bloomsbury Publishing PLC: The basic earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,95,0.0,earnings,,Bloomsbury Publishing PLC: The diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Basic earnings per share 16.91p 20.38p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,95,0.0,earnings,,Bloomsbury Publishing PLC: Adjusted basic earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,95,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2025-10-23,06:53:49,97C893,Bloomsbury Publishing PLC,100,0.78,earnings,above-expectations,Bloomsbury Publishing Expects to Beat Profit Forecasts,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Expects to Beat Profit Forecasts
BMY,2025-10-23,06:53:49,97C893,Bloomsbury Publishing PLC,100,-0.34,earnings,down,"Bloomsbury reported a pretax profit of 18.3 million pounds, down from 22.1 million pounds",FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Expects to Beat Profit Forecasts
BMY,2025-01-24,07:09:15,97C893,Bloomsbury Publishing PLC,100,0.39,products-services,,Bloomsbury Signs Long-Term Supply Deal with Amazon,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Signs Long-Term Supply Deal with Amazon
BMY,2025-01-24,07:24:15,97C893,Bloomsbury Publishing PLC,100,0.39,products-services,,Bloomsbury Signs Long-Term Supply Deal with Amazon,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Signs Long-Term Supply Deal with Amazon
BMY,2025-01-24,09:10:45,97C893,Bloomsbury Publishing PLC,100,0.95,analyst-ratings,positive,Bloomsbury Started at Buy by Peel Hunt,NEWS-FLASH,Dow Jones Newswires,Bloomsbury Started at Buy by Peel Hunt
BMY,2025-01-24,09:10:49,97C893,Bloomsbury Publishing PLC,100,0.0,price-targets,set,Bloomsbury Target Started at 815p by Peel Hunt,NEWS-FLASH,Dow Jones Newswires,Bloomsbury Target Started at 815p by Peel Hunt
BMY,2025-03-20,07:00:19,97C893,Bloomsbury Publishing PLC,100,0.47,labor-issues,,Bloomsbury Publishing PLC Trading Update and Board Appointment,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update and Board Appointment
BMY,2025-03-20,07:00:19,97C893,Bloomsbury Publishing PLC,100,0.0,earnings,,Bloomsbury Publishing PLC: our Preliminary Results,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Trading Update and Board Appointment
BMY,2025-03-20,07:47:16,97C893,Bloomsbury Publishing PLC,100,0.7,earnings,above-expectations,Bloomsbury Publishing Beats Expectations After,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Beats Expectations After Strong End to Year
BMY,2025-03-20,07:47:16,97C893,Bloomsbury Publishing PLC,100,0.47,labor-issues,,Bloomsbury also named Heather Rabbatts to its board,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Beats Expectations After Strong End to Year
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: GBP41m revenue in 2027/28,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.64,revenues,up,Bloomsbury Publishing PLC: BDR revenues were GBP27.0m with growth of 2%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.41,assets,open,Bloomsbury Publishing PLC: our business in Asia by opening an office,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.41,assets,open,Bloomsbury Publishing PLC: our established offices in India,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.53,labor-issues,,Bloomsbury Publishing PLC: We have hired a Head of,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation was GBP4.8m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,"Bloomsbury Publishing PLC: Diluted earnings per share, excluding highlighted items, were 41.45 pence",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,dividends,,Bloomsbury Publishing PLC: our full year dividend to 15.43 pence,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -2-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.47,labor-issues,,Bloomsbury Publishing PLC: Penny Scott-Bayfield was appointed Group Finance Director,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -3-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 203.9,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -3-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -3-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -3-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -3-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year 25,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -3-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Profit for the year - - - - - -,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -4-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,93,-0.13,equity-actions,up,Bloomsbury Publishing PLC: print costs are increased by 2% from 2025/2026,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -5-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,93,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 133.6,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -5-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,93,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -5-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 133.9,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -6-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -6-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -6-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.0,revenues,,Bloomsbury Publishing PLC: During the year sales,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -6-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.0,assets,,Bloomsbury Publishing PLC: Total assets,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -6-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,90,0.0,equity-actions,,Bloomsbury Publishing PLC: Factors affecting tax charge for the year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -6-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -7-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.0,equity-actions,,Bloomsbury Publishing PLC: Tax charge for the year before,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -7-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.0,dividends,,Bloomsbury Publishing PLC: Total dividend,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -7-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 30.71p 39.11 p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -7-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -7-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,97,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 41.45p 46.62 p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -7-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,94,0.0,equity-actions,,Bloomsbury Publishing PLC: Transaction costs of GBP0.7m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -8-
BMY,2025-05-22,06:00:16,97C893,Bloomsbury Publishing PLC,94,0.0,revenues,,"Bloomsbury Publishing PLC: From 28 May 2024, revenue of GBP19.8m",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -8-
BMY,2025-05-22,08:33:14,97C893,Bloomsbury Publishing PLC,100,0.41,revenues,up,Bloomsbury Digital Resources sales increased 2% to 27.0 million pounds,FULL-ARTICLE,Dow Jones Newswires,"Bloomsbury Publishing Shares Fall on Pretax Profit Decline, Finance Chief's Departure"
BMY,2025-06-13,16:33:37,97C893,Bloomsbury Publishing PLC,99,0.0,revenues,,Bloomsbury Publishing PLC: Global staff turnover,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -4-
BMY,2025-06-13,16:33:37,97C893,Bloomsbury Publishing PLC,99,-0.49,equity-actions,up,Bloomsbury Publishing PLC: staff costs mitigate cost increases,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Annual Financial Report -4-
BMY,2025-07-16,06:00:10,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Results for the full year,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC AGM Trading Update
BMY,2025-07-16,06:44:46,97C893,Bloomsbury Publishing PLC,93,0.0,revenues,,Bloomsbury Publishing PLC: on May 22 the company had guided for consensus revenue of 349.2 million pounds,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing to Meet Lowered Market Forecasts
BMY,2025-07-16,14:16:31,97C893,Bloomsbury Publishing PLC,99,0.0,investor-relations,,Bloomsbury Publishing PLC: The Company held its Annual General Meeting on Wednesday 16 July 2025,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Results of the 2025 Annual General Meeting
BMY,2025-08-29,14:39:48,97C893,Bloomsbury Publishing PLC,99,0.52,insider-trading,,"Bloomsbury Publishing PLC: the Company's Non-executive Chairman, purchased 253 ordinary shares of GBP0.0125",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Director/PDMR Shareholding
BMY,2025-09-18,06:00:19,97C893,Bloomsbury Publishing PLC,100,0.47,labor-issues,,Bloomsbury Publishing PLC Appointment of Chief Financial & Operating Officer,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Appointment of Chief Financial & Operating Officer
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Full year profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.41,revenues,up,Bloomsbury Publishing PLC: A&P revenue up 20% to GBP46.1m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Group profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.38,dividends,up,Bloomsbury Publishing PLC: Interim dividend increased by 5%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.53,labor-issues,,Bloomsbury Publishing PLC: Appointment of Keith Underwood as Chief,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.39,products-services,,Bloomsbury Publishing PLC: IP value of academic content enabled us to sign our first non-exclusive AI licensing agreement,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: First Half Results 2025/26,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted diluted earnings per share 22.98p 24.68p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Diluted earnings per share 16.79p 20.10p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim Results
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation was GBP13.1m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.0,equity-actions,,Bloomsbury Publishing PLC: Net finance costs were GBP0.7m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,"Bloomsbury Publishing PLC: Diluted earnings per share, excluding highlighted items, were 22.98p",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.38,dividends,up,Bloomsbury Publishing PLC: The interim dividend will increase by 5%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.39,products-services,,Bloomsbury Publishing PLC: we had signed our first non-exclusive AI licensing agreement,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.41,assets,open,Bloomsbury Publishing PLC: our business in Asia by opening an office,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.41,assets,open,Bloomsbury Publishing PLC: our established offices in Australia,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.65,revenues,up,Bloomsbury Publishing PLC: Consumer revenue of GBP113.4m,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -2-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.38,dividends,up,Bloomsbury Publishing PLC: The interim dividend will increase by 5%,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.47,labor-issues,,Bloomsbury Publishing PLC: Board changes,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.53,labor-issues,,Be joining Bloomsbury as Chief Financial and Operating Officer on 2 February 2026,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 94.6,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,99,0.0,earnings,,Bloomsbury Publishing PLC: Earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -3-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,94,-0.13,equity-actions,up,Bloomsbury Publishing PLC: Print costs are increased by 2% from 2026/2027,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -5-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,90,0.61,earnings,positive,Bloomsbury Publishing PLC: Gross profit 59.8,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,90,0.59,earnings,positive,Bloomsbury Publishing PLC: Profit before taxation,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -6-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,90,0.6,earnings,positive,Bloomsbury Publishing PLC: Operating profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,90,0.47,equity-actions,,"Bloomsbury Publishing PLC: For the six months ended 31 August 2025, integration and restructuring",PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,90,0.0,dividends,,Bloomsbury Publishing PLC: The proposed interim dividend of 4.08 pence per ordinary share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,90,0.0,earnings,,Bloomsbury Publishing PLC: The basic earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -7-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,95,0.0,earnings,,Bloomsbury Publishing PLC: The diluted earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Basic earnings per share 16.91p 20.38p,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,95,0.61,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,95,0.0,earnings,,Bloomsbury Publishing PLC: Adjusted basic earnings per share,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2025-10-23,06:00:14,97C893,Bloomsbury Publishing PLC,95,0.59,earnings,positive,Bloomsbury Publishing PLC: Adjusted profit before tax,PRESS-RELEASE,LSE Regulatory News Service (RNS),Bloomsbury Publishing PLC Unaudited Interim -8-
BMY,2025-10-23,06:53:49,97C893,Bloomsbury Publishing PLC,100,0.78,earnings,above-expectations,Bloomsbury Publishing Expects to Beat Profit Forecasts,FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Expects to Beat Profit Forecasts
BMY,2025-10-23,06:53:49,97C893,Bloomsbury Publishing PLC,100,-0.34,earnings,down,"Bloomsbury reported a pretax profit of 18.3 million pounds, down from 22.1 million pounds",FULL-ARTICLE,Dow Jones Newswires,Bloomsbury Publishing Expects to Beat Profit Forecasts
